<SEC-DOCUMENT>0001437749-26-008259.txt : 20260313
<SEC-HEADER>0001437749-26-008259.hdr.sgml : 20260313
<ACCEPTANCE-DATETIME>20260313170139
ACCESSION NUMBER:		0001437749-26-008259
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260313
DATE AS OF CHANGE:		20260313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		26753336

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>crvo20251231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:crvo="http://www.diffusionpharma.com/20251231" xmlns:rr="http://xbrl.sec.gov/rr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21"><head>
	<title>crvo20251231_10k.htm</title>


	<!-- Generated by ThunderDome Portal - 3/13/2026 8:11:48 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalPeriodFocus" id="ixv-11909">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFiscalYearFocus" id="ixv-11910">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CurrentFiscalYearEndDate" id="ixv-11911">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AmendmentFlag" id="ixv-11912">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCentralIndexKey" id="ixv-11913">0001053691</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:NonRule10b51ArrTrmntdFlag" id="c948" format="ixt:fixed-false">False</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:Rule10b51ArrTrmntdFlag" id="c947" format="ixt:fixed-false">False</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:NonRule10b51ArrAdoptedFlag" id="c946" format="ixt:fixed-false">False</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:Rule10b51ArrAdoptedFlag" id="c945" format="ixt:fixed-false">False</ix:nonNumeric>
<ix:nonFraction id="c867" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:NumberOfReportableSegments" scale="0" format="ixt:num-dot-decimal" decimals="INF">1</ix:nonFraction>
<ix:nonFraction id="c782" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c781" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c683" contextRef="d_2025-01-01_2025-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c640" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c637" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c634" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c633" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember" unitRef="Pure" name="crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" scale="0" format="ixt:num-dot-decimal" decimals="INF">5</ix:nonFraction>
<ix:nonFraction id="c631" contextRef="i_2025-12-31_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c630" format="ixt-sec:duryear">1</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c628" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c627" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c620" format="ixt:date-monthname-day-year-en">April 30, 2027</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c617" format="ixt:date-monthname-day-year-en">April 30, 2028</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" id="c614" format="ixt:date-monthname-day-year-en">February 28, 2026</ix:nonNumeric>
<ix:nonFraction id="c489" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="USD" name="crvo:PaymentsForLicenseAgreement" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c488" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="USD" name="crvo:PaymentsForLicenseAgreement" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2025-12-31" name="us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" id="c301">http://fasb.org/us-gaap/2025#GrantsReceivableCurrent</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="c300">http://fasb.org/us-gaap/2025#Revenues</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="c299">http://fasb.org/us-gaap/2025#Revenues</ix:nonNumeric>
<ix:nonFraction id="c298" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c297" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredOfferingCosts" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c295" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c294" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c293" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:ImpairmentOfMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c292" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="crvo:ImpairmentOfMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="c50" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="c49" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="c42" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="c41" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="c40" format="ixt:fixed-true">true</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="c38" format="ixt:fixed-true">true</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="crvo-20251231.xsd" xlink:type="simple"/></ix:references>
<ix:resources>
<xbrli:context id="d_2025-01-01_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:StockBasedCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:PersonnelCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:PersonnelCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherClinicalAndNonclinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherClinicalAndNonclinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:RecoveryAfterStrokeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:RecoveryAfterStrokeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:FrontotemporalDisordersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:FrontotemporalDisordersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:DementiaWithLewyBodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:DementiaWithLewyBodiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-01-01_2025-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2025EquityPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2025EquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-01-01_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:May2025AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-05-12_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:May2025AtthemarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-11</xbrli:startDate><xbrli:endDate>2024-12-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-26</xbrli:startDate><xbrli:endDate>2024-02-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:SeriesACommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalEIPCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalDiffusionCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalDiffusionCommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-01_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:SeriesAWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-03-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-08-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-01-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-08-01</xbrli:startDate><xbrli:endDate>2014-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-08-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:OpenMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:OpenMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2026-03-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2025-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f6ff8e636-6d49-477d-83f3-18bd69e4239d" fromRefs="c914 c913"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f2b6adf8e-c033-448f-a62e-7f630299d7ff" fromRefs="c920 c919"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a" fromRefs="c855 c854"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f" fromRefs="c932 c931"/></ix:resources>
</ix:header></div>
<div>&#160;</div>

<div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES</b></p>

<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Washington, D.C. 20549</b></p>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>FORM</b>&#160;<b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentType" id="c3">10-K</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt;">(Mark one)</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentAnnualReport" id="c4" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b>For the fiscal year ended <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentPeriodEndDate" id="c5" format="ixt:date-monthname-day-year-en">December 31, 2025</ix:nonNumeric></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>OR</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentTransitionReport" id="c6" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><b>For the transition period from</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b>to</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Commission file number: <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFileNumber" id="c7">001-37942</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center; margin: 0pt;"><img alt="logolg.jpg" src="logolg.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 24pt; font-variant: normal; text-align: center; margin: 0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityRegistrantName" id="c8">CervoMed Inc.</ix:nonNumeric></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Exact Name of Registrant as specified in its Charter)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityIncorporationStateCountryCode" id="c9" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityTaxIdentificationNumber" id="c10">30-0645032</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&#160;</td>
			<td style="vertical-align: bottom; width: 50%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressAddressLine1" id="c11">20 Park Plaza, Suite 424</ix:nonNumeric></b><br/>
			<b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressCityOrTown" id="c12">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressStateOrProvince" id="c13" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric></b><br/>
			(Address of Principal Executive Offices)</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityAddressPostalZipCode" id="c14">02116</ix:nonNumeric></b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:CityAreaCode" id="c15">617</ix:nonNumeric>) <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:LocalPhoneNumber" id="c16">744-4400</ix:nonNumeric></b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">(Registrant's telephone number, including area code)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Title of Each Class</span></b></p>
			</td>
			<td style="vertical-align: bottom; width: 20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Trading Symbol</span></b></p>
			</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Name of Each Exchange on Which Registered</span></b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:Security12bTitle" id="c17">Common Stock, par value $0.001 per share</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 20%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:TradingSymbol" id="c18">CRVO</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:SecurityExchangeName" id="c19">NASDAQ</ix:nonNumeric> Capital Market</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Securities registered pursuant to Section&#160;12(g) of the Act:</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>None</b>&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#160;&#9744; <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityWellKnownSeasonedIssuer" id="c20">No</ix:nonNumeric>&#160;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#160;&#9744; <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityVoluntaryFilers" id="c21">No</ix:nonNumeric>&#160;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityCurrentReportingStatus" id="c22">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityInteractiveDataCurrent" id="c23">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 70%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer &#9744;</p>
			</td>
			<td style="vertical-align: bottom; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#9744;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 70%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityFilerCategory" id="c24" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> &#9746;</p>
			</td>
			<td style="vertical-align: bottom; width: 30%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntitySmallBusiness" id="c25" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 70%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityEmergingGrowthCompany" id="c26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>
			</td>
			<td style="vertical-align: bottom; width: 30%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicated by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 USC. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:IcfrAuditorAttestationFlag" id="c27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160; <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:DocumentFinStmtErrorCorrectionFlag" id="c28" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160; &#9744;&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:EntityShellCompany" id="c29" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No&#160;&#9746;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The aggregate market value of the registrant&#8217;s common stock beneficially owned by non-affiliates of the registrant, calculated based upon the closing sale price of the common stock as quoted by the Nasdaq Capital Market on June 30, 2025 (the last business day of the registrant&#8217;s second fiscal quarter), was approximately $<ix:nonFraction id="c30" contextRef="i_2025-06-30" unitRef="USD" name="dei:EntityPublicFloat" scale="6" format="ixt:num-dot-decimal" decimals="-5">39.9</ix:nonFraction> million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">As of March 11, 2026, <ix:nonFraction id="c31" contextRef="i_2026-03-12" unitRef="Share" name="dei:EntityCommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,258,719</ix:nonFraction>&#160;shares of common stock of the registrant were outstanding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The&#160;following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated by reference from the Registrant&#8217;s Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<div>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Page No.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Introductory Notes</p>
			</td>
			<td style="vertical-align: top; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: middle; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part I</p>
			</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 1:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Business</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">9</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 1A:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Risk Factors</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">37</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 1B:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Unresolved Staff Comments</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">75</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 1C:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Cybersecurity</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">75</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 2:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Properties</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">76</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 3:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Legal Proceedings</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">76</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 4:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Mine Safety Disclosures</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">77</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part II</p>
			</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 5:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">77</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 6:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">[Reserved]</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">77</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 7:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">77</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 7A:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Quantitative and Qualitative Disclosure About Market Risk</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">85</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 8:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial Statements and Supplementary Data</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">85</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 9:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">105</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 9A:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Controls and Procedures</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">106</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 9B:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Other Information</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 9C:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part III</p>
			</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 10:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Directors, Executive Officers and Corporate Governance</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 11:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Executive Compensation</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 12:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 13:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Certain Relationships and Related Transactions, and Director Independence</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 14:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Principal Accountant Fees and Services</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: middle; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part IV</p>
			</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">&#160;</td>
			<td style="vertical-align: top; width: 87%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 15:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Exhibit and Financial Statement Schedules</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 7pt;">Item 16:</p>
			</td>
			<td style="vertical-align: top; width: 87%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Form 10-K Summary</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">111</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INTRODUCTORY NOTES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Company References and Other Defined Terms</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise requires, all references in this Annual Report to (i) &#8220;CervoMed,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; refer to the business of CervoMed Inc. for all dates and periods subsequent to (and including) August 16, 2023 and to the business of EIP Pharma, Inc. (&#8220;EIP&#8221;), our wholly-owned subsidiary and the accounting acquirer in the Merger (as defined below) for all dates and periods prior to August 16, 2023 and (ii) &#8220;common stock&#8221; refer to our common stock, par value $0.001 per share.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have also used several other defined terms in this Annual Report, many of which are explained or defined below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Term</b></p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Definition</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2015 Equity Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CervoMed Inc. 2015 Equity Incentive Plan, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2018 Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CervoMed Inc. 2018 Employee, Director and Consultant Equity Incentive Plan, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2020 Notes</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the previously outstanding convertible promissory notes of EIP, dated as of December 4, 2020, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2021 Notes</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the previously outstanding convertible promissory notes of EIP, dated as of December 10, 2021, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024 Private Placement</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">our private placement of an aggregate of 2,532,285 units, each consisting of (i) (A) one share of common stock or (B) one Pre-Funded Warrant in lieu thereof and (ii) one Series A Warrant, for aggregate gross proceeds of up to approximately $149.4 million, completed on April 1, 2024</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025 Equity Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CervoMed Inc. 2025 Equity Incentive Plan</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">401(k) Plan</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CervoMed Inc. 401(k) Defined Contribution Plan</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AD</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Alzheimer&#8217;s Disease</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Annual Report</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">this Annual Report on Form 10-K</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AAIC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Alzheimer's Association International Conference</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ACA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Affordable Care Act and the Healthcare and Education Reconciliation Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ADCS-CGIC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Alzheimer's Disease Cooperative Study &#8212;&#160;Clinical Global Impression of Change</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AI</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">artificial intelligence</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AIA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">America Invents Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AKS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">anti-kickback statute</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ALS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">amyotrophic lateral sclerosis</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ALT</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">alanine aminotransferase</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ANDA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">abbreviated new drug application</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">API</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">active pharmaceutical ingredient</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ASC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting Standard Codification of the FASB</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AscenD-LB Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our Phase 2a clinical trial evaluating neflamapimod for the treatment of patients with DLB, completed in the second half of 2021</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">AST</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">aspartate aminotransferase</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ASU</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting Standards Update</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Batch A</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the batch of neflamapimod DP capsules manufactured in October 2020 and administered for the Randomized Phase of the RewinD-LB Trial and a portion of the Extension</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Batch B</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the batch of neflamapimod DP capsules manufactured in March 2023 and administered for the majority of the RewinD-LB Trial Extension</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Bayh-Dole Act</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Bayh-Dole Act of 1980</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">BID</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">twice daily</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">BFC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">basal forebrain cholinergic</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Board</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our board of directors</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CARES Act</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Coronavirus Aid, Relief, and Economic Security Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CCPA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the California Consumer Privacy Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CDMO</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">contract development and manufacturing organization</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CDR-SB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical Dementia Rating Sum of Boxes test</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">cGMP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">current good manufacturing practices</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ChAT+ neurons</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">neurons staining positively for choline acetyl transferase</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CMC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">chemistry, manufacturing and controls</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CMO</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">contract manufacturing organization</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CMS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the US Centers for Medicare &amp; Medicaid Services</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CNPV</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commissioner's National Priority Voucher</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CNS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">central nervous system</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Code</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the US Internal Revenue Code of 1986, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CODM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">chief operating decision maker</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CPRA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the California Privacy Rights Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CREATES Act</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Creating and Restoring Equal Access to Equivalent Samples Act of 2019</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CRL</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Complete Response Letter</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">CRO</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">contract research organization</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DGCL</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Delaware General Corporation Law</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DGM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">deep grey matter</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DLB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">dementia with Lewy bodies</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DLB without AD co-pathology</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DLB without concomitant AD-related pathology. May also be referred to as "pure" DLB.</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DNP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the FDA&#8217;s Division of Neurology Products</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">drug product</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">drug substance</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DSCSA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Drug Supply Chain Security Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EEA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">European Economic Area</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EEG</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">electroencephalogram</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Effective Time</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the effective time of the Merger on August 16, 2023</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EIP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EIP Pharma, Inc., our wholly-owned subsidiary</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EIP Common Stock</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the common stock, par value $0.001, of EIP issued and outstanding prior to the Merger</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EMA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">European Medicines Agency</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EOAD</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Early Onset Alzheimer&#8217;s Disease</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EOT</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">end of treatment</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ERISA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Employment Retirement Income Security Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exchange Act</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Securities Exchange Act of 1934, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">EXPERTS-ALS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">a randomized, multicenter, open-label, multi-arm trial that evaluates investigational medicines for the treatment of ALS, funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Extension or Extension Phase</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">with respect to the RewinD-LB Trial, the 32-week open-label extension phase of the trial from which 16-week results were reported in March 2025</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FASB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Financial Accounting Standards Board</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FCA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">False Claims Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FCPA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Foreign Corrupt Practices Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FDA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Food and Drug Administration</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FDCA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal Food, Drug, and Cosmetic Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FDIC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal Deposit Insurance Corporation</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FTC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal Trade Commission</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FTD</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">frontotemporal disorders</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GCP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">good clinical practices</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GDPR</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">European Union General Data Protection Regulation</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GFAP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">glial fibrillary acidic protein</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GLP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">good laboratory practice</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">HIPAA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Health Insurance Portability and Accountability of Act of 1996</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IEEPA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">International Emergency Economic Powers Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IMM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">irreversible morbidity and mortality</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IND</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">investigational new drug (application)</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IRA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inflation Reduction Act of 2022</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IRB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">institutional review board</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IT</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">information technology</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">marketing authorization</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MAPK</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">mitogen-activated protein kinase</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MCI</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">mild cognitive impairment</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Merger</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the merger of Dawn Merger Sub Inc. with and into EIP, with EIP surviving the Merger as a wholly-owned subsidiary of the Company, pursuant to the Merger Agreement, completed on August 16, 2023</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Merger Agreement</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Agreement and Plan of Merger, dated March 30, 2023, by and among Diffusion Pharmaceuticals Inc., Dawn Merger Sub Inc., a wholly-owned subsidiary of Diffusion and EIP</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MMRM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">mixed-effects model for repeated measures</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MoCA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Montreal Cognitive Assessment</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MRI</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">magnetic resonance imaging</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MSN</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">medial septal nucleus</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nasdaq</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nasdaq Stock Market, LLC</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NbM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nucleus basalis of Meynert, the largest cluster of cholinergic neurons in the basal forebrain</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NCE</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">new chemical entity</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NDA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">new drug application</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NfL</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">neurofilament light chain protein</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">nfvPPA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">non-fluent variant primary progressive aphasia</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NGF</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">nerve growth factor</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NIA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the National Institute on Aging of the National Institutes of Health</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NIA Grant</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the $21.3 million grant awarded to us by the NIA to support the RewinD-LB Trial, $21.0 million of which was awarded in January 2023 and an additional $0.3 million of which was awarded in August 2024</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NIH</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">National Institutes of Health</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NOL</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">net operating loss</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NTB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Neuropsychological Test Battery</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">NYSE</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">New York Stock Exchange</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">OBBBA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">H.R. 1, formerly known as the One Big Beautiful Bill Act of 2025, enacted on July 4, 2025</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">p38&#945;</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">p38 mitogen-activated protein kinase alpha</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PBM</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">pharmacy benefit manger</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PD</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Parkinson&#8217;s disease</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PDAB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">prescription drug affordability board</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PDMA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prescription Drug Marketing Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PDUFA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Prescription Drug User Fee Act, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PK</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">pharmacokinetics</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">POC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">proof-of-concept</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PPA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">primary progressive aphasia</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pre-Funded Warrants</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the pre-funded warrants each to purchase one share of common stock at a purchase price of $0.001 per share issued in connection with the 2024 Private Placement</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">PREA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pediatric Research Equity Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proxy Statement</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the definitive proxy statement on Schedule 14A for our 2025 Annual Meeting of Stockholders</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ptau181</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">plasma phosphorylated tau at position 181</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">RA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">rheumatoid arthritis</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Randomized Phase</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">with respect to the RewinD-LB Trial, the initial, randomized, 16-week double-blind, placebo controlled phase of the trial from which topline results were reported in December 2024</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">RAS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recovery After Stroke</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Regulation S-K</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Regulation S-K promulgated under the Securities Act</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">REMS</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk Evaluation and Mitigation Strategy</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">RESTORE Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our ongoing Phase 2a clinical trial evaluating neflamapimod for the treatment of patients recovering from ischemic stroke, which we initiated in the second quarter of 2025</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">RewinD-LB Trial</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">our Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with DLB, from which we announced final results in October 2025</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">RLD</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">reference-listed drug</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ROU</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">right-of-use</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SAB</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">scientific advisory board</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SAE</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">serious adverse events</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales Agreement</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sales Agreement, dated May 12, 2025, by and between the Company and Leerink Partners, LLC</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SAP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">statistical analysis plan</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Securities and Exchange Commission</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Section 382</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Section 382 of the Code</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Securities Act</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Securities Act of 1933, as amended</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A Warrants</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the warrants to purchase an aggregate of 2,532,285 shares of common stock at a purchase price of $39.24 per share issued in connection with the 2024 Private Placement</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">TCJA</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax Cuts and Jobs Act of 2017</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">TEAE</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">treatment-emergent adverse event</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">TID</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">three times daily</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">TUG</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Timed Up and Go test</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UK</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United Kingdom</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">UPL</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">upper payment limit</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">United States of America</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US GAAP</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US generally accepted accounting principles</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">USPTO</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Patent and Trademark Office</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vertex</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vertex Pharmaceuticals Incorporated</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 20%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Vertex Agreement</p>
			</td>
			<td style="vertical-align: bottom; width: 80%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">the Option and License Agreement, dated as of August 27, 2012, by and between EIP Pharma LLC and Vertex, as amended</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note Regarding Forward-Looking Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Annual Report (including, for purposes of this Note Regarding Forward-Looking Statements, any information or documents incorporated herein by reference) includes express and implied forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, liquidity, and prospects may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results of operations, financial condition, liquidity, and prospects are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of actual results or reflect unanticipated developments in future periods.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Forward-looking statements appear in a number of places throughout this Annual Report. We may, in some cases, use terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements also include statements regarding our intentions, beliefs, projections, outlook, analyses or expectations concerning, among other things:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our cash balances, our ability to obtain additional financing in the future, and our ability to continue as a going concern;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the success and timing of our ongoing and planned clinical trials and nonclinical studies, including our ability to enroll participants in our studies at anticipated rates, our ability to manufacture an adequate amount of drug supply for our studies, and changes to our drug candidates' formulations&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">obtaining and maintaining intellectual property protection for our current or future product candidates and our proprietary technology&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the performance of third parties, including CROs, CDMOs, manufacturers, suppliers, and outside consultants, to whom we outsource certain operations, staff and other functions&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to obtain and maintain regulatory approval of our current or future product candidates and, if approved, our products, including the labeling under any approval we may obtain&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our plans and ability to develop and commercialize our current or future product candidates and the outcomes of our research and development activities&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our future obligations under the Vertex Agreement;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the accuracy of our estimates of the size and characteristics of the potential markets for our current or future product candidates, the rate and degree of market acceptance of any of our current or future product candidates that may be approved in the future, and our ability to serve those markets&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the success of products that are or may become available which also target the potential markets for our current or future product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to operate our business without infringing the intellectual property rights of others and the potential for others to infringe upon our intellectual property rights&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">any significant breakdown, infiltration, or interruption of our IT systems and infrastructure&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">recently enacted and future legislation related to the healthcare system&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">other regulatory developments in the US, European Union, and other foreign jurisdictions&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to satisfy the continued listing requirements of the Nasdaq or any other exchange on which our securities may trade in the future&#894;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">uncertainties related to general economic, political, business, industry, and market conditions, including the continued availability of funding for the NIA to support disbursements under our previously received grant; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">other risks and uncertainties, including those discussed under the heading "Risk Factors" herein and in our other public filings.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a result of these and other factors, known and unknown, actual results could differ materially from our intentions, beliefs, projections, outlook, analyses, or expectations expressed in any forward-looking statements in this Annual Report. Accordingly, we cannot assure you that the forward-looking statements contained in this Annual Report will prove to be accurate or that any such inaccuracy will not be material. You should also understand that it is not possible to predict or identify all such factors, and you should not consider any such list to be a complete set of all potential risks or uncertainties. In light of the foregoing and the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any forward-looking statements that we make in this Annual Report speak only as of the date of such statement, and, except as required by applicable law or by the rules and regulations of the SEC, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Trademarks, Trade Names, and Service Marks</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Annual Report includes trademarks, trade names, and service marks owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report are the property of their respective owners. To the extent any such terms appear without the trade name, trademark, or service mark notice, such presentation is for convenience only and should not be construed as being used in a descriptive or generic sense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Data from Clinical Trials and Nonclinical Studies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">All analyses reported from clinical trials and nonclinical studies are exploratory in nature. P-values and 95% confidence intervals are reported to provide a measure of the probability that any differences identified between the samples are due to chance. All ptau181 measurements for the RewinD-LB Trial are reported based on the Quanterix v2.1 assay scale, which utilizes a different standard than the prior version of such assay (v2.0) on which ptau181 measures for our AscenD-LB Trial are reported. Quantitative values on the v2.1 scale are approximately ten-fold higher than corresponding values on the v2.0 scale related to the standard that is used for the assay.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART I</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>BUSINESS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood brain barrier and selectively inhibits the enzyme p38&#945;, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, our lead indication, as well as nfvPPA, RAS, and ALS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our novel approach focuses on reducing the impact of neuroinflammation, which we believe is a key factor in the manifestation of degenerative diseases of the brain. Chronic activation of p38&#945; in the brains of people with certain neurodegenerative diseases is believed to impair how neurons communicate through synapses. This synaptic dysfunction leads to deterioration of cognitive and motor abilities. Left untreated, synaptic dysfunction can result in irreversible neuronal loss that leads to devastating disabilities, significant reliance on a caretaker, long term care living, and, ultimately, death. However, before neuronal loss commences, disease progression in many major neurodegenerative disorders, including DLB, initially involves a protracted period of reversible functional loss, particularly with respect to the synapses. We believe that inhibiting p38&#945; activity in the brain has the potential to reverse the clinical progression observed in the early stages of certain neurodegenerative diseases, as well as slow further progression by delaying permanent synaptic dysfunction and neuron death, by interfering with key pathogenic drivers of disease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe we are a leader in the industry in developing a treatment for DLB, a disease with no approved therapies in the US or European Union, despite being the second most common progressive dementia. Neflamapimod is the only clinical drug candidate that, to our knowledge, has shown statistically significant improvements on clinical endpoints and a biomarker of neurodegeneration in both a Phase 2a and Phase 2b clinical trial. Differentiating our approach from potential competitors, we believe we are also the only company specifically targeting the treatment of DLB patients without AD co-pathology. While DLB patients with AD co-pathology generally have significant, irreversible neuronal loss, DLB without AD co-pathology is primarily a disease of functional deficits of synapses that we believe is more treatable. We believe if neflamapimod is given in the early stages of certain degenerative diseases of the brain like DLB without AD co-pathology, it may reverse synaptic dysfunction, improve neuron health and function, and slow further progression by delaying synaptic dysfunction and neuronal death. We believe this approach enhances the alignment of our development path with neflamapimod&#8217;s mechanism of action, reduces the heterogeneity of our target patient population, and provides the opportunity to demonstrate heightened clinical effect in shorter duration trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Pipeline</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Set forth below is a table presenting our clinical pipeline:</p>

<div style="margin-left: 36pt;">
<div><img alt="pipeline.jpg" src="pipeline.jpg"/></div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Anticipated Milestones</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Set forth below are our anticipated clinical development milestones during the next 12 months, subject to, among other things, available funding:</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Anticipated Milestones</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2Q26</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Complete enrollment in Phase 2a clinical trial in nfvPPA</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mid-2026</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Complete enrollment in Phase 2a RESTORE Trial in RAS</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Mid-2026</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Initial Phase 2a biomarker data in nfvPPA</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2H26</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Topline Phase 2a clinical data in RAS</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2H26</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Initial Phase 2a clinical data in nfvPPA</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2H26</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Initiation of planned Phase 3 trial in DLB</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">YE26</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">First patient dosed with neflamapimod in EXPERTS-ALS trial in ALS</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1H27</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; border-left: 1px solid black; border-right: 1px solid black; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Topline Phase 2a clinical and biomarker data in nfvPPA</td>
		</tr>

</tbody></table>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Strategy</b></p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our mission is to develop and commercialize innovative medicines that change the course of the disease in patients who suffer from age-related brain disorders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The key elements of our strategy are:</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Capitalize on neflamapimod</i>&#8217;<i>s unique properties and our differentiated approach to progress the development of neflamapimod for the treatment of age-related brain disorders with high unmet medical need. </i>Our approach to treating neurodegenerative disorders is highly differentiated, focusing on reducing the impact of neuroinflammation in patients afflicted by diseases primarily of synaptic dysfunction who do not have significant, irreversible neuronal loss. We believe, if approved, the nature of neflamapimod&#8217;s mechanism of action, combined with the nature and prevalence of these diseases, could significantly improve patients&#8217;&#160;quality of life and ability to function, reduce caregiver burden and systemic health care costs, and present a significant commercial opportunity in one or more indications.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Advance clinical development of neflamapimod as a potential first-in-class treatment for DLB without AD co-pathology, including securing sufficient funding and initiating our planned Phase 3 trial in the second half of 2026, subject to available funding. </i>During 2025, we announced 16-week and 32-week results from the Extension Phase of our RewinD-LB Trial in which neflamapimod demonstrated significant, durable effects on the trial&#8217;s primary endpoint (CDR-SB), a key biomarker of neurodegeneration in DLB (plasma GFAP), and secondary endpoints including ADCS-CGIC when target blood concentrations were achieved. These results were even more pronounced in the patient population to be enrolled in our planned Phase 3 trial, which will use more restrictive criteria to exclude patients with AD co-pathology. In November 2025, we announced alignment with the FDA on key aspects of our planned Phase 3 clinical trial of neflamapimod, and we plan to initiate that trial in the second half of 2026, subject to available funding.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Advance clinical development of neflamapimod for other disease indications. </i>Beyond DLB, neflamapimod&#8217;s mechanism of action provides opportunities for advancement in a range of additional neurologic disorders. During 2025, we initiated Phase 2a clinical trials in nfvPPA and RAS, from which we expect initial biomarker results and topline clinical results in mid-2026 and the second half of 2026, respectively, subject to available funding to continue operations. In addition, in February 2026, we announced that neflamapimod has been selected for inclusion in EXPERTS-ALS, a platform funded by the UK government and leading charities to facilitate rapid testing of potential treatments for ALS to identify promising drug candidates and potentially accelerate their path to regulatory approval. We believe neflamapimod's inclusion in the EXPERTS-ALS platform serves to further validate its mechanism of action and potential in neurodegenerative diseases. We also believe there is strong scientific basis for evaluating neflamapimod in these indications and that differences in the treatment setting and disease processes involved provide development opportunities that are both differentiated from and complementary to our DLB program.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Explore strategic collaborations to maximize neflamapimod</i>&#8217;<i>s potential value, support its development, and expedite commercialization, if approved. </i>We believe that strategic collaborations may provide opportunities to maximize neflamapimod&#8217;s potential value for our stockholders and we intend to explore potential strategic collaborations in parallel with our planned clinical development program for neflamapimod, which may include region- or indication-specific partnerships. In addition, if neflamapimod receives regulatory approval, we intend to be prepared to commercialize as soon as practicable in the market(s) where it is first approved, if at all, which we expect would be in North America and/or Europe. In the future, we may seek partners to seek approval and commercialize our products in other regions.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Neflamapimod in Dementia with Lewy Bodies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>DLB Background</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Significant Disease Burden &amp; High Unmet Medical Need</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">DLB is the second most common progressive dementia after AD, representing approximately 10-20% of all dementia cases and affecting millions worldwide. The Lewy Body Dementia Association suggest there are more than 700,000 individuals with DLB in each of the US and the European Union, and neuropathology studies suggest true incidence may be significantly higher due to underdiagnosis in current practice. Despite this prevalence, there are currently no approved treatments specifically for DLB in the US or the European Union.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The disease is characterized by progressive dementia and fluctuating cognition (particularly deficits in attention), visual hallucination, motor dysfunction (disturbances in gait and balance), and sleep disturbances. While DLB afflicts fewer total patients than AD, it is arguably a more debilitating disease. With respect to life expectancy, in a large cohort of DLB and AD cases (251 DLB, 222 AD), after controlling for age at diagnosis, comorbidity, and antipsychotic prescribing, the average survival for DLB patients (&lt;4 years) was nearly 50% was shorter than the average survival for AD patients (~7 years). The average time progression to severe dementia was also shorter by nearly two years in DLB and, even in the mild-to-moderate stages, the disease burden with respect to quality of life and caregiver burden is greater in DLB than in AD, with deficits occurring in both cognitive and motor function. For example, in a large prospective study, mild dementia patients with DLB were admitted to a nursing home after only a median of 1.8 years from presentation and diagnosis, nearly two years shorter than the 3.7-year median in the AD group. Patients with DLB are also more frequently admitted to general hospitals, are more prone to falls, and utilize inpatient care to a substantially higher degree than patients with AD and the general elderly population.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In sum, DLB often progresses quickly and severely impacts not only the daily lives of patients suffering from the disease but that of their caregivers. There are currently no approved treatments available for DLB in the US or European Union, so management of DLB focuses on transient relief of symptoms, including its cognitive manifestations and motor components via cholinesterase inhibitors and dopaminergic medications, respectively. Even with these treatments, the cognitive and functional impairments progress rapidly, caregiver burden remains high, and new options are needed for these patients. No prior approaches have been shown to clinically slow neuronal loss or prevent cognitive decline in DLB, and neflamapimod is one of only a handful of drug candidates that have demonstrated positive effects in a Phase 2 clinical trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Neflamapimod</i>&#8217;<i>s Mechanism of Action &amp; Scientific Rationale</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our approach is based on an understanding of the mechanism by which neuroinflammation leads to the initiation and establishment of the neurodegenerative process in DLB. The process of neurodegeneration starts with dysfunction of synapses. Treating synaptic dysfunction has emerged as a major therapeutic objective to address progression of neurodegenerative diseases, particularly in the early stages prior to the onset of significant cell death. Importantly, in animal models, while neurodegeneration is irreversible, synaptic dysfunction has been observed to be reversible. In addition, even in animal models of rapidly progressive neurodegenerative disorders, interventions that reverse synaptic dysfunction both improve function and &#8220;arrest&#8221; the neurodegenerative process. Thus, therapeutic interventions that target synaptic dysfunction have the potential to both reverse and slow disease progression in the early stages of neurodegenerative dementias.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The basal forebrain &#8211; specifically, nerve cells producing the neurotransmitter acetylcholine known as cholinergic neurons &#8211; plays critical roles in controlling and optimizing a wide range of cognitive, motor, and visual tasks. Synaptic dysfunction in the BFC system is the primary pathogenic driver of disease expression and progression in DLB. In collaborative work we conducted with the New York University Langone Medical Center, and later published in the journal <i>Nature Communications</i>, we demonstrated that neflamapimod targets the specific molecular mechanisms underlying BFC dysfunction and degeneration, and may successfully reverse disease progression in the early stages of BFC dysfunction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Neflamapimod was hypothesized to reduce Rab5 protein activity &#8211; a key therapeutic target in this pathogenic model for cholinergic degeneration in DLB &#8211; because of scientific literature showing that the immediate target of neflamapimod, p38&#945;, is the major activator of Rab5. The protein Rab5 is a master regulator of endocytosis and endosomal trafficking. As shown in the figure below, cholinergic degeneration is believed to result from inflammation and various aggregated proteins that lead to aberrant activation of Rab5. This Rab5 activation leads to impaired retrograde axonal transport and a block in NGF signaling from the synapses at the ends of nerve fibers (or &#8220;axons&#8221;) back to cell body of cholinergic neurons in the basal forebrain. As NGF provides support for neuronal health, the resulting loss is then believed to lead to dysfunction, and, eventually, degeneration of cholinergic neurons &#8211; which, as noted above, plays a critical role in DLB disease expression &#8211; as these neurons&#8217; very long fibers make them particularly vulnerable to this pathogenic process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Molecular Mechanisms Underlying Cholinergic Neurodegeneration in DLB and Point of Intervention for Neflamapimod</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Our Differentiated Approach: DLB Without AD Co-Pathology</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Historically, a major challenge in developing effective drug treatments for chronic neurodegenerative diseases has been an inability to demonstrate clinically meaningful improvement in Phase 2 clinical trials of less than six-months in duration. Instead, due to a variety of factors including the nature of many such diseases, particularly AD, demonstrating effectiveness often depends on clinical trial durations of 12-18 months that enroll 1,000 or more participants. Further, prior Phase 2 clinical trial data &#8211; often utilizing a different primary endpoint than will be used in Phase 3, such as an indicative biomarker &#8211; may not provide as meaningful a predictor of these drug candidates' potential for a successful clinical outcome in Phase 3. Effectively requiring Phase 3 trials to see a clinical effect, late-stage clinical development in these indications is often associated with significant costs, time horizons, and clinical risk. Some incorrectly associate these same challenges with DLB drug development, in part due to the prominence of AD co-pathology in DLB patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In contrast, our DLB development program for neflamapimod is focused on the treatment of DLB without AD co-pathology, which we sometimes refer to as &#8220;pure DLB.&#8221; These patients comprise approximately 50% of all DLB patients, with hundreds of thousands of patients diagnosed in the US and millions worldwide. While DLB patients with AD co-pathology have significant, irreversible neuronal loss in the hippocampus, pure DLB is primarily a disease of reversible synaptic dysfunction in the BFC system. Relative to patients with AD co-pathology, these patients have limited neurodegeneration and neuronal loss in the cortical regions of the brain, particularly in the hippocampus. As those neurons are still alive, with successful pharmacological treatment, they can be rescued and the disease process reversed. Importantly, DLB remains a rapidly progressing disease, even in the absence of AD co-pathology, with families and caregivers often reporting seeing patients progress on a weekly or even daily basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The core of our differentiated approach sits at the intersection of these two features of pure DLB. The combination of less extensive neuronal loss and fixed clinical deficit, on the one hand, and rapid progression, on the other, provides the opportunity to demonstrate meaningful clinical effects compared to control in as soon as 16 weeks &#8211; as we have in our two Phase 2 trials described in more detail below &#8211; rather than the 52 weeks or more that is often required in AD trials. This approach was also central to our November 2025 alignment with the FDA on key aspects of our proposed Phase 3 clinical trial of neflamapimod for the treatment of DLB. With the FDA&#8217;s feedback, and subject to available funding, we plan to initiate a single Phase 3 clinical trial of 32 weeks duration in approximately 300 patients with DLB without AD co-pathology, utilizing the same primary endpoint (mean change in CDR-SB) as our recently completed Phase 2b trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe that, in contrast to many late-stage trials in other neurodegenerative diseases like AD, this consistency in primary endpoint from Phase 2b has the potential to increase our probability of success in Phase 3, while the ability to demonstrate a clinically meaningful effect with fewer patients and on a shorter timeline allows us to execute towards that outcome with more capital efficiency.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>AscenD-LB Trial: Our Phase 2a Trial in Dementia with Lewy Bodies</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The AscenD-LB Trial was an exploratory, Phase 2a clinical trial designed to evaluate the effects of neflamapimod against a range of clinical endpoints. A total of 91 participants were enrolled between October 2019 and March 2020 and randomized to receive neflamapimod capsules at one of two doses (40mg<sup style="vertical-align:top;line-height:120%;">6</sup> BID or 40mg TID) or matching placebo capsules (randomized 1:1) for 16 weeks. In the primary analysis of the AscenD-LB Trial, which included all participants enrolled and evaluated for treatment effects, neflamapimod demonstrated improvement compared to placebo in dementia severity (assessed by CDR-SB, p=0.023 vs. placebo) and functional mobility (as assessed by the TUG test, p=0.044 vs. placebo). In additional analyses, at the higher dose (40mg TID), improvement on NTB was evident as compared to placebo (p=0.049). Encouraging positive trends on the ten-item Neuropsychiatric Inventory were also seen, particularly with respect to visual hallucinations. This primary analysis of the AscenD-LB Trial data showing neflamapimod significantly improved dementia severity and motor function was published in <i>Nature Communications</i> in September 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">With progress in laboratory testing techniques for blood biomarkers of neurodegeneration during and shortly following completion of the AscenD-LB Trial, additional pre-specified analyses of the AscenD-LB Trial data were conducted to evaluate the results specifically in DLB patients without AD co-pathology, as assessed by plasma ptau181. As shown in the table below, participants without evidence of AD co-pathology had an average higher treatment response (evaluated by Cohen&#8217;s <i>d</i> effect size) compared to the average response in the overall trial population, and demonstrated significant improvement in CDR-SB, cognitive tests of attention, the TUG test, and in a test of recognition memory (International Shopping List Test recognition index), with Cohen&#8217;s <i>d</i> treatment effect sizes indicating, in each case, clinical effects that are moderate-to-large in magnitude (&gt; 0.7). By comparison, cholinesterase inhibitors &#8211; the current standard of care in DLB &#8211; have Cohen&#8217;s <i>d</i> effect size of approximately 0.3 in the treatment of both DLB and AD. Further, not only was the effect size with 40mg TID neflamapimod treatment comparatively larger, the effect demonstrated was on top of participant&#8217;s background therapies which, in many cases, included cholinesterase inhibitors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>RewinD-LB Trial: Our Phase 2b Trial in Dementia with Lewy Bodies</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Trial Background and Design</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based on our successes and advances in Phase 2a, we designed our Phase 2b RewinD-LB Trial and, in January 2023, we were awarded a $21.0 million grant from the NIA, and an additional $0.3 million was awarded in August 2024, to fund the majority of the trial&#8217;s costs. The trial, subsequently initiated in mid-2023, evaluated neflamapimod in 159 participants with DLB and incorporated in its design several important things we learned from the AscenD-LB Trial and our other clinical evaluations of neflamapimod:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Evaluating only a 40mg TID dosing regimen, as earlier clinical trials in DLB and AD demonstrated that achieving target plasma drug concentrations (which 40mg BID did not do in Phase 2a) was critical to maximizing neflamapimod&#8217;s effectiveness to date;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Selecting CDR-SB, increasingly viewed as the gold standard for clinical evaluation of early AD and arguably even more well-suited to DLB&#8217;s symptomology, as it can detect effects on both cognitive and motor function, as the trial&#8217;s primary endpoint; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Partially enriching the trial&#8217;s patient population by excluding certain patients with AD co-pathology, as assessed by screening levels of plasma ptau181, a blood biomarker of AD co-pathology.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The RewinD-LB Trial included two distinct parts. The Randomized Phase was a double-blind, placebo-controlled evaluation of neflamapimod administered orally, 40mg TID, randomized with placebo on a one-to-one basis, with a primary analysis after 16 weeks of treatment. Each treatment group included approximately 80 participants diagnosed with DLB by consensus criteria (global CDR = 0.5 or 1.0). To enrich for patients without AD co-pathology, patients with significantly elevated plasma ptau181 at screening (&#8805; 27.2 pg/ml) were excluded. The second phase of the trial was a 32-week open-label treatment Extension Phase for participants completing the Randomized Phase. The failure of Batch A to achieve target drug concentrations and the pre-planned introduction of Batch B (which did) allowed us to amend the trial&#8217;s statistical analysis plan in February 2025 &#8211; prior to our analysis and announcement of 16-week Extension Phase results in March 2025 &#8211; to include a pre-specified analysis of Batch B versus Batch A after both 16- and 32-weeks of treatment during the Extension Phase. Further, although the Extension Phase was open-label, both participants and site personnel were unaware of which batch they were receiving, allowing a controlled comparison of an effective batch of neflamapimod (Batch B, which served as the active arm) against an ineffective batch (Batch A, which served as a control).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The primary objective of the trial was to demonstrate that neflamapimod, compared with placebo or control, improved dementia severity, as assessed by mean change from baseline to Week 16 in CDR-SB. CDR-SB is designed to assess both cognition and function, and is obtained by clinicians rating the severity of symptoms across six domains &#8211; memory, orientation, judgment &amp; problem solving, community affairs, home &amp; hobbies, and personal care &#8211; after a semi-structured interview with the patient and a reliable informant (e.g., family member) on a 0&#8211;3 scale for each domain (total range 0-18, with a higher score indicating worse dementia). Secondary objectives included further evaluation of the safety and tolerability of neflamapimod and treatment effects on (1) global rating of treatment effect, assessed by the ADCS-CGIC, (2) motor function, as assessed by the TUG test, and (3) cognition, assessed by a DLB-specific cognitive test battery. Tertiary endpoints examined whether neflamapimod affects neuropsychiatric outcomes as assessed by the NPI-12, effect on fluctuations in cognition as assessed by the Dementia Cognitive Fluctuations Scale, impact on resting-state EEG (as well as alpha-reactivity evaluated by EEG) and in a sub-set of participants, basal forebrain atrophy assessed by structural MRI.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Randomized Phase Results</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In December 2024, we announced topline results from the Randomized Phase of the RewinD-LB Trial. In the Randomized Phase, during which all participants received Batch A, no significant differences were observed between the neflamapimod and placebo treatment groups with respect to CDR-SB or any of the trial's secondary endpoint. However, average trough plasma drug concentrations with Batch A during the Randomized Phase were more than 20% lower than our target concentration level. As described further below under <i>Alignment with FDA on Planned Phase 3 Trial </i>&#8211;<i> Pre-Phase 3 Manufacturing Improvements</i>, we subsequently determined that the reduction was caused by an unknown, latent property of neflamapimod DS. We are implementing a manufacturing improvement that will address this issue ahead of our planned Phase 3 trial and going forward. However, particularly given the importance of achieving target drug concentrations to maximizing neflamapimod&#8217;s effectiveness described above, we believe this issue was a primary driver of our failure to see during the Randomized Phase the same positive results with saw with Batch B during the Extension Phase.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Extension Phase Results</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Of the 159 participants randomized in the Randomized Phase, 152 completed the Randomized Phase and 149 entered the neflamapimod only Extension Phase. The chart below shows when the pre-planned introduction of Batch B to resupply the Extension Phase occurred for those 149 patients:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="p2bextention.jpg" src="p2bextention.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In March 2025, we announced that, in the first 16 weeks of the Extension Phase, treatment with Batch B &#8211; which, unlike Batch A, achieved target drug concentrations &#8211; demonstrated statistically significant improvement on CDR-SB, the trial&#8217;s primary outcome measure, and ADCS-CGIC, a key secondary outcome measure, in each case, compared to Batch A. In July 2025, we reported additional data from the Extension Phase showing significant, durable treatment effects out to 32 weeks, including a significant risk reduction in clinically significant worsening (&#8805; 1.5-point increase in CDR-SB) with Batch B neflamapimod treatment compared to control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The final results of the RewinD-LB Trial were presented in December 2025 at the Clinical Trials in Alzheimer&#8217;s Disease (CTAD) conference. The key results included:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Through the first 16 weeks of the Extension Phase, the change in CDR-SB was significantly lower in the Batch B group compared to the Batch A group (difference = -0.57, 95% CI: -0.98, -0.16; p=0.007).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On ADCS-CGIC, which was administered at Week 8 of the Extension Phase, administration of Batch B led to an improved score (4.02 vs. 4.42 Batch A, p&lt;0.05). In addition, in a within-participant analysis, mean ADCS-CGIC score was reduced in participants administered Batch B compared to placebo (4.00 vs. 4.44, p&lt;0.05).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Over the full course of the study, the risk of clinical progression (defined as &#8805;&#160;1.5 point increase in CDR-SB score) was reduced by over 50% with Batch B treatment, both vs. Batch A (hazard ratio=0.46 95%CI 0.30-0.69) and vs. placebo (hazard ratio=0.49, 95%CI 0.30-0.80) over 32 weeks of treatment.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Participants treated with Batch B for all 32 weeks of the Extension Phase demonstrated a statistically significant reduction from baseline in plasma GFAP levels, a validated biomarker of neurodegenerative disease activity, with a median change of -16.0 pg/mL (Interquartile range -35, 6.7) in all participants (N=107; p&lt;0.001 for change from baseline; p=0.014 vs. Batch A).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional data from the Extension Phase presented at the 19th International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Disease and Related Neurologic Disorders in April 2025 included that Batch B demonstrated improvements on endpoints measuring cognitive fluctuations and working memory.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;Both Batch B and Batch A demonstrated comparable tolerability profiles and no new safety signals were identified during the Extension Phase.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Alignment with FDA on Planned Phase 3 Trial </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In November 2025, we announced alignment with the FDA on key aspects of our planned Phase 3 clinical trial of neflamapimod for the treatment of DLB. Based on FDA feedback, we plan to initiate a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of neflamapimod in approximately 300 participants with DLB by consensus clinical criteria in the second half of 2026, subject to available funding. The trial will exclude patients who have historical evidence of AD co-pathology by brain imaging scan or cerebrospinal fluid sampling. In addition, the trial will be further enriched for participants who do not have AD co-pathology by excluding patients with plasma ptau181 &#8805; 21.0 pg/mL at screening. Participants will be randomized 1:1 to receive either oral neflamapimod or placebo for 32 weeks, followed by a neflamapimod only extension for 48 weeks. Worsening of global cognition and function as measured by change CDR-SB &#8211; the same primary endpoint as in our RewinD-LB Trial &#8211; will be the primary endpoint for the planned Phase 3 trial. Secondary endpoints will include the percentage of participants who have a greater than 1.5-point increase in CDR-SB and other well-established measures of cognitive and motor function. The trial will also include assessments of key biomarkers of the neurodegenerative process, such as GFAP, to further support regulatory review and clinical interpretation. CervoMed expects feedback from other global regulators in the coming months and to announce additional details regarding the planned Phase 3 trial design in early 2026 following these interactions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As we did between Phase 2a and Phase 2b, we will incorporate several important things we learned from the RewinD-LB Trial into the design of our planned Phase 3 trial, which we believe will further increase the trial&#8217;s probability of success.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Pre-Phase 3 Manufacturing Improvements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Despite the disparity in performance, Batch A and Batch B were manufactured using the same manufacturing process. While there was no evidence of chemical degradation in our customary release or stability testing prior to the trial's initiation, we conducted additional evaluations of Batch A and Batch B in late 2024 and early 2025 to determine the reason for Batch A's failure to achieve target plasma drug concentrations. Our investigations identified a previously undiscovered mixture of polymorphic forms of neflamapimod&#8217;s DS. These polymorphic forms have different physical chemistry properties, including solubility, potentially with a time-dependent change in relative amounts of the individual forms. The Batch A capsules were more than three years out from their manufacture date at the time of administration during the RewinD-LB Trial &#8211; much older than Batch B and the drug product utilized in our past clinical trials at their respective time of use. We believe this time-dependent change accounted for the reduced performance of Batch A in the RewinD-LB trial, as well as the difference in performance between the two batches despite using the same DS and DP manufacturing processes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To mitigate the potential for this reduction in performance over time, we identified the most stable polymorphic form, as well as a controlled manufacturing process to reliably manufacture DS that contains only (or predominantly) this stable form. In March 2025, we announced bioavailability data from a Phase 1 trial evaluating this stable crystal form of neflamapimod manufactured using the new, controlled manufacturing process. Following our evaluation of the results, we selected 50mg TID of the stable crystal form of neflamapimod as the dose and dosing regimen for our planned Phase 3 study in patients with DLB. While the PK profiles of 40mg of Batch B and 40mg of the stable crystal form of neflamapimod are largely overlapping, the dose will be increased to 50mg with the intent of ensuring the dosing regimen achieves the plasma drug concentrations observed with Batch B.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Enhanced Patient Enrichment Strategy</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">At the time RewinD-LB Trial was initiated in mid-2023, 27.2 pg/ml was estimated to be the optimal ptau181 cutoff for excluding patients with AD co-pathology from the trial, based on the limited data set available at that time. However, pre-specified analyses of the Extension Phase data, conducted in March 2025 and presented at the Alzheimer&#8217;s Association International Conference in July 2025, indicated that lower cutoff points (e.g., 25.2 pg/mL, 23.0 pg/mL, 21.0 pg/mL) led to progressively greater treatment effect size for CDR-SB and ADSC-CGIC in the RewinD-LB Trial, with the greatest effect size at 21.0 pg/mL. This finding was confirmed in a large (N=1298), third-party validation study published in June 2025, indicating that a ptau181 cutoff of 21.0 pg/mL was the high sensitivity cutoff for identifying AD pathology in AD and non-AD dementia (including DLB) by CSF criteria. This means the RewinD-LB Trial was only partially enriched for patients without AD co-pathology, as patients with screening ptau181 between 21.0 pg/mL and 27.2 pg/mL were enrolled in the trial. Based on recent scientific literature, we estimate that between 60-65% of those enrolled in the RewinD-LB Trial using the 27.2 pg/mL cutoff were patients without AD co-pathology, while reducing that cutoff to 21 pg/mL would increase that enrichment rate to approximately 80-90% of the patients.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accordingly, our planned Phase 3 clinical trial in DLB will be further enriched for patients who do not have AD co-pathology by excluding patients with plasma ptau181 greater than 21.0 pg/mL at screening. In our pre-specified analysis of this cohort in the RewinD-LB Trial, effectively representing our target patient population in Phase 3, we observed even more pronounced clinical effects, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">In secondary analyses of data from the RewinD-LB Trial, for both change in CDR-SB and ADCS-CGIC, the magnitude of the effect was greater in the subset of patients without AD co-pathology defined by the lower 21.0 pg/mL screening ptau181 cutoff. Specifically, in a within-participant comparison to placebo among participants who received placebo during Randomized Phase and Batch B during the Extension Phase, Batch B treatment improved change in CDR-SB by 1.12 points (p=0.004 vs. placebo) and the ADCS-CGIC score by 0.82 points (p=0.004 vs. placebo).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#8226;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A 75% reduction in the risk of clinically meaningful progression (&#8805;&#160;1.5-point increase in CDR-SB) over up to 32 weeks of treatment with Batch B treatment compared to placebo.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Other Ongoing DLB Trials</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In August 2024, we initiated a Phase 2a trial in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in 26 patients with DLB with MCI (MoCA score &#8805;&#160;18 during screening). Unlike our RewinD-LB Trial, the patient population in the Strasbourg trial was not enriched for patients without AD co-pathology. Rather, the primary objective of the trial is to obtain additional safety and PK data on a dosing regimen not previously evaluated in any of our clinical trials (80mg BID) that, among other things, may provide additional dosing flexibility in future trials. On an exploratory basis, we will also collect data on basal forebrain atrophy, as measured by MRI, and a broad range of clinical endpoints.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the first quarter of 2025, all patients completed dosing in the trial and, based on the topline data, the primary objectives around safety and PK were achieved. Neflamapimod was well tolerated with no new safety signals being identified. The mean C<sub>trough, </sub>defined as 12-hour post last dose plasma drug concentrations, demonstrated a dose-proportionate increase. One participant discontinued early due to Grade 3 elevations in ALT and AST, but there was no observed increase in bilirubin levels, values normalized after treatment discontinuation, and concomitant medications known to affect liver enzymes were considered to have been a contributory factor. We plan to present clinical endpoint and brain MRI results from the trial at a future medical conference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Neflamapimod</b>&#8217;<b>s Potential in Additional Indications</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Frontotemporal Disorders</i></b> <b><i>// Primary Progressive Aphasia</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">FTDs are a category of neurodegenerative disorders characterized by progressive deterioration in behavior, personality, and language abilities, typically affecting individuals between the ages of 40 and 65 including an estimated tens of thousands of individuals in the US alone. Unlike AD, which primarily targets memory, FTD primarily affects the frontal and temporal lobes of the brain, leading to changes in social conduct, emotional regulation, and decision-making. There are several subtypes of FTD, including the behavioral variant FTD, the most common subtype (approximately half the patients with FTD) and PPA, each presenting with distinct symptom profiles. PPA, a subtype of FTD itself, has three main variants: nonfluent/agrammatic variant PPA, semantic variant PPA, and logopenic variant PPA, though the latter is not considered an FTD subtype. The prevalence of these PPA subtypes varies, with approximately 40% of PPA patients being nonfluent/agrammatic variant PPA, 40% being semantic variant PPA, and 20% being logopenic variant PPA. As the disease progresses, individuals with FTD may require increasing levels of care and support, with management focusing on alleviating symptoms and maximizing function.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The rationale for potentially evaluating neflamapimod as a treatment for FTD is based on the effects of p38&#945; on axonal transport and tau pathologies, as well as atrophy of the BFC system being a driver of disease and the mechanisms that neflamapimod targets being operative in FTD. Additionally, when assessed by MRI, the volume of the basal forebrain is reduced, relative to age-matched healthy control, most prominently in patients who have &#8220;tauopathies&#8221; (i.e., patients at autopsy who have tau pathology, rather than TDP-43 pathology). Moreover, in March 2024, at the AD/PD 2024 scientific conference in Lisbon, Portugal, academic collaborators from University College London presented data that showed that p38 MAPK inhibitors generally, and neflamapimod specifically, enhanced axonal transport in a transgenic mouse model of FTD (rg4510 transgenic harboring P301L mutation). Based in part on these nonclinical results, in November 2024, the FDA granted neflamapimod Orphan Drug Designation for the treatment of frontotemporal dementia.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To best align with the scientific rationale described above, we have chosen to evaluate neflamapimod in nfvPPA because more than 90% of patients with this subtype of FTD at autopsy have tau pathology, rather than TDP-43 pathology. In 2025, we initiated our Phase 2a trial evaluating neflamapimod in up to 25 participants with nfvPPA. Participants in the trial will receive six months of open label treatment with neflamapimod, followed by a three month blinded (randomized 1:1 placebo or continued neflamapimod) washout period. The primary objective is to evaluate the safety and tolerability of neflamapimod in this patient population. In addition, treatment effects on a range of clinical measures of aphasia and plasma neurodegeneration biomarkers, including GFAP and NfL, will be evaluated. We expect to report initial plasma biomarker from the trial in mid-2026, subject to available funding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Acute Indication: Recovery after Ischemic Stroke</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A treatment to improve recovery from stroke remains a significant unmet medical need. Every year, more than 795,000 people in the US suffer a stroke, and approximately 610,000 of these are first or new strokes. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. During the last 10 years, the medical and scientific communities have gained a better understanding of the mechanisms underlying neuronal recovery following a stroke. The major translational opportunity for therapeutics that target recovery after stroke is the time window in which intervention must be initiated. Rather than just the first few hours after the stroke, the window for therapeutics that could improve recovery is days and even weeks after an acute stroke. From a drug development perspective, waiting to initiate therapy until 48 hours after the stroke allows inclusion of a homogenous patient population as the diagnosis and extent of the stroke can be definitively established by that time in most patients. As a result, a POC study in stroke recovery is in the range 50-100 patients per treatment arm, compared to 500+ per treatment arm in neuroprotection trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe the therapeutic benefit of targeting neuroinflammation-induced synaptic dysfunction is not limited to chronic neurodegenerative diseases. A drug that improves synaptic function could also be considered for evaluation of the potential to improve brain function after acute neurological injury. The scientific rationale for evaluating neflamapimod to promote recovery after stroke is that the BFC system plays a critical role in recovery after ischemic stroke, particularly motor function recovery. The BFC system is suppressed by residual inflammation in the weeks and months after the acute stroke event. Neflamapimod, through the same mechanisms operating in DLB, would be expected to reverse the suppression of BFC function, leading to improved recovery of motor function. Supporting that concept is our nonclinical data with neflamapimod demonstrating significant improvement in neurological recovery vs. vehicle treatment, and TUG results from the AscenD-LB clinical trial where positive effects of neflamapimod on basal forebrain mediated control of movement were observed in the clinic.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In a nonclinical study of neflamapimod that evaluated effects on recovery after stroke, which has been published in a peer-reviewed scientific journal, transient ischemia of sufficient duration was induced in rats such that significant neurologic disability developed without mortality, and the neurologic disability did not substantially reverse during follow-up without therapy. These rats were then treated with either vehicle or one of two different doses of neflamapimod. The three groups in the study were: vehicle control (n =18), 1.5 mg/kg neflamapimod (n = 21) and 4.5 mg/kg neflamapimod (n = 21). Six weeks of neflamapimod treatment, starting at 48-hours after stroke, led to substantial improvement on multiple parameters of neurologic function compared to vehicle controls (p&lt;0.001 for each of global neurologic scores; motor and sensory specific tests).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Based upon these data and hypotheses, we initiated our ongoing RESTORE Trial, a Phase 2 placebo-controlled trial evaluating neflamapimod in up to 90 participants recovering from a moderate to moderately-severe anterior circulation ischemic stroke, in the second quarter of 2025. Patients will be enrolled between 3 and 7 days after the onset of their qualifying stroke event, and randomized 1:1 to placebo or neflamapimod for 12 weeks. The primary objective of the study is to evaluate effects of neflamapimod on recovery of motor function. The major outcome measures include change from baseline to week 12 in the Fugl-Meyer Assessment of Motor Recovery after Stroke (FMMS), Timed Up and Go (TUG) test and the National Institutes of Health Stroke Scale (NIHSS) motor score. We anticipate completing enrollment at the end of the second quarter of 2026 and expect to report topline data in the second half of 2026, subject to available funding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Amyotrophic Lateral Sclerosis (ALS)</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord that control voluntary muscle movement and breathing. Over the course of the disease, people lose the ability to move, sometimes also to speak, and eventually, to breathe. There are no approved therapies that stop or reverse the progression of ALS. Approximately 168,000 people worldwide live with ALS, with an estimated 90-95% of cases occurring without a family history of the condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In ALS, p38&#945; is aberrantly activated and plays a key role in impairing axonal transport&#8212;a fundamental physiologic defect in the disease. Restoring axonal transport through p38&#945; inhibition has been demonstrated both in vitro and in vivo, including in the SOD1 transgenic mouse model. More recently, independent nonclinical studies have further validated p38&#945; as a disease-relevant, convergent target in ALS and, we believe, demonstrated the potential of neflamapimod. For example, recent third-party research related to both TDP-43 pathology and C9ORF72-associated ribotoxic stress response have independently concluded that p38&#945; inhibitors may find important applications in ALS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In February 2026, we announced that neflamapimod has been selected for inclusion in EXPERTS-ALS, a platform that facilitates rapid testing of potential ALS to identify promising drug candidates and potentially accelerate their path to regulatory approval. Funded by the United Kingdom National Institute for Health and Care Research and leading motor neuron disease charities and sponsored by Sheffield Teaching Hospitals NHS Foundation Trust, EXPERTS-ALS assesses potential therapies through a randomized, multicenter, open-label, multi-arm trial that evaluates investigational medicines through the measurement of the blood biomarker NfL. NfL levels are significantly elevated in ALS patients due to accelerated neuroaxonal damage and correlate with the rate of disability progression and survival. Neflamapimod will be initially evaluated in approximately 35 participants with ALS for 18-24 weeks to determine its impact on NfL levels, with the potential for further evaluation in up to a total of 80 patients. Secondary and exploratory endpoints include several clinical and survival measures. We anticipate the first patient will be dosed with neflamapimod in EXPERTS-ALS trial in the fourth quarter of 2026, subject to available funding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Additional Neflamapimod Development Background</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Toxicology</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A full chronic repeated dose toxicology program has been completed in rodents (rats) and non-rodents (dogs). In the rodent species, in the six-month chronic toxicology study, no human relevant findings were evident at dose levels that provided plasma neflamapimod drug concentration levels approximately ten-fold higher than those achieved in the CNS disease clinical trials. In shorter-term studies, the primary target organ was the liver, with findings commencing at plasma drug concentration levels 20-fold higher than the CNS clinical trial exposures. In the non-rodent species, in 9- and 12-month toxicology studies, dose dependent findings were evident beginning at plasma neflamapimod drug concentrations more than ten-fold higher than achieved with the doses utilized in our ongoing and anticipated clinical trials. The CNS findings indicated potential damage to axons, or nerve fibers, primarily in the spinal cord. p38&#945; and p38&#946; have been reported to have a role in transport of proteins in axons, and therefore we believe these toxicity findings are related to the inhibition of both p38&#945; and p38&#946; at the very high doses administered in the non-rodent studies. The plasma drug concentrations associated with doses we are using in our clinical trials in the US are at least ten-fold lower than the no adverse effect level for these effects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Regulatory Status</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We submitted an IND application to the FDA in February 2015. The FDA cleared our application in March 2015, and the IND remains open and active. In addition, the FDA granted neflamapimod Fast Track Designation for the treatment of DLB in October 2019 and Orphan Drug Designation for the treatment of frontotemporal dementia in November 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Following a review of the long-term animal toxicology studies discussed above, the FDA placed a partial clinical hold on our first Phase 2a Trial in mild AD (Study 303) in August 2015, limiting administration of neflamapimod to doses that lead to plasma drug levels which provide at least a 10-fold safety margin to the plasma drug levels in animals to the no adverse effect level in long-term animal toxicity studies . At the present time, based on agreements with the FDA and on our current understanding of plasma drug levels achieved with neflamapimod in humans, this partial clinical hold effectively limits our clinical dosing in the US in patients with a weight of greater than or equal to 50kg (110 pounds) to the plasma drug concentrations associated with doses we are using in our ongoing and anticipated clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In Europe, clinical trial applications in support of our clinical trials have been reviewed and approved in each of the Netherlands, United Kingdom, Czech Republic and Denmark. In addition, the Agence Nationale de S&#233;curit&#233; du M&#233;dicament et des Produits de Sant&#233; (the French national regulatory authority) has reviewed and approved a clinical trial application for an investigator-initiated study of neflamapimod in Toulouse, France. Our ongoing Phase 2a trial in Strasbourg, France, which is not subject to the FDA&#8217;s partial clinical hold, is evaluating an 80mg BID dosing regimen in participants with mild-to-moderate DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Clinical Safety Results</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Neflamapimod&#8217;s safety and tolerability profile has been extensively evaluated and is well understood. Specifically, long-term toxicology studies of neflamapimod have been completed and the drug has been administered to over 550 participants to date, including over 350 participants in Phase 2 clinical trials in CNS disorders. We also have several ongoing and planned clinical trials to further evaluate the safety, tolerability and PK profile of neflamapimod, including doses higher than the 40mg TID dose evaluated in our recent RewinD-LB Trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the RewinD-LB Trial, adverse events were similar to the safety profile seen in all other trials and are shown in the table below:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Overview of Treatment-emergent Adverse Events (TEAEs) (</b>&#8805;<b>5%) During the Randomized Phase (Safety Set) in Phase 2b RewinD-LB Study EIP21-NFD-504</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 0pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>System Organ Class</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Preferred Term</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-top: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Neflamapimod (40 mg</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TID) (N=79) n (%)</b></p>
			</td>
			<td style="border-width: 1px; border-style: solid; border-color: black black rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Placebo (N=80) n (%)</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Any TEAE</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">58 (73.4)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">59 (73.8)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Fall</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">12 (15.2)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">15 (18.8)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">COVID-19</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">8 (10.1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3 (3.8)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Diarrhea</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6 (7.6)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3 (3.8)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Urinary tract infection</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5 (6.3)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6 (7.5)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">URTI</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5 (6.3)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4 (5.0)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Headache</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5 (6.3)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">10 (12.5)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Fatigue</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5 (6.3)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">6 (7.5)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Dizziness</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4 (5.1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">3 (3.8)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Confusional state</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4 (5.1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1 (1.3)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Alanine aminotransferase increased</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4 (5.1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1 (1.3)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Back pain</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4 (5.1)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">1 (1.3)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 54.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 8pt;">Hallucination</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2 (2.5)</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 23.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-left: 1px solid black; border-right: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">5 (6.3)</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the Extension Phase of the RewinD-LB Trial, the profile remained similar with the following events reported by more than 5% of participants: fall, UTI, COVID-19, hallucination and diarrhea. In our previously completed clinical trials, the most commonly reported non-serious TEAEs included were headache, respiratory infection, diarrhea, fall, and somnolence all mild to moderate in severity. Headache, diarrhea, and somnolence appear to have the strongest association with neflamapimod treatment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of November 11, 2025, in clinical trials evaluating neflamapimod in patients with AD and DLB, there have been 44 SAEs reported in 273 participants treated with neflamapimod. The events of cerebral hemorrhage, syncope, pneumothorax, subcutaneous emphysema, and rib fracture were considered possibly related to neflamapimod by the trials&#8217; investigator(s).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">P38 MAPK inhibitors as a class have been associated liver enzyme elevations including transient, asymptomatic liver enzyme (transaminase) elevations without signs otherwise of hepatotoxicity (e.g., no elevation in bilirubin). ALT and AST and other liver function tests are routinely monitored in participants in neflamapimod clinical studies. Across the neflamapimod clinical development program, liver function testing elevations have been observed, primarily involving asymptomatic increases in ALT and AST. Most events were mild to moderate in severity, transient, and reversible upon dose interruption or discontinuation. No cases consistent with Hy&#8217;s Law were identified. Overall, the hepatic safety profile of neflamapimod supports continued clinical development with appropriate monitoring.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Among approximately 350 participants exposed to neflamapimod across the most recent clinical trials in AD, HD, DLB, recovery after stroke, and PPA, ALT or AST elevations &gt;3&#215; ULN were reported in 2 % of subjects. Elevations &gt;5&#215; ULN occurred in 0.2%, and elevations &gt;10&#215; ULN were uncommon (&lt;1%). Increases in total bilirubin were infrequent and generally not temporally associated with transaminase elevations. In the RewinD-LB Trial, one of 80 (1.3%) participants treated with neflamapimod discontinued because of liver enzyme elevation during the Randomized Phase but the event was determined to be reversible and not associated with bilirubin elevation. During the trial's Extension Phase, none of the 149 neflamapimod recipients discontinued for liver enzyme elevation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Nonclinical Studies </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Ts2 Transgenic Mice</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Nearly all individuals who have Down Syndrome, characterized by trisomic chromosome 21, develop AD by their fourth decade of life, and have typical AD pathology when autopsied at death. This may be explained by chromosome 21 containing the gene for amyloid-precursor-protein, which is the gene linked to familial or genetic EOAD in humans. The Ts2 transgenic mouse model of Down Syndrome utilizes mice that are partially trisomic at chromosome 16, which is the mouse equivalent of chromosome 21. Along with developmental behavioral abnormalities, Ts2 mice develop typical early onset dementia pathology, including endosomal abnormalities and cholinergic neurodegeneration in the BFC system. Accordingly, Ts2 mice provide an ideal opportunity to evaluate the effects of drug treatment on BFC dysfunction and degeneration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In a nonclinical study, wild-type mice, referred to as either wild-type or 2N, and Ts2 mice were treated over 28 days with either control or neflamapimod. Treatment was initiated at 6-7 months of age, representing a time point at which endosomal pathology and cholinergic neuronal loss is developing. To assess for effects on cholinergic neurodegeneration, ChAT+ neurons were quantitated in the region of the forebrain that is enriched for cholinergic neurons, which is known as the MSN.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">At the end of treatment, consistent with current scientific literature, the number of cholinergic neurons in the MSN region was significantly decreased in control-treated TS2 mice compared to control-treated wild-type mice (p&lt;0.001). This effect was reversed with neflamapimod treatment, with the number cholinergic neurons in the MSN increased in neflamapimod-treated Ts2 mice compared to vehicle-treated Ts2 mice, such that the number of ChAT+ neurons were similar to those seen in wild-type mice (p&lt;0.001). Neflamapimod treatment also normalized Rab5 activity and phosphorylated (i.e., activated) p38 MAP kinase and its downstream substrates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Neflamapimod restored numbers of cholinergic neurons in basal forebrain (i.e., reversed disease progression) in Ts2 transgenic mouse.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div style="text-align: center;"><img alt="mice.jpg" src="mice.jpg"/></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Cholinergic neurons, as assessed by staining positive for ChAT+ neurons in the MSN of the basal forebrain, in wild-type treated with vehicle or Ts2 transgenic mice after treatment for four weeks with either vehicle or neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The finding of reversal of disease progression is consistent with studies in the scientific literature that suggest that &#8220;loss&#8221; of cholinergic neurons in the BFC system is not due to cell death. Rather, the &#8220;degeneration&#8221; and loss of such BFC neurons appears to be due to a loss of cholinergic phenotype and functional properties, and neuronal shrinkage. In animal studies, all of this disease progression can be reversed, evidenced by the increased number of cholinergic neurons. This is not a regenerative effect, however. Rather, we believe it reflects that treatment with neflamapimod is restoring the function of diseased neurons, allowing them to express ChAT. There is also evidence from studies in early AD, that cholinergic phenotype loss, rather than frank neuronal death and loss, occurs in the basal forebrain of humans as well. We believe this is consistent with the results obtained from the MRI evaluation of neflamapimod-treated patients with AD discussed above in whom an increase in the volume of BFC neurons was observed in the NbM.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Aged Rat Model</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To obtain nonclinical proof-of-principle and confirm the role of p38&#945; in the development of synaptic dysfunction, we tested neflamapimod in a rat model of age-related cognitive decline. When evaluated in the Morris-Water-Maze test of spatial learning, rats show cognitive deficits starting at 20 to 22 months of age, which is equivalent to approximately 60 years of age in humans. Of note, because the deficits in Morris-Water-Maze performance can be fully reversed by implanting healthy cholinergic neurons in the basal forebrain, those deficits are believed to be due to BFC dysfunction and degeneration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The results of these nonclinical studies showed that treatment with neflamapimod fully reversed the learning deficits in the Morris-Water-Maze test in 20- to 22-month-old rats. Specifically, the performance of aged rats on the last day of testing (day 17) showed that animals treated with neflamapimod at the optimal dose performed significantly better than control&#8211;treated aged rats (p=0.007 for latency; p=0.01 for distance). Further, the performance of neflamapimod-treated aged rats was similar to that of young rats (i.e., cognitive deficits were fully reversed).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Vertex Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In August 2012, we entered into the Vertex Agreement, which granted us an option to acquire an exclusive worldwide license to develop and commercialize neflamapimod for the diagnosis, treatment and prevention of AD and other neurodegenerative diseases. This decision was made, in part, based on our team&#8217;s previous direct experience with this compound, our understanding of its profile, and emerging science around p38&#945; in the brain. In August 2014, we exercised that option to acquire the license to neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Vertex Agreement sets forth certain milestone events and the related payments we would be obligated to make to Vertex if and when such events occur. Each milestone payment is payable only once for each distinct licensed product, upon the first occurrence of the applicable milestone event. The first expected milestone events concern the filing of an NDA with the FDA for marketing approval of neflamapimod in the US and/or a similar filing for a non-US major market. The Vertex Agreement also provides that we will make royalty payments to Vertex in the event aggregate net sales for a commercialized licensed product meet specified thresholds. Such royalties will be on a sliding scale of percentages of net sales in the low- to mid-teens, depending on the amount of net sales in the applicable years. We are also obligated to make a one-time milestone payment to Vertex upon net sales reaching a certain specified amount in any 12-month period. The Vertex Agreement states that royalties will be reduced by 50% during any portion of the royalty term when there is no valid claim of an issued patent within specified patent rights covering the licensed product. We also have the right to deduct, on a country by country basis, from royalties otherwise payable to Vertex under the terms of the Vertex Agreement, 50% of all royalties, upfront fees, milestones and other payments paid by us or any of our affiliates or sublicensees to third parties under licenses that are necessary for the development, manufacture, sale or use of a licensed product, provided that in no event will the royalty payable to Vertex be reduced to less than 50% of the rates specified in the Vertex Agreement, subject to certain adjustments specified therein. In the aggregate, our potential milestone payment obligations, all of which relate to development milestones, under the Vertex Agreement are up to $117.0 million. To date, we have made an aggregate of $100,000 in payments to Vertex. In connection with our obligations under the Vertex Agreement, there is no minimum annual expenditure requirement. Our diligence obligations under the Vertex Agreement have included the making of annual expenditures in connection with the development of neflamapimod, completion of multiple Phase 2 clinical trials of neflamapimod, and our ongoing development efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Vertex Agreement provides that we may sublicense the rights granted to us by Vertex, in whole or in part, to a third party (through multiple levels of sublicensing) (i) who is providing services to us in connection with the manufacture or development of the licensed product, solely for the purpose of providing such services, or (ii) with the prior written consent of Vertex, which shall not be unreasonably withheld.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The license term under the Vertex Agreement is deemed to have commenced on August 21, 2014, and continues until the expiration of the royalty term, unless sooner terminated in accordance with the terms of the Vertex Agreement. The royalty term commences on the first commercial sale of a licensed product and ends upon the later of (i) the date of expiration, unenforceability or invalidation of the last valid claim of certain specified underlying patent rights, or (ii) ten years after the date of such first commercial sale. Upon the expiration of the royalty term, the license will convert to a perpetual, fully paid-up non-royalty bearing license with the same scope.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Vertex Agreement may be terminated by us for any reason upon 90 days&#8217; prior written notice to Vertex if such termination occurs before receipt of the first marketing approval of a licensed product, and otherwise upon twelve months&#8217; prior written notice to Vertex. Either party may terminate the Vertex Agreement if the other party is in material breach of its obligations thereunder, following a 60-day notice and cure period, or if the other party files for bankruptcy, reorganization, liquidation, receivership, or an assignment of a substantial portion of assets to creditors. The Vertex Agreement also provides that in the event we materially breach any of certain specified diligence obligations as to a specific major market, Vertex&#8217;s sole remedy for such breach, following the applicable notice and cure period, will be to terminate the license as to such specific major market country.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EIP200 </b>&#8211;<b> Novel Co-Crystal of Neflamapimod</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have an issued patent in the US, expiring in 2038, for novel co-crystals of neflamapimod with identified, specific, Generally Recognized as Safe compounds that have the potential to improve the solubility and other physical properties of neflamapimod. The development of one of these co-crystals as a product would be supported by composition of matter protection afforded by this patent, providing additional patent protection if we developed such a co-crystal product ourselves, the opportunity to license such a product to another pharmaceutical company while retaining the rights to neflamapimod and other potential benefits. The ability to develop one or more of these co-crystal products requires a fuller evaluation of the potential manufacturing processes than has been performed to date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">However, we believe these novel co-crystals of neflamapimod may provide additional optionality to multiple aspects of our development strategy, including related the partnering and/or commercialization of neflamapimod across the multiple indications in which it has demonstrated potential.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sales and Marketing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not currently have any infrastructure for the sales, marketing, or distribution of an approved DP. In order to market and successfully commercialize neflamapimod or any other future product candidate, to the extent it or they are approved, we must either develop these capabilities internally or make arrangements with third parties to perform these services. We may also collaborate with global or regional strategic partners that have experience in these fields. There are significant expenses and risks involved in establishing our own sales, marketing and distribution functions, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Alternatively, to the extent that we depend on third parties for such services, any revenues we receive will depend upon the efforts of those third parties, and there can be no assurance that such efforts will be successful.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not own or operate manufacturing facilities, nor do we have plans to develop our own manufacturing operations in the foreseeable future. Our lead product candidate, neflamapimod, is a small molecule drug that is manufactured using commercially available technologies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our DS is manufactured at established commercial CMOs that are approved for and manufactures DS both for investigational use and marketed products. We have used the same manufacturer for our neflamapimod DS in all our clinical trials prior to 2026 but have recently begun working with a second DS CMO to, in part, diversify our prior sole supplier risk. We anticipate utilizing these or similar CMOs for the manufacture of DS to be used in future clinical trials, as well as potentially for commercial use if neflamapimod is approved. However, supplies of our neflamapimod DS could be interrupted from time to time, and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also currently rely on a third-party CMO (different than those for DS) for the manufacture of our neflamapimod DP. We have used the same manufacturer for our neflamapimod DP in all our clinical trials to date but have recently begun working with a second DP CMO to, in part, diversify our prior sole supplier risk. If neflamapimod is ultimately approved for commercial sale, we expect to continue to rely on third-party contractors for manufacturing the DP. Although we may do so prior to any commercial launch, we have not yet entered into long-term agreements for the commercial supply of either drug substance or DP with our current manufacturing providers, or with any alternate manufacturers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For a further description of our planned pre-Phase 3 manufacturing improvements and certain risks related to our manufacturing, see &#8220;<i>Alignment with FDA on Planned Phase 3 Trial </i>&#8211;<i> Pre-Phase 3 Manufacturing Improvements,</i>&#8221; &#8220;<i>Item 1A. Risk Factors </i>&#8211;<i> Risks Related to Our Product Development and Regulatory Approval </i>&#8211;<i> Our reliance on third parties for the production of neflamapimod may result in delays in our clinical trials or regulatory approvals and may impair the development and ultimate commercialization of neflamapimod, which would adversely impact our business and financial position,</i>&#8221; and &#8220;<i>Item 1A. Risk Factors </i>&#8211;<i> Risks Related to Our Product Development and Regulatory Approval </i>&#8211;<i>&#160;Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i>&#8221;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Given the potential market opportunity for the treatment of DLB and other neurodegenerative diseases, an increasing number of established pharmaceutical firms and smaller biotechnology/biopharmaceutical companies are pursuing a range of potential therapies for these diseases in various stages of clinical development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">While there are numerous companies pursuing AD disease modifying approaches, we believe there are a limited number of companies in later-stage development for DLB. With regard to public biopharmaceutical companies that we would consider competitive with our approach, and actively evaluating treatments in DLB, we are aware of Cognition Therapeutics, Inc., although their lead indication remains AD and, in March 2026, they announced plans to advance zervimesine as a symptomatic treatment for DLB-related psychosis, rather than as a treatment for the underlying disease process. In addition, we are also aware of a recent NIA-supported, Phase 2 clinical trial of nilotinib, an FDA-approved leukemia drug, is evaluating its potential to break down abnormal alpha-synuclein proteins in DLB. However, we are not aware of any other companies developing a treatment specifically targeting DLB patients without AD co-pathology, the target patient population of our planned Phase 3 trial, or utilizing our mechanism of action.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize, including neflamapimod, may compete with existing therapies and new therapies that may become available in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our competitors may have significantly greater financial resources, an established presence in the market, and significantly greater expertise in research and development, manufacturing, nonclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The key competitive factors affecting the success of neflamapimod, and any other product candidates that we develop to address DLB and other CNS diseases, if approved, are likely to be their efficacy, safety, convenience, price, the level of competition, and the availability of reimbursement from government and other third-party payors. Our potential commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the US and in jurisdictions outside of the US related to our proprietary technology, inventions, improvements and our product candidates that are important to the development and implementation of our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have made a number of discoveries related to our lead product candidate, neflamapimod, which are reflected in ten main patent families, each of which we wholly own (dates below are without consideration of potential patent term extension, see section titled &#8220;&#8212;Patent Term Restoration&#8221; below):</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The first patent family relates to methods of treating patients suffering from AD, as well as methods of reducing amyloid plaque burden. In this family, we hold issued patents in the US, Europe, Japan, China, Canada, Australia, and Hong Kong. These patents are set to expire in 2032.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The second patent family relates to the use of neflamapimod for improving cognition. In this family, we hold issued patents in the US, Europe, and Japan. In China, we hold an issued patent related to improving cognition in certain conditions including improving functional recovery after stroke, as well as a pending application with respect to certain other claims. These patents are set to expire in 2035.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The third patent family relates to co-crystals of neflamapimod. In this family, we hold an issued patent in the US This patent is set to expire in 2038.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The fourth patent family relates to methods for promoting recovery of function in patients who have suffered acute neurologic injuries, including those resulting from various forms of stroke. In this family, we hold an issued patent in the US, Europe, and Japan, and pending applications in Korea and China. These patents are set to expire in 2035-2036.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The fifth patent family relates to methods of treating patients suffering from dementia. In this family, we have an issued patent in the US for the treatment of patients with MCI to improve episodic memory and a pending application in Europe, with respect to which we received in notice of allowance in late 2025. The issued patent in the US is set to expire in 2037, and other patents that issue in this family in the future, if any, are also expected to expire in 2037.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The sixth patent family relates to formulations of neflamapimod, including pharmaceutical compositions for oral administration exhibiting desirable PK and processes for the manufacture thereof. In this family, we have an issued patent in the US that is set to expire in 2039.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The seventh patent family relates to the treatment of DLB. In this family we have issued patents in Europe and Japan and pending applications in the US, Europe, Japan, China, Canada, and Hong Kong. Patents issued and that may issue in this family are expected to expire in 2040.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The eighth patent family relates to treatment of gait dysfunction related to neurodegenerative disease. In this family we have pending applications in the US, Europe, Japan, China, Canada, Australia, Hong Kong, and Israel. Patents that issue in this family, if any, are expected to expire in 2041.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The ninth patent family relates to treatment of a subpopulation of patients having DLB but no substantial Alzheimer&#8217;s like tau pathology (i.e., no AD co-pathology). In this family we have pending applications in the US, Europe, Japan, China, Canada, Australia, New Zealand, Korea, and Israel. Patents that issue in this family, if any, are expected to expire in 2042.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The tenth patent family relates to treatment of aphasia. In this family we have pending applications in the US and other jurisdictions. Patents that issue in this family, if any, are expected to expire in 2044.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the terms and conditions of the Vertex Agreement, Vertex has granted us an exclusive license under specified Vertex patent rights, including US patent No. 5,945,418, which relates to the composition of matter for neflamapimod. This patent expired in 2017.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the US are granted a term of 20 years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the USPTO delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements and invention assignment agreements with our collaborators, employees and consultants, as we determine necessary. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses from third parties or cease certain activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">From time to time, we may find it necessary or prudent to obtain licenses from third-party patent owners. Where licenses are available at reasonable cost, such licenses are considered a normal cost of doing business. In other instances, we may use the results of freedom-to-operate studies to guide our early-stage research away from areas where we are likely to encounter obstacles in the form of third-party intellectual property. We strive to identify potential third-party intellectual property issues in the early stages of research in our programs in order to minimize the cost and disruption of resolving such issues.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future drugs may have an adverse impact on us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For more information, please see &#8220;Item 1A. Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Regulation</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA and comparable regulatory authorities in other countries impose requirements upon companies involved in the clinical development, manufacture, marketing and distribution of drugs, such as those we are developing. These requirements can, in some instances, be substantial and burdensome. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of pharmaceutical products. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>US Government Regulation of Drug Products</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the US, the FDA regulates drugs under the FDCA and its implementing regulations. Failure to comply with the applicable US requirements at any time during the product development and approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve a pending NDA, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters or other notices of violation, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The process required by the FDA before a drug may be marketed in the US generally involves the following:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Completion of nonclinical laboratory tests, potentially animal studies, and formulation studies in compliance with the FDA&#8217;s GLP regulations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Approval by an IRB covering each clinical trial site before each trial may be initiated at that site;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Performance of adequate and well-controlled human clinical trials in accordance with GCP regulations and other clinical trial-related requirements to establish the safety and efficacy of the proposed DP for each indication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Submission to the FDA of an NDA seeking marketing approval;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A determination by the FDA within 60 days of its receipt of an NDA that the NDA is sufficiently complete to permit a substantial review, in which case the NDA is filed;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Satisfactory completion of FDA audits of clinical trial sites that generated data in support of the NDA to assure compliance with GCP regulations and the integrity of the clinical data and/or FDA audits of the nonclinical studies submitted as part of the NDA; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">FDA review and approval of the NDA, including consideration of the views of an FDA advisory committee, if one was involved, prior to any commercial marketing or sale of the drug in the US.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><i>Nonclinical Studies and IND</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Nonclinical studies generally include laboratory evaluation of product chemistry, toxicity and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for the investigational product&#8217;s therapeutic use. In December 2022, Congress amended the FDCA to specify that nonclinical testing for drugs may, but is not required to, include in vivo animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various in vitro assays (e.g., cell-based assays, organ chips, or microphysiological systems), in silico studies (i.e., computer modeling), other human or non-human biology-based tests (e.g., bioprinting), or <i>in vivo</i> animal tests. The conduct of nonclinical studies is subject to federal regulations and requirements, including GLP regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An IND sponsor must submit the results of preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational new drug to humans, and it must become effective before human clinical trials may begin. Some long-term nonclinical testing may continue even after the IND is submitted and clinical trials have been initiated. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA issues a notice expressly authorizing the proposed trial to proceed or raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. If the agency imposes a hold, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns or non-compliance. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Clinical Trials</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators (generally physicians not employed by or under the trial sponsor&#8217;s control) in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval of the trial by an IRB for each participating site. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, subject selection and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB acting on behalf of each institution participating in the clinical trial must review and approve the trial plan, informed consent forms, and communications to trial subjects before the trial commences at that institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are reasonable in relation to anticipated benefits, and whether the planned human subject protections are adequate. The IRB must continue to oversee the clinical trial while it is being conducted and must operate in compliance with FDA regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Sponsors of certain clinical trials generally must register such trials and disclose certain trial information within specific timeframes to the NIH for public dissemination on the ClinicalTrials.gov data registry. Information related to the investigational product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion, but such disclosures may be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical trial or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant party from receiving future grant funds from the federal government. Both the NIH and the FDA have brought enforcement actions against non-compliant clinical trial sponsors. Competitors may use the publicly available information about clinical trials to gain knowledge regarding the progress of development programs. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Phase 1</i>: The drug candidate is initially administered to healthy human volunteers and tested for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution, and excretion. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to administer ethically to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition. If possible, Phase 1 trials may also be used to gain an initial indication of product effectiveness.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Phase 2</i>: The drug candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more extensive clinical trials.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Phase 3</i>: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for its intended use, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product as well as an adequate basis for marketing approval. Historically, two adequate, well-controlled multicenter trials have been required by the FDA for drug product approval. However, in early 2026, the FDA announced it has changed the base standard to require a single adequate, well-controlled clinical trial plus certain confirmatory evidence to support approval, although the FDA has not yet clarified what types or amount of confirmatory data will be required.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Post-approval Trials: </i>Sometimes referred to as &#8220;Phase 4&#8221;&#160;clinical trials, these trials may be conducted after initial marketing approval and are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Reports detailing the progress of and safety data from the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the investigational drug, findings from animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. It is possible that Phase 1, Phase 2 or Phase 3 trials may not be completed successfully within any specified period, or at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated checkpoints based on access to certain data from the trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Congress amended the FDCA in December 2022 to require each sponsor of a Phase 3 clinical trial, or other &#8220;pivotal study&#8221; of a new drug to support MA, to design and submit a diversity action plan for such clinical trial. The action plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. A sponsor must submit a diversity action plan to the FDA by the time the sponsor submits the relevant clinical trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. If the FDA objects to a sponsor&#8217;s diversity action plan or otherwise requires significant changes to be made, it could delay initiation of the relevant clinical trial.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Concurrent with clinical trials, companies may perform additional nonclinical studies and develop additional information about a drug candidate&#8217;s physiochemical characteristics as well as finalize a process for its manufacturing in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final DP. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that a drug candidate does not undergo unacceptable deterioration over its proposed labeled shelf life. For a further description of our planned pre-Phase 3 manufacturing improvements to address the stability issues identified during our RewinD-LB Trial, see &#8220;<i>Alignment with FDA on Planned Phase 3 Trial </i>&#8211;<i> Pre-Phase 3 Manufacturing Improvements</i>&#8221; and &#8220;<i>Item 1A. Risk Factors </i>&#8211;<i> Risks Related to Our Product Development and Regulatory Approval</i><i>.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Marketing Application Submission, Review by the FDA, and Marketing Approval</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The NDA must contain proof of the product candidate&#8217;s safety and substantial evidence of effectiveness for its proposed indication or indications in the form of relevant data available from pertinent nonclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. In particular, a marketing application must demonstrate that the manufacturing methods and quality controls used to produce the DP are adequate to preserve the drug&#8217;s identity, strength, quality, and purity. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of the product, or from a number of alternative sources, including studies initiated by investigators. FDA approval of an NDA must be obtained before the corresponding drug may be marketed in the US.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under PDUFA, each NDA submission is subject to a substantial application user fee, and the sponsor of an approved NDA is also subject to an annual program fee. The FDA adjusts the PDUFA user fees on an annual basis. The application user fee must be paid at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for products with Orphan Drug designation or for the first application filed by a small business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA reviews all NDAs submitted to determine if they are substantially complete before it accepts them for filing and may request additional information rather than accepting a submission for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt and must inform the sponsor by the 74th day after the FDA&#8217;s receipt of the submission whether the application is sufficiently complete to permit substantive review. The FDA may refuse to file any submission that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the marketing application must be resubmitted with the additional information requested by the agency. The resubmitted application is also subject to review before the FDA accepts it for filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Once an NDA is accepted for filing, the FDA&#8217;s goal is to review the application within 10 months after it accepts the application for filing, or, if the application meets the criteria for &#8220;priority review,&#8221; within six months after the FDA accepts the application for filing. The review process is often significantly extended by FDA requests for additional information or clarification after the NDA has been accepted for filing. The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">During the review process, the FDA reviews the NDA to determine, among other things, whether the product is safe and effective and whether the facility in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued strength, quality, and purity. The FDA may refer any NDA, including applications for novel drug candidates which present difficult questions of safety or efficacy to an advisory committee to provide clinical insight on application review questions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations carefully when making final decisions on approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent manufacture of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies as part of the review process and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the PREA, amendments to the FDCA, an NDA or supplement to an NDA must contain data that are adequate to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric populations and to support dosing and administration for each pediatric population for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The PREA requires a sponsor that is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from pre-clinical studies, early-phase clinical trials or other clinical development programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. The FDA may not grant approval on a timely basis, or at all, and we may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing its products. After the FDA evaluates an NDA and conducts inspections of the manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing, information or clarification for the FDA to reconsider the application. The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. If a CRL is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. In September 2025, the FDA began publishing CRLs, with trade secret and confidential commercial information redacted, soon after issuing them to the respective sponsors, breaking with long-standing agency tradition of publishing CRLs with approval documentation after the product is approved. If and when the deficiencies cited in the CRL have been addressed to the FDA&#8217;s satisfaction in a resubmission of the marketing application, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If regulatory approval of a product is granted, such approval is limited to the conditions of use (e.g., patient population, indication) described in the application and may entail further limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS to obtain approval for the product. The FDA also may condition approval on, among other things, changes to proposed labeling (e.g., adding contraindications, warnings or precautions) or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. Some types of changes to an approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and separate FDA review and approval. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Fast Track, Breakthrough Therapy, Priority Review Designations, and CNPV</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#8217;s review and approval of new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track Designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast track Designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed, meaning that the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept the sections and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. A fast track Designated product candidate may also qualify for Accelerated Approval (described below) or Priority Review, under which the FDA sets the target date for FDA action on the NDA or biologics license application at six months after the FDA accepts the application for filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Priority Review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. If criteria are not met for Priority Review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, a sponsor may seek FDA designation of its product candidate as a Breakthrough Therapy if the product candidate is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy Designation provides all the features of fast track Designation in addition to intensive guidance on an efficient development program beginning as early as Phase 1, and FDA organizational commitment to expedited development, including involvement of senior managers and experienced review and regulatory staff in a proactive, collaborative, cross-disciplinary review, where appropriate. A drug designated as a Breakthrough Therapy is also eligible for Accelerated Approval if the relevant criteria are met.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In 2025, the FDA created a new pilot program called the CNPV with the goal of radically expediting the drug and biological product review and approval process. The agency may award a CNPV to a company or a specific product candidate that demonstrates alignment with certain national health priorities. The FDA aims to take action on a marketing application for which a CNPV is used within one to two months after the filing date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. None of these programs change the scientific or medical standards for approval or the quality of evidence necessary to support approval but may expedite the development or approval process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Accelerated Approval</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant Accelerated Approval for such a drug or biologic when it has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on IMM, and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug or biologic, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Accelerated Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, Accelerated Approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Accelerated Approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product candidate&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the product. Congress amended the FDCA in December 2022 to provide the FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs or biologics previously being considered for accelerated approval. Under the act&#8217;s amendments to the FDCA, the FDA may require the sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports are published on the FDA&#8217;s website. The amendments also give the FDA the option of using expedited procedures to withdraw product approval if the sponsor&#8217;s confirmatory trial fails to verify the claimed clinical benefits of the product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All promotional materials for product candidates being considered and approved under the Accelerated Approval program are subject to prior review by the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Orphan Drugs</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 individuals in the US, or a patient population greater than 200,000 individuals in the US and when there is no reasonable expectation that the cost of developing and making available the drug in the US will be recovered from sales in the US for that drug. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants Orphan Drug Designation, the generic identity of the therapeutic agent and its potential orphan indication are disclosed publicly by the FDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If a drug product that has Orphan Drug Designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan product exclusivity or if the FDA finds that the holder of the orphan product exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Orphan product exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application user fee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A drug with Orphan Drug Designation may not receive orphan product exclusivity if it is approved for a use that is broader than the indication for which it received Orphan Drug Designation. In addition, orphan product exclusive marketing rights in the US may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have obtained Orphan Drug Designation in the US for neflamapimod in frontotemporal dementia.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Patent Term Restoration</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Depending upon the timing, duration and specifics of FDA approval of our product candidates, some of our US patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act, informally known as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of the NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Pediatric Exclusivity</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pediatric exclusivity is a type of non-patent marketing exclusivity available in the US and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a written request does not require the sponsor to undertake the described studies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Hatch-Waxman Exclusivity</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In 1984, with passage of the Hatch-Waxman Act, which established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs based on an innovator or &#8220;reference&#8221; product, Congress also enacted Section 505(b)(2) of the FDCA, which provides a hybrid pathway combining features of a traditional NDA and a generic drug application. To obtain approval of a generic drug, an applicant must submit an ANDA to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the RLD.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if&#8201;&#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. Clinicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing clinicians or patient.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In contrast, Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2) NDAs may provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products; for example, an applicant may be seeking approval to market a previously approved drug for new indications or for a new patient population that would require new clinical data to demonstrate safety or effectiveness. A Section 505(b)(2) applicant may eliminate the need to conduct certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously-approved product is scientifically appropriate. Unlike the ANDA pathway used by developers of bioequivalent versions of innovator drugs, which does not allow applicants to submit new clinical data other than bioavailability or bioequivalence data, the 505(b)(2) regulatory pathway does not preclude the possibility that a follow-on applicant would need to conduct additional clinical trials or nonclinical studies. The FDA may then approve the new product for all or some of the label indications for which the RLD has been approved, or for any new indication sought by the Section 505(b)(2) applicant, as applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the RLD has expired. These market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing an NCE. For the purposes of this provision, an NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA or 505(b)(2) NDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification (described below), in which case the applicant may submit its application four years following the original product approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDCA also provides for a period of three years of exclusivity for an NDA, 505(b)(2) NDA or supplement thereto if one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. The three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving follow-on applications for drugs containing the original active agent. Five-year and three-year exclusivity also will not delay the submission or approval of a traditional NDA filed under Section 505(b)(1) of the FDCA. However, an applicant submitting a traditional NDA would be required to either conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Hatch-Waxman Patent Certification and the 30-Month Stay </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that the Section 505(b)(2) NDA applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Specifically, the applicant must certify with respect to each patent that:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the required patent information has not been filed by the original applicant;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the listed patent has expired;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the listed patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the new product.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If a Paragraph I or II certification is filed, the FDA may make approval of the application effective immediately upon completion of its review. If a Paragraph III certification is filed, the approval may be made effective on the patent expiration date specified in the application, although a tentative approval may be issued before that time. If an application contains a Paragraph IV certification, a series of events will be triggered, the outcome of which will determine the effective date of approval of the ANDA or 505(b)(2) application.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the follow-on applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the follow-on application in question has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. Alternatively, if the listed patent holder does not file a patent infringement lawsuit within the required 45-day period, the follow-on applicant&#8217;s ANDA or 505(b)(2) NDA will not be subject to the 30-month stay.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Post-Approval Requirements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations (i.e., &#8220;off-label use&#8221;) and limitations on industry-sponsored scientific and educational activities. The manufacturer and its products are also subject to similar post-approval requirements by regulatory authorities comparable to FDA in jurisdictions outside of the US where the products are approved. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or a supplement to an NDA, which may require the applicant to develop additional data or conduct additional nonclinical studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and DP containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. The manufacturing facilities for our product candidates must meet applicable cGMP requirements to the FDA's or comparable foreign regulatory authorities' satisfaction before any product is approved and our commercial products can be manufactured. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic prescheduled or unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by the FDA and other regulatory agencies may identify compliance issues at the facilities of our CMOs that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including voluntary recall and regulatory sanctions as described below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Once an approval or clearance of a drug is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Other potential consequences include, among other things:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Fines, warning letters or other enforcement-related letters, or clinical holds on post-approval clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Refusal of the FDA to approve pending marketing applications or supplements to approved MAs, or suspension or revocation of product approvals;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Product seizure or detention, or refusal to permit the import or export of products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Injunctions or the imposition of civil or criminal penalties;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; and/or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Mandated modification of promotional materials and labeling and the issuance of corrective information.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the distribution of prescription pharmaceutical products is subject to the PDMA, which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Most recently, the DSCSA was enacted with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the US The DSCSA mandates resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers. The DSCSA also replaced certain provisions from the PDMA pertaining to wholesale distribution of prescription drugs with a more comprehensive statutory scheme, requiring uniform national standards for wholesale distribution and, for the first time, for third-party logistics providers. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, whether FDA regulations, guidance or interpretations will be changed or what the impact of such changes, if any, may be.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Other US Health Care Laws and Regulations</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If our product candidates are approved in the US, we will have to comply with various US federal and state laws, rules and regulations pertaining to health care fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations of the fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. These laws include:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The federal AKS prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the AKS or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA or federal civil money penalties statute;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the federal False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221;&#160;the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221;&#160;to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">HIPAA imposes criminal and civil liability for executing a scheme to defraud any health care benefit program or making false statements relating to health care matters;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the CMS information related to payments and other transfers of value to physicians, certain advanced non-physician health care practitioners, and teaching hospitals or to entities or individuals at the request of, or designated on behalf of, such physicians, non-physician health care practitioners, and teaching hospitals as well as certain ownership and investment interests held by physicians and their immediate family members; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by nongovernmental third-party payors, including private insurers.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State and foreign laws also govern the privacy and security of personal data, including health information in some circumstances, and many such laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Due to the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that business activities can be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Ensuring that business arrangements with third parties comply with applicable healthcare laws and regulations is costly and time consuming. If business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s ability to operate its business and the results of its operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Pharmaceutical Coverage, Pricing, and Reimbursement</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of our products, when and if approved for marketing in the US, will depend, in part, on the extent to which our products will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. In addition, these third-party payors are increasingly reducing reimbursements for medical products, drugs and services. Furthermore, the US government, state legislatures and foreign governments have continued implementing cost containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Limited third-party reimbursement for our product candidates or a decision by a third-party payor not to cover our product candidates could reduce physician usage of our products once approved and have a material adverse effect on our sales, results of operations and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Healthcare Reform</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the US and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product and therapeutic candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product and therapeutic candidates that obtain marketing approval. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product and therapeutic candidates. In addition, future legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have historically operated. We cannot be sure whether additional legislative changes will be enacted, or whether any of the FDA&#8217;s regulations, guidances or interpretations will be changed, or what the impact of such changes on the agency and its scientific review staff, if any, may be. For example, negotiations on the next FDA user fee reauthorization package began in mid-2025 and the resulting agreement is expected to be sent to Congress in early 2027 for purposes of initiating the legislative process. Reauthorization of the prescription drug user fee program must be finalized by Congress by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for NDAs and other activities supported by user fees assessed against industry. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As previously mentioned, the primary trend in the US healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products and services, implementing reductions in Medicare and other healthcare funding and applying new payment methodologies. The US Congress has considered reductions in Medicare reimbursement levels for medicines administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for most drugs and biologics. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products we may market in the future. While Medicare regulations apply only to pharmaceutical benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In recent years, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for DPs. Notably, the CREATES Act was enacted to address concerns articulated by both the FDA and others in the industry that some brand manufacturers have improperly restricted the distribution of their products, including by invoking the existence of a REMS for certain products, to deny generic and biosimilar product developers access to samples of brand products. Because generic and biosimilar product developers need samples of an RLD to conduct certain comparative testing required by the FDA, some attributed the inability to timely obtain such samples as a cause of delay in the entry of generic and biosimilar products. To remedy this concern, the CREATES Act establishes a private cause of action that permits a generic or biosimilar product developer to sue the brand manufacturer to compel it to furnish the necessary samples on &#8220;commercially reasonable, market-based terms.&#8221; Although lawsuits have been filed under the CREATES Act since its enactment, those lawsuits have settled privately; therefore, to date no federal court has reviewed or opined on the statutory language and there continues to be uncertainty regarding the scope and application of the law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In August 2022, the IRA was signed into law. Among other things, the IRA has multiple provisions that may impact the prices of DPs that are both sold into the Medicare program and throughout the US For example, a manufacturer of a drug or biological product covered by Medicare Parts B or D must pay a rebate to the federal government if the DP&#8217;s price increases faster than the rate of inflation. This calculation is made on a DP by DP basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a DP that is paid for by Medicare Parts B or D. Additionally, CMS will negotiate drug prices annually for a select number of single-source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a DP is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities announcing the first round of negotiated &#8220;maximum fair&#8221; prices for the first ten drug products in August 2024, which will become applicable for payment year 2026. The second round of negotiated priced for 15 drug products was announced in November 2025, and CMS published the next group of drug products selected for negotiation in January 2026. However, the IRA&#8217;s impact on the pharmaceutical industry in the US remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the US Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Separately, the Trump Administration announced the creation of a government website called TrumpRx, which will allow consumers to purchase certain drugs at reduced prices as negotiated between the drug manufacturers and the administration. As of December 2025, the Trump Administration secured deals with five major drug manufacturers to offer certain drugs at most-favored-nation prices. In addition, recent US federal actions include initiatives incorporating most-favored-nation (international reference pricing) concepts for certain prescription drugs, as well as agency testing of new payment models that could tie Medicare reimbursement or manufacturer rebates to prices in specified reference countries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, in recent years, several states have formed PDABs. Much like the IRA&#8217;s drug price negotiation program, these PDABs have attempted to implement UPLs on drugs sold in their respective states in both public and commercial health plans. For example, in August 2023, Colorado&#8217;s PDAB announced a list of five prescription drugs that would undergo an affordability review. The effects of these efforts remain uncertain pending the outcomes of several federal lawsuits challenging state authority to regulate prescription drug payment limits. We expect that federal, state and local governments in the US will continue to consider legislation directed at lowering the total cost of healthcare. Furthermore, in December 2020, the US Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate PBMs and other members of the healthcare and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FTC in mid-2022 launched sweeping investigations into the practices of the PBM industry, and published interim reports with its findings in mid-2024 and January 2025, that appear to be contributing to additional federal and state legislative and regulatory proposals, as well as enforcement action and private litigation, targeting PBM operations, pharmacy networks, and financial arrangements. In February 2026, President Trump signed into law several PBM regulatory reforms as part of a federal budget package, including but not limited to requirements for PBMs to pass back 100% of rebates and fees to commercial health plan sponsors; to provide extensive informational disclosures related to patients&#8217; coverage and benefits; and to accept only bona fide service fees from drug companies when providing services under Medicare Part D. The Department of Labor also issued a proposed rule in January 2026 that would mandate specific PBM fee disclosures to self-insured plan fiduciaries under ERISA. If finalized as proposed, the Department of Labor rule would also allow plan fiduciaries to audit those PBM disclosures to confirm accuracy. Additional proposals and legislative changes aimed at PBMs and their business practices are likely to continue to be introduced and considered in Congress and by executive agencies. Significant efforts to change the PBM industry as it currently exists in the US may affect the entire pharmaceutical supply chain and the business of other stakeholders, including pharmaceutical developers like us. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the US or abroad. We expect that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Regulation Outside the United States</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For countries outside of the US, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, clinical trials must be conducted in accordance with GCP and the other applicable regulatory requirements. To the extent that any of our product candidates, once approved, are sold in a foreign country, we and our collaborators will be subject to applicable foreign laws and regulations, which may include, for instance, post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. If we or our collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, to market our future products in the EEA (which is comprised of the 28 Member States of the European Union plus Norway, Iceland and Liechtenstein) and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining an MA. There are two types of MAs:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The Community MA, which is issued by the European Commission through the Centralized Procedure, is based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, including medicines containing novel active substances to treat neurodegenerative disorders. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA (other than those intended for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, or viral diseases, which must be authorized through the Centralized Procedure), or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the procedures described above, before granting the MA the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In April 2023 the European Commission issued a proposal that will revise and replace the existing general pharmaceutical legislation, which was subsequently finalized and adopted in December 2025. The revisions will significantly change several aspects of drug development and approval in the European Union.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Data and Marketing Exclusivity</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon MA. The data exclusivity period prevents generic applicants from relying on the nonclinical and clinical trial data contained in the dossier of the reference product when applying for a generic MA in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic applicant from commercializing its product in the European Union until 10 years have elapsed from the initial authorization of the reference product in the European Union. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the MA holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Other Regulatory Requirements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are or may become subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the FDA has broad regulatory and enforcement authority, including, among other things, the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have an adverse effect on our ability to operate our business and generate revenues. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could negatively impact our business, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our People</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Overview</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2025, we had 15 employees, all of whom we classify as full-time employees. We had the same number of employees as of December 31, 2024. We consider the relationship with our employees to be good. We also engage outside consultants and contractors with unique expertise and skills for specific purposes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our success depends upon our ability to attract and retain highly qualified management and technical employees. Talent management is critical to our ability to execute our long-term growth strategy, including providing career growth, on-the-job learning opportunities and competitive compensation. We are committed to an inclusive culture which values equality, opportunity and respect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None of our employees are represented by labor unions or covered by collective bargaining agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Company Culture</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are committed to creating and maintaining a workplace free from discrimination or harassment, including on the basis of any class protected by applicable law, and our recruitment, hiring, development, training, compensation, and advancement practices are based on qualifications, performance, skills, and experience without regard to gender, race, ethnicity or other demographics. Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace, including adhering to the standards for appropriate behavior set forth in our code of conduct. An &#8220;open door&#8221; policy is maintained at all levels of the organization and any form of retaliation against an employee reporting or registering complaints in the event of any violation of our policies is strictly prohibited.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Compensation and Benefits</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We operate in a highly competitive environment, particularly as it relates to attracting and retaining talent with relevant experience in the biotechnology and pharmaceutical sectors. Therefore, we strive to provide our employees a total rewards package that is competitive with our peer companies. This package currently includes competitive salaries, a cash bonus plan, a comprehensive healthcare benefits package (including a 90% employer contribution to family medical coverage), unlimited paid time off, a company-sponsored 401(k) savings plan, short-term and long-term disability, and other benefits, as well as remote working and flexible work schedules. We also offer every full-time employee the opportunity to benefit financially from our potential future growth through stock option grants. As these grants generally vest over a three- or four-year period, we believe these grants also help promote retention and align the interests our employees and stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Employee Engagement, Safety and Wellness</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At CervoMed, the safety, health, and wellness of our employees is one of our top priorities. We are committed to developing and fostering a work environment that is safe and professional, promotes teamwork and trust, and affords all of our employees the opportunity to contribute to the best of their abilities. We have also made investments designed, in part, to support our employees' work-life balance, including, in recent years, investing in technology solutions to support increased work-from-home capabilities and moving to an unlimited paid leave policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Development and Training</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We strive to provide employees access to a broad set of internal resources intended to help them be successful, including a variety of training and educational experiences. We have also implemented a comprehensive employee evaluation program tied to the achievement of individual, team, and company goals to help further support, retain, and develop our people and further promote alignment of interests between our employees and our stockholders. In addition, many of our employees attend scientific, clinical, technological, and other meetings and conferences relevant to their area of expertise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Our Team</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have assembled a diverse team of experienced company builders and drug developers, complemented by an experienced Board and world-class scientific advisors. This group shares a long-term commitment to execute our strategy, advance the development of neflamapimod, and improve treatment outcomes and quality of life for patients suffering from age-related brain disorders. Moreover, we benefit from the significant pharmaceutical development experience of our management team members and directors, several of whom have worked on neflamapimod in the past at Vertex and are well acquainted with the unique properties of the compound for application in DLB and other potential target indications.</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Our Co-Founder, Director, President and Chief Executive Officer, John Alam, MD</i>, has more than 30 years&#8217;&#160;experience and is an industry leader in translational medicine. He has a proven track record of creating value through clinical development success, including having played major roles during the clinical development of five innovative drugs that are now on the market. Dr. Alam is an emerging drug development leader in neurodegenerative diseases, including having been the global head of all research and development activities directed towards neurodegenerative diseases at Sanofi S.A. (Nasdaq: SNY), a top ten global pharmaceutical company. Dr. Alam also has direct experience with neflamapimod from his time at Vertex, where he was Executive Vice President, Medicines Development, and Chief Medical Officer. Dr. Alam also led the clinical development of Biogen&#8217;s first approved drug for the treatment of multiple sclerosis, Avonex.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>Our Co-Founder and Director, Dr. Sylvie Gr</i>&#233;<i>goire, PharmD.,</i>&#160;has more than 30 years&#8217;&#160;experience and previously held executive leadership posts in several multinational life sciences firms. Dr. Gr&#233;goire also has extensive experience with corporate governance and board operations. She is currently chair of the board of directors of Abivax S/A (ABVX), a publicly-traded life sciences company, and on the board of directors of F2G, a private biotechnology company. Previously, Dr. Gr&#233;goire was chair of Corvidia Therapeutics (acquired by Novo Nordisk) and a member of the board of directors of Novo Nordisk A/S (NYSE: NVO), Revvity (Nasdaq: RVTY) (formerly known as PerkinElmer, Inc. (NYSE: PKI)), ViFor Pharma (acquired by CSL) and Cubist Pharmaceuticals (acquired by Merck).</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><i>The Chair of our Board, Joshua S. Boger, PhD</i>, has served in multiple scientific and business leadership roles during his multi-decade career. Dr. Boger founded Vertex in 1989 and served as its Chief Executive Officer from 1992 until 2009, and currently serves as an Investor Director of mOm Incubators, Ltd., a private, UK-based, medical device company. Prior to founding Vertex, Dr. Boger was Senior Director of Basic Chemistry at Merck Sharp &amp; Dohme Research Laboratories in Rahway, NJ, where he headed both the Departments of Biophysical Chemistry and Medicinal Chemistry of Immunology &amp; Inflammation.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Our Directors</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below sets forth, as of March 11, 2026, certain information concerning our current directors.</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 80%; margin-left: 0pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Age</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Director Since</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Joshua S. Boger, Ph.D. (Chair)</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">74</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2024</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">John Alam, M.D.</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sylvie Gr&#233;goire, PharmD.</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jane Hollingsworth, J.D.</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">67</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2020</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Jeff Poulton</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">58</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">David Quigley</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">58</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marwan Sabbagh, M.D.</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">60</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Frank Zavrl</p>
			</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">60</p>
			</td>
			<td style="vertical-align: top; width: 30%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">2023</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Our Executive Officers</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The table below sets forth, as of March 11, 2026, certain information concerning our current executive officers.</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 0pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Age</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Position</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">John Alam, M.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">64</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">President and Chief Executive Officer (Principal Executive Officer)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Kelly Blackburn, M.H.A.</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">62</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Executive Vice President, Clinical Development</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Mark De Rosch, Ph.D., FRAPS</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">62</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Executive Vice President, Regulatory and Govt. Affairs and Program Mgmt.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">William Elder</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">43</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer and General Counsel (Principal Financial Officer)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marco Verwijs, Ph.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">49</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Executive Vice President, Technical Operations</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Matthew Winton, Ph.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">48</p>
			</td>
			<td style="vertical-align: bottom; width: 11%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Commercial and Business Officer</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Our Scientific Advisory Board</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have assembled a highly qualified SAB comprised of thought leaders in the fields of cell biology, intracellular signal transduction, neurotherapeutics, and translational neuroscience.</p>

<table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 0pt; margin-right: auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Name</b></p>
			</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Affiliated Entity</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ole Isacson, Dr.Med.Sci.</p>
			</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professor of Neurology at Harvard Medical School, Founding Director of the Neuroregeneration Research Institute at McLean Hospital</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lewis Cantley, Ph.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professor of Cell Biology at Harvard Medical School. Prior to this appointment, he was the Margaret and Herman Sokol Professor and Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College/Ronald P. Stanton Clinical Cancer Program at New York Presbyterian Hospital (2012-22)</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 25%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Heidi McBride, Ph.D.</p>
			</td>
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Canada Research Chair in Mitochondrial Cell Biology, Professor in the Department of Neurology and Neurosurgery at McGill University</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Corporate Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Our History</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We were originally incorporated under the laws of the State of Nevada on January 10, 1995, and reincorporated under the laws of the State of Delaware on June 18, 2015. On August 16, 2023, we completed the Merger, which was treated as a "reverse recapitalization" under US GAAP pursuant to which EIP&#8217;s historical results of operations replaced the Company's for all periods prior to the Merger. Immediately following the closing of the Merger, we changed our name from "Diffusion Pharmaceuticals Inc." to "CervoMed Inc."</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Where to Find Us</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our principal corporate office is located at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116, and our telephone number is (617) 744-4400. Our website, www.cervomed.com, including the Investor Relations section, ir.cervomed.com, contains a significant amount of information about the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">However, the information included on our website is not incorporated by reference into, and should not be considered part of, this Annual Report or any other filings we make with the SEC.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Other Available Information</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We make available on or through our website certain reports that we file with or furnish to the SEC in accordance with Exchange Act. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K, as well as any amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The SEC also maintains a website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. We also make available, free of charge and through our website, the charters of the committees of the Board, our Corporate Governance Guidelines, and our Code of Business Conduct and Ethics.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1A.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>RISK FACTORS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Investing in our securities involves a high degree of risk. Set forth below are certain material risks and uncertainties known to us that could adversely affect our business, financial condition, or results of operations or could cause our actual results to differ materially from our expectations expressed in our filings with the SEC and other public statements. The occurrence of the events contemplated by one or more of the factors we describe below could cause the market price of our securities to decline, resulting in the loss of all or part of any investment in our common stock. Furthermore, other risks that are currently unknown to us or that we currently believe to be immaterial may also, nevertheless, adversely affect our business, financial condition, or results of operations in a way that is material.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>You should carefully consider the risk factors set forth below as may be updated by our subsequent filings under the Exchange Act together with all the other information in this Annual Report, including our consolidated financial statements and the related notes included in Part II, Item 8 </i>&#8211;<i> Financial Statements and Supplementary Data of this Annual Report and the information set forth in Part II, Item 7A -- Management</i>&#8217;<i>s Discussion and Analysis of Financial Condition and Results of Operations, as well as in our other filings with the SEC, before making any investment decisions. Furthermore, the risks and uncertainties described below and in the other information mentioned above are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could, nevertheless, adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Risk Factors</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We are a clinical stage biopharmaceutical company and have incurred significant losses since our inception. We expect our net losses to continue for the foreseeable future. We are not currently profitable and may never achieve or sustain profitability. We are unable to predict the extent of future losses or when it might become profitable, if ever. This raises substantial doubt regarding our ability to continue as a going concern.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We will require additional capital to fund our operations, including any Phase 3 trial evaluating neflamapimod in patients with DLB. If we fail to obtain necessary financing on acceptable terms, or at all, we may not be able to complete the development and commercialization of neflamapimod.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We currently do not have, and may never have, any products that generate significant revenues.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We are heavily dependent on the success of our lead product candidate, neflamapimod, which is still under clinical development. If neflamapimod does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. There is no guarantee that our planned clinical trials for neflamapimod to treat patients with DLB, or in any other indications that we may pursue, will be successful. If we are ultimately unable to obtain regulatory approval for neflamapimod on a timely basis, or at all, our business will be substantially harmed.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of neflamapimod or any other product candidates we may develop or acquire.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have concentrated our research and development efforts on the treatment of DLB, a disease that has seen limited success in drug development. The ability to successfully develop drugs for DLB and other age-related brain disorders is extremely difficult and is subject to a number of unique challenges. In addition, our rationale for neflamapimod in the treatment of DLB is based on a scientific understanding of the disease that may be wrong.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Results of nonclinical studies, early clinical trials, and analyses of open-label results, including the Extension Phase results from the RewinD-LB Trial, may not be indicative of results obtained in later large, well-controlled, randomized clinical trials. In addition, preliminary, topline and interim data from our clinical trials that we may announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We face substantial competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we do not adequately protect our proprietary rights, we may not be able to compete effectively.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for their future viability.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Even if neflamapimod or any other product candidate we develop receives marketing approval, it may fail to achieve the level of acceptance necessary for commercial success.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our future success depends in large part on our ability to retain our key employees, as well as our ability to attract, train and motivate additional qualified personnel. We may also encounter difficulties in managing our growth, which could disrupt our operations.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">AI presents risks and challenges that can impact our business including by posing security risks to confidential information, proprietary information, and personal data, as well as emerging, unknown business risks.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are a clinical stage biopharmaceutical company and have incurred significant losses since our inception. We expect our net losses to continue for the foreseeable future. We are not currently profitable and may never achieve or sustain profitability. We are unable to predict the extent of future losses or when we might become profitable, if ever. This raises substantial doubt regarding our ability to continue as a going concern.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval, and become commercially viable. We have incurred net losses in each fiscal year since our inception, and as of December 31, 2025, we had an accumulated deficit of approximately $97.7 million. We expect to incur net losses for the foreseeable future as we incur significant clinical development costs related to the advancement of neflamapimod. We have not commercialized any products and have never generated revenue from neflamapimod or any other product. In order to obtain revenues from any product candidate, we must succeed, either alone or in collaboration with others, in developing, obtaining regulatory approval for, and manufacturing and marketing drugs with significant market potential. We may never succeed in these activities and may never generate revenues that are significant enough to achieve profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect to incur significant additional operating losses for at least the next several years as we advance neflamapimod through clinical development, conduct clinical trials, seek regulatory approval, and commercialize neflamapimod, if it is ultimately approved for marketing. The costs of advancing product candidates into each successive clinical phase of the clinical development process tend to increase substantially. Therefore, the total costs to advance neflamapimod to marketing approval in even a single jurisdiction will be substantial. Due to the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses, or when or if we will be able to begin generating revenue from the commercialization of neflamapimod, let alone achieve or maintain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The amount of our future net losses will depend, in part, on the rate of future growth of our expenses, if and when neflamapimod is approved for marketing in various jurisdictions and our ability to generate revenues from any drug candidate that may ultimately be approved. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain it, which could materially and adversely affect our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As discussed further in Note 2 to our consolidated financial statements included elsewhere in this Annual Report, we have a history of operating losses and expect to continue to incur losses in the foreseeable future, which raises substantial doubt regarding our ability to continue as a going concern within one year after the date our consolidated financial statements are issued. As described in further detail elsewhere in this Annual Report, our ability to continue as a going concern is dependent on our ability to raise capital and pursue our business strategies to fund operations and future business plans. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We intend to continue to seek funds through equity offerings, debt financings, royalty arrangements, or other dilutive or non-dilutive capital sources, including potential collaborations, licenses and/or other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise sufficient capital when needed, we may need to delay, reduce or terminate planned activities to reduce costs, including development or commercialization activities for neflamapimod. We might also be required to seek funds through arrangements with third parties that require us to relinquish certain of our rights to neflamapimod or otherwise agree to terms unfavorable to us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, volatility in the capital markets and general economic and geopolitical conditions in the US and globally may be a significant obstacle to raising the required funds as and when needed. Our consolidated financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. If the going concern basis were not appropriate for these consolidated financial statements, adjustments would be necessary in the carrying value of assets and liabilities, the reported expenses, and the balance sheet classifications used. If we are unable to continue as a going concern, our stockholders could suffer the loss of all or a substantial portion of their investment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will require additional capital to fund our operations. If we fail to obtain necessary financing on acceptable terms, or at all, we may not be able to complete the development and commercialization of neflamapimod.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect to spend substantial amounts to complete the development of, seek regulatory approvals for, and commercialize neflamapimod, if it is ultimately approved for marketing. These expenditures will include costs related to our planned clinical trials and costs associated with our license agreement with Vertex, under which we are obligated to make certain payments in connection with the achievement of specified events.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Until such time, if ever, that we can generate sufficient product revenue and achieve profitability, we expect to seek to finance future cash needs through equity or debt financings and/or corporate collaboration, licensing arrangements and grants. Based upon our current operating plan, we believe that our cash and cash equivalents as of December 31, 2025, will not be sufficient to enable us to fund our operating expenses and capital expenditure requirements for a period of at least 12 months following the issuance of the consolidated financial statements included elsewhere in this Annual Report without an additional equity or debt financing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">However, our estimates and expectations regarding our cash runway are based on assumptions that may prove to be incorrect, and changing circumstances could cause us to consume capital faster or in different ways than we currently expect. For example, our planned clinical trials may be more expensive, time-consuming, or difficult to implement than we currently anticipate. Because the length of time and activities associated with the successful development of neflamapimod are highly uncertain, we are unable to estimate the actual funds we will require to complete research and development and ultimately commercialize our drug candidate for one or more indications.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the enrollment, progress, timing, costs and results of our ongoing and future clinical trials evaluating neflamapimod in DLB and other indications;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to reach certain milestone events set forth in our collaboration agreements and the timing of such achievements, triggering obligations to make applicable payments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the hiring of additional clinical, scientific and commercial personnel to pursue our development plans, as well the increased costs of internal and external resources as to support our operations as a public reporting company;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the cost and timing of securing manufacturing arrangements for clinical or commercial production;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the cost of establishing, either internally or in collaboration with others, sales, marketing and distribution capabilities to commercialize neflamapimod, if approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the cost of filing, prosecuting, enforcing, and defending our patent claims and other intellectual property rights, including defending against any patent infringement actions brought by third parties against us;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the ability to receive additional non-dilutive funding, including our grants from organizations, foundations, and governmental entities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to establish strategic collaborations, licensing or other arrangements with other parties on favorable terms, if at all; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the extent to which we may in-license or acquire other product candidates or technologies.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may raise additional capital in the future through a variety of sources, including public or private equity offerings, debt financings, grant funding, or strategic collaborations and licensing arrangements. However, adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative effect on our financial condition and our ability to pursue our business strategy. If we are unable to secure additional capital in sufficient amounts or on terms acceptable to us, we may have to delay, scale back or discontinue our development or commercialization activities for neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, current stockholder&#8217;s ownership interest in us will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. Even if we were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to us or our stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We currently do not have, and may never have, any products that generate significant revenues.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a clinical-stage biopharmaceutical company focused on developing treatments for age-related brain disorders, currently have no products that are approved for commercial sale, and it is possible we may never be able to develop a marketable product. To date, we have not generated any revenues from our lead product candidate, neflamapimod, or from any other product candidate. We cannot guarantee that neflamapimod, or any other product candidate that we may develop or acquire in the future, will ever become a marketable product.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug products are subject to extensive regulation in the US and in other countries. Before the FDA and other regulatory authorities in the European Union and elsewhere will approve neflamapimod (or any other drug candidate) for commercialization, we must demonstrate that it satisfies rigorous standards of safety and efficacy for each of its intended uses. If approved, in order to compete effectively in the commercial marketplace, drugs must be easy to administer, cost-effective and economical to manufacture on a commercial scale. We may not achieve any of these objectives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot be certain that our ongoing trials or any future clinical development of neflamapimod will be successful, or that it will receive the regulatory approvals required to commercialize neflamapimod for any intended use, or that any future research and drug discovery programs undertaken by us will yield a drug candidate suitable for investigation through clinical trials. Even if we are able to successfully develop neflamapimod through approval and commercialization, any revenues from sales of the drug may not materialize for several years, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be required to make significant payments to Vertex in connection with our license agreement.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the Vertex Agreement, we previously acquired an exclusive license to develop and commercialize neflamapimod for the diagnosis, treatment, and prevention of AD and other CNS disorders. Under the Vertex Agreement, we are subject to significant potential future obligations, including payment of development milestones and royalties on net product sales, as well as other material obligations. The Vertex Agreement sets forth specific regulatory and product approval events and the related payments that we would be obligated to make to Vertex, if and when such events occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Among other obligations, the Vertex Agreement provides that we will make royalty payments to Vertex in the event aggregate net sales for a commercialized licensed product meet specified thresholds, subject to adjustment in the event of certain events, such as the absence of a valid patent claim or if fees are due to a third party for a license necessary for the development, manufacture, sale or use of a licensed product. Such royalties will be on a sliding scale as a percentage of net sales, depending on the amount of net sales in the applicable years. We are also obligated to make a milestone payment to Vertex upon net sales reaching a certain specified amount in any 12-month period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The first expected milestone events concern filing of an NDA with the FDA for marketing approval of a licensed product in the US, or a similar filing for a non-US major market. Thus, although we do not expect any milestone or royalty payments to be due until such time, these potential obligations represent significant cash amounts that we may ultimately be obligated to pay. We cannot guarantee that we will have sufficient funds available to meet our obligations if and when these payments become due. The obligation to pay some or all of these milestone and royalty amounts may materially harm our development efforts, as well as our overall financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We intend to focus our limited financial and other resources on developing neflamapimod and future product candidates for specific indications that we identify as most likely to succeed, in terms of both regulatory approval and commercialization. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that may prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Spending on current and future research and development programs and on product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business may be impacted by macroeconomic conditions, including fears concerning the financial services industry, inflation, volatility in interest rates and volatile market conditions, and other uncertainties beyond our control. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. Our ability to effectively run our business could be adversely affected by general conditions in the global economy and in the financial services industry. Various macroeconomic factors could adversely affect our business, including fears concerning the banking sector, volatility in inflation and interest rates and overall changes in economic conditions and uncertainties. A severe or prolonged economic downturn could result in a variety of risks, including our ability to raise additional funding on a timely basis or on acceptable terms, or at all. A weak or declining economy could also impact third parties upon whom we depend to run our business. Concerns over bank failures and bailouts and their potential broader effects and potential systemic risk on the banking sector generally and on the biotechnology industry and its participants may adversely affect our access to capital and our business and operations more generally. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain regulatory limitations may affect our ability to consummate future financings.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If our public float as measured pursuant to General Instruction I.B.6 to Form S-3 falls below $75 million, we will be subject to the restrictions set forth in General Instruction I.B.6 to Form S-3 that limit our ability to conduct primary offerings under a Form S-3 registration statement to one-third of our public float in any 12 calendar months &#8211; often referred to as the &#8220;baby shelf rules.&#8221; As of March 11, 2026, our public float calculated in accordance with General Instruction I.B.6 of Form S-3 was approximately $47.5&#160;million and, accordingly, we will be limited by the &#8220;baby shelf rules&#8221; unless and until our public float as measured pursuant to General Instruction I.B.6 to Form S-3 exceeds $75 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We could be subject to audit and repayment of the NIA Grant.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In connection with the NIA Grant, we may be subject to routine audits by certain government agencies. As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations, policies and standards and the terms and conditions of the applicable NIA Grant. If any of our expenditures are found to be unallowable or allocated improperly or if we have otherwise violated terms of the NIA Grant, the expenditures may not be reimbursed and/or we may be required to repay funds already disbursed. Any such audit may result in a material adjustment to our results of operations and financial condition and harm our ability to operate in accordance with our business plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Product Development and Regulatory Approval</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We are heavily dependent on the success of our lead product candidate, neflamapimod, which is still under clinical development. If neflamapimod does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have invested almost all of our efforts and financial resources to date in the development of neflamapimod. To date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidate, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful product commercialization. Our future success is substantially dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and successfully commercialize neflamapimod as a treatment for DLB and additional indications, which may never occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We expect a substantial portion of our efforts and expenditures over the next few years will be devoted to the advancement of neflamapimod&#8217;s clinical development. In order to be successful, we will need to successfully manage clinical and manufacturing activities, the pursuit of regulatory approval in multiple jurisdictions, securing manufacturing supply, building a commercial organization, and significant marketing efforts, among other requirements, before we can generate any revenues from commercial sales. We cannot be certain that we will be able to successfully complete any or all of these activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, we have not submitted an NDA to the FDA or comparable applications to other regulatory authorities for neflamapimod, and we do not expect to be in a position to do so in the near future, if ever. Significant additional clinical testing and research will be required before we can file an NDA or any other application seeking approval of neflamapimod for the treatment of DLB, or any other indication. If we are unable to obtain the necessary regulatory approvals for and commercialize neflamapimod, it would materially adversely affect our financial position, and we may not be able to generate sufficient revenue to continue our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The development and commercialization of drug products is subject to extensive regulation, and the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. There is no guarantee that our planned clinical trials for neflamapimod to treat patients with DLB, or in any other indications that we may pursue, will be successful. If we are ultimately unable to obtain regulatory approval for neflamapimod on a timely basis, or at all, our business will be substantially harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Clinical trials are expensive and can be difficult to design and implement. Such trials can take many years to complete, and their outcomes are inherently uncertain. Failure can occur at any stage during the clinical development process. We may experience difficulties in initiating and completing the clinical trials that we intend to conduct, and we do not know whether such trials will enroll patients on time, need to be redesigned, or be completed on schedule, if at all. In connection with designing and conducting our clinical trials, we face significant risks, including that our product candidate may not prove to be efficacious, patients may suffer adverse effects for reasons that may or may not be related to the product candidate being tested, the results may not confirm the positive results of our earlier nonclinical studies and clinical trials, the FDA may disagree with our interpretation of the clinical trial data or how those data inform the design of future clinical trials, and the results may not meet the level of statistical significance required by the FDA or other regulatory agencies to support approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot predict with any certainty if or when we might complete our development efforts and submit an NDA for regulatory approval of neflamapimod, or whether any such NDA will be approved by the FDA. An NDA or comparable foreign submission seeking marketing approval for neflamapimod also may not be accepted by FDA or foreign regulatory authorities due to, among other reasons, the content or formatting of the submission.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failure to obtain regulatory approval to market neflamapimod as a treatment for DLB or any other indication, which would significantly harm our business, results of operations, and prospects. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any new product candidate. Accordingly, even if we believe the data collected from our clinical trials are promising, such data may not be sufficient to support approval by the FDA or any comparable foreign regulatory authority. As a result, we may be required to conduct additional nonclinical studies, alter our proposed clinical trial designs, or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market neflamapimod or any of other product candidates, if approved.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are also generally required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, such as ClinicalTrials.gov in the US, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of neflamapimod or any other product candidates we may develop or acquire.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The risk of failure in drug development is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, a company must complete nonclinical development and conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical trials are expensive, difficult to design and implement and can take several years to complete, and their outcomes are inherently uncertain with the potential for failure at any time during the clinical development process. Nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in nonclinical studies and early-stage clinical trials have nonetheless failed to obtain marketing approval of their products. It is impossible to predict when or if neflamapimod will receive marketing approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may experience numerous unforeseen events during, or as a result of, our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize neflamapimod for DLB or any other indication. Clinical trials may be delayed, suspended or prematurely terminated because costs are greater than we anticipate or for a variety of other reasons, such as:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able to execute;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delay or failure in obtaining authorization to commence a trial, including approval from the appropriate IRB or ethics committee at each clinical site to conduct testing of a candidate on human subjects, or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">inability, delay or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">inability, delay or failure in identifying, recruiting, and training suitable clinical investigators;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delay or failure in recruiting, screening, and enrolling suitable subjects to participate in a trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delay or failure in having subjects complete a trial or return for post-treatment follow-up;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays caused by operational issues at clinical trial sites, including insufficient staffing;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">changes to the clinical trial protocols and/or changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical sites and investigators deviating from the clinical protocol, failing to conduct the trial in accordance with GCP or other regulatory requirements, or dropping out of a trial;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure to initiate or delay of or inability to complete a clinical trial as a result of the authorizing IND or foreign clinical trial application being placed on temporary or permanent clinical hold by the FDA or comparable foreign regulatory authority;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">lack of adequate funding to continue a clinical trial, including as a result of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials and increased expenses associated with the services of our CROs and other third parties, or the cost of clinical trials being greater than we anticipated;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of DP for use in clinical trials or the inability to do any of the foregoing;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">developments on trials conducted by competitors for related technology that raise FDA or foreign regulatory authority concerns about risk to patients of a technology or in any indication more broadly;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical studies, clinical trials or abandon product development programs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulators, the IRB or a Data Safety Monitoring Board if one is used for our clinical trials, may require that we suspend or terminate our clinical trials for various reasons, including noncompliance with regulatory requirements, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, or a finding that the participants are being exposed to unacceptable health risks;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">transfer of manufacturing processes to larger-scale facilities operated by a CMO, and delays or failure by our CMOs or we to make any necessary changes to such manufacturing process;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA or comparable foreign regulatory authorities may require us to submit additional data or impose other requirements before permitting us to initiate a clinical trial; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">changes in governmental regulations or administrative actions.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for neflamapimod or any other future product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after the FDA has reviewed and commented on the design for our clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are required to conduct additional clinical trials or other nonclinical studies of neflamapimod in various disease conditions beyond those that we currently contemplates, or we are unable to successfully complete clinical trials of our product candidates or other studies, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">be delayed in obtaining marketing approval for our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">not obtain marketing approval for our product candidates at all;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings that would reduce the potential market for our products or inhibit our ability to successfully commercialize our products;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">be subject to additional post-marketing restrictions or requirements, including post-marketing testing; or</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">have the product removed from the market after obtaining marketing approval.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any failure or delay in commencing or completing clinical trials or obtaining regulatory approvals for neflamapimod would delay our commercialization prospects, substantially increase the costs of commercializing neflamapimod, and severely harm our business and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As product candidates progress through nonclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, if we change the formulation of neflamapimod, this could increase our costs and/or could delay regulatory approval.</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any of these changes could cause our product candidate to perform differently and affect the results of clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. In connection with alternative formulations or other changes to any of our product candidates, the FDA and other regulatory authorities may require additional studies, including bridging studies, which may significantly delay our clinical trial timelines and potential regulatory approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have concentrated our recent research and development efforts on the treatment of DLB, a disease that has seen limited success in drug development. The ability to successfully develop drugs for DLB and other age-related brain disorders is extremely difficult and is subject to a number of unique challenges. In addition, our rationale for neflamapimod in the treatment of DLB is based on a scientific understanding of the disease that may be wrong.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Drug development in the field of brain diseases, including age-related brain disorders and other neurodegenerative diseases in particular, has seen very limited success historically. There have been limited efforts by biopharmaceutical and pharmaceutical companies to develop treatments for DLB and there are no therapies available for patients that have been approved with a specific indication to treat DLB. Only symptomatic therapies that are approved for other diseases, generally either AD or PD, are currently utilized to manage patients with DLB. In addition, many potential disease-modifying therapies have been evaluated in other neurodegenerative diseases, particularly in AD, and these have encountered challenges in their development and, as a result, only recently two disease-modifying treatments to treat AD have been approved in the US Developing a product candidate for treatment of these brain diseases is extremely difficult and subjects us to a number of challenges, including obtaining regulatory approval from the FDA and other regulatory authorities who have only a limited set of precedents to rely on.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our approach to the treatment of DLB focuses in large part on neflamapimod&#8217;s ability to inhibit the intra-cellular enzyme p38&#945;. The expression of p38&#945; is considered to be a critical contributor in the toxicity of inflammation, alpha-synuclein, amyloid-beta and tau to neurons and synapses, which we and other scientific experts believe leads to synaptic dysfunction. Synaptic dysfunction, specifically impaired synaptic plasticity, leads to disruption of episodic memory and is a significant event in the development and symptomatology of DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">However, we cannot be certain that our approach will lead to the development of approvable or marketable products. To date, there has never been an approval of a drug in DLB and therefore, there are no regulatory precedents for endpoints in that indication. Consequently, the FDA has a limited set of products to rely upon in evaluating neflamapimod. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of neflamapimod for the treatment of DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may result in further negative perception of the likelihood of success in this field, which may significantly and adversely affect our business and the market price of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Clinical results observed in our Phase 1, Phase 2 and open-label clinical trials, including the 16-week Extension phase data from the RewinD-LB Trial, evaluating neflamapimod are not regulatory evidence of drug safety or efficacy.</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Data results from our non-Phase 3 studies do not constitute, and should not be interpreted as, regulatory evidence of safety or efficacy for neflamapimod in DLB or any other indication. Rigorous evidence for drug safety and efficacy is derived from one or more large, randomized, placebo-controlled studies. The size and open-label design of portions of our non-Phase 3 studies may introduce clinical or statistical bias or may generate results that may not fully distinguish between drug effects and random variation. Different methods of statistical analysis on clinical data from the same study may lead to objectively different numerical results. These and other statistical and clinical features of our non-Phase 3 studies add complexity or limitations to the scope of data interpretation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, conclusions based on data from analyses of Phase 1 and Phase 2 clinical studies and open-label results may not be reproduced when implemented in large, well-controlled, randomized clinical trials. Particular caution should be exercised when interpreting preliminary data, data relating to a small number of patients and data from open-label uncontrolled studies, which are generally not capable of providing interpretable evidence of efficacy. There can be no assurance that future large, well-controlled, multi-dose studies will demonstrate the safety, tolerability or efficacy of neflamapimod to treat patients with any indication, including DLB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if our clinical trials for neflamapimod are completed as planned, we cannot be certain that their results will support the substantial evidence of safety and efficacy needed to obtain regulatory approval. The failure of neflamapimod to show safety, tolerability or efficacy in any future clinical studies would significantly harm our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Enrollment and retention of participants in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of research participants who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of individuals to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of participants to complete any of our trials. Subject enrollment and retention in clinical trials depends on many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the eligibility criteria defined in the protocol;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the nature of the trial protocol;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the proximity of potential subjects to clinical sites;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the existing body of safety and efficacy data with respect to the product candidate;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our ability to recruit clinical trial investigators with the appropriate competencies and experience;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">clinicians&#8217;&#160;and patients&#8217;&#160;perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">competing clinical trials being conducted by other companies or institutions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the risk that participants enrolled in clinical trials will drop out of the trials before completion; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the operational efficiency of trial sites, including sufficient staffing.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the US Congress recently amended the FDCA to require sponsors of a Phase 3 clinical trial or other &#8220;pivotal study&#8221; of a new drug or biologic to support MA, to design and submit a diversity action plan for such clinical trial. The action plan must describe appropriate diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Although none of our product candidates has reached Phase 3 of clinical development, we or our licensing partners must submit a diversity action plan to the FDA by the time a Phase 3 trial, or pivotal study, protocol is submitted to the agency for review, unless we or our licensing partners are able to obtain a waiver for some or all of the requirements for a diversity action plan. Initiation of such trials may be delayed if the FDA objects to a proposed diversity action plans for any future Phase 3 trial of our product candidates. We or our licensing partners may experience difficulties recruiting a diverse population of patients in attempting to fulfill the requirements of any approved diversity action plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, any negative results we may report in clinical trials may make it difficult or impossible to recruit and retain subjects in other clinical trials of that same product candidate. Delays or failures in planned enrollment or retention of clinical trial subjects may result in increased costs or program delays, which could have a harmful effect on our ability to develop a product candidate or could render further development impossible.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Results of nonclinical studies, early clinical trials, and analyses of open-label results, including the Extension Phase results from the RewinD-LB Trial, may not be indicative of results obtained in later large, well-controlled, randomized clinical trials. In addition, preliminary, topline and interim data from our clinical trials that we may announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The results of nonclinical studies and early clinical trials of a product candidate, including neflamapimod, may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry, both generally and in the DLB treatment space in particular, have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Even if our clinical trials for neflamapimod are completed as planned, including any future Phase 3 trial, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval, and we may decide, or regulators may require it, to conduct additional clinical trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, from time-to-time, we may announce or publish preliminary, topline, or interim data from our clinical trials, which are based on a preliminary analysis of then-available data. Such results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, which may prove to be incomplete or flawed, and we may not have received or had the opportunity to fully and carefully evaluate all data. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary and interim data are not necessarily predictive of final results and should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in nonclinical studies and clinical trials have nonetheless failed to obtain approval from the FDA, the EMA or other regulatory agencies for their products. Others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and we in general.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. Others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding neflamapimod, a future product candidate, or our business. If the interim, preliminary, or topline data that we report differ from later, final or actual results, or if others, including the FDA and comparable foreign regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and, if approved, commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Regulatory authorities, including the FDA, may not accept data from clinical trials conducted outside of their jurisdiction.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have in the past and may in the future conduct additional clinical trials evaluating our product candidates, including neflamapimod, outside the US The acceptance of trial data from clinical trials conducted outside the US by the FDA may be subject to certain conditions or may not be accepted at all, and other comparable non-US regulatory authorities may have similar restrictions and conditions with respect to clinical trials conducted outside of their jurisdiction. In cases where data from non-US clinical trials are intended to serve as the basis for marketing approval in the US and the trial is not conducted under the IND, the FDA will generally not accept such foreign trial data unless: (i) the data are determined to be applicable to the US population and US medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the FDA is able to validate the data through an onsite inspection, if necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many comparable non-US regulatory authorities have similar approval requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There can be no assurance that the FDA will accept data from trials conducted outside of the US or that any comparable non-US regulatory authority will accept data form trials conducted outside of the applicable jurisdiction. If the FDA or any comparable non-US regulatory authority does not accept such data or believes that additional data is necessary to supplement such data, it would result in the need for additional trials, which would be costly and time-consuming, could delay a product candidate&#8217;s development plan, and which may result in product candidates not receiving approval for commercialization in the applicable jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Conducting clinical trials outside the US may also expose us to additional risks, including risks associated with the following, among other things: additional foreign regulatory requirements; foreign exchange fluctuations; compliance with foreign manufacturing, customs, shipment and storage requirements; the failure of enrolled subjects in foreign countries to adhere to clinical protocol as a result of differences in standard-of-care; cultural differences in medical practice and clinical research; diminished protection of intellectual property rights; and compliance with general local legal requirements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In August 2024, we initiated a Phase 2a study in Strasbourg, France, to evaluate a twice daily regimen (80mg BID) of neflamapimod in up to 25 patients with DLB with MCI (MoCA score &#8805;&#160;18 during screening). The primary objective of the study is to obtain additional PK data on a dosing regimen not previously used in any of our clinical trials (80mg BID) that is above the maximum dosage currently permitted by the FDA&#8217;s partial clinical hold on neflamapimod. If it is determined that the 80mg BID dosing regimen is safe and tolerable, we may in the future seek to use data from this trial to support an application to increase neflamapimod&#8217;s no adverse event level and remove the existing partial clinical hold. However, because this data is being obtained from a trial conducted outside of the US, it is possible the FDA will not accept such data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Safety issues with neflamapimod or with any other product candidate we may develop or acquire in the future, or with product candidates or approved products of third parties that are similar to our product candidates, could give rise to delays in the regulatory approval process, restrictions on labeling or product withdrawal after approval, if any, or may otherwise cause us to modify or supplement our clinical development program.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. SAEs or undesirable side effects caused by neflamapimod, or any other product candidates we may develop or acquire, could cause it or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Many compounds that have initially shown promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Further, problems with product candidates or approved products marketed by third parties that utilize the same therapeutic target or that belong to the same therapeutic class as neflamapimod or any future product candidates of ours could adversely affect the development, regulatory approval and commercialization of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, to date, neflamapimod has been evaluated in over 550 participants, at doses up to 750mg twice a day, and up to 32 weeks of treatment. The adverse effects seen in more than 5% of neflamapimod-treated participants in completed trials, which include headache, diarrhea, abdominal pain, respiratory infection, and falls, were generally mild. In addition, increased levels of certain &#8220;liver enzymes&#8221; in the blood are a well-known dose-dependent side effect of p38 MAPK inhibitors. These liver enzymes, aspartate aminotransferase and alanine aminotransferase, are proteins commonly produced in the liver, the measurements of which can help doctors evaluate liver function. In an early 2000s study of neflamapimod conducted by Vertex, during 12 weeks of dosing at 250mg BID (i.e., four-fold higher daily dosing than the dose in the RewinD-LB Trial) in 44 subjects with RA, elevations in such liver enzymes levels were noted in six subjects (14%).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">After we acquired an exclusive license from Vertex to develop and commercialize neflamapimod for the treatment of AD and other CNS disorders, we submitted an IND application to the DNP in February 2015. The DNP cleared our clinical trial application in March 2015. However, in August 2015, following a standard review of the long-term animal toxicity studies, the DNP placed a partial clinical hold on our then ongoing Phase 2a study in AD and any subsequent studies proposed under the IND. A partial clinical hold means that the FDA suspends part of the clinical work requested under the IND (e.g., a specific protocol or part of a protocol is not allowed to proceed); however, all other protocols and/or remaining parts of the protocol are allowed to proceed under the IND. Under DNP&#8217;s partial clinical hold that remains in effect for the neflamapimod IND, the agency limited administration of neflamapimod to doses that lead to plasma drug levels that provide a ten-fold safety margin to human subjects, based on the plasma drug levels in animals that had previously led to minimal or equivocal toxicity findings. Our current understanding of plasma drug levels achieved with neflamapimod in humans means that our investigational dosing in the US is limited by this partial clinical hold to no more than 40mg TID in patients weighing 50 kg (110 lbs.) or more.)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">With respect to the adverse effects discussed above, the participants were asymptomatic, there were no associated increases in bilirubin, and the elevations resolved with treatment discontinuation. Furthermore, no liver enzyme abnormalities were observed in the AscenD-LB Trial. However, as we continue the development and clinical trials of neflamapimod, treatment-related SAEs may arise in the future. Side effects that are deemed to be drug-related could affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Undesirable side effects in one of our clinical trials for neflamapimod in one indication could adversely affect enrollment in clinical trials, regulatory approval and commercialization of our product candidate in other indications. These side effects may not be appropriately recognized or managed by the treating medical staff. In addition, discovery of previously unknown class effect problems may prevent or delay clinical development and commercial approval of product candidates or result in restrictions on permissible uses after their approval. On the other hand, many drugs provide superior efficacy at higher doses and, if determined to be safe and tolerable, higher doses of neflamapimod may be desirable for a variety of reasons. Accordingly, we are currently undertaking a number of studies, including our Phase 2a DLB trial in Strasbourg, France, and several nonclinical studies, to further evaluate the safety and tolerability profile of higher doses of neflamapimod, including 80mg BID.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we or others identify undesirable side effects caused by the mechanisms of action of a product candidate or a class of product candidates, the FDA may require us to conduct additional clinical trials, or to implement a REMS program prior to commercial approval. Alternatively, regulatory authorities may not approve the product candidate or, as a condition of approval, may require specific warnings and contraindications or place certain limitations on how we can promote the drug. Following a potential future drug product approval, regulatory authorities might also withdraw such approval due to the discovery of previously unknown safety issues relating to the product and require us to take our drug off the market. Any of these occurrences may harm our business, financial condition and prospects significantly.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, clinical trials, by their nature, utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of neflamapimod or future product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. If neflamapimod, or any other product candidates we may develop or acquire, receives marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such approval, a number of potentially significant negative consequences could result, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulatory authorities may withdraw or limit their approval of such product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulatory authorities may require the addition of labeling statements, such as a &#8220;Boxed&#8221;&#160;Warning or a contraindication;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling of the product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools, and regulatory authorities in other jurisdictions may require comparable risk mitigation plans;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may be subject to regulatory investigations and government enforcement actions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the product;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may decide to recall such product candidates from the marketplace after they are approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we could be sued and held liable for injury caused to individuals exposed to or taking its product candidates; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our reputation may suffer.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be unable to obtain regulatory approval in the US or foreign jurisdictions and, as a result, be unable to commercialize our product candidates and our ability to generate revenue will be materially impaired. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating companies such as ours are not always applied predictably or uniformly and can change. Any analysis we perform of data from CMC, nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. Any delay or failure in obtaining required approvals could adversely affect our ability to generate revenues from the particular product candidate for which we are seeking approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, similar foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval and licensure procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the US, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the US, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we seek to enter into collaborative arrangements or strategic alliances for our drug candidates, but fails to enter into and maintain successful relationships, we may have to reduce or delay our drug development activities or increase our expenditures.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">An important element of a biotechnology company&#8217;s strategy for developing, manufacturing and commercializing our drug candidates may be to enter into strategic alliances with pharmaceutical companies or other industry participants to advance our programs and enable us to maintain our financial and operational capacity. Biotechnology companies at our stage of development sometimes rely upon collaborative arrangements or strategic alliances to complete the development and commercialization of drug candidates, particularly after the Phase 2 stage of clinical testing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To date, we have not entered into any collaborative arrangements or strategic alliances, and we may face significant competition in seeking such relationships. In addition, such arrangements may place the development of our drug candidates outside our control, require us to relinquish important rights, or may otherwise be on terms unfavorable to us. We may not be able to negotiate collaborations and alliances on acceptable terms, if at all. If we enter into a collaborative arrangement and it proves to be unsuccessful, we may have to delay, or limit the size or scope of, certain of our drug development activities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Alternatively, if we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may not be available to us on acceptable terms, if at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to take full advantage of regulatory programs designed to expedite drug development or provide other incentives, our development programs may be adversely impacted.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There are a number of programs administered by the FDA and other regulatory bodies to facilitate and expedite development of drugs in areas of unmet medical need. For example, neflamapimod received fast track designation in October 2019 from the FDA for investigation as a treatment of DLB. Fast track designation is granted by FDA, in response to a sponsor&#8217;s request, upon a determination that the product candidate is intended to treat a serious or life-threatening disease or condition and has the potential to address an unmet medical need, meaning it could provide a therapeutic option for patients where none exists or a therapy that may be potentially superior to existing therapy based on efficacy or safety factors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Fast track designation does not ensure that neflamapimod will receive marketing approval or that approval will be granted within any particular timeframe. Although fast track designation and other available FDA programs may expedite the development or approval process for certain drug candidates, such programs do not change the standards for approval, and we may not experience a faster development or regulatory review or approval process with fast track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation for neflamapimod if it believes that the designation is no longer supported by data from our clinical development program.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Neflamapimod may not qualify for or maintain designations under this or other programs under any of the FDA&#8217;s existing or future programs to expedite drug development in areas of unmet medical need. Our inability to fully take advantage of these programs may require us to run larger trials, incur delays, lose opportunities that may not otherwise be available to us, and incur greater expense in the development of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The FDA granted orphan drug designation for neflamapimod for certain indications, which might not provide the intended benefit thereof.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug product if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the US In November 2024, we received orphan designation from the FDA for neflamapimod for the treatment of frontotemporal dementia. There is no guarantee that neflamapimod will be successfully approved by the FDA for such indication, neflamapimod will be commercially successful for such indication in the marketplace, if approved, or that another product will not be approved for the same indication ahead of neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if we obtain orphan product exclusivity for neflamapimod for the treatment of FTD, such exclusivity may not effectively protect the product from competition because different drugs can be approved for the same disease or condition. Even after an orphan drug product is approved, the FDA can subsequently approve another drug or biologic for the same disease or condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, orphan product exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, our business will be harmed.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we design and manages our nonclinical studies and clinical trials, we have a limited number of employees and do not currently have the ability to conduct clinical trials for neflamapimod on our own. We have relied, and will continue to rely, on third parties such as CROs, medical institutions, and clinical investigators to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, but we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, as well as legal and regulatory and scientific standards. We have limited control over these third parties, and they may not devote sufficient time and resources to our projects, or their performance may be substandard, resulting in clinical trial delays or suspensions, delays in submission of marketing applications or failure of a regulatory authority to accept our applications for filing. There is no assurance that the third parties we engage will be able to provide the functions, tests, activities or services as agreed upon, or provide them at the agreed upon price and timeline or to our requisite quality standards, including due to geopolitical events, natural disasters, public health emergencies or pandemics, or poor workforce relations or human capital management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We and our CROs are required to comply with GLP requirements for nonclinical studies and GCP requirements for clinical trials, which are regulations and guidelines enforced by the FDA and required by comparable foreign regulatory authorities. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving marketing applications for our product candidates. There is also no assurance these third parties will not make errors in the design, management or retention of our data or data systems. Any failures by such third parties could lead to a loss of data, which in turn could lead to delays in clinical development and obtaining regulatory approval. Third parties may not pass FDA or other regulatory audits, which could also delay or prohibit regulatory approval. In addition, the cost of such services could significantly increase over time. If these third parties do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develops. As a result, our financial results and the commercial prospects for neflamapimod would be harmed, our costs could increase, and our ability to generate revenue could be delayed, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have employed several different CROs for clinical trial services. Although we believe there are numerous alternatives to provide these services, in the event that we seek a new CRO, we may not be able to enter into replacement arrangements without delays or incurring additional expenses. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our reliance on third parties for the production of neflamapimod may result in delays in our clinical trials or regulatory approvals and may impair the development and ultimate commercialization of neflamapimod, which would adversely impact our business and financial position.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have no manufacturing facilities and do not have extensive experience in the manufacturing of drugs or in designing drug-manufacturing processes. We currently rely on third parties for the manufacture of DS, the manufacture of DP, and the packaging of DP for clinical use. This reliance on CMOs and suppliers subjects us to inherent uncertainties related to product safety, availability, security and cost. Holders of NDAs, or other forms of FDA approvals, or those distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third party.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We further intend to rely on third-party CMOs for the production of commercial supply of neflamapimod if it is ultimately approved. If CMOs cannot successfully manufacture DS and DP for our neflamapimod program, or any other product candidate that we may develop or acquire in the future, in conformity to its specifications and the applicable regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of that product candidate in clinical trials, or for commercial distribution of that product candidate, if approved. Additionally, any problems we experience with any such CMOs could delay the manufacturing of our product candidates, which could harm our results of operations. All drug manufacturers and packagers are required to operate in accordance with FDA-mandated cGMPs. The failure of any of our current or future CMOs to establish and follow adequate procedures to ensure compliance with applicable cGMP requirements and to document their adherence to such practices may lead to significant delays in obtaining regulatory approval of product candidates or the ultimate launch of products based on our product candidates into the market. In the event of such failure, we could also face fines, injunctions, civil penalties, and other sanctions. Further, if the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve a CMO&#8217;s facilities for the future commercial manufacture of neflamapimod, or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to obtain regulatory approval for or commercialize neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, if any facility of our third-party drug manufacturers or suppliers were to suffer an accident or a force majeure event such as war, missile or terrorist attack, earthquake, major fire or explosion, major equipment failure or power failure lasting beyond the capabilities of its backup generators or similar event, we could be materially adversely affected and any of our clinical trials could be materially delayed. An extended shutdown may force us to procure a new research and development facility or another manufacturer or supplier, which could be time-consuming.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our RewinD-LB Trial was conducted with a DS previously manufactured at a third-party CMO. Future supplies of the neflamapimod DS could be interrupted from time to time, and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. During this period, we may be unable to receive investigational neflamapimod supplies or any other product candidates we may develop or acquire. In addition, a disruption in the supply of DS could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost-effectively manufacture our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also currently rely on a third-party CMO (different than that for the DS) for the manufacture of neflamapimod DP. We have used the same manufacturer for our neflamapimod DP in all our clinical trials to date. If neflamapimod is ultimately approved for commercial sale, we expect to continue to rely on third-party contractors for manufacturing the DP. Although we intend to do so prior to any commercial launch, we have not yet entered into long-term agreements for the commercial supply of either DS or DP with our current manufacturing providers, or with any alternate manufacturers.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">While we believe that there are multiple alternative sources available for manufacturing of both DS and DP in our neflamapimod program, we may not be able to enter into replacement arrangements, on acceptable terms or at all, without delays or additional expenditures. We cannot estimate these delays or costs with certainty but, if they were to occur, they could cause a delay in our development and commercialization efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we generally have not, and do not intend to, begin a clinical trial unless we believe we had on hand, or will be able to obtain, a sufficient supply of neflamapimod to complete the clinical trial, any significant delay in the supply of neflamapimod DS or DP could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, third-party suppliers, manufacturers, or distributors may not perform as agreed or may terminate their agreements with us, including due to the effects related to geopolitical events, natural disasters, public health emergencies or pandemics, or force majeure events that affect their facilities or ability to perform. Any significant problem that our suppliers, manufacturers, distributors or regulatory service providers experience could delay or interrupt supply of materials necessary to produce our product candidates. Failure to obtain the needed quantities of our product candidates could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we change the manufacturers of our product candidates, we may be required to conduct comparability studies evaluating the manufacturing processes of the product candidates and incur other costs related to the technology transfer.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA and other regulatory agencies maintain strict requirements governing the manufacturing process for prescription DPs that would apply to our product candidates, if approved. For example, when a manufacturer seeks to make any change to the manufacturing process, the FDA typically requires the applicant to conduct nonclinical and, depending on the magnitude of the changes, potentially clinical comparability studies that evaluate the potential differences in the product candidates resulting from the change in the manufacturing process. If we were to change manufacturers of our DS or DP during or after the clinical trials and regulatory approval process for neflamapimod or any of our other product candidates, we will be required to conduct comparability studies assessing product candidates manufactured at the new manufacturing facility. Further, manufacturing changes are generally categorized as having either a substantial, moderate, or minimal potential to adversely affect the identity, strength or quality of the DP as they may relate to the safety or effectiveness of the product, and if a change has a substantial potential to have an adverse effect on the DP, an applicant must submit and receive FDA approval of a prior approval supplemental application before the product made with the manufacturing change is distributed. Other forms of notice to the FDA are also required for manufacturing changes that have a moderate or minimal potential to have an adverse effect on the DP&#8217;s safety or effectiveness. Regardless of the type of manufacturing change, the methods used and the facilities and controls used for the manufacture, processing, packaging, or holding of human drugs must comply with applicable cGMP regulations. For example, if we decide to utilize a different CMO to manufacture future DS batches, certain compatibility studies may be required, and we may incur additional costs related to the technology transfer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Delays in designing and completing a comparability study to the satisfaction of the FDA or other regulatory agencies could delay or preclude our development plans and, thereby, delay our ability to receive marketing approval or limit our revenue and growth, once approved. In addition, in the event that the FDA or other regulatory agencies do not accept nonclinical comparability data, we may need to conduct a study involving dosing of patients comparing the two products. That study may result in a delay in the approval or launch of any of our product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we do not adequately protect our proprietary rights, we may not be able to compete effectively.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to neflamapimod. Our commercial success depends in part on obtaining and maintaining proprietary rights in the US and in international jurisdictions and successfully defending these rights against third-party challenges if and as they occur. We seek to protect our proprietary position by filing patent applications related to neflamapimod in the US and in other countries.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we have already obtained several issued patents and are working to expand our estate with additional patent applications, third parties may challenge the validity, enforceability, or scope of our patents, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of neflamapimod, or any other product candidates we may develop. Further, if we encounter delays in regulatory approvals due to patent-related issues, the period of time during which we could market a product candidate under patent protection could be reduced.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our issued patents and patent applications also remain subject to uncertainty and continued monitoring. Our patent applications may fail to result in issued patents with claims that provide further coverage for neflamapimod in the US or in foreign countries. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may also fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection, including as a result of the publication of prior art. There is also no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The patent position of life sciences companies can often involve complex legal and factual questions and in recent years has been the subject of significant litigation. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the US and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether it was the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that it was the first to file for patent protection of such inventions. Further, the issuance of a patent is not conclusive as to our inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the US or other jurisdictions. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to prevent others from using or commercializing similar or identical technology and products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may also develop, seek approval for and launch generic versions of our products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Without patent protection for our current or future product candidates, these candidates may be open to competition from other products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may also seek to rely on regulatory exclusivity for protection of our product candidates, if approved for commercial sale. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, vary widely from country to country. Failure to qualify for regulatory exclusivity, or failure to obtain or to maintain the extent or duration of such protections that we expect for our product candidates, if approved, could affect our decision on whether to market the products in a particular country or countries or could otherwise have an adverse impact on our revenue or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>There is currently no composition of matter patent protection that covers neflamapimod.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We acquired an exclusive license from Vertex in 2014 to develop and commercialize neflamapimod for the treatment of AD and other CNS disorders. This license covers know-how, nonclinical and clinical data, and certain specified Vertex patent rights, including a composition of matter patent for neflamapimod that expired in 2017. We have thus focused our efforts on discoveries related to neflamapimod that are reflected in issued patents and patent applications covering a range of subjects, including: methods of treating patients suffering from DLB or AD, as well as methods of reducing amyloid plaque burden; methods of improving cognition and treating neurologic disorders; methods for promoting recovery of function in patients who have suffered acute neurologic injuries, including those resulting from various forms of stroke; and methods of treating patients suffering from dementia. In addition, EIP has filed patents related to formulations of neflamapimod, including pharmaceutical compositions for oral administration exhibiting desirable PK and processes for the manufacture thereof. In the US, the natural expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent is limited.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accordingly, there is currently no composition matter patent protection that covers neflamapimod. Rather, our patents provide protection around either the use of neflamapimod for specific or medical indication (so called &#8220;use patents&#8221;) or the administration of neflamapimod in specific manner (e.g., at a specific dose or in a specific formulation). Patents that are not around composition of matter are narrower in scope (i.e., they do not protect against development of neflamapimod in an indication other than that the patent defines), may be more difficult to defend against challenges against validity, and may be more difficult to enforce against infringement. For these reasons, some pharmaceutical companies choose not to develop and/or license compounds that are not covered by a composition of matter patent. We own a patent that is issued in the US around co-crystals of neflamapimod, any of which if they were successfully developed would be afforded composition of matter patent protection under this patent.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accordingly, the lack of composition of matter patent protection that covers neflamapimod may subject us to increased risk of third-party litigation and/or reduce third party collaborators&#8217; interest in or valuation of neflamapimod, any of which could have an adverse effect on our business, financial condition or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we fail to comply with our obligations under our existing license agreement with Vertex, or with any future intellectual property licenses with third parties, we could lose license rights that are important to our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are party to the Vertex Agreement pursuant to which we acquired an exclusive license to develop and commercialize neflamapimod for the diagnosis, treatment, and prevention of AD and other CNS disorders. Under the terms of the Vertex Agreement, we must use commercially reasonable efforts during the license term to develop and obtain regulatory approval for a licensed product in specified major markets, and to promptly and effectively commercialize the licensed product once such approval is obtained. The Vertex Agreement also contains certain specified minimum diligence requirements, including making annual expenditures set forth in a development plan, and commencing a Phase 2 clinical trial of the licensed product within a specified time period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Vertex Agreement provides that either party may terminate the agreement if the other party is in material breach of our obligations thereunder, following a 60-day notice and cure period, or if the other party files for bankruptcy, reorganization, liquidation, receivership, or an assignment of a substantial portion of assets to creditors. The Vertex Agreement also provides that in the event we materially breach any of certain specified diligence obligations as to a specific major market, Vertex&#8217;s sole remedy for such breach, following the applicable notice and cure period, would be to terminate the license as to such specific major market country.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accordingly, any uncured, material breach under the Vertex Agreement could result in the loss of certain of our rights to neflamapimod and could compromise our development and commercialization efforts. This in turn would have an adverse effect on our business, which could be material.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>We may become subject to third parties</i></b>&#8217;<b><i> claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, either of which could be costly and time consuming, potentially delay or prevent the development and commercialization of ours product candidates, or put our patents and other proprietary rights at risk.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our lead product candidate, neflamapimod, without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. While we are not currently subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed to future litigation by third parties based on claims that our product candidates, technologies or activities infringe the intellectual property rights of others. Some claimants may have substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than us. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us in the future. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, reexamination proceedings, post-grant review and <i>inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize our applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. These proceedings may also result in our patent claims being invalidated or narrowed in scope. In addition, a court may hold that a third-party is entitled to certain patent ownership rights instead of ours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the corresponding patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing our patents or other intellectual property rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, which could damage our reputation, harm our business, and the price of our common stock could be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">From time to time, we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing certain product candidates. We might also be forced to redesign our product candidates so that it no longer infringes on the third-party intellectual property rights, if such redesign is even possible. Any of these events, even if we were to ultimately prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be involved in lawsuits to protect or enforce our patents or other intellectual property or the intellectual property of our licensors, which could be expensive, time-consuming, and unsuccessful.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Competitors may infringe our patents or other intellectual property or the intellectual property of our licensors. To cease such infringement or unauthorized use, we may be required to file patent infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues therefrom. In addition, in an infringement proceeding or a declaratory judgment action, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, may involve substantial litigation expense and may be a substantial diversion of employee resources from our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Interference or derivation proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to, or the correct inventorship of, our patents or patent applications. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer we a license on commercially reasonable terms. Litigation, interference, derivation or other proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even if we establish infringement, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, we could have a substantial adverse effect on the price of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our success is heavily dependent on intellectual property, particularly patents, and obtaining and enforcing patents in our industry involves both technological and legal complexity. Changes in either the patent laws or interpretation of the patent laws in the US and other countries may diminish the value of our patents or narrow the scope of our patent protection.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, the AIA, which was passed in September 2011, resulted in significant changes to the US patent system. Pursuant to the AIA, the US transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before we could therefore be awarded a patent covering our invention even if we made the invention before it was made by the third party. This requires us to be cognizant going forward of the time from invention to filing of a patent application.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The AIA also introduced changes that provide opportunities for third parties to challenge any issued patent with the USPTO. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in US federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Such changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the laws of other countries may not protect our rights to the same extent as the laws of the US The complexity and uncertainty of European patent laws have increased in recent years, and the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Complying with these laws and regulations could limit our ability to obtain new patents in the future, which may be important for our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We enjoy only limited geographical protection with respect to certain patents, and we may not be able to protect our intellectual property rights throughout the world.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive and time-consuming with diminishing marginal returns. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the US or the European Union. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we intend to seek protection of our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. We may also decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding, which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The legal systems of certain countries do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Some countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to any third parties with respect to any patents relevant to our business, our competitive position may be impaired.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The lives of our patents may not be sufficient to effectively protect our products and business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Patents have a limited lifespan. For example, in the US, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. The launch of a generic version of one of our products, in particular, would be likely to result in an immediate and substantial reduction in the demand for that product, which could have a material adverse effect on our business, financial condition, results of operations and prospects. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our product candidates. In addition, although upon issuance in the US a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may be available in the US However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and nonclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Intellectual property discovered or developed through government funded programs may be subject to federal regulations such as </i></b>&#8220;<b><i>march-in</i></b>&#8221;<b><i> rights, certain reporting requirements and a manufacturing preference for US-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-US manufacturers.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We received the NIA Grant to support our RewinD-LB Trial. Pursuant to the Bayh-Dole Act, the US government may have certain rights in any invention developed or reduced to practice with this funding. In addition, in the future we may discover, develop, acquire, or license intellectual property that has been generated through the use of US government funding or grants in which the US government may have certain rights pursuant to the Bayh-Dole Act. These US government rights include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the US government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). Such &#8220;march-in&#8221; rights would apply to new subject matter arising from the use of such government funding or grants and would not extend to pre-existing subject matter or subject matter arising from funds unrelated to the government funding or grants. If the US government exercises its march-in rights in our intellectual property rights that are generated through the use of US government funding or grants, we could be required to license or sublicense intellectual property discovered or developed by it or that it licenses on terms unfavorable to us, and there can be no assurance that we would receive compensation from the US government for the exercise of such rights. The US government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. Should any of these events occur, it could significantly harm our business, results of operations and prospects. In addition, the US government requires that, in certain circumstances, any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the US This preference for US industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the US or that under the circumstances domestic manufacture is not commercially feasible. This preference for US industry may limit our ability to contract with non-US product manufacturers for products covered by such intellectual property.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may rely on trade secrets or confidential know-how to protect various aspects of our business, especially where patent protection is believed by us to be of limited value. Due to our reliance on third parties in various aspects of our business, including CMC, research and development, and collaborations, we must, at times, share trade secrets with such parties. We may also conduct joint research and development programs that require us to share trade secrets under the terms of our research and development partnerships or similar agreements. Such trade secrets or confidential know-how can be difficult to protect as confidential.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time-consuming and unpredictable. In addition, the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">others may be able to make product candidates that are similar to ours but that are not covered by the claims of the patents that we own or have exclusively licensed;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">it is possible that our pending patent applications will not lead to issued patents;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may not develop additional proprietary technologies that are patentable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">we may fail to adequately protect and police our trademarks and trade secrets; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Should any of these events occur, they could significantly harm our business, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">58</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. Although an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. In any such event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Commercialization</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have not yet demonstrated, either on our own or through collaboration with third parties, an ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial product, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they may be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, complications, delays and other known and unknown factors. If we are able to successfully develop neflamapimod, we may eventually need to transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition and, as a result, our business may be adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As we continue to build our business, we expect that our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, investors should not rely upon the results of any particular quarterly or annual period as indications of our future operating performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business operations are subject to applicable healthcare laws and regulations. If neflamapimod is approved, we will also be subject to stringent regulation and ongoing regulatory obligations and restrictions, which could delay our marketing and commercialization activities and also expose us to penalties if we fail to comply with applicable regulations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we do not currently have any products on the market, once we begin commercializing neflamapimod or any other future product candidates, we will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which we conduct our business. Physicians, other healthcare providers and third-party payors will play a primary role in the recommendation, prescription and use of any product candidates for which we obtain marketing approval. Our future arrangements with such third parties may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing approval. Among others, restrictions under applicable domestic and foreign healthcare laws and regulations include:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the US federal AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">US federal false claims, false statements and civil monetary penalties laws, including the FCA, which impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">HIPAA, which imposes (i) criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services and (ii) obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws and regulations relating to healthcare fraud and abuse, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the US federal &#8220;Physician Payments Sunshine Act&#8221;, which requires manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report to CMS information related to physician payments and other transfers of value to physicians, certain advanced non-physician health care practitioners, and teaching hospitals, as well as the ownership and investment interests of physicians and their immediate family members;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">analogous state and foreign laws that require pharmaceutical companies to track, report and disclose to the government or the public information related to payments, gifts, and other transfers of value or remuneration to physicians and other healthcare providers, marketing activities or expenditures, or product pricing or transparency information, or that require pharmaceutical companies to implement compliance programs that meet certain standards or to restrict or limit interactions between pharmaceutical manufacturers and members of the healthcare industry;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">US federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of health care reform, including due to lack of applicable precedent and regulations. Any action against us for violation of these laws, even if we successfully defend against them, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases the possibility that a health care company may run afoul of one or more of the requirements. If the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to an expanded number of these laws and regulations and will need to expend resources to develop and implement policies and processes to promote ongoing compliance. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, resulting in government enforcement actions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from federal healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from federal healthcare programs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Even if neflamapimod or any other product candidate we develop receives marketing approval, we may fail to achieve the level of acceptance necessary for commercial success.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If neflamapimod, or any other product candidate we may develop or acquire in the future, receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, health care professionals, patients, third-party payors and others in the medical community. If our drug does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance will depend on a number of factors, including but not limited to:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the ability to provide acceptable evidence of efficacy and potential advantages compared to alternative treatments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our ability to offer our drug for sale at competitive prices, which may be subject to regulatory control;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the availability of third-party insurance coverage and adequate reimbursement;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the availability of alternative treatments and the cost of a new treatment in relation to those alternatives, including any similar generic treatments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the relative convenience and ease of administration of a new treatment compared to alternatives, and the prevalence and severity of any side effects of a new treatment;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the strength and effectiveness of our sales, marketing and distribution capabilities, either internally or in collaboration with others;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">any restrictions on the use of our product together with other medications; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">any restrictions on the distribution of our product such as those imposed under a mandatory REMS program.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If neflamapimod or any other product candidate that we may develop in the future does not provide a treatment regimen that is at least as beneficial as the current standard of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will not achieve market acceptance, and we will not generate sufficient revenues to achieve profitability. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would materially harm our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer. </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We intend to initially focus our product candidate development on treatments for various CNS and neurodegenerative indications, in particular DLB. The addressable patient populations that may benefit from treatment with our product candidates, if approved, are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these CNS and neurodegenerative diseases. Any regulatory approval of our product candidates would be limited to the therapeutic indications examined in our clinical trials and as determined by the FDA, which would not permit us to market our products for any other therapeutic indications not expressly reviewed and approved as safe and effective. In DLB, in particular, prevalence estimates among experts and practitioners vary greatly, as do estimates of the percentage of DLB patients that have AD co-pathology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Even if we receive regulatory approval for any of our product candidates, such approval could be conditioned upon label restrictions that materially limit the addressable patient population. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face substantial competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. If neflamapimod is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies, biopharmaceutical companies in the US and other jurisdictions, academic institutions and governmental agencies and public and private research institutions. These organizations may have significantly greater resources than we do. They may also conduct similar research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with neflamapimod.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Currently, there are a limited number of companies developing treatments specifically for DLB. However, given the potential market opportunity for the treatment of DLB and other neurodegenerative diseases, an increasing number of established pharmaceutical firms and smaller biotechnology/biopharmaceutical companies are pursuing a range of potential therapies for these diseases in various stages of clinical development. In addition to these current and potential competitors, we anticipate that more companies will enter the DLB market in the future. Our potential competitors could have significantly greater financial resources, as well as drug development, manufacturing, marketing, and sales expertise. They may also be able to develop and commercialize products that are safer, more effective, less expensive, more convenient, easier to administer, or have fewer severe effects, than existing treatments or, if it is ultimately approved, neflamapimod. Competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for neflamapimod, which could result in their establishing or strengthening a commercial position before we are able to enter the market. The highly competitive nature of the biotechnology and pharmaceutical industries, as well as the rapid technological changes in those fields, could limit our ability to advance neflamapimod commercially. If we are unable to compete effectively, this could have a material adverse effect on our business and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The successful commercialization of neflamapimod, or any other product candidate we may develop or acquire, depends in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and also affect the prices we may set. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There have been, and we expect will continue to be, a number of legislative and regulatory proposals and changes to the healthcare systems in the US and other jurisdictions that could affect our future results of operations. In particular, a number of initiatives at the US federal and state levels have aimed to reduce healthcare costs and improve the quality of healthcare. Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of neflamapimod or any future product candidates we may develop or acquire. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the US or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the US, the availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers, and other third-party payors are essential for most patients to be able to afford prescription medications such as neflamapimod, if it is approved. Our ability to achieve acceptable levels of coverage, payment, and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize neflamapimod and any other potential future product candidates. Assuming we obtain coverage for neflamapimod by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage, payment, and reimbursement in the US or elsewhere will be available for any drug product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There have recently been and may continue to be a number of significant legislative initiatives in the US to contain healthcare costs. Federal and state governments continue to propose and pass legislation designed to reform delivery of, or payment for, healthcare, which includes initiatives to reduce the cost of healthcare. For example, in March 2010, the US Congress enacted the ACA, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the US pharmaceutical industry. We expect that future changes or additions to the ACA, the Medicare and Medicaid programs, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry in the US</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In August 2022, the IRA was signed into law, which, among other things, requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. In addition, multiple large pharmaceutical companies and other stakeholders (e.g., the US Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. For these and other reasons, the implementation of the IRA and our impact on our business is currently unclear.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In December 2020, the US Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that may lead to appears to be leading to further and more aggressive efforts by states in this area. The FTC in mid-2022 also launched sweeping investigations into the practices of the PBM industry, prompting further legislative and regulatory actions and litigation. In particular, several PBM regulatory reforms became law in February 2026, including but not limited to requirements for PBMs to pass back 100% of rebates and fees to commercial health plan sponsors; to provide extensive informational disclosures related to patients&#8217; coverage and benefits; and to accept only <i>bona fide</i> service fees from drug companies when providing services under Medicare Part D. The Department of Labor also issued a proposed rule in January 2026 that would mandate specific PBM fee disclosures to self-insured plan fiduciaries under ERISA and would allow plan fiduciaries to audit those PBM disclosures to confirm accuracy. In addition, in the last few years, several states have formed PDABs with the authority to implement UPLs on drugs sold in their respective jurisdictions. There are several pending federal lawsuits challenging the authority of states to impose UPLs, however.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Further, if neflamapimod is approved in any jurisdictions outside of the US, we may also be subject to extensive governmental price controls and other market regulations in those countries. Governments outside of the US, particularly the countries of the European Union, tend to impose strict price controls on prescription pharmaceutical products. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In addition, recent US federal government actions include initiatives incorporating most-favored-nation (international reference pricing) concepts for certain prescription drugs, as well as agency testing of new payment models that could tie Medicare reimbursement or manufacturer rebates to prices in specified reference countries with strict price controls. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. As a result, we might obtain regulatory approval for a product in a particular country but then be subject to price regulations that delay our commercial launch of the product and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in our product candidates, even after obtaining regulatory approval.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the US or any other jurisdiction. In the US, future laws and regulation may result in more rigorous coverage criteria and increased downward pressure on the price pharmaceutical companies may receive for any approved product. Reductions in reimbursement from Medicare or other government programs may result in similar reductions in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Further, if we or any third parties with whom we engages in the future are slow or unable to adapt to changes in existing requirements or policies, or if we are not able to maintain regulatory compliance, our ability to generate revenue, attain profitability, or commercialize neflamapimod or any other products for which it receives regulatory approval may be materially and adversely affected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are unable to obtain adequate coverage and payment levels for our products from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer them, and patients may decline to purchase them. This in turn would affect our ability to successfully commercialize any approved products and thereby adversely impact our profitability, results of operations, and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to establish sales, marketing and distribution capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing neflamapimod, if approved.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not currently have any infrastructure for the sales, marketing or distribution of an approved drug product, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize neflamapimod, if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities, or make arrangements with third parties to perform these services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There are significant expenses and risks involved in establishing our own sales, marketing and distribution functions, including our ability to hire, retain and appropriately incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Alternatively, to the extent that we depend on third parties for such services, any revenues we receive will depend upon the efforts of those third parties, and there can be no assurance that such efforts will be successful.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are unable to establish adequate sales, marketing, and distribution capabilities, either on our own or in collaboration with others, we will not be successful in commercializing neflamapimod, if it is ultimately approved, and it may never become profitable. We will be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Consumers may sue us for product liability, which could result in substantial liabilities that exceed our available resources and damage our reputation.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Researching, developing, and commercializing drug products entail significant product liability risks. The use of neflamapimod or any other product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, patients, healthcare providers, pharmaceutical distributors or others selling or otherwise coming into contact with our product candidates or future commercial products. We have obtained limited product liability insurance coverage for our clinical trials, which we believe to be reasonable given our current operations. However, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Although we currently have limited product liability insurance that covers our clinical trials, we will need to increase and expand this coverage as we commence larger scale trials, as well as if neflamapimod is ultimately approved for commercial sale. This insurance may be extremely expensive or may not fully cover our potential liabilities. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could prevent or inhibit the commercialization of neflamapimod, if it is approved. Product liability claims could have a material adverse effect on our business and results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experiences unanticipated problems with our products, when and if any of them are approved.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If the FDA or a comparable foreign regulatory authority approves neflamapimod or any of our future product candidates for marketing, activities such as the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called &#8220;Phase 4 trials&#8221;) and post-marketing surveillance to monitor the safety or efficacy of the product. If we or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, production problems or issues with the facility where the product is manufactured or processed, such as product contamination or significant not-compliance with applicable cGMPs, a regulator may impose restrictions on that product, the manufacturing facility or us. If we or our third-party providers, including our CMOs, fail to comply fully with applicable regulations, then we may be required to initiate a recall or withdrawal of our products.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. The FDA and other agencies closely oversee the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products, and if we promote our products beyond their approved indications, we may be subject to enforcement actions or prosecution arising from that off-label promotion. Violations of the FDCA relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. Accordingly, to the extent we receive marketing approval for neflamapimod, we and our CMOs and other third-party partners will continue to expend time, money and effort in all areas of regulatory compliance, including promotional and labeling compliance, manufacturing, production, product surveillance, and quality control. If we are not able to comply with post-approval regulatory requirements, we could have marketing approval for any of our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Securities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our stock price may be volatile, there may be limited liquidity in the trading market for our common stock, and the market price of our common stock may drop in the future.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The market price of our common stock may be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been volatile. Some of the factors that may cause the market price of our common stock to fluctuate include, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the ability of us or our partners to develop product candidates and conduct clinical trials that demonstrate such product candidates are safe and effective;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the ability of us or our partners to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure of any of our product candidates to demonstrate safety and efficacy, receive regulatory approval and achieve commercial success;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure by us to maintain our existing third-party license, manufacturing and supply agreements;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure by us or our licensors to prosecute, maintain, or enforce our intellectual property rights;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">changes in laws or regulations applicable to our product candidates;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">any inability to obtain adequate supply of product candidates or the inability to do so at acceptable prices;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">adverse regulatory authority decisions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">introduction of new or competing products by our competitors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">failure to meet or exceed financial and development projections we may provide to the public;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain intellectual property protection for our technologies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">additions or departures of key personnel;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">significant lawsuits, including intellectual property or stockholder litigation;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">if securities or industry analysts do not publish research or reports about us, or if they issue adverse or misleading opinions regarding our business and stock;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">changes in the market valuations of similar companies;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">general market or macroeconomic conditions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">sales of our common stock by us or our stockholders in the future;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the trading volume of our common stock;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the limited percentage of our outstanding shares that are currently freely tradeable as a result of the significant holdings of our directors and officers;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">adverse publicity relating to our markets generally, including with respect to other products and potential products in such markets;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">changes in the structure of health care payment systems; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">period-to-period fluctuations in our financial results.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Accordingly, the market price of our common stock may be highly volatile and could fluctuate widely in price as a result of these or other factors. In particular, we have relatively few shares of common stock outstanding in the &#8220;public float&#8221; as a higher percentage of our outstanding shares are held by a small number of shareholders. In addition, the shares of common stock may be sporadically or thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by shareholders may disproportionately influence the price of those shares in either direction, particularly over short periods of time. The price for such shares could, for example, decline precipitously in the event that a large number of the shares are sold on the market without commensurate demand, as compared to a seasoned issuer which could better absorb those sales without a material reduction in share price. An active trading market for our shares of common stock may never develop or be sustained. If an active market for our common stock does not develop or is not sustained, it may be difficult for our stockholders to sell their shares at an attractive price or at all.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, in the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of our securities. We may in the future be the target of similar litigation if our stock continues to experience price volatility. Securities litigation could result in substantial costs and liabilities and could divert management&#8217;s attention and resources.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have funded our operations to date through the issuance of securities, including common stock, warrants to purchase common stock (including pre-funded warrants), convertible preferred stock, and convertible debt securities, and expects that in the future we will need to raise additional capital through similar means to fund our continued operations and liquidity needs. Assuming funding is available on acceptable terms, any future issuance of common stock or securities convertible for or exchangeable into common stock will result in dilution to our existing stockholders and could depress the market price of our common stock. Furthermore, the terms of future financing transactions may contain provisions that restrict our operations or require us to relinquish certain rights to our product candidates or other technologies.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will likely need to raise additional funds in the future to continue our operations, fund research and development, and, if approved, commercialize our product candidates. We currently plan to continue to finance operations with a combination of equity issuances, debt arrangements, and, potentially, licensing, or other partnering relationships. The Board may determine at any time to raise additional capital if we believe the terms are in the best interests of our stockholders. In addition, we may also issue securities to counterparties as part of an acquisition, merger, or similar transaction, including as part of our strategic review process.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any issuance or sale of shares, or the perception in the market of an intent to issue or sell shares in the near-term, by us or holders of a large number of shares could reduce the market price of our common stock, including in connection with the exercise of any Series A Warrants issued in connection with the 2024 Private Placement. We also cannot assure you that any such sale of common stock or other securities will be at a price per share that is equal to or greater than the price per share paid by you for our common stock. Furthermore, a depressed stock price could limit our ability to raise necessary capital through the sale of additional equity securities on terms that are acceptable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Ownership of our common stock is highly concentrated among our officers and directors, which may prevent our stockholders from influencing significant corporate decisions and may result in perceived conflicts of interest that could cause us stock price to decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of March 11, 2026, our executive officers and directors owned, directly or indirectly, approximately 32.0% of the outstanding shares of our common stock. Accordingly, these stockholders, in the aggregate, may exercise substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of us asset or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of ours, even if such a change of control would benefit the other stockholders of ours. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future sales of shares by existing stockholders could cause our stock price to decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If existing stockholders of ours sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after certain legal and contractual restrictions on resale lapse, the trading price of our common stock of us could decline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business, or our market, our stock price and trading volume could decline.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The trading market for our common stock will be influenced by the research and reports that equity research analysts may publish about us and our business from time to time. Equity research analysts may choose not to provide or continue research coverage of our common stock, which may adversely affect the market price of the stock. In the event we do have equity research analyst coverage at any given time, we will not have any control over the analysts, or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts cease coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we cannot continue to satisfy the Nasdaq Capital Market continued listing standards and other Nasdaq rules, our common stock could be delisted, which could harm our business, the trading price of our common stock, our ability to raise additional capital and the liquidity of the market for our common stock.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our common stock is currently listed on the Nasdaq Capital Market. To maintain this listing, we are required to meet certain listing requirements related to, among other things, the trading price of our common stock, our market capitalization and certain corporate governance-related requirements. In the event our common stock is delisted from Nasdaq for a failure to meet such requirements and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult for us to raise capital and for our stockholders to dispose of, or obtain accurate price quotations for, our common stock. There would likely also be a decline in the liquidity of the trading market for our common stock and a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Provisions in our corporate charter documents and under Delaware law could make an acquisition, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Provisions in our certificate of incorporation, as amended, and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors are willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because the Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of the Board. Among other things, these provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">allow the authorized number of our directors to be changed only by resolution of the Board;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">66</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">limit the manner in which stockholders can remove directors from the Board;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to the Board;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">limit who may call stockholder meetings and our stockholder's&#160;ability to act by written consent;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">authorize the Board to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221;&#160;that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the Board; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">require the approval of the holders of at least 2/3 of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation, as amended, or for stockholders to amend or repeal our amended and restated bylaws.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which generally prohibits a person who, together with their affiliates and associates, owns 15% or more of a company&#8217;s outstanding voting stock from, among other things, merging or combining with the company for a period of three years after the date of the transaction in which the person acquired ownership of 15% or more of the company&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against us and our directors, officers and employees.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for certain proceedings, including: (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to the Company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These exclusive-forum provisions may make it more expensive for our stockholders to bring a claim than if the stockholders were permitted to select another jurisdiction, and may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find the choice of forum provisions contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition and operating results.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not anticipate that we will pay any cash dividends in the foreseeable future.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our current expectation is that we will retain future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, will be your sole source of potential gain on an investment in our common stock for the foreseeable future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General Risks Related to Our Business and Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>AI presents risks and challenges that can impact our business including by posing security risks to confidential information, proprietary information, and personal data, as well as emerging, unknown business risks.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Issues in the development and use of AI, combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. We may adopt and integrate generative AI tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative AI tools into their offerings, and the providers of these generative AI tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit our or our vendors&#8217; ability to maintain an adequate level of service and experience. Additionally, AI algorithms may be flawed, datasets may be insufficient or biased, and ineffective AI development or deployment could lead to other compliance violations. While we have implemented controls intended to, among other things, limit the risk that proprietary or confidential information is used to train AI models, no such controls can completely eliminate the inherent risks associated with AI. If we, our vendors, or our third-party partners experience an actual or perceived violation of applicable privacy or data protection, intellectual property, or other laws or regulations, or a cybersecurity incident due to the use of generative AI, we could be subject to regulatory fines, investigations, enforcement actions, penalties and other liabilities, claims for damages from affected individuals, and we may lose valuable intellectual property and confidential information, including the risk that AI-generated outputs may infringe third-party intellectual property, and our reputation and the public perception of the effectiveness of our privacy or cybersecurity measures could be harmed. Additionally, potential future overreliance on AI or dependence on a specific model or vendor could limit our flexibility, increase costs, or expose us to operational risks if the AI provider modifies or discontinues its services, or experiences service interruptions or security incidents. Several jurisdictions around the globe, including Europe and the US, have already proposed or enacted laws governing AI, and we may need to commit significant resources to maintain business practices that comply with the evolving regulatory landscape. Our competitors or other third parties may incorporate AI into their products more quickly and successfully than we, which could impair our ability to compete effectively and adversely affect our results of operations. Any of these outcomes could damage our reputation, result in the loss of valuable property and information, and adversely impact our business. For example, our approach to the treatment of DLB focuses in large part on neflamapimod&#8217;s ability to inhibit the intra-cellular enzyme p38&#945;. Through the use of AI and large language models, competitors could seek to identify alternative p38&#945; inhibiting compounds and repurpose those assets to compete with neflamapimod in the future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The development and use of AI presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information, and personal data and could give rise to legal and/or regulatory actions, damage our reputation, or otherwise materially harm our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">AI is increasingly being used in the biopharmaceutical, pharmaceutical, technology, and consumer health industries. We evaluate different AI technologies and identify areas where we can apply AI to improve our operations. Issues relating to the use of new and evolving technologies such as AI, machine learning, generative AI, and large language models, may cause us to experience perceived or actual brand or reputational harm, technical harm, competitive harm, legal liability, cybersecurity risks, privacy risks, compliance risks, security risks, ethical issues, and new or enhanced governmental or regulatory scrutiny, and we may incur additional costs to resolve such issues. In addition, uncertainties regarding developing legal and regulatory requirements and standards may require significant resources to modify and maintain business practices to comply with US and non-US laws concerning the use of AI, the nature of which cannot be determined at this time. For example, the European Union recently passed the Artificial Intelligence Act, whose regulations will be developed over the coming year and, in the United States, the recent Executive Order concerning AI may result in extensive new federal rule-making. Further, market demand and acceptance of AI technologies are uncertain, and we may be unsuccessful in our product development efforts.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As necessary, we have developed policies governing the use of AI to encourage appropriate use of AI by our employees, contractors, and authorized agents and that our assets, including intellectual property, competitive information, personal information we may collect or process, and customer information, are protected. Any failure by our personnel, contractors, or other agents to adhere to any policies that we may establish could violate confidentiality obligations or applicable laws and regulations, jeopardize our intellectual property rights, cause or contribute to unlawful discrimination, or result in the misuse of personally identifiable information or the injection of malware into our systems, any of which could have a material adverse effect on our business, results of operations, and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our future success depends in large part on our ability to retain our key employees, as well as our ability to attract, train and motivate additional qualified personnel. We may also encounter difficulties in managing our growth, which could disrupt our operations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have a small number of employees, and we are highly dependent on the principal members of our management team, including our President and Chief Executive Officer, John Alam, M.D. Although we have employment agreements or offer letters with our executive officers and certain key employees, these agreements do not prevent them from terminating their services at any time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Competition in the biotechnology industry for skilled and experienced employees is intense, particularly in the greater Boston, Massachusetts area, where our headquarters are located. We also face competition for the hiring of scientific and clinical personnel from universities and research institutions, many of which are near our headquarters. The loss of the services of any member of our senior management, clinical development or scientific staff, or any other key employee, may significantly delay or prevent the achievement of drug development and other business objectives and could have a material adverse effect on our business, operating results and financial condition.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also rely on consultants and advisors to assist us in formulating and executing our business strategy. Many of our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, which may affect their ability to contribute to us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As we continue to develop neflamapimod, we expect to experience significant growth in the number of employees and the scope of our operations. This strategy will require us to recruit additional clinical development, regulatory, scientific, and technical personnel, as well as sales and marketing personnel if neflamapimod is approved. If we are unable to attract, retain and motivate a sufficient number of highly qualified personnel to match such growth, our ability to further develop and commercialize neflamapimod, or any future product candidates we may develop or acquire, will be limited.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">68</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may also be required to implement and improve managerial, operational and financial systems to manage our potential growth. Due to our limited financial and personnel resources, we may not be able to effectively manage the expansion of our operations or recruit and train a sufficient number of additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. This requires that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">However, we believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the future, we could identify one or more material weaknesses in our control environment. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements would not be prevented or detected on a timely basis. The identified material weaknesses, if not corrected, could result in a material misstatement to our consolidated financial statements that may not be prevented or detected. We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For example, in connection with the audit of our financial statements for the years ended December 31, 2024, 2023 and 2022, material weaknesses in our internal control over financial reporting were identified related to the absence of effective controls regarding the accurate identification, evaluation and proper recording of various expense accounts. We may identify additional material weaknesses in our internal controls over financing reporting in the future which we may not be able to remedy in a timely manner. Any material weaknesses will not be considered remediated until a remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and it has been concluded, through testing, that the newly implemented and enhanced controls are operating effectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. More generally, any failure by us to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and could cause us to fail to meet our reporting obligations, any of which could diminish investor confidence in us and cause a decline in the price of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our IT systems, or those of our vendors, collaborators or other contractors or consultants, may fail or suffer security incidents, loss of data and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the ordinary course of our business, we collect and store sensitive data, intellectual property, and proprietary business information. This data encompasses a wide variety of business-critical information including research and development information, clinical trial information, commercial information, and business and financial information. We face risks related to protecting this critical information including loss of access, unauthorized disclosure, unauthorized modification, and inadequate monitoring of our controls over these risks. We also rely on IT systems and networks, including third-party "cloud-based" service providers, and our third-party CROs, to process, transmit and store electronic information in connection with our business activities. This includes crucial systems such as email, other communication tools, electronic document repositories, and archives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">69</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Despite the implementation of security measures, our internal IT systems and those of our current and any future third-party vendors, collaborators and other contractors or consultants are vulnerable to system failures, accidents, security incidents, damage, interruption or data theft from computer viruses, computer hackers, malicious code, employee theft or misuse, ransomware, social engineering (including phishing attacks), denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. Additionally, developments in AI and machine learning provide threat actors with the capability to use more sophisticated means to attack our systems and may exacerbate cybersecurity risk. These threats pose a risk to the security of our IT systems and networks and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in detecting or preventing cybersecurity incidents, or successfully mitigating their effects. As a result, we may experience cybersecurity incidents that may remain undetected for an extended period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any such disruption or security incident could cause interruptions to our operations and result in disruption of our development programs and business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. A successful cyberattack could also cause misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. If we were to experience a significant cybersecurity incident that impacts our information systems or data, the costs associated with the investigation, remediation, and potential notification of the cybersecurity incident to counterparties, regulatory authorities, and data subjects could be material. In addition, our remediation efforts may not be successful. Cybersecurity incidents could also lead to significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information. In addition, our recently increased remote workforce could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruption.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To the extent that any disruption or cybersecurity incident were to result in a loss of, or damage to, our or our third-party vendors&#8217;, collaborators&#8217; or other contractors&#8217; or consultants&#8217; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability including litigation exposure, penalties and fines, we could become the subject of regulatory actions or investigations, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Any of the above could have a material adverse effect on our business, financial condition, reputation, competitive advantage, results of operations or prospects. While we maintain cyber-liability insurance, such insurance may not be adequate to cover any losses experienced as a result of a cybersecurity incident.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business may be affected from time to time by government investigations and litigation with third parties, including our ongoing matter with Paul Feller.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may from time to time receive inquiries and subpoenas and other types of information requests from government authorities and other third parties and may become subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquiries, information requests and legal proceedings is difficult to predict, defense of litigation claims (even if ultimately successful) can be expensive, time-consuming and distracting, and adverse resolutions or settlements of those matters may result in, among other things, modifications to business practices, costs and significant payments, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, in August 2014, Paul Feller, the former Chief Executive Officer of our legal predecessor, filed a complaint asserting various causes of action related to his past affiliations with our legal predecessor. While we are defending itself vigorously against the claims alleged in this matter, we are unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on our financial position. Depending on the outcome or resolution of this matter, it could have a material effect on our consolidated financial position, results of operations and cash flows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business is, or may in the future become, subject to complex and evolving US and foreign laws and regulations relating to privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and</i></b> <b><i>our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The global data protection landscape is rapidly evolving, and we are currently and may become subject to or impacted by a wide variety of provincial, state, national, and international laws and regulations applying to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. These data protection and privacy-related laws and regulations are evolving and may result in increased regulatory and public scrutiny and escalating levels of enforcement and sanctions. Implementation standards and enforcement practices are likely to remain uncertain and unpredictable for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Failure to comply with data protection laws and regulations, where applicable, could result in government enforcement actions, which could include civil or criminal penalties, private litigation and/or adverse publicity and could negatively affect our operating results and business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">70</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In the US, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws govern the collection, use, disclosure and protection of health-related and other personal information. For example, the CCPA, which became effective in 2020, broadly defines personal information, gives California residents expanded individual privacy rights and protections and provides for civil penalties for violations and a private right of action for data breaches. Further, the CPRA, which became effective in 2023 and amends the CCPA, creates additional obligations with respect to processing and storing personal information. While there is limited exception for protected health information that is subject to HIPAA and clinical trial regulations, the CCPA may regulate or impact our processing of personal information depending on the context. Unlike other state privacy laws, the CCPA also regulates personal information collected in a business to business and in human resources contexts. Further, there continues to be some uncertainty about how provisions of the CCPA and the new regulations will be interpreted and how the law will be enforced. In addition to California, more US states have enacted and are continuing to enact similar legislation, increasing compliance complexity and increasing risks of failures to comply. The existence of differing comprehensive privacy laws in different states in the country may make our compliance obligations more complex and costly and may require us to modify our data processing practices and policies and to incur substantial costs and potential liability in an effort to comply with such legislation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Even when HIPAA does not apply, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice), may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. The FTC and states' Attorneys Generals have brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and comparable state laws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, other federal and state laws establish additional requirements for protecting the privacy and security of health information that is not protected by HIPAA. For instance, Washington state passed the &#8220;My Health My Data&#8221; Act, which came into force in 2024 and regulates &#8220;consumer health data,&#8221; which is broadly defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221; The &#8220;My Health My Data&#8221; Act provides exemptions for personal data used or shared in connection with certain research activities, including data subject to 45 C.F.R. Parts 46, 50 and 56. Notably, the &#8220;My Health My Data&#8221; Act contains a private right of action. In addition, Nevada enacted a consumer health data privacy bill, SB 370, which took effect in 2024, and regulates &#8220;consumer health data.&#8221; SB 370 shares many similarities with Washington&#8217;s &#8220;My Health My Data&#8221; Act, and Connecticut has amended its comprehensive privacy law to include heightened regulation of &#8220;consumer health data.&#8221; Furthermore, several states, including Illinois, Texas, and Washington, have enacted biometric privacy laws that regulate the collection and use of biometric identifiers, which may be relevant to certain activities or research involving biometric data. Additional states are considering and may adopt health-specific privacy laws that could impact our business activities and our collection and handling of health-related data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well. For example, the European Parliament and the Council of the European Union adopted a comprehensive general data privacy framework called the GDPR which became fully effective in May 2018 and governs the collection and use of personal data in the European Union, including by companies outside of the European Union., The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the US The GDPR imposes stringent data protection requirements and provides penalties for noncompliance of up to the greater of &#8364;20 million or four percent of worldwide annual turnover. The GDPR and many other laws and regulations relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of providing our products and services or even prevent us from offering certain services in jurisdictions that we may operate in. The GDPR may increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Ensuring our continued compliance with the GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Many jurisdictions outside of US and Europe are also considering and/or enacting comprehensive data protection legislation that could have an impact on market expansion and clinical trials as well.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Additionally, following the United Kingdom&#8217;s withdrawal from the European Union (i.e., Brexit), and the expiry of the Brexit transition period, which ended on December 31, 2020, the GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR sits alongside the UK Data Protection Act 2018 which implements certain derogations in the GDPR into UK law. Under the UK GDPR, companies not established in the UK but who process personal data in relation to the offering of goods or services to individuals in the UK, or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">71</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Transfers of personal data to certain countries outside of the EEA and the UK are also highly regulated under the GDPR and UK GDPR. For example, the GDPR only permits exports of personal data outside of the EEA to &#8220;non-adequate&#8221; countries where there is a suitable data transfer mechanism in place to safeguard personal data (e.g., the European Commission approved Standard Contractual Clauses or certification under European Union-US the Data Privacy Framework). On July 10, 2023, the European Commission adopted an adequacy decision for a new mechanism for transferring data from the EEA to the certain US organizations, the EU-US Data Privacy Framework, which provides European Union individuals with several new rights, including the right to obtain access to their data, or obtain correction or deletion of incorrect or unlawfully handled data. The adequacy decision followed the signing of an executive order introducing new binding safeguards to address transfers of personal data from the European Union to the US. Notably, the new obligations were geared to ensure that data can be accessed by US intelligence agencies only to the extent necessary and proportionate and to establish an independent and impartial redress mechanism to handle complaints from Europeans concerning the collection of their data for national security purposes. The European Commission will continually review developments in the US along with its adequacy decision. Adequacy decisions can be adapted or even withdrawn in the event of developments affecting the level of protection in the applicable jurisdiction. Additionally, the Data Privacy Framework may be subject to legal challenges, and there can be no assurance that it will remain a valid transfer mechanism. Prior transfer frameworks, including the European Union-US Privacy Shield, were invalidated by the Court of Justice of the European Union in its July 2020 decision in Maximilian Schrems vs. Facebook (Case C-311/18) (Schrems II), which also heightened the burden on companies to assess US national security laws and implement supplementary measures when relying on standard contractual clauses. Consequently, there is some risk that data transfers from the EEA could be challenged or halted. Future actions of European Union data protection authorities are difficult to predict. Some customers or other service providers may respond to these evolving laws and regulations by asking us to make certain privacy or data-related contractual commitments that we are unable or unwilling to make. This could lead to the loss of current or prospective customers or other business relationships.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because the interpretation and application of many privacy and data protection laws (including laws in the US and the GDPR), commercial frameworks, and standards are uncertain, it is possible that these laws, frameworks, and standards may be interpreted and applied in a manner that is inconsistent with our existing data management practices and policies. If so, in addition to the possibility of fines, lawsuits, breach of contract claims, and other claims and penalties, we could be required to fundamentally change our business activities and practices or modify our solutions, which could have an adverse effect on our business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable privacy and security or data security laws, regulations, and policies, could result in additional cost and liability to us, damage our reputation, inhibit our ability to conduct trials, and adversely affect our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Applicable data privacy and data protection laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. That could require us to incur significant expenses, which could significantly affect our business. Failure to comply with data protection laws or to protect personal data or other data we process or maintain may expose us to risk of enforcement actions taken by data protection authorities or other regulatory agencies, private rights of action in some jurisdictions, potential significant fines, penalties and other liabilities if we are found to be non-compliant, and damage to our reputation, any of which could materially affect our business, financial condition, results of operations and prospects. Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and reputation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Past or future transactions resulting in an ownership change under Section 382 may subject our NOL carryforwards and certain other tax attributes to limitation.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2025, we had US federal NOL carryforwards of approximately $16.6 million. Under Sections 382 and 383 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (within the meaning of Section 382), the corporation&#8217;s NOL carryforwards and certain other tax attributes (such as research tax credits) arising before the ownership change are subject to limitation on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds fifty percentage points (by value) over a rolling three-year period. Similar rules may apply under state tax laws. Past or future transactions to which we are a party may, alone or in the aggregate, result in such an ownership change and, accordingly, our NOL carryforwards and certain other tax attributes may be subject to limitations (or disallowance) on their use in the future. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">72</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We incur significant legal, accounting and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the laws, rules and regulations of the SEC, as well as the rules and regulations of Nasdaq. These laws, rules and regulations also may make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our Board or as executive officers of ours, which may adversely affect investor confidence in us and could cause our business or stock price to suffer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-US government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-US governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, any of our dealings with these prescribers and purchasers are subject to regulation under the FCPA. There is no certainty that all our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, future international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. However, in February 2025, President Trump issued an executive order directing the Department of Justice to pause enforcement of the FCPA and to issue new enforcement guidelines that take into consideration US national security and the competitiveness of US companies abroad. It is unclear how, if at all, this presidential directive may affect the pharmaceutical industry as a whole or our business in particular.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our employees, independent contractors, consultants, vendors and future commercial partners, if any, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are exposed to the risk of fraud, misconduct or other illegal activity by our employees, independent contractors, consultants, vendors and other third parties. Misconduct by these parties could include intentional, reckless and negligent conduct that may fail to, among other things: comply with the rules and regulations of the FDA, EMA and other comparable foreign regulatory authorities; provide true, complete and accurate information to such authorities; comply with manufacturing standards we have established; comply with healthcare fraud and abuse laws; or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive legal and regulatory requirements designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and promotion, sales and commission, certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of subject recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in defending itself or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of ours business may rely, which could negatively impact our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, our ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the FDA, the NIA, the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">73</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Future legislative and regulatory proposals may materially impact the ability of the FDA and other regulatory agencies to operate as they have historically operated. We cannot be sure whether additional legislative changes or executive orders will be enacted, or whether any of the FDA&#8217;s regulations, guidance or interpretations will be changed, or what the impact of such changes on the agency and its scientific review staff, if any, may be. For example, the FDA has experienced significant and rapid fluctuations in leadership and scientific review personnel, which may be key contributing factors in multiple reported delays in agency decision making on marketing applications and agency requests for additional data that are inconsistent with prior regulatory feedback. Additionally, the next FDA user fee reauthorization package entered stakeholder negotiations in mid-2025, and any agreement is expected to be sent to Congress in early 2027 for purposes of initiating the legislative process. Reauthorization of the prescription drug user fee program must be finalized by Congress by the end of September 2027 in order to avoid a disruption in FDA&#8217;s review goals for NDAs and other activities supported by user fees assessed against industry.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may slow the time necessary for clinical trial applications and/or marketing applications for new drugs to be reviewed or approved, which would adversely affect our business. For example, political disputes in Congress may result in a shutdown of the US government and, in such cases, certain regulatory agencies, such as the FDA and the SEC, may have to furlough critical staff and stop critical activities. Government shutdowns or slowdowns can increase the time needed for an agency to complete its review or make final approvals or other administrative decisions. If a prolonged government or slowdown shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and the ability of the SEC to timely review our public filings, to the extent such review is necessary, and our ability to access the public markets, each of which could have a material adverse effect on our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Future government shutdowns or slowdowns could also result in delays in our interactions with the SEC and other government agencies, which could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>US federal income tax reform or other changes in applicable tax law could adversely affect our business and financial condition.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The rules dealing with US federal, state, and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, the US Treasury Department, and other governmental bodies. In recent years, many such changes have been made and may continue to occur in the future. For example, in March 2020, the CARES Act was signed into law, which included certain changes in tax law intended to stimulate the US economy in response to the COVID-19 coronavirus outbreak, including temporary beneficial changes to the treatment of NOLs, interest deductibility limitations and payroll tax matters. Additionally, in December 2017, the TCJA was signed into law, which significantly reformed the Code. The TCJA included significant changes to corporate and individual taxation, some of which could adversely impact an investment in our common stock. For example, under the TCJA, in general, NOLs generated in taxable years beginning after December 31, 2017, may offset no more than 80 percent of such year&#8217;s taxable income and there is no ability for such NOLs to be carried back to a prior taxable year. The CARES Act modified the TCJA with respect to the TCJA&#8217;s limitation on the deduction of NOLs and provided that NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80 percent of current year taxable income for taxable years beginning before January 1, 2021 (but reinstated the limitation for taxable years beginning after December 31, 2020). As a result of such limitations, we may be required to pay federal income tax in some future year notwithstanding that we had a net loss for all years in the aggregate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">More generally, recent and future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face risks associated with increased geopolitical uncertainty, including as a result of evolving domestic and foreign tariff policies.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Ongoing and potential military actions across the globe, including the ongoing conflicts in Ukraine and the Middle East, as well as the sanctions, bans and other measures taken by governments, organizations and companies against the involved countries and certain citizens of those countries in response thereto, has increased the global political uncertainty and has strained the relations between a significant number of governments, including the US The duration and outcome of these conflicts, any retaliatory actions or escalation, and the impact on regional or global economies is unknown but could have a material adverse effect on our business, financial condition and results of our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, the Trump administration has signaled intentions to substantially alter prior US government international trade policy and has commenced activities to renegotiate, or potentially terminate, certain existing bilateral or multi-lateral trade agreements and treaties with foreign countries. Further, President Trump has increased, and has indicated his willingness to continue to increase, the use of tariffs by the US to accomplish certain US policy goals. On April 2, 2025, a universal 10% tariff on all US imports was announced, with higher tariffs ranging from 11% to 50% on imports from 57 countries. Tariff rates have since fluctuated as a result of bilateral negotiations and legal challenges, and product-specific tariffs have also been implemented. On February 20, 2026, the US Supreme Court ruled against the Trump administration&#8217;s use of tariffs under the IEEPA and US Customs and Border Protection halted collections of IEEPA tariffs on February 24, 2026. However, the decision creates uncertainty related to various aspects of the tariffs previously collected under the IEEPA, including whether, and if so, how, companies may be able to recover any portion of IEEPA tariffs previously paid. Additionally, in response to the US Supreme Court ruling, the Trump administration imposed a new worldwide tariff effective for 150 days from February 24, 2026. These ongoing measures have led to retaliatory tariffs from affected countries and have contributed to increased trade tensions and economic uncertainty. Such tariffs and any countermeasures could increase the cost of raw materials and components necessary for our operations, disrupt our supply chain and create additional operational challenges. Further, it is possible that government policy changes and related uncertainty about policy changes could increase market volatility. Because of these dynamics, we cannot predict the impact of any future changes to the US&#8217; or other countries&#8217; trading relationships or the impact of new laws or regulations adopted by the US or other countries on our business. Such changes in tariffs and trade regulations could have a material adverse effect on our financial condition, results of operations and cash flows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">74</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and, more recently, the COVID-19 pandemic caused significant volatility and uncertainty in US and international markets. A severe or prolonged economic downturn, or additional global financial crises, could result in a variety of risks to our business, including weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Epidemics, pandemics or other public health crises, including COVID-19, could adversely affect our business.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our operations could be significantly adversely affected by the effects of a widespread outbreak of epidemics, pandemics or other health crises, including COVID-19. We cannot accurately predict the impact of epidemics and pandemics would have on our operations and the ability of third parties to meet their obligations under contracts or arrangements with us, including uncertainties relating to the ultimate geographic spread of epidemics and pandemics, the severity of the underlying diseases, the duration of outbreaks, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect our operations and ability to finance our operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Political uncertainty may have an adverse impact on our operating performance and results of operations</i></b><i>.</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">General political uncertainty may have an adverse impact on our operating performance and results of operations. In particular, the US continues to experience significant political events that cast uncertainty on global financial and economic markets. It is presently unclear exactly what actions our current administration in the US will implement, and if implemented, how these actions may impact the pharmaceutical industry in the US</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We hold our cash and cash equivalents that we use to meet our working capital needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We hold our cash and cash equivalents that we use to meet working capital needs in deposit accounts at certain third-party financial institutions. The balances held in these accounts may exceed the FDIC, standard deposit insurance limit or similar government guarantee schemes. If a financial institution in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our obligations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For example, on March 10, 2023, Silicon Valley Bank, and on March 12, 2023, Signature Bank, were closed by state regulators and the FDIC was appointed receiver for each bank. The FDIC created successor bridge banks and all deposits of Silicon Valley Bank and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the US Department of the Treasury, the Federal Reserve and the FDIC. While we did not hold any of our funds in accounts with either of these institutions, if financial institutions in which we hold funds for working capital were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We may also, from time to time, maintain investment accounts with other financial institutions in which we holds our investments and, if access to the funds we use for working capital is impaired, we may not be able to sell investments or transfer funds from our investment accounts to new accounts on a timely basis sufficient, or without incurring a loss or penalty as a result of such sale, to meet our working capital needs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain stockholders could attempt to influence changes within our Company which could adversely affect our operations, financial condition and the value of our common stock.</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">One or more of our stockholders may from time to time seek to acquire a significant or controlling stake in us, engage in proxy solicitations, advance stockholder proposals or otherwise attempt to effect changes to our Board or corporate governance policies. Campaigns by stockholders to effect changes at publicly traded companies are sometimes led by investors seeking to increase short-term stockholder value through actions such as financial restructuring, increased debt, special dividends, stock repurchases or sales of assets or the entire company. Responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, could disrupt our operations and divert the attention of our Board and senior management, and could adversely affect our operations, financial condition, and the value of our common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">75</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1B.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>UNRESOLVED STAFF COMMENTS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1C.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CYBERSECURITY</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="c35" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cybersecurity Risk Management Program Overview</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c38"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="c39">We recognize the critical role that properly managing cybersecurity risk plays in maintaining the trust and confidence of our stockholders, the patients in our clinical trials, our employees, our business partners and our other stakeholders. Accordingly, our cybersecurity program is designed to identify, assess, manage and mitigate material risks from cybersecurity threats through a variety of measures, including risk assessments, implementation of security measures, and ongoing monitoring of systems and networks. In collaboration with our third-party IT service providers, a cross-functional team comprised of representatives from our administrative, finance and legal functions actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We also engage external experts, including IT experts, other consultants, and auditors to evaluate our cybersecurity measures and risk management processes.</ix:nonNumeric></span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also identify our cybersecurity threat risks by comparing our processes to industry standards and best practices as well as by engaging experts to manage our information systems. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, the activities we undertake include the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws, including industry-specific laws such as HIPAA, as applicable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">through our policies, practices and contracts (as applicable), employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, which are evaluated and improved through vulnerability assessments and other evaluations on a routine basis;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">leverage threat intelligence available to us and our third-party IT service provider to help us identify, protect, detect, respond and recover if there is an actual or potential cybersecurity incident; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Board Oversight of Cybersecurity Risk Management and Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c43"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="c44"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="c45"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="c46">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">76</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management's Role in Cybersecurity Risk Management and Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="c47"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="c48">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.</ix:nonNumeric></ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c49">We depend on and engage various other third parties, including suppliers, vendors, and service providers, to support key elements of our business including our IT infrastructure. We have implemented various control processes designed to address cybersecurity threat risks associated with our use of such third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, and continually monitor cybersecurity threat risks identified through such diligence. Our management is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents, including through the receipt of notifications from service providers and reliance on communications with risk management, legal, IT, and/or compliance personnel. In addition, cybersecurity risks and posture are, as appropriate and applicable, a factor considered in the selection process prior to our engagement of third-party service providers.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c50">In response to an identified cybersecurity incident, a group comprised of appropriate management personnel, our third-party IT service providers and, depending on the scope and severity of the incident, additional third-party subject matters experts, will be assembled to develop and implement a response strategy to contain, control, and remediate the cybersecurity incident, including securing our affected systems and/or information, mitigating harmful effects of the incident, preventing further compromises, and communicating information to affected parties, regulatory agencies and law enforcement, as necessary. This group will also report any such cybersecurity incident to the Audit Committee of the Board.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Assessment of Cybersecurity Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The potential impact of risks from cybersecurity threats are assessed on an ongoing basis by both management and the Board, including how such risks could materially affect our business strategy, operational results, and financial condition, and from time-to-time we engage third-parties to provide independent risk assessments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="c51">As of the date of this Annual Report, we have not experienced a cybersecurity incident that results in a material effect on our business strategy, results of operations or financial condition, but we cannot provide assurance that we will not be materially affected in the future by such an incident or risks related thereto.</ix:nonNumeric></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading <i>Item 1A. Risk Factors </i>&#8211;<i> General Risks Related to Our Business and Operations</i>, which disclosures are incorporated by reference herein.</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PROPERTIES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We currently have a short-term lease for office space in Boston, Massachusetts which we use for our corporate offices. In addition, we previously had a short-term agreement to utilize membership-based co-working space in Charlottesville, Virginia, which was terminated in the first quarter of 2024. Rent expense related to our short-term agreements was approximately $57,112 and $34,692 for the years ended December&#160;31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe the space is adequate to meet our near-term needs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>LEGAL PROCEEDINGS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information in <i>Note 8, Commitments and Contingencies </i>&#8212;<i> Legal Proceedings</i> to our consolidated financial statements included in, <i>Part II </i>&#8212;<i> Item 8 </i>&#8212;<i> Financial Statements and Supplementary Data</i> of this Annual Report is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, from time to time, we are subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. We record a liability in our consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when we have assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, we record the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. We disclose a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect our consolidated results of operations, financial position or cash flows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">77</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MINE SAFETY DISCLOSURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MARKET FOR REGISTRANT</b>&#8217;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our common stock trades publicly on the Nasdaq Capital Market under the symbol &#8220;CRVO.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of March&#160;11, 2026, there were 102&#160;record holders of our common stock. This does not include beneficial owners of our common stock whose stock is held in nominee or &#8220;street name&#8221;.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">To date, we have not declared or paid any cash dividends on our common stock and do not intend to do so in the near future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information set forth in, <i>Part III </i>&#8212;<i> Item 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters)</i> of this Annual Report is incorporated herein by reference to the extent required by Item 201(d) of Regulation S-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Unregistered Sales of Equity Securities and Use of Proceeds</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>[RESERVED]</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MANAGEMENT</b>&#8217;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>This discussion and analysis contains information related to historical and prospective events intended to enable you to assess our financial condition and results of operations. The information contained in this discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes contained elsewhere in this Annual Report, as well as the risks and uncertainties discussed under the headings, "Item 1A </i>&#8212;<i> Risk Factors" and </i>&#8220;<i>Note Regarding Forward-Looking Statements.</i>&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are a clinical-stage biotechnology company developing treatments for age-related brain disorders. Our lead drug candidate, neflamapimod, is an investigational, orally administered small-molecule drug that readily crosses the blood&#8211;brain barrier and selectively inhibits the enzyme p38&#945;, a key driver of neuroinflammation and synaptic dysfunction. By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of DLB, our lead indication, as well as nfvPPA, RAS, and ALS.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">78</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our novel approach focuses on reducing the impact of neuroinflammation, which we believe is a key factor in the manifestation of degenerative diseases of the brain. Chronic activation of p38&#945; in the brains of people with certain neurodegenerative diseases is believed to impair how neurons communicate through synapses. This synaptic dysfunction leads to deterioration of cognitive and motor abilities. Left untreated, synaptic dysfunction can result in irreversible neuronal loss that leads to devastating disabilities, significant reliance on a caretaker, long term care living, and, ultimately, death. However, before neuronal loss commences, disease progression in many major neurodegenerative disorders, including DLB, initially involves a protracted period of reversible functional loss, particularly with respect to the synapses. We believe that inhibiting p38&#945; activity in the brain has the potential to reverse the clinical progression observed in the early-stages of certain neurodegenerative diseases, as well as slow further progression by delaying permanent synaptic dysfunction and neuron death, by interfering with key pathogenic drivers of disease.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We believe we are a leader in the industry in developing a treatment for DLB, a disease with no approved therapies in the US or European Union despite being the second most common progressive dementia. Neflamapimod is the only clinical drug candidate that, to our knowledge, has shown statistically significant improvements on clinical endpoints and a biomarker of neurodegeneration in both a Phase 2a and Phase 2b clinical trial. Differentiating our approach from potential competitors, we believe we are also the only company specifically targeting the treatment of DLB patients without AD co-pathology. While DLB patients with AD co-pathology generally have significant, irreversible neuronal loss, DLB without AD co-pathology is primarily a disease of functional deficits of synapses that we believe is more treatable. We believe if neflamapimod is given in the early stages of certain degenerative diseases of the brain like DLB without AD co-pathology, it may reverse synaptic dysfunction, improve neuron health and function, and slow further progression by delaying synaptic dysfunction and neuronal death. We believe this approach enhances the alignment of our development path with neflamapimod&#8217;s mechanism of action, reduces the heterogeneity of our target patient population, and provides the opportunity to demonstrate heightened clinical effect in shorter duration trials.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Summary</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2025, we had cash, cash equivalents and marketable securities of approximately $20.9 million. To date, we have not had any products approved for sale and have not generated any revenue from product sales, and our ability to do so in the future will depend on the successful development and eventual commercialization of neflamapimod (or another product candidate that we could acquire or develop in the future). We do not expect to generate revenue from product sales until such time, if ever.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our accumulated deficit as of December 31, 2025, was $97.7 million. We have never been profitable, and we will continue to require additional capital to develop neflamapimod and fund operations for the foreseeable future. We have historically incurred net losses in each year since inception. Our net losses were $27.0 million and $16.3 million in the years ended December 31, 2025 and 2024, respectively. We expect our expenses will increase in connection with our ongoing activities, as we:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">advance neflamapimod through clinical trials, including our planned Phase 3 trial in DLB, subject to available funding;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">manufacture supplies for our nonclinical studies and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">obtain, maintain, expand, and protect our intellectual property portfolio;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">hire additional personnel to support our operations and growth; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">continue to operate as a public company.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Based on our current operating plan, we do not believe our existing cash, cash equivalents and marketable securities on hand as of December&#160;31, 2025 will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months from the issuance of the consolidated financial statements included in this Annual Report. The consolidated financial statements appearing elsewhere in this Annual Report have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business and do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Operations Overview</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Revenue</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To date, we have not generated any revenue from product sales and we do not expect to do so in the near future. In January 2023, we were awarded our $21.0 million NIA Grant and, in August 2024, we were awarded an additional $0.3 million under our NIA Grant. Funding from the NIA Grant was to be received in three annual installments and recognized as grant revenue as the qualifying expenses related thereto are incurred. During the year ended December 31, 2025, $4.0 million of grant funding was recognized as revenue, of which $3.6 million had been received and the remaining $0.4 million was recorded as grant receivable. During the year ended December 31, 2024, $9.7 million of grant funding was recognized as revenue, of which $7.5 million had been received and the remaining $2.3 million was recorded as grant receivable. In January 2026, we were informed that we will not receive the final 2% of year 3 grant funding that remained unavailable as of December 31, 2025, or approximately $0.1 million, as a result of agency-wide reductions in NIA funding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">79</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development Expenses</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Research and development expenses account for a significant portion of our operating expenses and primarily consist of costs incurred for the discovery and development of our product candidates, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">expenses incurred under agreements with CROs, nonclinical testing organizations, consultants, and other third-party vendors, collaborators and service providers;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">costs related to production of clinical materials, including fees paid to CDMOs;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">vendor expenses related to the execution of nonclinical studies and clinical trials;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel engaged in research and development functions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">costs related to the preparation of regulatory submissions;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">third-party license fees; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">expenses for rent and other supplies.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We recognize research and development expenses as incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators, and third-party service providers. Non-refundable advance payments made by us for future research and development activities are capitalized and expensed as the related goods are delivered and as services are performed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">Specific program expenses include expenses associated with the development of our lead product candidate, neflamapimod. Personnel and other operating expenses incurred for our research and development programs primarily relate to salaries and benefits, stock-based compensation, and facility expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, neflamapimod, or for any other product candidates that we may develop or acquire. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing neflamapimod such as conducting larger clinical trials, seeking regulatory approval and incurring expenses associated with hiring personnel to support other research and development efforts. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming, and the successful development of product candidates, including neflamapimod, is highly uncertain.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>General and Administrative Expenses</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation for our personnel in executive, finance and accounting, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, consulting, and tax services, insurance costs, and facility costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research and development activities and as we continue development activities pursuant to the NIA Grant. We also anticipate that we will incur increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and those of any national securities exchange on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Interest Income</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest income consists of interest earned on our marketable securities and on our cash and cash equivalent balances held with financial institutions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">80</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comparison of the Years Ended December 31, 2025 and 2024</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes our results of operations:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>$ Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>% Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,006,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,737,974</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,731,464</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(59</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,817,072</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,798,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,018,729</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,484,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,166,762</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,317,553</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">32,301,387</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">27,965,105</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,336,282</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28,294,877</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(18,227,131</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,067,746</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,327</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(991</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">(a)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,336,837</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,937,427</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(600,590</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,328,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,936,436</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(607,926</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,966,367</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(16,290,695</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10,675,672</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">66</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">*(a) Not meaningful</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Grant Revenue</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Grant revenue was $4.0 million and $9.7 million for the years ended December 31, 2025 and 2024, respectively. In each year, all grant revenue is related to the NIA Grant which funded our RewinD-LB Trial. The year-over-year decrease of $5.7 million is due to the completion of the Randomized Phase of the RewinD-LB Trial in late 2024, followed by the subsequent completion of the Extension Phase in mid-2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Research and Development Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table summarizes our research and development expenses by functional area for the years ended December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>$ Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>% Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dementia with Lewy bodies</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,052,512</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,102,842</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,050,330</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(42</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Frontotemporal disorders (incl. nfvPPA)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,217,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,180,931</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">(a</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Recovery after stroke</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,427,966</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,659</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,036,307</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">265</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other clinical* and nonclinical</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,504,863</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,499,202</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,661</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,745,558</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,187,221</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,558,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">163</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">263,847</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other research and development expenses, including CMC</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,385,720</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,361,744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,023,976</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">149</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">21,817,072</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,798,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,018,729</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* Includes early-stage clinical studies that are not indication-specific and related costs.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a) Not meaningful.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Research and development expenses were $21.8 million for the year ended December 31, 2025, compared to $18.8 million for the year ended December 31, 2024. The increase of $3.0 million was due to several factors. The increase of personnel costs of $3.6 million and increase in stock-based compensation of $0.3 million were driven by higher headcount and an increase in outsourced consulting costs. The increase of $2.0 million in costs related to CMC activities and other research and development expenses is primarily related to the analysis of the batch issues identified during the Randomized Phase of the RewinD-LB Trial and the implementation of our planned pre-Phase 3 manufacturing improvements. Finally, we saw an aggregate increase of $2.2 million related to non-DLB clinical work for neflamapimod, including costs related to our RESTORE Trial in RAS and Phase 2a trial in nfvPPA, which were both initiated during 2025. These amounts were offset by a decrease of $5.1 million in DLB-related clinical spend due to the completion of the Randomized Phase of the RewinD-LB Trial in December 2024, followed by the subsequent completion of the Extension Phase in mid-2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">81</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>General and Administrative Expenses</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes our general and administrative expenses by functional area for the years ended December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"><b>&#160;</b></td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>$ Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>% Change</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,988,705</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,995,114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">993,591</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">965,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,186,900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(220,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,752,710</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,684,386</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">68,324</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance, taxes and similar fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,166,374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">985,481</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">180,893</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other general and administrative expenses, including IT, facilities, supplies and similar costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">610,561</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">314,879</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">295,682</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">94</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total general and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,484,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,166,760</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,317,555</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">General and administrative expenses were $10.5 million for the year ended December 31, 2025, compared to $9.2 million for the year ended December 31, 2024. The increase of $1.3 million was primarily due to the increase of $1.0 million in personnel costs, the increase of $0.3 million in other general and administrative expenses, the increase of $0.2 million in insurance and taxes, and the increase of $0.1 million in professional fees, partially offset by a decrease of $0.2 million in stock-based compensation. The increase in personnel costs was primarily driven by headcount and additional severance costs. The decrease in stock-based compensation was primarily due to higher stock compensation expense related to stock option modifications in the prior year in comparison to current year.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Other Expense</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">There was a <i>de minimis</i> amount of other expense for the years ended December&#160;31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Interest Income</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Interest income was $1.3 million and $1.9 million for the years ended December&#160;31, 2025 and 2024, respectively. The decrease was primarily due to lower investment balances as cash was used for operations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Capital Requirements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">From the date of our inception through December 31, 2025, our operations have primarily been financed through the issuance of common stock, convertible preferred stock and convertible debt financings. As of December 31, 2025, we had approximately $20.9 million of cash, cash equivalents and marketable securities. We have not generated positive cash flows from operations and as of December 31, 2025, we had an accumulated deficit of approximately $97.7 million. In January 2023, we were awarded a $21.0 million grant from the NIA to support the RewinD-LB Trial, which was received over a three-year period. In August 2024, we received an additional $0.3 million from the NIA. As of December 31, 2025, total cash funding of $20.5 million had been received from the NIA Grant and approximately $0.6 million in funding is remaining. In March 2025, we received access to 90% of the year 3 funding and, in June 2025, we received access to an additional 8% of the year 3 funding provided for in the NIA Grant, due to then-current NIA policy as a result of the US government currently being funded on the basis of a continuing resolution. Accordingly, as of December&#160;31, 2025, we determined that the receipt of the remaining 2% of funding was not probable and we would not account for the remaining 2% of funding unless and until received. In January 2026, we were informed that we will not receive the final 2% of year 3 grant funding that remained unavailable as of December 31, 2025, or approximately $0.1 million, as a result of agency-wide reductions in NIA funding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:33pt;">On April 1, 2024, pursuant to and in accordance with the terms of a securities purchase agreement with certain purchasers named therein, we completed the 2024 Private Placement of an aggregate of 2,532,285 units, each comprised of (i) (A) one share of common stock or (B) one Pre-Funded Warrant and (ii) one Series A Warrant. The aggregate upfront gross proceeds from the 2024 Private Placement were approximately $50.0 million, before deducting offering fees and expenses, and additional gross proceeds of up to approximately $99.4 million may be received if the Series A Warrants are exercised in full for cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On May 21, 2025, we entered into the Sales Agreement with Leerink Partners, LLC, as sales agent, pursuant to which we may offer and sell shares of common stock from time-to-time with an aggregate offering price of up to $50.0 million under an &#8220;at-the-market" offering program. During the year ended December&#160;31, 2025, we sold 550,000 shares of common stock to an institutional investor in a block sale for proceeds of $4.7 million, net of $0.1 million of issuance costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">82</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs and, to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">Any product candidates we may develop may never achieve commercialization, and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In addition, we expect to incur costs associated with operating as a public company. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, costs related to clinical research, manufacturing and development services; compensation and related expenses; costs relating to the build-out of our headquarters, other offices and laboratories; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; manufacturing costs; legal and other regulatory expenses and general overhead costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">Based on our current operating plan, we do not believe our existing cash, cash equivalents and marketable securities on hand as of December&#160;31, 2025, will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months from the issuance of the consolidated financial statements included in this Annual Report. Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the consolidated financial statements included elsewhere in this Annual Report are issued. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings, royalty arrangements, or other dilutive or non-dilutive capital sources, including potential collaborations, licenses and/or other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through a debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we may need to delay, reduce or terminate planned activities to reduce costs, including our development or commercialization activities for neflamapimod. We might also be required to seek funds through arrangements with third parties that require us to relinquish certain of our rights to neflamapimod or otherwise agree to terms unfavorable to us.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our operating capital requirements. Our future capital requirements will depend on, and could increase significantly as a result of, many factors, including:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the enrollment, progress, timing, costs and results of our clinical trials and other development activities for neflamapimod;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to reach certain milestone events set forth in our collaboration agreements and the timing of such achievements, triggering our obligation to make applicable payments;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the hiring of additional clinical, scientific and commercial personnel to pursue our development plans, as well the increased costs of internal and external resources as to support our operations as a public reporting company;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the cost and timing of securing manufacturing arrangements for clinical or commercial production;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the cost of establishing, either internally or in collaboration with others, sales, marketing and distribution capabilities to commercialize neflamapimod, if approved;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the cost of filing, prosecuting, enforcing, and defending our patent claims and other intellectual property rights, including defending against any patent infringement actions brought by third parties against us;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">our ability to establish strategic collaborations, licensing or other arrangements with other parties on favorable terms, if at all; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">the extent to which we may in-license or acquire other product candidates or technologies.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">83</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A change in the outcome of any of these or other variables could significantly alter the costs and timing associated with the development of neflamapimod. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash Flows</i></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23,449,963</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16,530,827</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by (used in) investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,097,249</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28,661,129</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,588,687</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,398,606</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(764,027</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,206,650</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Operating Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2025, cash used in operating activities was $23.4 million. The net cash outflow from operations primarily resulted from net loss of $27.0 million and accretion of discount on marketable securities of $0.9 million, offset by changes in operating assets and liabilities of $2.9 million and $1.4 million for stock-based compensation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2024, cash used in operating activities was $16.5 million. The net cash outflow from operations primarily resulted from net loss of $16.3 million, accretion of discount on marketable securities of $1.2 million and changes in operating assets and liabilities of $0.4 million, partially offset by a non-cash expense of $1.4 million for stock-based compensation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Investing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2025, cash provided by investing activities was $18.1 million due to the maturities of marketable securities, partially offset by the purchases of marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2024, cash used in investing activities was $28.7 million due to the purchase of marketable securities, partially offset by the maturities of marketable securities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Financing Activities</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2025, net cash provided by financing activities was $4.6 million due to proceeds from the sale of common stock for $4.6 million, net of offering costs, pursuant to the Sales Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the year ended December 31, 2024, net cash provided by financing activities was $46.4 million due to proceeds from the sale of common stock and the Pre-Funded Warrants for gross proceeds of approximately $50.0 million, partially offset by the payment of issuance costs related to the sale of common stock and the Pre-Funded Warrants of $3.6 million, in each case, in connection with the 2024 Private Placement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Contractual Obligations and Other Commitments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, nonclinical studies and manufacturing, and other services for operating purposes. The amount and timing of contractual obligations may vary based on the timing of services. We can generally elect to discontinue the work under these agreements at any time. In the future, we could also enter into additional collaborative research, contract research, manufacturing and supplier agreements which may require upfront payments or long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Accounting Polices and Estimates</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with US GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">84</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Research and Development Costs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe research and development costs is a critical accounting policy and estimate. Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on our behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">A substantial portion of our ongoing research and development activities are conducted by third-party service providers. We record an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, we record expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. We monitor subject enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">If we underestimate or overestimate the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, we have not experienced significant changes in our estimates of nonclinical studies and clinical trial expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Stock-based Compensation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We believe stock-based compensation is one of our more significant accounting policies used in the preparation of our consolidated financial statements. Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. We account for forfeitures as they occur. The fair value of stock options is determined by us using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected Term</i>. The expected term represents the period that stock-based awards are expected to be outstanding. We use the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of our stock options, taking into consideration multiple vesting tranches. We utilize this method due to lack of historical data and the plain-vanilla nature of our stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected Volatility</i>. We have limited information on the volatility of common stock as the shares were not actively traded on any public markets until August 2023. As such, expected volatility is derived from the historical stock volatilities of comparable peer public companies within our industry. These companies are considered to be comparable to our business over a period equivalent to the expected term of the stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Risk-Free Interest Rate</i>. The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the stock options expected term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected Dividend Rate</i>. The expected dividend is zero as we have not paid, nor do we anticipate paying, any dividends on our stock options in the foreseeable future.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information in <i>Note 3, Basis of Presentation and Summary of Significant Accounting Policies</i> to our consolidated financial statements set forth in, &#8220;<i>Part II </i>&#8212;<i> Item 8 </i>&#8212;<i> Financial Statements</i>&#8221; of this Annual Report is incorporated herein by reference.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">85</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 7A.</b></p>
			</td>
			<td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a &#8220;smaller reporting company&#8221; (as such term is defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information described in Item 305 of Regulation S-K and, accordingly, the information required by Item 7A of Form 10-K has been omitted from this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 8.</b>&#160;</p>
			</td>
			<td style="width: 91%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Description</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorFirmId" id="c55">49</ix:nonNumeric>)</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">86</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">88</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">89</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Stockholders&#8217;&#160;Equity for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">90</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">91</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">&#160;</td>
			<td style="vertical-align: bottom; width: 5%;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: bottom; width: 9%;">&#160;</td>
			<td style="vertical-align: bottom; width: 86%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to the Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align: bottom; width: 5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">92</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">86</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">To the Stockholders and the Board of Directors of CervoMed Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Opinion on the Financial Statements</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have audited the accompanying consolidated balance sheets of CervoMed Inc. and its subsidiaries (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders' equity and cash flows for the years then ended, and the related notes to the consolidated financial statements&#160;(collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>The Company</b>&#8217;<b>s ability to Continue as a Going Concern</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and will be required to raise additional capital to fund operations. This raises substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters also are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Basis for Opinion</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the&#160;Public Company Accounting Oversight Board (United States) (PCAOB)&#160;and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">87</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Critical Audit</b>&#160;<b>Matter</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Research and Development Expenses Related to Nonclinical Studies and Clinical Trials</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As discussed in Note 3 to the financial statements, the Company estimates the amount of nonclicinal study and clinical trial expenses incurred in each period. Estimates are based on the services performed by research institutions, contract research organizations, investigative sites, vendors in connection with clinical activities, and contract manufacturing organizations. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement and makes judgments and estimates in determining the amount of research and development expense and related accrued or prepaid balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and may be reflected in the consolidated financial statements as an accrued or prepaid expense. Research and development expenses related to clinical trials, as described above, are included within the $21.8 million of research and development expenses recorded on the Company&#8217;s statement of operations and comprehensive loss. The Company's accrual for clinical development costs totaled $1.5 million at December 31, 2025, as disclosed in Note 7 and prepayment for clinical expenses totaled $0.7 million at December 31, 2025, as disclosed in Note 6.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We identified the research and development expenses related to nonclinical studies and clinical trials to be a critical audit matter because auditing the Company&#8217;s expenses is complex as the information necessary to make an estimate is accumulated from multiple sources and there may be delays in invoicing from clinical study sites and other vendors, or payments may depend on factors such as the completion of clinical trial milestones. Additionally, in certain circumstances, it requires judgment, as the timing and pattern of vendor invoicing may not correspond to the level of services provided.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our audit procedures to test the research and development expenses related to nonclinical studies and clinical trials included, among others:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We inspected contracts and purchase orders with certain third parties and agreed key milestones, activities, timing, and costs to management&#8217;s schedules.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We tested the completeness and accuracy of the underlying data used by management to estimate the service performed and associated costs incurred to date.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We corroborated the progress of a sample of research and development activities through inquiries with the Company&#8217;s research and development personnel and sent confirmations directly to certain third-party vendors.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We tested a sample of invoices received from third parties and cash disbursements before and after year-end to assess completeness of accrued expenses or the existence of prepaid expenses.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorName" id="c56">RSM US LLP</ix:nonNumeric></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company's auditor since 2017.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="dei:AuditorLocation" id="c57">Boston, Massachusetts</ix:nonNumeric></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">88</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p>
</div>

<div>&#160;</div>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consolidated Balance Sheets</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c63" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="0">8,235,469</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c64" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:num-dot-decimal" decimals="0">8,999,496</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c65" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">12,628,970</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c66" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:MarketableSecuritiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">29,922,523</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c67" contextRef="i_2025-12-31" unitRef="USD" name="crvo:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0">1,267,005</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c68" contextRef="i_2024-12-31" unitRef="USD" name="crvo:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0">1,905,360</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c69" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredOfferingCosts" scale="0" format="ixt:num-dot-decimal" decimals="0">320,581</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c70" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredOfferingCosts" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Grant receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c71" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:GrantsReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">426,993</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c72" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:GrantsReceivableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">2,254,231</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c73" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">22,879,018</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c74" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">43,081,610</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c75" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="0">22,879,018</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c76" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:num-dot-decimal" decimals="0">43,081,610</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Liabilities and Stockholders</b>&#8217;<b> Equity</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Current liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c78" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,454,118</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c79" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,511,440</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accrued expenses and other current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c80" contextRef="i_2025-12-31" unitRef="USD" name="crvo:AccruedExpensesAndOtherCurrentLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">3,201,999</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81" contextRef="i_2024-12-31" unitRef="USD" name="crvo:AccruedExpensesAndOtherCurrentLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">2,367,842</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total current liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">4,656,117</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c83" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">3,879,282</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c84" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">4,656,117</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c85" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">3,879,282</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commitments and Contingencies (Note 8)</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders&#8217; Equity:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0pt 0pt 0pt 18pt;">Series A preferred stock $<ix:nonFraction id="c87" contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c88" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="c89" contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c90" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">30,000,000</ix:nonFraction></ix:nonFraction> authorized at December 31, 2025 and 2024, <ix:nonFraction id="c91" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3"><ix:nonFraction id="c92" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3"><ix:nonFraction id="c93" contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="-3"><ix:nonFraction id="c94" contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="-3">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2025 and 2024</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c95" contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c96" contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Common stock, $<ix:nonFraction id="c97" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c98" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:num-dot-decimal" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="c99" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c100" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:num-dot-decimal" decimals="INF">1,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2025 and 2024: <ix:nonFraction id="c101" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c102" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,252,719</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="c103" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:num-dot-decimal" decimals="INF"><ix:nonFraction id="c104" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,702,719</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2025 and 2024, respectively</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c105" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="0">9,252</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c106" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c107" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="0">115,905,684</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c108" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="0" format="ixt:num-dot-decimal" decimals="0">109,868,913</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated other comprehensive income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c109" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0">5,816</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c110" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0">56,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c111" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">97,697,851</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c112" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">70,731,484</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c113" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">18,222,901</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c114" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">39,202,328</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Total liabilities and stockholders' equity</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c115" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">22,879,018</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c116" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">43,081,610</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to consolidated financial statements</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">89</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consolidated Statements of Operations and Comprehensive Loss</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c120" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:num-dot-decimal" decimals="0">4,006,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c121" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:num-dot-decimal" decimals="0">9,737,974</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Operating expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c123" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">21,817,072</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c124" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">18,798,343</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c125" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">10,484,315</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c126" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">9,166,762</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total operating expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c127" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">32,301,387</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c128" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">27,965,105</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Loss from operations</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c129" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">28,294,877</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c130" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">18,227,131</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other income (expense):</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c132" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">8,327</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c133" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherNonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">991</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Interest income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c134" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:num-dot-decimal" decimals="0">1,336,837</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c135" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:num-dot-decimal" decimals="0">1,937,427</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total other income, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c136" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,328,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c137" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,936,436</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c138" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">26,966,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c139" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,290,695</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Per share information:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss per share of common stock, basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c141" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.98</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c142" contextRef="d_2024-01-01_2024-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF" sign="-">2.02</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Weighted average shares outstanding, basic and diluted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c143" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,041,760</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c144" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,073,155</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Net unrealized (loss) gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c146" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">50,381</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c147" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0">56,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Total comprehensive loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c148" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">27,016,748</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c149" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,234,498</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to consolidated financial statements</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">90</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consolidated Statements of Stockholders</b>&#8217;<b> Equity</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31, 2025 and 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Common Stock</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Additional</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Paid-in</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>other</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>comprehensive </b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Accumulated</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Stockholders'</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Shares</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Capital </b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>income</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Deficit </b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Equity </b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2023</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c153" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">5,674,520</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c154" contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">5,674</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c155" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">61,811,889</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c156" contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c157" contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">54,440,789</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c158" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">7,376,774</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c159" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,083,262</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c160" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">2,083</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c161" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">46,396,523</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c162" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c163" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c164" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">46,398,606</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options granted in lieu of compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c166" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">255,724</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c168" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c169" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c170" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:num-dot-decimal" decimals="0">255,724</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cashless exercise of prefunded warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c171" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">944,937</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c172" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="crvo:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0">945</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c173" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="crvo:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">945</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c174" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="crvo:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c175" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="crvo:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c176" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:StockIssuedDuringPeriodValueExerciseOfWarrants" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c178" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c179" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,405,722</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c180" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c181" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c182" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,405,722</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized gain on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c184" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c185" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c186" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0">56,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c187" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c188" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0">56,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c190" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c191" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c192" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c193" contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,290,695</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c194" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,290,695</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2024</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c195" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">8,702,719</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c196" contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">8,702</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c197" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">109,868,913</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c198" contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">56,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c199" contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">70,731,484</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c200" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">39,202,328</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sale of common stock, net of issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c201" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">550,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c202" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">550</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c203" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">4,588,137</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c204" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c205" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c206" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="0">4,588,687</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c207" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c208" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,448,634</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c209" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c210" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c211" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:num-dot-decimal" decimals="0">1,448,634</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Unrealized loss on marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c212" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c213" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c214" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">50,381</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c215" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c216" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">50,381</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c217" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c218" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c219" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c220" contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">26,966,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c221" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">26,966,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at December 31, 2025</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c222" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">9,252,719</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c223" contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">9,252</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c224" contextRef="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">115,905,684</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c225" contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">5,816</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c226" contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">97,697,851</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c227" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:num-dot-decimal" decimals="0">18,222,901</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to consolidated financial statements</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">91</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div>&#160;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Consolidated Statements of Cash Flows</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="null">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from operating activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c232" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">26,966,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c233" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,290,695</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accretion of discount on marketable securities, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c235" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="0" format="ixt:num-dot-decimal" decimals="0">854,077</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c236" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="0" format="ixt:num-dot-decimal" decimals="0">1,205,197</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c237" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="0">1,448,634</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c238" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="0">1,405,722</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Prepaid expenses and other current assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c240" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">638,355</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c241" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:num-dot-decimal" decimals="0">641,089</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Deferred offering costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c242" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="0" format="ixt:num-dot-decimal" decimals="0">310,581</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c243" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDeferredCharges" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c244" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">67,322</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c245" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" format="ixt:num-dot-decimal" decimals="0">848,969</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Accrued expenses and other liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c246" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">834,157</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c247" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">690,290</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Grant receivable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c248" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">1,827,238</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c249" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" format="ixt:num-dot-decimal" decimals="0">1,338,827</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash used in operating activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c250" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">23,449,963</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c251" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,530,827</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from investing activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Purchase of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c253" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">25,402,751</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c254" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">48,101,129</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Maturities of marketable securities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c255" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">43,500,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c256" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">19,440,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by (used in) investing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c257" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0">18,097,249</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c258" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">28,661,129</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash flows from financing activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Proceeds from sale of common stock, prefunded warrants and common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c260" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="crvo:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c261" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0">46,398,606</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Sale of common stock under At-the-Market Sales Agreement, net of issuance costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c262" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:num-dot-decimal" decimals="0">4,588,687</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c263" contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net cash provided by financing activities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c264" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0">4,588,687</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c265" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:num-dot-decimal" decimals="0">46,398,606</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net (decrease) increase in cash and cash equivalents</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c266" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">764,027</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c267" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:num-dot-decimal" decimals="0">1,206,650</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at beginning of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c268" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">8,999,496</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c269" contextRef="i_2023-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">7,792,846</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash and cash equivalents at end of the year</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c270" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">8,235,469</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c271" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:num-dot-decimal" decimals="0">8,999,496</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Supplemental disclosure of non-cash investing and financing activities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock options granted in lieu of cash bonus</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c273" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="crvo:OptionsGranted" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c274" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:OptionsGranted" scale="0" format="ixt:num-dot-decimal" decimals="0">255,724</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Cashless exercise of pre-funded warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c275" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="crvo:CashlessExerciseOfWarrants" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c276" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:CashlessExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="0">945</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred offering costs in accounts payable</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c277" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" format="ixt:num-dot-decimal" decimals="0">10,000</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c278" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">See accompanying notes to consolidated financial statements</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">92</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Notes to the Consolidated Financial Statements</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:NatureOfOperations" id="c279" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 1. The Company and Description of Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is a corporation organized under the laws of the state of Delaware and headquartered in Boston, Massachusetts. The Company is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. The Company recently completed its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB funded primarily by a $<ix:nonFraction id="c282" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:GovernmentAssistanceAmountCumulative" scale="6" format="ixt:num-dot-decimal" decimals="-5">21.3</ix:nonFraction> million grant from the NIA.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="crvo:LiquidityDisclosureTextBlock" id="c283" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 2. Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Liquidity and Capital Resources</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has $<ix:nonFraction id="c286" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">20.9</ix:nonFraction> million of cash, cash equivalents, and marketable securities as of December&#160;31, 2025, has generated negative cash flows from operations and had an accumulated deficit of $<ix:nonFraction id="c287" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" format="ixt:num-dot-decimal" decimals="-5" sign="-">97.7</ix:nonFraction> million as of December&#160;31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s future viability is dependent on its ability to raise additional capital to finance its operations and pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. These conditions cause substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company will continue to require additional financing to advance its current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. The Company intends to continue to seek funds through equity offerings, debt financings or other capital sources, including grants, potential collaborations, licenses and other similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. If the Company does raise additional capital through public or private equity offerings, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect the Company's stockholders&#8217; rights. If the Company raises additional capital through a debt financing, it may be subject to covenants limiting or restricting the Company's ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on the Company's financial condition and on its ability to pursue its business plans and strategies. If the Company is unable to raise sufficient capital when needed, it may need to delay, reduce or terminate planned activities to reduce costs, including development or commercialization activities for neflamapimod. The Company might also be required to seek funds through arrangements with third parties that require it to relinquish certain of its rights to neflamapimod or otherwise agree to terms unfavorable to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accordingly, substantial doubt about the Company&#8217;s ability to continue as a going concern is not alleviated. Based on its current operating plan, the Company does not believe its existing cash, cash equivalents and marketable securities on hand of $<ix:nonFraction id="c288" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:num-dot-decimal" decimals="-5">20.9</ix:nonFraction> million as of December&#160;31, 2025 will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty described in this Note 2.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risks and Uncertainties</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#8217;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#8217;s control, including internal and external factors that may affect the success or failure of the Company&#8217;s research and development efforts, the length of time and cost of developing and commercializing the Company&#8217;s current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug&#8217;s market share will be, if approved, among others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">93</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c289" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 3. Summary of Significant Accounting Policies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c1230626933632093" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Basis of presentation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements have been prepared in conformity with US GAAP as defined by the FASB.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c672057077238655" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Consolidation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:UseOfEstimates" id="c195056151544557" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of estimates</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company&#8217;s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c186189958115787" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in US government securities, commercial paper, and corporate debt securities.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c1501932333504427" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the years ended December&#160;31, 2025 and 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:MarketableSecuritiesPolicy" id="c198602627716646" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Marketable Securities</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, US government debt securities, and corporate debt securities with original maturities of greater than 90 days from date of purchase. These securities are carried at fair value, with unrealized gains and losses reported on the consolidated statements of operations and comprehensive loss and accumulated other comprehensive income within stockholders&#8217; equity until realized. Purchase discounts are accreted using the effective interest method over the term of the related security and such accretion is included in interest income on the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluates its investments in marketable securities for impairment at each reporting period when the fair value is below amortized cost. If the Company intends to sell the security, or it is more likely than not the Company will be required to sell the security before recovery of amortized cost, the entire impairment is included in earnings. The Company did <span style="-sec-ix-hidden:c292"><span style="-sec-ix-hidden:c293">not</span></span> record any impairment on marketable securities during years ended December&#160;31, 2025 and 2024. There was <span style="-sec-ix-hidden:c294"><span style="-sec-ix-hidden:c295">no</span></span> allowance for credit losses as of December&#160;31, 2025 or December 31, 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:DeferredChargesPolicyTextBlock" id="c1248359349055138" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Equity Issuance Costs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company capitalizes costs directly associated with equity financings as deferred offering costs on its consolidated balance sheet. These costs remain capitalized until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. With respect to financings conducted on an ongoing basis, such as at-the-market offerings, costs are recognized ratably as funds are received in proportion to the aggregate offering amount. If a financing is abandoned, any remaining deferred offering costs are expensed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, there were $<ix:nonFraction id="c296" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredOfferingCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million of deferred offering costs related to the Sales Agreement. There were <span style="-sec-ix-hidden:c297">no</span> deferred offering costs as of December 31, 2024, as the Sales Agreement was entered into in May 2025.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">94</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c1407950745977928" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 1</i> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement&#160; &#160; date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 2</i> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 3</i> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c1360073335887342" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for leases in accordance with ASC Topic 842, Leases, which requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and expense recognition in the statement of operations and comprehensive loss as well as the reduction of the ROU asset. The standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU assets, lease liabilities, current and lease liabilities, non-current. Fixed rent payments are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c1328155059331015" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A substantial portion of the Company's ongoing research and development activities are conducted by third-party service providers. The Company records an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. The Company monitors subject enrollment levels and related activity to the extent reasonably possible and makes judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of nonclinical studies and clinical trial expenses.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:LegalCostsPolicyTextBlock" id="c939816001636911" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Patent Costs </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">95</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c228747670814631" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. The Company accounts for forfeitures as they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of stock options is determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Term</i>&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The Company uses the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the Company stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical data and the plain-vanilla nature of the Company&#8217;s stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Volatility</i>&#8212;The Company has limited information on the volatility of its common stock as the shares were not actively traded on any public markets until recently. The expected volatility is derived from the historical stock volatility of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the expected term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Dividend Rate</i>&#8212;The expected dividend is <span style="-sec-ix-hidden:c298">zero</span> as the Company has not paid, nor does it anticipate paying, any dividends on its stock options in the foreseeable future.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c1454054950249432" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Grant Revenue</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes funding received from the NIA Grant as <span style="-sec-ix-hidden:c299"><span style="-sec-ix-hidden:c300">grant revenue</span></span>, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#8217;s consolidated balance sheets as accounts receivable. Amounts received in advance of services rendered are recorded as <span style="-sec-ix-hidden:c301">deferred grant revenue</span> on the Company's consolidated balance sheets. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c361740509823571" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statements of operations and comprehensive loss for the period that includes the enactment date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes interest and penalties, if any, related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related liability lines in the consolidated balance sheet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">96</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>
<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c971734295572104" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss Per Share</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that, when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c324" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c327" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,598,337</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c328" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,609,289</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c329" contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">992,701</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c330" contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">636,802</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c331" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,591,038</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c332" contextRef="d_2024-01-01_2024-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:num-dot-decimal" decimals="INF">3,246,091</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c1170336935306844" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): &#8220;Improvements to Income Tax Disclosures&#8221; ("ASU 2023-09"). ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements as well. The guidance in ASU 2023-09 is effective for annual reporting periods in fiscal years beginning after December 15, 2024 and was adopted prospectively by the Company during the year ended December 31, 2025. The adoption of ASU 2023-09 impacted the Company&#8217;s income tax disclosures only and did not have an impact on its consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses" ("ASU 2024-03"). ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the statement of operations and comprehensive loss, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p>
</ix:nonNumeric></ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueDisclosuresTextBlock" id="c333" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 4. Fair Value of Financial Instruments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s financial instruments consist primarily of cash, cash equivalents, marketable securities, and accounts payable. The Company&#8217;s cash, cash equivalents, and accounts payable approximate fair value due to their relatively short maturities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">97</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="DA23F0E7-2DC8-4577-86A4-2D574B981D73" escape="true" continuedAt="c8FBB43A7-E204-4C67-B809-F855835A80A4">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market accounts</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c404" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">6,300,291</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c405" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c406" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c407" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c408" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">999,330</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c409" contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c410" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c411" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">11,139,880</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c412" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c413" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c414" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">1,238,538</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c415" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c416" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c417" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">250,552</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c418" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c419" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">6,300,291</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c420" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">13,628,300</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c421" contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<ix:continuation id="c8FBB43A7-E204-4C67-B809-F855835A80A4">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents (money market accounts)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c425" contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">7,559,336</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c426" contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c427" contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c428" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c429" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">18,032,943</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c430" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c431" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c432" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">7,951,060</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c433" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c434" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c435" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">3,938,520</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c436" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c437" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">7,559,336</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c438" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:num-dot-decimal" decimals="0">29,922,523</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c439" contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair values of the Company&#8217;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a summary of the Company's marketable securities which provides a reconciliation of amortized cost basis to fair value including cumulative unrealized gains and losses as of December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:MarketableSecuritiesTextBlock" id="c5F8349FF-4697-4E6E-901C-B39E13217903" escape="true" continuedAt="c2C7108CA-D57D-42F2-BA42-7E09E5D1C263">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c443" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">11,134,856</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c444" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">5,024</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c445" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c446" contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">11,139,880</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c447" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">1,237,794</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c448" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">744</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c449" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c450" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">1,238,538</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c451" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">250,504</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c452" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">48</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c453" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c454" contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">250,552</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c455" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">12,623,154</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c456" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">5,816</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c457" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c458" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">12,628,970</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="c2C7108CA-D57D-42F2-BA42-7E09E5D1C263">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c462" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">18,019,334</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c463" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">16,393</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c464" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">2,784</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c465" contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">18,032,943</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c466" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">7,920,620</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c467" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">30,440</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c468" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c469" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">7,951,060</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c470" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">3,926,372</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c471" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">12,148</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c472" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:fixed-zero" decimals="-3" sign="-">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c473" contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">3,938,520</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c474" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="0" format="ixt:num-dot-decimal" decimals="0">29,866,326</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c475" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">58,981</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c476" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" format="ixt:num-dot-decimal" decimals="0">2,784</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c477" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt:num-dot-decimal" decimals="0">29,922,523</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">98</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December&#160;31, 2025 and 2024.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c478" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 5. Significant Agreements and Contracts</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Vertex Option and License Agreement</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In August 2012, the Company entered the Vertex Agreement to acquire an exclusive license to develop and commercialize a drug candidate, &#8220;VX-745,&#8221; from Vertex. In August 2014, the Company exercised its option to acquire the license and paid an option fee of $<ix:nonFraction id="c481" contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">100,000</ix:nonFraction>, which was expensed as incurred as a component of research and development expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Vertex Agreement granted the Company the exclusive worldwide use of VX-745 in the field of diagnosis, treatment and prevention of AD and related CNS disorders in humans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As part of the Vertex Agreement, the Company is obligated to make certain payments totaling up to approximately $<ix:nonFraction id="c482" contextRef="i_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="USD" name="us-gaap:ContractualObligation" scale="6" format="ixt:num-dot-decimal" decimals="-6">117.0</ix:nonFraction> million upon achievement of certain regulatory and sales milestones, and royalties on net sales of products on indications covered by the Vertex Agreement. The first expected milestone events concern filing of an NDA with the FDA for marketing approval of neflamapimod in the US, or a similar filing for a non-US major market, as specified in the Vertex Agreement, and such royalties will be on a sliding scale of percentages of net sales in the low- to mid-teens, depending on the amount of net sales in the applicable years. The Company is also obligated to make a milestone payment to Vertex upon net sales reaching a certain specified amount in any <ix:nonNumeric contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" name="crvo:AgreementMilestonePeriodForNetSales" id="c483" format="ixt-sec:durmonth">12</ix:nonNumeric>-month period. The Vertex Agreement states that royalties will be reduced by <ix:nonFraction id="c484" contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="Pure" name="crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% during any portion of the royalty term when there is no valid claim of an issued patent within specified patent rights covering the licensed product. The Company also has the right to deduct, on a country by country basis, from royalties otherwise payable to Vertex under the terms of the Vertex Agreement, <ix:nonFraction id="c485" contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="Pure" name="crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% of all royalties, upfront fees, milestones and other payments paid by the Company or any of the Company&#8217;s affiliates or sublicensees to third parties under licenses that are necessary for the development, manufacture, sale or use of a licensed product, provided that in no event will the royalty payable to Vertex be reduced to less than <ix:nonFraction id="c486" contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="Pure" name="crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments" scale="-2" format="ixt:num-dot-decimal" decimals="1">50</ix:nonFraction>% of the rates specified in the Vertex Agreement, subject to certain adjustments specified therein. The Company has made a total of $<ix:nonFraction id="c487" contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember" unitRef="USD" name="crvo:PaymentsForLicenseAgreement" scale="0" format="ixt:num-dot-decimal" decimals="0">100,000</ix:nonFraction> in payments to Vertex related to the Vertex Agreement. <span style="-sec-ix-hidden:c488"><span style="-sec-ix-hidden:c489">No</span></span> payments were made during the years ended December&#160;31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>National Institute of Aging Grant</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In January 2023, the Company was awarded a $<ix:nonFraction id="c492" contextRef="i_2023-01-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:GovernmentAssistanceAmountCumulative" scale="6" format="ixt:num-dot-decimal" decimals="-6">21.0</ix:nonFraction> million grant from the NIA to support its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB and, in August 2024, the Company was awarded an additional $<ix:nonFraction id="c493" contextRef="i_2024-08-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:GovernmentAssistanceAmountCumulative" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million under the grant. The grant monies were expected to be received over a period of three years including $<ix:nonFraction id="c494" contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.7</ix:nonFraction> million in 2023, $<ix:nonFraction id="c495" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">8.4</ix:nonFraction> million in 2024 and $<ix:nonFraction id="c496" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:GovernmentAssistanceAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">6.2</ix:nonFraction> million in 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The total revenue recognized from the NIA Grant was $<ix:nonFraction id="c497" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:num-dot-decimal" decimals="-6">4.0</ix:nonFraction> million and $<ix:nonFraction id="c498" contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:Revenues" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.7</ix:nonFraction> million for the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, aggregate total cash funding of $<ix:nonFraction id="c499" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="crvo:ProceedsFromGrants" scale="6" format="ixt:num-dot-decimal" decimals="-5">20.5</ix:nonFraction> million has been received from the NIA Grant, resulting in approximately $<ix:nonFraction id="c500" contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="crvo:GrantFundingRemaining" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.6</ix:nonFraction> million in funding remaining. The Company has recorded $<ix:nonFraction id="c501" contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million as a receivable in the consolidated balance sheet at December&#160;31, 2025, for allowable expenses incurred prior to December&#160;31, 2025, which is expected to be received subsequent to December&#160;31, 2025. As of December 31, 2024, $<ix:nonFraction id="c502" contextRef="i_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.3</ix:nonFraction> million was recorded as a receivable in the consolidated balance sheet, for allowable expenses incurred during the year ended December 31, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2025, the Company received access to <ix:nonFraction id="c503" contextRef="d_2025-01-01_2025-03-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="Pure" name="crvo:GrantAmountReceivedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="1">90</ix:nonFraction>% of the year 3 funding and, in June 2025, the Company received access to an additional <ix:nonFraction id="c504" contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="Pure" name="crvo:GrantAmountReceivedPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">8</ix:nonFraction>% of the year 3 funding provided for in the NIA Grant, due to then-current NIA policy as a result of the US government currently being funded on the basis of a continuing resolution. Accordingly, as of December 31, 2025, we determined that the receipt of the remaining <ix:nonFraction id="c505" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="Pure" name="crvo:GrantAmountRemainingPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">2</ix:nonFraction>% of funding is not probable and we would not account for the remaining <ix:nonFraction id="c506" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="Pure" name="crvo:GrantAmountRemainingPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">2</ix:nonFraction>% of funding unless and until received. In January 2026, we were informed that we will not receive the final <ix:nonFraction id="c507" contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="Pure" name="crvo:GrantAmountCanceledPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">2</ix:nonFraction>% of year 3 grant funding that remained unavailable as of December 31, 2025, or approximately $<ix:nonFraction id="c508" contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember" unitRef="USD" name="crvo:GrantFundingCanceled" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction>&#160;million, as a result of agency-wide reductions in NIA funding.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="c509" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 6. Prepaid Expenses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="c524" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c527" contextRef="i_2025-12-31" unitRef="USD" name="crvo:PrepaidClinicalExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">677,604</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c528" contextRef="i_2024-12-31" unitRef="USD" name="crvo:PrepaidClinicalExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">1,149,343</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c529" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:num-dot-decimal" decimals="0">405,795</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c530" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidInsurance" scale="0" format="ixt:num-dot-decimal" decimals="0">443,141</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c531" contextRef="i_2025-12-31" unitRef="USD" name="crvo:PrepaidProfessionalServices" scale="0" format="ixt:num-dot-decimal" decimals="0">119,803</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c532" contextRef="i_2024-12-31" unitRef="USD" name="crvo:PrepaidProfessionalServices" scale="0" format="ixt:num-dot-decimal" decimals="0">95,218</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dues and memberships</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c533" contextRef="i_2025-12-31" unitRef="USD" name="crvo:PrepaidDuesAndMembershipsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">43,828</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c534" contextRef="i_2024-12-31" unitRef="USD" name="crvo:PrepaidDuesAndMembershipsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">11,777</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c535" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">19,975</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c536" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">205,881</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c537" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,267,005</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c538" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,905,360</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">99</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="c539" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 7. Accrued Expenses and Other Current Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and other current liabilities consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="c554" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee compensation costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c557" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,061,766</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c558" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">803,193</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical development costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c559" contextRef="i_2025-12-31" unitRef="USD" name="crvo:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,484,318</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c560" contextRef="i_2024-12-31" unitRef="USD" name="crvo:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">1,158,783</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c561" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">532,076</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c562" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">249,527</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State franchise and excise tax</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c563" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">40,456</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c564" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">40,456</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c565" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">83,383</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c566" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">115,883</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c567" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">3,201,999</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c568" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:num-dot-decimal" decimals="0">2,367,842</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c569" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 8. Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Leases</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has a short-term lease for office space in Boston, Massachusetts. Lease expense was approximately $<ix:nonFraction id="c572" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">57,112</ix:nonFraction> and $<ix:nonFraction id="c573" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">34,692</ix:nonFraction> for the years ended December&#160;31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the course of normal business operations, the Company enters into agreements with universities and CROs to assist in the performance of research and development activities and with CDMOs to assist with CMC-related activities. Expenditures to CROs and other CDMOs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Defined Contribution Retirement Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to <ix:nonFraction id="c574" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" format="ixt:num-dot-decimal" decimals="1">90</ix:nonFraction>% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <ix:nonFraction id="c575" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:num-dot-decimal" decimals="2">4</ix:nonFraction>% of the participant&#8217;s compensation. There were total contributions under the 401(k) Plan of $<ix:nonFraction id="c576" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.4</ix:nonFraction> million and $<ix:nonFraction id="c577" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million for the years ended December&#160;31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Legal Proceedings</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#8217;s legal predecessor, under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, and the parties have agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff&#8217;s counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties' joint stipulation, the court entered an order continuing the trial date to October 25, 2023, on October 6, 2023, the court entered an order further continuing the trial date to April 24, 2024, and on March 3, 2024, based on an additional joint stipulation of the parties, the court entered an order continuing the trial date to October 23, 2024. On September 4, 2024, due to certain delays in discovery as a result of, among other things, plaintiff's counsel's health complications, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto. On October 9, 2024, based on the parties' joint stipulation, the court entered an order continuing the trial date to April 30, 2025. On January 6, 2025, the Company filed a Motion for Summary Adjudication against plaintiff&#8217;s claims for promissory fraud, negligent misrepresentation, and common counts. On February 21, 2025, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto and, on March 12, 2025, the court entered an order continuing the trial date to November 26, 2025. On October 22, 2025, pursuant to an additional joint stipulation to continue the trial and certain deadlines related thereto filed by the parties, the court entered an order continuing the trial date to May 13, 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is defending itself vigorously against the claims alleged in this matter. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material adverse effect on the Company&#8217;s financial position, results of operations and cash flows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">100</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c578" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 9. Stockholders' Equity and Common Stock Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>April 2024 Private Placement</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 1, 2024, pursuant to and in accordance with the terms of a securities purchase agreement with certain purchasers named therein, the Company completed the 2024 Private Placement of an aggregate of <ix:nonFraction id="c581" contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,083,262</ix:nonFraction> shares of common stock, <ix:nonFraction id="c582" contextRef="i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,532,285</ix:nonFraction> Series A Warrants and <ix:nonFraction id="c583" contextRef="i_2024-04-01_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:num-dot-decimal" decimals="INF">449,023</ix:nonFraction> Pre-Funded Warrants. The aggregate upfront gross proceeds from the 2024 Private Placement were approximately $<ix:nonFraction id="c584" contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:num-dot-decimal" decimals="-7">50.0</ix:nonFraction> million, before deducting approximately $<ix:nonFraction id="c585" contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">3.6</ix:nonFraction> million of offering fees and expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Pre-Funded Warrants and Series A Warrants were classified as a component of stockholders&#8217; equity within additional paid-in capital. The Pre-Funded Warrants and Series A Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c609" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of exercise price per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical Diffusion common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c612" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">22,434</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c613" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">96.12</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c614">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical EIP common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c615" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">43,618</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c616" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">19.81</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c617">April 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c618" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,532,285</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c619" contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:num-dot-decimal" decimals="INF">39.24</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c620">April 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c621" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:num-dot-decimal" decimals="INF">2,598,337</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15%;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 11, 2026, the remaining historical Diffusion common stock warrants expired unexercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>February 2024 Pre-Funded Warrant Exercise</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 26, 2024, following the effectiveness of an amendment eliminating certain beneficial ownership limitations set forth therein, <ix:nonFraction id="c596" contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="crvo:ClassOfWarrantOrRightExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">499,995</ix:nonFraction> previously outstanding pre-funded warrants to purchase common stock issued in connection with the closing of the Merger were exercised in full by the holder thereof pursuant to the cashless exercise provision of the pre-funded warrants. Upon exercise, <ix:nonFraction id="c597" contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">36</ix:nonFraction> shares were withheld in lieu of a cash payment of the exercise price and the holder was issued <ix:nonFraction id="c598" contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">495,959</ix:nonFraction> shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>December 2024 Pre-Funded Warrant Exercise</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On December 11, 2024, <ix:nonFraction id="c599" contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="crvo:ClassOfWarrantOrRightExercised" scale="0" format="ixt:num-dot-decimal" decimals="INF">449,023</ix:nonFraction> Pre-Funded Warrants to purchase common stock issued in connection with the closing of the 2024 Private Placement were exercised in full by the holder thereof pursuant to the cashless exercise provision of the Pre-Funded Warrants. Upon exercise, <ix:nonFraction id="c600" contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" format="ixt:num-dot-decimal" decimals="INF">45</ix:nonFraction> shares were withheld in lieu of a cash payment of the exercise price and the holder was issued <ix:nonFraction id="c601" contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember" unitRef="Share" name="crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="0" format="ixt:num-dot-decimal" decimals="INF">448,978</ix:nonFraction> shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>May 2025 At-The-Market Offering</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On May 12, 2025, the Company entered into the Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock from time-to-time with an aggregate offering price of up to $<ix:nonFraction id="c602" contextRef="i_2025-05-12_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember" unitRef="USD" name="crvo:ShareSalesAgreementMaximumAmount" scale="6" format="ixt:num-dot-decimal" decimals="-7">50.0</ix:nonFraction> million under an &#8220;at-the-market" offering program. During the year ended December&#160;31, 2025, the Company sold <ix:nonFraction id="c604" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:num-dot-decimal" decimals="INF">550,000</ix:nonFraction> shares of common stock to an institutional investor in a block sale for proceeds of $<ix:nonFraction id="c606" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.7</ix:nonFraction> million, net of $<ix:nonFraction id="c608" contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember" unitRef="USD" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of issuance costs.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c622" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 10. Stock-Based Compensation Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2015 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to <ix:nonFraction id="c625" contextRef="d_2025-01-01_2025-12-31_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Pure" name="crvo:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" scale="-2" format="ixt:num-dot-decimal" decimals="2">4.0</ix:nonFraction>% of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company&#8217;s Board. On January 1, 2025, the number of shares available for future issuance under the 2015 Equity Plan increased by <ix:nonFraction id="c626" contextRef="i_2025-01-01_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Share" name="crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" scale="0" format="ixt:num-dot-decimal" decimals="INF">348,109</ix:nonFraction>. As of December&#160;31, 2025, the term of the 2015 Equity Plan had expired and no additional shares will be issued thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">101</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2018 Employee, Director and Consultant Equity Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On March 28, 2018, EIP adopted the 2018 Plan, which was assumed by the Company pursuant to and in accordance with the terms of the Merger Agreement. Under the 2018 Plan, the Company may issue incentive stock options, non-qualified stock options, stock grants, and other stock-based awards to employees, directors, and consultants, as specified in the 2018 Plan and subject to applicable SEC and Nasdaq rules and regulations. The Board has the authority to determine to whom options or stock will be granted, the number of shares, the term, and the exercise price. Options granted under the 2018 Plan have a term of up to <span style="-sec-ix-hidden:c627">ten</span> years and generally vest over a <span style="-sec-ix-hidden:c628">four-year</span> period with <ix:nonFraction id="c629" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:num-dot-decimal" decimals="2">25</ix:nonFraction>% of the options vesting after <span style="-sec-ix-hidden:c630">one-year</span> of service and the remainder vesting monthly thereafter. As of December&#160;31, 2025, there were <span style="-sec-ix-hidden:c631">no</span> shares available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Inducement Grants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended December 31, 2024, the Company granted stock options to purchase an aggregate of <ix:nonFraction id="c632" contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">71,712</ix:nonFraction> shares of common stock as material inducements to the employment of <span style="-sec-ix-hidden:c633">five</span> new employees, in each case, in accordance with Nasdaq Listing Rule 5635(c)(4). Each such inducement option has a term of <span style="-sec-ix-hidden:c634">ten</span> years and vests over a <ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c635" format="ixt-sec:durmonth">36</ix:nonNumeric>-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2025, the Company granted a stock option to purchase an aggregate of <ix:nonFraction id="c636" contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">54,000</ix:nonFraction> shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of <span style="-sec-ix-hidden:c637">ten</span> years and vests over a <ix:nonNumeric contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c638" format="ixt-sec:durmonth">36</ix:nonNumeric>-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In October 2025, the Company granted a stock option to purchase an aggregate of <ix:nonFraction id="c639" contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">75,000</ix:nonFraction> shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of <span style="-sec-ix-hidden:c640">ten</span> years and vests over a <ix:nonNumeric contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c641" format="ixt-sec:durmonth">36</ix:nonNumeric>-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2025 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 14, 2025, the Board approved the 2025 Equity Plan, and the 2025 Equity Plan was subsequently approved by the Company's stockholders at its 2025 Annual Meeting of Stockholders on June 23, 2025. As of December&#160;31, 2025, there were <ix:nonFraction id="c642" contextRef="i_2025-12-31_PlanNameAxis-The2025EquityPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:num-dot-decimal" decimals="INF">735,200</ix:nonFraction> shares available for future issuance under the 2025 Equity Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c691" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c694" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">482,669</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c695" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">218,822</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c696" contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">965,965</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c697" contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,186,900</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c698" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,448,634</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c699" contextRef="d_2024-01-01_2024-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,405,722</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the activity related to all stock option grants for the year ended December&#160;31, 2025:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c700" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise price</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>contractual term (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c703" contextRef="i_2024-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">636,802</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c704" contextRef="i_2024-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">19.38</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c705" format="ixt-sec:duryear">7.6</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c706" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">466,600</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c707" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">4.61</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c708" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">68,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c709" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">45.84</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c710" contextRef="d_2025-01-01_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:num-dot-decimal" decimals="INF">42,334</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c711" contextRef="d_2025-01-01_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">8.22</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c712" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">992,701</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c713" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">11.76</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c714" format="ixt-sec:duryear">8.0</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c715" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c716" contextRef="i_2025-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:num-dot-decimal" decimals="INF">561,358</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c717" contextRef="i_2025-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:num-dot-decimal" decimals="INF">15.92</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c718" format="ixt-sec:duryear">7.2</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c719" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">102</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Black-Scholes option pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c720" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c723" format="ixt-sec:duryear">5.24</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c724" format="ixt-sec:duryear">5.76</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c725" format="ixt-sec:duryear">5.25</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c726" format="ixt-sec:duryear">5.76</ix:nonNumeric></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c727" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.68</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c728" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.35</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c729" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">3.89</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c730" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">4.46</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c731" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">71.55</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c732" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">76.68</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><ix:nonFraction id="c733" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">76.06</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c734" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:num-dot-decimal" decimals="4">80.03</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c735" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c736" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At December&#160;31, 2025, there was $<ix:nonFraction id="c680" contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:num-dot-decimal" decimals="-5">1.9</ix:nonFraction> million of unrecognized compensation expense that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c681" format="ixt-sec:duryear">2.0</ix:nonNumeric> years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended December 31, 2024, the Company granted <ix:nonFraction id="c682" contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:num-dot-decimal" decimals="INF">39,721</ix:nonFraction> options in lieu of 2023 executive bonus compensation. <span style="-sec-ix-hidden:c683">No</span> similar event occurred during the year ended December&#160;31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Effective May 31, 2024, the Company separated from its former Chief Financial Officer. Based on the terms of his separation agreement, unvested shares under previously granted option awards continued to vest on the schedule provided for in the applicable option award agreement through September 30, 2025. The Company accounted for the change in vesting terms as an improbable-to-probable modification of his stock options and recognized $<ix:nonFraction id="c685" contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.3</ix:nonFraction> million of expense in relation to this modification during the year ended December 31, 2024. In addition, the exercise period for any shares under previously granted option awards vested as of May 31, 2024 was extended to September 30, 2025. The Company accounted for the change in exercise terms as a probable-to-probable modification of his stock options and recognized $<ix:nonFraction id="c687" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="0">12,000</ix:nonFraction> of expense in relation to this modification during the year ended December 31, 2024. As of October 1, 2025, all such option awards expired unexercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 14, 2025, the Board approved a separation agreement with the Company&#8217;s former Chief Operating Officer, pursuant to which the executive's employment with the Company concluded effective July 1, 2025. Based on the terms of his separation agreement, unvested shares under previously granted option awards will continue to vest on the schedule provided for in the applicable option award agreement through September 30, 2026. The Company accounted for the change in vesting terms of his unvested stock options as an improbable-to-probable modification of his stock options and recognized $<ix:nonFraction id="c688" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.2</ix:nonFraction> million of expense in relation to this modification during the year ended December&#160;31, 2025. In addition, the exercise period for any shares under previously granted option awards vested as of April 14, 2025 was extended to September 30, 2026. The Company accounted for the change in exercise terms as probable-to-probable modification of his stock options and recognized $<ix:nonFraction id="c690" contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million of expense in relation to this modification during the year ended December&#160;31, 2025.</p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c737" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 11. Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosures required for income taxes in the Company&#8217;s annual consolidated financial statements. The guidance is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 prospectively, and the adoption impacted the Company&#8217;s income tax disclosures only and did not have an impact on its consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c7593A477-E1C1-401C-A587-1E6BE6E78E83" escape="true" continuedAt="E5C2ADBB-6B18-46AA-8108-B586165AB0ED">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b style="font-size: 10pt; text-align: center;">2024</b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rate reconciliation:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal tax benefit at statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5,671,648</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c805" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3,421,046</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c806" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c807" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(710,002</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c808" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.4</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1,121,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c809" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3">4.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(526,015</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c810" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" format="ixt:num-dot-decimal" decimals="3">3.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,188,171</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c811" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">22.9</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,443,812</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c812" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">27.3</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c813" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">176,562</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c814" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">1.1</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">605,298</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c815" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">2.3</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">36,689</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c816" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">0.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c817" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c818" contextRef="d_2024-01-01_2024-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">103</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Significant components of the Company's deferred tax assets for federal income taxes as of December&#160;31, 2025 and 2024 consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c819" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c823" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">21,388,936</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c824" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">10,417,666</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c825" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:num-dot-decimal" decimals="0">2,367,496</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c826" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:num-dot-decimal" decimals="0">1,228,255</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized research expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c827" contextRef="i_2025-12-31" unitRef="USD" name="crvo:DeferredTaxAssetsCapitalizedResearchExpenditures" scale="0" format="ixt:num-dot-decimal" decimals="0">3,289,629</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c828" contextRef="i_2024-12-31" unitRef="USD" name="crvo:DeferredTaxAssetsCapitalizedResearchExpenditures" scale="0" format="ixt:num-dot-decimal" decimals="0">6,392,545</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c829" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="0">977,321</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c830" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:num-dot-decimal" decimals="0">698,886</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Charitable contributions</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c831" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">2,130</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c832" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="0" format="ixt:num-dot-decimal" decimals="0">1,321</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangibles</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c833" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="0">182,441</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c834" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="0" format="ixt:num-dot-decimal" decimals="0">193,106</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c835" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">28,207,953</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c836" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="0" format="ixt:num-dot-decimal" decimals="0">18,931,779</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c837" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">27,687,487</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c838" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:num-dot-decimal" decimals="0">18,557,844</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c839" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:num-dot-decimal" decimals="0">520,466</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c840" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:num-dot-decimal" decimals="0">373,935</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaids</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c842" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">520,466</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c843" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="0" format="ixt:num-dot-decimal" decimals="0">373,935</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c844" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">520,466</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c845" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" format="ixt:num-dot-decimal" decimals="0">373,935</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred tax assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c846" contextRef="i_2025-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c847" contextRef="i_2024-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company does <span style="-sec-ix-hidden:c781"><span style="-sec-ix-hidden:c782">not</span></span> have unrecognized tax benefits as of December&#160;31, 2025 or 2024. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&#160;31, 2025, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance increased by $<ix:nonFraction id="c783" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">9.1</ix:nonFraction> million during the year ended December&#160;31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company had NOL carryforwards of approximately $<ix:nonFraction id="c784" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">16.6</ix:nonFraction> million and $<ix:nonFraction id="c785" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:num-dot-decimal" decimals="-5">4.8</ix:nonFraction> million for federal and state tax purposes, respectively. Federal NOL carryforwards will not expire and state NOL carryforwards will begin to expire in 2038, if not utilized. The TCJA enacted on December 22, 2017 limits a taxpayer&#8217;s ability to utilize NOL deduction in a year to 80% taxable income for federal NOLs arising in tax years beginning after 2017, however, federal NOLs post 2017 have no expiration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company also had federal and state research credit carryforwards of $<ix:nonFraction id="c786" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">2.3</ix:nonFraction> million and $<ix:nonFraction id="c787" contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:num-dot-decimal" decimals="-5">0.1</ix:nonFraction> million, respectively. The federal and state research credits will begin to expire in 2038 and 2034, respectively. Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Code, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383 of the Code, which provides for special limitations on certain excess credits, as well as similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; A formal Section 382 study was performed through December 31, 2023 which concluded&#160;there have been no historical section 382 ownership changes, thus the NOL carryforwards were not subject to an annual limitation through December 31, 2023. The Company has not conducted a study since December 31, 2023 to assess whether a change of control has occurred. If the Company has experienced a change of control, as defined by Section 382, subsequent to the last study, utilization of the net operating loss carryforwards or research and development tax credit carryforwards could be subject to an annual limitation under Section 382. With respect to Diffusion, the Company deems the historical Diffusion tax attributes (NOLs/Credits) are unusable due to the IRC Section 382 limitation. ASC 740-10-25 states that a &#8220;write off might be appropriate if there is only a remote likelihood that the entity will utilize the carryforward (i.e. NOL), it is acceptable for the entity to write off the deferred tax assets against the valuation allowance, thereby eliminating the need to disclose the gross amounts.&#8221; As such, the Company has written off these attributes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company files federal and state income tax returns in jurisdictions with varying statutes of limitations. Due to its NOL carryforwards, the Company&#8217;s income tax returns generally remain subject to examination by federal and state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company uses the &#8220;more likely than not&#8221; criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and believes that its income tax filing positions and deductions will be sustained upon examination. Accordingly, no reserves for uncertain income tax positions or related accruals for interest and penalties have been recorded as of December&#160;31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">104</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p></ix:exclude>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements as of December&#160;31, 2025:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:continuation id="E5C2ADBB-6B18-46AA-8108-B586165AB0ED">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Rate reconciliation:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Federal statutory tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c852" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:num-dot-decimal" decimals="0">5,671,648</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c853" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:num-dot-decimal" decimals="2">21.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and local income tax, net of federal (national) income tax effect (a)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c854" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c855" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c856" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" format="ixt:num-dot-decimal" decimals="0">1,121,821</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c857" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">4.2</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowances</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c858" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:num-dot-decimal" decimals="0">6,188,171</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c859" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">22.9</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c860" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">605,298</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c861" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" format="ixt:num-dot-decimal" decimals="3" sign="-">2.3</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c862" contextRef="d_2025-01-01_2025-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:fixed-zero" decimals="-3">&#8212;</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c863" contextRef="d_2025-01-01_2025-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:num-dot-decimal" decimals="-3">0.0</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>
</ix:continuation>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a) <ix:footnote xml:lang="en-us" id="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a">State taxes in Illinois and Massachusetts&#160;made up the majority of the tax effect in this category</ix:footnote></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">During the year ended December 31, 2025, the Company did not pay any federal income taxes. Additionally, the amount paid in state income taxes, net of refunds received, was immaterial for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On July 4, 2025, the US government enacted the OBBBA, which includes, among other provisions, changes to the US corporate income tax system including the allowance of immediate expensing of qualifying research and development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act. The Company has analyzed the impacts of the OBBBA and reflected them in the current period, resulting in a decrease to the deferred tax asset and valuation allowance of approximately $18.0 million gross ($5.1M tax effected) due to immediate expensing of domestic research and development expenditures.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">105</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div></ix:exclude>

<ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;&#160;</p></ix:exclude>
</ix:nonNumeric>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SegmentReportingDisclosureTextBlock" id="c864" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 12. Segments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM, or decision-making group, in deciding how to allocate resources in assessing performance. CervoMed Inc. has one reportable segment which consists of the development of clinical and nonclinical product candidates for treatments for age-related neurologic disorders and other medical indications. The Company&#8217;s CODM is the Chief Executive Officer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accounting policies of the Company&#8217;s <span style="-sec-ix-hidden:c867">single</span> segment are the same as those described in the summary of significant accounting policies. To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. The CODM assesses the financial performance for the Company's segment based on net loss. The CODM also uses internal budget versus forecasted expense and cash forecast models in making certain decisions. Such models are reviewed to assess the entity-wide/single-segment operating results and performance, including how long cash-on-hand is expected to be sufficient. The measure of segment assets is reported on the consolidated balance sheet as total assets. The segment measure of loss is reported on the consolidated statement of operations and comprehensive loss as net loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the year ended December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="c902" escape="true">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c905" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:num-dot-decimal" decimals="0">4,006,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c906" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:Revenues" scale="0" format="ixt:num-dot-decimal" decimals="0">9,737,974</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dementia with Lewy bodies</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c907" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">7,052,512</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c908" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">12,102,842</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Frontotemporal disorders (incl. nfvPPA)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c909" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,217,784</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c910" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">36,853</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recovery after stroke</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c911" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,427,966</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c912" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">391,659</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other clinical* and nonclinical</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c913" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">2,504,863</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c914" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">2,499,202</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c915" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">5,745,558</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c916" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">2,187,221</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c917" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">482,669</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c918" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">218,822</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other research and development expenses, including CMC**</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c919" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">3,385,720</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c920" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,361,744</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c921" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">21,817,072</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c922" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">18,798,343</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c923" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LaborAndRelatedExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">4,988,705</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c924" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:LaborAndRelatedExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">3,995,114</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c925" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">965,965</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c926" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,186,900</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c927" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:num-dot-decimal" decimals="0">2,752,710</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c928" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:ProfessionalFees" scale="0" format="ixt:num-dot-decimal" decimals="0">2,684,386</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Insurance, taxes and similar fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c929" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" scale="0" format="ixt:num-dot-decimal" decimals="0">1,166,374</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c930" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:TaxesExcludingIncomeAndExciseTaxes" scale="0" format="ixt:num-dot-decimal" decimals="0">985,481</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other general and administrative expenses, including IT, facilities, supplies and similar costs***</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c931" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">610,561</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c932" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">314,879</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total general and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c933" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">10,484,315</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c934" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">9,166,760</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c935" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,328,510</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c936" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:num-dot-decimal" decimals="0">1,936,436</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c937" contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">26,966,367</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c938" contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:num-dot-decimal" decimals="0" sign="-">16,290,693</ix:nonFraction></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
</ix:nonNumeric>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* - <ix:footnote xml:lang="en-us" id="f6ff8e636-6d49-477d-83f3-18bd69e4239d">Includes early-stage clinical studies that are not indication-specific and related costs.</ix:footnote></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">** - <ix:footnote xml:lang="en-us" id="f2b6adf8e-c033-448f-a62e-7f630299d7ff">Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.</ix:footnote></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">*** - <ix:footnote xml:lang="en-us" id="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f">Includes, among other things, costs related to IT systems, rent and other facilities, office supplies, and similar costs.</ix:footnote></p>
</ix:nonNumeric>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c939" escape="true">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 13. Subsequent Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The company evaluated subsequent events from December&#160;31, 2025 to the date the financial statements were issued, noting no events requiring disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
</ix:nonNumeric>

<div>&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">106</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9A.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CONTROLS AND PROCEDURES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We maintain disclosure controls and procedures (as defined in Rules 13a-15I and 15d-15(e) promulgated under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and we are required to apply our judgment in evaluating the cost-benefit relationship of possible internal controls. Our management evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective as of December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Attestation Report of the Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. As a "smaller reporting company" (as such term is defined in Rule 12b-2 of the Exchange Act), pursuant to Section 989G of the Dodd-Frank Act, we are exempt from the requirement subjecting management&#8217;s report to attestation by our independent registered public accounting firm.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Change in Internal Control Over Financial Reporting</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Remediation of Previously Identified Material Weakness</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 30pt;">In connection with the audit of our consolidated financial statements for the years ended December 31, 2024, 2023, and 2022, a material weakness in our internal control over financial reporting was identified in relation to the absence of effective controls regarding the accurate identification, evaluation and proper recording of various expense accounts. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements would not be prevented or detected on a timely basis. The identified material weakness, if not remediated, could result in a material misstatement to our consolidated financial statements that may not be prevented or detected. A material weakness will not be considered remediated until a remediation plan has been fully implemented, the applicable controls operate for a sufficient period of time, and it has been concluded, through testing, that the newly implemented and enhanced controls are operating effectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:30pt;">On August 16, 2023, we completed the Merger. For financial reporting purposes, EIP was determined to be the accounting acquirer and, accordingly, for all periods prior to the Merger, EIP&#8217;s historical financial statements and results of operations replace and are deemed to be our financial statement and results of operations for such periods. While Diffusion was previously subject to the provisions of the Sarbanes-Oxley Act of 2002, EIP, as a private, non-reporting operating company prior to the Merger, was not. Accordingly, upon consummation of the Merger, we began the process of integrating the pre-Merger business of EIP into Diffusion&#8217;s pre-established public company, internal control framework, including internal controls and information systems and we continued to implement measures designed to improve our internal control over financial reporting to remediate the remaining material weakness through the year ended December 31, 2025. During the three-month period ended December 31, 2025, we completed our remediation plan with respect to the material weakness.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Except as set forth above, there were no changes in our internal control over financial reporting (as such term is defined in Exchange Act Rule 13a-15(f)) that occurred during the quarter ended December&#160;31, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">107</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:MtrlTermsOfTrdArrTextBlock" id="c942" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9B.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Adoption, Termination or Modification of Trading Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">During the year ended&#160;December&#160;31, 2025, <span style="-sec-ix-hidden:c945"><span style="-sec-ix-hidden:c946"><span style="-sec-ix-hidden:c947"><span style="-sec-ix-hidden:c948">none</span></span></span></span> of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act),&#160;adopted,&#160;terminated&#160;or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9C.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Not applicable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART III</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 10 of Form 10-K is <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="c952" format="ixt:fixed-true">incorporated herein by reference from our Proxy Statement</ix:nonNumeric>, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the captions, &#8220;<i>Corporate Governance</i>,&#8221; "<i>Delinquent Section 16(a) Reports</i>," &#8220;<i>Election of Directors</i>,&#8221; &#8220;<i>Executive Officers</i>,&#8221; and &#8220;<i>Certain Relationships and Related Party Transactions</i>.&#8221;&#160;</p>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div>&#160;</div>

<ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgHowMnpiCnsdrdTextBlock" id="c953" escape="true">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 11 of Form 10-K is <ix:nonNumeric contextRef="d_2025-01-01_2025-12-31" name="ecd:AwardTmgMnpiCnsdrdFlag" id="c956" format="ixt:fixed-false">incorporated herein by reference from our Proxy Statement</ix:nonNumeric>, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the captions, &#8220;<i>Executive Compensation</i>,&#8221; &#8220;<i>Director Compensation</i>,&#8221; &#8220;<i>Compensation Committee Report</i>,&#8221; and &#8220;<i>Corporate Governance </i>&#8211;<i> Compensation Committee Interlocks and Insider Participation</i>.&#8221;</p>
</ix:nonNumeric>

<div>&#160;</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 12 of Form 10-K is incorporated herein by reference from our Proxy Statement, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the caption, &#8220;<i>Security Ownership of Certain Beneficial Owners and Management</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 13 of Form 10-K is incorporated herein by reference from our Proxy Statement, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the captions, &#8220;<i>Corporate Governance</i>&#8221; and &#8220;<i>Certain Relationships and Related Party Transactions</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 14 of Form 10-K is incorporated herein by reference from our Proxy Statement, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the caption, &#8220;<i>Ratification of Selection of Independent Registered Public Accounting Firm</i>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>PART IV</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:18pt;">(a)&#160;&#160;&#160;&#160;Our financial statements are included in <i>Part II, Item 8</i> of this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">108</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:54pt;">(b)&#160;&#160;&#160;&#160;All financial statement schedules have been omitted from this Item 15 as the required information is not applicable, is not present in amounts sufficient to require submission of such schedules, or because the information required is included in our financial statements or the related notes included in <i>Part II, Item 8</i> of this Annual Report.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:54pt;">(c)&#160;&#160;&#160;&#160;The exhibits set forth in the following "Index to Exhibits" are filed with, furnished with, and/or incorporated by reference into this Annual Report, as set forth therein. A copy of any of such exhibit will be furnished at a reasonable cost, upon receipt from any person of a written request for any such exhibit. Such request should be sent to CervoMed Inc., 20 Park Plaza, Suite 424, Boston, Massachusetts 02116, Attention: General Counsel.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO EXHIBITS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>No.</b></p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:1%;">&#160;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.1&#916;</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923008519/ex_494918.htm" style="-sec-extract:exhibit;">Agreement and Plan of Merger, dated as of March 30, 2023, by and among Diffusion Pharmaceuticals Inc., EIP Pharma, Inc. and Dawn Merger Sub Inc.</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on March 30, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#160;</td>
			<td style="vertical-align: top; width: 56%;">&#160;</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923007795/ex_488532.htm" style="-sec-extract:exhibit;">Certificate of Incorporation of CervoMed Inc., as amended</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Annual Report on Form 10-K filed on March 24, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#160;</td>
			<td style="vertical-align: top; width: 56%;">&#160;</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_561998.htm" style="-sec-extract:exhibit;">Certificate of Amendment, dated August 16, 2023, to the Certificate of Incorporation, as amended, of CervoMed Inc. (Reverse Stock Split)</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 3.3 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#160;</td>
			<td style="vertical-align: top; width: 56%;">&#160;</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_561999.htm" style="-sec-extract:exhibit;">Certificate of Amendment, dated August 16, 2023, to the Certificate of Incorporation, as amended, of CervoMed Inc. (Name Change)</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 3.4 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#160;</td>
			<td style="vertical-align: top; width: 56%;">&#160;</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_562000.htm" style="-sec-extract:exhibit;">Bylaws of CervoMed Inc., as amended</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 3.5 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2023.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">&#160;</td>
			<td style="vertical-align: top; width: 56%;">&#160;</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p>
			</td>
			<td style="vertical-align: top; width: 56%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774921003299/ex_227273.htm" style="-sec-extract:exhibit;">Form of February 2021 Underwriter Warrant</a></p>
			</td>
			<td style="vertical-align:top;width:1%;">&#160;</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on February 18, 2021.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.2</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_562001.htm" style="-sec-extract:exhibit;">Form of EIP 2018 Investor Warrant</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.3</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923024064/ex_562002.htm" style="-sec-extract:exhibit;">Form of EIP 2018 Investor Warrant (AI EIPP Holdings LLC)</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.4</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/ex_646585.htm" style="-sec-extract:exhibit;">Form of&#160;Series A Warrant issued in connection with the 2024 Private Placement</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on March 28, 2024</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.5</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924010064/ex_643173.htm" style="-sec-extract:exhibit;">Specimen Stock Certificate</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 4.15 to the Company&#8217;s Annual Report on Form 10-K filed on March 29, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4.6</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924010064/ex_643086.htm" style="-sec-extract:exhibit;">Description of Securities of CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 4.16 to the Company&#8217;s Annual Report on Form 10-K filed on March 29, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.1#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924002955/ex_619845.htm" style="-sec-extract:exhibit;">Amended &amp; Restated Employment Agreement, dated as of February 1, 2024, by and between John Alam, M.D. and CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on February 2, 2024.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">109</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/ex_803313.htm" style="-sec-extract:exhibit;">Amended &amp; Restated Employment Agreement, effective as of April 16, 2025, by and between Kelly Blackburn, MHA, and CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on April 18, 2025.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.3#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/ex_803314.htm" style="-sec-extract:exhibit;">Employment Agreement, effective as of May 1, 2025, by and between Mark De Rosch, PhD, FRAPS, and CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on April 18, 2025</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.4#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924025875/ex_711250.htm" style="-sec-extract:exhibit;">Amended &amp; Restated Employment Agreement, effective as of June 1, 2024, by and between William Elder and CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 9, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.5#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932188.htm" style="-sec-extract:exhibit;">Employment Agreement, effective as of October 6, 2025, by and between Matthew Winton and CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.6#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925025570/ex_850097.htm" style="-sec-extract:exhibit;">CervoMed Inc. 2025 Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 8, 2025.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.7#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923013739/ex_515235.htm" style="-sec-extract:exhibit;">EIP Pharma, Inc. 2018 Employee, Director and Consultant Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.31 to the Company&#8217;s Registration Statement on Form S-4/A filed on July 12, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.8#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">CervoMed Inc. 2015 Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Appendix C to the Company&#8217;s definitive proxy statement on Schedule 14A filed on June 10, 2016.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.9#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Amendment No. 1 to CervoMed Inc. 2015 Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Appendix B to the Company&#8217;s definitive proxy statement on Schedule 14A filed on June 10, 2016.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.10#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932189.htm" style="-sec-extract:exhibit;">Form of Stock Option Award Agreement under 2025 Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.11#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924010064/ex_643087.htm" style="-sec-extract:exhibit;">Form of Stock Option Award Agreement under 2018 Employee, Director and Consultant Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K filed on March 29, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.12#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774922006737/ex_348717.htm" style="-sec-extract:exhibit;">Form of Stock Option Award Agreement under 2015 Equity Incentive Plan</a></p>
			</td>
			<td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.7 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.13#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/ex_790703.htm" style="-sec-extract:exhibit;">Form of Inducement Stock Option Award Agreement</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.10 to the Company's Annual Report on Form 10-K filed on March 17, 2025.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.14*</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923013739/ex_515228.htm" style="-sec-extract:exhibit;">Option and License Agreement, dated as of August 27, 2012, by and between EIP Pharma LLC and Vertex Pharmaceuticals Incorporated</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.23 to the Company&#8217;s Registration Statement on Form S-4/A filed on July 12, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.15*</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923013739/ex_515229.htm" style="-sec-extract:exhibit;">Amendment No.1, dated as of April 8, 2014, to Option and License Agreement, dated August 27, 2012, by and between EIP Pharma LLC and Vertex Pharmaceuticals Incorporated</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.24 to the Company&#8217;s Registration Statement on Form S-4/A filed on July 12, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.16*</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774923013739/ex_515230.htm" style="-sec-extract:exhibit;">Amendment No.2, dated as of November 17, 2015, to Option and License Agreement, dated August 27, 2012, as amended April 18, 2014, by and between EIP Pharma LLC and Vertex Pharmaceuticals Incorporated</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.25 to the Company&#8217;s Registration Statement on Form S-4/A filed on July 12, 2023.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.17</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925016131/ex_815690.htm" style="-sec-extract:exhibit;">Sales Agreement, by and between the Company and Leerink Partners, LLC, dated May 12, 2025</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K filed on May 12, 2025.</p>
			</td>
		</tr>

</tbody></table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">110</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.18</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924009697/ex_646646.htm" style="-sec-extract:exhibit;">Securities Purchase Agreement, dated March 28, 2024, by and between CervoMed Inc. and each of the purchasers party thereto, related to the 2024 Private Placement</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.19 to the Company's Registration Statement on Form S-1 filed on May 10, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.19#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924010064/ex_643088.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement between CervoMed Inc. and each of its directors and officers</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.12 to the Company&#8217;s Annual Report on Form 10-K filed on March 29, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">10.20#</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925025570/ex_850102.htm" style="-sec-extract:exhibit;">Separation Agreement, by and between the Company and Robert J. Cobuzzi, PhD, dated July 1, 2025</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on August 8, 2025.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">19.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/ex_790704.htm" style="-sec-extract:exhibit;">CervoMed Inc. Insider Trading Policy, effective as of March 14, 2025</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 19.1 to the Company's Annual Report on Form 10-K filed on March 17, 2025.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: bottom; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">21.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774925007829/ex_790705.htm" style="-sec-extract:exhibit;">Subsidiaries of CervoMed Inc.</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 21.1 to the Company's Annual Report on Form 10-K filed on March 17, 2025.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">23.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932424.htm" style="-sec-extract:exhibit;">Consent of RSM US LLP, independent registered public accounting firm</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">31.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932190.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">31.2</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932191.htm" style="-sec-extract:exhibit;">Certification of Acting Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932192.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer Pursuant to 18 USC. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of CervoMed Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">32.2</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="ex_932193.htm" style="-sec-extract:exhibit;">Certification of Acting Principal Financial Officer Pursuant to 18 USC. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The certification attached as Exhibit 32.2 that accompanies this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of CervoMed Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">97.1</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774924010064/ex_643094.htm" style="-sec-extract:exhibit;">CervoMed Inc. Clawback Policy</a></p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Incorporated by reference to Exhibit 97.1 to the Company&#8217;s Annual Report on Form 10-K filed on March 29, 2024.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">101</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">The following materials from the Company&#8217;s annual report on Form 10-K for the year ended December 31, 2025, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Filed herewith.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">104</p>
			</td>
			<td style="vertical-align: top; width: 56%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).</p>
			</td>
			<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">#</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 57%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Indicates a management contract or compensatory plan or arrangement.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">&#916;</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 57%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Schedules and exhibits have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish on a supplemental basis a copy of any omitted schedule or exhibit to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">*</p>
			</td>
			<td colspan="3" style="vertical-align: top; width: 57%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">111</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 16.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FORM 10-K SUMMARY</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: March 13, 2026</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CERVOMED INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%;">&#160;</td>
			<td style="vertical-align: top; width: 3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">/s/ John Alam, MD</span></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">John Alam, MD</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>President, Chief Executive Officer and Director</i></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Name and Signature</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Title</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Date</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ John Alam, MD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">President, Chief Executive Officer and Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">John Alam, MD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Executive Officer)</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ William Elder</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chief Financial Officer and General Counsel</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">William Elder</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Principal Financial Officer)</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Joshua S. Boger, PhD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Chair of the Board</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Joshua S. Boger, PhD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Sylvie Gr&#233;goire, PharmD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Sylvie Gr&#233;goire, PharmD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jane H. Hollingsworth, JD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jane H. Hollingsworth, JD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jeffrey V. Poulton</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jeffrey V. Poulton</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ David Quigley</p>
			</td>
			<td style="vertical-align:bottom;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:bottom;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">David Quigley</p>
			</td>
			<td style="vertical-align:bottom;width:3.6%;">&#160;</td>
			<td style="vertical-align:bottom;width:29.3%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:38.3%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.6%;">&#160;</td>
			<td style="vertical-align:bottom;width:29.3%;">&#160;</td>
			<td style="vertical-align:bottom;width:3.8%;">&#160;</td>
			<td style="vertical-align:bottom;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Marwan Sabbagh, MD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Marwan Sabbagh, MD</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Frank Zavrl</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Director</p>
			</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">March 13, 2026</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:38.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Frank Zavrl</p>
			</td>
			<td style="vertical-align:top;width:3.6%;">&#160;</td>
			<td style="vertical-align:top;width:29.3%;">&#160;</td>
			<td style="vertical-align:top;width:3.8%;">&#160;</td>
			<td style="vertical-align:top;width:25.5%;">&#160;</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">112</div>
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>2
<FILENAME>ex_932188.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<html><head>
	<title>ex_932188.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 10:22:27 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.5</b></font></p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>EXECUTION VERSION</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>EMPLOYMENT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This Employment Agreement (this &#8220;<u>Agreement</u>&#8221;) is entered into as of October 6, 2025 (the &#8220;<u>Effective Date</u>&#8221;) by and between CervoMed Inc. (the &#8220;<u>Company</u>&#8221;) and Matthew Winton (the &#8220;<u>Executive</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Recitals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">WHEREAS, the Company and the Executive previously entered into that certain offer letter, dated as of September 2, 2025, related to the Executive&#8217;s prospective employment with the Company (the &#8220;<u>Offer Letter</u>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">WHEREAS, the Company and the Executive each desire to set forth the terms and conditions of Executive&#8217;s employment with the Company as described in this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">NOW THEREFORE, in consideration of the premises and the mutual covenants hereinafter set forth, and intending to be legally bound hereby, it is hereby agreed as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>1.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>Definitions.</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 72pt;"><b>1.1.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Affiliate</u>&#8221; means as to any Person, any other Person that directly or indirectly controls, or is under common control with, or is controlled by, such first Person. As used in this definition, &#8220;control&#8221; (including, with its correlative meanings, &#8220;controlled by&#8221; and &#8220;under common control with&#8221;) shall mean possession, directly or indirectly, of power to direct or cause the direction of management or policies (whether through ownership of voting equity interests, by contract or otherwise). For the avoidance of doubt, each member of the Company Group (other than the Company) is an Affiliate of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.2.</b>&nbsp; &nbsp; &nbsp; &nbsp; &#8220;<u>Board</u>&#8221;&nbsp;means the Board of Directors of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.3.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Cause</u>&#8221; means the Executive&#8217;s (i) indictment for, or entering of a plea of guilty or nolo contendere (or its equivalent under any applicable legal system) with respect to (A) a felony or (B) any crime involving moral turpitude; (ii) commission of fraud, misrepresentation, embezzlement or theft against any Person; (iii) engaging in any intentional activity that injures or would reasonably be expected to injure (monetarily or otherwise), in any material respect, the reputation, the business or a business relationship of the Company or any of its Affiliates; (iv) gross negligence or willful misconduct in the performance of the Executive&#8217;s duties to the Company or its Affiliates under this Agreement, or willful refusal or failure to carry out the lawful instructions of the CEO that are consistent with the Executive&#8217;s title and position; (v) violation of any fiduciary duty owed to the Company or any of its Affiliates; or (vi) breach of any Restrictive Covenant (as defined below) or material breach or violation of any other provision of this Agreement, of a written policy or code of conduct of the Company or any of its Affiliates (as in effect from time to time) or any other agreement between the Executive and the Company or any of its Affiliates. Except when such acts constituting Cause which, by their nature, cannot reasonably be expected to be cured, the Executive shall have twenty (20) days following the delivery of written notice by the Company of its intention to terminate the Executive&#8217;s employment for Cause within which to cure any acts constituting Cause. Following such 20-day cure period, the Executive shall be given five (5) business days prior written notice to appear (with or without counsel) before the full Board for the opportunity to present information regarding Executive&#8217;s views on the alleged Cause event. After the Company provides the original notice of its intent to terminate Executive&#8217;s employment for Cause, the Company may suspend the Executive from all Executive&#8217;s duties and responsibilities and prevent Executive from accessing the Company&#8217;s or its Affiliates&#8217; premises or contacting any personnel of the Company or any of its Affiliates until a final determination on the hearing is made. Notwithstanding the foregoing or anything contained in this Agreement to the contrary, Executive&#8217;s resignation from employment at a time when Cause exists shall be treated as a termination of employment by the Company for Cause, and no cure rights or right to be heard by the Board shall be provided.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 72pt;"><b>1.4.</b>&nbsp; &nbsp; &nbsp; &nbsp; &#8220;<u>CEO</u>&#8221;&nbsp;means the Chief Executive Officer of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.5.&nbsp; &nbsp; &nbsp; &nbsp;</b>&#8220;<u>Change of Control</u>&#8221; means (i) the accumulation (if over time, in any consecutive twelve (12) month period), whether directly, indirectly, beneficially or of record, by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of 50.1% or more of the shares of the outstanding voting securities of the Company, whether by merger, consolidation, sale or other transfer of shares (other than a merger or consolidation where the stockholders of the Company immediately prior to the merger or consolidation are immediately after such merger or consolidation the direct or indirect beneficial owners of a majority of the voting securities of the entity that survives such merger or consolidation), (ii) a sale of all or substantially all of the assets of the Company and its Subsidiaries, determined on a consolidated basis or (iii) during any period of twelve (12) consecutive months, the individuals who, at the beginning of such period, constitute the Board, and any new director whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the 12-month period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; provided, however, that the following acquisitions shall not constitute a Change of Control for the purposes of this Agreement: (A) any acquisitions of voting securities or securities convertible, exercisable or exchangeable into voting securities directly from the Company or (B) any acquisition of voting securities or securities convertible, exercisable or exchangeable into voting securities by any employee benefit plan (or related trust) sponsored by or maintained by the Company or any of its Subsidiaries; provided further, that a transaction will not be a Change of Control unless it also satisfies the requirements of Treasury Regulation 1.409A-3(i)(5)(v), (vi) or (vii).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 72pt;"><b>1.6.&nbsp; &nbsp; &nbsp; &nbsp;</b>&nbsp;&#8220;<u>Code</u>&#8221;&nbsp;means the Internal Revenue Code of 1986, as amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.7.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Company Group</u>&#8221; means the Company and the direct and indirect Subsidiaries of the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.8.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Company Invention</u>&#8221; means any Invention that is Invented by the Executive (alone or jointly with others) (whether before, on or after the Effective Date) (i) in the course of, in connection with, or as a result of the Executive&#8217;s employment or other service with any member of the Company Group, (ii) at the direction or request of any member of the Company Group, or (iii) through the use of, or that is related to, facilities, equipment, Confidential Information, other Company Inventions, intellectual property or other resources of any member of the Company Group, whether or not during the Executive&#8217;s work hours.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.9.&nbsp; &nbsp; &nbsp; &nbsp;</b>&#8220;<u>Confidential Information</u>&#8221; shall mean all information of a sensitive, confidential or proprietary nature respecting the business and activities of any member of the Company Group or any of their respective Affiliates, or the predecessors and successors of any member of the Company Group or any of their respective Affiliates, including, without limitation, the terms and provisions of this Agreement (except for the terms and provisions of Sections 4.4 through 4.17), and the clients, customers, suppliers, computer or other files, projects, products, computer disks or other media, computer hardware or computer software programs, marketing plans, financial information, methodologies, Inventions, know-how, research, developments, processes, practices, approaches, projections, forecasts, formats, systems, data gathering methods and/or strategies of any member of the Company Group or any of their respective Affiliates. &#8220;Confidential Information&#8221; also includes all information received by the Company or any other member of the Company Group under an obligation of confidentially to a third party. Notwithstanding the foregoing, Confidential Information shall not include any information that is generally available, or is made generally available, to the public other than as a result of a direct or indirect unauthorized disclosure by the Executive or any other Person subject to a confidentiality obligation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.10.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Disability</u>&#8221; means that the Executive has been unable, as determined by the Company in good faith, to perform the Executive&#8217;s duties under this Agreement for a period of ninety (90) consecutive days or for a total of one hundred and twenty (120) days (whether or not consecutive) during any period of twelve (12) consecutive months, as a result of injury, illness or any other physical or mental impairment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.11.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Good Reason</u>&#8221; means any of the following actions taken by the Company without the Executive&#8217;s prior written consent: (i) a material reduction in the Executive&#8217;s duties, responsibilities or authority; (ii) a material reduction of the Executive&#8217;s Base Salary (as defined below); (iii) failure or refusal of a successor to the Company to either materially assume the Company&#8217;s obligations under this Agreement or enter into a new employment agreement with the Executive on terms that are materially similar to those provided under this Agreement, in any case, in the event of a Change of Control; or (iv) a material breach of this Agreement by the Company. Notwithstanding the foregoing, Good Reason shall not be deemed to exist unless (A) the Executive gives the Company written notice within sixty (60) days after the first occurrence of the event which the Executive believes constitutes the basis for Good Reason, specifying the particular act or failure to act which the Executive believes constitutes the basis for Good Reason, (B) the Company fails to cure such act or failure to act within thirty (30) days after receipt of such notice and (C) the Executive terminates Executive&#8217;s employment within thirty (30) days after the end of such 30- day cure period specified in clause (B). In addition, and notwithstanding anything in this Agreement to the contrary, in connection with a pandemic, national emergency or other event that provides (or is expected to provide) a significant disruption to the Company&#8217;s business, the compensation and/or benefits set forth in this Agreement may be reduced if such reduction applies generally to the Company&#8217;s officers, and no such reduction (individually or combined with any other reduction(s)) shall give rise to Good Reason or be treated as a breach of this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.12.&nbsp; &nbsp; &nbsp; </b>&#8220;<u>Invented</u>&#8221; means made, conceived, invented, authored, or first actually reduced to practice (in any case, whether partially or fully).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.13.&nbsp; &nbsp; &nbsp;</b>&#8220;<u>Invention</u>&#8221; means any invention, formula, therapy, diagnostic technique, discovery, improvement, idea, technique, design, method, art, process, methodology, algorithm, machine, development, product, service, technology, strategy, software, work of authorship or other Works (as defined in Section 4.13), trade secret, innovation, trademark, data, database, or the like, whether or not patentable, together with all intellectual property rights therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.14.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Person</u>&#8221; means an individual, partnership, limited liability company, corporation, association, joint stock company, trust, joint venture, unincorporated organization, investment fund, any other business entity and a governmental entity or any department, agency or political subdivision thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.15.&nbsp; &nbsp; &nbsp; </b>&#8220;<u>Subsidiary</u>&#8221; means, with respect to any Person, any other Person in which such first Person has a direct or indirect equity ownership interest of at least 50%.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.16.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Term of Employment</u>&#8221; means the period of the Executive&#8217;s employment with the Company under this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>1.17.&nbsp; &nbsp; &nbsp;&nbsp;</b>&#8220;<u>Termination Date</u>&#8221; means the date the Executive&#8217;s employment with the Company terminates for any reason.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>2.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><u>Employment</u></b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>2.1.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Executive</u></b><u>&#8217;<b>s Representations</b></u>. The Executive represents that (i) the Executive is entering into this Agreement voluntarily and that the Executive&#8217;s employment hereunder and compliance with the terms and conditions hereof will not conflict with or result in the breach by the Executive of any agreement to which the Executive is a party or by which the Executive may be bound, and does not violate any duties owed by Executive to other third parties and (ii) in connection with the Executive&#8217;s employment with the Company or any other member of the Company Group, the Executive will not (A) violate any non-competition, non-solicitation or other similar covenant or agreement by which the Executive is or may be bound or (B) use any confidential or proprietary information that the Executive may have obtained in connection with the Executive&#8217;s employment or engagement with any other Person.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>2.2.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Position; Duties and Responsibilities</u></b>. During the Term of Employment, the Executive shall be employed as the Company&#8217;s Chief Commercial and Business Officer, with such duties and responsibilities that are consistent with such position as may be assigned by the CEO, from time to time. In addition, during the Term of Employment, the Executive shall serve in such other officer and/or director positions with any member of the Company Group (for no additional compensation) as may be determined by the Board and/or the CEO from time to time. The Executive further agrees that, during the Term of Employment, Executive shall not knowingly take any action that is contrary to, or in conflict with, the best interests of the Company Group.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>2.3.&nbsp; &nbsp;&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Reporting; Outside Activities</u></b>. During the Term of Employment, the Executive shall report to the CEO, and the Executive shall diligently and conscientiously devote the Executive&#8217;s full business time, attention, energy, skill and best efforts to the business and affairs of the Company Group. Notwithstanding the foregoing, the Executive may (i) continue to serve as a member of the board of any organization listed in Exhibit A hereto, (ii) serve on other boards as may be approved by the CEO in their sole discretion, (iii) engage in educational, charitable and civic activities and (iv) manage the Executive&#8217;s personal and business investments and affairs, so long as such activities (A) do not, individually or in the aggregate, interfere with the performance of the Executive&#8217;s duties under this Agreement and (B) are not contrary to the interests of the Company Group or competitive in any way with the Company Group. Subject to the foregoing, during the Term of Employment, the Executive shall not, directly or indirectly, render any services of a business, commercial, or professional nature to any other Person, whether for compensation or otherwise, without the prior written consent of the CEO.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:72pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><u>Compensation and Other Benefits</u></b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>3.1.&nbsp; &nbsp;&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Base Salary</u></b>. During the Term of Employment, the Executive shall receive an initial base salary per annum of $470,000, which shall be payable in accordance with the Company&#8217;s normal payroll practices as in effect from time to time. During the Term of Employment, the Board may review the Executive&#8217;s base salary and the Board may, in its sole discretion, increase (but not decrease) such base salary by an amount it determines to be appropriate. The Executive&#8217;s base salary, as may be in effect from time to time, is referred to herein as &#8220;<u>Base Salary</u>.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>3.2.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Annual Bonus</u></b>. During the Term of Employment, the Executive shall be eligible to earn an annual performance bonus based on the achievement of the performance goals established by the Board or a committee thereof in its sole discretion, with an annual target bonus opportunity of 40% of the Base Salary and the potential to earn a higher bonus for above target performance, with the amount of any such bonus to be determined by the Board or a committee thereof in its sole discretion (the &#8220;<u>Annual Bonus</u>&#8221;); provided that, for the avoidance of doubt, the Executive&#8217;s Annual Bonus for the year ending December 31, 2025, will be pro-rated based on the Executive&#8217;s employment start date. Any earned Annual Bonus shall be paid in a lump sum by no later than the first March 15<sup style="vertical-align:top;line-height:120%;">th</sup> to occur after the end of the applicable performance period. Except as set forth in Section 4.2, the Executive must be employed by the Company on the bonus payment date in order to receive an earned Annual Bonus with respect to any performance period.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>3.3.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Equity Grants</u></b>. During the Term of Employment, the Executive shall be eligible for equity or equity-based awards that may be granted to the Executive at such times, in such amounts and in such manner as the Board may determine in its sole discretion. Any such equity or equity-based awards shall be subject to the terms and conditions set forth in the applicable plan and award agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>3.4.</b><b>&nbsp;&nbsp; &nbsp; &nbsp; <u>Expense Reimbursement</u></b>. During the Term of Employment, the Company shall reimburse the Executive&#8217;s reasonable and necessary business expenses incurred in connection with performing the Executive&#8217;s duties hereunder in accordance with its then-prevailing policies and procedures for expense reimbursement (which shall include appropriate itemization and substantiation of expenses incurred).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>3.5.&nbsp; &nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Benefit Plans; Vacation</u></b>. During the Term of Employment, the Executive shall be entitled to participate in all broad-based employee benefit plans and programs maintained from time to time for the benefit of the Company&#8217;s employees (e.g., medical, dental and disability benefits) to the extent that the Executive satisfies the eligibility requirements of such plans or programs (including, without limitation, minimum hours worked) and subject to applicable law and the terms and conditions of such plans or programs; provided, however, that the Company may amend, modify or terminate any such plans or programs at any time in its discretion. During the Term of Employment, the Executive shall be entitled an allotment of 25 days of paid time off per calendar year, prorated for partial years, or such greater amount provided for pursuant to the Company&#8217;s paid time off policy, as in effect from time to time, in each case, subject to the terms and conditions of such policy.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><b>4.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; <u>Termination; Restrictive Covenants</u></b>. Upon the Termination Date, the Executive shall be deemed to have immediately resigned from any and all officer, director (unless otherwise directed in writing by the Company) and other positions the Executive then holds with the Company and its Affiliates (and this Agreement shall constitute notice of resignation by the Executive without any further action by the Executive), and the Executive agrees to execute and deliver such further instruments as are requested by the Company in furtherance of the foregoing. Except as expressly provided in Section 4.2, all rights the Executive may have to compensation and employee benefits from the Company or its Affiliates shall terminate immediately upon the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.1.</b><b>&nbsp; &nbsp; &nbsp; <u>General</u></b>. The Company may terminate the Term of Employment and the Executive&#8217;s employment at any time, with or without Cause or due to Disability, upon written notice to the Executive. The Executive may terminate the Term of Employment and the Executive&#8217;s employment for Good Reason or for any other reason at any time upon not less than ninety (90) days&#8217; advance written notice to the Company; provided, that following its receipt of the Executive&#8217;s notice of termination, the Company may elect to reduce the notice period and cause the Termination Date to occur earlier, and no such action by the Company shall entitle the Executive to notice pay, severance pay or benefits or pay in lieu of notice or lost wages or benefits. In addition, the Term of Employment and the Executive&#8217;s employment with the Company shall terminate immediately upon the Executive&#8217;s death.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 72pt;">&nbsp;<b>4.2.&nbsp; &nbsp; &nbsp; &nbsp;</b> <b><u>Separation Payments</u></b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 108pt; text-align: justify;"><b>4.2.1.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>General</u></b>. Except as otherwise provided in this Section 4.2, in the event that the Executive&#8217;s employment with the Company terminates for any reason, the Executive (or the Executive&#8217;s estate or legal representative, as applicable) shall be entitled to receive only (i) the cash portion of the Base Salary earned but unpaid through the Termination Date, paid in accordance with the Company&#8217;s normal payroll policies (or at such earlier time as required by applicable law), (ii) any accrued but unused vacation in accordance with the Company&#8217;s policies and applicable law, (iii) any unreimbursed business expenses incurred prior to the Termination Date that are otherwise reimbursable, with such expenses to be reimbursed in accordance with the Company&#8217;s expense reimbursement policies (as may be in effect from time to time), and (iv) any vested benefits earned by the Executive under any employee benefit plan of the Company or its Affiliates under which the Executive was participating immediately prior to the Termination Date, with such benefits to be provided in accordance with the terms of the applicable employee benefit plan (the items described in the foregoing clauses (i) through (iv), collectively, the &#8220;<u>Accrued</u> <u>Benefits</u>&#8221;). All other rights the Executive may have to compensation and employee benefits from the Company or any of its Affiliates, other than as set forth in Sections 4.2.2, 4.2.3 or 4.2.4, shall immediately terminate upon the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 108pt; text-align: justify;"><b>4.2.2.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Death and Disability</u></b>. In the event that the Executive&#8217;s employment is terminated due to the Executive&#8217;s death or by the Company due to Disability, in either case, during the Term of Employment, then in addition to the Accrued Benefits, and subject to Section 4.2.5, the Executive (or the Executive&#8217;s estate or legal representative, as applicable) shall be entitled to receive: (i) the Annual Bonus earned in the fiscal year immediately preceding the fiscal year in which such termination occurred, to the extent that such Annual Bonus is unpaid as of the Termination Date, with such amount to be payable in cash and/or fully vested shares of the Company&#8217;s common stock (as determined by the Company in its sole discretion) at the same time as if no such termination had occurred (the &#8220;<u>Unpaid Prior Year Bonus</u>&#8221;); (ii) the Annual Bonus for the year in which the Termination Date occurs, but multiplied by a fraction (A) the numerator of which is the number of days Executive was employed as the Company&#8217;s Chief Commercial and Business Officer, during the fiscal year of such termination and (B) the denominator of which is the number of days in such fiscal year (to be paid in cash at the same time as if no such termination had occurred); (iii) if the Executive and Executive&#8217;s eligible dependents are eligible for, and timely elect, COBRA continuation coverage, the Company shall reimburse the Executive (or the Executive&#8217;s estate or legal representative, as applicable) for the COBRA premiums for the Executive and Executive&#8217;s eligible dependents under the Company&#8217;s medical, dental and vision benefit plans for a period of 12 months immediately following the Termination Date (the &#8220;<u>COBRA</u> <u>Benefit</u>&#8221;); provided, however, that notwithstanding the foregoing, the COBRA Benefit shall not be provided to the extent that it would result in any fine, penalty or tax on the Company or any of its Affiliates (under Section 105(h) of the Code or the Patient Protection and Affordable Care Act of 2010, or otherwise); provided further, that the COBRA Benefit shall cease earlier if the Executive or Executive&#8217;s dependents become eligible for health coverage under the health plan of another employer; and (iv) to the extent the following will not result in a violation of Section 409A, with respect to each equity award received by Executive from the Company or any of its direct or indirect parent companies that is outstanding as of the Termination Date, accelerated vesting immediately upon the Termination Date of, (I) with respect to any such equity award received in payment of Base Salary or an Annual Bonus, 100% of such equity award and, (II) with respect to any equity award not described in clause (I), the greater of (x) the portion of the unvested equity award that would have become vested within 12 months after the Termination Date had the Executive remained employed by the Company during such 12-month period (without regard for the vesting schedule set forth in any applicable plan or agreement governing such equity award) or (y) the portion of the unvested equity award that is subject to accelerated vesting (if any) upon such termination under the applicable equity plan or award agreement; provided, however, that any equity awards that are subject to the satisfaction of performance goals shall be deemed earned at not less than target performance; and provided, further, that, with respect to any equity award that is in the form of a stock option or stock appreciation right, the option or stock appreciation right shall remain outstanding and exercisable for 12 months following the Termination Date or, if longer, such period following the Termination Date as provided under the applicable equity plan or award agreement (but in no event beyond the expiration date of the applicable option or stock appreciation right). All other rights the Executive may have to compensation and employee benefits from the Company or any of its Affiliates, other than as set forth in this Section 4.2.2, shall immediately terminate upon the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 6pt;text-indent:108pt;"><b>4.2.3.</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Without Cause or for Good Reason </u></b><u>&#8211;<b> Not In Connection with a Change of Control</b></u>. If, during the Term of Employment, the Executive&#8217;s employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either case, and such termination is not covered by Section 4.2.4, then the Executive shall be entitled to receive the Accrued Benefits and, subject to Section 4.2.5:&nbsp;(i) the Unpaid Prior Year Bonus, with such amount to be payable in cash at the same time as if no such termination had occurred; (ii) the Annual Bonus for the year in which the Termination Date occurs, but multiplied by a fraction (A) the numerator of which is the number of days the Executive was employed as the Company&#8217;s Chief Commercial and Business Officer, during the fiscal year of such termination and (B) the denominator of which is the number of days in such fiscal year (to be paid in cash at the same time as if no such termination had occurred); (iii) continuation of the Base Salary as of the Termination Date for nine months immediately following the Termination Date, with all portions of such Base Salary to be paid in cash in substantially equal installments in accordance with the Company&#8217;s normal payroll policies, with the first such payment to be made on the 60<sup style="vertical-align:top;line-height:120%;">th</sup> day following the Termination Date and to include a catch-up covering any payroll dates between the Termination Date and the date of the first payment and (iv) the COBRA Benefit for a period of 12 months immediately following the Termination Date; provided, however, that notwithstanding the foregoing, the COBRA Benefit shall not be provided to the extent that it would result in any fine, penalty or tax on the Company or any of its Affiliates (under Section 105(h) of the Code or the Patient Protection and Affordable Care Act of 2010, or otherwise); provided further, that the COBRA Benefit shall cease earlier if the Executive (or Executive&#8217;s dependents) become eligible for health coverage under the health plan of another employer. All other rights the Executive may have to compensation and employee benefits from the Company or any of its Affiliates, other than as set forth in this Section 4.2.3, shall immediately terminate upon the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 108pt;"><b>4.2.4.&nbsp;&nbsp;&nbsp;&nbsp;</b><u><b>Termination Without Cause or for Good Reason </b>&#8211;<b>&nbsp;In Connection with a Change of Control</b></u>. If, during the Term of Employment, the Executive&#8217;s employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either case, (A) upon or within 24 months following a Change of Control or (B) within 60 days prior to a Change of Control, then the Executive shall be entitled to receive the Accrued Benefits and, subject to Section 4.2.5: (i) the Unpaid Prior Year Bonus, with such amount to be payable in cash at the same time as if no such termination had occurred; (ii) the Annual Bonus for the year in which the Termination Date occurs, but multiplied by a fraction (x) the numerator of which is the number of days the Executive was employed as the Company&#8217;s Chief Commercial and Business Officer, during the fiscal year of such termination and (y) the denominator of which is the number of days in such fiscal year (to be paid in cash at the same time as if no such termination had occurred); (iii) a lump sum payment equal to 1.5 times the sum of Executive&#8217;s Base Salary (at the highest rate in effect during the 24 month period commencing on the date of such Change of Control) and the higher of Executive&#8217;s target Annual Bonus opportunity and the Annual Bonus paid to Executive with respect to the fiscal year immediately preceding the fiscal year in which such termination occurred, with such payment to be paid in cash on the first payroll date after the effective date of the release (as described in Section 4.2.5) and in all events no later than 70 days after such termination and (iv) a payment equal to 18 times the monthly COBRA premium for Executive and Executive&#8217;s eligible dependents (at the rate in effect for Executive&#8217;s coverage at the time of Executive&#8217;s termination, regardless of whether Executive elects COBRA coverage), with one-third of such payment to be paid in cash on the first payroll date after the effective date of the release (as described in Section 4.2.5) and in all events no later than 70 days after such termination, and with the remaining two-thirds to be paid according to the same schedule as the COBRA Benefit is provided in clause (iv) of Section 4.2.3 (i.e., in installments over 12 months immediately following the Termination Date). Notwithstanding the foregoing, in the event that a termination described in clause (B) of this Section 4.2.4 occurs, then the payments described in clauses (iii) and (iv) of this Section 4.2.4 shall be paid over the same nine-month period (or the same 12-month period, as applicable) and in the same manner as set forth in clauses (iii) and (iv) of Section 4.2.3, respectively, rather than being paid in a lump sum. In addition, if (and only if), during the Term of Employment, the Executive&#8217;s employment is terminated by the Company without Cause (and not due to death or Disability) or by Executive for Good Reason, in either case, upon or within 24 months following a Change of Control, then, to the extent the following will not result in a violation of Section 409A, the Executive shall be entitled to, in addition to the Accrued Benefits and the payments set forth in the foregoing clauses through (iv), and subject to Section 4.2.5, immediate and full accelerated vesting of all equity awards received by Executive from the Company or any of its direct or indirect parent companies that are outstanding as of the Termination Date without regard for the vesting schedule set forth in any applicable plan or agreement governing such equity awards; provided that, any equity awards that are subject to the satisfaction of performance goals shall be deemed earned at not less than target performance; and provided, further, that, with respect to any equity award that is in the form of a stock option or stock appreciation right, the option or stock appreciation right shall remain outstanding and exercisable for 24 months following the Termination Date (but in no event beyond the expiration date of the applicable option or stock appreciation right). All other rights the Executive may have to compensation and employee benefits from the Company or any of its Affiliates, other than as set forth in this Section 4.2.4, shall immediately terminate upon the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 108pt;"><b>4.2.5.&nbsp;&nbsp;&nbsp;&nbsp;<u>Release Requirement</u></b>. Payment and provision of the benefits set forth in Sections 4.2.2, 4.2.3 and 4.2.4 (other than the Accrued Benefits) is subject to the Executive&#8217;s (or, as applicable, the Executive&#8217;s estate&#8217;s or legal representative&#8217;s) execution of a general release of claims and covenant not to sue in form and substance satisfactory to the Company, such that such release becomes effective, with all revocation periods having expired unexercised, within sixty (60) days after the Termination Date. Notwithstanding the foregoing, if payment of any of the severance benefits set forth in Sections 4.2.2, 4.2.3 or 4.2.4 (other than the Accrued Benefits) could commence in more than one taxable year based on when the release could become effective, then to the extent required by Section 409A (as defined below), any such payments that would have been made during the calendar year in which the Executive&#8217;s employment terminates instead shall be withheld and paid on the first payroll date in the calendar year immediately after the calendar year in which the Executive&#8217;s employment terminates, with all remaining payments to be made as if no such delay had occurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.3.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Violation of Restrictive Covenants</u></b>. Without limiting the remedies provided to the Company and its Affiliates as set forth in this Article 4, upon the Executive&#8217;s breach of any of the Restrictive Covenants (as defined below), other than any immaterial and unintentional breach by the Executive of the confidentiality obligations set forth in Section 4.11, the Company will have no obligation to continue to pay or provide any of the compensation or benefits under Section 4.2 (other than the Accrued Benefits) and the Executive shall repay to the Company any amounts paid under Section 4.2 (other than the Accrued Benefits) after such breach occurred.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.4.&nbsp;&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictive Covenants</u></b>. As an inducement and as essential consideration for the Company to enter into this Agreement, and in exchange for other good and valuable consideration, the Executive hereby agrees to the restrictive covenants contained in Sections 4.5 through 4.17 (the &#8220;<u>Restrictive Covenants</u>&#8221;). The Company and the Executive agree that the Restrictive Covenants are essential and narrowly tailored to preserve the goodwill of the business of the Company and its Affiliates, to maintain the confidential and trade secret information of the Company and its Affiliates, and to protect other legitimate business interests of the Company and its Affiliates, and that the Company would not have entered into this Agreement without the Executive&#8217;s agreement to the Restrictive Covenants. For purposes of the Restrictive Covenants, each reference to &#8220;<u>Company</u>,&#8221; &#8220;<u>Company Group</u>&#8221; and &#8220;<u>Affiliate</u>,&#8221; shall also refer to the predecessors and successors of the Company, the members of the Company Group and any of their respective Affiliates (as the case may be).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.5.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Non-Competition</u></b>. During the period commencing on the Effective Date and ending 12 months after the Termination Date, regardless of the reason for Executive&#8217;s termination of employment, the Executive shall not, anywhere in the United States, engage in, or own, manage, operate or control, or participate in the ownership, management, operation or control of any business or entity that develops, sells or provides products or services competitive with the products or services developed, sold or provided by any member of the Company Group. Notwithstanding the foregoing, nothing in this Section 4.5 shall prevent the Executive from owning, as a passive investor, up to two percent (2%) of the securities of any entity that are publicly traded on a national securities exchange. For the avoidance of doubt, nothing in this Section 4.5 prevents the Executive from working in the pharmaceutical industry as long as such positions and activities are not competitive with the business of the Company Group.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.6.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Customer Non-Solicitation</u></b>. During the period commencing on the Effective Date and ending 24 months after the Termination Date, regardless of the reason for Executive&#8217;s termination of employment, the Executive shall not (except on the Company&#8217;s behalf during the Executive&#8217;s employment with the Company), for purposes of providing products or services that are competitive with those provided by any member of the Company Group, on the Executive&#8217;s own behalf or on behalf of any other Person, solicit any customer or client of any member of the Company Group with whom the Executive had contact, solicited, or served within the twelve (12) months prior to the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.7.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Customer Non-Acceptance</u>. </b>During the period commencing on the Effective Date and ending 24 months after the Termination Date, regardless of the reason for Executive&#8217;s termination of employment, the Executive shall not (except on the Company&#8217;s behalf during the Executive&#8217;s employment with the Company), for purposes of providing products or services that are competitive with those provided by any member of the Company Group, on the Executive&#8217;s own behalf or on behalf of any other Person, accept business from any customer or client of any member of the Company Group with whom the Executive had contact, solicited, or served within the twelve (12) months prior to the Termination Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.8.</b><b>&nbsp; &nbsp; &nbsp; <u>Employee and Independent Contractor Non-Solicitation</u></b>. During the period commencing on the Effective Date and ending 24 months after the Termination Date, regardless of the reason for Executive&#8217;s termination of employment, the Executive shall not (except on the Company&#8217;s behalf during the Term of Employment), on the Executive&#8217;s own behalf or on behalf of any other Person, solicit for employment or engagement any individual who (A) is employed by, or an independent contractor of, any member of the Company Group at the time of such solicitation or (B) was employed by, or an independent contractor of, any member of the Company Group within 12 months prior to such solicitation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.9.</b><b>&nbsp; &nbsp; &nbsp; <u>Employee and Independent Contractor Non-Acceptance</u></b>. During the period commencing on the Effective Date and ending 24 months after the Termination Date, regardless of the reason for Executive&#8217;s termination of employment, the Executive shall not (except on the Company&#8217;s behalf during the Term of Employment), on the Executive&#8217;s own behalf or on behalf of any other Person, employ or engage any individual who (A) is employed by, or an independent contractor of, any member of the Company Group at the time of such employment or engagement or (B) was employed by, or an independent contractor of, any member of the Company Group within twelve (12) months prior to such employment or engagement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.10.&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Disparagement</u></b>. During the Term of Employment and at all times thereafter, the Executive shall not, directly or through any other Person make any public or private statements (whether orally, in writing, via electronic transmission, or otherwise) that disparage, denigrate or malign the Company, any of the Company&#8217;s Affiliates or any of their respective businesses, products, services, activities, operations, affairs, reputations or prospects; or any of their respective officers, employees, directors, partners (general and limited), agents, members or shareholders. For purposes of clarification, and not limitation, a statement shall be deemed to disparage, denigrate or malign a Person if such statement could be reasonably construed to adversely affect the opinion any other Person may have or form of such first Person. The foregoing limitations shall not be violated by truthful statements made by the Executive (i) to any governmental authority or (ii) which are in response to legal process, required governmental testimony or filings, or administrative or arbitral proceedings (including, without limitation, depositions in connection with such proceedings).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.11.</b><b>&nbsp; &nbsp; &nbsp;<u>Confidentiality; Return of Property</u></b>. During the Term of Employment and at all times thereafter, the Executive shall not, without the prior express written consent of the Company, directly or indirectly, use on the Executive&#8217;s behalf or on behalf of any other Person, or divulge, disclose or make available or accessible to any Person, any Confidential Information, other than when required to do so in good faith to perform the Executive&#8217;s duties and responsibilities hereunder while employed by any member of the Company Group, when required to do so by a lawful order of a court of competent jurisdiction, any governmental authority or agency, or any recognized subpoena power, or in connection with reporting possible violations of federal law or regulation to any governmental agency or entity, or making other disclosures that are protected under the whistleblower provisions of federal law or regulation. In the event that the Executive becomes legally compelled (by oral questions, interrogatories, request for information or documents, subpoena, criminal or civil investigative demand or similar process) to disclose any Confidential Information, then prior to such disclosure, the Executive will provide the Board with prompt written notice so that the Company may seek (with the Executive&#8217;s cooperation) a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. In the event that such protective order or other remedy is not obtained, then the Executive will furnish only that portion of the Confidential Information which is legally required, and will cooperate with the Company in the Company&#8217;s efforts to obtain reliable assurance that confidential treatment will be accorded to the Confidential Information. In addition, the Executive shall not create any derivative work or other product based on or resulting from any Confidential Information (except in the good faith performance of the Executive&#8217;s duties under this Agreement while employed by any member of the Company Group). The Executive shall also proffer to the Board&#8217;s designee, no later than the Termination Date (or upon the earlier request of the Company), and without retaining any copies, notes or excerpts thereof, all property of the Company and its Affiliates, including, without limitation, memoranda, computer disks or other media, computer programs, diaries, notes, records, data, customer or client lists, marketing plans and strategies, and any other documents consisting of or containing Confidential Information, that are in the Executive&#8217;s actual or constructive possession or which are subject to the Executive&#8217;s control at such time. To the extent the Executive has retained any such property or Confidential Information on any electronic or computer equipment belonging to the Executive or under the Executive&#8217;s control, the Executive agrees to so advise Company and to follow Company&#8217;s instructions in permanently deleting all such property or Confidential Information and all copies. Notwithstanding the foregoing, in accordance with the Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law (1)&nbsp;&nbsp;&nbsp;&nbsp;for the disclosure of a trade secret that (a) is made (I) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (II) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (2) if, in connection with any lawsuit filed by the Executive for retaliation by the Company for reporting a suspected violation of law, the Executive discloses a trade secret to Executive&#8217;s attorney and uses the trade secret information in the court proceeding, if the Executive files any document containing the trade secret under seal and does not disclose the trade secret except pursuant to court order.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.12.</b><b>&nbsp; &nbsp; &nbsp;<u>Ownership of Inventions</u></b>. The Executive acknowledges and agrees that all Company Inventions (including all intellectual property rights arising therein or thereto, all rights of priority relating to patents, and all claims for past, present and future infringement, misappropriation relating thereto), and all Confidential Information, hereby are and shall be the sole and exclusive property of the Company (collectively, the &#8220;<u>Company IP</u>&#8221;). The Executive further acknowledges and agrees that any rights arising in the Executive in any Invention Invented by the Executive, whether alone or jointly with others, during the twelve (12) months following the Termination Date and relating in any way to work performed by the Executive for any member of the Company Group during the Executive&#8217;s employment with or service for any member of the Company Group (&#8220;<u>Post-employment Inventions</u>&#8221;), shall hereby be deemed to be Company Inventions and the sole and exclusive property of the Company; provided, however, that the Board in its sole discretion may elect to compensate the Executive for any Post-employment Inventions. For consideration acknowledged and received, the Executive hereby irrevocably assigns, conveys and sets over to the Company all of the Executive&#8217;s right, title and interest in and to all Company IP. The Executive acknowledges and agrees that the compensation received by the Executive for employment or services provided to the Company is adequate consideration for the foregoing assignment. The Executive further agrees to disclose in writing to the CEO any Company Inventions (including, without limitation, all Post-employment Inventions), promptly following their conception or reduction to practice. Such disclosure shall be sufficiently complete in technical detail and appropriately illustrated by sketch or diagram to convey to one skilled in the art of which the Company Invention pertains, a clear understanding of the nature, purpose, operations, and other characteristics of the Company Invention. The Executive agrees to execute and deliver such deeds of assignment or other documents of conveyance and transfer as the Company may request to confirm in the Company or its designee the ownership of the Company Inventions, without compensation beyond that provided in this Agreement. The Executive further agrees, upon the request of the Company and at its expense, that the Executive will execute any other instrument and document necessary or desirable in applying for and obtaining patents in the United States and in any foreign country with respect to any Company Invention. The Executive further agrees, whether or not the Executive is then an employee or other service provider of any member of the Company Group, upon request of the Company, to provide reasonable assistance with respect to the perfection, recordation or other documentation of the assignment of Company IP hereunder, and the enforcement of the Company&#8217;s rights in any Company IP, and to cooperate to the extent and in the manner reasonably requested by the Company in any litigation or other claim or proceeding (including, without limitation, the prosecution or defense of any claim involving a patent) involving any Company IP covered by this Agreement, without further compensation but all reasonable out-of-pocket expenses incurred by the Executive in satisfying the requirements of this Section 4.12 shall be paid by the Company or its designee. The Executive shall not, on or after the date of this Agreement, directly or indirectly challenge the validity or enforceability of the Company&#8217;s ownership of, or rights with respect to, any Company IP, including, without limitation, any patent issued on, or patent application filed in respect of, any Company Invention.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.13.</b><b>&nbsp; &nbsp; &nbsp; <u>Works for Hire</u></b>. The Executive also acknowledges and agrees that all works of authorship, in any format or medium, and whether published or unpublished, created wholly or in part by the Executive, whether alone or jointly with others (and whether before, on or after the Effective Date), (i) in the course of, in connection with, or as a result of the Executive&#8217;s employment or other service with any member of the Company Group, (ii) at the direction or request of any member of the Company Group, or (iii) through the use of, or that is related to, facilities, equipment, Confidential Information, other Company Inventions, intellectual property or other resources of any member of the Company Group, whether or not during the Executive&#8217;s work hours (&#8220;<u>Works</u>&#8221;), are works made for hire as defined under United States copyright law, and that the Works (and all copyrights arising in the Works) are owned exclusively by the Company and all rights therein will automatically vest in the Company without the need for any further action by any party. To the extent any such Works are not deemed to be works made for hire, for consideration acknowledged and received, the Executive hereby waives any &#8220;moral rights&#8221; in such Works and the Executive hereby irrevocably assigns, transfers, conveys and sets over to the Company or its designee, without compensation beyond that provided in this Agreement, all right, title and interest in and to such Works, including without limitation all rights of copyright arising therein or thereto, and further agrees to execute such assignments or other deeds of conveyance and transfer as the Company may request to vest in the Company or its designee all right, title and interest in and to such Works, including all rights of copyright arising in or related to the Works.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.14.&nbsp;</b><b>&nbsp; &nbsp; <u>Cooperation</u></b>. During and after the Term of Employment, the Executive agrees to cooperate with the Company Group in any internal investigation, any administrative, regulatory, or judicial proceeding or any dispute with a third party concerning issues about which the Executive has knowledge or that may relate to the Executive or the Executive&#8217;s employment or service with any member of the Company Group. The Executive&#8217;s obligation to cooperate hereunder includes, without limitation, being available to the Company Group upon reasonable notice for interviews and factual investigations, appearing in any forum at the Company Group&#8217;s request to give testimony (without requiring service of a subpoena or other legal process), volunteering to the Company Group pertinent information, and turning over to the Company Group all relevant documents which are or may come into the Executive&#8217;s possession. The Company shall promptly reimburse the Executive for the reasonable out of pocket expenses incurred by the Executive in connection with such cooperation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.15.</b><b>&nbsp; &nbsp; &nbsp;<u>Injunctive Relief</u></b>. The Executive acknowledges and agrees that the Company and its Affiliates will have no adequate remedy at law and would be irreparably harmed if the Executive breaches or threatens to breach any of the Restrictive Covenants. The Executive agrees that the Company and its Affiliates shall be entitled to equitable and/or injunctive relief to prevent any breach or threatened breach of any of the Restrictive Covenants, and to specific performance of each of the terms thereof, in each case, in addition to any other legal or equitable remedies that the Company and its Affiliates may have, as well as the costs and reasonable attorneys&#8217; fees it/they incur in enforcing any of the Restrictive Covenants. The Executive further agrees that (i) any breach or claimed breach of the provisions set forth in this Agreement by, or any other claim the Executive may have against, the Company or any of its Affiliates will not be a defense to enforcement of any Restrictive Covenant and (ii) the circumstances of the Executive&#8217;s termination of employment with the Company will have no impact on the Executive&#8217;s obligations to comply with any Restrictive Covenant. The Restrictive Covenants are intended for the benefit of the Company and each of its Affiliates. Each Affiliate of the Company is an intended third party beneficiary of the Restrictive Covenants, and each Affiliate of the Company, as well as any successor or assign of the Company or such Affiliate, may enforce the Restrictive Covenants. The Executive further agrees that the Restrictive Covenants are in addition to, and not in lieu of, any non-competition, non-solicitation, protection of confidential information or intellectual property, or other similar covenants in favor of the Company or any of its Affiliates by which the Executive may be bound.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.16.</b><b>&nbsp; &nbsp; &nbsp; <u>Tolling During Periods of Breach</u></b>. The parties hereto agree and intend that the Restrictive Covenants (to the extent not perpetual) be tolled during any period that the Executive is in breach of any such Restrictive Covenant, with such tolling to cease with respect to a Restrictive Covenant once the Executive is in compliance with such Restrictive Covenant, so that the Company and its Affiliates are provided with the full benefit of the restrictive periods set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>4.17.</b><b>&nbsp; &nbsp; &nbsp;<u>Notification of New Employer</u></b>. In the event that the Executive is employed or otherwise engaged by any other Person following the Termination Date, the Executive agrees to notify, and consents to the notification by Company and its Affiliates of, such Person of the Restrictive Covenants.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b><u>Miscellaneous</u></b>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.1.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Applicable Law</u></b>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, applied without reference to principles of conflicts of law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.2.</b><b>&nbsp; &nbsp; &nbsp; &nbsp;<u>Venue</u></b>. Both the Executive and the Company agree to appear before and submit exclusively to the jurisdiction of the state and federal courts located in Wilmington, Delaware (including the Delaware Court of Chancery) with respect to such controversy, dispute or claim; provided, however, that any relief sought under Section 4.15 may be sought in any court of competent jurisdiction. Both the Executive and the Company also agree to waive, to the fullest possible extent, the defense of an inconvenient forum or lack of jurisdiction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.3.&nbsp; &nbsp;</b><b>&nbsp; &nbsp;<u>WAIVER OF JURY TRIAL</u>. THE COMPANY AND THE EXECUTIVE HEREBY WAIVE, TO THE EXTENT PERMITTED BY APPLICABLE LAW, TRIAL BY JURY IN ANY LITIGATION IN ANY COURT WITH RESPECT TO, IN CONNECTION WITH, OR ARISING OUT OF THE EXECUTIVE</b>&#8217;<b>S EMPLOYMENT BY, OR SERVICE WITH, ANY MEMBER OF THE COMPANY GROUP OR THE TERMINATION THEREOF, OR THIS AGREEMENT OR THE VALIDITY, PROTECTION, INTERPRETATION, COLLECTION OR ENFORCEMENT THEREOF (WHETHER ARISING IN CONTRACT, EQUITY, TORT OR OTHERWISE).</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.4.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Amendments</u></b><u>.</u> This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.5.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Clawback</u></b>. The Executive expressly acknowledges and agrees that Executive is subject to any clawback policy of the Company as in effect from time to time, and any compensation or benefits provided under this Agreement (whether payable in cash or equity or equity-based awards) may be reduced or be subject to recoupment pursuant to any such policy as in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.6.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Withholding</u></b>. The Company may withhold from any amounts payable under this Agreement such federal, state or local income taxes as are required to be withheld pursuant to any applicable law or regulation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 72pt;"><b>5.7.</b>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<b><u>Code Section 409A Compliance</u></b>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-align: justify; text-indent: 81pt;"><b>5.7.1.</b>&nbsp;&nbsp;&nbsp;&nbsp;The provisions of this Agreement are intended to comply with Section 409A of the Code and any final regulations and guidance promulgated thereunder (&#8220;<u>Section 409A</u>&#8221;) or an exemption thereunder and shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A. The Company and Executive agree to work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment or provision of any benefit to Executive under Section 409A (without increasing the cost to the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 81pt; text-align: justify;"><b>5.7.2.</b>&nbsp;&nbsp;&nbsp;&nbsp;To the extent that Executive will be reimbursed for costs and expenses or be provided in-kind benefits, except as otherwise permitted by Section 409A, (a) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit, (b) the amount of expenses eligible for reimbursement, or in-kind benefits, <i>provided </i>during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year; <i>provided </i>that the foregoing clause (b) shall not be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect and (c) such payments shall be made on or before the last day of the taxable year immediately following the taxable year in which Executive incurred the expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 81pt; text-align: justify;"><b>5.7.3.</b>&nbsp;&nbsp;&nbsp;&nbsp;To the extent required by Section 409A, a termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment unless such termination constitutes a &#8220;<u>Separation from</u> <u>Service</u>&#8221; within the meaning of Section 409A and, for purposes of any such provision of this Agreement references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean Separation from Service.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 81pt; text-align: justify;"><b>5.7.4.</b>&nbsp;&nbsp;&nbsp;&nbsp;Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. Each installment payable hereunder shall constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b), including Treasury Regulation Section 1.409A-2(b)(2)(iii). Each payment that is made within the terms of the &#8220;short- term deferral&#8221; rule set forth in Treasury Regulation Section 1.409A-1(b)(4) is intended to meet the &#8220;short-term deferral&#8221; rule. Each other separation payment is intended to be a payment upon an involuntary termination from service and payable pursuant to Treasury Regulation Section 1.409A-1(b)(9)(iii), et. seq., to the maximum extent permitted by that regulation, with any amount that is not exempt from Section 409A being subject to Section 409A.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 81pt; text-align: justify;"><b>5.7.5.</b>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, if Executive is a &#8220;specified employee&#8221; within the meaning of Section 409A at the time of Executive&#8217;s termination, then only that portion of the severance and benefits payable to Executive pursuant to this Agreement, if any, and any other severance payments or separation benefits, in either case, which may be considered deferred compensation under Section 409A that is payable on account of the Executive&#8217;s termination (other than by reason of death) (together, the &#8220;<u>Deferred Compensation Separation Benefits</u>&#8221;) that are due to Executive on or within the six (6) month period following Executive&#8217;s termination will accrue during such six (6) month period and will become payable in one lump sum payment on the date that is six (6) months and one (1) day following the date of Executive&#8217;s termination of employment. All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following termination but prior to the six (6) month anniversary of Executive&#8217;s termination date, then any payments delayed in accordance with this paragraph will be payable in a lump sum within thirty (30) days after the date of Executive&#8217;s death (but not earlier than such payment would have been made absent such death) and all other Deferred Compensation Separation Benefits will be payable in accordance with the payment schedule applicable to each payment or benefit.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="16" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: 81pt; text-align: justify;"><b>5.7.6.</b>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, neither the Company nor any of its Affiliates shall have any liability to the Executive or to any other Person if the payments and benefits provided in this Agreement that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.8.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Excess Parachute Payments under Code Section 280G</u></b>. Notwithstanding any other provisions of this Agreement, if any &#8220;payments&#8221; (including, without limitation, any benefits or transfers of property or the acceleration of the vesting of any benefits) in the nature of compensation under any arrangement that is considered contingent on a Change of Control for purposes of Section 280G of the Code, together with any other payments that the Executive has the right to receive from the Company or any corporation that is a member of an &#8220;affiliated group&#8221; (as defined in Section 1504(a) of the Code without regard to Section 1504(b) of the Code) of which the Company is a member or from any other Person, would constitute a &#8220;parachute payment&#8221; (as defined in Section 280G(b)(2) of the Code), such &#8220;payments&#8221; may, at the Executive&#8217;s sole election, be reduced to the largest amount that will result in no portion of such &#8220;payments&#8221; being subject to the excise tax imposed by Section 4999 of the Code. Any such reduction in &#8220;payments&#8221; shall be applied first against the latest scheduled cash payments; then current cash payments; then any equity or equity derivatives that are included under Section 280G of the Code at full value rather than accelerated value (with the highest value reduced first); then any equity or equity derivatives included under Section 280G of the Code at an accelerated value (and not at full value), with the highest value reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&amp;A 24); and finally any other non-cash benefits will be reduced (in the order of latest scheduled payments to earliest scheduled payments). All calculations hereunder shall be performed by a nationally recognized independent accounting firm selected by the Company, with the full cost of such firm being borne by the Company. Any determinations made by such firm shall be final and binding on the Executive and the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.9.</b><b>&nbsp; &nbsp; &nbsp; &nbsp; <u>Severability</u></b>. The terms and provisions of this Agreement are intended to be separate and divisible provisions and if, for any reason, any one or more of them is held to be invalid or unenforceable, neither the validity nor the enforceability of any other provision of this Agreement shall thereby be affected. It is the intention of the parties to this Agreement that the Restrictive Covenants be reasonable in duration, geographic scope and in all other respects. The Executive agrees that the Restrictive Covenants, including, without limitation, the duration, geographic scope and activity restrictions of each restriction, are reasonable in light of the Executive&#8217;s senior position. However, if for any reason any court of competent jurisdiction shall find any provisions of the Restrictive Covenants unreasonable in duration or geographic scope or otherwise, it is the intention of the parties that the restrictions and prohibitions contained therein shall be modified by the court to be effective to the fullest extent allowed under applicable law in such jurisdiction.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="17" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.10.</b><b>&nbsp; &nbsp; &nbsp; <u>Captions</u></b><u>.</u> The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.11.&nbsp;&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u></b>. This Agreement may be executed in counterparts and delivered by facsimile transmission or electronic transmission in &#8220;portable document format,&#8221; each of which shall be an original and which taken together shall constitute one and the same document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.12.</b><b>&nbsp; &nbsp; &nbsp;<u>Entire Agreement</u></b>. This Agreement contains the entire agreement concerning the subject matter hereof and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the parties and their respective Affiliates relating to such subject matter (including, without limitation, the Offer Letter or any other employment agreement, term sheet or offer letter).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.13.&nbsp;&nbsp;</b><b>&nbsp;&nbsp;&nbsp;&nbsp;<u>Survivorship</u></b>. The provisions of Article 1, Article 5, Section 2.1 and Sections 4.4 through 4.17 shall survive the termination of the Term of Employment, the termination of Executive&#8217;s employment with the Company and the termination of this Agreement, in each case, in accordance with their terms.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;"><b>5.14.</b><b>&nbsp; &nbsp; &nbsp;<u>Successors and Assigns</u></b>. The Company may assign, without the Executive&#8217;s consent, its rights and/or delegate its obligations under this Agreement to any successor of the Company, whether by operation of law, agreement or otherwise (including, without limitation, any Person who acquires all or a substantial portion of the business of the Company Group (whether direct or indirect and whether structured as a stock sale, asset sale, merger, recapitalization, consolidation or other transaction)) and, in connection with any such delegation of its obligations hereunder (but only so long as such assignee or delegee has consented in writing to be bound by the obligations hereunder) shall be released from such obligations hereunder. This Agreement may not be assigned by the Executive. Except as otherwise provided herein, this Agreement shall bind and inure to the benefit of and be enforceable by the Executive, the Company and their respective successors and permitted assigns.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><i>[signature page follows]</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="18" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 10pt;text-indent:37pt;"><b>IN WITNESS WHEREOF, </b>Executive and the Company have caused this Agreement to be executed as of the day and year first above written.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CERVOMED INC.</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>John Alam, MD</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name: John Alam, MD<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 227pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>EXECUTIVE</b><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>Matthew Winton</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name: Matthew Winton<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 155pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u><b>EXHIBIT A</b></u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><u><b>OUTSIDE ACTIVITIES</b></u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">None.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 176pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>ex_932189.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<html><head>
	<title>ex_932189.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 9:51:20 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.10</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="cm01.jpg" src="cm01.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>STOCK OPTION AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This STOCK OPTION AGREEMENT (this &#8220;<b><i>Agreement</i></b>&#8221;<b><i>)</i></b> is entered into and effective as of [_______], 202[__] (the &#8220;<b><i>Grant Date</i></b>&#8221;) by and between CervoMed Inc., a Delaware corporation (the &#8220;<b><i>Company</i></b>&#8221;), and [_______] (&#8220;<b><i>Optionee</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A.&nbsp; &nbsp; &nbsp;The Company has adopted the CervoMed Inc. [2025 Equity Incentive Plan] (as such plan may be amended from time to time, the &#8220;<b><i>Plan</i></b>&#8221;) authorizing the Board of Directors (the &#8220;<b><i>Board</i></b>&#8221;) of the Company, or a committee as provided for in the Plan (the Board or such a committee to be referred to as the &#8220;<b><i>Committee</i></b>&#8221;), to grant stock options, among other incentive awards, to certain individuals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.&nbsp; &nbsp; &nbsp;The Company desires to grant [an incentive/a non-qualified] stock option to purchase shares of common stock, par value $0.001 per share, of the Company (the &#8220;<b><i>Common Stock</i></b>&#8221;) to Optionee pursuant to the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">C.&nbsp; &nbsp; &nbsp; All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Company and Optionee agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.&nbsp; &nbsp; &nbsp;&nbsp;<u>Grant of Option; Exercise Price</u>. The Company hereby grants to Optionee, upon the terms and subject to the conditions set forth in this Agreement and the Plan, and effective as of the Grant Date, an option (the &#8220;<b><i>Option</i></b>&#8221;) to purchase all or any portion of [_______] shares (the &#8220;<b><i>Option Shares</i></b>&#8221;) of the Company&#8217;s Common Stock, at an exercise price of $[_______] per share, which represents 100% of the Fair Market Value of a share of Common Stock on the Grant Date, as determined in accordance with the Plan (such exercise price, as adjusted from time to time pursuant to Section 5 of this Agreement and Section 4.3 of the Plan, the &#8220;<b><i>Exercise Price</i></b>&#8221;). The Option [is/is not] intended to be an &#8220;incentive stock option,&#8221; as that term is used in Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;<b><i>Code</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.&nbsp; &nbsp; &nbsp;&nbsp;<u>Vesting</u>. The option will vest and become exercisable in [__] equal (or as nearly equal as possible) installments on the last calendar day of each month over a [__]-month period beginning on [_______].</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.&nbsp; &nbsp; &nbsp;&nbsp;<u>Exercise of Option</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1.&nbsp; &nbsp;Notice; Payment. Subject to the terms and conditions set forth in this Agreement, including vesting of the Option in Section 2 of this Agreement and termination of the Option in Section 4 of this Agreement, and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time, by delivery to the Company of written notice of the exercise of the Option, in substantially the form as provided by the Company, stating the number of Option Shares being purchased (the &#8220;<b><i>Purchased Shares</i></b>&#8221;), and accompanied by payment in full of the total aggregate Exercise Price of the Purchased Shares. The Exercise Price shall be payable in full in any one of the following alternative forms:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Full payment in cash, personal check or certified bank or cashier&#8217;s check;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any broker assisted cashless exercise procedure which is acceptable to the Company;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cashless net exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">X = Y &#8211; [(A)(YB )]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Where:&nbsp; &nbsp;X = the number of shares of Common Stock to be issued to Optionee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">Y = the number of Purchased Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">A = the Exercise Price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 36pt;">B = the Fair Market Value of one share of Common Stock on the date of exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2.&nbsp; &nbsp;<u>Issuance of Purchased Shares; No Fractional Shares</u>. Following receipt of the exercise notice and the payment referred to above (or upon a cashless net exercise), Optionee shall receive the number of shares of Common Stock equal to a number (as determined below) of shares of Common Stock computed using the following formula: and the payment referred to above, the Company shall, as soon as reasonably practicable thereafter, cause certificates (or book-entry notations) representing the Purchased Shares (or such fewer number of Purchased Shares if a cashless net exercise is used) to be delivered to Optionee either at Optionee&#8217;s address set forth in the records of the Company or at such other address as Optionee may designate in writing to the Company or issue and deposit the Purchased Shares for Optionee&#8217;s benefit with any broker with which Optionee has an account relationship or the Company has engaged to provide such services under the Plan; provided, however, that the Company shall not be obligated to issue a fraction or fractions of a share otherwise issuable upon exercise of the Option, and may pay to Optionee, in cash or cash equivalent, the Fair Market Value of any such fraction or fractions of a share as of the date of exercise. If requested by the Company in connection with any exercise of the Option, Optionee shall also deliver this Agreement to the Company, which shall endorse hereon a notation of the exercise and, and if the Option is exercised in part, shall return this Agreement to Optionee. The date of exercise of an Option that is validly exercised shall be deemed to be the date on which there shall have been delivered to the Company the notice referred to in Section 3.1 of this Agreement and full payment of the Exercise Price of the Purchased Shares. Optionee shall not be deemed to be a holder of any Purchased Shares pursuant to exercise of the Option until the date of issuance of a stock certificate or book-entry notation to Optionee for such shares following payment in full for the Purchased Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3.&nbsp; &nbsp;<u>Tax Withholding</u>. The Company is entitled to (a) withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary), or make other arrangements for the collection of, all amounts the Company reasonably determines are necessary to satisfy any and all federal, foreign, state and local withholding and employment related tax requirements attributable to the Option, including, without limitation, the grant, exercise or vesting of, the Option; (b) withhold cash paid or payable or shares of Common Stock from the shares issued or otherwise issuable to Optionee in connection with the Option; or (c) require Optionee promptly to remit the amount of such withholding to the Company before taking any action, including issuing any shares of Common Stock, with respect to the Option. Shares of Common Stock issued or otherwise issuable to Optionee in connection with the Option that gives rise to the tax withholding obligation that are withheld for purposes of satisfying Optionee&#8217;s withholding or employment-related tax obligation will be valued at their Fair Market Value on the Tax Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4.&nbsp; &nbsp;<u>Remaining Option Shares</u>. Option Shares will no longer be outstanding under the Option (and will therefore not thereafter be exercisable) following the exercise of the Option to the extent of (a) shares used to pay the Exercise Price of an Option under the &#8220;cashless net exercise&#8221; method (b) shares actually delivered to Optionee as a result of such exercise and (c) any shares withheld for purposes of tax withholding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.&nbsp; &nbsp; &nbsp;&nbsp;<u>Termination of Option</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1.&nbsp; &nbsp;<u>Time of Termination</u>. Except as provided in this Section 4 and Section 5 of this Agreement, the Option shall terminate, no longer be exercisable and expire at 5:00 p.m., Eastern Time, on [_______] (the &#8220;<b><i>Time of Termination</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2.&nbsp; &nbsp;<u>Termination for Cause</u>. In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated by the Company for Cause, the Option will immediately terminate without notice of any kind, and the Option will no longer be exercisable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3.&nbsp; &nbsp;<u>Termination Due to Death, Disability or Retirement</u> . In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated by reason of Optionee&#8217;s death, Disability or Retirement, the Option will remain exercisable, to the extent exercisable as of the date of such termination, for a period of one (1) year after such termination (but in no event after the Time of Termination).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4.&nbsp; &nbsp;<u>Termination for Other Reasons</u>. In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated for any other reason, the Option will, to the extent exercisable as of such termination, remain exercisable for a period of three (3) months after such termination (but in no event after the Time of Termination).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5.&nbsp; &nbsp;<u>Effect of Actions Constituting Cause or Adverse Action</u>. Notwithstanding anything in this Agreement to the contrary and in addition to the rights of the Committee under Sections 13.5 and 13.6 of the Plan, if Optionee is determined by the Committee, acting in its sole discretion, to have taken any action that would constitute Cause or an Adverse Action during or after the termination of employment or other service with the Company or a Subsidiary, irrespective of whether such action or the Committee&#8217;s determination occurs before or after termination of Optionee&#8217;s employment or other service with the Company or any Subsidiary and irrespective of whether or not Optionee was terminated as a result of such Cause or Adverse Action, (a) all rights of Optionee under the Option and this Agreement will terminate and be forfeited without notice of any kind, and (b) the Committee in its sole discretion will have the authority to rescind the exercise, vesting, settlement or issuance of, or payment in respect of, the Option that was exercised, vested, settled or issued, or as to which such payment was made, and to require Optionee to pay to the Company, within ten (10) days of receipt from the Company of notice of such rescission, any amount received or the amount of any gain realized as a result of such rescinded exercise, vesting, settlement, issuance or payment (including any dividends paid or other distributions made with respect to any shares of Common Stock subject to the Option). The Company may defer the exercise of the Option for a period of up to six (6) months after receipt of Optionee&#8217;s written notice of exercise or the issuance of Purchased Shares upon the vesting of the Option for a period of up to six (6) months after the date of such vesting in order for the Committee to make any determination as to the existence of Cause or an Adverse Action. The Company will be entitled to withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary) or make other arrangements for the collection of all amounts necessary to satisfy such payment obligations. This Section 4.5 will not apply to the Option following a Change in Control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6.&nbsp; &nbsp;<u>Clawback/Forfeiture</u>. The Option and Option Shares issued or issuable pursuant to the Option are subject to forfeiture or clawback by the Company to the extent required and allowed by law, including the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the Sarbanes Oxley Act of 2002 and any implementing rules and regulations promulgated thereunder, and pursuant to any forfeiture, clawback or similar policy of the Company, as such laws, rules, regulations and policy may be in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.&nbsp; &nbsp; &nbsp;&nbsp;<u>Adjustments</u>. In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture, or extraordinary dividend (including a spin-off), or any other similar change in the corporate structure or shares of the Company, the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), will make appropriate adjustment (which determination will be conclusive) as to the number and kind of securities or other property (including cash) subject to, and the Exercise Price of, the Option in order to prevent dilution or enlargement of the rights of Optionee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.&nbsp; &nbsp; &nbsp;&nbsp;<u>Change in Control</u>. The Option shall become immediately vested and exercisable upon completion of a Change in Control and remain exercisable through the Time of Termination regardless of whether Optionee remains in the employment or service of the Company. Notwithstanding any of the foregoing, in connection with a Change in Control, the Committee, in its sole discretion, at any time after the grant of the Option, may take whatever action it deems appropriate pursuant to Section 15.3 of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.&nbsp; &nbsp; &nbsp;&nbsp;<u>Rights as a Stockholder</u>. Optionee will have no rights as a stockholder of the Company unless and until all conditions to the effective exercise of the Option (including, without limitation, the conditions set forth in Section 3 of this Agreement) have been satisfied and Optionee has become the holder of record of such shares. No adjustment will be made for dividends or distributions with respect to the Option as to which there is a record date preceding the date Optionee becomes the holder of record of such shares, except as may otherwise be provided in the Plan or determined by the Committee in its sole discretion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.&nbsp; &nbsp; &nbsp;&nbsp;<u>Restrictions on Transfer</u>. Except pursuant to testamentary will or the laws of descent and distribution or as otherwise expressly permitted by the Plan, no right or interest of Optionee in the Option prior to exercise may be assigned or transferred, or subjected to any lien, during the lifetime of Optionee, either voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise. Optionee, however, will be entitled to designate a beneficiary to receive the Option upon Optionee&#8217;s death, and, in the event of Optionee&#8217;s death, exercise of the Option (to the extent permitted pursuant to Sections 2 and 4 of this Agreement) may be made by Optionee&#8217;s legal representatives, heirs and legatees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.&nbsp; &nbsp; &nbsp;&nbsp;<u>Market Stand-off</u>. Optionee, if so requested by the Company or any representative of the underwriters in connection with a firmly underwritten public offering of securities by the Company pursuant to a registration statement under the Securities Act following the date of this Agreement, shall not sell or otherwise transfer any Option Shares during the 180-day period following the effective date of such registration statement. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restriction until the end of such 180-day period. This <u>Section 9</u> will not apply to the sale of any Option Shares to an underwriter pursuant to an underwriting agreement and shall only be applicable to Optionee if all then current executive officers and directors of the Company enter into similar agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.&nbsp; &nbsp;&nbsp;<u>Employment or Service</u>. Nothing in this Agreement or the Plan will interfere with or limit in any way the right of the Company or any Subsidiary to terminate the employment or service of Optionee at any time, nor confer upon Optionee any right to continue in the employment or other service with the Company or any Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.&nbsp; &nbsp;&nbsp;<u>Option Subject to Plan</u>. The Option and the Option Shares granted and issued pursuant to this Agreement have been granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and Optionee, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will be interpreted by reference to the Plan. In the event that any provision of this Agreement is inconsistent with the terms of the Plan, the terms of the Plan will prevail. All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.&nbsp; &nbsp;&nbsp;<u>General Provisions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.1. <u>Governing Law; Venue</u>. This Agreement and all rights and obligations under this Agreement will be governed by and construed exclusively in accordance with the laws of the State of Delaware, notwithstanding the conflicts of laws principles of any jurisdictions. By acceptance of the Option, Optionee is deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of the State of Illinois to resolve any and all issues that may arise out of or relate to the Option or this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.2. <u>Entire Agreement</u>. This Agreement and the Plan set forth the entire agreement and understanding of the parties to this Agreement with respect to the grant and exercise of the Option and the administration of the Plan and supersede all prior agreements, arrangements, plans, and understandings relating to the grant and exercise of the Option and the administration of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.3. <u>Failure to Enforce Not a Waiver</u>. The failure of the Company or Optionee to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.4. <u>Notices</u>. All notices, requests, demands and other communications (collectively, &#8220;<b><i>Notices</i></b>&#8221;) given pursuant to this Agreement shall be in writing, and shall be delivered by personal service, courier, facsimile transmission, email transmission of a pdf format data file or by United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the signature page of this Agreement. Any Notice, other than a Notice sent by registered or certified mail, shall be effective when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the earlier of when received or the third day following deposit in the United States mails. Any party may from time to time change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Section 12.4.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.5. <u>Successors and Assigns</u>. Except to the extent specifically limited by the terms and provision of this Agreement, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns, heirs, and personal representatives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.6. <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email delivery of a &#8220;pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;pdf&#8221; signature page were an original thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.7. <u>Titles, Captions and Sections</u>. Titles and captions contained in this Agreement are inserted for convenience of reference only and do not constitute a part of this Agreement for any other purpose. References to Sections in this Agreement refer to Sections of this Agreement unless otherwise stated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.8. <u>Nature of the Grant</u>. In accepting the Option and by execution of this Agreement, Optionee acknowledges that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company in its sole discretion at any time, unless otherwise provided in the Plan.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future Option grants, or benefits in lieu of Option grants, even if Option grants have been granted repeatedly in the past.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All decisions with respect to future Option grants, if any, will be at the sole discretion of the Company.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Optionee is voluntarily participating in the Plan.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Option grant is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and in no event shall be considered as compensation for, or relating in any way to, past services for the Company.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event that Optionee is not an employee of the Company, the Option will not be interpreted to form an employment contract or relationship with the Company.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The future value of the Common Stock is unknown and cannot be predicted with certainty and if the Option vests and Optionee exercises the Option in accordance with the terms of this Agreement and is issued Purchased Shares, the value of those shares may increase or decrease.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In consideration of the grant of the Option, no claim or entitlement to compensation or damages shall arise from termination of the Option or diminution in value of the Option or Purchased Shares acquired upon exercise of the Option resulting from termination of Optionee&#8217;s employment or service by the Company (for any reason whatsoever and whether or not in breach of local labor laws) and Optionee irrevocably releases the Company and its Subsidiaries, and their respective directors, officers, employees and agents, from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by acceptance of the Option and execution of this Agreement, Optionee shall be deemed irrevocably to have waived his or her entitlement to pursue such claim.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan, or Optionee&#8217;s purchase or sale of the underlying Option Shares.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Optionee is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan or the Option.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.&nbsp;&nbsp;&nbsp;[<u>Incentive Stock Option Limitations</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.1&nbsp;<u>Limitation on Amount</u>. To the extent that the aggregate Fair Market Value (determined as of the Grant Date) of the shares of Common Stock with respect to which incentive stock options (within the meaning of Section 422 of the Code) are exercisable for the first time by the Optionee during any calendar year (under the Plan and any other incentive stock option plans of the Company or any subsidiary or parent corporation of the Company (within the meaning of the Code)) exceeds $100,000 (or such other amount as may be prescribed by the Code from time to time), such excess incentive stock options will be treated as non-statutory stock options in the manner set forth in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.2&nbsp;<u>Limitation on Exercisability; Disposition of Option Shares</u>. Any incentive stock option that remains unexercised more than one year following termination of employment by reason of death or disability or more than three months following termination for any reason other than death or disability will thereafter be deemed to be a non-statutory stock option. In addition, in the event that a disposition (as defined in Section 424(c) of the Code) of shares of Common Stock acquired pursuant to the exercise of an incentive stock option occurs prior to the expiration of two years after its date of grant or the expiration of one year after its date of exercise (a &#8220;disqualifying disposition&#8221;), such incentive stock option will, to the extent of such disqualifying disposition, be treated in a manner similar to a non-statutory stock option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.3. <u>No Representation or Warranty</u>. Section 422 of the Code and the rules and regulations thereunder are complex, and neither the Plan nor this Agreement purports to summarize or otherwise set forth all of the conditions that need to be satisfied in order for this Option to qualify as an incentive stock option. In addition, this Option may contain terms and conditions that allow for exercise of this Option beyond the periods permitted by Section 422 of the Code, including, without limitation, the periods described in Sections 2 and 4 of this Agreement. Accordingly, the Company makes no representation or warranty regarding whether the exercise of this Option will qualify as the exercise of an incentive stock option, and the Company recommends that the Optionee consult with the Optionee&#8217;s own advisors before making any determination regarding the exercise of this Option or the sale of the Option Shares.]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[<i>Remainder of page intentionally left blank; Signature page follows</i>]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement effective as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">OPTIONEE:&nbsp;&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CERVOMED INC.&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td align="left" style="text-align: left; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name: [_______]&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">By: [_______________]</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title: [______________]&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">Address: 20 Park Plaza, Suite 424</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;" valign="top" width="50%">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 20%;" valign="top" width="3%">&nbsp;</td>
			<td style="padding-left: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 45%;" valign="top" width="35%">&nbsp;Boston, MA 02116</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By execution of this Agreement, Optionee acknowledges having received a copy of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_932424.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_932424.htm</title>

	<!-- Generated by ThunderDome Portal - 3/13/2026 12:54:57 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 18pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in the Registration Statements (Nos. 333-206408, 333-206409, 333-218060, 333-2267182, 333-233381, 333-238233, 333-258760, 333-266827, 333-274785, 333-281455, 333-285847, and 333-291401) on Form S-8, Registration Statements (Nos. 333-218062, 333-222879, 333-231541, 333-249057, 333-279343, and 333-282494) on Form S-3, and Registration Statements (Nos. 333-222203, 333-233686, 333-234234, 333-235670 and 333-238818) on Form S-1 of CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) of our report dated March 13, 2026, relating to the consolidated financial statements of CervoMed Inc. and its subsidiaries, appearing in this Annual Report on Form 10-K of CervoMed Inc. for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ RSM US LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Boston, Massachusetts</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 13, 2026</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex_932190.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_932190.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 9:51:59 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I, John J. Alam, M.D., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 10-K of CervoMed Inc.&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 13, 2026<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>John J. Alam, M.D.</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">John J. Alam, M.D.<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">President and Chief Executive Officer</p>

			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(Principal Executive Officer)<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex_932191.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_932191.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 9:53:09 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 31.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">I, William Elder, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 36pt;">1.&nbsp; &nbsp; I have reviewed this annual report on Form 10-K of CervoMed Inc.&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#894;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 63pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 13, 2026<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer &amp; General Counsel</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(Principal Financial Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex_932192.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_932192.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 9:53:34 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 32.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In connection with the Annual Report on Form 10-K of CervoMed Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:52pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:52pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 13, 2026<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>John J. Alam, M.D.</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">John J. Alam, M.D.<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">President and Chief Executive Officer</p>

			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">(Principal Executive Officer)<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex_932193.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_932193.htm</title>

	<!-- Generated by ThunderDome Portal - 3/12/2026 9:54:26 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 32.2</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In connection with the Annual Report on Form 10-K of CervoMed Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:52pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#894;&nbsp;and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:52pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 13, 2026<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="1" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder<font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer &amp; General Counsel</p>

			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">(Principal Financial Officer)</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 6pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>crvo-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:12PM UTC 2026-03-13--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:crvo="http://www.diffusionpharma.com/20251231" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20251231">
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://xbrl.org/2020/extensible-enumerations-2.0" schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crvo-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-" roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-parentheticals" roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" roleURI="http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows" roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-the-company-and-description-of-business" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995550 - Disclosure - Note 1 - The Company and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-and-capital-resources" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995551 - Disclosure - Note 2 - Liquidity and Capital Resources</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-of-financial-instruments" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995553 - Disclosure - Note 4 - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-significant-agreements-and-contracts" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995554 - Disclosure - Note 5 - Significant Agreements and Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-prepaid-expenses" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995555 - Disclosure - Note 6 - Prepaid Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995556 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995557 - Disclosure - Note 8 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-and-common-stock-warrants" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995558 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995559 - Disclosure - Note 10 - Stock-based Compensation Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995560 - Disclosure - Note 11 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segments" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995561 - Disclosure - Note 12 - Segments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-subsequent-events" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995562 - Disclosure - Note 13 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995563 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995564 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-of-financial-instruments-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995565 - Disclosure - Note 4 - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-prepaid-expenses-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995566 - Disclosure - Note 6 - Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995567 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-and-common-stock-warrants-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995568 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995569 - Disclosure - Note 10 - Stock-based Compensation Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995570 - Disclosure - Note 11 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segments-tables" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995571 - Disclosure - Note 12 - Segments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-the-company-and-description-of-business-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995572 - Disclosure - Note 1 - The Company and Description of Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-and-capital-resources-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995573 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995574 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995575 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995576 - Disclosure - Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995577 - Disclosure - Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-significant-agreements-and-contracts-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995578 - Disclosure - Note 5 - Significant Agreements and Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995579 - Disclosure - Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995580 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-commitments-and-contingencies-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995581 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995582 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995583 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995584 - Disclosure - Note 10 - Stock-based Compensation Stock (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995585 - Disclosure - Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock-stock-option-activity-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995586 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-stockbased-compensation-stock-stock-assumptions-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995587 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995588 - Disclosure - Note 11 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995589 - Disclosure - Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995590 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segments-details-textual" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995591 - Disclosure - Note 12 - Segments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-segments-schedule-of-segment-information-details" roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">995592 - Disclosure - Note 12 - Segments - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="crvo_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" name="AgreementMaximumDeductionPercentageOfFeesAndPayments" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_AgreementMilestonePeriodForNetSales" name="AgreementMilestonePeriodForNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="crvo_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" name="DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" name="DeferredTaxAssetsCapitalizedResearchExpenditures" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="crvo_DementiaWithLewyBodiesMember" name="DementiaWithLewyBodiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_EquityIncentivePlan2015Member" name="EquityIncentivePlan2015Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_FrontotemporalDisordersMember" name="FrontotemporalDisordersMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_GrantAmountCanceledPercentage" name="GrantAmountCanceledPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_GrantAmountReceivedPercentage" name="GrantAmountReceivedPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_GrantAmountRemainingPercentage" name="GrantAmountRemainingPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_GrantFundingCanceled" name="GrantFundingCanceled" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_GrantFundingRemaining" name="GrantFundingRemaining" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="crvo_HistoricalDiffusionCommonStockWarrantsMember" name="HistoricalDiffusionCommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_HistoricalEIPCommonStockWarrantsMember" name="HistoricalEIPCommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_ImpairmentOfMarketableSecurities" name="ImpairmentOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_InducementOptionsMember" name="InducementOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_May2025AtthemarketOfferingMember" name="May2025AtthemarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_NationalInstituteOfAgingGrantMember" name="NationalInstituteOfAgingGrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_OpenMarketSalesAgreementMember" name="OpenMarketSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_OptionsGranted" name="OptionsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_OtherClinicalAndNonclinicalMember" name="OtherClinicalAndNonclinicalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_OtherResearchAndDevelopmentCostsMember" name="OtherResearchAndDevelopmentCostsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_PaymentsForLicenseAgreement" name="PaymentsForLicenseAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_PersonnelCostsMember" name="PersonnelCostsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_PolicyTable" name="PolicyTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_PrefundedWarrantMember" name="PrefundedWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_PrepaidClinicalExpenses" name="PrepaidClinicalExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_PrepaidDuesAndMembershipsCurrent" name="PrepaidDuesAndMembershipsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_PrepaidProfessionalServices" name="PrepaidProfessionalServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="crvo_ProceedsFromGrants" name="ProceedsFromGrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_RecoveryAfterStrokeMember" name="RecoveryAfterStrokeMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_SeriesACommonStockWarrantsMember" name="SeriesACommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_SeriesAWarrantMember" name="SeriesAWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="crvo_ShareSalesAgreementMaximumAmount" name="ShareSalesAgreementMaximumAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="crvo_StockBasedCompensationMember" name="StockBasedCompensationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_StockOptionVestingTermsAsImprobableToProbableMember" name="StockOptionVestingTermsAsImprobableToProbableMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" name="The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_The2025EquityPlanMember" name="The2025EquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_VertexOptionAndLicenseAgreementMember" name="VertexOptionAndLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-insider-trading-policy" name="statement-statement-insider-trading-policy" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" name="statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" name="statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-10-stockbased-compensation-stock-tables" name="statement-statement-note-10-stockbased-compensation-stock-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" name="statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-detailsCC4AE1F8-5361-4511-B0EB-75B5A3EAAB94" name="statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-detailsCC4AE1F8-5361-4511-B0EB-75B5A3EAAB94" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-11-income-taxes-tables" name="statement-statement-note-11-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" name="statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" name="statement-statement-note-12-segments-schedule-of-segment-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-12-segments-tables" name="statement-statement-note-12-segments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" name="statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" name="statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-detailsD3A9D5FF-3785-4E6B-9322-F9DE595E1ACA" name="statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-detailsD3A9D5FF-3785-4E6B-9322-F9DE595E1ACA" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" name="statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-detailsAFA7F805-0D23-4930-8228-E9B66DD7FAFE" name="statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-detailsAFA7F805-0D23-4930-8228-E9B66DD7FAFE" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" name="statement-statement-note-4-fair-value-of-financial-instruments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" name="statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-6-prepaid-expenses-tables" name="statement-statement-note-6-prepaid-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" name="statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" name="statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" name="statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" name="statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="crvo_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>crvo-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:12PM UTC 2026-03-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events" xlink:href="crvo-20251231.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information" xlink:href="crvo-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_GrantsReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:href="crvo-20251231.xsd#statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_CashlessExerciseOfWarrants" xlink:label="crvo_CashlessExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OpenMarketSalesAgreementMember" xlink:label="crvo_OpenMarketSalesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OptionsGranted" xlink:label="crvo_OptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvo_OpenMarketSalesAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_OptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_CashlessExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business" xlink:href="crvo-20251231.xsd#statement-note-1-the-company-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources" xlink:href="crvo-20251231.xsd#statement-note-2-liquidity-and-capital-resources" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_LiquidityDisclosureTextBlock" xlink:label="crvo_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="crvo_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts" xlink:href="crvo-20251231.xsd#statement-note-5-significant-agreements-and-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NationalInstituteOfAgingGrantMember" xlink:label="crvo_NationalInstituteOfAgingGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_VertexOptionAndLicenseAgreementMember" xlink:label="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="crvo_NationalInstituteOfAgingGrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies" xlink:href="crvo-20251231.xsd#statement-note-8-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalEIPCommonStockWarrantsMember" xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_May2025AtthemarketOfferingMember" xlink:label="crvo_May2025AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrefundedWarrantMember" xlink:label="crvo_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesACommonStockWarrantsMember" xlink:label="crvo_SeriesACommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesAWarrantMember" xlink:label="crvo_SeriesAWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_SeriesAWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_PrefundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_SeriesACommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvo_May2025AtthemarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_EquityIncentivePlan2015Member" xlink:label="crvo_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_InducementOptionsMember" xlink:label="crvo_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2025EquityPlanMember" xlink:label="crvo_The2025EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_InducementOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_The2025EquityPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments" xlink:href="crvo-20251231.xsd#statement-note-12-segments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DementiaWithLewyBodiesMember" xlink:label="crvo_DementiaWithLewyBodiesMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_FrontotemporalDisordersMember" xlink:label="crvo_FrontotemporalDisordersMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherClinicalAndNonclinicalMember" xlink:label="crvo_OtherClinicalAndNonclinicalMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherResearchAndDevelopmentCostsMember" xlink:label="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PersonnelCostsMember" xlink:label="crvo_PersonnelCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_RecoveryAfterStrokeMember" xlink:label="crvo_RecoveryAfterStrokeMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockBasedCompensationMember" xlink:label="crvo_StockBasedCompensationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_DementiaWithLewyBodiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_FrontotemporalDisordersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_RecoveryAfterStrokeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_OtherClinicalAndNonclinicalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_PersonnelCostsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_StockBasedCompensationMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="crvo-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PolicyTable" xlink:label="crvo_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="crvo_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PolicyTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables" xlink:href="crvo-20251231.xsd#statement-note-12-segments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual" xlink:href="crvo-20251231.xsd#statement-note-1-the-company-and-description-of-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:href="crvo-20251231.xsd#statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ImpairmentOfMarketableSecurities" xlink:label="crvo_ImpairmentOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ImpairmentOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskTable" xlink:label="us-gaap_FairValueConcentrationOfRiskTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueConcentrationOfRiskTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual" xlink:href="crvo-20251231.xsd#statement-note-5-significant-agreements-and-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMilestonePeriodForNetSales" xlink:label="crvo_AgreementMilestonePeriodForNetSales" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountCanceledPercentage" xlink:label="crvo_GrantAmountCanceledPercentage" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountReceivedPercentage" xlink:label="crvo_GrantAmountReceivedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountRemainingPercentage" xlink:label="crvo_GrantAmountRemainingPercentage" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingCanceled" xlink:label="crvo_GrantFundingCanceled" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingRemaining" xlink:label="crvo_GrantFundingRemaining" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NationalInstituteOfAgingGrantMember" xlink:label="crvo_NationalInstituteOfAgingGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PaymentsForLicenseAgreement" xlink:label="crvo_PaymentsForLicenseAgreement" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromGrants" xlink:label="crvo_ProceedsFromGrants" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_VertexOptionAndLicenseAgreementMember" xlink:label="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="crvo_NationalInstituteOfAgingGrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AgreementMilestonePeriodForNetSales" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PaymentsForLicenseAgreement" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ProceedsFromGrants" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantFundingRemaining" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountReceivedPercentage" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountRemainingPercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountCanceledPercentage" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantFundingCanceled" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidClinicalExpenses" xlink:label="crvo_PrepaidClinicalExpenses" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidDuesAndMembershipsCurrent" xlink:label="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidProfessionalServices" xlink:label="crvo_PrepaidProfessionalServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidClinicalExpenses" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidProfessionalServices" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedClinicalStudiesExpensesCurrent" xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:href="crvo-20251231.xsd#statement-note-8-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ClassOfWarrantOrRightExercised" xlink:label="crvo_ClassOfWarrantOrRightExercised" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_May2025AtthemarketOfferingMember" xlink:label="crvo_May2025AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrefundedWarrantMember" xlink:label="crvo_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesAWarrantMember" xlink:label="crvo_SeriesAWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareSalesAgreementMaximumAmount" xlink:label="crvo_ShareSalesAgreementMaximumAmount" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_SeriesAWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_PrefundedWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="crvo_May2025AtthemarketOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ClassOfWarrantOrRightExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareSalesAgreementMaximumAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalEIPCommonStockWarrantsMember" xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesACommonStockWarrantsMember" xlink:label="crvo_SeriesACommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="crvo_SeriesACommonStockWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_EquityIncentivePlan2015Member" xlink:label="crvo_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_InducementOptionsMember" xlink:label="crvo_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2025EquityPlanMember" xlink:label="crvo_The2025EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_InducementOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="crvo_The2025EquityPlanMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:href="crvo-20251231.xsd#statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual" xlink:href="crvo-20251231.xsd#statement-note-12-segments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details" xlink:href="crvo-20251231.xsd#statement-note-12-segments-schedule-of-segment-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DementiaWithLewyBodiesMember" xlink:label="crvo_DementiaWithLewyBodiesMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_FrontotemporalDisordersMember" xlink:label="crvo_FrontotemporalDisordersMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherClinicalAndNonclinicalMember" xlink:label="crvo_OtherClinicalAndNonclinicalMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherResearchAndDevelopmentCostsMember" xlink:label="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PersonnelCostsMember" xlink:label="crvo_PersonnelCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_RecoveryAfterStrokeMember" xlink:label="crvo_RecoveryAfterStrokeMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockBasedCompensationMember" xlink:label="crvo_StockBasedCompensationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_DementiaWithLewyBodiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_FrontotemporalDisordersMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_RecoveryAfterStrokeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_OtherClinicalAndNonclinicalMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_PersonnelCostsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_StockBasedCompensationMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <link:definitionArc order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivableCurrent" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>crvo-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:12PM UTC 2026-03-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DocumentAndEntityInformation" xlink:label="crvo_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="crvo_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_DocumentAndEntityInformation" xlink:to="crvo_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="crvo_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="crvo_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Federal statutory tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-significant-accounting-policies-policies" xlink:label="crvo_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-significant-accounting-policies-policies" xlink:to="crvo_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:to="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:label="crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-6-prepaid-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Prepaid Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:to="crvo_statement-statement-note-6-prepaid-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:to="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity and Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:to="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:to="crvo_statement-statement-note-10-stockbased-compensation-stock-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-tables" xlink:label="crvo_statement-statement-note-11-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-11-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-11-income-taxes-tables" xlink:to="crvo_statement-statement-note-11-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-12-segments-tables" xlink:label="crvo_statement-statement-note-12-segments-tables" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-12-segments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-12-segments-tables" xlink:to="crvo_statement-statement-note-12-segments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net unrealized (loss) gain on marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:to="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:to="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:label="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:to="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:label="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:to="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:to="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:to="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:label="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:to="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:label="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:type="locator"/>
    <link:label xlink:label="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Segments - Schedule of Segment Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:to="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrantsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatements" xlink:label="crvo_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="crvo_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_NotesToFinancialStatements" xlink:to="crvo_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="crvo_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="crvo_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasurySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_CashlessExerciseOfWarrants" xlink:label="crvo_CashlessExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="crvo_CashlessExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_CashlessExerciseOfWarrants</link:label>
    <link:label xlink:label="crvo_CashlessExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise of pre-funded warrants</link:label>
    <link:label xlink:label="crvo_CashlessExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cashless exercise of warrants in noncash investing and financing transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_CashlessExerciseOfWarrants" xlink:to="crvo_CashlessExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator"/>
    <link:label xlink:label="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred offering costs in accounts payable</link:label>
    <link:label xlink:label="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of debt offering costs that were incurred during a noncash or partial noncash transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireMarketableSecurities</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidDuesAndMembershipsCurrent" xlink:label="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrepaidDuesAndMembershipsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dues and memberships</link:label>
    <link:label xlink:label="crvo_PrepaidDuesAndMembershipsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of prepaid dues and memberships, classified as current.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrepaidDuesAndMembershipsCurrent" xlink:to="crvo_PrepaidDuesAndMembershipsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SalesAndExciseTaxPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State franchise and excise tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:to="crvo_PrepaidExpensesDepositsAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeRelatedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, number of shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesACommonStockWarrantsMember" xlink:label="crvo_SeriesACommonStockWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_SeriesACommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Common Stock Warrants [Member]</link:label>
    <link:label xlink:label="crvo_SeriesACommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_SeriesACommonStockWarrantsMember" xlink:to="crvo_SeriesACommonStockWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_EquityIncentivePlan2015Member" xlink:label="crvo_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:label xlink:label="crvo_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label xlink:label="crvo_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the 2015 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_EquityIncentivePlan2015Member" xlink:to="crvo_EquityIncentivePlan2015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingenciesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ImpairmentOfMarketableSecurities" xlink:label="crvo_ImpairmentOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="crvo_ImpairmentOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ImpairmentOfMarketableSecurities</link:label>
    <link:label xlink:label="crvo_ImpairmentOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Marketable Securities</link:label>
    <link:label xlink:label="crvo_ImpairmentOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of impairment of marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ImpairmentOfMarketableSecurities" xlink:to="crvo_ImpairmentOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Vesting Terms As Improbable to Probable [Member]</link:label>
    <link:label xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents stock options vesting terms as improbable to probable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:to="crvo_StockOptionVestingTermsAsImprobableToProbableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleSecuritiesDebtSecurities</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxesExcludingIncomeAndExciseTaxes</link:label>
    <link:label xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance, taxes and similar fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:to="us-gaap_TaxesExcludingIncomeAndExciseTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherGeneralAndAdministrativeExpense</link:label>
    <link:label xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other general and administrative expenses, including IT, facilities, supplies and similar costs***</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total general and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_FrontotemporalDisordersMember" xlink:label="crvo_FrontotemporalDisordersMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_FrontotemporalDisordersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Frontotemporal Disorders [Member]</link:label>
    <link:label xlink:label="crvo_FrontotemporalDisordersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Frontotemporal disorders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_FrontotemporalDisordersMember" xlink:to="crvo_FrontotemporalDisordersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LaborAndRelatedExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LaborAndRelatedExpense</link:label>
    <link:label xlink:label="us-gaap_LaborAndRelatedExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel costs, excluding stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountRemainingPercentage" xlink:label="crvo_GrantAmountRemainingPercentage" xlink:type="locator"/>
    <link:label xlink:label="crvo_GrantAmountRemainingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_GrantAmountRemainingPercentage</link:label>
    <link:label xlink:label="crvo_GrantAmountRemainingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Amount Remaining, Percentage</link:label>
    <link:label xlink:label="crvo_GrantAmountRemainingPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of grant amount remaining.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_GrantAmountRemainingPercentage" xlink:to="crvo_GrantAmountRemainingPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:type="locator"/>
    <link:label xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments</link:label>
    <link:label xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, Maximum Deduction Percentage of Fees and Payments</link:label>
    <link:label xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of maximum deduction of fees and payments under agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:to="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMilestonePeriodForNetSales" xlink:label="crvo_AgreementMilestonePeriodForNetSales" xlink:type="locator"/>
    <link:label xlink:label="crvo_AgreementMilestonePeriodForNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_AgreementMilestonePeriodForNetSales</link:label>
    <link:label xlink:label="crvo_AgreementMilestonePeriodForNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, Milestone, Period for Net Sales</link:label>
    <link:label xlink:label="crvo_AgreementMilestonePeriodForNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period for net sales that is used for milestone under the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_AgreementMilestonePeriodForNetSales" xlink:to="crvo_AgreementMilestonePeriodForNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountReceivedPercentage" xlink:label="crvo_GrantAmountReceivedPercentage" xlink:type="locator"/>
    <link:label xlink:label="crvo_GrantAmountReceivedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_GrantAmountReceivedPercentage</link:label>
    <link:label xlink:label="crvo_GrantAmountReceivedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Amount, Received, Percentage</link:label>
    <link:label xlink:label="crvo_GrantAmountReceivedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total percentage amount of a grant received at the during the current period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_GrantAmountReceivedPercentage" xlink:to="crvo_GrantAmountReceivedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_CityAreaCode</link:label>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockSharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDeferredCharges</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentPeriodEndDate</link:label>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFileNumber</link:label>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityEmergingGrowthCompany</link:label>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentType</link:label>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntitySmallBusiness</link:label>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityShellCompany</link:label>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityPublicFloat</link:label>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityFilerCategory</link:label>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCurrentReportingStatus</link:label>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityVoluntaryFilers</link:label>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityWellKnownSeasonedIssuer</link:label>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingCanceled" xlink:label="crvo_GrantFundingCanceled" xlink:type="locator"/>
    <link:label xlink:label="crvo_GrantFundingCanceled-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_GrantFundingCanceled</link:label>
    <link:label xlink:label="crvo_GrantFundingCanceled-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Funding Canceled</link:label>
    <link:label xlink:label="crvo_GrantFundingCanceled-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of grant funding canceled.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_GrantFundingCanceled" xlink:to="crvo_GrantFundingCanceled-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgDiscLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgDiscLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountCanceledPercentage" xlink:label="crvo_GrantAmountCanceledPercentage" xlink:type="locator"/>
    <link:label xlink:label="crvo_GrantAmountCanceledPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_GrantAmountCanceledPercentage</link:label>
    <link:label xlink:label="crvo_GrantAmountCanceledPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Amount Canceled, Percentage</link:label>
    <link:label xlink:label="crvo_GrantAmountCanceledPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of grant amount canceled.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_GrantAmountCanceledPercentage" xlink:to="crvo_GrantAmountCanceledPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_AwardTmgMnpiCnsdrdFlag</link:label>
    <link:label xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityTaxIdentificationNumber</link:label>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityRegistrantName</link:label>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:label xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressAddressLine1</link:label>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_InducementOptionsMember" xlink:label="crvo_InducementOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_InducementOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Options [Member]</link:label>
    <link:label xlink:label="crvo_InducementOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents inducement options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_InducementOptionsMember" xlink:to="crvo_InducementOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressCityOrTown</link:label>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrTrmntdFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrTrmntdFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_Rule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_Rule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressPostalZipCode</link:label>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:type="locator"/>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees</link:label>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees</link:label>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of employees affected by share-based payment arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityAddressStateOrProvince</link:label>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:type="locator"/>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ecd_NonRule10b51ArrAdoptedFlag</link:label>
    <link:label xlink:label="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:label xlink:label="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityCommonStockSharesOutstanding</link:label>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:label xlink:label="ecd_TradingArrByIndTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USTreasuryBondSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Bond Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBondSecuritiesMember" xlink:to="us-gaap_USTreasuryBondSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProfessionalFees</link:label>
    <link:label xlink:label="us-gaap_ProfessionalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_TradingSymbol</link:label>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfProductInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of common stock, prefunded warrants and common stock warrants</link:label>
    <link:label xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_LocalPhoneNumber</link:label>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2025EquityPlanMember" xlink:label="crvo_The2025EquityPlanMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_The2025EquityPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2025 Equity Plan [Member]</link:label>
    <link:label xlink:label="crvo_The2025EquityPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents 2025 Equity Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_The2025EquityPlanMember" xlink:to="crvo_The2025EquityPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OpenMarketSalesAgreementMember" xlink:label="crvo_OpenMarketSalesAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_OpenMarketSalesAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Sales Agreement [Member]</link:label>
    <link:label xlink:label="crvo_OpenMarketSalesAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Open Market Sales Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_OpenMarketSalesAgreementMember" xlink:to="crvo_OpenMarketSalesAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_May2025AtthemarketOfferingMember" xlink:label="crvo_May2025AtthemarketOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_May2025AtthemarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">May 2025 At-the-market Offering [Member]</link:label>
    <link:label xlink:label="crvo_May2025AtthemarketOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the May 2025 At-The-Market Offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_May2025AtthemarketOfferingMember" xlink:to="crvo_May2025AtthemarketOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingMaturityDate</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, number of shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, number of shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options granted in lieu of compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RetainedEarningsAccumulatedDeficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_LiquidityDisclosureTextBlock" xlink:label="crvo_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="crvo_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Text Block]</link:label>
    <link:label xlink:label="crvo_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the liquidity of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_LiquidityDisclosureTextBlock" xlink:to="crvo_LiquidityDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label xlink:label="us-gaap_Revenues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</link:label>
    <link:label xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on marketable securities, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidProfessionalServices" xlink:label="crvo_PrepaidProfessionalServices" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrepaidProfessionalServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional services</link:label>
    <link:label xlink:label="crvo_PrepaidProfessionalServices-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for professional services that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrepaidProfessionalServices" xlink:to="crvo_PrepaidProfessionalServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cashless exercise of prefunded warrants (in shares)</link:label>
    <link:label xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cashless exercise of prefunded warrants</link:label>
    <link:label xlink:label="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued during period for exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockSharesIssued</link:label>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockParOrStatedValuePerShare</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label xlink:label="us-gaap_DeferredOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label xlink:label="us-gaap_OtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAssetsCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredChargesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockValue</link:label>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A preferred stock $0.001 par value: 30,000,000 authorized at December 31, 2025 and 2024, 0 shares issued and outstanding at December 31, 2025 and 2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidInsurance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskTable" xlink:label="us-gaap_FairValueConcentrationOfRiskTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueConcentrationOfRiskTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Concentration of Risk [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FairValueConcentrationOfRiskTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NumberOfReportableSegments</link:label>
    <link:label xlink:label="us-gaap_NumberOfReportableSegments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsAndShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charitable contributions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefOperatingOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ChiefFinancialOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of the year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of the year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingRemaining" xlink:label="crvo_GrantFundingRemaining" xlink:type="locator"/>
    <link:label xlink:label="crvo_GrantFundingRemaining-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_GrantFundingRemaining</link:label>
    <link:label xlink:label="crvo_GrantFundingRemaining-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant Funding Remaining</link:label>
    <link:label xlink:label="crvo_GrantFundingRemaining-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of grant funding remaining.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_GrantFundingRemaining" xlink:to="crvo_GrantFundingRemaining-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ConsolidationItemsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MarketableSecuritiesPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaids</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:label xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</link:label>
    <link:label xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:to="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock under At-the-Market Sales Agreement, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PolicyTable" xlink:label="crvo_PolicyTable" xlink:type="locator"/>
    <link:label xlink:label="crvo_PolicyTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_PolicyTable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PolicyTable" xlink:to="crvo_PolicyTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockByClassTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PaymentsForLicenseAgreement" xlink:label="crvo_PaymentsForLicenseAgreement" xlink:type="locator"/>
    <link:label xlink:label="crvo_PaymentsForLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_PaymentsForLicenseAgreement</link:label>
    <link:label xlink:label="crvo_PaymentsForLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for License Agreement</link:label>
    <link:label xlink:label="crvo_PaymentsForLicenseAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash outflow for license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PaymentsForLicenseAgreement" xlink:to="crvo_PaymentsForLicenseAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredRevenueCurrent</link:label>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_VertexOptionAndLicenseAgreementMember" xlink:label="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_VertexOptionAndLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vertex Option and License Agreement [Member]</link:label>
    <link:label xlink:label="crvo_VertexOptionAndLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Vertex Option and License Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_VertexOptionAndLicenseAgreementMember" xlink:to="crvo_VertexOptionAndLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromGrants" xlink:label="crvo_ProceedsFromGrants" xlink:type="locator"/>
    <link:label xlink:label="crvo_ProceedsFromGrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ProceedsFromGrants</link:label>
    <link:label xlink:label="crvo_ProceedsFromGrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Grants</link:label>
    <link:label xlink:label="crvo_ProceedsFromGrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from grants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ProceedsFromGrants" xlink:to="crvo_ProceedsFromGrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_IcfrAuditorAttestationFlag</link:label>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NationalInstituteOfAgingGrantMember" xlink:label="crvo_NationalInstituteOfAgingGrantMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_NationalInstituteOfAgingGrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Aging Grant [Member]</link:label>
    <link:label xlink:label="crvo_NationalInstituteOfAgingGrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Aging Grant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_NationalInstituteOfAgingGrantMember" xlink:to="crvo_NationalInstituteOfAgingGrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrefundedWarrantMember" xlink:label="crvo_PrefundedWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrefundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prefunded Warrant [Member]</link:label>
    <link:label xlink:label="crvo_PrefundedWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents prefunded warrant,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrefundedWarrantMember" xlink:to="crvo_PrefundedWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedClinicalStudiesExpensesCurrent" xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_AccruedClinicalStudiesExpensesCurrent</link:label>
    <link:label xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical development costs</link:label>
    <link:label xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:to="crvo_AccruedClinicalStudiesExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidClinicalExpenses" xlink:label="crvo_PrepaidClinicalExpenses" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrepaidClinicalExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical expenses</link:label>
    <link:label xlink:label="crvo_PrepaidClinicalExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of prepaid clinical expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrepaidClinicalExpenses" xlink:to="crvo_PrepaidClinicalExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
    <link:label xlink:label="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for prepaid expenses and other current assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalEIPCommonStockWarrantsMember" xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Historical EIP Common Stock Warrants [Member]</link:label>
    <link:label xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Historical EIP common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:to="crvo_HistoricalEIPCommonStockWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2018 Employee, Director and Consultant Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2018 Employee, Director and Consultant Equity Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:to="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Historical Diffusion Common Stock Warrants [Member]</link:label>
    <link:label xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Historical Diffusion common stock warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:to="crvo_HistoricalDiffusionCommonStockWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentAnnualReport</link:label>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityIncorporationStateCountryCode</link:label>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentTransitionReport</link:label>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_DocumentFinStmtErrorCorrectionFlag</link:label>
    <link:label xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_EntityInteractiveDataCurrent</link:label>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAmount</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmount" xlink:to="us-gaap_GovernmentAssistanceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_SecurityExchangeName</link:label>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_Security12bTitle</link:label>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="us-gaap_GovernmentAssistanceAmountCumulative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmountCumulative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceAmountCumulative</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceAmountCumulative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceAmountCumulative" xlink:to="us-gaap_GovernmentAssistanceAmountCumulative-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ClassOfWarrantOrRightExercised" xlink:label="crvo_ClassOfWarrantOrRightExercised" xlink:type="locator"/>
    <link:label xlink:label="crvo_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ClassOfWarrantOrRightExercised</link:label>
    <link:label xlink:label="crvo_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label xlink:label="crvo_ClassOfWarrantOrRightExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ClassOfWarrantOrRightExercised" xlink:to="crvo_ClassOfWarrantOrRightExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DementiaWithLewyBodiesMember" xlink:label="crvo_DementiaWithLewyBodiesMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_DementiaWithLewyBodiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dementia with Lewy bodies [Member]</link:label>
    <link:label xlink:label="crvo_DementiaWithLewyBodiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development for Dementia with Lewy bodies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_DementiaWithLewyBodiesMember" xlink:to="crvo_DementiaWithLewyBodiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</link:label>
    <link:label xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherResearchAndDevelopmentCostsMember" xlink:label="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_OtherResearchAndDevelopmentCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Costs [Member]</link:label>
    <link:label xlink:label="crvo_OtherResearchAndDevelopmentCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the other research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_OtherResearchAndDevelopmentCostsMember" xlink:to="crvo_OtherResearchAndDevelopmentCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PersonnelCostsMember" xlink:label="crvo_PersonnelCostsMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_PersonnelCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Personnel Costs [Member]</link:label>
    <link:label xlink:label="crvo_PersonnelCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the personnel costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_PersonnelCostsMember" xlink:to="crvo_PersonnelCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockBasedCompensationMember" xlink:label="crvo_StockBasedCompensationMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_StockBasedCompensationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Based Compensation [Member]</link:label>
    <link:label xlink:label="crvo_StockBasedCompensationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stock based compensation classified under the research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_StockBasedCompensationMember" xlink:to="crvo_StockBasedCompensationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_RecoveryAfterStrokeMember" xlink:label="crvo_RecoveryAfterStrokeMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_RecoveryAfterStrokeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery After Stroke [Member]</link:label>
    <link:label xlink:label="crvo_RecoveryAfterStrokeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the research and development for recovery after stroke.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_RecoveryAfterStrokeMember" xlink:to="crvo_RecoveryAfterStrokeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherClinicalAndNonclinicalMember" xlink:label="crvo_OtherClinicalAndNonclinicalMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_OtherClinicalAndNonclinicalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Clinical and Nonclinical [Member]</link:label>
    <link:label xlink:label="crvo_OtherClinicalAndNonclinicalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the other clinical and nonclinical research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_OtherClinicalAndNonclinicalMember" xlink:to="crvo_OtherClinicalAndNonclinicalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorName</link:label>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dei_AuditorLocation</link:label>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractualObligation</link:label>
    <link:label xlink:label="us-gaap_ContractualObligation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplierFinanceProgramTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Finance Program [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_SupplierFinanceProgramTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:type="locator"/>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease</link:label>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Number of Shares Available for Grant, Increase (in shares)</link:label>
    <link:label xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the increase in the number of shares available for grant under a share based compensation arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OptionsGranted" xlink:label="crvo_OptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="crvo_OptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options granted in lieu of cash bonus</link:label>
    <link:label xlink:label="crvo_OptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the monetary value of options granted during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_OptionsGranted" xlink:to="crvo_OptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of liability of accrued expenses and other current liabilities recorded as of a point in time.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="crvo_AccruedExpensesAndOtherCurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowances</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesAPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationNondeductibleExpense</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nontaxable or nondeductible items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:type="locator"/>
    <link:label xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_DeferredTaxAssetsCapitalizedResearchExpenditures</link:label>
    <link:label xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research expenditures</link:label>
    <link:label xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to capitalized research expenditures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:to="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingSegmentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareSalesAgreementMaximumAmount" xlink:label="crvo_ShareSalesAgreementMaximumAmount" xlink:type="locator"/>
    <link:label xlink:label="crvo_ShareSalesAgreementMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">crvo_ShareSalesAgreementMaximumAmount</link:label>
    <link:label xlink:label="crvo_ShareSalesAgreementMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Sales Agreement, Maximum Amount</link:label>
    <link:label xlink:label="crvo_ShareSalesAgreementMaximumAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum amount for share sales agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_ShareSalesAgreementMaximumAmount" xlink:to="crvo_ShareSalesAgreementMaximumAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCredits</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesAWarrantMember" xlink:label="crvo_SeriesAWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="crvo_SeriesAWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Warrant [Member]</link:label>
    <link:label xlink:label="crvo_SeriesAWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Series A Warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="crvo_SeriesAWarrantMember" xlink:to="crvo_SeriesAWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income tax, net of federal (national) income tax effect (a)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>crvo-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:12PM UTC 2026-03-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events" xlink:href="crvo-20251231.xsd#statement-note-13-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information" xlink:href="crvo-20251231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_GrantsReceivableCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:href="crvo-20251231.xsd#statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_CashlessExerciseOfWarrants" xlink:label="crvo_CashlessExerciseOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OpenMarketSalesAgreementMember" xlink:label="crvo_OpenMarketSalesAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OptionsGranted" xlink:label="crvo_OptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="crvo_OpenMarketSalesAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_OptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_CashlessExerciseOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business" xlink:href="crvo-20251231.xsd#statement-note-1-the-company-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources" xlink:href="crvo-20251231.xsd#statement-note-2-liquidity-and-capital-resources" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_LiquidityDisclosureTextBlock" xlink:label="crvo_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="crvo_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts" xlink:href="crvo-20251231.xsd#statement-note-5-significant-agreements-and-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NationalInstituteOfAgingGrantMember" xlink:label="crvo_NationalInstituteOfAgingGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_VertexOptionAndLicenseAgreementMember" xlink:label="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="crvo_NationalInstituteOfAgingGrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies" xlink:href="crvo-20251231.xsd#statement-note-8-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalEIPCommonStockWarrantsMember" xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_May2025AtthemarketOfferingMember" xlink:label="crvo_May2025AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrefundedWarrantMember" xlink:label="crvo_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesACommonStockWarrantsMember" xlink:label="crvo_SeriesACommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesAWarrantMember" xlink:label="crvo_SeriesAWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_SeriesAWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_PrefundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_SeriesACommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="crvo_May2025AtthemarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_EquityIncentivePlan2015Member" xlink:label="crvo_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_InducementOptionsMember" xlink:label="crvo_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2025EquityPlanMember" xlink:label="crvo_The2025EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_InducementOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_The2025EquityPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefOperatingOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments" xlink:href="crvo-20251231.xsd#statement-note-12-segments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DementiaWithLewyBodiesMember" xlink:label="crvo_DementiaWithLewyBodiesMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_FrontotemporalDisordersMember" xlink:label="crvo_FrontotemporalDisordersMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NotesToFinancialStatementsAbstract" xlink:label="crvo_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherClinicalAndNonclinicalMember" xlink:label="crvo_OtherClinicalAndNonclinicalMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherResearchAndDevelopmentCostsMember" xlink:label="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PersonnelCostsMember" xlink:label="crvo_PersonnelCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_RecoveryAfterStrokeMember" xlink:label="crvo_RecoveryAfterStrokeMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockBasedCompensationMember" xlink:label="crvo_StockBasedCompensationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_DementiaWithLewyBodiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_FrontotemporalDisordersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_RecoveryAfterStrokeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_OtherClinicalAndNonclinicalMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_PersonnelCostsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_StockBasedCompensationMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable" xlink:label="ecd_TradingArrByIndTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_TradingArrByIndTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems" xlink:label="ecd_AwardTmgDiscLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AwardTmgDiscLineItems" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies" xlink:href="crvo-20251231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PolicyTable" xlink:label="crvo_PolicyTable" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-significant-accounting-policies-policies" xlink:label="crvo_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-significant-accounting-policies-policies" xlink:to="crvo_PolicyTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_PolicyTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_PolicyTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:label="crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-6-prepaid-expenses-tables" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-tables" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-tables" xlink:label="crvo_statement-statement-note-11-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-11-income-taxes-tables" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables" xlink:href="crvo-20251231.xsd#statement-note-12-segments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-12-segments-tables" xlink:label="crvo_statement-statement-note-12-segments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-12-segments-tables" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual" xlink:href="crvo-20251231.xsd#statement-note-1-the-company-and-description-of-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="us-gaap_GovernmentAssistanceAmountCumulative-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfProductInformationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmountCumulative-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:href="crvo-20251231.xsd#statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ImpairmentOfMarketableSecurities" xlink:label="crvo_ImpairmentOfMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ImpairmentOfMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="crvo-20251231.xsd#statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueConcentrationOfRiskTable" xlink:label="us-gaap_FairValueConcentrationOfRiskTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details" xlink:to="us-gaap_FairValueConcentrationOfRiskTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueConcentrationOfRiskTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:href="crvo-20251231.xsd#statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:label="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryBondSecuritiesMember" xlink:label="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details" xlink:to="us-gaap_MarketableSecuritiesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasuryBondSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USTreasurySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n9" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual" xlink:href="crvo-20251231.xsd#statement-note-5-significant-agreements-and-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments" xlink:label="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AgreementMilestonePeriodForNetSales" xlink:label="crvo_AgreementMilestonePeriodForNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountCanceledPercentage" xlink:label="crvo_GrantAmountCanceledPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountReceivedPercentage" xlink:label="crvo_GrantAmountReceivedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantAmountRemainingPercentage" xlink:label="crvo_GrantAmountRemainingPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingCanceled" xlink:label="crvo_GrantFundingCanceled-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_GrantFundingRemaining" xlink:label="crvo_GrantFundingRemaining-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NationalInstituteOfAgingGrantMember" xlink:label="crvo_NationalInstituteOfAgingGrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PaymentsForLicenseAgreement" xlink:label="crvo_PaymentsForLicenseAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromGrants" xlink:label="crvo_ProceedsFromGrants-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_VertexOptionAndLicenseAgreementMember" xlink:label="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmount" xlink:label="us-gaap_GovernmentAssistanceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GovernmentAssistanceAmountCumulative" xlink:label="us-gaap_GovernmentAssistanceAmountCumulative-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="crvo_VertexOptionAndLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="crvo_NationalInstituteOfAgingGrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AgreementMilestonePeriodForNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PaymentsForLicenseAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmountCumulative-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentAssistanceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ProceedsFromGrants-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantFundingRemaining-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountReceivedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountRemainingPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantAmountCanceledPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_GrantFundingCanceled-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidClinicalExpenses" xlink:label="crvo_PrepaidClinicalExpenses" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidDuesAndMembershipsCurrent" xlink:label="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidProfessionalServices" xlink:label="crvo_PrepaidProfessionalServices" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:label="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidClinicalExpenses" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidProfessionalServices" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsCurrent-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedClinicalStudiesExpensesCurrent" xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplierFinanceProgramTable" xlink:label="us-gaap_SupplierFinanceProgramTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="us-gaap_SupplierFinanceProgramTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplierFinanceProgramTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:href="crvo-20251231.xsd#statement-note-8-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_LossContingenciesTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ClassOfWarrantOrRightExercised" xlink:label="crvo_ClassOfWarrantOrRightExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_May2025AtthemarketOfferingMember" xlink:label="crvo_May2025AtthemarketOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrefundedWarrantMember" xlink:label="crvo_PrefundedWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesAWarrantMember" xlink:label="crvo_SeriesAWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareSalesAgreementMaximumAmount" xlink:label="crvo_ShareSalesAgreementMaximumAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_SeriesAWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_PrefundedWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="crvo_May2025AtthemarketOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ClassOfWarrantOrRightExercised-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareSalesAgreementMaximumAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="crvo-20251231.xsd#statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:label="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_HistoricalEIPCommonStockWarrantsMember" xlink:label="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_SeriesACommonStockWarrantsMember" xlink:label="crvo_SeriesACommonStockWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_HistoricalDiffusionCommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_HistoricalEIPCommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="crvo_SeriesACommonStockWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_EquityIncentivePlan2015Member" xlink:label="crvo_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_InducementOptionsMember" xlink:label="crvo_InducementOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease" xlink:label="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:label="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:label="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_The2025EquityPlanMember" xlink:label="crvo_The2025EquityPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_InducementOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="crvo_The2025EquityPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="crvo_StockOptionVestingTermsAsImprobableToProbableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefOperatingOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:href="crvo-20251231.xsd#statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:label="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:href="crvo-20251231.xsd#statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:label="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:label="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-n2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits-n2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits-n2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-2" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-n9" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses-n9" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n9" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual" xlink:href="crvo-20251231.xsd#statement-note-12-segments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_NoteToFinancialStatementDetailsTextual" xlink:label="crvo_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportableSegments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details" xlink:href="crvo-20251231.xsd#statement-note-12-segments-schedule-of-segment-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DementiaWithLewyBodiesMember" xlink:label="crvo_DementiaWithLewyBodiesMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_FrontotemporalDisordersMember" xlink:label="crvo_FrontotemporalDisordersMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherClinicalAndNonclinicalMember" xlink:label="crvo_OtherClinicalAndNonclinicalMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_OtherResearchAndDevelopmentCostsMember" xlink:label="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PersonnelCostsMember" xlink:label="crvo_PersonnelCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_RecoveryAfterStrokeMember" xlink:label="crvo_RecoveryAfterStrokeMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_StockBasedCompensationMember" xlink:label="crvo_StockBasedCompensationMember" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:label="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesExcludingIncomeAndExciseTaxes" xlink:label="us-gaap_TaxesExcludingIncomeAndExciseTaxes-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="crvo_statement-statement-note-12-segments-schedule-of-segment-information-details" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ConsolidationItemsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="us-gaap_OperatingSegmentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_DementiaWithLewyBodiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_FrontotemporalDisordersMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_RecoveryAfterStrokeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_OtherClinicalAndNonclinicalMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_PersonnelCostsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_StockBasedCompensationMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="crvo_OtherResearchAndDevelopmentCostsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LaborAndRelatedExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfessionalFees-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesExcludingIncomeAndExciseTaxes-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>crvo-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 08:12PM UTC 2026-03-13--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:label="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrantsReceivableCurrent" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="crvo_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivableCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="crvo_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:href="crvo-20251231.xsd#statement-condensed-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="crvo_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:href="crvo-20251231.xsd#statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidClinicalExpenses" xlink:label="crvo_PrepaidClinicalExpenses" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidDuesAndMembershipsCurrent" xlink:label="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="crvo-20251231.xsd#crvo_PrepaidProfessionalServices" xlink:label="crvo_PrepaidProfessionalServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="crvo_PrepaidProfessionalServices" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="crvo_PrepaidDuesAndMembershipsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="crvo_PrepaidClinicalExpenses" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="crvo-20251231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_AccruedClinicalStudiesExpensesCurrent" xlink:label="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="crvo_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="crvo-20251231.xsd#statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="crvo-20251231.xsd#crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:label="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="crvo_DeferredTaxAssetsCapitalizedResearchExpenditures" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cm01.jpg
<TEXT>
begin 644 cm01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M S2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>logolg.jpg
<TEXT>
begin 644 logolg.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !_ 9L# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6^,_]M*Y(4^>?LR^=01[]36 K\%&_P"#O'XF'_FCW@;_ ,'%Q7US_P $:O\
M@NWJG_!2SX]Z_P" O%7@_0O">H6&C_VKIC6%Y)<?:_+E$=PG[STWQ_K7H5,J
MQ$*?M*BT.>GC:$Y^S1^FE-*_NZ7H*^'?^"TG_!6*Z_X);_#;P9?Z)X?T[Q/X
MB\8:I<6T5A?WCV\4=O!$/,ERG/\ K)+<?]M*XJ%*=2I[.!U5*GLS[E!I,@-7
MX(M_P=X_$UO^:/>!O_!Q<5^C7_!%O_@IAK__  5"^"7BSQ5K_AK2?#%SH&O_
M -DQP:=>/<1RQ_9XY/,^?_KI75B,MQ%"'/41S4L;3J3Y('VD5R*1C@5^0/\
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M<?\ ;6VDDCJY_P $T=-F_P""M?\ P77\>?'W5$EN?!'PVN/MFC[X_P!WE/\
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M'PD_X-[/$/A2[_X^_#'@_0-*F_W[>XL8_P"<=?#W[ _PT\7_ /!=+_@JK?\
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M"W39&D<>R.-*O-C;7RF+Q'MI_N]$?KN1994P5#DJSYZA;HI!TI:P/="BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ QBDQFEHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ZT8H
MHH ,8HQFBB@!,48I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>mice.jpg
<TEXT>
begin 644 mice.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X0Y-17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    4    <@$R  (    4    AH=I  0    !    G    ,@   !?
M 0   %\    !061O8F4@4&AO=&]S:&]P(#<N,  R,#(V.C S.C$R(#$X.C$R
M.C(U      .@ 0 #     ?__  "@ @ $     0   OR@ P $     0   4T
M        !@$#  ,    !  8   $:  4    !   !%@$;  4    !   !'@$H
M  ,    !  (   (!  0    !   !)@("  0    !   -'P        !(
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))300*       !   X0DE-)Q        H  0
M   !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @
M.$))300"       "   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #10    8              4T   +\
M    " !2 &D 9 !E '( (  Q #D    !                          $
M             OP   %-                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %-     %)G:'1L;VYG   "_     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M30    !29VAT;&]N9P   OP    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
M    #3L    !    @    #@   &   !4    #1\ &  !_]C_X  02D9)1@ !
M @$ 2 !(  #_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #@
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
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M -8   $$ P$! 0$           < !08( P0) @H!"P$  04! 0$!
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M$C#2=/@ERM\UV!P&<D!=-[=.3-M4"YN ,)F1VIRTJ/1 <;#A%3Z5T"<,'")
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M<RUV2S;WS/O$6W+]U42CGRH?4I-/Y@*]*Z,]O\:RW;9$XD ^7R4#D[;H('/
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MPK^P^T^U2M$J;4V@>;9Z@FG]UU)'^[)6!EQUSH?L0]G#3L&QDI#/EK]ZL)W
M?9YY/1W)VKO+[$.\*Z=K/<?<<>A\=<Q7>_VB)DEISEF#!:@HFW2(^4-N3%!H
M....-N K 6 E774.EW-'['L6(@]F<C7!'R^"?L<.[W/<B?M=C!\<JU?V\^PS
ME;M&N',_(W/G=YE?=ES3SS+AW/,;UEJE0L>MB8)?4TU:;7[CPCC_ !!"J+VT
M"0A" "".YKF([(:V.(,8WICK]I4KCZ#X2XN>7.=]WV+IKH"B:YC?;&^W:_\
M;OP[GW&9?*B>597.'(-^YN5/8M)M#=O;O$MR0W##:I4HN%L.44YN&[QVC1[G
MN;^M<P[=NUH'7*'<=0^G#AG.3E2CM<[$YG;EW=]\W= _R6WEL/O!N>.Y!;,+
M;M9AN8^FRV]<1QMR49+HE%U2]R2&V]HZ$'QUQR'+^_6ABVX]L'7/7*56C[<S
MWYSNQ]BI#S#]G[G##>[/E?O"^W+WF2.T+->X$)D<X8#?<=@Y/CEUG[RM4UB/
M,^1MQ2U+<(6A9"U*V*0#MT5K=RPOK-ALQ>X&=#G!"A3<.]LIDA?M+NHZA,=X
M^Q5*SCL<Y4[;>6.\S->5.=^4<J@\].]P>;./SXMKR^UN^[%7$M$F2L(B= '&
M@\%*%**30 =M[NV6VRLB#6-&W:/(_'S7+N"W0%CGDN)SGXH7W;[*'>WS7RWV
MQ<R]V?W+5\OWGM6RNP9E@.(0L)C0+*JUVB0F1(0XU"EQ@9TCV6TB4M*U)2"%
M!=>DAO=56*.1D,&T/!!.==?^WP31X6=[VNDESM/DK&=U7VJNX[.>_P!/?QV=
M]YB>V#.\SQ>!Q+RU;KMB\3)1-ML)UA)5%$USV4*6S%;2-S>Y*@5)6 HIU!X[
MN&!E/Z>:+> <C7"DVN*D=8]V-^TD8.F5'N5OL_\ .^&]SG(/=I]O;O6E=IW(
MW.<2/'Y^Q.^8W!R7&K[=&DI2Y<X\.6KVXSSJ@5K3L6 K]!0.FNZW<L+H&PV8
MM[6_A.<$?!<R\1(V4R1/VD]=,A3;!_LKX=?>S[GCMH[M^XK,NZ3,.X^\'DK.
M>6LHFNL.V;)&JF+,L,-YV0B'[%$C:5*"TI"#\@"0U-W2X662PL# P8 'B/CY
MKN/A6F%S)'%Q=KGX_!5,SG[)OW!.:N&F.U/G'[M=YRSM?L<--IL^+VC#XL*]
MW)J%'4W 8N]P1+#TR.TX&U.MO.+#FT4VFA!*'NJE%+[T=8"3SSI\<#P423A+
M#V>VZ;+?E^M=Q>R#MPE]H7:3P#VRS\N;SV;PICD+!9691(2K:U<5Q=U7DQ5/
M2"T%;NB2XJGJ=5+EKWU-E\N,;CG".4JWLQ-9G. K4:'J4OP>)_'_ %:227F?
MX:22_=))+222TDDM))5$[^N-LTYA[*^Y_B_CFRJR/.\XPR^8_B=@:=997-G/
MPU!IA*Y"D-I4XH;05* J>I ZZ)</.R*U&]QP 1E0^0B<^!S1U(02^WKQ/SWP
M/]KSMXXDN6(1,2[C,!X[8L#>%YS);<A0<C;BN%EB<]:UR$EM+I3[A:4KI6A.
MI?-689N0>\'+"[J/+X)FA#)'5:W'J _2OEEYB[ ._;NMR3AVVVW[2&-]G7=Y
MB^:QLFY*[V>(<ICX]B+\:-<EON3(ULM,EQ2"\H!WW0'73_<2I1IH-7F:=9KB
M;)DC(T81D_>55Y^/GE(Q"&N!_$#@(P=PG _W:^8/N'7ON([AOMWW'N]XEX&N
MLO&^U7C"5E^+VG#VX-ODJCL7J1!>GK6^_-#2)*PX =QVJ&U(2(U*YQL5(113
M^VYP]1P2?EGX=$[8KVWV-[X]P'09&/FOI"["^XOOEYQF\AVWN^[&#V@VS%F+
M>Y@-T1D]HOC=Z4\7$/L)8MKKY:]@(2=RE '=0#I75&YBE4B#3#-[F>NA&%9*
M%B=^?<CV_:JW?=O[7N>>XCEG[:-_X8X^?S>S\-<Q0<[Y4N$.5 C)LED1$*5S
M7A-?94MM*A0AH+7_ ,W4[MOD(8(YP]V"YF!\2HW+5))'Q%HSAV2J"_<;^RIR
M+W-?=5X,YEP2U+_\+/-KUKR'O-:8F--0Q.PHAQCZJ*N0VMW]QCAN.T6VU[5A
M:E$5J3/!]U,K\<]CC_$;G9]O[$/Y'A72VFN'X#^+[/VJXF:]G//LC[X-@[E[
M#QNI7;FC@*_\.M<@L2X"(D*^O*98C0'(ZGA)"E)02E26B@)'50/30R+E(?\
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MWB<:<YV;M:[U.RJR<2\W<W8_>KMVDSL%S>!>L7R[*H$=Q46PS+DSO;B./O\
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MX*F[*4\ZTU]/%=9>]MQ14%+2ZE1Z^VFM-66;G^/MELDX>UX&H:=#A"8^+M0
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MI7/.6O 'Z%SPP+[9GWE^U[BO)^SWMXY/X6SKA%Z5)A<4=QG+EGD.Y]B5DE2
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M26DDEI)+\ "11(H!X :22_=))+227X0"""*@]"#I)+]TDDB 10]0>A!TDE^
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M79T*@/W #;O<V[=@IKBC'[]IV253;\;0?3T4V?XXO'[==+7>7$31!4DVA7Z
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M;4\JBQY3*$- (6$["IOQH-$V,("K#7;)G'S6 JC6]GV'8Y?=_E=!-!^---M
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MV AN"0)#,@%-#7J ::FU?<W 8R$/LR@@G&%(+I;(KJ(B9LA;4MXI%630&AZ
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M^6Q,2T>U;+9%0Y%2@1([,9( : \@!HJUK2W*%UJ;HH'EWFMMU]N*B2B0L)?
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MGH=9KZ)B5^UJT+C$B-R8\=:ELOWE2@%1B2D*2*]=#?8.5*JV [JHU)M+/O\
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M+EJFS64QKI;615I"MO10\NNKM 6.5<<[5$M,=4;&E7!J>A"DK4Y+3T]Q0(Z
MG5JX_8T$!0O;W^GS4(6\N1].J2\4MREI;CA0^=/7QKH9::3,I3&0QC85)9#4
M80)+[[I<$.H2VWT4X4^?QT4=.1&!A1G@9TZ*)VA2;F'YMN;6OWD*;5)D$[>A
MI2AZ]-"Y69.5XTX4AL>/I2MB8M].YM12J.H=23TK^&NZS<%0[#M5ZGVMF/\
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MHD-WBWW!2(?LJ2S!<<JBH'B!X:OO#C&,K+.X.1=]8&A;$).1SN256PL,*QN
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MXU&HK\[E,?" $\N2YA:?A-#VT%1#ZB?$4Z :(1S!O5"7'0JXO#J4(P.U)0"
MDN [O7=K0^$D#H,_%4/EOYR&7<DZ&K9C505(<D.H4$]2/DT [T@]QK I_;I_
MBX5-)]PB*+<8+VDK"(YE'J>M#JE[<#"T2O7P,K=ELNEMI 1N:1UH.G]FHWTV
MW5-,FWG&%LR$1YT8,K=]EQH?)1(*@?QTVZ4MU4N.H2H%>+]_EYBC[3TU15L2
MID;Z*\N@T%LVSE2H8MJV&PU-CLS7UE;S[:C]-)30(41XD#3+&>X,J8V8_A4:
M:OD6VWB! A 3W%-J=D_3I(0W3KUKZ:1;C1/MJ$#JLUSEID+7<VYCD9* 2OV5
M; >E?/RU[:_"%[6'@F#]\]NQ-S3.1(:DJJY;WQ0A&[J13RT'?T*)-ZH8.1DY
M5<;U=%.I:A0]C<6W+71MMIOJ5U\]!VC,B,M_E*+Y;W,\'VNS2;>_R#:W+A%6
M+8W%@2&EJ2X@4(VI-:UZ:=Y2$F('R46A5<^4C"%<KE&==;%.E6)D_2O[$+E)
M4$[VE>?7677N=$9+<K1J7;9: Y1S)X[UMM>(Y)"#;2I#@CS'%%!<V*\:TU5[
M%QUAW0JW5X,,&B@'^\BSQ7<HM%D5^XR()^H=6L_,V#^O^S4&TUS1CP13B^(W
M/)5;&<=O7+7)F*X]; F1*?<+\AE:E)4XGW/#IH74XIUR[[0&H5M[FY8<51][
MS5CN[GMBN/ IP_D*TO!B-(0PJYQQXLO@!1Z^FKOW/V%-QL#97>*K787>O^]-
M>#H&JO68M2+E:I65Q'0F))^GN;[[BZ(+R0/X>.LDM&=[P(CJK7>GAC:0X:*2
M<>\X6#)LJ3C-OOL9V]/L-IN%I84%+4MH4KMU9QQ$U>(22C*I#;,#Y/040<F]
MRZ.7TOQE),((:CEQ*$)*B*]!YZBM86#&=#JCC(MXVHC\(Y1:Y%M@V"]6E:77
MIJT(EFNTT33I76C=LUF&N3IE9]W"PUGD@H_PV9T&]W1;Z5KMR%MKA^0VI/BJ
MGD-'Z_I/I_0J7><9ADHY0Y2;I$=CQ$"2MXI<<=M[B:I2?$FAKJ]\98W#!5+N
M,"T2YFUXR.?!Q^"+9:\;:;BHR2[U+FQ8W+]H#Q.K:R3:W*&OM>V//*.V/R(:
M;0PJ7,,E2*H$E'194!TW >IU[]6,=$#DR7Y30W*:<JQ#C.-NMA;SK;U=BE$_
MJZ^NG8Y=P7MIWJ'R3DTMJ0AM*6O;E( <"6P=E1IS*BY*?42I#R0R^IJ-4 J(
M/S'IYZ?JULI$X3K&=89;"$N;2H]"=$#5('50C:!35)=<8N:S&<]U*OF6*>/X
M:"78=NN42KS9&%O6=<RX+6WO+36X[DN5'7^.B=&+<%%D&I1LX1;4SR/';]DM
MA,=\%1!^8 >.K=VK'MN?8J_W.?\ *?:KQU^6OPKK4?%9RO_7^]O)_P#\NWWK
M3_!2^O\ [NO42\PNA</@?U*33&96_,?K7.OZD&(M]+PH5?-3K0 ^.L3\2M?;
M&6G5:ZOI_JFWE2*(< 4=OBJHTS:Z(JSH%^--O*,EQQ'T\91]IJ*3^L*Z5.H2
M<<W3JF-R)#1+<;:C*0\V"4[A\A_CJ7%(,834<#W#+5ILK2Y(*2A-6$U"*^!!
M\>FH;L IT5YAU6M<U29$:X&(5%:?FJA/\JO&F@MR(I^F3[H!Z*K>0W;)\7S-
MME]I4Z+-*?IP5$%/3T^&J7=<YLF,+6JD43H?2B8+(WE;C1O8^N8D !+9 *6Q
MX$"OGKQL>[JACN1=5?D%.MUA8YC+-OQN PCZ"4E2'HBU'Q/\=.\H&,K;3U*
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M8-4*2M/2I\M IG^E6&H!E )<*X6K&+[!<D)#<UQZ2T]&^9:4+%!UK7I75,Y
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M$)E/J**/;I&#?)D5Y3Q?6[$?7N7_ "U'AJT=FG_/?8JUW2?\J/FNA?\ V?\
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MCMF?4U1*]4NF+<:A0O D9=)Q3(+)96([LRZNN0[="N*TI45$]5)W4H/34ZA
M(SN"XY,!KMJM]P;CX;LL-JZNI_S!:UJCK8*ZMJ4!0_I/D=:-P<FXY*QSNO0N
M5CHR5W&%/@,O->TRJDAML@J4L?W=W@-7J$%XT5%=8=&\-;U*:L=QBV66;)NE
MM?*6I1)N$=]9^5VG4BOEHQ5K :E-7Y).@1(M[L&\E^&V$ *;#*G$$5"CY]-$
MA ",@(9%O!R[HME;@9DQ0NA,=!BI2X 0L)Z5-=28Z+_ +V2T,:%:B&''7&E6
MAE:9*5[I+C@_4/'Y"/#1%L+LA"W1F0'*=KQ>9+5N>AR&U2IBEH^GBI.SI\2:
M:E.*'&HX: *41I*WX)4_&^F<;0A*V1U&T#U&EA>Q':[5-<51=F/+6VYM"@&%
MHJ !\=2J\3CJE9E:"KS<0;1AL$!SW/ZCGS?QUK_:S2*ZR#N@YM(J'PU8GG 0
M$+FE"N?[B]=K@M)MS,=UR,E+FT^Y59!(!&L?D/J*VB/\(3I[+#BS"]U3C+20
M^VACH/G'4Z<ZA=O86]4U QFGP_*)2B,][:8^W>E2:4^8:C/DVKUAP4_,M19#
M4V,T]1#H+S2D42&Z"M /77L5@.4<0%SU )SSSUVQD)=6RW&+G[B^Y^I=11-=
M!KYRY'+$0:QN$V7JVR51+G'7?G$MO.(*DTW4!/0Z$6/PIVDH1=,?N$"++CHN
MK<M.]*W7'4C>MLCHD?AJNV@2U'N/.)%7>[B^67)YD+<A5GN#(WJ9H%I56O6F
MJA?! \E=<%V"$/KIQ9B,;,8&3*>5'NMU)^ON;A0I;B0.B05=0-5F6E)(W:YV
M04:-Z7&UHR"HU=,4O$7([I?$O"1&B*;DXU"14[@V>AH.A%=0.8,KWQQ1] =2
MBE$[/6>JH)W8=B/-_=3S9Q-SI;>0U62%A,IIR_X@ZM;:)#3*MQ4AM) /3IJ^
M]G=Q1TZ$E9\><GJA$I$DP)\%='@P,XN]?(ER<;EW*%)4RVIUH>\&T': 0?$=
M-4UP->P=FH.J(\K&V8!SO 85F)61VJX8]>ENJ;2Z4$/Q6$[%!(\#3P%=62O=
M?-&]JKW'5F-G)SH@G8LB?BY#:3_E]M3+[:F(34LD$^=::K)I@'5$N5/DA=ED
MB5>;VF7<83<.2[</:CH2H[&DMJJ?$^>@EFVZ)VG1-^\2C(_EC3LF<_:+A%G3
M;-#"IL>W.(65[:)*5!)Z$#1^A=D.,CJA98U\NW*GMF>_=)LG(XZG;?'5$:JA
MQP@?II5/\='H][O!2V5(8^HRF:ZVRY*RJ3?XC1E!5O6S&?2-[N_::_-Y #0^
M>;VV$%2Z]J"-V SJ@?BD.1'L=XE32XZM4A;SC8JI)&[\]4IEIQL%6JN\/;N
MP$8K1,=RB-;8UO6(C5G*)+K3.[>LJ^4I41X#5FEA:^/<AMWDX6.P6]$YXO;7
M[G?YL=RYEAU^?]+&:<^;VAMZ$^@KIFG ,9;J5'YCDHGO #418DIRTW*XVMQ/
M]:))3&=F0S1"E>BS\=7'AYG-ZA5;D7L=EN58S&KZ'X3J/H6'I$-8CO.-JK\J
MAX)KJ^4;969<I3!<IM;WGY\E"G640VHM6F]@^<_ ZM].0.&"@CH=JWKH W%D
MHM[*7C3WI32%!/3S/XZ?EK-C.6ZKM@P%JQIB8\..\K^A#6 %,@[E$_$Z9@LO
M>_#EY8=D+93(4Q(5<VE[0H%MB OP /GUT_;QH%'W!/J&(B$Q7WGRZ[-(#D<D
M[37UIIV"B"W50Y)0'@IJEVAIN<]++14F-0LJ2HE/]AUQ8HAC<A28[FNB:,GN
M5Z8M7M08A>^J2I49T5^103Z: S##2BW',$TFO@KH=N$B9)XEQUR>:RP7D/D"
MGS!PZVSM<'Z1JR?NN$,N. 4+[G6G#:\:D,;5/Q'WGFFGOT*^3K75:_,1[O;8
M %-[/< 7JD$F'/;>]YAMDVYY*9"PQU6A=?F&LN%IRO;1D+(IQM(HE:A'4*%#
MWB=3!,XZ%=/KC:2$XK<COP$O.OK9<:3[;+<3H*U\37422,%Q)Z*538'Z(0X]
MR?8<@R'(\<AWMJ7=+ ^J'/CI*4ANJ10+T/EN^Y@,UPITU4PX+A@%;-PS"WV5
M3D.7<PHNU'T44_,5GR%-#WV_5CQ1B.BYT>_&BB)NKK[\5^/%5%C.*+;!F'<M
M+E?U$'4^%V6J*,9P"BO:HJ?:_IJ"'74F2X? $CY3^&NZD3'DX*&[27:*MUZY
MSXKA<GWWB]N[1GLNL2&Y<RPA: X%+&ZM*U/35;[D>^O&7 :*T\/![I+!U0^Y
M+D6BZJ?N :^E@W)(96J&HH&[U)'@1K)K]CW(R[X+3>"KNA>&X7(;N?[2.)^0
M,AM%RR6<N\18+J7V($YPN[B17Q56HU5^W>]'T92,X6GS=M&U"TM.#^M;''>&
MX1Q[DT1GCV(Y8[BF"8CT&,ZOZ=2 *=&3TKJ/W%W!<Y!SI&Z!OZO-6*"*J(FL
M!P6Z%!O+>R3F'DON;Q;GK'<K:L4C%62Y:VY6ZKBP*[5('2A\-:IV9W!6CXU\
M=AN21U\UG_=O&E\@=$_*OWB?)'($26,#Y)Q%V#?GA[*[O$!^B6BGZDT\SK)N
M0;&'N=%TS]RD\=!)(T!_@K <492EJ;=[.^VIR.I@^Y'0BBB:D!05YZG\?R(!
M\R%![AXXL< .A4PCW>1 L%^CW249;,AU;3!6G:4(4DC;4>.K .YXW1$!N"FN
M(XF,R $JM6+(C1,4F)M<<+?8G/2T)'4J"5E7AK/I>;;[SB1N5X?4;%AA1-G7
M7(OV@OQHZ'DW:,OW8J.K@WH*10:ETN4;)*WTZ9Z*+<RQ@#3@YZKFKV==O/*^
M#9?SG+Y 3+M=AOU^-TQ!<YU2T.)<)4>JC\H%=77OVW7DCB^E;APQE4KM>"[%
M/*Z1^A<<%7!S&'D.+2UV3+C'DLNO,.V"6T4^V''#4=?6FJE/9EG!#M<>*NL5
MED4+LNRXHCWS';;#Q"-<A<%0+U*<2I;T=S:U5(J5;0?#3561F2W.J8D87XPA
M[*S_ !ZYX?D+;<Y:<KP^+)O3>/[B4RDLME14C=X!8'4Z*4JP?*UK78.4&Y2M
M[;3E4I[2>RS'\TY5L/=SC-ZDQ7LJ;DSI^-71]R3&BO\ NE"PD$TIT\-;/S?/
MN;697/I=YK(:W&PLF+B,DGHKX85W9\.KYDS?B-N4^K*,3 CW!4EM:HQ(Z$((
M\!753AXMC';W/SE')IVN86AN,*]V-M6'))..N1KDEH24*4W%;"B 2*T^;PKJ
MX0Q-;C'14ZR\;"C8<*CVQ;4N-;Q&MSS>^9M.Y:U-CI4_'1/WG-"$ME:>ARI7
MC!L2K8W(;;$E#3JD)9=17J3^GKHW$TN 0]W4J60(;#$MY]$418CGSLLQ]J4!
M7H0-%(80!\5 LC)"WKE,AM0A/71"5+2F0R:!6VM"1KA\VU/5JQSIJH+%D3H^
M43%0DL7NVO($B Q!ZK:)'4K^(UQ'=34L+VNU"M!VZ(<_WA1G7WDF0Y'?4MA/
MB.GGJZ=DR[[WV*G=X'_)_:N@VX;:UZ:VW&JRG&B__];[V\G 5CE^2H52J%+2
MH'T,=>HUP?P7_(_J4JC_ #V?,?K7+K_*=O5=V7&&OI0PE0>>0*[]QK37SP!J
M?FOHN;E&.8!@] MV5$^F00J"Y%03_2FQ^J5?_#KM#LMETPG1N2RP'VIRU*>6
ME+B"X*5J* :ZWKKZ0$:*+WV>V['>%L09,:,@KF+:!-'$^6H3YCG!4BAF-P3;
M;6XLFUQ;A 0X)2E%UQMP[0".I%-0WU2YV=$3L7B!JG*8E5TDPHXAAN6\2])0
MHU*D]*#\=<FB5&') ZJ+WRQVR3>W[1<(#UMM[S12J='3N;J!6GP.A')T7=49
MXCDFN\-57[([<W8'H4''72TAV1N]]\[]K23U)KY'5"Y"R(LYU6K<(8GM&1JA
MGR%@N+7V]6?,+Q:6)-XMJE*ANI2E#CZ:4J"D D:SOF)VLB()/J5FXCD'8?&/
M-5#Y:><GYW.@6<H<6]#2A=D<.Q-0/,^FJ ^BR-X.3E:?Q$ %;;XJOV7YOB'$
M/'N:99R%#^L<M\50AN6M)<CL524A*".@4#XZ*<7Q$G(3!@\2!A!N4EDB]3!D
MA5[X@XN',4KC+F.0E^1:L>?7>V(;S:MZD+&Y!JKR&KYW'R1X=KZ6/#&GFO8+
MIG9M<-0NGG&LFR1LOD3/=<=9DH7+N6Y-?8Z4 2#JD<76<8M2,H'R3'1$8\4<
M+U#ES+YC<RTT^E(2IXK 4AQ)\SZ4U+PHE4Y<F6YWAFT\CV5EZ4B=;GVW&I"0
M*44@5H!IV%Y:?@I%IA=T"?UWJ)EUZCM%A42-9VERE2$U"BD=!T_#3[IR?%-?
M2[<$J V>]0D6J_SXC*GY\284-,4-7&POH1J$3HN;<T>5YO;&4WR)/O5QEM0+
M(HAP6E/S*"MM*]?#42Q"7MPB-+4>G0JG'+'$&'<K8RU=[[=',+3@2EW%[(%*
M*"ZTVK?[:S_=)&F.*DLBPUC-%:I.2@C@((.[P4[<Y ,[#L5_R=>F\AAO)8MT
MOZ97RM,(2 "/QIJ1RL3VV3N R/) ^WI"^<D]48N)'&'\VDS;B''';>T%-- 4
M;15- ?QTT;0:>J9YAN)_FG6Q\^89QURE:L ?,R?=\M?>?8?2A188423M*AT&
MKGV[=!QJJ9W/PX#<DC*Z,XA MZH*[J)(;N$CYFFDJ-/F_O:T7C[.W.JQ.XPB
MV/@MFUR9$J^3+9'BMR(--LEQPT 4?'5DIV<Z)JW(7#("+=OLMDM@*HJ?;?<*
M4;D'Y0M/^K5C@((5>L6G-&H3S%M\9T2_W)L*W':RI'B*]!HZW1H07WG$Y3;%
M@W2UOGZ2*9;+55[$J_J;3U\-=YRGF6'!.$B.UD"V([UO,-92IQMU\]=R=28X
M X94Z&8.&/%:EL9N[32VWF@[%AN%9<;\5 &E*::='A/OC:T9*E!=8:4I*$+*
M921)<W  ) \M3(9 T85?L,W%7 XBV'#;>M#7M)6MQ:4GT)\=:QVPX&NLF[C_
M -2BB=6%R"KGB(L=4B5"DMI4E:ENHV?R$J/]NL:D_&5K(F<1HM.XP8,3W'3,
M4TAT(89=:\0?0^FG72 -3U>RY_XDTRPQ9Y/O%MQ2G7&V7B?G!2H?J.J[8L$Z
MJ:&Y3+":G0[K<8CI7M<6I\N^265"HTU#:P5W \;U'H-T?FY2XW.D-&!! ;+#
M"@KW.O0D^5//4=\VNJ+W&':"I#?!'=E1DV*4E:7P52D=%-A"?$%7D=,VCZ5S
M3> A=D4F/8H<B=(EA)D5,9IQ52H@TZ#0*7.$<IC<\@*HMQR-F-RFTW.<4MIT
M)<=C()6D-J16I]!K.>:M;<K4*, V?8M'+KC<)EYM=SM\.MNC+-O##E2%,$U]
MRFJJV])U1NEQQ+"X>"D$N_6J%%LD5I:H5WGJ4W!=N"#L-#7^D#Y:F1W(_M3[
M:I)U6]/R:;=K6ZS:7A;<CCI4Q'GN"C:R#\Q(\!J0VT#T0JYQ[FO!4(D2',=R
M=A^:Q&G/W5E,FYO0TH2E*DI^91 ZG7ALQ@X<=4UR0>8M/!%2UJQ>^V&:PW(C
MRVKL\TW'C-C8\H@]37QH-63@)H<N!.I5-BDF8<^"8^0K0W N]MCP+>%)@@1V
MI9'SMKV> /IKCDJS6Y4^I=,SL.\$+TX[9+Q9E(EQG/??=<4N6ZDE7OU((^'X
MZJ5^B?;W@([6C#W #Q7'/M@XZY3>^Y+S4UBV1SO]U%DMBGI]LEO+5%>EN']"
M=YI7X:T<M@DXQI  >,)CE.*DKO#CXKM^^P[%PBZL6DJD71FB$Q5D@1T!52A1
M_'PU"J6&#(<H$<CB=4YSQ=[5CEMN[KPLZ9T(!QU:TD;@FJ@17P/KJJ]RV&-
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M-^;9;/R'MCSUS",JN3J'LB$]UQF/*4C^<$>/AH1Q=Z*H_P!0RK%RKI+D :T
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MI+SS84=Q_$^.C-&Q7;9(><$*G3<<#'GHC7,2/W*X1+Y+2N6I]I]332TJ+*:
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MRU2G'OHOZC4)]-4*\R.NLH.['5:VYK<KS.R26^[;D(81 4^HCV$)VCI\?CJ
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M+S=Q]G-BL,VW7F'*R\21$@-);2E:E#H:&G0:9X[MRQ2L.,A):@?<=6=F8W#
M'BNH>(W$7"UR8DM&]R5&0E"GR D.4Z]?/KX:TCC&!RRVU(6Z!/%G^G0Q;X]_
M?;2Y%4Y]+](FJR1T Z5U;JE0X52Y"(@$E2VV6]^7*AO7B1[4(.*<CI= +I3Y
M(\*T.K'5KEHRA?UI8W U3A*R#"<7<8^L?;L]VG.F.S5)*EDGH/E'AJPU'D80
MFY4+AN=XHU8[:FKFN+/=45MI274>RH[!0>=?75OKU&@950EF._"U<JO35J@I
MBPEA;DA59*P:! 'KI6Y"T:(]QK00M&VWF$E#'U+P0H 2$!8KO5ZCX:&1/R5&
MY"34IYEW%?L&5&!"'E NI3TI3TT5=,W&$S7D+BK9\22/JL/@O>JW$]?QUI7:
MI_RZRGN<;;9^**)U97=$ "YP75UB$I*V6/K5N.N)>CQ^A0=YI4G6,790,A;1
M'^$)L4J).+LN6XN F"0VH'Q'P!\]#7[''5%!.X-QA9GDVJVI:N"7-X>!4\]'
M!+BD@5^8#2EC9MZJ"R-Q.,* 9!'@W+Z)NUWAQ,25_B7&"HCYU*Z@C0:>4-Z*
M?6C<TDA;ESAQ8DFT.1Y0;]H!E26SN4OU\=1_J"I)DDR!A0'-KI<(OO,QI8=@
M(45JC-@E2MWB*>HT(Y&VX*P<;&'.P0A2[?'G[LWM=]N#.#+4A#=6WFBCIT^.
MJY<L.V95KLUVLB!;U7%7&>:;EQK]S7FGCR]2'1;,EC6^XXU^XK7[5-NPA*CT
M!-=2.<KP,XML@/\ $)Z*%4XVV^0$CT>:ZOW--NNPN#)FK^HFLN1;I[W4)4H5
M20?,#6378O<&?%7FCNA(VG51GA/"(ECGNGZM#TEUUTHG*2/ZA (\#Z#1C@*L
M1D >4N?EEC().04\9;CW,DZ[+N''4"WS+>T4"='F#:\II"J+** "M.HT0Y[B
MR#MCU0FEW!'NPJ#=U?9O;^9>:>-<\OEWF1)_&K7UK%FB*-%R5+"QN!\AY:$<
M1>M4*[V;1ZCXK08>09-5+?#*OA:;=<6)-D3'M;;TB4W&C267T_,"A(2%[OX=
M= ^%J RES]256N1>[)P-%M7MJ^0+E?)>06UJW6%24Q7'853)6XE7Z@:^%-7R
M2X3'[>-%#B@F>/2%YN335FQZ[W&SW1<^(VVAX"2:.!M0!->M>F@%J$M:2PJ5
MQ@>Z0M>,80=Q^//EYK>;G)FI799UN*W89/\ 2=<*:$^M0-!(8W2/]2M1K QH
MCVJZO6JTW:]OSDPK5:D!-FFO.!+2 D#HHG1+B.2]JP&D:*H\EQ9>X!G51+)\
MAC<HY9A:+9<6(Z&E(ESBOJ)(2FJRT?,:D\ZYHDWM\USQTLD <'#4%$\XM:G[
M9=BS54A,QN;%G-D;4);3U10ZZV @)GDN2GG(\ $W.0I<:W7:1:VU)-S0%257
M052/;ZG:#XZYCL%AZ91#C))''5-UCN\Q]./&7'4FTVYYZ:$1FJ-NG90 [?*N
MK'Q9^H;KHJ_RTL7O%I.@1:M4*'DJ8-SN45:)T4"5'@24*VH&[H4=?3PT3B?[
M3M%6Y1NT;T1+MDUYE$N-<'OIF" ]#DN(/N--J/6HT8C=[@U3(@P"I3BUT:VK
M8@7%4Q*W%OQWBDA)IXD:F,>X' Z(!9@:3G.JF7U;;ACE4PAU:S,*5@54A'11
MK_HU+!>TY 4-V_&%FB/-O-.38NXM(*W(Y<45;JGKN!_+1.G.XE1)X-/4OUVZ
MQTN>S#D):D+;0%L!55DGU3HE[A3/T3?-2F>_<';>EZXI"8L -G^DA(*@KH:Z
M>%HJ*^ -&5Y<9?;M<AJ$GW(LY/NLETG<D^51Z5U)=(0S*YAE =JO%MBRK6XV
M_?%M/7*2A+(?C?(G8.H  Z:%N:6@G*=]XN>-H5[N'HZ(V"6U#>[:I;KE'#6F
MY=>GPUN/;<I?4:5D/<#<6G*LG>I8(UTC<;W.3NV66>^\0@'KO; ZZJWYAC+&
M(]V*?XKCY*K[KK+A"PZ$.*"4M-@4!]*ZS01C"U#Z@J,W6(N1,D,NR/96=J4+
M ILKYIT*M0#=U7GU+O);UOQEFULO.,74NO+ JY*&[<KQZ$C7 < -$HYBYP">
MX#K3TI]MZ0@R'&Z$+2D%PI\J_#4JLT/!SX)R<[)<!#_()*[K<&(JUHMBV_Z7
MN0TA*R0>@KYZ'6!F3")QSEH4.Y$DY#9K(TUC:A-NSBDK$!0)4\E)^<#=\-1[
M,AB9D+ESLG*BLRT0LBMA8NK@MS\A"'HS3@W$OH^=2>@Z$'IJOO9+.<EQ"-<=
M'YE1:\7L/VEUZ,/I4PV5PKD%M[5!2$[1U&A/(\I[$9'4*_\ :?&Q_4./DOG*
M[Y?M_9+SUR7:N<(&;)A''4HFBW24K-!%=#J0".GS4U.[5_,.I1K2,:T%SP>J
M)<]VH[D)VD#&"ND';7>[[EN/V1+C :5 B-PYR4 I*!'2&S5)I6M*Z^?^3V"V
M7M.CBKO'QLD<0#@!CR1TSB%*>O5LC0WD" M8]YMKY5J0!1053J-6.:$/A].%
M%C!;(%3SNZS3E;!N*>4[?Q0U(=R-B&AO'(]N;+CVQT?,4T]-2^Q^*B=:(GQA
M/<Q'*Z/='^),WVU&<Q7P8K)>6Y$Z;F=S>4B[F]$A;.Q54@I6*BFK#WA:IPW
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M<H)P[+>LSB9+DV9/;\FRS>AWV7*H#1'R)J*^ T,[QY]UPC3 5X[6JR4';0,
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MI;RVU_X!M0]ECQ)KJ(VVIHI$)8]<$RXMM7(B.--$#8I8 ('H3IR!P<Y<6Q@
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M;2I6MJH?E5)+QOU$?4CH@MGF'=/%=G^W[)H>;P,6OC=N#<*XH0'9BB%*2A2
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MX06E4IQ/0J!H?'Q^&K]QTC7#*I'(OD8_;^ZB9A\1ZYL28%W@+8,9)98?1T
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MH(<AW%AHL/)? 6XZ-]/ _#3D%YS9@/ *#?XX^P[<BCFJ9EXPO(G)[C;NP-2
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MU@LUUD0FUMW+^C;[?$%%G:BGN;1X==<68VEX!&JJ%GD"V73H@[E/%4#D7-K
MEF_W&U_Y495=&(=M?6VR^]7<E+M/&FCD#=K!A=S>W*S)ZJ^6-1XZ,.@R+XXE
MSZ6-LE)!KO6!3KZ^&I[6%X))Z*E2&1DX#3H@Q=K):9KL"\65IJWW%*EMMN10
M/;<)_O@:@V",85M#I0!ZE(&%,FP>U.G&',>*S'?;(]MQQL4*0-0"\MT4BO&7
MG4Y4:LN00$W^[,6.,/W21%6W)D2_T+HGYMI]=0+5AP*,5*XSC"#>89U)5!MU
MDC0F[I*;D*7[C?\ V*DG^8^1UW9=D91B2C$&G 4JNV0W"UXG<Y-PEL2I[#;3
M[5M40=R7@ >A\AH-)7$IZJ-48YC\L&J"U_XXPJZW_C_.[YAT6/,A+=1+>C)'
M5M]N@6DCSJ=-Q<E8A);&"<_H1*^^RZ+^*?2J#Y3PZ[V?1N5^?HV-JN>-Y/<%
MN+2D%;BFG'-P-/3KK5^,NP\D(89C^!IU\$$N<:)HFF$8PKV=L/,^*9KB-JR^
M\XY^VQ[XA";&_L"FV KIN43X4U2.<XWZ>Z0UV6)[ZFS[8;)X(\3[9?K+FR(\
M"ZHG6C)G6I$B1&ZT%/E\.@\=.59/6@UJR0.J,.!P,NQ7*[ZN^.BY6R2GW[>I
M*:%+8\371[C)-KCE5'G=[P,(VM<DX9#D/M6>;%%[F)0J1:?=;3(/E7;6NK;#
M8DQD:!4:W+&S1P^U&? 9MS-IN<TO!EZ:"B,9'S%/X?#5W[;<&L(/4JG=Q3GW
MV8Z*.<@P8]T;M2))>C7!M]A;<B(HI)*5"M?AH]/8]O'Q1"X=]4>*/\>X>RF,
MX'BS.ALH2PISP6:>*M'N/L[VZK+7UOXA)&%MWW(&/H*^\S]:\D//(:/\X.BC
M!ARG-&F@6:#<$NP$(6VN0) #M".GN$> ^&B0(\T[69EQSHFN]"XH=@)B5CL(
M&UY"O/=J#,,^*(Z9ZJY/"*E?Y'A;_P!0==02/@JG^K6M]G_Z58IWG_K"C"KP
M.K)8_ 55@N7SDUMAUE],0N>XM]M^I)_2LTZ#6$C^:<^:W&J-S0/@M*3-@W6S
M.1PZ7I9>+8>8&Q+9 J ?PU)BE :=47C_ (;2L#4"]JAQ[9*83*@OJ&YUD .T
M^&ACY2\H:+Q6*_M2K;#2P)JBEDE+/N ;AZ)H-!;S2#E$N,M;I=5P/^XCVBYI
MW'W#![A&S24O&\3N"K]F&%6 EMZ5&#FY/5)'S"FJQ)=B@=N(6D0N:Y@ *ZR]
MLF<R^.L4L=LQW&OW*PVZWP[?#9N[O]9A3381\Y\SZC3W;7*1ME<YPR"54.Y^
MWGR2-<-?DHME*K@K)LGS!3/L3\E>2B=:&"=J&R?%('@#KSGXHY9=S= %;^/=
M#7C#''! 7)7N=X YLN'?KPGR?C-@%JPBTV1]N;D'S%EMU76BTCQ)]=0J<4,7
M&/W#7)1RM,9?PJ]&1X/9LUQ,0,RQR%D$M"#,88D .MO*;\20H&E=9QQ@Q*=H
MP"I=/E+%-SB/%&3 \.M]@Q:,[9[:U9H9MR6IT"U?*RSUZ;4]!TU;N*XB-C7'
M=ZBJ+?YJ=[W-=XK+?;@F9^S-;U2_V[VEM(+>U*D ]:TZ5U$DJGW%/BE-:!NN
M<H6]SO,]FX1MK66,V:7=F'HON^U88BY'M)V&I5M'3\-=68@TC<K)VK6'(R%K
M='#S\4 NVONKP'FOCEZ!A$Y4O((4LW&ZP)+90ZRLNGHL*\*>FH5ID4<0D:<Y
M1";CKD-APG86M"NSD#5RN6*1EJ1]9=[E'7$<D;RA3;2A_(I.H</(;PHE2O')
M9W'HJ;6+%YUHRART%O<J"VY-99 0I2RM7C4>&L_MUS)=./P^*T[D;,3:0:!G
M*M8NXQD8M:[+<(J(TB4H>TAX_*Z3Y#UU>:M"M#!N'XEDUBJ_WMV=%*7I\R:;
M59H-K;WQPAEEYE"4I"@.M3^&I]"8N?CP4>?VW-QT(1!7!@7.Y6Z'<V$PV[<V
MTN4\>@0LGKU\.NKE'",9*J]EFP[@5)I=H;>>NRK+);=@P4%-9"1O3N33Q&G+
M,+?:4CB+?N2=,*G3,#_+N1WVWWB:]*MDA8=3*C_,A*G%;MM/,#6:7VNB<2/%
M7*R\8T5=>YSG5OB+*^.+4SCDBY8//"7LDR6,I8CV_P @I93T'CJ17,LD9UR4
M8XJM&^%SW> 4KOUUE9-9HF387%:N6-R6FKG'FRGPXA<=-"XX$@FM/35.E,\5
MH$M1*MR\'LEHTR%<3!%8K-L#$]J6T428S(><M]-G44W)"?#KXC6H4+3I(F@K
M.[$9]0^U$:R7)NTRDQ9BEK2AY%L2A9.P;^H/X4/75MXX@=55+3MQ(4O<RZUV
M"9)3$E*^K%6=C 2I/C0T \=%IK\0. U"BPM/199T65(;CR&IHD_N#9D+2KHH
M^833RUXYP RO##G4%1UMYZ \S)OH]R6VG9'2TK>!N- .GA0:\1:W5;M4YDWF
M,IYIJ;)6RZMDEF2T?F( \/PU(9.0W"%?1A1VY93,A6^/;&Y7M-74^Q];4%7M
M*-"E0\]<^ZXKT5&^*G=AN<2>J!;(+CCD& GZ94BFU-1^.C#8A[>4$L2.;( %
MT2X?6E>!VHI-0%.IJ?@LC6W=K/+J@6,=P$_5.R@AW9W2';+)BZY@^5V2ZA"U
M)W)'R>>JQ^9#PV)B/]A F5ZH1)5;ISC4F-.0LL%+RFV5!/R$^IZZQ@'5:*6'
MR3Q/@7*%"$MM#+K<E7N,OE0J1Z&FGB#Y)Z.%SAD(<.YK@62W-5DE8LB/E^/H
M*'[O&4HN[%^"CY4TS(_!'Q1&+CYBTN.@"?7935LMR51DK3&6G8XN54MN*\:I
M'KIV1FQV%$@R_7"C\N#C&:0;6U>K27#;7Q,@LRT%LEYH[@4U\M2(IF-;DH@(
M7$;@57ON$QR_\HX%EMEP'*'<'R](5[%WC !UAQI!V)(KU22- >2NQDG 5JX>
M$V6AF<%40[,LM[EL*QJ\V/N%R6T7:X-3G;98IWU(5.DA*RG<I%:^%#35,YB:
MF)06@DX_2C\/%GCIL3'(*B/?!P7,Y?XSRC HKRD2K^EQ]J[QQ4*61[H0=WEY
M:S#@N>^@OF=XZG1;(V.O9HAH/5<E^ .S3BOAK'X?)659I_E_++&^++<H3JT(
M"5*<]O<"K5^[C[UM\H R-N68ZA+CN#J5O5(<$=,KJEBG&E@NK]NR+ 9Z)%O4
M:Y+>8P'^(24CKT\1K']D$;BPG#RCEJ]&^'<TY*GW+^?N\?<9NF[XW*NUC?D(
MALL,,="$]4*!^.DZBZ-I>1@*K17G%CB?-$?'\MQG(^*[!+N.)ICN%ANXI@ST
M['6.OG3Q/IJ6P@M"]@M.?'TPIW;I:G,*R&!8(A<8N+?U39D"BFU!( '7J*:F
M5 U1F':XDH;Q6'7<=N E%B'-:4VXI$HA"W*"A()U2[+GB<N\U8:L[@W*F=MQ
MV.,+GW28I-P<;05-CHDL C^6GCHU1R&]%%%\>Z/2JM9I<[5BJ;-F#KDEI%R?
M:@%QMPI4'5.!*5#X>5-1Z-=S[!T7O)\B# X85W+]?K>]A4V5,?2X[,@-17&R
M>JP&P00//17D9  8V_:@7&1DQ9<,>2'UJ_;SCV(2FHR=L@JBR%2!4;1X#KX:
MG<;9:YKL],*<(<NTT*XE_<F[J.1N.N=>(,<0INS8W 6N*56M1W/!;E$E[;Y#
M6J?EQVQQUNA-M_F']"H?=<UMER-LO\I6!Y"[C5Y.OAB5=8+%RNEJ$1V%+F':
M%LE("@W7SUG/(\;/7L>V-1G7Y+:NVF-AI;H^GQ5L>5>(.-^YC',<?S;$$76&
ME"5MS5&@BK2 :CR)&A5;N%_'3''X2@]Z@RU*72ZJBG<#-N?$/)7;]QM%N1&
M9;,:L29#Q(2&6W E#9/F?35\XZM-R=.68D!H:2/FJWSW.T*,S(HL[B<+M;PO
MRCBO'=]=M32ER;LEA#2(\+K*;;3\J5* Z[=-_EWR$E9P<Y9;WSPS[CW8<KSW
M7D*W<@S,4=>M@F,PF3'?7<B*/KI4$@^--:Y+S/U$^5GD7$F*'&W&%,43E?5I
MM\PN6]A;24H1%H$FHZ;:>@T6DL^@!1ZD+2_"9G[W)?GMVFVR_81";]YZ0L^
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M8=<JE^ =OV'\/YW>K_@=G;L0RQHNWB.V@)86M74J'D"3XZI$;IWC:1HM=O\
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M;KC:5-?4H*W7EIJX%?CY:$B4L.B-?PR=4.+Y"9MTEIF]SVQ;98"8T:/3> ?
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M!(I0ZS;A>1L57$/&&M.5>XBRU#L+_!#KM^[:K#P,_D3-HBBZ7*2\+[<,@?4
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M0X_D\XW"P*?7M#J9!J/:KY&NA/YJ5H98VQPZ&/0HO=IS>X)'Z%=26V%XQ%Y
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M7TULU;G:_P#MSF;1G",]SW8'1"%K0,KLU>K-?,GO./QLOCQHL!F&B.\ZPO\
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M#BR/Y?/1'E^T9N(K O\ 'HJ!S'$$6&'S78;%KI?K799<?));-TR:6NB),/\
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M=C;9%%'4&]2,8U&JN7;?MWH3KH%BPF]7F?;X\V^1$0)RZ,LJ2DA(>'173\=
MK,S ,A/2TW1$@IT92O'YLYO((SDE=Q<-Q1+<\ BE.G_)IPGVQZE+XZ-I=DH-
MN7INV90A-@NJI3LI\%V,EP(6ILJ\O[==TI YV0>JZYOTCX*Q^4XBUD5D_<YD
M=!EPE,24&8KYD*'IZZL$#@!Z5098&EP(3)*N#[L6T8W)?4U)>7[C[200G8/
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M:E*I"4I<#B=A7T)J/ Z^>^U.\#PO(Q6XV[WL\/VX6V_F!V7'S7$RT+#MD4H
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M-J:6OP">OAJZQR]M\-S5SN-EUDGU,9V1MZY(\5GKW<U>XRIPTE8L]IX#G'Q
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M]X3XVY7N]JO6>8';;E<[</<M<JZ,(=6TYXU2HBH-=._2.DU!T1%O<UG:(G:
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M >Z?\*G3':1S&\M<JY8>PMYQ"D,)CRFT.,K2/E5N!Z]=2?\ \8]P2.!?$/\
M$HTGYG<*W02./R&%&,C[,>:\@3]1(Q-D2(K83%8;EM44Y2A*B3UKKFU^4?,O
M&?:'^)%:'YM\*QH!D/\ A6@CL]Y^M&)&SV'!V8LA*B^ZVB<R \I7B%5.F_\
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MB>3H[BVRW)^""<[_ %'\9<9M-9^OQ5G\0^T9?<=Q:Q8Y+SN!,&.QQ;K241G
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H^>DDET^/YZ2273X_GI))=/C^>DDET^/YZ2273X_GI))=/C^>DDO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>p2bextention.jpg
<TEXT>
begin 644 p2bextention.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $0 B@# 2(  A$! Q$!_\0
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M>T=KD3ERJY]Q_P!KS?W8_P C_C1_:\W]V/\ (_XU\<>&;;PM)\4_&$NOZMX
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M$RI/+N)(;;DC^+&>:4J7*KW&IW=CVW^UYO[L?Y'_ !H_M>;^['^1_P :^/\
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MG'O\M &Q16)O\1_\\-+_ ._TG_Q-&_Q'_P \-+_[_2?_ !- &W16)O\ $?\
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M:@B"ZEA5I8AZ*Q&1U/YFH'\&Z#*9"^BV#&2V%DQ-LGS0#@1'C[G ^7IP*/\
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M_$/\)_S_ )?<C\U?^%4>-/\ H4]<_P#!;/\ _$4?\*H\:?\ 0IZY_P""V?\
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MD?\ 09A_\ H/_B*/[(Q/E]X?Z]93VG_X"O\ ,^]:*^"O^&K_ (D?]!F'_P
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M_C5'_"R/$W_0:G_[\V__ ,:KD_UFP/:7W?\ !.OZW3\SZ HKY_\ ^%D>)O\
MH-3_ /?FW_\ C5'_  LCQ-_T&I_^_-O_ /&J/]9L#VE]W_!#ZW3\SZ HKY__
M .%D>)O^@U/_ -^;?_XU1_PLCQ-_T&I_^_-O_P#&J/\ 6; ]I?=_P0^MT_,^
M@*YM_&<%KXPDT.Z58 R1F"<MP[MGY#Z$]CT)XZD ^1_\+(\3?]!J?_OS;_\
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M,?#\.D7\C0VE_)JD"P7#@D%(Y"VUV!!R 2>#75 Y% $MK_Q\P_[X_G11:_\
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MF (^<]C74[D_YZQ?]_%_QKVGX06%M/X'C>2WBD<ZAJ&69 2?]-GKM/[+LO\
MGT@_[]+_ (5^48[AI8K%U<1[6W/)NW+M=W[GWN"P"IX6E#FVC%;=DCYBW)_S
MUB_[^+_C1N3_ )ZQ?]_%_P :^G?[+LO^?2#_ +]+_A1_9=E_SZ0?]^E_PKB_
MU37_ #__ /)?^"=GU+^]^!\Q;D_YZQ?]_%_QHW)_SUB_[^+_ (U]._V79?\
M/I!_WZ7_  H_LNR_Y](/^_2_X4?ZIK_G_P#^2_\ !#ZE_>_ ^8MR?\]8O^_B
M_P"-&Y/^>L7_ '\7_&OIW^R[+_GT@_[]+_A1_9=E_P ^D'_?I?\ "C_5-?\
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M?"<4,NM:K::7',Q6-KN98PY') SUII-Z(F4E!7D[(UJ*X[_A<O@7_H;M'_\
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MSIO;^\?SHWM_>/YU]%_\,3>)_P#H-:1_W\E_^-T?\,3>)_\ H-:1_P!_)?\
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MM<+XD_93U_P)H\VOW>J:;/;V#1RO'"\A=AO48&8P._K7M3?"3Q'N.(+0C/\
MS]G_ .(K\HXWH5,SJ8>6#CSJ*E?ROR]['Z#PKE&.R^-:&)I<K?*UJGW[-G'>
M=)_?;\Z/.D_OM^==A_PJ3Q'_ ,^]I_X%G_XBC_A4GB/_ )][3_P+/_Q%?F7]
MB9A_SY?X?YGW?U>K_*<?YTG]]OSH\Z3^^WYUV'_"I/$?_/O:?^!9_P#B*/\
MA4GB/_GWM/\ P+/_ ,11_8F8?\^7^'^8?5ZO\IQ_G2?WV_.CSI/[[?G78?\
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M1_8F8?\ /E_A_F'U>K_*<?YTG]]OSH$TF?OM^==A_P *D\1_\^]I_P"!9_\
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M?_B*/[$S#_GR_P /\P^KU?Y3C_.D_OM^='G2?WV_.NP_X5)XC_Y][3_P+/\
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M3_P%/^-'_"4#_H%:I_X"G_&MJB@#+LM>%[<I#_9]_#NS^\FMRJ#C/)K4HHH
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MTS2B''R A<9_(_E7;@I1CB(.3LCYWB*G5JY57A13<FM$KM[K:VI\7_VE=?\
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MK_H&7?\ X#R?_$T?\(7K?_0,N_\ P'D_^)H^IX__ )]3_P# 9?Y!R5.S./\
M%*1#PYJ!%O;@^5U$" ]1[5JM'%N/^C6W7_G@G^%'C7POJEAX3U2XN+"YAACA
MRSO X Y'M6XW@O6MQ_XEEWU_Y]Y/_B:ZI83'?5X+V<[\TNDNT/+U.>-.K[>6
MCVC^<C"\N+_GVMO^_"?X4>7%_P ^UM_WX3_"MS_A"];_ .@9=_\ @/)_\31_
MPA>M?] R[_\  >3_ .)KE^IX_P#Y]3_\!E_D=')4[,P_+B_Y]K;_ +\)_A1Y
M<7_/M;?]^$_PK<_X0O6O^@9=_P#@/)_\31_PA>M_] R[_P# >3_XFCZGC_\
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MHG]C#XU:Y\;_ (7:AJGB.XCO-6L=4DL9+BVMXXX' CC<;'C=XY0/,(WH1V!
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M_P">,G_?)H^RS?\ /&3_ +Y-=M'%U:$>6#T/)Q668;&5/:54[VMN8?@_29M
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L?\\9/^^31]EF_P">,G_?)H +7_CYA_WQ_.BI+:VE6XB)B< ,,DJ?6B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pipeline.jpg
<TEXT>
begin 644 pipeline.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_X0NO17AI9@  34T *@    @ !P$2  ,
M   !  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    4    <@$R  (    4    AH=I  0    !    G    ,@   !?
M 0   %\    !061O8F4@4&AO=&]S:&]P(#<N,  R,#(V.C S.C$R(#$X.C$S
M.C0V      .@ 0 #     ?__  "@ @ $     0   KR@ P $     0   2\
M        !@$#  ,    !  8   $:  4    !   !%@$;  4    !   !'@$H
M  ,    !  (   (!  0    !   !)@("  0    !   *@0        !(
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M0DE- ^T      !  7_RL  $  0!?_*P  0 !.$))300F       .
M     #^    X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-! H       $  #A"24TG$       "@ !
M          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300
M   "   X0DE-! (       (  #A"24T$"       $     $   )    "0
M   X0DE-!!X       0     .$))300:      -#    !@             !
M+P   KP    ' %( :0!D &4 <@ @ #D    !
M  $              KP   $O                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   $O     %)G:'1L;VYG   "O     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   !+P    !29VAT;&]N9P   KP    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!!$       $! #A"24T$%       !     ,X0DE-
M! P     "IT    !    @    #<   &   !2@   "H$ &  !_]C_X  02D9)
M1@ ! @$ 2 !(  #_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M #< @ ,!(@ "$0$#$0'_W0 $  C_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&
M!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /2,OK71
M\*WT,S/QL:Z [T[KF5N@\.V6.:[;H@_\Y_JU_P"6V%_[$5?^E%1ZY]7^G9?4
M!E9&9EXUN2QK-F.&EA]'?L<[=CY#F._6;/SUFCZK]!L!8.H9YWD;AZ58F1[9
M_4/H^U/$8UN?L8S*=Z1'VO0_\Y?JY_Y:X7_L15_Y-+_G+]7/_+7#_P#8BK_R
M:Y>SZB_5:ZRVZS-SWO+MUC]-2]T;M,3]_P#=4\?_ !;_ %9R6EU.5G$-,$DL
M;K_US%:CPX^Y^Q;Q9OW(_P",[E_UKZ56\"G+PKVGEPRZ61S^:]R:KZV]+?8&
MV9.)4PDCU#ET.@ >TEK+-WN7&9G1/J9AY=V)8SJ#GT/+'.;97!([MG:@_L[Z
MD?Z/J7^?4G^R*_2^QKGGH@D&6,$:$<3W-WULZ2S?Z6=A6EH.QOVFL;C&C=^[
M:W=^\A5_7# <\BR[#J;V><NETC7\UCEQ)Z=]39,5=1CM^DJ_N2_9WU._T74/
M^W*O_(I>R.TOL5]_A^]C_P 9[^KZT]$<#OZCA-(X_6*__)(;_K;TMMVQN3AO
MKW "T9E T(;+]CG[O;+_ /,7"CIWU+_.JZCY194G_9WU(_T?4O\ /J2]D=I?
M8K[_  _>Q_XSW[?K/T(L#G=2PFN(DL^TUF#'T9#U6M^M_3F &O)P[B>0,JID
M?]N.7,=(^JWU0ZL^ZO'^W5OI:'D66,$@Z>W8QZM#Z@_5^.<K_MUO_I)-,81-
M$R^QFQY<F2/% 0E$]1)W:_K?TQ[9LRL.EVGM.36[\6.5FSZS]":UQ9U+">X
MEK?M-0DCZ+9+]K=RYG_F#]7O'*_[=;_Z21+O\7_U7IL%;WY4ZR1?4-L?O->&
M/]WYOL0K'W/V+^+-^Y'_ !G;9];^E%H+[\9KB!N'VO&,'OKZZN4?6#HV1<RB
MGJ&);;8=K*Z[V.<X^#&-=N<N2'U(^JQ,;<X.B0TW4@D C=M$_F_35[HOU-^K
M=.=1G8=EYOQG"QM;[JW1(<UOJUU-=['?UDC''6Y^Q0EEO6,?M?_0].R,GT7L
M::['AX<=U8#@-L?2_.]^Y"=U%C3 JO>=P#@UFK09][F_N>U2RQA.LK9E-J<Y
M\MJ%K0Z9@/:W=^][57KLZ*/TK/LX%>TEX8!LXV;C_@MNW\[Z"*$SL_:2#1D&
M)XKF8,=E:;J =1.L'E5AU'$(:1>PAQ(#@#$CD;D:JT7,%E3VO8[APU!_%)+C
MY-/0CD6F_#KLN+CZCS6TDN_>W$H7H?5S_N!7_P!M-_O6C9;ABQP>ZG>"=VYN
ML_RE'U<#]ZC_ #4\'3:7VM<PC9_F_P#%BY;\/HA>XMPJ@TG0>FU1^Q=&_P"X
M=7^8U7;7XYL<6FO;.D#2%'=3XU_<E?A+[5>W'_5?XL4%6+T!H/J8-9)(C]&T
M_P 58HP.@9#BVO!I!:)UK:-./-%Q[,4!V]U4R(W-5FE]#BX4.K)CW;!'PF(2
M)-?I?:F..-B_;/@(Q8X^#A8@L^RT,H]0>_TVALP';=W]7<JPX"OG=!U'!['P
M^*SQN@<?C_>HV8  4  .P7^95V\4-+K+&AT2"=@>XC]T#:Y[E1]WE]Q_O5W)
M;7M<^]C+&5R[6LV1^;[6#>[=_422B^UX) =J9X(I>3SLG^9_>_\ )JU6UH>"
MT 2>6@"?\T*B3TW:/T5.TGV_J[B)!VS]#][8KM5?IN;6UK&,:8#&M@ :_1 .
MU$J?_]'N^K=4Q:LO[-8RWU*V!P?7<*=+#MC6VK?_ #:I#JN$W<P5Y1B6S]L!
MY'9QR_=]+Z:V\S%]5[7LQ<>]T$.=?H1J-D?HKMS?YQ!;@$EI?@X;6R-X W$"
M==KO19N=L41CGL\.0 7H*6D2O=RF]8PBZ15EZB3.6(@@-_.RO;]%1_YP=+QK
M@XX^1O\ I0;A8TS^<[=?8S=[5T'[-Z=_W%I_[;;_ .13_L[IXXQ:?^VV_P#D
M4WAYG_.C_%14NX>:L^L72+'N>[&N+GF2=[1J?[:C^W^C?]QKO^W&_P#DUL68
MK_4=Z=%.R3M]E?'W)ABVR)HIB1/LKX^Y1\?-[<9_\+6<'@/\5Q7=<Z:7$MHM
M#>WO;_Y)-^W.G_Z"S_.;_>MF^C&%SP*JP =!L;_Y%0]'&_T5?^8W_P BI:YK
M_/#_ !$^UX1_Q0Y;.N]* ._'M)[0]H_[\C4_67I5+BZO&M!(@DO8=/F]:V+C
MXKFOFFHP1^8WP/\ )1_LV)_H*O\ ,;_Y% QYK_/#_%2,=&QP_P"*XQ^MV#!'
MH6ZB/I,[_P!I5Q]8\3_0V?>S^]= <7$@_H*N#^8WP_JJ@*<:!^BK_P QO_D4
M.#F?\['_ !%U3[_@YW_./$_T-G^<S^]'M^M72[M+<1]@!) ?Z;@"=.'.*M>C
MC?Z*O_,;_P"16@[%Q XCT*N3^8W_ ,BEP<S_ )V/^(JI]Q]C@_\ .+HD1]@T
M' VU=N%:P/K)T^W)HPZ,=]0L=L8 6!K9D_1:Y:GV;$_T%7^8W_R*E5CXS;&N
M;36' R"&-!'P("0AS-B\L2.OI54NX^Q__]+T'.IS#E.?4RQU<-/L>X>YL[O:
MW,QV_N^WT/\ /0CC]2]H:RTL#!J7OF9^C_3_ '?O/>_\Q?-R22GZ1^SYY<UP
M9>TC7:7DC=[0YSMO4/YOV^RM*O&Z@7,%K;VL=H_989;^;.]V<_\ -_X+Z:^;
MDDE/TYBFRD #&R3N:"XVVLL@C=I[LA_N_P"+1&Y>08G"O:3VW4_PR%\OI)*?
MJ+[5?!_5+NVDU=_^O_F)OM.1(_5+8.A)=5IY_P ]]%?+R22GZ@&7D'_M%<.)
MEU/\+W)G9MX^CA7ND2(-0G28]U[=O[OO7S DDI^J*W.>P.<PUD_FNB1_F.>W
M_I*2^54DE/U4DOE5))3]5)+Y5224_P#_V0 X0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  -P N #     ! #A"24T$!@
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M 0$!             0,"! 4&!P@)$   !@$" @,&#0T,!P0(!@,! @,$!08
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & ?_0^_C & , 8 P!@# & , 8 P!@# &
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MQ?))#W0QW6XG[&E=P>(;5_WFAO*'TEGS<'M7<7R20]T,=UN)^QI7<'B&U?\
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M0A!/+3Y#J=V3FX<V\/FP<LITVS!%2#701(VHQ6OU8)52IJP;D6YPBR58AO\
M+O8SS%Q!Z-?BD4&RCE12-B GW2"J9%A,W<),1!R9!<"*]7X0$$,ZW:*Y0<O.
M)!M?G6'G2-$4H/-KJ'BR.8WF5B^,$A30EI47,MFF"TPI.FT\CW-Y2H-6RV;E
M[L4?!)##CXQ00;O"J)V%<C6,62*Q66.J@[64*DBLF4R9E! @&XNC)DZPW*8Z
MRV8D:=JOSIE0QO>HN*R):O=)6&]_50U4SHJT(M2K16=CGD:YO&EK8T=;8&=]
M]4E&2]R912'8%@/&5]<C:57%9%R=$O85%"E=$,<#HB/X0I<A-8KDK%?SB014
M3SK5IR9\AF[4+%4FI+YE;2HJ^9OK<7+FRP+HB>1??!]"7:'?;?6EEOA7K)3]
MO:UM&VKW:498UP9.W[57QL1X5!,RJ38#M2E(H5P41,4X 7IJ?K#(16JCF\VJ
M.55C59A&B&S3F+Y6H=\5'L5KDG(YC4;9546VBJF^C1%$HH6U6BT%I67D@YN:
M?59>\678"?BZC QBMUE9\2,UD$XALX[&X>%[,NH91)NK^#<&3 W4FZ%> <ND
MZPW-[T8V8D56'GS>?)GR&K>M1<5DRG3'25LM2U'8C!5\B+0N;+ I,QR><T\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P#]'+S!W_ -J/E?\ QMX__L.=S\P_47_>)W^7_E:?T/\
MH3_\M=?\_P#_ $>>Q&>(/KI__]7[^, ^>_\ ZE__ .W-$?\ \DU7^H2N?2/I
M9_N:_P"!?S0^#_<5_P#/I_W&_P#*X^-GENYNK!RS[:[UURD,'3/<3<22H-MH
MU_CW9$2P+ZC6$T\4ZB!DS"N5?7JQ*!BAIJ!M0'3/N.*X*V]S9;G>JU'(J9[2
M0/Q[JUK8_#;M.;+14F/66K71]56.M50IC^(GIY;//;PMSO$_9C\OKBAQ2\CM
MWN;4V%!<4Y=W$6BAU]U @5HI::[,(-6:I7!3(*-D".F_!H100.8N>2DZA.ER
MT;SEI8.18VJ4<J+3!R17/%8+F/IUY^LTJ;/<]9%E(RW)9L[US&JVA7,<B)31
M!$5L*%5%5#44?.+Q;JFEKTKM6ZD)=?9JV<K<M+'E&I$W+^T7M2ZGDS$2:$T2
M+UHI'1#03#J8!+W,[?9ER3+2/HYQKZLB-LPK/(+]06+)L++55YA\I::U=,MV
MJO-#;-IW_GC=MDH]2/JW+Q/5^--,VNYP]53LD.G"UX+1M-(;9^+8ALQB6P)-
M&JCP'93'XE5!X@.83"!@X[=2)T8NF(JP1(P6*P>CXK36L(9CU4WZN72S"7(5
MJ1<J):H;:E.EP:B-2")&.=<N<U\J/G+JC7F$'&SFP9KS$Q6TFU7+#(UBQ3!/
M%LG\7-V0MKE=P1)N!NS/R)"AU)1XB:ZB8W<SI3M5'N5529!5>]\42E+35;GK
M2LX4CZE26M:UTBVB294M45:%YMZ/6-%2PA#)&M3;ZB><CV#WH?7"OW2"F-NZ
M=1]I>8B$C%;_ &F"0=3*FY01SII!1(1L:Q;-56_9A09HII"4Y0#4@B)M>)>-
M5[S(1JM5'.=,E5(M%F-*TJJQC2>MN7U"N%]<]KT5C&2;PE+DBO.651K8-1$A
M""(B0V#"-%\[C4Z'8]NCQVP\FYI.T$SL\_H48]L#0\JI#;4Q4LP%*0= R BC
MM\I*&4XR$*FD!0(!1#0<Z-XU,?,8Z,Q+3T?&BB+U1:$C4D/.<*Y_5:3(FRX2
M5L2W2;.^IA*1R4K9I5UJ-20J@86IGG((RG[?T&GI[6/7K^B[1;S<M"$BK+H=
MG6?[JV]6TH21D3-A'JF76 FJCQ<2HAJ!B]S-R\:JNF3G/MI2]CJN B)"O+#S
M'-N'U*9)N39'-*JME361CEF.<Y%A#)&K+"M#+S#SND-4MU+7O%1-AW:%IWRW
M%@.8OF,B[98B/&"[R$A9*&,QK@H,TEF"2WC9PJ"JQE5"> 0-2%'7274ISY22
MW3*&,5K8)G5%BZFFI,QU.]QDN\K/ER=],F-F3$5T4BB.2#:$5J+:58TJE">7
M1_F;YD=M]W-I^6+9C:W;^<IE4Y:X^S0#&3W FF<Q(2Q;%.FF^L4%BT:)I"F)
MQ)PD+PCIJ&@B.>BPG"YLB=-FS'(JS%2I((D$AG4\+K1K'=KW=;M=Y+'-;(1R
M1<L56TZUD1$3S&F&=T\2, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , _1R\P=_P#:CY7_ ,;>/_[#G<_,
M/U%_WB=_E_Y6G]#_ *$__+77_/\ _P!'GL1GB#ZZ?__6^_C -$?.*<B]=\X9
MR\#L#9-P'NV;="<CK['VF"9(2"B;N-2<(D(HW<*) =,P.3:@!RCT!TYZ#5K6
M!V&WGGFMM4*D*J_^!XG7[4N7CUPZL]ZLWR.BB1I1%2JC/G/!7Z*E2_\ G8E_
M(9C[LY]$[WYG0)QO0?#/"_(^<7B?UCZ*E2_^=B7\AF/NSCO?F= G&] \+\CY
MQ>)_6/HJ5+_YV)?R&8^[..]^9T"<;T#POR/G%XG]8^BI4O\ YV)?R&8^[..]
M^9T"<;T#POR/G%XG]8^BI4O_ )V)?R&8^[..]^9T"<;T#POR/G%XG]8^BI4O
M_G8E_(9C[LX[WYG0)QO0/"_(^<7B?UCZ*E2_^=B7\AF/NSCO?F= G&] \+\C
MYQ>)_6/HJ5+_ .=B7\AF/NSCO?F= G&] \+\CYQ>)_6/HJ5+_P"=B7\AF/NS
MCO?F= G&] \+\CYQ>)_6/HJ5+_YV)?R&8^[..]^9T"<;T#POR/G%XG]8^BI4
MO_G8E_(9C[LX[WYG0)QO0/"_(^<7B?UCZ*E2_P#G8E_(9C[LX[WYG0)QO0/"
M_(^<7B?UCZ*E2_\ G8E_(9C[LX[WYG0)QO0/"_(^<7B?UCZ*E2_^=B7\AF/N
MSCO?F= G&] \+\CYQ>)_6/HJ5+_YV)?R&8^[..]^9T"<;T#POR/G%XG]8^BI
M4O\ YV)?R&8^[..]^9T"<;T#POR/G%XG]8^BI4O_ )V)?R&8^[..]^9T"<;T
M#POR/G%XG]8^BI4O_G8E_(9C[LX[WYG0)QO0/"_(^<7B?UCZ*E2_^=B7\AF/
MNSCO?F= G&] \+\CYQ>)_63\7_TK&W#>4C'$WSESLG"H.$%YF-CJ=',W+EH1
M4IEDDG"DFX*BH<@"4J@I' HB B0VG".+_J]-@L)"1_Q>@SE?;!=D<EJ]JJ1I
M@R"PRP6TL/+!?(IE,?\ IMN0S4=-Q-U0#Z@#8:N/_P#K><OO8Q+@2]"\H]%X
M:\ Z2=QF?_YD/HVW(;\HNZOE#5_\.8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%
MW5\H:O\ X<QWL8EP)>A>4/#5@'23N,SD#Z-MR&_*+NKY0U?_  YCO8Q+@2]"
M\H>&K .DG<9G('T;;D-^47=7RAJ_^',=[&)<"7H7E#PU8!TD[C,Y ^C;<AOR
MB[J^4-7_ ,.8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%W5\H:O_AS'>QB7 EZ%
MY0\-6 =).XS.0/HVW(;\HNZOE#5_\.8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E
M%W5\H:O_ (<QWL8EP)>A>4/#5@'23N,SD#Z-MR&_*+NKY0U?_#F.]C$N!+T+
MRAX:L Z2=QF<@?1MN0WY1=U?*&K_ .',=[&)<"7H7E#PU8!TD[C,Y!3+_P#]
M.#R*56L1$U';B;IJNGZY6JR;R?K!B 44SGZ )7"CKJ4/JX[V,2X$O0[E#PU8
M!TD[C,Y!ACY@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[
M<KGN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'
M23N,SD#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KG
MN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N
M,SD#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KGN!C
MO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N,SD
M#Y@7DN^'FY/[<KGN!CO8Q+@2]#N4/#5@'23N,SD#Y@7DN^'FY/[<KGN!CO8Q
M+@2]#N4/#5@'23N,SD ?,#<EP (^_P W)_;E<]P,=[&)<"7H=RAX:L Z2=QF
M<@V!9_\ 38<ACBJU^<4W&W5!W+)D5<)DL%7!,HF()AX0&MB/U/1QWL8EP)>A
MW*'AJP#I)W&9R#H^C;<AORB[J^4-7_PYCO8Q+@2]"\H>&K .DG<9G('T;;D-
M^47=7RAJ_P#AS'>QB7 EZ%Y0\-6 =).XS.0/HVW(;\HNZOE#5_\ #F.]C$N!
M+T+RAX:L Z2=QF<@?1MN0WY1=U?*&K_X<QWL8EP)>A>4/#5@'23N,SD#Z-MR
M&_*+NKY0U?\ PYCO8Q+@2]"\H>&K .DG<9G('T;;D-^47=7RAJ_^',=[&)<"
M7H7E#PU8!TD[C,Y ^C;<AORB[J^4-7_PYCO8Q+@2]"\H>&K .DG<9G('T;;D
M-^47=7RAJ_\ AS'>QB7 EZ%Y0\-6 =).XS.0/HVW(;\HNZOE#5_\.8[V,2X$
MO0O*'AJP#I)W&9R!]&VY#?E%W5\H:O\ X<QWL8EP)>A>4/#5@'23N,SD#Z-M
MR&_*+NKY0U?_  YCO8Q+@2]"\H>&K .DG<9G('T;;D-^47=7RAJ_^',=[&)<
M"7H7E#PU8!TD[C,Y!1-Q_P#IQN16H0U>D8S</=)9:64,DX*]GZP8I0!+C\'@
MKI?J^CCO8Q+@2]#N4/#5@'23N,SD&(/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-
M6 =).XS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_M
MRN>X&.]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =
M).XS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_MRN>
MX&.]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =).X
MS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_MRN>X&.
M]C$N!+T.Y0\-6 =).XS.0/F!>2[X>;D_MRN>X&.]C$N!+T.Y0\-6 =).XS.0
M=S?S /):JX;I&OFY0%5.1(PA.5O70Q@ ?_R#'>QB7 EZ'<H>&K .DG<9G(-C
MY[_IH^0>+<H(H;D;KG*J3K1%6PU;77B$/J5L,=[&)<"7H7E#PU8!TD[C,Y!1
M/HVW(;\HNZOE#5_\.8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%W5\H:O\ X<QW
ML8EP)>A>4/#5@'23N,SD#Z-MR&_*+NKY0U?_  YCO8Q+@2]"\H>&K .DG<9G
M('T;;D-^47=7RAJ_^',=[&)<"7H7E#PU8!TD[C,Y ^C;<AORB[J^4-7_ ,.8
M[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%W5\H:O_AS'>QB7 EZ%Y0\-6 =).XS.
M0/HVW(;\HNZOE#5_\.8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%W5\H:O_ (<Q
MWL8EP)>A>4/#5@'23N,SD#Z-MR&_*+NKY0U?_#F.]C$N!+T+RAX:L Z2=QF<
M@?1MN0WY1=U?*&K_ .',=[&)<"7H7E#PU8!TD[C,Y ^C;<AORB[J^4-7_P .
M8[V,2X$O0O*'AJP#I)W&9R!]&VY#?E%W5\H:O_AS'>QB7 EZ%Y0\-6 =).XS
M.0/HVW(;\HNZOE#5_P##F.]C$N!+T+RAX:L Z2=QF<@?1MN0WY1=U?*&K_X<
MQWL8EP)>A>4/#5@'23N,SD'NKR9<M-!Y0>6_;WEZVQDI:6I%"-+GAI"[N&KN
M34&6G'DTMURK)LS2-HJ[.!>%(NA0 !U'41\+C.+3;]>73YB(CG0JJH1$V<Q]
MBU4U9N^#W!ETD*Y6,C"U!5I57+&"(E:YC:+.6>B/_]?[^, 8 P!@# & , 8
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MG9R=NB)?<Y*'/0VLY(V>Q2L7.M*]Q5=+KII!G-.V2<>]<1X ;M3=JNHJEPF
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M%VH:*\I97*_YS2(WQ'E]K5QVBD*A<=XF%9;S\O"R44^AHFR6RL25QCH]-('
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M1 0']S/('=,I5K_@S3ZZG\:; *[@'__2^_C & , 8 P!@# & , 8 P!@# &
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M+3NM$H0UOV8KQF:4HRMC@\+#13)9VX9/&K_J72B3;5=LX.R0!R@?4BQ4RE.
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M[*;+U.:A;+5-GJI5['6VCB KEAK=;AF#^/8.W"CM=LU<-6R:B**JJIU%$R&
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M/.5RIWZ"NMGIG,#5;)7=N8SWZ7:;BY=JHUCH?54H/55.+A[.(HG %0$2B("
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MYV\WDY:XR\4Z/Y>-SW-ENK"QOX*4D;FPE[$@14&H=J>]G,S0=%'PU%5%%&@
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M"8@"(IF*.H /U,OEWB8QJM:Y41:X+7Y2MTIKE151%5"^Q'7I'I$>D1'*2P8
MP#*=:_X,T^NI_&FP"NX!_]'[^, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M0X!U*'$;H'H#T< <!Q$  @B)@XBAH/2& 6KOB C5Z5H&NJQP#3_P^ :T<)@
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M"IJ ^"/[OH8 %-0!$!(("4.,P" ]!>[K];  )J")0!,PB<-2  #T@'H>E@$
M(<0*8"")3CPE$ '01] , "0X 81*( 0>$XB ] ^@/I8!$4E $P"F8!('$<!
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M2VBYI^7S?9O(.MK-THZRHQ4?'VB0Z[M$<9./DV7;T5N&43;&$I4M>NT 11,
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M=X[.AIU)U5#(\(:!PB<1#0/K9X=#T1+8 P#*=:_X,T^NI_&FP"NX!__6^_C
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ML!98^#@-Y)@;#NP^VPJ$!4H^0CWKMB24C&\9$%*5-%]',NPG57577 AQ$5#
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M_*\;X9!^:?P\=MDZ/;'<_P#ZC]/I'^5XWPR#\T_AX[;)T>V.Y_\ U'Z?2/\
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MM1_6_P#NOX6.VWN]L=SZ_,?I](^+4?UO_NOX6.VWN]L=SZ_,?I](^+4?UO\
M[K^%CMM[O;'<^OS'Z?2/BU'];_[K^%CMM[O;'<^OS'Z?2/BU'];_ .Z_A8[;
M>[VQW/K\Q^GTCXM1_6_^Z_A8[;>[VQW/K\Q^GT@=M1#I\;_[K^%CMM[O;'<^
MOS'Z?29F:\K)G->AI[WY\'C<A5NS"SUX.(HFTUX^GN>ACMLG1[8[H/?_ *?2
M='^5XWPR#\T_AX[;)T>V3W/_ .H_3Z1_E>-\,@_-/X>.VR='MCN?_P!1^GTC
M_*\;X9!^:?P\=MDZ/;'<_P#ZC]/I'^5XWPR#\T_AX[;)T>V.Y_\ U'Z?2/\
M*\;X9!^:#]_D]MDZ/;'<_P#ZC]/I-HH6):P41&PK$O"TBT4V2 = "($+H)AT
M^J8=1']T<\/>9[ILQSW5JL3Z_<+DR[2&2F>JU$1"IY2;8P!@# & , M;?+^Z
M]*_''_J^ :T8 P!@# & , 8 P!@# )EE^6L_QR7W88!O)</RYI^)'[L< M+
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M ?"',Y_W#ZV3$F?^6B6W1H8S>UT-WJP2FI8U)2$UBOG2+M;AP;<XO-:T9P+
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M-F,:".T%]Z1=K<.+?F]YLFS1%F3F2MBB:$V>^E5<.(Y14SH[H78MC',RU,Q
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MJ[&V3VBOW2+M;A)L.:WFACO>?U/,'9U_>0@JPC.W+QZ_:R*H@@)G_6-![6<
M#4IE=1 W2'3ELW[A=;W\Y_Y<+:QH8S>TQ@S>T)DIC0$UBOO2+M;A(H<SO,XA
M'1T83F*MQT(R84NR+A9ZS.X4<JN5'0H*JBTXE&@&4$I6YO  H 4 T ,M=]Q6
MMZO5W6DI;9A89!*(6DH]?+&J,:".T-]Z1=HF7_-/S/R#2V,U>8:U()W)PC)2
M*K%TQ15:G1211 K$Y&@"U3$$0$Q$] $1,(])ARN5]P^M['2UZW&PD*6,@ZNE
MV]I6FBJA$':*^](NUN$T]YL^:-])V*65Y@;*BO9HXM:>MF:L<BV;HE%4>M:(
MD9\*#C\*.JQ-#=!>GP0S"7]P>M[6,;UN-ET8JQD5JH<MFEM%5%:TCM%?>D7:
MW",?S:<TD:YK#M'F!LBZE3CS5M@F_5CETW*)BH$ZUX11F(.7'X NBRFIM1-T
M^$.)OW!ZWO:].MPMNC0QD6UT-WM#::J:DIH)[17WI%VMPD&W-%S.M6M79I\Q
M%L43J3Q><8*N';)15RJXZ[B3>G,TU<HEZX>!-34I="Z?8AEK_N(UO<YZ]:1+
M:(GJ,@V$*6T4*L*5IK6@CM#?>D7:W""G-%S.JMIQJ;F(MA23\NE=':B;MD51
M%RDJBL"#8X--46@BB &;D\ 0$P"&AAPW[B-;T5J]:]5MGU&4U[Y:*7TT+0D4
M2@=H;[TB[1./^:_FBD5K:NMS!69 UR9HPDB1@M'H$:I(I'1!1B5-F -5A!01
M,HGH81 !'I ,KD_<)K>Q):=;C86-+&;[8=O:4S)11&D=HK]TB[6X>_7FU-T=
MP-U^71S,;CV9:W34!8'U4934D1 KD[-LQ9+I@L9N1,#G RYM3B74?JY^Q/M_
MUOQ'&\$?/OLSG)B37-C!$H@U42A$2B*PV('O]6;[-GW973%BL53\CT%S[B>B
M/__1^_C /,GSLG_TM,?_ -UPO\0\S\X?=+_\RW_O,_)QY77#_P!3_,G\3R8Y
M6I)&"V>YH[ +R8BG,6TJH-)K;U!HM-MQ6F%$S=F[88A0 X=!_"#P<_+7TRO#
M9&$8G-B]JM25!TM$5Z1>M4:*<NP>-PA]F1.=2D(55UFTG*XX;6R.A[!**R4Z
MLZW;! D_N,T:GFQ;I[;/SE[05'C)X!R\12E-H(  ]W/I7TS>V]2V37JYZK?/
M6F(EN"79]<(I0M*(BY$RG7PA4>B.6*_]2M:_44Q'4[!8-\K9M1M[M!;SS&Y%
M3;61QNAS$V^#9,#LJ\Y=$7'3M8.%?Z(F0036$P*<1N @@77/*X5?Y^-7JZW6
MX3K5XEI,YV\/8UMF6JHN6*[Q*G11T5@D$-.3-=>'L9+=%Z1BY4R>@S[7S;87
M"=E)2@UI$-M[O<K;6]UWKZ-12%S#Q5!*H@Y<$.D7LR2JQ57B8 !0ZP>(  W<
M]S<?VV]SW/NTM.KS9\ULU5:B18R1%'*D-ZBK%Z5;ZFLZ,OFGN56)O'.<BT9$
M;M9_*82W>@Z\WY>;2Q2C&Z-,KE-V@L>U,BFV2(56?FA=>.3I+E*!CK+D!0S@
MO$/20-0#A#/&ZV7&[MP":U&HDEDBZ.E+!*9C[7.*BY5<D5<D<E-1S[[+:EV<
MD-ZC6*WRK&/I+,:[7428H6W$186KPT%4MGYCF4<C6%FS1U(SS^=5;G277607
MU3(DU21#HU* :A]4!Y$O5JXSKC=Y<U'6)=R?>5LJB*Y[GJBHJJBT(C4;L0TT
MI=);I;46I):OHRJJ^B!4W_*IMC%/4I1%I9K=#6>6V_K,'4ZZ[:>-(9"[0!)D
M[YXL#)0JZ:!CBDGHDF!Q =3%S9G_ $PPV4]'HDV8R8^0UK&JEIB3I=M7.6RM
MI&KO4H:BJE*H9.PB4BQI5%5J02M+21BM%)(/>5+:AC5;%=POB[ZKU!Q,;03,
MH@\:$*O>T[(2)C%4 %(W] 59J=L4+TCH4Q0/]7*)WTOPMEVF7CGU65+5\E5M
M)3/28C&*E'J*Q;:IL*B.,781)1BOM4)%O^:,$\T*3+<9R[[<;1WZ\)UN4=RS
M^)@-U*(^CYM%\[0<DC:>=TE(D<.(I@W26ZPP@=LDHMP )# H8!$<]5=M0</P
MJ_3DE.5SFR[TQ4<CE1;,F*/BLMC46-;$5\(HJ.5%-UF&RI,QUE8JB/30VNI-
M%/E-.-H=I*G9-K7NX<_7;+N%(*VIEM<QI>U:B!)%L5U$JR/;3$5;.A6,8Q03
M22T(4P@;4X#T9\CU4U5NMXPQUZFRYLYW/-E(R4J6DBQ76J6NC%:$2A%II.'<
MKFQ\FVJ*Y;4()75&.4R/(<LU,0I#X4%Y=O9&&WT?OJ&X,HX:(UU9T^D"M/$@
MI'1+U:I>/JP5%QKUI3 8@!TYZ&?].+FVY.@KTF)=FS^<5426JN=#FH0H7)&U
MZR*BHB&T["F<WEC81T<GD_"UEMU7E^AF&W@6JXUZ9W&L<K:#;;,ZML=+PDLI
M'D\1^-B/#*1@2:+@ZAC<)4>,@:$-J8!Z YV&:AR68?SUXEOG3'3>;1LA['JW
M>6T=%MM'*JT(V*5+%8E4G#6I*M.17*KH0:J+"B,:(Q\A>"'+MM;+3^WNU<.G
M-([G;H;<I;DU.6DY1F2/4M3MFH[:L#M^QE,5!3LYRZ];Q<1BA^Z/79J!ADV?
M=[E+MI>9]V28Q5<EGG515:R%GU5@J5QBJ%Z8;)<YLM(VW,BE-$<B55%_2W*1
MLXM#[@,*;)SDY=:<$O$IM99ZG&MW;ZOPR#E\K'KKQIF;Q--UUQ5$A<IJ$3*4
M0XA'I[E[^E>$+)GMN[ICYTNVD%=9172V(KE8JLL/1'6HMMM5$1*S9?@TBRY&
MJJN2.Q4E,*(+3'*5A[RU[16JY01T:5*5JE,JAM>K(K5F3%0SF6N@$1%8"%C7
M*JBFO&!C '!Q!Q',F&A<W)WT[PJ]7MBI)>R2DF[1LNK?.@D86'*JUQR1I56I
M09NPN0]Z;U4;994N5WF_&P7/*;8P-=:4S9-RB1Y"*P&^-,?S;]NB1QQ5>9<2
M#%Z<0#H536CD]!UZ.(2]P=,Z-YU;D7=DG#E1%9S=]8KE1(_])ZN8Y=E%8FE4
MJ+7W1K4;*R0F)'R+%%VCR/3,)TTSB&@G*!A#T-0US\JM6*'C4.>2!@# & ,
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M,K/[S*OEK(1-O8U7LL^6-(II?]V5V*BPBN4G^R"G$ ?4RR;C=[>KU=/>JO\
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M2Q;Y2=\-_)'4I_ =H4?%]N#\ )W]C27\CCLEBWRD[X;^2.I3^ [0H^+[<'X
M3O[&DOY''9+%OE)WPW\D=2G\!VA2>)M5NJHD1=/:RS*(*]*2Y*],"0P?N&!M
MH/\ HQV2Q;Y2=\-_)'4I_ =H4C\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA
M1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%OE)WP
MW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T
M;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.Z
MWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2
MG\!VA1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%
MOE)WPW\D=2G\!VA1\5.ZWR5V?R>F/T;'9/%OE)WPW\D=2G\!VA1\5.ZWR5V?
MR>F/T;'9/%OE)WPW\D=2G\!VA3J<;8;GM (9WME9&A5.A,SJ!EDP-T:]'&W#
M7'9+%OE)WPW\DCJ4_@.T*2OQ?;@_ "=_8TE_(X[)8M\I.^&_DD]2G\!VA1\7
MVX/P G?V-)?R..R6+?*3OAOY(ZE/X#M"CXOMP?@!._L:2_D<=DL6^4G?#?R1
MU*?P':%'Q?;@_ "=_8TE_(X[)8M\I.^&_DCJ4_@.T*/B^W!^ $[^QI+^1QV2
MQ;Y2=\-_)'4I_ =H4?%]N#\ )W]C27\CCLEBWRD[X;^2.I3^ [0H^+[<'X 3
MO[&DOY''9+%OE)WPW\D=2G\!VA1\7VX/P G?V-)?R..R6+?*3OAOY(ZE/X#M
M"CXOMP?@!._L:2_D<=DL6^4G?#?R1U*?P':%'Q?;@_ "=_8TE_(X[)8M\I.^
M&_DCJ4_@.T* V^W!$0 -OYX1'H  AI+^0QV2Q;Y2=\-_)'4I_ =H4J)MIMV2
M:<>U%H)Q=)>.NS(:A_I;8[)8M\I.^&_DCJ4_@.T*<?BIW6^2NS^3TQ^C8[)X
MM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS
M^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T
M*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^
M&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^
MC8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW
M6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ
M4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)X
MM\I.^&_DCJ4_@.T*/BIW6^2NS^3TQ^C8[)XM\I.^&_DCJ4_@.T*?09YJ6*E8
M3ESM<7-Q3J%E&MRD^U1DRW6:.4N.(BU"\:3@I#EXBF P:AT@(#W!S]W_ &P7
M2=(U?FLFL5CTGNBCD5%3>,6E%@M5)]'U08YMU5%2"VE_)#TTS]''J3__T_OX
MP#K4226(*:R952#W2* !@](<Q<U%2"D*A*^+(W]7H>Q)][*^K2^"F@BPF8>+
M(W]7H>Q)]['5I?!30+"9AXLC?U>A[$GWL=6E\%- L)F'BR-_5Z'L2?>QU:7P
M4T"PF8>+(W]7H>Q)]['5I?!30+"9AXLC?U>A[$GWL=6E\%- L)F'BR-_5Z'L
M2?>QU:7P4T"PF8>+(W]7H>Q)]['5I?!30+"9AXLC?U>A[$GWL=6E\%- L)F'
MBR-_5Z'L2?>QU:7P4T"PF8>+(W]7H>Q)]['5I?!30+"9AXLC?U>A[$GWL=6E
M\%- L)F'BR-_5Z'L2?>QU:7P4T"PF8>+(W]7H>Q)]['5I?!30+"9AXLC?U>A
M[$GWL=6E\%- L)F'BR-_5Z'L2?>QU:7P4T"PF8>+(W]7H>Q)]['5I?!30+"9
MAXLC?U>A[$GWL=6E\%- L)F'BR-_5Z'L2?>QU:7P4T"PF8#'1Y XR,42G)X1
M#%2( @(=(" @&$N\M/Y4T"PF8Q'U[@1Z%CB/_:-FS;=G,XD>M<^N'],V3:?L
MBD=:Y]</Z9L6G[(I'6N?7#^F;%I^R*1UKGUP_IFQ:?LBD=:Y]</Z9L6G[(I'
M6N?7#^F;%I^R*1UKGUP_IFQ:?LBD=:Y]</Z9L6G[(I'6N?7#^F;%I^R*3CUZ
M_KQ_MAR.<=G$2@;RJ*>\&MFXQXC/"<0ZCJ/X!7(1ZYQ$U=ZU7UPWICD\X[.(
MJ.M5]<-Z8XYQV<14=:KZX;TQQSCLXBHZU7UPWICCG'9Q%1UJOKAO3''..SB*
MCK5?7#>F..<=G$5'6J^N&],<<X[.(J.M5]<-Z8XYQV<14=:KZX;TQQSCLXBH
MZU7UPWICCG'9Q%1UJOKAO3''..SB*D!55T'\(;N>B..<=G$5-S8M50NWM,$J
MABB9!/B$!$-?P8Y%I8D1)3KU_7C_ &PY/..SDQ'7K^O'^V''..SB(Z]?UX_V
MPXYQV<1'7K^O'^V''..SB(Z]?UX_VPXYQV<1'7K^O'^V''..SB(Z]?UX_P!L
M..<=G$1UZ_KQ_MAQSCLXB.O7]>/]L..<=G$1UZ_KQ_MAQSCLXB.O7]>/]L..
M<=G$1UZ_KQ_MAQSCLXB6IOBHI[V*8/6&U,L<3#J.H_T?ZN0CU3*(FM/6J^N&
M],<GG'9Q%1UJOKAO3''..SB*CK5?7#>F..<=G$5'6J^N&],<<X[.(J.M5]<-
MZ8XYQV<14=:KZX;TQQSCLXBHZU7UPWICCG'9Q%1UJOKAO3''..SB*CK5?7#>
MF..<=G$5'6J^N&],<<X[.(J3+)57MK/\(;_ODOJCZL,<X[.(J;QVY10CYJ!%
M#$ 4A$0*(A_MCZ&0CE0@M3KU_7C_ &PY/..SDQ'7K^O'^V''..SB(Z]?UX_V
MPXYQV<1'7K^O'^V''..SB(Z]?UX_VPXYQV<1'7K^O'^V''..SB(Z]?UX_P!L
M..<=G$1UZ_KQ_MAQSCLXB.O7]>/]L..<=G$1UZ_KQ_MAQSCLXB.O7]>/]L..
M<=G$1UZ_KQ_MAQSCLXB.O7]>/]L..<=G$1UZ_KQ_MAQSCLXB9.K?3$-CCTG.
M*ACF'NB(*"741^L !F!!7< __]3[^, 8!UF52(=-,ZA2*+:@DF80 QN$-1T
M>[I@$2JIF.HF50IE$M.M3*("8O$&H:A]37  *$$QR <!.F &.0!#4H#KIJ'U
M-=, B0Y%"E.F<#D-TE.00$!#]P0P 0Y%"%43."A#AQ$.00$!#]P0P#I<NVC)
M,%GCI-HD(@0%7)RIEXA[@:G$ U')1%4*IV@HF8PD*H!CE #B0! 1 IM=!T]
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M & , 8 P!@# & 3++\M9_CDONPP#>2X?ES3\2/W8X!:6 , 8 P!@# & , 8
MP!@# & , RG6O^#-/KJ?QIL KN ?_];[^, 8!++LVCH2F<M4W!BE.B4RY"G$
M"*APG*'$ ]!@Z!#ZN2BJ($FZ@H1ZW5:O(9J[:K@D1=LZ;HJ)G! =4@,4Y1 >
M ?L=>Y]3)1ZIE(LH#P4(HGU2D,U.EJBIU1VZ(EXFYQ.D.@ETU(81$OH#W,6U
MSBRAC2I;&;?TO<K<S=>(CSJ6W=1:(>SBS_J5468PL,E!(%8E!(ID"&01+U@
M8>(>GH#HR^9>WNEM8M38[:Q*F2&HY795,E'@()1:-<'A6AW$, EB%SMD1.U
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M!E.M?\&:?74_C38!7< __]?[^, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MXTV 5W /_]#[^, UDWMYP-A>7@-P/C7M3FOJ;:5AIN_9&S6)E'ZIX1],^]]
M[0C%NJ9TL=Z8B ((@93C.0.'PBZ@5R+YI>7^5D;)'EW3B8LE7D:]3WLO9')(
MN.<RUI@VUDBV;)W(BBBZ7<,GJ"Q4T#&-HH74-1TP"8F>9S82 OJ>VDINI#(6
MTD=8+5,M"/D%$(=C5RLCR2DHX(84F'4ED$1T<F()@$1#4"FT []LN9+8W>"'
M<3VW^YD3.1B$[)[<IN.UHHBXE8J8D()1- JYB"L15Q%N0;J)@)%BIF.F)BAK
M@%O7+FYY>]OJ9*7ZY[DL("MQ\HYIS%P[5*9>6?M#HIJIQ:"0G5?:"N7\G*?H
MU'N . 9BK^X-"MDU9JW5[M$V.QTI5)C<Z_!2+-V^B%UR=:FF];H*&4;G.7I*
M54I1$.D, M=;?G8UM"R-D<;S51"NP\Q\7LO/+6*'*R:SXF GBQ9<S@"$><0@
M'4&$%-1^QP#E+;[;(0$O)U^=WDJL+/0BK1E,PDM88AL\:+/W1639-9%9P4Z9
MEECE23 P )CB!0U$=, Y.]\]DF$R[KC_ 'BJK*PL'C2O/H)W88E-ZC(/W2S%
MLV40.X Y5EEFZJ2:8AQ&.0Q0 1*( !W/MZ]FHM2YHR>[=8CEMN#(I;AI/IZ*
M1- F<D%1$)$%%P%J*A2B) 6X=0#4, E/CSVE<2AX2'OT59Y9G(LZO.QU4?M)
M):)=/V2LBW\8$9J',U(H@B90IE0* ET$.@< H4%S,[$6VU4.GTK<Z)OLIN4%
MB"I/*"[2FXY92J)LU91)1[%BNW150*_1$4U#E,/%T .@X!,*<Q^Q:3NPI'W4
M@0BZ>V=R%RM?C:/\2PQF3MLR6;OW_7=0V<%4=I *2IBFT, Z8!:2O.3RR-[)
MN54W6\D(SG-J(I.\6UJ\>)) :(/$K3AG;(YQ KU))JW4.L9L)P3X1 ^@]& 9
M!VWWXV6W?;P2^V.ZE?O"ED@HS<Z'CJW+L';Q6OS")5V4AV9%4RI6ZY3@)%!*
M!1[@#@$ZGO3LXK*WB"2W9K*LWMD@:2W)ATYZ*,ZKS8A>(RLFD"_&T( =(F6
MH8!3E>8+85%F,@MO=4$F 0I=QQ?*V6&*C[WC'*D64XQ<\/8A,<I0<:]7J(!Q
M=. 5U#=G:QS,0U>;;EU]Q/V.)-?:]!H3,<=X_@RZ\4BW1*L)U6@:=*Y $G_K
M8!SB]U=KYND_&7"[D0$OMP!%%QW BYB.<0G DH*)S=N26,AH4X"4P\?0/0/3
M@%%'?G8T&,))CO-4PC;-'.[=7) ;%#]1(1+!,ZKIZV4[1PJMT"IF,HJ01(4
M$3"  . 32N]>S2+2DOEMVJPDQW,**NW#Q6>BBHV G@=,:<5]'8?A2=*(F^R#
MT0P"@H;Y\N;J:A:VVWBI+BQ61\K6:[ (6&".]?R2 %%1HV0*X%15<G&7B3(
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MWF />G5?@S'_ )DV^\P![TZK\&8_\R;?>8 ]Z=5^#,?^9-OO, >].J_!F/\
MS)M]Y@#WIU7X,Q_YDV^\P![TZK\&8_\ ,FWWF />G5?@S'_F3;[S 'O3JOP9
MC_S)M]Y@#WIU7X,Q_P"9-OO, B6J5<H@8M;8%,4>(IBLVX" A_[& 5A5JV7,
M!EVR:QBAP@94A3" ?Z0P#J\71_M%'V(G>P!XNC_:*/L1.]@#Q='^T4?8B=[
M'BZ/]HH^Q$[V /%T?[11]B)WL >+H_VBC[$3O8 \71_M%'V(G>P!XNC_ &BC
M[$3O8 \71_M%'V(G>P!XNC_:*/L1.]@#Q='^T4?8B=[ 'BZ/]HH^Q$[V /%T
M?[11]B)WL >+H_VBC[$3O8!,IIII$!-),J29?L2)@!0#7I[@8!SP#__1^_C
M-(.9;E!5Y@=[N6O<HMH:P=2VN?2!=YZ>Z:*+JW*" B<M$Q_7$5(")64XS9R
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MI:I:PUAPU:K+!&K N9PW.4HM@23,;C'4-3 70#R,+$\[_)W&;DK;0[1)<O\
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MI2"4#VNP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P#__T_OXP#3?F"WOYD-N-T:34]H.6L=WZ-,U>XVZV7LTHY8IQLY#
MQ@N86+X$&3H1-)."]3Q !N$!XATT*"@&G\WST\U]7G=BU]U]GJURS56W0--F
M-P76]3*ZO(E6QS\PK%2D(G:*^U7CH-PPX$Q1\8I*%='5(5,P$U6P#(6Z/G,:
M_#,=HB[2;263<6S;G3L-&-ZB+:)0=KQ+O<%?;UV#4ZTJ@W([!RW,HD+A9-N"
M>AU52=( !<][\XO2D-IMK[WL]3'>Y^X=_M=4V^F^7LTG5XR\5]":M@5205?1
MTI,-2%.R<IJH> L8AU0#@,=/4^ 2;OSH&T[T^WT?MSLON+O)9MQ@9LHNH;<1
MM9%^RF5JY/VIY#O334]'((OX]G7E3.4^M$O$J@5(ZHJ>"!RV)\ZQRK\R._4+
ML%M(:Q624L;!.7A;ZG%(A7U5SUAK;Q:*"5T9ZW4*Q>$-UR[1-N935$BQE@X,
M Q;S&^=(?T[;^TK;!<O5INM_E9IG0=A9^ZMZXSJ=S<_&%%;>2CM@=:QL'!DH
M]S)E,"3KL9G :&1,*/&LF!=',ES;<R5#YN*%RU;61<02,DZ?7-P[3;W.UNYV
MXI1?3EHD*^9)0U$>((P[4A& J%</S&(.IAUT2/@%7;>=/VH6CD9@^R&XY(1N
MQE[_ &:;".JAD8>D04\:L.[2Z23L)UACNW)+$321(J].1(ZI6PH@"@@6C-^=
M5B9!6E,-MN6F^2K^\V>(K58<7 M/C&<W7%;X2@R\U&J^^(W$DQ=J)CU;CJ5%
M2*$42(H01$ .RS^=8JZ2FUPT_8*Z*1NY<U6)*$L-V)5XME)[9SR\@BI<HX33
MHJ&:) PXNS.")/.%5)3LW5G V 4FE^>@Y<MRZZI.;9[0;F[@.E7BK*'K];@Z
M]VB0CT8%Y9C22#AW.(,@0*R8JJ'15<D=)FX"*($452*<"]&?G6=L)B*CG=9Y
M=MU;5/3"RKF*I,)$U+QHO EHK3<=&;_I5C1;D:.(EX11)%18KOK=4#-RKZ)B
M!"?\[7R^PM<D[\SVWW M&UJZ3]';/=&MPT,I$WF7BF[5T\BH4CJ70=@Z2(Y$
M0,];MD%.J6!-4XI&T H&Z_G5Z?3;9=MFX?:N8@=\:Q#EM[*%ODA3'\6?L<Q#
MQTHR<C3+'+NFKIJ26*( X1334$H]6<X!J(%9YE>:_FDVUW-YG76UD+09/9_D
M^H$%O[N/7+XVL(6:R,GB$W)R#:-D6#TC1DJFUA3=0*S18#J& #<)?" #&=&Y
M\>3*@<P+U5?8E.D[K;X2%B:63?2KTNLP*CN-K[HY.&6?J2?C.642!'B6%HDO
MU8<)U4T"B& 9DAO.E;5R\O0JRIL5N3"VS<@L99JU6IMA4$5_>;,0DE8FMK75
M"Q&;I18LX=V<Y#*]L3,D*:C8JAB%,!@^;\\]MI0Y.9EMT-E+G2:98(ZDS6Q=
M>DV=>2M5K0M</-V,SXA5)WQ<BS*PB05*1=TDY*<W4J(E7$J6 9+M7G>MAZO4
M++N,;9[<B2VVKL]7-MB7XT76(B/=S%CI4??TT +9)^-<-3(1THAUH/4D!.N;
MJ$ 66\# -EN<7F3N.PO*1;^8':';=7=2Y$;0"="I3Q1DQ*L[LTLRAVAW82;Z
M,*":1WQ3J)]H(8=.$#%UX@ U\<>=+VYKL:P1L6S5^G9N8>.*-MX]I\5609;@
MV&%N\9MI.(5Y-U8S*(E8S4HDD;QD9L!T^)5$ZZ91/@&;M[.?79OEYN-3HV[,
M'8:U/7%U1HN-(1I&.DD_?S,N8$BZIVS\X WC'2!"2*Q>(B77)"05 ,.@&H$#
MYVR/F(C<B4EMF;-3:\$K+P^R>YDE$1KV"EDHVJL[BFV=H)3Z#OMB\>N=R02%
M*V$G"05P6U2P#*-T\Y*](G2Y#:KEEOM[KEJW 9[-UVUJQT"A'7),).7@) U>
M74G$BHKMWT68H>.!9$.EJN43(Z*8!ER=Y^Z SV;Y>MX:CM'>MT"\S JH[=[=
M4=A7T["DJUAW<VZ3?EG9B-9MQ;I,5BJ&[4)1.4"E$W$74#56V>>MY=W+#<V*
MV4HMKW6OE0V[E][ZTS08QC**>/8^@#N&2)>+.Y%)=DH#(Q>M7<(D;@IJB18Z
MXE2,!U5+SL1-N=I:I;>;C;%:M7":LWQ;3\=M>ZJQ2PZB,; *KN'#"8LYG;@J
M;F:$AR19GXE*01U-W3 9:B?.J[4RE@BXI;8/<^%@I:0BHQO?9J+JB4.$=+WL
M=LT9813L*CDS0)LR;42%0%P)5"KD1,W ZI0*=!^=HV?MMVL&UU&V.W!W!W2B
M)V,HL30:$?;F77ESR\58YAL[;OF=M/'(H=55GH*@\=(*I& G6)E*;B "V7OG
M@=DXMI+VIGM_=]R*.->+O,S<[>5R-(ZA:@RJ<7:91]*!+SK8QS-4I,O$B@EU
MYC 9-))4Q=3 9+<>=!VL8+SS"4V.W)C)G;A617W[A%XRKJK[=PL=*(1GCB:.
MUGUD56BW: 62+&J.W'5%4.=$G5* 4"9VPY_7&]&Z5[K]'VHEH':R%VUE-]-N
M]R-PD6C5&W@PL3J"3=1P1S]X8L>MV43E!VFW<B42GZH$SD,(&,JQYVFD-.7X
M-VMUMB[A3+;"PE*NMBHCE>B12DA'76+DI!G)PZMBM#)%5J<8=T4K==9-\ E*
M!FP<1=0,Z;*><<V-WZWRA-AZ17+.WG;+487>:O6:QLHIG'.XF=K[*RM^! 9$
MTB&C9^0HKF9@V%4ITB+&.42X!AK<#SP_+GMDI')6W;3<!HI/6JZ[:51NSC:T
MZ=3#?;ZT+4R:F6;5O.G7.R3D4#HHI"F5XXT$R+8Y0$0 N:]>=;V+V[I4_N=9
MMKMP&>UH2Y:'M9N6K$P2$+?I@99:'.UAUW<PB+<Q56RI^*6*R*=(AE""<@:X
M!3:IYUG8Z;;3=ND(BR,: ZB26>H+R%=)%O2.4J2K<SQ#D'\IQ*2#M%JX*R*1
M$B2ID^$JAP.DHH!2JUYXWEEN5NN-"J-$OMDN-<?HTRMP45$0AC66P*6EO2U(
MIDLK,$0:N$I%P"8FE%&:1TR*+)J'1(90 *'N3YP;>N.Y.*#OY4=KD:QN3N#N
MLIR]EI-HK-FMCR&:$MDG!&55@:<Y,_?/4TF &.@T6,43"8Q3&3#40*'(\WW/
M.*ED-68_;=^79W:*,YJ]S(O<:E[BT:3GB2,_:&7BMFRGI0SJ#4(UK8_A'Z+C
M510#"0I Z0+[VP\Z!4MS>=2G<N#). C*/N!5XPU:=/)MK[[R[@NZHAN*XB'$
M6"O$5LE O4%2K 0>)7C* Z%' *GO1SE\PM8D>;'<G:^CTY_R^\BJIVV],7>7
M,PG;[1XLJS*ZS1H51F)6K$&C!^0&P.4EA=+%,7\"02J"!/ROG3=NF"2CUCRW
M;K6*'*XW).A-0453S(K0FTDJRA[/-D(YLJ*O86JSX@)@*8.%^$P)(G-H4P%$
MVY\Z/5YB)W%?WW:2P1#2O2FYYML[I&*U=C6KK!T'<):H%&.?6*>8]2Z[.JT6
M7&0!J@)SJ%14/P"4 .^H>=QV)O,;29^N[1[AOJM8VL9,7*VH,*HM'4U"5OK[
M;5$995M8%>N_^*,#%UC0=@*1@5*)DP4$@'7S \VW-/0-VN:=7;*!H$KLSR=U
M6I;IWZKW=&?1M-E;S365DWZ4?*-'I63(Z3>.T0ZYFL!U!T,)2CJ %^-/.9;1
M+H;ORCO:F^1%8VDB-S+H6V2C"N%:6-IM(N=I8BQ2:<V=SQI+%ZI+M:+<JAAZ
M#  &$ ,E[0\[]!WHWA;[2UG;>XQC"=9W6;H.[EB8PR55LJ&WT]&5F<[ HWE%
MWQ3(/I0B) =,T>LX%#I\1  Q@-,[3YY';.E7)W+6G:NS0.PTI4XVY;0W&5;P
MC>3W D9FW.J\Q/"@K,E;(L%D&2KH#RBC-0J104,4I#$$P%\2OG==A7K:%CZK
M3[BQF[QMI,<Q%0E[C ,&;5!"-AY>4%LO'OIAA(.E$QAE2K&9IG;%$2%.Y3ZP
MAL JTKYU_:.#1:N%MD]R;%"S:<PEM]=:O#5P\7<7U;M,)2)1O$$<6 CHAD)6
M=20#MJ2!3@FJ<ASD)QF K,OYT_9.O/\ 9>*L.VUO@I?>*V*[&K0<BO0BR-:M
M2.X)]L#LI)D6SF<N"!+DZH7,8F\;@005%7@Z< QMLMYTYW>Z_4#6SETMOQM;
MCH,AHW+S04:H[GG:AGMQ%RX)).[0G%F038U11<2JKHG*/@%ZTZA" !G;93SD
M6SF_NX=.IU"V^NWO1W#?EIU'WLFXN(:U62G3T!'<T(U/_P"*'DB+^*%#JB95
MB1,ITE$C'!0"E,!Z$8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P#_]3[^, 8!I=O-L1R@WBZ6G<G=VQ%CY"II01MUXI7<.P5
M^M+H(+=;$^^>$8S#2+>$$P_@/&+8X&#0H:AH& :YN.53S5TM8UE4K?"(VS<&
M29S%7\0[PV)F^:OQW!=O&A:V5C8TSQH>^<7 (I1H)%[;UB92]9Q%P#+[#:WS
M=\G0ZAMC69>C(1<8K76E*EZA;D6UE,]C+*1>*,E.QDBG*K+FED=.(71CK+B<
MIQ.8YP$#5F&Y,N3JPMJ?#67FHAK%8XK>+<G>+=MWM;:4Z8[L5]GZ!-1LK#)*
M52<0?1HQL.[,NHS3<G4!N@85@%,QQP#<#8W9KD;B[Q&;K\N\Y"*NUS$K,##;
M7WE\\J 2"569)]8UK\?*J0Y9$84C;B<)M>T&:\ B<4Q 1 L/X@O-N(6Q];UK
M%6C3%YFCRT0Q>[CR"D:WFHS<>)DWA8..5FA:1YSVA!B5^DP22!9V)$5RG,?@
M,!N0TKNTB>^<];6CEB.^[RIQ-=GV9)0QI,M1;3$DYCSGCNO$I$!>+NP(XZD!
M.8#$XQX-"@:;6G87S;<]!TLE@L58;5O;2OR<\Q[)N,^CF;NE*68'#\DT+291
M)*P7C;0%4)$5F@+^ )0-T8!<;[8_D E6FVD2>>@$#,6[AAM,O$;@/V;XR1MP
M&$\L,<X:2Z:ZA_? V;D$Z9A,"@]GUX%#)& Q]"<N/FPH\&HP]GK2A;A[W[[3
M_P#_ *A*.2H1,=-/WT4C  K.G!E"&>]L &+#JV2H]<F9,Y>(N 7W2>7OD'IB
M-8"NV2/?H23!S/[?>^/<R>G2DK\A67S("0_C>;= E%$BU'0MT&VC9)+C42*7
MAX@ PGN#RE^;LOUFVJ<%W>AJM7J<P<N7U2J6Y,C&+V"&2VK;0C4#R$;/-GA&
M;>MHIKK%(<4W#4>L7 Z9C'$"ZW.P'FKGKYS=CV*E$BKDJ^AH>/9;D.$*N@_:
MIQBDD>%BT)HD:Q>F209@]58HIK'()05,)3B!@.,KRX>:W6W*L]UF+/5@OEFD
M[T\EV#O=*33;HRCBQ,1N -HL9T&S50)=%OXR(@B3@<B *@50X@(&4=^.7+DB
MOM^W&W3WRM 1TI PM?1WTAG^Z%FKM65K[)T[7B!M, RG&<2X:BH=P"8R#4Q%
M XBCQ% 0 "T[7L1YM9W; W N-AJA'E?MI9F7C9G<-VC7E;E(3O7M2R4.I,%C
M7+PDAT,T7*!C)*^"B4H]& 3NT.POFZMN+C47.VUBKLI>D(UK::,6<W%D+1(^
M]E_6)-I'ILTYN9?'-"%B3/A8-B +1)'KCH$* ', %@57E(\V$=2(JE%N;(ME
MM3>NV&A/:AO1;0M"$0WJ\LK"IU^0967Q@SC1@UGX-T&"I&YV(* !10(/"!D6
MR; >;UMFW5SK#ZQPK&@O9PUOO3NK;D2T/PRC/;^+C'";I_$S3=5-$U<;LS.6
MIE014;"594A@4$Y@,IH;3<OK;8J;A[C>&,_RW7-]6K;2B/IX6-6AXAL:')76
M,.\0>$(FQZYDV.W*DL":JBFA2\*G"(&(&VPOFXV>X,?=R6&M*6ZXV-]/4>/>
M;BOUF"%CB]QHQ]+$KL4M,F:,53VE)D$FA'HI@L]ZM-R4ZA@*(%Y<V>UW(+N%
M/M5.;V5J$;9QHMTIC$-PK<6LO/>+."P1L*B92R+$_4)G2:B+P XFQQ*9-1,Q
MM1 H]NVA\WA-UCJ;3,U!"H.9^2L"(ENQH]B$Z[I2<:[(D9O*(D(8(,"&Z@@@
M4B.BI2%^SP!4]A^0*'OE=O=7L,,O9;%:7EFVYCB[BRKV*1M#.;DB2)(")6F5
M6+90TFJ\%ZV9($*HY XK$,H4= ,G57;GE&CJ?R]1E4DX)6FTM25/RZJLK0JZ
M;KJ.(MZW?]A7%^<7X@U5<"<!,KP% QNCAU # =;Y;_-K)U&=GJG9X,=K#5AS
MM;9&L%NE-FIWBH-O/%KEPX:(3PQP2'O9#B5DCD[7V3\*9;A\/ +;W/Y;/-56
M^9GWVXUHJC*6CF[AU=DR[J2<+QL'TI&):2B3*>;%4;E?H,A0*X*)$W D%,"J
M'\(#+#S9[S?)J[&M'\S5?>TU8Q#6..YO"P("P:[GHS\>/6&E/#(-I(F0IA$>
M-?1L(F >J$#5)IR0^:^G+!LFQV>WICZH_8N:?8J[';>[PV%>:G:X2IW%K4H^
M&?-K-VYBS*WEI!S&GCE" =!N=-/5%,0(!G5CLGYKAW6[,$+.T(E1F-OG]1L'
MO>OP(QQ-NEZK&1SI0.QRY4T&01+=F879.'A3$JH* )Q.8"K[E[#>;?M5]NMD
MW$L-99W>ONW=XW=:FW%?P_6HJ/XLKA*R,FDRW2<Q@.V[+B9OTSM05$GX,#*#
MQ 7)LOL=R$T^X7JV;,S\(]L&XM6E?';.*W DIMBUI+FPO5GWBN.<2[IK&102
MAG7%V%)%$B_6%#0P"  6!N%R[^;(N#F@QUTLM98S$96()GMVK';G24))GI\+
M!3*;(6JT=.-EU6"D:ZD.N.!C$<(@<514*GJ4"[]I=C/-[U'<S9&];56"OO;R
MVATZERZQS7<)_-,A8M:>@W,K 1+N8=-#N#01$Q6=-D!6.UT.<YB#Q"!/36P7
M(A<6U;B/?%',5*P[W&N\8O1-R)N#?K(R%V4DKLB[<P,TU7=QA9U42R+-P<[5
M%<"I'3)PE( %I/N6SS<DY(N'9;3%-G^[%A<$I):YNI/, 96Q"<67=C3TX^>2
M+#20R)5NTC# @J97K"J:B)P$"=L.R7FVFE2=0ETG:@I5FMIV[D95>ZW]=;BN
M%;73]Z@.74C+F4.]552#@34.)WAA-U@+"8VH$W,<N/(#)*V:4D[.R2;[MV%R
MPCD4=T;"U8,;B2_I*N35=NA.IH0TN-H*3K3Q!4' R'@F'KAT$"_J9M)R65[:
MG9VH5.8A'.U],OOODVC>JW1Y)D7W$2F'ZIR$DG<FNL_?B^5==8W564,93C*8
M@B70 *-S%<N?)ANE?+EN!OU:#P]AK%)8,-X(Q/<^T5&&7V]0D95XU&T0\1.1
M[!W%BN>0 %)! Z1@ZX@B)0,4 +2B]M?-BFM5<A8.4VS#<EON03<BKKP]JBPM
M8[BB\6G2(H.D'_;S*\!E"%CP.*?9-6X(]F#JP K^\NR'(3=K]N3N1N]/P;">
MIZE8_P PD4XO\A 0#A5+J5:][]81E+M(UZ;04NQ>-FZ@F+P%)J4"A@&+-W.5
MWD1W L^UL[<-VHFO;=;?QN^3]QM_%7YY"M)T]DM<+-79T\?1\TU758QSQBHC
M)LCF.T(#D4ER$*4A, NS<#8OS;%MJ%0@;G8*FQJ[RP6EQMPY8;A.88Q;1.;A
M-Y>6\4.X^8;*$>IV0$2D*W.!VSCA02!/H3P#KHNP_FU8&EV^$I%@JKBFO21C
M:ZKH;BO)$A09[DR$PT%PZ7F5CIG-:%'91,)P%1SQH&$PE%, +FWOY<.1FZ[A
M;J;M[UVE-A*1$;66_,#"2>Z%E@:BI%,%7"T(-JKK:<:PZR)A44!(S]H8%0\$
M1,!0  +7WFY>O-N7ZGR4-NS9*_&U&.=;M7"RK([F2M<*=.9EUUMQ$I!U&3;(
MZD>1ZN<)-HN<6S=0"E.1,2$ H%M\N7++LM2N<:V<P%9YC:]=)"Y1=_@]H-B]
MOWJR<=#,GUH@U[>Z0:.;%,(J+I24>S3>J1[5FD1=4W7IF65*8 .F.Y7?-=N[
M )X&VP9+3NJC&C0O>WNY/HOF3?WU/I"/]YQ6=A*>'3\;@[!#Q," =9UR1>CC
M)@%<O?+AYM)5*J26Y%H@2Q5=CE=N8!&X[I3)(U4ZM?F&PKJHO)T$',L$:M(B
M605*=X5(%3@J $$2@8*I_)_R9Q_,3([T7'F7I]FH]C\?QNQFQU<L;F)A8IY[
M]*P\F7*':+5()+O$YF+C4W0Q[=F0SA71RDJJL7 ,S3G+EYKR8W4=V^4L]70W
M+A[7&3%A8L=T)-B*EP=;K/IV)+)1K6=217=EMQG1&"+A(PD==8W1* @*0 3+
M#E?\VM+$AZK7+;&(35D=^^&BO:7NW8V=C1.12U2)B03^,L";]JVZM[.%,@R5
M(D* .$A***(E(!E_9W;?D3BVVUCW8V3J"L5&6LMLV?3H%J3>1YK2?:P\"1..
M2:/U$53!4S"<C4@&(#;^D@3HZW -VL 8 P!@# & , 8 P!@# & , 8 P!@#
7& , 8 P!@# & , 8 P!@# & , 8!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 12, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CervoMed Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20 Park Plaza, Suite 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-4400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRVO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,258,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,235,469<span></span>
</td>
<td class="nump">$ 8,999,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">12,628,970<span></span>
</td>
<td class="nump">29,922,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,267,005<span></span>
</td>
<td class="nump">1,905,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">320,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grant receivable</a></td>
<td class="nump">426,993<span></span>
</td>
<td class="nump">2,254,231<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,879,018<span></span>
</td>
<td class="nump">43,081,610<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">22,879,018<span></span>
</td>
<td class="nump">43,081,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,454,118<span></span>
</td>
<td class="nump">1,511,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,201,999<span></span>
</td>
<td class="nump">2,367,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,656,117<span></span>
</td>
<td class="nump">3,879,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,656,117<span></span>
</td>
<td class="nump">3,879,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively</a></td>
<td class="nump">9,252<span></span>
</td>
<td class="nump">8,702<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">115,905,684<span></span>
</td>
<td class="nump">109,868,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">5,816<span></span>
</td>
<td class="nump">56,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(97,697,851)<span></span>
</td>
<td class="num">(70,731,484)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">18,222,901<span></span>
</td>
<td class="nump">39,202,328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">22,879,018<span></span>
</td>
<td class="nump">43,081,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A preferred stock $0.001 par value: 30,000,000 authorized at December 31, 2025 and 2024, 0 shares issued and outstanding at December 31, 2025 and 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of liability of accrued expenses and other current liabilities recorded as of a point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding (in shares)</a></td>
<td class="nump">9,252,719<span></span>
</td>
<td class="nump">8,702,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued (in shares)</a></td>
<td class="nump">9,252,719<span></span>
</td>
<td class="nump">8,702,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 4,006,510<span></span>
</td>
<td class="nump">$ 9,737,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,817,072<span></span>
</td>
<td class="nump">18,798,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,484,315<span></span>
</td>
<td class="nump">9,166,762<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">32,301,387<span></span>
</td>
<td class="nump">27,965,105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(28,294,877)<span></span>
</td>
<td class="num">(18,227,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(8,327)<span></span>
</td>
<td class="num">(991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,336,837<span></span>
</td>
<td class="nump">1,937,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,328,510<span></span>
</td>
<td class="nump">1,936,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,966,367)<span></span>
</td>
<td class="num">$ (16,290,695)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (2.98)<span></span>
</td>
<td class="num">$ (2.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic and diluted (in shares)</a></td>
<td class="nump">9,041,760<span></span>
</td>
<td class="nump">8,073,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Net loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities</a></td>
<td class="num">$ (50,381)<span></span>
</td>
<td class="nump">$ 56,197<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (27,016,748)<span></span>
</td>
<td class="num">$ (16,234,498)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">5,674,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 5,674<span></span>
</td>
<td class="nump">$ 61,811,889<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (54,440,789)<span></span>
</td>
<td class="nump">$ 7,376,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs (in shares)</a></td>
<td class="nump">2,083,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs</a></td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="nump">46,396,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,398,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock options granted in lieu of compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">255,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Cashless exercise of prefunded warrants (in shares)</a></td>
<td class="nump">944,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Cashless exercise of prefunded warrants</a></td>
<td class="nump">$ 945<span></span>
</td>
<td class="num">(945)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,405,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,405,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,197<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,290,695)<span></span>
</td>
<td class="num">(16,290,695)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">8,702,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 8,702<span></span>
</td>
<td class="nump">109,868,913<span></span>
</td>
<td class="nump">56,197<span></span>
</td>
<td class="num">(70,731,484)<span></span>
</td>
<td class="nump">39,202,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs (in shares)</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">4,588,137<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,588,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,448,634<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,448,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized (loss) gain on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,381)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(50,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,966,367)<span></span>
</td>
<td class="num">(26,966,367)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">9,252,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 9,252<span></span>
</td>
<td class="nump">$ 115,905,684<span></span>
</td>
<td class="nump">$ 5,816<span></span>
</td>
<td class="num">$ (97,697,851)<span></span>
</td>
<td class="nump">$ 18,222,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,966,367)<span></span>
</td>
<td class="num">$ (16,290,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on marketable securities, net</a></td>
<td class="num">(854,077)<span></span>
</td>
<td class="num">(1,205,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,448,634<span></span>
</td>
<td class="nump">1,405,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">638,355<span></span>
</td>
<td class="num">(641,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred offering costs</a></td>
<td class="num">(310,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(67,322)<span></span>
</td>
<td class="nump">848,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">834,157<span></span>
</td>
<td class="nump">690,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Grant receivable</a></td>
<td class="nump">1,827,238<span></span>
</td>
<td class="num">(1,338,827)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,449,963)<span></span>
</td>
<td class="num">(16,530,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(25,402,751)<span></span>
</td>
<td class="num">(48,101,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">43,500,000<span></span>
</td>
<td class="nump">19,440,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">18,097,249<span></span>
</td>
<td class="num">(28,661,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from sale of common stock, prefunded warrants and common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46,398,606<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,588,687<span></span>
</td>
<td class="nump">46,398,606<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(764,027)<span></span>
</td>
<td class="nump">1,206,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the year</a></td>
<td class="nump">8,999,496<span></span>
</td>
<td class="nump">7,792,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of the year</a></td>
<td class="nump">8,235,469<span></span>
</td>
<td class="nump">8,999,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_OptionsGranted', window );">Stock options granted in lieu of cash bonus</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">255,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_CashlessExerciseOfWarrants', window );">Cashless exercise of pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs in accounts payable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvo_OpenMarketSalesAgreementMember', window );">Open Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock under At-the-Market Sales Agreement, net of issuance costs</a></td>
<td class="nump">$ 4,588,687<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cashless exercise of warrants in noncash investing and financing transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt offering costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_OptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the monetary value of options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_OptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvo_OpenMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvo_OpenMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Award Timing Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable', window );"><strong>Schedule of Segment Reporting Information, by Segment [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock', window );">Award Timing, How MNPI Considered [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The additional information required by Item 11 of Form 10-K is incorporated herein by reference from our Proxy Statement, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the captions, &#8220;<i>Executive Compensation</i>,&#8221; &#8220;<i>Director Compensation</i>,&#8221; &#8220;<i>Compensation Committee Report</i>,&#8221; and &#8220;<i>Corporate Governance </i>&#8211;<i> Compensation Committee Interlocks and Insider Participation</i>.&#8221;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AwardTmgMnpiCnsdrdFlag', window );">Award Timing MNPI Considered [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgHowMnpiCnsdrdTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgHowMnpiCnsdrdTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AwardTmgMnpiCnsdrdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection x<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AwardTmgMnpiCnsdrdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about profit (loss) and total assets by reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement [Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 54pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9B.</b></p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Adoption, Termination or Modification of Trading Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">During the year ended&#160;December&#160;31, 2025, <span style="-sec-ix-hidden:c945"><span style="-sec-ix-hidden:c946"><span style="-sec-ix-hidden:c947"><span style="-sec-ix-hidden:c948">none</span></span></span></span> of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act),&#160;adopted,&#160;terminated&#160;or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cybersecurity Risk Management Program Overview</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c38">We recognize the critical role that properly managing cybersecurity risk plays in maintaining the trust and confidence of our stockholders, the patients in our clinical trials, our employees, our business partners and our other stakeholders. Accordingly, our cybersecurity program is designed to identify, assess, manage and mitigate material risks from cybersecurity threats through a variety of measures, including risk assessments, implementation of security measures, and ongoing monitoring of systems and networks. In collaboration with our third-party IT service providers, a cross-functional team comprised of representatives from our administrative, finance and legal functions actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We also engage external experts, including IT experts, other consultants, and auditors to evaluate our cybersecurity measures and risk management processes.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We also identify our cybersecurity threat risks by comparing our processes to industry standards and best practices as well as by engaging experts to manage our information systems. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, the activities we undertake include the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws, including industry-specific laws such as HIPAA, as applicable;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">through our policies, practices and contracts (as applicable), employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, which are evaluated and improved through vulnerability assessments and other evaluations on a routine basis;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">leverage threat intelligence available to us and our third-party IT service provider to help us identify, protect, detect, respond and recover if there is an actual or potential cybersecurity incident; and</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident.</p>
			</td>
		</tr>

</tbody></table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Board Oversight of Cybersecurity Risk Management and Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management's Role in Cybersecurity Risk Management and Governance</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c49">We depend on and engage various other third parties, including suppliers, vendors, and service providers, to support key elements of our business including our IT infrastructure. We have implemented various control processes designed to address cybersecurity threat risks associated with our use of such third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, and continually monitor cybersecurity threat risks identified through such diligence. Our management is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents, including through the receipt of notifications from service providers and reliance on communications with risk management, legal, IT, and/or compliance personnel. In addition, cybersecurity risks and posture are, as appropriate and applicable, a factor considered in the selection process prior to our engagement of third-party service providers.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><span style="-sec-ix-hidden:c50">In response to an identified cybersecurity incident, a group comprised of appropriate management personnel, our third-party IT service providers and, depending on the scope and severity of the incident, additional third-party subject matters experts, will be assembled to develop and implement a response strategy to contain, control, and remediate the cybersecurity incident, including securing our affected systems and/or information, mitigating harmful effects of the incident, preventing further compromises, and communicating information to affected parties, regulatory agencies and law enforcement, as necessary. This group will also report any such cybersecurity incident to the Audit Committee of the Board.</span></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Assessment of Cybersecurity Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The potential impact of risks from cybersecurity threats are assessed on an ongoing basis by both management and the Board, including how such risks could materially affect our business strategy, operational results, and financial condition, and from time-to-time we engage third-parties to provide independent risk assessments.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of the date of this Annual Report, we have not experienced a cybersecurity incident that results in a material effect on our business strategy, results of operations or financial condition, but we cannot provide assurance that we will not be materially affected in the future by such an incident or risks related thereto.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading <i>Item 1A. Risk Factors </i>&#8211;<i> General Risks Related to Our Business and Operations</i>, which disclosures are incorporated by reference herein.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We recognize the critical role that properly managing cybersecurity risk plays in maintaining the trust and confidence of our stockholders, the patients in our clinical trials, our employees, our business partners and our other stakeholders. Accordingly, our cybersecurity program is designed to identify, assess, manage and mitigate material risks from cybersecurity threats through a variety of measures, including risk assessments, implementation of security measures, and ongoing monitoring of systems and networks. In collaboration with our third-party IT service providers, a cross-functional team comprised of representatives from our administrative, finance and legal functions actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We also engage external experts, including IT experts, other consultants, and auditors to evaluate our cybersecurity measures and risk management processes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">As of the date of this Annual Report, we have not experienced a cybersecurity incident that results in a material effect on our business strategy, results of operations or financial condition, but we cannot provide assurance that we will not be materially affected in the future by such an incident or risks related thereto.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - The Company and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 1. The Company and Description of Business</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is a corporation organized under the laws of the state of Delaware and headquartered in Boston, Massachusetts. The Company is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. The Company recently completed its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB funded primarily by a $21.3 million grant from the NIA.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity and Capital Resources<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 2. Liquidity and Capital Resources</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Liquidity and Capital Resources</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has $20.9 million of cash, cash equivalents, and marketable securities as of December&#160;31, 2025, has generated negative cash flows from operations and had an accumulated deficit of $97.7 million as of December&#160;31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s future viability is dependent on its ability to raise additional capital to finance its operations and pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. These conditions cause substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company will continue to require additional financing to advance its current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. The Company intends to continue to seek funds through equity offerings, debt financings or other capital sources, including grants, potential collaborations, licenses and other similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. If the Company does raise additional capital through public or private equity offerings, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect the Company's stockholders&#8217; rights. If the Company raises additional capital through a debt financing, it may be subject to covenants limiting or restricting the Company's ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on the Company's financial condition and on its ability to pursue its business plans and strategies. If the Company is unable to raise sufficient capital when needed, it may need to delay, reduce or terminate planned activities to reduce costs, including development or commercialization activities for neflamapimod. The Company might also be required to seek funds through arrangements with third parties that require it to relinquish certain of its rights to neflamapimod or otherwise agree to terms unfavorable to the Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Accordingly, substantial doubt about the Company&#8217;s ability to continue as a going concern is not alleviated. Based on its current operating plan, the Company does not believe its existing cash, cash equivalents and marketable securities on hand of $20.9 million as of December&#160;31, 2025 will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty described in this Note 2.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risks and Uncertainties</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#8217;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#8217;s control, including internal and external factors that may affect the success or failure of the Company&#8217;s research and development efforts, the length of time and cost of developing and commercializing the Company&#8217;s current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug&#8217;s market share will be, if approved, among others.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidity of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 3. Summary of Significant Accounting Policies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Basis of presentation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements have been prepared in conformity with US GAAP as defined by the FASB.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Consolidation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of estimates</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company&#8217;s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in US government securities, commercial paper, and corporate debt securities.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the years ended December&#160;31, 2025 and 2024.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Marketable Securities</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, US government debt securities, and corporate debt securities with original maturities of greater than 90 days from date of purchase. These securities are carried at fair value, with unrealized gains and losses reported on the consolidated statements of operations and comprehensive loss and accumulated other comprehensive income within stockholders&#8217; equity until realized. Purchase discounts are accreted using the effective interest method over the term of the related security and such accretion is included in interest income on the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluates its investments in marketable securities for impairment at each reporting period when the fair value is below amortized cost. If the Company intends to sell the security, or it is more likely than not the Company will be required to sell the security before recovery of amortized cost, the entire impairment is included in earnings. The Company did <span style="-sec-ix-hidden:c292"><span style="-sec-ix-hidden:c293">not</span></span> record any impairment on marketable securities during years ended December&#160;31, 2025 and 2024. There was <span style="-sec-ix-hidden:c294"><span style="-sec-ix-hidden:c295">no</span></span> allowance for credit losses as of December&#160;31, 2025 or December 31, 2024.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Equity Issuance Costs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company capitalizes costs directly associated with equity financings as deferred offering costs on its consolidated balance sheet. These costs remain capitalized until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. With respect to financings conducted on an ongoing basis, such as at-the-market offerings, costs are recognized ratably as funds are received in proportion to the aggregate offering amount. If a financing is abandoned, any remaining deferred offering costs are expensed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, there were $0.3 million of deferred offering costs related to the Sales Agreement. There were <span style="-sec-ix-hidden:c297">no</span> deferred offering costs as of December 31, 2024, as the Sales Agreement was entered into in May 2025.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 1</i> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement&#160; &#160; date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 2</i> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 3</i> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for leases in accordance with ASC Topic 842, Leases, which requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and expense recognition in the statement of operations and comprehensive loss as well as the reduction of the ROU asset. The standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU assets, lease liabilities, current and lease liabilities, non-current. Fixed rent payments are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A substantial portion of the Company's ongoing research and development activities are conducted by third-party service providers. The Company records an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. The Company monitors subject enrollment levels and related activity to the extent reasonably possible and makes judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of nonclinical studies and clinical trial expenses.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Patent Costs </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>






<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. The Company accounts for forfeitures as they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of stock options is determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Term</i>&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The Company uses the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the Company stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical data and the plain-vanilla nature of the Company&#8217;s stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Volatility</i>&#8212;The Company has limited information on the volatility of its common stock as the shares were not actively traded on any public markets until recently. The expected volatility is derived from the historical stock volatility of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the expected term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Dividend Rate</i>&#8212;The expected dividend is <span style="-sec-ix-hidden:c298">zero</span> as the Company has not paid, nor does it anticipate paying, any dividends on its stock options in the foreseeable future.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Grant Revenue</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes funding received from the NIA Grant as <span style="-sec-ix-hidden:c299"><span style="-sec-ix-hidden:c300">grant revenue</span></span>, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#8217;s consolidated balance sheets as accounts receivable. Amounts received in advance of services rendered are recorded as <span style="-sec-ix-hidden:c301">deferred grant revenue</span> on the Company's consolidated balance sheets. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</p>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statements of operations and comprehensive loss for the period that includes the enactment date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes interest and penalties, if any, related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related liability lines in the consolidated balance sheet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>






<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss Per Share</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that, when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,598,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,609,289</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">992,701</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">636,802</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,591,038</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,246,091</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): &#8220;Improvements to Income Tax Disclosures&#8221; ("ASU 2023-09"). ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements as well. The guidance in ASU 2023-09 is effective for annual reporting periods in fiscal years beginning after December 15, 2024 and was adopted prospectively by the Company during the year ended December 31, 2025. The adoption of ASU 2023-09 impacted the Company&#8217;s income tax disclosures only and did not have an impact on its consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses" ("ASU 2024-03"). ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the statement of operations and comprehensive loss, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 4. Fair Value of Financial Instruments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company&#8217;s financial instruments consist primarily of cash, cash equivalents, marketable securities, and accounts payable. The Company&#8217;s cash, cash equivalents, and accounts payable approximate fair value due to their relatively short maturities.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market accounts</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,300,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999,330</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,139,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,238,538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,552</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,300,291</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,628,300</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents (money market accounts)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,559,336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,032,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,951,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,938,520</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,559,336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,922,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair values of the Company&#8217;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following is a summary of the Company's marketable securities which provides a reconciliation of amortized cost basis to fair value including cumulative unrealized gains and losses as of December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,134,856</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,024</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,139,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,237,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,238,538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,504</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">48</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,552</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,623,154</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,816</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,628,970</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,019,334</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,393</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,032,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,920,620</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,440</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,951,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,926,372</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,938,520</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,866,326</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,981</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,922,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December&#160;31, 2025 and 2024.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Significant Agreements and Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 5. Significant Agreements and Contracts</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Vertex Option and License Agreement</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In August 2012, the Company entered the Vertex Agreement to acquire an exclusive license to develop and commercialize a drug candidate, &#8220;VX-745,&#8221; from Vertex. In August 2014, the Company exercised its option to acquire the license and paid an option fee of $100,000, which was expensed as incurred as a component of research and development expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Vertex Agreement granted the Company the exclusive worldwide use of VX-745 in the field of diagnosis, treatment and prevention of AD and related CNS disorders in humans.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As part of the Vertex Agreement, the Company is obligated to make certain payments totaling up to approximately $117.0 million upon achievement of certain regulatory and sales milestones, and royalties on net sales of products on indications covered by the Vertex Agreement. The first expected milestone events concern filing of an NDA with the FDA for marketing approval of neflamapimod in the US, or a similar filing for a non-US major market, as specified in the Vertex Agreement, and such royalties will be on a sliding scale of percentages of net sales in the low- to mid-teens, depending on the amount of net sales in the applicable years. The Company is also obligated to make a milestone payment to Vertex upon net sales reaching a certain specified amount in any 12-month period. The Vertex Agreement states that royalties will be reduced by 50% during any portion of the royalty term when there is no valid claim of an issued patent within specified patent rights covering the licensed product. The Company also has the right to deduct, on a country by country basis, from royalties otherwise payable to Vertex under the terms of the Vertex Agreement, 50% of all royalties, upfront fees, milestones and other payments paid by the Company or any of the Company&#8217;s affiliates or sublicensees to third parties under licenses that are necessary for the development, manufacture, sale or use of a licensed product, provided that in no event will the royalty payable to Vertex be reduced to less than 50% of the rates specified in the Vertex Agreement, subject to certain adjustments specified therein. The Company has made a total of $100,000 in payments to Vertex related to the Vertex Agreement. <span style="-sec-ix-hidden:c488"><span style="-sec-ix-hidden:c489">No</span></span> payments were made during the years ended December&#160;31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>National Institute of Aging Grant</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In January 2023, the Company was awarded a $21.0 million grant from the NIA to support its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB and, in August 2024, the Company was awarded an additional $0.3 million under the grant. The grant monies were expected to be received over a period of three years including $6.7 million in 2023, $8.4 million in 2024 and $6.2 million in 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The total revenue recognized from the NIA Grant was $4.0 million and $9.7 million for the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, aggregate total cash funding of $20.5 million has been received from the NIA Grant, resulting in approximately $0.6 million in funding remaining. The Company has recorded $0.4 million as a receivable in the consolidated balance sheet at December&#160;31, 2025, for allowable expenses incurred prior to December&#160;31, 2025, which is expected to be received subsequent to December&#160;31, 2025. As of December 31, 2024, $2.3 million was recorded as a receivable in the consolidated balance sheet, for allowable expenses incurred during the year ended December 31, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2025, the Company received access to 90% of the year 3 funding and, in June 2025, the Company received access to an additional 8% of the year 3 funding provided for in the NIA Grant, due to then-current NIA policy as a result of the US government currently being funded on the basis of a continuing resolution. Accordingly, as of December 31, 2025, we determined that the receipt of the remaining 2% of funding is not probable and we would not account for the remaining 2% of funding unless and until received. In January 2026, we were informed that we will not receive the final 2% of year 3 grant funding that remained unavailable as of December 31, 2025, or approximately $0.1&#160;million, as a result of agency-wide reductions in NIA funding.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 6. Prepaid Expenses</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prepaid expenses consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">677,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,149,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">405,795</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">443,141</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,803</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95,218</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dues and memberships</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,975</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">205,881</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,267,005</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,905,360</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 7. Accrued Expenses and Other Current Liabilities</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses and other current liabilities consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee compensation costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,061,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">803,193</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical development costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,484,318</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,158,783</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">532,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">249,527</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State franchise and excise tax</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,456</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,456</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">83,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">115,883</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,201,999</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,367,842</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 8. Commitments and Contingencies</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Leases</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has a short-term lease for office space in Boston, Massachusetts. Lease expense was approximately $57,112 and $34,692 for the years ended December&#160;31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Research and Development Arrangements</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In the course of normal business operations, the Company enters into agreements with universities and CROs to assist in the performance of research and development activities and with CDMOs to assist with CMC-related activities. Expenditures to CROs and other CDMOs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Defined Contribution Retirement Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#8217;s compensation. There were total contributions under the 401(k) Plan of $0.4 million and $0.2 million for the years ended December&#160;31, 2025 and 2024, respectively.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Legal Proceedings</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#8217;s legal predecessor, under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, and the parties have agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff&#8217;s counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties' joint stipulation, the court entered an order continuing the trial date to October 25, 2023, on October 6, 2023, the court entered an order further continuing the trial date to April 24, 2024, and on March 3, 2024, based on an additional joint stipulation of the parties, the court entered an order continuing the trial date to October 23, 2024. On September 4, 2024, due to certain delays in discovery as a result of, among other things, plaintiff's counsel's health complications, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto. On October 9, 2024, based on the parties' joint stipulation, the court entered an order continuing the trial date to April 30, 2025. On January 6, 2025, the Company filed a Motion for Summary Adjudication against plaintiff&#8217;s claims for promissory fraud, negligent misrepresentation, and common counts. On February 21, 2025, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto and, on March 12, 2025, the court entered an order continuing the trial date to November 26, 2025. On October 22, 2025, pursuant to an additional joint stipulation to continue the trial and certain deadlines related thereto filed by the parties, the court entered an order continuing the trial date to May 13, 2026.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company is defending itself vigorously against the claims alleged in this matter. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material adverse effect on the Company&#8217;s financial position, results of operations and cash flows.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note 9. Stockholders' Equity and Common Stock Warrants</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>April 2024 Private Placement</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 1, 2024, pursuant to and in accordance with the terms of a securities purchase agreement with certain purchasers named therein, the Company completed the 2024 Private Placement of an aggregate of 2,083,262 shares of common stock, 2,532,285 Series A Warrants and 449,023 Pre-Funded Warrants. The aggregate upfront gross proceeds from the 2024 Private Placement were approximately $50.0 million, before deducting approximately $3.6 million of offering fees and expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Pre-Funded Warrants and Series A Warrants were classified as a component of stockholders&#8217; equity within additional paid-in capital. The Pre-Funded Warrants and Series A Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#8217;s common stock and (vi) meet the equity classification criteria.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Warrants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company had the following warrants outstanding to acquire shares of its common stock:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of exercise price per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical Diffusion common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,434</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c614">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical EIP common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,618</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c617">April 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,532,285</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c620">April 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,598,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15%;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 11, 2026, the remaining historical Diffusion common stock warrants expired unexercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>February 2024 Pre-Funded Warrant Exercise</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On February 26, 2024, following the effectiveness of an amendment eliminating certain beneficial ownership limitations set forth therein, 499,995 previously outstanding pre-funded warrants to purchase common stock issued in connection with the closing of the Merger were exercised in full by the holder thereof pursuant to the cashless exercise provision of the pre-funded warrants. Upon exercise, 36 shares were withheld in lieu of a cash payment of the exercise price and the holder was issued 495,959 shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>December 2024 Pre-Funded Warrant Exercise</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On December 11, 2024, 449,023 Pre-Funded Warrants to purchase common stock issued in connection with the closing of the 2024 Private Placement were exercised in full by the holder thereof pursuant to the cashless exercise provision of the Pre-Funded Warrants. Upon exercise, 45 shares were withheld in lieu of a cash payment of the exercise price and the holder was issued 448,978 shares of common stock.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>May 2025 At-The-Market Offering</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On May 12, 2025, the Company entered into the Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock from time-to-time with an aggregate offering price of up to $50.0 million under an &#8220;at-the-market" offering program. During the year ended December&#160;31, 2025, the Company sold 550,000 shares of common stock to an institutional investor in a block sale for proceeds of $4.7 million, net of $0.1 million of issuance costs.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payment Arrangement [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 10. Stock-Based Compensation Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2015 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company&#8217;s Board. On January 1, 2025, the number of shares available for future issuance under the 2015 Equity Plan increased by 348,109. As of December&#160;31, 2025, the term of the 2015 Equity Plan had expired and no additional shares will be issued thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2018 Employee, Director and Consultant Equity Incentive Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On March 28, 2018, EIP adopted the 2018 Plan, which was assumed by the Company pursuant to and in accordance with the terms of the Merger Agreement. Under the 2018 Plan, the Company may issue incentive stock options, non-qualified stock options, stock grants, and other stock-based awards to employees, directors, and consultants, as specified in the 2018 Plan and subject to applicable SEC and Nasdaq rules and regulations. The Board has the authority to determine to whom options or stock will be granted, the number of shares, the term, and the exercise price. Options granted under the 2018 Plan have a term of up to <span style="-sec-ix-hidden:c627">ten</span> years and generally vest over a <span style="-sec-ix-hidden:c628">four-year</span> period with 25% of the options vesting after <span style="-sec-ix-hidden:c630">one-year</span> of service and the remainder vesting monthly thereafter. As of December&#160;31, 2025, there were <span style="-sec-ix-hidden:c631">no</span> shares available for issuance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Inducement Grants</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended December 31, 2024, the Company granted stock options to purchase an aggregate of 71,712 shares of common stock as material inducements to the employment of <span style="-sec-ix-hidden:c633">five</span> new employees, in each case, in accordance with Nasdaq Listing Rule 5635(c)(4). Each such inducement option has a term of <span style="-sec-ix-hidden:c634">ten</span> years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In June 2025, the Company granted a stock option to purchase an aggregate of 54,000 shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of <span style="-sec-ix-hidden:c637">ten</span> years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In October 2025, the Company granted a stock option to purchase an aggregate of 75,000 shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of <span style="-sec-ix-hidden:c640">ten</span> years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>2025 Equity Plan</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 14, 2025, the Board approved the 2025 Equity Plan, and the 2025 Equity Plan was subsequently approved by the Company's stockholders at its 2025 Annual Meeting of Stockholders on June 23, 2025. As of December&#160;31, 2025, there were 735,200 shares available for future issuance under the 2025 Equity Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">965,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,186,900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,448,634</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,405,722</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following table summarizes the activity related to all stock option grants for the year ended December&#160;31, 2025:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise price</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>contractual term (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">636,802</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">466,600</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.61</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,367</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.84</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(42,334</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">992,701</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">561,358</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Black-Scholes option pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">5.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">5.25</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.46</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">71.55</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">76.06</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At December&#160;31, 2025, there was $1.9 million of unrecognized compensation expense that will be recognized over a weighted-average period of 2.0 years.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">During the year ended December 31, 2024, the Company granted 39,721 options in lieu of 2023 executive bonus compensation. <span style="-sec-ix-hidden:c683">No</span> similar event occurred during the year ended December&#160;31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Effective May 31, 2024, the Company separated from its former Chief Financial Officer. Based on the terms of his separation agreement, unvested shares under previously granted option awards continued to vest on the schedule provided for in the applicable option award agreement through September 30, 2025. The Company accounted for the change in vesting terms as an improbable-to-probable modification of his stock options and recognized $0.3 million of expense in relation to this modification during the year ended December 31, 2024. In addition, the exercise period for any shares under previously granted option awards vested as of May 31, 2024 was extended to September 30, 2025. The Company accounted for the change in exercise terms as a probable-to-probable modification of his stock options and recognized $12,000 of expense in relation to this modification during the year ended December 31, 2024. As of October 1, 2025, all such option awards expired unexercised.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On April 14, 2025, the Board approved a separation agreement with the Company&#8217;s former Chief Operating Officer, pursuant to which the executive's employment with the Company concluded effective July 1, 2025. Based on the terms of his separation agreement, unvested shares under previously granted option awards will continue to vest on the schedule provided for in the applicable option award agreement through September 30, 2026. The Company accounted for the change in vesting terms of his unvested stock options as an improbable-to-probable modification of his stock options and recognized $0.2 million of expense in relation to this modification during the year ended December&#160;31, 2025. In addition, the exercise period for any shares under previously granted option awards vested as of April 14, 2025 was extended to September 30, 2026. The Company accounted for the change in exercise terms as probable-to-probable modification of his stock options and recognized $0.1 million of expense in relation to this modification during the year ended December&#160;31, 2025.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 11. Income Taxes</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosures required for income taxes in the Company&#8217;s annual consolidated financial statements. The guidance is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 prospectively, and the adoption impacted the Company&#8217;s income tax disclosures only and did not have an impact on its consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b style="font-size: 10pt; text-align: center;">2024</b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rate reconciliation:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal tax benefit at statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5,671,648</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3,421,046</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(710,002</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1,121,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(526,015</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,188,171</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,443,812</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(27.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">176,562</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">605,298</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">36,689</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Significant components of the Company's deferred tax assets for federal income taxes as of December&#160;31, 2025 and 2024 consisted of the following:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,388,936</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,417,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,367,496</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,228,255</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized research expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,289,629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,392,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">977,321</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">698,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Charitable contributions</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,130</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,321</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangibles</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">182,441</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">193,106</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,207,953</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,931,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27,687,487</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18,557,844</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaids</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred tax assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company does <span style="-sec-ix-hidden:c781"><span style="-sec-ix-hidden:c782">not</span></span> have unrecognized tax benefits as of December&#160;31, 2025 or 2024. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&#160;31, 2025, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance increased by $9.1 million during the year ended December&#160;31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company had NOL carryforwards of approximately $16.6 million and $4.8 million for federal and state tax purposes, respectively. Federal NOL carryforwards will not expire and state NOL carryforwards will begin to expire in 2038, if not utilized. The TCJA enacted on December 22, 2017 limits a taxpayer&#8217;s ability to utilize NOL deduction in a year to 80% taxable income for federal NOLs arising in tax years beginning after 2017, however, federal NOLs post 2017 have no expiration.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, the Company also had federal and state research credit carryforwards of $2.3 million and $0.1 million, respectively. The federal and state research credits will begin to expire in 2038 and 2034, respectively. Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Code, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383 of the Code, which provides for special limitations on certain excess credits, as well as similar state provisions. Accordingly, the Company&#8217;s ability to utilize NOL carryforwards may be limited as the result of such an &#8220;ownership change.&#8221; A formal Section 382 study was performed through December 31, 2023 which concluded&#160;there have been no historical section 382 ownership changes, thus the NOL carryforwards were not subject to an annual limitation through December 31, 2023. The Company has not conducted a study since December 31, 2023 to assess whether a change of control has occurred. If the Company has experienced a change of control, as defined by Section 382, subsequent to the last study, utilization of the net operating loss carryforwards or research and development tax credit carryforwards could be subject to an annual limitation under Section 382. With respect to Diffusion, the Company deems the historical Diffusion tax attributes (NOLs/Credits) are unusable due to the IRC Section 382 limitation. ASC 740-10-25 states that a &#8220;write off might be appropriate if there is only a remote likelihood that the entity will utilize the carryforward (i.e. NOL), it is acceptable for the entity to write off the deferred tax assets against the valuation allowance, thereby eliminating the need to disclose the gross amounts.&#8221; As such, the Company has written off these attributes.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company files federal and state income tax returns in jurisdictions with varying statutes of limitations. Due to its NOL carryforwards, the Company&#8217;s income tax returns generally remain subject to examination by federal and state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company uses the &#8220;more likely than not&#8221; criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and believes that its income tax filing positions and deductions will be sustained upon examination. Accordingly, no reserves for uncertain income tax positions or related accruals for interest and penalties have been recorded as of December&#160;31, 2025 and 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>





<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements as of December&#160;31, 2025:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Rate reconciliation:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Federal statutory tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,671,648</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and local income tax, net of federal (national) income tax effect (a)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,121,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowances</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,188,171</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">605,298</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a) State taxes in Illinois and Massachusetts&#160;made up the majority of the tax effect in this category</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">During the year ended December 31, 2025, the Company did not pay any federal income taxes. Additionally, the amount paid in state income taxes, net of refunds received, was immaterial for the year ended December 31, 2025.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">On July 4, 2025, the US government enacted the OBBBA, which includes, among other provisions, changes to the US corporate income tax system including the allowance of immediate expensing of qualifying research and development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act. The Company has analyzed the impacts of the OBBBA and reflected them in the current period, resulting in a decrease to the deferred tax asset and valuation allowance of approximately $18.0 million gross ($5.1M tax effected) due to immediate expensing of domestic research and development expenditures.</p>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting Disclosure [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 12. Segments</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM, or decision-making group, in deciding how to allocate resources in assessing performance. CervoMed Inc. has one reportable segment which consists of the development of clinical and nonclinical product candidates for treatments for age-related neurologic disorders and other medical indications. The Company&#8217;s CODM is the Chief Executive Officer.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The accounting policies of the Company&#8217;s <span style="-sec-ix-hidden:c867">single</span> segment are the same as those described in the summary of significant accounting policies. To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. The CODM assesses the financial performance for the Company's segment based on net loss. The CODM also uses internal budget versus forecasted expense and cash forecast models in making certain decisions. Such models are reviewed to assess the entity-wide/single-segment operating results and performance, including how long cash-on-hand is expected to be sufficient. The measure of segment assets is reported on the consolidated balance sheet as total assets. The segment measure of loss is reported on the consolidated statement of operations and comprehensive loss as net loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the year ended December&#160;31, 2025 and 2024:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,006,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,737,974</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dementia with Lewy bodies</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,052,512</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,102,842</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Frontotemporal disorders (incl. nfvPPA)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,217,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recovery after stroke</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,427,966</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,659</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other clinical* and nonclinical</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,504,863</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,499,202</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,745,558</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,187,221</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other research and development expenses, including CMC**</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,385,720</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,361,744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,817,072</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,798,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,988,705</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,995,114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">965,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,186,900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,752,710</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,684,386</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Insurance, taxes and similar fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,166,374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">985,481</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other general and administrative expenses, including IT, facilities, supplies and similar costs***</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">610,561</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">314,879</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total general and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,484,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,166,760</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,328,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,936,436</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,966,367</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(16,290,693</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>


<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* - Includes early-stage clinical studies that are not indication-specific and related costs.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">** - Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">*** - Includes, among other things, costs related to IT systems, rent and other facilities, office supplies, and similar costs.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note 13. Subsequent Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The company evaluated subsequent events from December&#160;31, 2025 to the date the financial statements were issued, noting no events requiring disclosure.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Basis of presentation </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements have been prepared in conformity with US GAAP as defined by the FASB.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Consolidation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of estimates</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company&#8217;s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in US government securities, commercial paper, and corporate debt securities.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the years ended December&#160;31, 2025 and 2024.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Marketable Securities</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, US government debt securities, and corporate debt securities with original maturities of greater than 90 days from date of purchase. These securities are carried at fair value, with unrealized gains and losses reported on the consolidated statements of operations and comprehensive loss and accumulated other comprehensive income within stockholders&#8217; equity until realized. Purchase discounts are accreted using the effective interest method over the term of the related security and such accretion is included in interest income on the accompanying consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluates its investments in marketable securities for impairment at each reporting period when the fair value is below amortized cost. If the Company intends to sell the security, or it is more likely than not the Company will be required to sell the security before recovery of amortized cost, the entire impairment is included in earnings. The Company did <span style="-sec-ix-hidden:c292"><span style="-sec-ix-hidden:c293">not</span></span> record any impairment on marketable securities during years ended December&#160;31, 2025 and 2024. There was <span style="-sec-ix-hidden:c294"><span style="-sec-ix-hidden:c295">no</span></span> allowance for credit losses as of December&#160;31, 2025 or December 31, 2024.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Charges, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Equity Issuance Costs</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company capitalizes costs directly associated with equity financings as deferred offering costs on its consolidated balance sheet. These costs remain capitalized until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. With respect to financings conducted on an ongoing basis, such as at-the-market offerings, costs are recognized ratably as funds are received in proportion to the aggregate offering amount. If a financing is abandoned, any remaining deferred offering costs are expensed.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of December&#160;31, 2025, there were $0.3 million of deferred offering costs related to the Sales Agreement. There were <span style="-sec-ix-hidden:c297">no</span> deferred offering costs as of December 31, 2024, as the Sales Agreement was entered into in May 2025.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fair Value of Financial Instruments</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 1</i> &#8211; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement&#160; &#160; date;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 2</i> &#8211; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"><i>Level 3</i> &#8211; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for leases in accordance with ASC Topic 842, Leases, which requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and expense recognition in the statement of operations and comprehensive loss as well as the reduction of the ROU asset. The standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the standard.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU assets, lease liabilities, current and lease liabilities, non-current. Fixed rent payments are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Research and Development </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#8217; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on the Company&#8217;s behalf.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A substantial portion of the Company's ongoing research and development activities are conducted by third-party service providers. The Company records an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. The Company monitors subject enrollment levels and related activity to the extent reasonably possible and makes judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of nonclinical studies and clinical trial expenses.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Patent Costs </i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payment Arrangement [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Stock-based Compensation</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. The Company accounts for forfeitures as they occur.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The fair value of stock options is determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Term</i>&#8212;The expected term represents the period that stock-based awards are expected to be outstanding. The Company uses the &#8220;simplified method&#8221; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the Company stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical data and the plain-vanilla nature of the Company&#8217;s stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Volatility</i>&#8212;The Company has limited information on the volatility of its common stock as the shares were not actively traded on any public markets until recently. The expected volatility is derived from the historical stock volatility of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#8217;s business over a period equivalent to the expected term of the stock-based awards.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Risk-Free Interest Rate</i>&#8212;The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the expected term.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Expected Dividend Rate</i>&#8212;The expected dividend is <span style="-sec-ix-hidden:c298">zero</span> as the Company has not paid, nor does it anticipate paying, any dividends on its stock options in the foreseeable future.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Grant Revenue</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes funding received from the NIA Grant as <span style="-sec-ix-hidden:c299"><span style="-sec-ix-hidden:c300">grant revenue</span></span>, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#8217;s consolidated balance sheets as accounts receivable. Amounts received in advance of services rendered are recorded as <span style="-sec-ix-hidden:c301">deferred grant revenue</span> on the Company's consolidated balance sheets. The related costs incurred by the Company are included in research and development expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Income Taxes</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statements of operations and comprehensive loss for the period that includes the enactment date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#8217;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company recognizes interest and penalties, if any, related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related liability lines in the consolidated balance sheet.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Net Loss Per Share</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that, when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#160;</p>


<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,598,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,609,289</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">992,701</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">636,802</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,591,038</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,246,091</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>


<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): &#8220;Improvements to Income Tax Disclosures&#8221; ("ASU 2023-09"). ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements as well. The guidance in ASU 2023-09 is effective for annual reporting periods in fiscal years beginning after December 15, 2024 and was adopted prospectively by the Company during the year ended December 31, 2025. The adoption of ASU 2023-09 impacted the Company&#8217;s income tax disclosures only and did not have an impact on its consolidated financial statements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses" ("ASU 2024-03"). ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the statement of operations and comprehensive loss, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480102/450-20-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,598,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,609,289</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock options</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">992,701</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">636,802</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,591,038</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,246,091</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Money market accounts</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,300,291</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999,330</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,139,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,238,538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,552</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td class="q2qselectedlineitem" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,300,291</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,628,300</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td class="q2qselectedlineitem" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 1)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 2)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>(Level 3)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Assets</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash equivalents (money market accounts)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,559,336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Marketable securities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,032,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,951,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,938,520</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total assets measured at fair value</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,559,336</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,922,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,134,856</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,024</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,139,880</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,237,794</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,238,538</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,504</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">48</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">250,552</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,623,154</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,816</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,628,970</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amortized Cost</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized gains</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Unrealized losses</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Fair Value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Commercial paper</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,019,334</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,393</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,032,943</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US treasury bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,920,620</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,440</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,951,060</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US government agency bonds</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,926,372</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">12,148</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,938,520</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,866,326</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">58,981</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,922,523</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">677,604</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,149,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Insurance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">405,795</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">443,141</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional services</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,803</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">95,218</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dues and memberships</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,828</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,777</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,975</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">205,881</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,267,005</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,905,360</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31, 2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Employee compensation costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,061,766</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">803,193</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical development costs</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,484,318</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,158,783</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">532,076</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">249,527</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State franchise and excise tax</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,456</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">40,456</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">83,383</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">115,883</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,201,999</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,367,842</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Outstanding</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Range of exercise price per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration date</b></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical Diffusion common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22,434</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">96.12</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c614">February 2026</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Historical EIP common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">43,618</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.81</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c617">April 2028</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Series A common stock warrants</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,532,285</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">$</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c620">April 2027</span></p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 51%;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,598,337</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right; width: 7%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 15%;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">965,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,186,900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,448,634</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,405,722</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Number of</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Options</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>exercise price</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>per share</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Weighted</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>average</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>remaining</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>contractual term (in years)</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Aggregate intrinsic value</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Balance at January 1, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">636,802</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19.38</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.6</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Granted</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">466,600</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.61</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expired</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(68,367</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">45.84</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Forfeited</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(42,334</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8.22</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outstanding at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">992,701</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable at December 31, 2025</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">561,358</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">15.92</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected term (in years)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">5.24</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">5.25</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.76</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.35</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">3.89</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.46</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected volatility</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">71.55</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76.68</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">76.06</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">-</td>
			<td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">80.03</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dividend yield</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b style="font-size: 10pt; text-align: center;">2024</b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>Total</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b><b>%</b></b></b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Rate reconciliation:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Federal tax benefit at statutory rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(5,671,648</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(3,421,046</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State tax, net of federal benefit</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(710,002</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.4</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1,121,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(526,015</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Change in valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6,188,171</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4,443,812</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(27.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Share-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">176,562</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1.1</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">605,298</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">36,689</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Amount</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Percentage</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Rate reconciliation:</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">US Federal statutory tax rate</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(5,671,648</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">State and local income tax, net of federal (national) income tax effect (a)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Tax credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,121,821</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.2</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Changes in valuation allowances</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,188,171</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22.9</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Nontaxable or nondeductible items</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">605,298</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2.3</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total provision</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.0</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax assets:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net operating loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,388,936</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,417,666</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development credits</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,367,496</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,228,255</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Capitalized research expenditures</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,289,629</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,392,545</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">977,321</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">698,886</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Charitable contributions</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,130</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,321</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Intangibles</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">182,441</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">193,106</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">28,207,953</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,931,779</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Less valuation allowance</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(27,687,487</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(18,557,844</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total deferred tax assets</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Deferred tax liabilities:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Prepaids</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gross deferred tax liabilities</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(520,466</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(373,935</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Deferred tax assets, net</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment [Table Text Block]</a></td>
<td class="text">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Year Ended</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>December 31,</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2025</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2024</b></p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Grant revenue</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,006,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,737,974</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Dementia with Lewy bodies</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,052,512</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12,102,842</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Frontotemporal disorders (incl. nfvPPA)</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,217,784</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,853</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Recovery after stroke</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,427,966</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">391,659</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other clinical* and nonclinical</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,504,863</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,499,202</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,745,558</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,187,221</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">482,669</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">218,822</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other research and development expenses, including CMC**</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,385,720</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,361,744</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total research and development expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21,817,072</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,798,343</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative expenses:</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Personnel costs, excluding stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,988,705</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,995,114</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Stock-based compensation</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">965,965</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,186,900</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Professional fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,752,710</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,684,386</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Insurance, taxes and similar fees</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,166,374</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">985,481</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other general and administrative expenses, including IT, facilities, supplies and similar costs***</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">610,561</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">314,879</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total general and administrative expenses</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,484,315</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,166,760</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Other income</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,328,510</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,936,436</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Net loss</p>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,966,367</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(16,290,693</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
		</tr>

</tbody></table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - The Company and Description of Business (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance, Asset</a></td>
<td class="nump">$ 21.3<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Liquidity and Capital Resources (Details Textual) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-Term Investments</a></td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (97,697,851)<span></span>
</td>
<td class="num">$ (70,731,484)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)<br> Pure in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ImpairmentOfMarketableSecurities', window );">Impairment of Marketable Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Debt Securities, Available-for-Sale, Allowance for Credit Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="nump">$ 320,581<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Revenues<span></span>
</td>
<td class="text">Revenues<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration', window );">Government Assistance, Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Grant receivable<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ImpairmentOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ImpairmentOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes asset from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">3,591,038<span></span>
</td>
<td class="nump">3,246,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">2,598,337<span></span>
</td>
<td class="nump">2,609,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="nump">992,701<span></span>
</td>
<td class="nump">636,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">$ 12,628,970<span></span>
</td>
<td class="nump">$ 29,922,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">11,139,880<span></span>
</td>
<td class="nump">18,032,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">250,552<span></span>
</td>
<td class="nump">3,938,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">6,300,291<span></span>
</td>
<td class="nump">7,559,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | US Government Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">6,300,291<span></span>
</td>
<td class="nump">7,559,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">13,628,300<span></span>
</td>
<td class="nump">29,922,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">11,139,880<span></span>
</td>
<td class="nump">18,032,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">1,238,538<span></span>
</td>
<td class="nump">7,951,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | US Government Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">250,552<span></span>
</td>
<td class="nump">3,938,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">999,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | US Government Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 12,623,154<span></span>
</td>
<td class="nump">$ 29,866,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Commercial paper</a></td>
<td class="nump">5,816<span></span>
</td>
<td class="nump">58,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,784)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">12,628,970<span></span>
</td>
<td class="nump">29,922,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,134,856<span></span>
</td>
<td class="nump">18,019,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Commercial paper</a></td>
<td class="nump">5,024<span></span>
</td>
<td class="nump">16,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">11,139,880<span></span>
</td>
<td class="nump">18,032,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember', window );">US Treasury Bond Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,237,794<span></span>
</td>
<td class="nump">7,920,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Commercial paper</a></td>
<td class="nump">744<span></span>
</td>
<td class="nump">30,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">1,238,538<span></span>
</td>
<td class="nump">7,951,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">US Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">250,504<span></span>
</td>
<td class="nump">3,926,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Commercial paper</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">12,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Commercial paper</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Commercial paper</a></td>
<td class="nump">$ 250,552<span></span>
</td>
<td class="nump">$ 3,938,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Significant Agreements and Contracts (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,817,072<span></span>
</td>
<td class="nump">$ 18,798,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,006,510<span></span>
</td>
<td class="nump">9,737,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvo_VertexOptionAndLicenseAgreementMember', window );">Vertex Option and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation</a></td>
<td class="nump">$ 117,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_AgreementMilestonePeriodForNetSales', window );">Agreement, Milestone, Period for Net Sales</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments', window );">Agreement, Maximum Deduction Percentage of Fees and Payments</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PaymentsForLicenseAgreement', window );">Payments for License Agreement</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=crvo_NationalInstituteOfAgingGrantMember', window );">National Institute of Aging Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmountCumulative', window );">Government Assistance, Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government Assistance, Income, Increase (Decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ProceedsFromGrants', window );">Proceeds From Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_GrantFundingRemaining', window );">Grant Funding Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred Revenue, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_GrantAmountReceivedPercentage', window );">Grant Amount, Received, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_GrantAmountRemainingPercentage', window );">Grant Amount Remaining, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_GrantAmountCanceledPercentage', window );">Grant Amount Canceled, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_GrantFundingCanceled', window );">Grant Funding Canceled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum deduction of fees and payments under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_AgreementMilestonePeriodForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for net sales that is used for milestone under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_AgreementMilestonePeriodForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_GrantAmountCanceledPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of grant amount canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_GrantAmountCanceledPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_GrantAmountReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total percentage amount of a grant received at the during the current period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_GrantAmountReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_GrantAmountRemainingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of grant amount remaining.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_GrantAmountRemainingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_GrantFundingCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of grant funding canceled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_GrantFundingCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_GrantFundingRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of grant funding remaining.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_GrantFundingRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PaymentsForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PaymentsForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ProceedsFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ProceedsFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmountCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmountCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=crvo_VertexOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=crvo_VertexOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=crvo_NationalInstituteOfAgingGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=crvo_NationalInstituteOfAgingGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PrepaidClinicalExpenses', window );">Clinical expenses</a></td>
<td class="nump">$ 677,604<span></span>
</td>
<td class="nump">$ 1,149,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">405,795<span></span>
</td>
<td class="nump">443,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PrepaidProfessionalServices', window );">Professional services</a></td>
<td class="nump">119,803<span></span>
</td>
<td class="nump">95,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PrepaidDuesAndMembershipsCurrent', window );">Dues and memberships</a></td>
<td class="nump">43,828<span></span>
</td>
<td class="nump">11,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">19,975<span></span>
</td>
<td class="nump">205,881<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,267,005<span></span>
</td>
<td class="nump">$ 1,905,360<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PrepaidClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PrepaidClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PrepaidDuesAndMembershipsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid dues and memberships, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PrepaidDuesAndMembershipsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PrepaidProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for professional services that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PrepaidProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation costs</a></td>
<td class="nump">$ 1,061,766<span></span>
</td>
<td class="nump">$ 803,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_AccruedClinicalStudiesExpensesCurrent', window );">Clinical development costs</a></td>
<td class="nump">1,484,318<span></span>
</td>
<td class="nump">1,158,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">532,076<span></span>
</td>
<td class="nump">249,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">State franchise and excise tax</a></td>
<td class="nump">40,456<span></span>
</td>
<td class="nump">40,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">83,383<span></span>
</td>
<td class="nump">115,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 3,201,999<span></span>
</td>
<td class="nump">$ 2,367,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 57,112<span></span>
</td>
<td class="nump">$ 34,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Feb. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesAWarrantMember', window );">Series A Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,532,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_PrefundedWarrantMember', window );">Prefunded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ClassOfWarrantOrRightExercised', window );">Class of Warrant or Right, Exercised</a></td>
<td class="nump">449,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Stock Issued During Period, Shares, Exercise Of Warrants</a></td>
<td class="nump">448,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,083,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crvo_May2025AtthemarketOfferingMember', window );">May 2025 At-the-market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ShareSalesAgreementMaximumAmount', window );">Share Sales Agreement, Maximum Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ShareSalesAgreementMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount for share sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ShareSalesAgreementMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesAWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesAWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_PrefundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvo_PrefundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crvo_May2025AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crvo_May2025AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2,598,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalDiffusionCommonStockWarrantsMember', window );">Historical Diffusion Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">22,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Feb. 28,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalDiffusionCommonStockWarrantsMember', window );">Historical Diffusion Common Stock Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 96.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalEIPCommonStockWarrantsMember', window );">Historical EIP Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">43,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Apr. 30,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesACommonStockWarrantsMember', window );">Series A Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2,532,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and Rights Outstanding, Maturity Date</a></td>
<td class="text">Apr. 30,  2027<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalDiffusionCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalDiffusionCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalEIPCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvo_HistoricalEIPCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesACommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crvo_SeriesACommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation Stock (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crvo_StockOptionVestingTermsAsImprobableToProbableMember', window );">Stock Option Vesting Terms As Improbable to Probable [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-Based Payment Arrangement, Plan Modification, Incremental Cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-Based Payment Arrangement, Accelerated Cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crvo_StockOptionVestingTermsAsImprobableToProbableMember', window );">Stock Option Vesting Terms As Improbable to Probable [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Share-Based Payment Arrangement, Plan Modification, Incremental Cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-Based Payment Arrangement, Accelerated Cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease', window );">Share Based Compensation Arrangement By Share Based Payment Award, Number of Shares Available for Grant, Increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">The 2018 Employee, Director and Consultant Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">The 2018 Employee, Director and Consultant Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember', window );">The 2018 Employee, Director and Consultant Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_InducementOptionsMember', window );">Inducement Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crvo_The2025EquityPlanMember', window );">The 2025 Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees affected by share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the increase in the number of shares available for grant under a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crvo_StockOptionVestingTermsAsImprobableToProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crvo_StockOptionVestingTermsAsImprobableToProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvo_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvo_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvo_InducementOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvo_InducementOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crvo_The2025EquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crvo_The2025EquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 1,448,634<span></span>
</td>
<td class="nump">$ 1,405,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">482,669<span></span>
</td>
<td class="nump">218,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 965,965<span></span>
</td>
<td class="nump">$ 1,186,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, number of shares (in shares)</a></td>
<td class="nump">636,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 19.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance, weighted average remaining contractual term (Year)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of shares (in shares)</a></td>
<td class="nump">466,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, number of shares (in shares)</a></td>
<td class="num">(68,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 45.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, number of shares (in shares)</a></td>
<td class="num">(42,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, shares (in shares)</a></td>
<td class="nump">992,701<span></span>
</td>
<td class="nump">636,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 11.76<span></span>
</td>
<td class="nump">$ 19.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, shares (in shares)</a></td>
<td class="nump">561,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 15.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual term (Year)</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 2 months 26 days<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.68%<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.55%<span></span>
</td>
<td class="nump">76.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years) (Year)</a></td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.35%<span></span>
</td>
<td class="nump">4.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.68%<span></span>
</td>
<td class="nump">80.03%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">16,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">US Federal statutory tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,671,648<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income tax, net of federal (national) income tax effect (a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.20%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,121,821<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(22.90%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(27.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,188,171<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 605,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">State taxes in Illinois and Massachusetts&#160;made up the majority of the tax effect in this category</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 21,388,936<span></span>
</td>
<td class="nump">$ 10,417,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">2,367,496<span></span>
</td>
<td class="nump">1,228,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crvo_DeferredTaxAssetsCapitalizedResearchExpenditures', window );">Capitalized research expenditures</a></td>
<td class="nump">3,289,629<span></span>
</td>
<td class="nump">6,392,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">977,321<span></span>
</td>
<td class="nump">698,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contributions</a></td>
<td class="nump">2,130<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">182,441<span></span>
</td>
<td class="nump">193,106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">28,207,953<span></span>
</td>
<td class="nump">18,931,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Less valuation allowance</a></td>
<td class="num">(27,687,487)<span></span>
</td>
<td class="num">(18,557,844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets</a></td>
<td class="nump">520,466<span></span>
</td>
<td class="nump">373,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaids</a></td>
<td class="num">(520,466)<span></span>
</td>
<td class="num">(373,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(520,466)<span></span>
</td>
<td class="num">(373,935)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crvo_DeferredTaxAssetsCapitalizedResearchExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to capitalized research expenditures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crvo_DeferredTaxAssetsCapitalizedResearchExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crvo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Segments - Schedule of Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,006,510<span></span>
</td>
<td class="nump">$ 9,737,974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,817,072<span></span>
</td>
<td class="nump">18,798,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,448,634<span></span>
</td>
<td class="nump">1,405,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,484,315<span></span>
</td>
<td class="nump">9,166,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,328,510<span></span>
</td>
<td class="nump">1,936,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,966,367)<span></span>
</td>
<td class="num">(16,290,695)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,006,510<span></span>
</td>
<td class="nump">9,737,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,817,072<span></span>
</td>
<td class="nump">18,798,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel costs, excluding stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,988,705<span></span>
</td>
<td class="nump">3,995,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">965,965<span></span>
</td>
<td class="nump">1,186,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,752,710<span></span>
</td>
<td class="nump">2,684,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes', window );">Insurance, taxes and similar fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,166,374<span></span>
</td>
<td class="nump">985,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses, including IT, facilities, supplies and similar costs***</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">610,561<span></span>
</td>
<td class="nump">314,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,484,315<span></span>
</td>
<td class="nump">9,166,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,328,510<span></span>
</td>
<td class="nump">1,936,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(26,966,367)<span></span>
</td>
<td class="num">(16,290,693)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Dementia with Lewy bodies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,052,512<span></span>
</td>
<td class="nump">12,102,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Frontotemporal Disorders [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,217,784<span></span>
</td>
<td class="nump">36,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Recovery After Stroke [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,427,966<span></span>
</td>
<td class="nump">391,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Other Clinical and Nonclinical [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,504,863<span></span>
</td>
<td class="nump">2,499,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Personnel Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,745,558<span></span>
</td>
<td class="nump">2,187,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Stock Based Compensation [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">482,669<span></span>
</td>
<td class="nump">218,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Other Research and Development Costs [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 3,385,720<span></span>
</td>
<td class="nump">$ 1,361,744<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes, among other things, costs related to IT systems, rent and other facilities, office supplies, and similar costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes early-stage clinical studies that are not indication-specific and related costs.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesExcludingIncomeAndExciseTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesExcludingIncomeAndExciseTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_DementiaWithLewyBodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_DementiaWithLewyBodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_FrontotemporalDisordersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_FrontotemporalDisordersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_RecoveryAfterStrokeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_RecoveryAfterStrokeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_OtherClinicalAndNonclinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_OtherClinicalAndNonclinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_PersonnelCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_PersonnelCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_StockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_StockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=crvo_OtherResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=crvo_OtherResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>143</ContextCount>
  <ElementCount>282</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit</Role>
      <ShortName>Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995443 - Disclosure - Award Timing Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure</Role>
      <ShortName>Award Timing Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Note 1 - The Company and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business</Role>
      <ShortName>Note 1 - The Company and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995551 - Disclosure - Note 2 - Liquidity and Capital Resources</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources</Role>
      <ShortName>Note 2 - Liquidity and Capital Resources</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995553 - Disclosure - Note 4 - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments</Role>
      <ShortName>Note 4 - Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995554 - Disclosure - Note 5 - Significant Agreements and Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts</Role>
      <ShortName>Note 5 - Significant Agreements and Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Note 6 - Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses</Role>
      <ShortName>Note 6 - Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995556 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Note 8 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies</Role>
      <ShortName>Note 8 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995558 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants</Role>
      <ShortName>Note 9 - Stockholders' Equity and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995559 - Disclosure - Note 10 - Stock-based Compensation Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock</Role>
      <ShortName>Note 10 - Stock-based Compensation Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995560 - Disclosure - Note 11 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-</Role>
      <ShortName>Note 11 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995561 - Disclosure - Note 12 - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments</Role>
      <ShortName>Note 12 - Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995562 - Disclosure - Note 13 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events</Role>
      <ShortName>Note 13 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995563 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995564 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Note 4 - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables</Role>
      <ShortName>Note 4 - Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995566 - Disclosure - Note 6 - Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables</Role>
      <ShortName>Note 6 - Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995568 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables</Role>
      <ShortName>Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995569 - Disclosure - Note 10 - Stock-based Compensation Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables</Role>
      <ShortName>Note 10 - Stock-based Compensation Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995570 - Disclosure - Note 11 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables</Role>
      <ShortName>Note 11 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995571 - Disclosure - Note 12 - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables</Role>
      <ShortName>Note 12 - Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995572 - Disclosure - Note 1 - The Company and Description of Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual</Role>
      <ShortName>Note 1 - The Company and Description of Business (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995573 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual</Role>
      <ShortName>Note 2 - Liquidity and Capital Resources (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995574 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details</Role>
      <ShortName>Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995576 - Disclosure - Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details</Role>
      <ShortName>Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details</Role>
      <ShortName>Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995578 - Disclosure - Note 5 - Significant Agreements and Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual</Role>
      <ShortName>Note 5 - Significant Agreements and Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995579 - Disclosure - Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details</Role>
      <ShortName>Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995580 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995581 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 8 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995582 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual</Role>
      <ShortName>Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995583 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details</Role>
      <ShortName>Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995584 - Disclosure - Note 10 - Stock-based Compensation Stock (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual</Role>
      <ShortName>Note 10 - Stock-based Compensation Stock (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details</Role>
      <ShortName>Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995586 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details</Role>
      <ShortName>Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details</Role>
      <ShortName>Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995588 - Disclosure - Note 11 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual</Role>
      <ShortName>Note 11 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995589 - Disclosure - Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details</Role>
      <ShortName>Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995590 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995591 - Disclosure - Note 12 - Segments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual</Role>
      <ShortName>Note 12 - Segments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="crvo20251231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995592 - Disclosure - Note 12 - Segments - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details</Role>
      <ShortName>Note 12 - Segments - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crvo-20251231.xsd</File>
    <File>crvo-20251231_cal.xml</File>
    <File>crvo-20251231_def.xml</File>
    <File>crvo-20251231_lab.xml</File>
    <File>crvo-20251231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="crvo20251231_10k.htm">crvo20251231_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logolg.jpg</File>
    <File>mice.jpg</File>
    <File>p2bextention.jpg</File>
    <File>pipeline.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="497">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "crvo20251231_10k.htm": {
   "nsprefix": "crvo",
   "nsuri": "http://www.diffusionpharma.com/20251231",
   "dts": {
    "schema": {
     "local": [
      "crvo-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "crvo-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crvo-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "crvo-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crvo-20251231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "crvo20251231_10k.htm"
     ]
    }
   },
   "keyStandard": 252,
   "keyCustom": 30,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 31,
   "memberCustom": 21,
   "hidden": {
    "total": 41,
    "http://fasb.org/us-gaap/2025": 21,
    "http://www.diffusionpharma.com/20251231": 5,
    "http://xbrl.sec.gov/cyd/2025": 6,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "contextCount": 143,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 448,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 497,
    "http://xbrl.sec.gov/dei/2025": 37,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 8
   },
   "report": {
    "R1": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit",
     "longName": "004 - Statement - Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
     "longName": "995443 - Disclosure - Award Timing Disclosure",
     "shortName": "Award Timing Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:AwardTmgHowMnpiCnsdrdTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
     "longName": "995550 - Disclosure - Note 1 - The Company and Description of Business",
     "shortName": "Note 1 - The Company and Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
     "longName": "995551 - Disclosure - Note 2 - Liquidity and Capital Resources",
     "shortName": "Note 2 - Liquidity and Capital Resources",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "crvo:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "crvo:LiquidityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
     "longName": "995552 - Disclosure - Note 3 - Summary of Significant Accounting Policies",
     "shortName": "Note 3 - Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
     "longName": "995553 - Disclosure - Note 4 - Fair Value of Financial Instruments",
     "shortName": "Note 4 - Fair Value of Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
     "longName": "995554 - Disclosure - Note 5 - Significant Agreements and Contracts",
     "shortName": "Note 5 - Significant Agreements and Contracts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
     "longName": "995555 - Disclosure - Note 6 - Prepaid Expenses",
     "shortName": "Note 6 - Prepaid Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
     "longName": "995556 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities",
     "shortName": "Note 7 - Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
     "longName": "995557 - Disclosure - Note 8 - Commitments and Contingencies",
     "shortName": "Note 8 - Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
     "longName": "995558 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants",
     "shortName": "Note 9 - Stockholders' Equity and Common Stock Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
     "longName": "995559 - Disclosure - Note 10 - Stock-based Compensation Stock",
     "shortName": "Note 10 - Stock-based Compensation Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
     "longName": "995560 - Disclosure - Note 11 - Income Taxes",
     "shortName": "Note 11 - Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
     "longName": "995561 - Disclosure - Note 12 - Segments",
     "shortName": "Note 12 - Segments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events",
     "longName": "995562 - Disclosure - Note 13 - Subsequent Events",
     "shortName": "Note 13 - Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies",
     "longName": "995563 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
     "longName": "995564 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables",
     "longName": "995565 - Disclosure - Note 4 - Fair Value of Financial Instruments (Tables)",
     "shortName": "Note 4 - Fair Value of Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
     "longName": "995566 - Disclosure - Note 6 - Prepaid Expenses (Tables)",
     "shortName": "Note 6 - Prepaid Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
     "longName": "995567 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Note 7 - Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
     "longName": "995568 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "shortName": "Note 9 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
     "longName": "995569 - Disclosure - Note 10 - Stock-based Compensation Stock (Tables)",
     "shortName": "Note 10 - Stock-based Compensation Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables",
     "longName": "995570 - Disclosure - Note 11 - Income Taxes (Tables)",
     "shortName": "Note 11 - Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
     "longName": "995571 - Disclosure - Note 12 - Segments (Tables)",
     "shortName": "Note 12 - Segments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual",
     "longName": "995572 - Disclosure - Note 1 - The Company and Description of Business (Details Textual)",
     "shortName": "Note 1 - The Company and Description of Business (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:GovernmentAssistanceAmountCumulative",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual",
     "longName": "995573 - Disclosure - Note 2 - Liquidity and Capital Resources (Details Textual)",
     "shortName": "Note 2 - Liquidity and Capital Resources (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "crvo:LiquidityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "crvo:LiquidityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
     "longName": "995574 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "longName": "995575 - Disclosure - Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "shortName": "Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
     "longName": "995576 - Disclosure - Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details",
     "longName": "995577 - Disclosure - Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)",
     "shortName": "Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual",
     "longName": "995578 - Disclosure - Note 5 - Significant Agreements and Contracts (Details Textual)",
     "shortName": "Note 5 - Significant Agreements and Contracts (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
     "longName": "995579 - Disclosure - Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "crvo:PrepaidClinicalExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "crvo:PrepaidClinicalExpenses",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "longName": "995580 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "shortName": "Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual",
     "longName": "995581 - Disclosure - Note 8 - Commitments and Contingencies (Details Textual)",
     "shortName": "Note 8 - Commitments and Contingencies (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
     "longName": "995582 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "shortName": "Note 9 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "longName": "995583 - Disclosure - Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "shortName": "Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
     "longName": "995584 - Disclosure - Note 10 - Stock-based Compensation Stock (Details Textual)",
     "shortName": "Note 10 - Stock-based Compensation Stock (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
     "longName": "995585 - Disclosure - Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)",
     "shortName": "Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
     "longName": "995586 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)",
     "shortName": "Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "i_2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
     "longName": "995587 - Disclosure - Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)",
     "shortName": "Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual",
     "longName": "995588 - Disclosure - Note 11 - Income Taxes (Details Textual)",
     "shortName": "Note 11 - Income Taxes (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
     "longName": "995589 - Disclosure - Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)",
     "shortName": "Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
     "longName": "995590 - Disclosure - Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "i_2025-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual",
     "longName": "995591 - Disclosure - Note 12 - Segments (Details Textual)",
     "shortName": "Note 12 - Segments (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
     "longName": "995592 - Disclosure - Note 12 - Segments - Schedule of Segment Information (Details)",
     "shortName": "Note 12 - Segments - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "crvo20251231_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r759"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments",
        "negatedLabel": "Accretion of discount on marketable securities, net",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "crvo_AccruedClinicalStudiesExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "AccruedClinicalStudiesExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_AccruedClinicalStudiesExpensesCurrent",
        "terseLabel": "Clinical development costs",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "documentation": "Represents the amount of liability of accrued expenses and other current liabilities recorded as of a point in time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccruedProfessionalFeesCurrent",
        "terseLabel": "Professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r49",
      "r102",
      "r578",
      "r599",
      "r603",
      "r911"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r4",
      "r10",
      "r451",
      "r454",
      "r526",
      "r594",
      "r595",
      "r828",
      "r829",
      "r830",
      "r841",
      "r842",
      "r843",
      "r844"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r759",
      "r941"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r841",
      "r842",
      "r843",
      "r844",
      "r912",
      "r945"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "AgreementMaximumDeductionPercentageOfFeesAndPayments",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_AgreementMaximumDeductionPercentageOfFeesAndPayments",
        "terseLabel": "Agreement, Maximum Deduction Percentage of Fees and Payments",
        "documentation": "Percentage of maximum deduction of fees and payments under agreement."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_AgreementMilestonePeriodForNetSales": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "AgreementMilestonePeriodForNetSales",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_AgreementMilestonePeriodForNetSales",
        "terseLabel": "Agreement, Milestone, Period for Net Sales",
        "documentation": "The period for net sales that is used for milestone under the agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation expense",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r365",
      "r374"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r74",
      "r98",
      "r126",
      "r128",
      "r129",
      "r163",
      "r176",
      "r186",
      "r190",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r438",
      "r440",
      "r505",
      "r568",
      "r569",
      "r575",
      "r649",
      "r718",
      "r719",
      "r729",
      "r759",
      "r762",
      "r763",
      "r774",
      "r867",
      "r868",
      "r928"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r104",
      "r126",
      "r128",
      "r129",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r438",
      "r440",
      "r505",
      "r759",
      "r867",
      "r868",
      "r928"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsFairValueDisclosure",
        "terseLabel": "Total assets measured at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r748"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorLocation",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_AuditorName",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
        "terseLabel": "Commercial paper",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedTerseLabel": "Commercial paper",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
        "terseLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r241",
      "r574"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
        "terseLabel": "Commercial paper",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r241",
      "r475",
      "r496",
      "r497",
      "r498",
      "r499",
      "r564",
      "r699",
      "r748",
      "r751",
      "r758",
      "r853",
      "r916",
      "r917",
      "r918"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_AwardTmgMnpiCnsdrdFlag",
        "terseLabel": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r700"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashAndCashEquivalentsFairValueDisclosure",
        "terseLabel": "Money market accounts",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r914",
      "r915"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
        "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodStartLabel": "Cash and cash equivalents at beginning of the year",
        "periodEndLabel": "Cash and cash equivalents at end of the year",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r123"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r54"
     ]
    },
    "crvo_CashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "CashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_CashlessExerciseOfWarrants",
        "terseLabel": "Cashless exercise of pre-funded warrants",
        "documentation": "Amount of cashless exercise of warrants in noncash investing and financing transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r927"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_CityAreaCode",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r100",
      "r101",
      "r126",
      "r129",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r231",
      "r266",
      "r269",
      "r270",
      "r271",
      "r275",
      "r276",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r292",
      "r295",
      "r296",
      "r299",
      "r302",
      "r309",
      "r505",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r637",
      "r657",
      "r675",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r813",
      "r836",
      "r837",
      "r845"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r131",
      "r310"
     ]
    },
    "crvo_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ClassOfWarrantOrRightExercised",
        "terseLabel": "Class of Warrant or Right, Exercised",
        "documentation": "Number of warrants or rights exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r435",
      "r436"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r265",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r256",
      "r257",
      "r695",
      "r862",
      "r864"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r765",
      "r766",
      "r768",
      "r769",
      "r770",
      "r771",
      "r841",
      "r842",
      "r844",
      "r912",
      "r940",
      "r945"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CommonStockParOrStatedValuePerShare",
        "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CommonStockSharesAuthorized",
        "terseLabel": "Common Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r637"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CommonStockSharesIssued",
        "terseLabel": "Common Stock, Shares, Issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CommonStockSharesOutstanding",
        "terseLabel": "Common Stock, Shares, Outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r43",
      "r637",
      "r655",
      "r945",
      "r946"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r284",
      "r291",
      "r577",
      "r759"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r108",
      "r110",
      "r116",
      "r566",
      "r584",
      "r585"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r126",
      "r127",
      "r132",
      "r133",
      "r163",
      "r178",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r571",
      "r718",
      "r719",
      "r867",
      "r868"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r126",
      "r127",
      "r132",
      "r133",
      "r163",
      "r178",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r190",
      "r191",
      "r192",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r571",
      "r718",
      "r719",
      "r867",
      "r868"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r706"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ContractualObligation",
        "terseLabel": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r840",
      "r937"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296",
      "r299",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r808"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r808"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r810"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r808"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r801"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r802"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r800"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r803"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r805"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r805"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r787",
      "r806"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r809"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r807"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r804"
     ]
    },
    "crvo_DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs in accounts payable",
        "documentation": "The amount of debt offering costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
        "terseLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r241",
      "r245",
      "r246"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTerseLabel": "Gross deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r68",
      "r400"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "terseLabel": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredRevenueCurrent",
        "terseLabel": "Deferred Revenue, Current",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "crvo_DeferredTaxAssetsCapitalizedResearchExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "DeferredTaxAssetsCapitalizedResearchExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_DeferredTaxAssetsCapitalizedResearchExpenditures",
        "terseLabel": "Capitalized research expenditures",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to capitalized research expenditures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards",
        "terseLabel": "Charitable contributions",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets",
        "terseLabel": "Intangibles",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Gross deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsNet",
        "negatedTerseLabel": "Less valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards",
        "terseLabel": "Net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch",
        "terseLabel": "Research and development credits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilities",
        "totalLabel": "Deferred tax assets, net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses",
        "negatedTerseLabel": "Prepaids",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_DementiaWithLewyBodiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "DementiaWithLewyBodiesMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dementia with Lewy bodies [Member]",
        "documentation": "Represents the research and development for Dementia with Lewy bodies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r325",
      "r356",
      "r357",
      "r360",
      "r737"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentAnnualReport",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentFinStmtErrorCorrectionFlag",
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792",
      "r794"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentPeriodEndDate",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentTransitionReport",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_DocumentType",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share of common stock, basic and diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r117",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r153",
      "r154",
      "r157",
      "r158",
      "r159",
      "r162",
      "r282",
      "r363",
      "r425",
      "r434",
      "r472",
      "r473",
      "r567",
      "r586",
      "r709"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r161"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Total provision",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r740"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
        "terseLabel": "Federal tax benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r130",
      "r384",
      "r412",
      "r740"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r740",
      "r834",
      "r839",
      "r903"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
        "terseLabel": "Nontaxable or nondeductible items",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r834",
      "r839",
      "r903"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
        "terseLabel": "Share-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r834",
      "r839",
      "r903",
      "r905"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r834",
      "r839",
      "r903",
      "r904"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
        "terseLabel": "State tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r740",
      "r834",
      "r839",
      "r903"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r385",
      "r740"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
        "terseLabel": "Tax credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r391",
      "r834",
      "r839",
      "r903"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
        "terseLabel": "Research and development credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r740",
      "r834",
      "r839",
      "r903",
      "r905"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
        "terseLabel": "Employee compensation costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressAddressLine1",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressCityOrTown",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressPostalZipCode",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityAddressStateOrProvince",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCommonStockSharesOutstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityCurrentReportingStatus",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityEmergingGrowthCompany",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFileNumber",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityFilerCategory",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityIncorporationStateCountryCode",
        "terseLabel": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityInteractiveDataCurrent",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityPublicFloat",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityRegistrantName",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityShellCompany",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntitySmallBusiness",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityTaxIdentificationNumber",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityVoluntaryFilers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_EntityWellKnownSeasonedIssuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r84",
      "r91",
      "r92",
      "r112",
      "r113",
      "r114",
      "r134",
      "r135",
      "r136",
      "r139",
      "r147",
      "r149",
      "r151",
      "r164",
      "r232",
      "r235",
      "r248",
      "r281",
      "r311",
      "r363",
      "r407",
      "r408",
      "r421",
      "r422",
      "r423",
      "r426",
      "r433",
      "r434",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r471",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r519",
      "r526",
      "r582",
      "r594",
      "r595",
      "r596",
      "r615",
      "r675"
     ]
    },
    "crvo_EquityIncentivePlan2015Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "EquityIncentivePlan2015Member",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan 2015 [Member]",
        "documentation": "Represents the information pertaining to the 2015 equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r499",
      "r699",
      "r758",
      "r923",
      "r924"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r485",
      "r486",
      "r488",
      "r497",
      "r533",
      "r534",
      "r535",
      "r699",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r751",
      "r758"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r479",
      "r748",
      "r917",
      "r920"
     ]
    },
    "us-gaap_FairValueConcentrationOfRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueConcentrationOfRiskTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration of credit or market risk or both from financial instrument."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501",
      "r814"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r481",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r563",
      "r748",
      "r752"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r313",
      "r318",
      "r319",
      "r476",
      "r486",
      "r497",
      "r533",
      "r699",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r758"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r313",
      "r318",
      "r319",
      "r321",
      "r476",
      "r477",
      "r486",
      "r497",
      "r534",
      "r699",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r758"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r476",
      "r477",
      "r478",
      "r479",
      "r486",
      "r497",
      "r535",
      "r699",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r751",
      "r758"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r479",
      "r748",
      "r917",
      "r920"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r485",
      "r486",
      "r488",
      "r497",
      "r533",
      "r534",
      "r535",
      "r699",
      "r727",
      "r728",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r748",
      "r751",
      "r758"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r920"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r243",
      "r244",
      "r278",
      "r307",
      "r446",
      "r461",
      "r493",
      "r504",
      "r507",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r573",
      "r583",
      "r724",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r855",
      "r856",
      "r857",
      "r858",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r922",
      "r923"
     ]
    },
    "crvo_FrontotemporalDisordersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "FrontotemporalDisordersMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frontotemporal Disorders [Member]",
        "documentation": "Represents the Frontotemporal disorders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "Total general and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r659"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAmount",
        "terseLabel": "Government Assistance, Income, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_GovernmentAssistanceAmountCumulative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceAmountCumulative",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceAmountCumulative",
        "terseLabel": "Government Assistance, Asset",
        "documentation": "Amount of asset from government assistance."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration",
        "terseLabel": "Government Assistance, Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes asset from government assistance."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
        "terseLabel": "Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "crvo_GrantAmountCanceledPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "GrantAmountCanceledPercentage",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_GrantAmountCanceledPercentage",
        "terseLabel": "Grant Amount Canceled, Percentage",
        "documentation": "Percentage of grant amount canceled."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_GrantAmountReceivedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "GrantAmountReceivedPercentage",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_GrantAmountReceivedPercentage",
        "terseLabel": "Grant Amount, Received, Percentage",
        "documentation": "The total percentage amount of a grant received at the during the current period"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_GrantAmountRemainingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "GrantAmountRemainingPercentage",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_GrantAmountRemainingPercentage",
        "terseLabel": "Grant Amount Remaining, Percentage",
        "documentation": "Percentage of grant amount remaining."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_GrantFundingCanceled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "GrantFundingCanceled",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_GrantFundingCanceled",
        "terseLabel": "Grant Funding Canceled",
        "documentation": "Represents the amount of grant funding canceled."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_GrantFundingRemaining": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "GrantFundingRemaining",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_GrantFundingRemaining",
        "terseLabel": "Grant Funding Remaining",
        "documentation": "Represents the amount of grant funding remaining."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrantsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrantsReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant receivable",
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "crvo_HistoricalDiffusionCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "HistoricalDiffusionCommonStockWarrantsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical Diffusion Common Stock Warrants [Member]",
        "documentation": "Represents Historical Diffusion common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_HistoricalEIPCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "HistoricalEIPCommonStockWarrantsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical EIP Common Stock Warrants [Member]",
        "documentation": "Represents Historical EIP common stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_IcfrAuditorAttestationFlag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r792"
     ]
    },
    "crvo_ImpairmentOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ImpairmentOfMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ImpairmentOfMarketableSecurities",
        "terseLabel": "Impairment of Marketable Securities",
        "documentation": "Amount of impairment of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r255",
      "r442",
      "r443",
      "r444",
      "r445",
      "r480",
      "r482",
      "r487",
      "r506",
      "r507",
      "r508",
      "r589",
      "r591",
      "r660",
      "r698",
      "r699",
      "r741",
      "r742",
      "r746",
      "r747",
      "r750",
      "r758",
      "r909",
      "r910",
      "r939"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r255",
      "r442",
      "r443",
      "r444",
      "r445",
      "r480",
      "r482",
      "r487",
      "r506",
      "r507",
      "r508",
      "r589",
      "r591",
      "r660",
      "r698",
      "r699",
      "r741",
      "r742",
      "r746",
      "r747",
      "r750",
      "r758",
      "r909",
      "r910",
      "r939"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r384",
      "r385",
      "r395",
      "r404",
      "r740",
      "r907"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r384",
      "r385",
      "r395",
      "r404",
      "r740",
      "r907"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r130",
      "r379",
      "r384",
      "r392",
      "r393",
      "r394",
      "r397",
      "r403",
      "r413",
      "r415",
      "r416",
      "r417",
      "r572",
      "r605",
      "r614",
      "r740"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "totalLabel": "Total provision",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r79",
      "r126",
      "r150",
      "r151",
      "r163",
      "r180",
      "r190",
      "r383",
      "r384",
      "r414",
      "r587",
      "r702",
      "r704",
      "r705",
      "r740"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r381",
      "r382",
      "r397",
      "r398",
      "r402",
      "r406",
      "r608"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
        "terseLabel": "Changes in valuation allowances",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r740",
      "r903"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
        "terseLabel": "US Federal statutory tax rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r740"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpense",
        "terseLabel": "Nontaxable or nondeductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391",
      "r903"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes",
        "terseLabel": "State and local income tax, net of federal (national) income tax effect (a)",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r740",
      "r903"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncomeTaxReconciliationTaxCredits",
        "terseLabel": "Tax credits",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r391",
      "r903"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Grant receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "terseLabel": "Accrued expenses and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInDeferredCharges",
        "negatedLabel": "Deferred offering costs",
        "documentation": "The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "crvo_InducementOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "InducementOptionsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inducement Options [Member]",
        "documentation": "Represents inducement options."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r799"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r799"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r179",
      "r190",
      "r718",
      "r832"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LaborAndRelatedExpense",
        "terseLabel": "Personnel costs, excluding stock-based compensation",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r704",
      "r831"
     ]
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalCostsPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r41",
      "r126",
      "r128",
      "r129",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r439",
      "r440",
      "r441",
      "r505",
      "r636",
      "r713",
      "r729",
      "r774",
      "r867",
      "r928",
      "r929"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r69",
      "r580",
      "r759",
      "r762",
      "r763",
      "r834",
      "r838",
      "r859",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r95",
      "r126",
      "r128",
      "r129",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r439",
      "r440",
      "r441",
      "r505",
      "r759",
      "r867",
      "r928",
      "r929"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_LiquidityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "LiquidityDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity Disclosure [Text Block]",
        "documentation": "The entire disclosure for the liquidity of the company."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_LocalPhoneNumber",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r258",
      "r259",
      "r260",
      "r264",
      "r375",
      "r726",
      "r865",
      "r866"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable securities",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_MarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table]",
        "documentation": "Disclosure of information about investment in marketable security."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r259",
      "r260",
      "r261",
      "r262",
      "r322",
      "r351",
      "r352",
      "r353",
      "r375",
      "r479",
      "r561",
      "r588",
      "r590",
      "r604",
      "r628",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r723",
      "r730",
      "r736",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r756",
      "r757",
      "r761",
      "r869",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "crvo_May2025AtthemarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "May2025AtthemarketOfferingMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2025 At-the-market Offering [Member]",
        "documentation": "Represents the May 2025 At-The-Market Offering."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r259",
      "r260",
      "r261",
      "r262",
      "r322",
      "r351",
      "r352",
      "r353",
      "r375",
      "r479",
      "r561",
      "r588",
      "r590",
      "r604",
      "r628",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r723",
      "r730",
      "r736",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r756",
      "r761",
      "r869",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "crvo_NationalInstituteOfAgingGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "NationalInstituteOfAgingGrantMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "National Institute of Aging Grant [Member]",
        "documentation": "Represents National Institute of Aging Grant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r168",
      "r710",
      "r711"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss",
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r56",
      "r70",
      "r92",
      "r93",
      "r107",
      "r109",
      "r114",
      "r126",
      "r128",
      "r129",
      "r132",
      "r138",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r156",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r282",
      "r285",
      "r288",
      "r293",
      "r363",
      "r425",
      "r434",
      "r473",
      "r505",
      "r581",
      "r656",
      "r673",
      "r674",
      "r702",
      "r704",
      "r705",
      "r772",
      "r867"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r118",
      "r119",
      "r120",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r145",
      "r152",
      "r162",
      "r197",
      "r198",
      "r232",
      "r233",
      "r234",
      "r235",
      "r247",
      "r248",
      "r254",
      "r279",
      "r280",
      "r281",
      "r282",
      "r361",
      "r362",
      "r363",
      "r364",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r494",
      "r495",
      "r517",
      "r518",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r606"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrAdoptedFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_NonRule10b51ArrTrmntdFlag",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income, net",
        "terseLabel": "Other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_NoteToFinancialStatementDetailsTextual": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "NoteToFinancialStatementDetailsTextual",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_NotesToFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "NotesToFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfReportableSegments",
        "terseLabel": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r722",
      "r847"
     ]
    },
    "crvo_OpenMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "OpenMarketSalesAgreementMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Market Sales Agreement [Member]",
        "documentation": "Represents the Open Market Sales Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r702",
      "r705",
      "r714",
      "r846",
      "r848",
      "r849",
      "r850",
      "r851"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r191",
      "r718",
      "r719"
     ]
    },
    "crvo_OptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "OptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted in lieu of cash bonus",
        "documentation": "Represents the monetary value of options granted during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherAccruedLiabilitiesCurrent",
        "totalLabel": "Total",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "us-gaap_OtherAssetsCurrent",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r759"
     ]
    },
    "crvo_OtherClinicalAndNonclinicalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "OtherClinicalAndNonclinicalMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Clinical and Nonclinical [Member]",
        "documentation": "Represents the other clinical and nonclinical research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net unrealized (loss) gain on marketable securities",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r230"
     ]
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherGeneralAndAdministrativeExpense",
        "terseLabel": "Other general and administrative expenses, including IT, facilities, supplies and similar costs***",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r944"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r745"
     ]
    },
    "crvo_OtherResearchAndDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "OtherResearchAndDevelopmentCostsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Costs [Member]",
        "documentation": "Represents the other research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OtherSundryLiabilitiesCurrent",
        "terseLabel": "Other",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r34"
     ]
    },
    "crvo_PaymentsForLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PaymentsForLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_PaymentsForLicenseAgreement",
        "terseLabel": "Payments for License Agreement",
        "documentation": "Amount of cash outflow for license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquireMarketableSecurities",
        "negatedLabel": "Purchase of marketable securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
        "terseLabel": "Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis",
        "documentation": "The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_PersonnelCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PersonnelCostsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Personnel Costs [Member]",
        "documentation": "Represents the personnel costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "crvo_PolicyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PolicyTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_PolicyTable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PolicyTextBlockAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r295"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r637"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r295"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r637",
      "r655",
      "r945",
      "r946"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PreferredStockValue",
        "terseLabel": "Series A preferred stock $0.001 par value: 30,000,000 authorized at December 31, 2025 and 2024, 0 shares issued and outstanding at December 31, 2025 and 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r284",
      "r290",
      "r576",
      "r759"
     ]
    },
    "crvo_PrefundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrefundedWarrantMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrant [Member]",
        "documentation": "Represents prefunded warrant,"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_PrepaidClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrepaidClinicalExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical expenses",
        "documentation": "Amount of prepaid clinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_PrepaidDuesAndMembershipsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrepaidDuesAndMembershipsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dues and memberships",
        "documentation": "Amount of prepaid dues and memberships, classified as current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
        "totalLabel": "Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "crvo_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_PrepaidExpensesDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrepaidExpensesDepositsAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r725",
      "r860"
     ]
    },
    "crvo_PrepaidProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "PrepaidProfessionalServices",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional services",
        "documentation": "Amount of asset related to consideration paid in advance for professional services that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_ProceedsFromGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ProceedsFromGrants",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ProceedsFromGrants",
        "terseLabel": "Proceeds From Grants",
        "documentation": "Amount of cash inflow from grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock under At-the-Market Sales Agreement, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "crvo_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, prefunded warrants and common stock warrants",
        "documentation": "Amount of cash inflow from issuance of common stock and warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r609"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProfessionalFees",
        "terseLabel": "Professional fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r718",
      "r772",
      "r943",
      "r944"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r259",
      "r260",
      "r261",
      "r262",
      "r312",
      "r322",
      "r351",
      "r352",
      "r353",
      "r360",
      "r375",
      "r479",
      "r536",
      "r545",
      "r561",
      "r588",
      "r590",
      "r604",
      "r628",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r723",
      "r730",
      "r736",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r756",
      "r757",
      "r761",
      "r766",
      "r863",
      "r869",
      "r917",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r259",
      "r260",
      "r261",
      "r262",
      "r312",
      "r322",
      "r351",
      "r352",
      "r353",
      "r360",
      "r375",
      "r479",
      "r536",
      "r545",
      "r561",
      "r588",
      "r590",
      "r604",
      "r628",
      "r629",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r723",
      "r730",
      "r736",
      "r741",
      "r743",
      "r744",
      "r751",
      "r752",
      "r756",
      "r757",
      "r761",
      "r766",
      "r863",
      "r869",
      "r917",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935"
     ]
    },
    "crvo_RecoveryAfterStrokeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "RecoveryAfterStrokeMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery After Stroke [Member]",
        "documentation": "Represents the research and development for recovery after stroke."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r698",
      "r702",
      "r703",
      "r718",
      "r936"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RetainedEarningsAccumulatedDeficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r63",
      "r579",
      "r598",
      "r603",
      "r613",
      "r638",
      "r759"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r91",
      "r92",
      "r134",
      "r135",
      "r136",
      "r139",
      "r147",
      "r149",
      "r151",
      "r232",
      "r235",
      "r248",
      "r281",
      "r363",
      "r407",
      "r408",
      "r421",
      "r422",
      "r423",
      "r426",
      "r433",
      "r434",
      "r449",
      "r452",
      "r453",
      "r456",
      "r471",
      "r517",
      "r519",
      "r594",
      "r596",
      "r615",
      "r945"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant revenue",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r115",
      "r126",
      "r128",
      "r129",
      "r163",
      "r177",
      "r178",
      "r184",
      "r190",
      "r193",
      "r195",
      "r196",
      "r231",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r505",
      "r568",
      "r570",
      "r718",
      "r745",
      "r762",
      "r763",
      "r867"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrAdoptedFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ecd_Rule10b51ArrTrmntdFlag",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SalesAndExciseTaxPayableCurrent",
        "terseLabel": "State franchise and excise tax",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r740",
      "r903"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r20"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r7",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r61",
      "r62",
      "r63",
      "r99",
      "r100",
      "r101",
      "r165",
      "r295",
      "r296",
      "r297",
      "r299",
      "r302",
      "r307",
      "r309",
      "r446",
      "r609",
      "r610",
      "r611",
      "r612",
      "r730",
      "r813",
      "r834",
      "r836"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_Security12bTitle",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_SecurityExchangeName",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r163",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r181",
      "r182",
      "r183",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r715",
      "r716",
      "r717",
      "r718",
      "r720",
      "r721",
      "r722"
     ]
    },
    "crvo_SeriesACommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "SeriesACommonStockWarrantsMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Common Stock Warrants [Member]",
        "documentation": "Series A Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r825",
      "r870",
      "r871"
     ]
    },
    "crvo_SeriesAWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "SeriesAWarrantMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrant [Member]",
        "documentation": "Represents Series A Warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "us-gaap_ShareBasedCompensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
        "terseLabel": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r352"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r353"
     ]
    },
    "crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Employees",
        "documentation": "Number of employees affected by share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Number of Shares Available for Grant, Increase (in shares)",
        "documentation": "Represents the increase in the number of shares available for grant under a share based compensation arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, shares (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average exercise price per share (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired, number of shares (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited, number of shares (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, number of shares (in shares)",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodStartLabel": "Balance, number of shares (in shares)",
        "periodEndLabel": "Outstanding, shares (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodStartLabel": "Balance, weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted average exercise price per share (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
        "terseLabel": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expired, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r329",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "crvo_ShareSalesAgreementMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "ShareSalesAgreementMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "crvo_ShareSalesAgreementMaximumAmount",
        "terseLabel": "Share Sales Agreement, Maximum Amount",
        "documentation": "The maximum amount for share sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years) (Year)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance, weighted average remaining contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesOutstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation",
        "terseLabel": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r99",
      "r100",
      "r101",
      "r126",
      "r129",
      "r154",
      "r155",
      "r157",
      "r159",
      "r165",
      "r166",
      "r231",
      "r266",
      "r269",
      "r270",
      "r271",
      "r275",
      "r276",
      "r283",
      "r284",
      "r286",
      "r287",
      "r289",
      "r292",
      "r295",
      "r296",
      "r299",
      "r302",
      "r309",
      "r505",
      "r609",
      "r610",
      "r611",
      "r612",
      "r615",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r637",
      "r657",
      "r675",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r813",
      "r836",
      "r837",
      "r845"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r43",
      "r46",
      "r47",
      "r84",
      "r91",
      "r92",
      "r112",
      "r113",
      "r114",
      "r134",
      "r135",
      "r136",
      "r139",
      "r147",
      "r149",
      "r151",
      "r164",
      "r232",
      "r235",
      "r248",
      "r281",
      "r311",
      "r363",
      "r407",
      "r408",
      "r421",
      "r422",
      "r423",
      "r426",
      "r433",
      "r434",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r471",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r519",
      "r526",
      "r582",
      "r594",
      "r595",
      "r596",
      "r615",
      "r675"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business",
      "http://www.diffusionpharma.com/20251231/role/statement-note-1-the-company-and-description-of-business-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources",
      "http://www.diffusionpharma.com/20251231/role/statement-note-2-liquidity-and-capital-resources-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-8-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r164",
      "r283",
      "r284",
      "r286",
      "r289",
      "r519",
      "r562",
      "r607",
      "r616",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r675",
      "r704",
      "r705",
      "r767",
      "r942"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss",
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r164",
      "r199",
      "r283",
      "r284",
      "r286",
      "r289",
      "r519",
      "r562",
      "r607",
      "r616",
      "r627",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r637",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r658",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r675",
      "r704",
      "r705",
      "r767",
      "r942"
     ]
    },
    "crvo_StockBasedCompensationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "StockBasedCompensationMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation [Member]",
        "documentation": "Represents the stock based compensation classified under the research and development."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of prefunded warrants (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "documentation": "Number of shares issued during period for exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r42",
      "r43",
      "r63",
      "r609",
      "r675",
      "r686"
     ]
    },
    "crvo_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of prefunded warrants",
        "documentation": "Value of stock issued during period for exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock options granted in lieu of compensation",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, prefunded warrants and common stock warrants, net of offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r42",
      "r43",
      "r63",
      "r615",
      "r675",
      "r686",
      "r773"
     ]
    },
    "crvo_StockOptionVestingTermsAsImprobableToProbableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "StockOptionVestingTermsAsImprobableToProbableMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Vesting Terms As Improbable to Probable [Member]",
        "documentation": "Represents stock options vesting terms as improbable to probable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20251231/role/statement-consolidated-statements-of-changes-in-convertible-preferred-stock-and-stockholders-equity-deficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46",
      "r47",
      "r57",
      "r639",
      "r655",
      "r676",
      "r677",
      "r759",
      "r774",
      "r834",
      "r837",
      "r838",
      "r859",
      "r925",
      "r945"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-balance-sheets-"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r294",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r446",
      "r462",
      "r678",
      "r679",
      "r690"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r528"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-13-subsequent-events"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r529"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-cash-flows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierFinanceProgramTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplierFinanceProgramTable",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier Finance Program [Table]",
        "documentation": "Disclosure of information about supplier finance program."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253"
     ]
    },
    "us-gaap_TableTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TableTextBlock",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-6-prepaid-expenses-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-",
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_TaxesExcludingIncomeAndExciseTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesExcludingIncomeAndExciseTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-12-segments-schedule-of-segment-information-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TaxesExcludingIncomeAndExciseTaxes",
        "terseLabel": "Insurance, taxes and similar fees",
        "documentation": "All taxes not related to income of the entity or excise or sales taxes levied on the revenue of the entity that are not reported elsewhere. These taxes could include production, real estate, personal property, and pump tax."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "crvo_The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2018 Employee, Director and Consultant Equity Incentive Plan [Member]",
        "documentation": "Represents the 2018 Employee, Director and Consultant Equity Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "crvo_The2025EquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "The2025EquityPlanMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "The 2025 Equity Plan [Member]",
        "documentation": "Represents 2025 Equity Plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r927"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "dei_TradingSymbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r278",
      "r307",
      "r446",
      "r461",
      "r493",
      "r504",
      "r507",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r573",
      "r583",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r855",
      "r856",
      "r857",
      "r858",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r922",
      "r923"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_USTreasuryBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryBondSecuritiesMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Bond Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities greater than ten and as long as thirty years, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
      "http://www.diffusionpharma.com/20251231/role/statement-note-4-fair-value-of-financial-instruments-marketable-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r708",
      "r731",
      "r733",
      "r735",
      "r748",
      "r938"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "terseLabel": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r396",
      "r739"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-significant-accounting-policies-policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r167",
      "r169",
      "r170",
      "r171",
      "r568",
      "r570",
      "r712"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-11-income-taxes-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r399"
     ]
    },
    "crvo_VertexOptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "VertexOptionAndLicenseAgreementMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts",
      "http://www.diffusionpharma.com/20251231/role/statement-note-5-significant-agreements-and-contracts-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vertex Option and License Agreement [Member]",
        "documentation": "Represents the Vertex Option and License Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock",
      "http://www.diffusionpharma.com/20251231/role/statement-note-10-stockbased-compensation-stock-details-textual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20251231/role/statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r765",
      "r768",
      "r769",
      "r770",
      "r771"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_WarrantsAndRightsOutstandingMaturityDate",
        "terseLabel": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.diffusionpharma.com/20251231/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding, basic and diluted (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r159"
     ]
    },
    "crvo_statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-10-stockbased-compensation-stock-stock-assumptions-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation Stock - Stock Assumptions (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-10-stockbased-compensation-stock-stock-option-activity-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation Stock - Stock Option Activity (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-10-stockbased-compensation-stock-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-10-stockbased-compensation-stock-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Stock-based Compensation Stock"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-11-income-taxes-deferred-tax-assets-and-liabilities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-11-income-taxes-rate-reconciliation-of-income-tax-rate-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Income Taxes - Rate Reconciliation of Income Tax Rate (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-11-income-taxes-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-11-income-taxes-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-11-stockbased-compensation-stock-stockbased-compensation-expense-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 11 - Stock-based Compensation Stock - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-12-segments-schedule-of-segment-information-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-12-segments-schedule-of-segment-information-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Segments - Schedule of Segment Information (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-12-segments-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-12-segments-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Segments"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-3-summary-of-significant-accounting-policies-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-3-summary-of-significant-accounting-policies-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-4-fair-value-of-financial-instruments-assets-measured-at-fair-value-on-recurring-basis-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Fair Value of Financial Instruments - Assets Measured at Fair Value on Recurring Basis (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-4-fair-value-of-financial-instruments-marketable-securities-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Fair Value of Financial Instruments - Marketable Securities (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-4-fair-value-of-financial-instruments-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-4-fair-value-of-financial-instruments-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Fair Value of Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-6-prepaid-expenses-prepaid-expenses-and-other-current-assets-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Prepaid Expenses - Prepaid Expenses and Other Current Assets (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-6-prepaid-expenses-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-6-prepaid-expenses-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Prepaid Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-9-stockholders-equity-and-common-stock-warrants-tables",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stockholders' Equity and Common Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-note-9-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)"
       }
      }
     },
     "auth_ref": []
    },
    "crvo_statement-statement-significant-accounting-policies-policies": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.diffusionpharma.com/20251231",
     "localname": "statement-statement-significant-accounting-policies-policies",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-23"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001437749-26-008259-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-26-008259-xbrl.zip
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MG0:N3>UH<KGAA:+29L2,\(W[.)3'R\,IX0N*&Y8NV51H%,B%W-#8_IPM-W<
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M XL9H1-$6K(5+%;8N.C$C@E_#6S[X>*PS.*UZ-:O"0>'1VGGGF5TN\%RML
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MY'DASRU3'VS] *[]K3I*&OE6;\NA+]8CBS4^R6:$G\D;I<5)F:8DJRVG83\
M#L<A+FJ\&_/X'$$#<VP45])3PLM(.KGE[(D'<Z4'2M_#.SF\DZ,E#1ZPV+PJ
M/GQ5'"I3AJI3-]6;>E*I_RXOW!(SM]-#BX@_DV2/PI+N44R#1QH72"I#A=MV
M>-?J>#,Z?0U:K_.J MIEF>GT-EA)>3<N5]KU;C5MY,3>5SNILQ8>N@AP-P_Q
MMH&W#;QMX&T#;QMXV\#;!K:V@8LSNB?[X<>1:#*GV4NP,$V>2&)Q<S%P--?6
M@1%9WACPQH#F:H3U2I+ID?OKR 3N:3.(5^:-.+AF:?IB:E5ZL;KQ,1DA7H7W
M*CQ<A=?L"Z^]#UY[ATB^H2ON3<[;GA3SGT:IO*QRQF(QM>F(_)F+1;G67>=S
ML;R+GT??ROM/315UR]%=*^Z-R&P$P?D7%4-S&@;Q^8;HL^*1Q16BZUMGJS.8
MK/NWD/"X>^S%U:TEP9">+9#Z-5C)+\>9,)CG176JR71*:N]D,.K3 GGRSMA<
M+A_5I>R EBV0<B\X).G8Z'5"^[1'GG:>5.UP&+NXJ'D;IG?*LSVC2/RUHTS\
M\?M7<:S,\WGEJJK]O7.J[B32MF*F*G]S0TWM#%7\BH>B?M-VXR!-)].U0)KP
M._HT4Z4-:MOW3[WR\@E C^%RT.M*&KZS[);3I5"];^,@K"^- 6OLUED6R/20
M0L&Y">;BXU[*AW(IP3L>"S_]WI>T3>4I2#Q=%5L9ED=?V^.8W+(=T+NSG"\*
MP_E&F-3P&(5Q?\?(E\>41C3@J[V%KSB[M>V]R]R[S!LP4JWY,XT*CHD#N);+
M+%1*C)SJ90*SUQ>0QG,@IRHS%IOHX@,&;XN9Z;6HHED=K60,112Z6M% (Q[=
MBH9(6@;VM*)<Q6V=/!B6;\MO%!)C #+HKIBV"8/V\3*W;+<MEA0>8S0BJ$Z%
M95H7/"HQ U71&XD/=[78[787/+@+9+BE^NK=G(#MLNKN:#!37RU"XVY7<]M"
MTT/.C#E"!3D#NW;1'(&6N#-+'VI/D+.3[TL\U6,@YE BK&0F=5%HKOQ^0R00
M8P8=SC6HS(RN1BBR\IU?):%X.%U*QT+R\?N3S_48&5"'%C [5TF4ESZ.LI2D
M DFD:=H&@$C.>CGXKR25T,P'PN?I.+V:+SA[E&+A@=VN/RGP1?;#M,#$PXR(
M-_7CA5C%;$7$'N<D%(.5<--4R'.A?%2\W7IV6AFP+<8^?BX?!2"YOBD.6!4N
M:CS(2QA?9S-*=C=%";V5AH?W$N[!AP"MW5 \$5IMD!4W8 $H5K?NG.*+9Q+F
M4DCHB%4W[![P%SRK 7]5OWL8XBN*/ RQ5QBBAK('FDGS1^A6=$FC/(AKWJ*R
MG7LJY<6@=R0NE.5T1A</3''4-1CA^#CK%7PU_A;P2%9<5P!D*MOT!**4]9YW
M5EDQJ41HO6F6W@L;CYQ*P^TV6!7Y7#H84TNC>CBI$0<;JV7/)E,B2K7MG5+_
MA21"5XN%J36.YN)DEQ,I-:)U74 E)T9]G7(ES$0V)SL/G7RJ]*/5RP1 #PP<
M*'&QH#[#YJ+7LT6:^3)&H5A&54UZH5$YQ=6-L-/9Z[N_(RD)>"COB3\G2Q*S
MA5R<$"EIT+,GF/KV1"JNN28[%6%?B1C'\7HG3J9W)&1/"?U+*!&$4U9J%C"
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M)4 5<8#F;1#%64A(E,I"TP7;E:*JOE4+)/Q*N#A:)L4%A$) 'S);__J,.N+
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MA40ZH%=AU]R0;\5/]3R8='8,$7Y,:40#OMK;Y@J=6MO>!ZJ<E''7VS;,PI#
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MPJ(8NTOBV<V,VX)2)YI*2G6_DF?YF5C>"-3V8YT7H.J$?EAA*E]>Y)C*BQB
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MS[>6APV-_!QK"G:GCKF!Y6<["XH--%>[7\_C4%.X'06^WERV-@P]\N92LYL
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M)W:,_SUIDL(MYL=3NL:9JC#L&.>C*1WC_ D[YH_#"=WA"T"T.492$[N"C?I
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M +G?H0N.'9>C,XZ=^#OZM<5N1C)DN<5*$7*Q;[XDZ.T; 9V%:')\>M= BQ5
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M<@(P]BW/[Q/ZS_2OQVZV81J'![ U)[R:DWFPTGU3P],)K807Z:26XN5;P@>
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M\H<-\ZZP-/\V^:IB@1(59K]-JNUPD'@:EDB@FTFAU9FL@(>27#LL(5(=FBX
MB6]11$/PO-OD">K01'MX[H^,6(77$<<3/]L5SC)E?J1?Z%6S2@JJWA;9*B]S
MYOED0:B*NOL&GT+M5PT0P4Q:#5Q 5JZ7-4)J]G.7XJ/ A!_=R1XNO25\PMJI
MBG,17=V?H&62]FWC:]9F)C\X^E-6\^EO__9OXYC0)FQ*;/8EF-#"Y-6OJ$:6
MTE^D; N1R3F(H[B':HAC%*D""-0\94ER:G],7O+59K4HRPTKL[S[(WL@[ H=
MM%W,S6QJR,QN#6L3#");UR:H.C2Q_5+(K9W=XHH$LGLC1!9\AR\ONJXF5%A[
M&R0-:J,;OH&Q%4]W7?B8-.D3M;#V_@[1-P83^KF_3P">R=U] D,/]W:G]/!T
M9^]PW!O4*Q!>:*,5HOIWZ)>*9<K=)-LY*183MM>_Q&OO7;C\NJ1^8LE2]#\7
M?][DSTG!TZ>:LZ2JMA33/R;%1G8C,/H6FDVG R-(B@$SH7EW5[S#(TZBG!'9
MB14M+9,'+BO*Z*3!JS6AIOMY7I,JHQI'GB:@]0$D(6!R8M_\LP\<]=#AX?V.
MEV,=R-\\872PRJQ#*D*\OAX;$7-BALN:3QY(186U[6<P[9J9'@S-FA^=-)3)
M-0X=8DZY6@? 5*)'>TW*DF+&79@G"'</@B+SY?2!EV],!R6ZX]0&F.8?8D;,
M<'DJHD\ SL:KG4_+C-G'T!P5+2#FO/B,JP<":K^&CEFN\P2"$E,\+1"F-/2P
MF=,Z(5WTYJ0Y#*6(V%'4TAK]A=42%<^EMYA5Q*&*N+U])8^'>L+@"X@].CUS
MD/(,TR@8FZ2N5P00#8Y"UVBG1Z+W.\QA53!+>P>1^4X>^3(3L<RJPRJ"F:TI
M'@1 2TM17SQ6F-?!;CVYYSC;I -O"X5WO;S$F!6*Z9J#C2D FWD@:@$"+XBR
M@"!F+&QA5@\):>\0V[V7]+BA?>%DZ'%?T<RIX$(1K5I:9#TMZ"^7'0'6+6YH
M4]+K-$JZ94505%9B3)SMBS.EEA>87B!+W#?H_80;ELFLT&'*S^Q4EG3ZP!I*
MBH>%*#I<FZ7^Z3#9:X+-&L?,:(DPY7+_A-%ZMZ:2KJEF\%'SE#0HIXJ$W7G8
MGU8=KJUN8>['>>@7M8@=JQ--PKN\_:0X?^8M%74O/[(/K.\^AQ.'O_H<8F!W
M1[!?C^7%YP1U2+B[^-@O"JX1&I&'NS,\DKY(7=)>A:H60435!%,%V:;B=83H
MC^FFJMB3L] KD:](4B$:O2%-$QWD9:UQ^OTC>?XAP[EPL-(?=GY5^H\_+>@F
M96RC+HOD\4 K2/]NJ 2.YO%>Z+D#AABTH$P@IQE1$B)DD=UUA9]P6?<]%>D1
M=+V\3UX4Q6<,OH27TU5!\,T^75>^.%5H3$A,+.@V!VXSYS)_W!7JT6("!<A+
MA=,5@?.?TR$6\5I:ZC".GLP$.7S/\F:[J'!R1K)#BUSV9\#1.YS&-Y,?PC/A
M:'M<(<7M*$#$("(UNAY,A=$M)BI:!%/=GVM\O;RHFWR5--)T_/%!0 6]/YEO
M=J70>'!J!X_>H$B1IUOTI?UO["+Y$MH2/8(%K&_]M:V<PIYX*E+2'U/1=UX0
M4OROJF\#=!IP;6LS</[MSJ]HAQ#:QVAVK G>+.)J!X*Q-P]9J*\W3=TD)0OG
MDO"O=!R008_F"V6C'@&&6*8.L!=>G+LFJ1JS8_U]4K#"(NC;O!351>OOHB[A
MHLP\+\"3E,M9FFB3*6CS(%+R@"E=D=7YQ*(QD&SJ@)=-*0[ VZ;#-0&+49,2
M<0Q.1,=>>C0.L(@N,5H<12 D#29'-W0:7%4X,Q(ES:^ TJ28W7N9Z@[\/NO-
MBO-T-X  J>K+"R*>;"[S.DV*?\=)10_+<WJ9&?.(*(9"O".2*;WGF+4/50(P
M8I 1!8T8[/!N"!5=B0FQ(E:=/6_9^8QR\J-!R7/)=\ZJSA[,'Z_J[ $B;JK.
MPE?WDUA=B1]9:+B9*=!!161)?V *F&?=S*3\K(RC)LO/3A(RHEC18V*=Y%F'
M7ANLOR@S7O5H4=?X*)S6S63.!% ':#RIU,'.C:@ZIH.-_+:HC#4JZ*(X$HV5
M!Y-H([Z=%'/S3?!D>IVW43KB0._BT=+-H3!KC0487](Y?8MB![@SO]K02@X[
MN/6EIBPQ(E<09F'6GQZK'(VT9I1^QM!LPJWT.3#),4U'641"J( .N;(F19[Q
M*$"]-R"=3\ ..?G4WJ][0]BS>\O1(CJ!4-*S+KKIO.L2A\'D. L]M#=?B*"*
M4<"FT16.L(<4D>H4:7O01O-T3#,$T::3)[Z^*)N\V5[F!?ZT&:F9,S4$P,V'
M4X5@Y$.8ICQLCS. ?050Q* B';0],*YTVXD.7;RRZ\4*5X]Y^?A+1;XV3RRH
M+BFW4LZ=' UFXM%9P_'S*'@8:SM:"9S+.P20P !IK<8;QT^S"S&DG&=SY)Y.
M/V&%#/]L87RP:4+:' P>U-2 X6IC8:BQ]6A6[.TP49$BH$>74C1?"7OFC'G)
M/Y%&5&1Y*/ Y8<49I/Y;_4_!WEHU"-_\WN+0VJ<GB*.!*!ZH1P1]$:C$N:(9
M[0.Q(:Y76^%NE13%^TV=E[@><QU-C +;!GNSA;,)]L#"; %+S.$V  >,])#W
M=O2/<P'1))!?-G["1:&R=,<&P9EX,%E 'AY !;*P%=X6',S@1K9=1QF Z%''
MLZ5Z52Y)M>+^NP]4>*X:O)KRY$\-M[!DQZ8-YM,? $=?&'C$X8<]WK6)3$PI
M%XZ![D<:/.L,=<,X]R':.(\S#0<]"WZY/VQQK$^L<$E"2;.I6+)2^]S]DLMB
M1B9&0E-]CF?TGLW#0?+T,@$4?6%@(R7K3%"4&)#)JU%ULWDH\O2R(,EA^8')
M,6"3:C!7.(MJ !1F4%EA#;>G!%BD@;@W<VIL[XD6:;R_UE1G28,?226_#(R.
MLGJSZ6<+^VS3@X6_W%A@;O=X4R$]Y+V^WQQSP=$3CH1 7MFXC>V^Q6M2L73,
MNX8>!G(7S?1P,&./3QN.P\?APUC=U5K@/-\E&?0H()WU>.-^!<\04^)YE8<_
MDF)3-DDE!%(N"))Q8 DXF"\<ZQ\ AO&\-?9P9N]!(YT%>&-R&3\0;3)Y9>M?
M<5'\6TF^EG<XJ4F)LZNZWDP$FBC&@]E<,F\X=I<@ &-[9ZN!LS]#X?0WA@/J
MD$ Z2_(F""K.(<8$=%$1]7+#,QO/6'9]@;,#OE>. ]<_/9@O7-G3 \"PPJ#6
MV(.+G+:0463\G71,VU4R%75,E^W:TA:M6"T=9+Q.M$EH=63A-&O]AVFV.[+H
M/_ZT^)I4V?WJ\3ROTP^29PKE.$.1E<[GO6HI XKN\Q5C"0:Y(/6&Y9A'>YQ0
MDY9HT\N%[A:5<CL.U*YF+?\ K,UE$X>N9GV,@4WA9Q?KL6WCT^'@JIBUBS4Y
M;^(36^$KY6*D0+6*D)Z/@'\E7S^6Z_RLK#/Z;TD2D?X'%H?"^,0A3X<31'%
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M'ZXI@JFJ8A)B0C1+WJ9F2BD>2.[HU:=>/%:8OR/*65SO"PBG3\_LF^$9="3
M(PX?]0C ^=[UDIPT*)M8:01IT.0G J"HI6Q\3+;LEXN&$FW%05XOE[C*RT>Y
M=.A^ Y$/U=S^GX6W0GTNFE.*PJG  75(P*7$_<*<R,EPO507GW[<7V\$6='F
M+@*B;#!CO_.E+,KL-G]\:H8Q0A_9!9K5G$L:F9_<]'/@!4$73*BK@RX^D$N%
MO[4"KAN_#KVL IUA6-P)ZC!"ZN5ZNI 8LR"QI76XURMHSE=;8HJW9ZFO2M%
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M+#?",)PIC" PB',6@E?!^7O;!N?ZX[T(QO&WU*XJ-YB5H'\L<X:67CJ(]G=
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MG5,Y/=@R*VQ_TM!I8/O0;?*^;-<!D/F^E%T+^P1IK<-SRI>$2T9RO*9(9GG
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M,NN?"0$BD[A*5UMKVO_Q%XPH$UD6F\]HC1(!;U/K;&M=7U#(=Q&_7:\I^JM
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M*STW[9?M$8D:?CX^+[!BT%U/Y(,E1<&2;#(F*AQ@% 04"]OZ4#,#F]@'IOG
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M:6&#0B'CK6WC6!9%%T5U>]/WQAY0==*I$6++[>MR-;W*-ZY 6<<T"8A?N8)
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M^VS K$[!. H$O]6#7\J'PJ<&>IUPK/B]VAOWB)LDV7US0=@ZPXB7B^65* P
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M.KE6E)2>SLOYY,1[YQ454%I(3[H[;E^6,5(=7G,\LPH"__DI5A8IMD1^<P
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M]"K\"%=AQ\'(L8@608OD4<QV&LP'5EE?BD#=3[2&*4Q(&MH(,8^33*ZVUO9
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M@ISV5T>D1*2CB8JU&@^EQ[#L"Z9>1%X@M(KD3#R-DZC/1:P7CEB16 ,>8GM
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M@HDV6L.9%RO,_J,$8PS<X3Z(91G% E](%9$./%$C6)!O=1FK?'?$M2PH?&8
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MKC!/#P_B@-,I 5 #?) O81Y!FM(7)-L)^]0C@[PO?8%I& :$*!7&\%3!DG
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M6=E9(EA9TI08/VO:22F<4SX'X[ VGO&Q\94A6=MT4TJ)1$\$'[D#U!V@CW^
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MLIE'U!.+JK>7" D EO5I0#$+B,=]YB K7T?0M1I)0W\D8UN#G+,PT>2)&BK
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MC\/B52;6B5;ZDIH1JQ"OPXI!]HC;?^)CT$!) ,03]A6VB"I*>D6P3[:;V5]
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M!2IK)5NJ#6HD6?(E3J9*8]D9K]@>E>79.76^@21$(28!!@ E<W[][GZZ^[T
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MJ*\+UW%MZM)D[WA_*(ZQ&>##8]E[M.\/:?SXC&UIW[ ASG>S5J6]79.-R"&
MN(L>D\!*J]/K7-&FX1+HI,LN2D=QELW0J-]=O!X=':>6.>5J<.-Q5J:#X*KU
MO^[2?2_<+%Z%W[_D\Y2Z;K0E.NC1)C!ZE@3/RY=_ UB*PT]X_)PL\A%MCA&#
M1)@%^O2^3_DWJ_%(^;!"$ROMT031(E3+ZW7L?^M=H@^^??]Z"W.VQ;<]C_:]
M&-F_PXSD:\Y+3QQ,ZZ3;5$R[H/7Z<_:64(52)[K@\(_=SZ?F4XAIW(,Y*NAS
MFC@;NJPBB$S8Q IN@.->,Y2I\%IU!*&IZX[GW_2 >*IHN7JZC).8_ZL9Z.-Y
MD'Q/'N0-_"!C[J[A#=V1H,$[S1D+?*Q^Q"6/6A)P-P1V6+4J"O55XA1'+Y
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MJ\%LH/E.#T='("!2^V@99<,R+NL,$3"GAX?_N_\96&!HGEF39R9@'LUT;YW
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M>&Z-T>O6ON;.?-QO8;W,L<1LA2D]*?>!(QNO@*?D/T5WXOB=7&BW+[!GS)
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M&>!];QI95JZNI/(BQ<GC-REH-!N0E"H@5#\B(F (43Y)X0GIKVEPSNB7\QR
M8RZGDB7$ES%;?S[TSO677;'!$L65^Y%-&0PM:QJ*$3J>JNYQ?4T^B5FQK%H
MI.8#EU/O<F&A11ZDV&ZBV (;#)_WVYP&YZ<O:1E^O.0O__?1T9.#0_[>',#8
M#_0\C.Q6BW;8H.);Y(4J#>&_CPX/T\/#0S&TNM(8$R5]4TIYEV@7GFDPFSM&
MET;W>4'.ZF+%D;]RQ<BR3Q"3B,LS$)HL(A1F)3^LV)6BYXO2_*PWR0Q=K1J
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MK%.UT:,V9S4QY:@)KI>DL7S</$5XL&QR+TR4;R33CE/H/L3U@&PF2TXO;[E
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MJ)NBFIMQI8O,";ZYM$-0AG8_G,9_K,F+G[A)6:KY,(YU<#P($;-F*6F2H F
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MKBP<Y>V>*9 @'&L"[$T]7AW0W3 "5]@6YO DZ":9 O[$JG1M%\%>**(XJG0
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MQ'<9=! :VP\NY)F3%D+GD^RF,JIQY*%QD.")A0U5)$Q5*.^H,\]X?R2A/I!
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M!A^L11$MIG*;(OH6/KG4T+[5!O##O$>;3?^Y:M1!QFC="QN$AMRW@=S08,+
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M<%A2%0GL9SY7KBRK)AU OH9*T,B.>/)T4!'*)=3%2N^JGC/#-V/O^)"8A'*
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MTMFZSYF?@1CQA*%]/DN<)X4#U1]B/IF.9^2DUW&C[O3XN?<C%]@5^344B@8
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M\O"8++.)/7#1:) ]+FM^&XDG$^8)=?$U>+UGEZI>/KOWV4>+CS]Z\+%-34!
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M^"5Y!D2]X@7E'V4DR,8,-/EZ2K0>K5ORTIFG%_]Y&<M_NFG(K.#&U?1@H B
ME<*42O=<N\DT%9W,'0YRPSV,\#?4UMYH^G9;[*6L;=/7P4AZ5R5[--7>&'KE
M7])3NNBNY<>S5R5;$ #5<LMMT8*W9';X+B[Q'@L8CY]&)D0O+3OF%O/:DD5W
M7;"<D)Y:>!2 RVSUB;TT!TCWJFD$/![:&U0!)YI'FLHFI$H@IC10)NY&2<UK
M7-9Y1'/<$9"(12D'[N:%[@#"' P%=CT9K+,"9"T;(_0*U_!&^0-HCWD>5H
M<Q8.CV$RRUU\""^%]'4M]->EMMS.W2TQB^(J, 2F-3I'82=U4J?< ; 4U[)3
MX Z GZCH3N_RHV94"!K]@#=_3=9Q$& 12=X>K33D33#%,]Y[,K,>HM3*%EXD
MKP!\8UQ3+;YPBF^>A.X[%+IR%F$/F'$@9UM9?:.ED@XMT,-R;O=JJ.35=_;L
M)WC00WF0:[=I0GY:QB=AV44Q4X:1S&<_DG\'*=^2%%/V8%#&ZR_9_3AX4]5K
M5O')1,B>89RL)9.!\R@ YPD:D0O1@8V31KDI7F&$,KC1.$% P\4('82<C%6J
M.R"BV(Y2N2:1.2&I/RQ]A' WK_Z@*4+CM$7=<>A%!(_&F&P>289BDFD&H-PM
MK$@UU[FNMK:X:<J5?@AQ\R+..#U@<FBO&<ZP%D5+B:Y#M4)I+@DGURZ%!"W#
M0=GIA!>PCPT.I2I6=SZJ>GJMTQXT''Z%D%OL?5,"^IQ6I?,&6C6Z2!ZXZXZG
M?GW'F=/JUMCH07N;,;ZUO)$$0S05N)J %XU_K2^G^]/MJK"HFMO0YH.@\]0:
MA8"BUA;ANJC6T4<8+2VST0>4O]V,/ H,L=9V\@6*1;3B604 GU+&[Y[TU4E?
MO>7!??OT^<6%1GN[*2<VENAK#[NP[+6+@_9L1K&Z.<G[S/)=A#JLRUVT@ 'N
M?"5E0'R+HPS.*UK](T@X,R3N=!-.-^%=W 3IXL9.8@KD:CSPJ2-!?AF6US5W
MJ));\9CT<+-1/I2'!LS4[\$X,^Z3&*K.26ZL1:S=0Y=_\ 9@*GZ0II[B"#++
M7#<?<79SB<)57[31=(0:Y"J-CNZPY-DEC\*F2]2O24E6L1A13('8\3654+QG
MM_)4V/;)_5-AV_M7V';2%D>G+;R?#Q&Z+;C7S*#4+WE/SV,RXKEXQ=WLLJ^[
M:Z8'O5A&-H-!&3O)XR>/+L[R O\Y> 60.%AHYT0)(PB-3B5 :^'#NF&24N]P
MLPUF+K>0 S!&%3P07!-9UZQ1%N1@=G/S&Q\^NQPT?)8\I_B8J:910PV\&&L=
M//= EYQGI,Z:IPZ:JYL"% %HB!G7)P^=LLO%;PV64-]QV2.KM.NFVY8[C60
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MR7_Z&?':)3)DK5A-0BZ"SUQT+J[B\Z^?>?M2F3+,'W4I0L0@<X$%(A7 V$H
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MEYVLOJK.$'>-GP>:D1\"0[R@7R6>C/@A_N[$"#X55FVK?1/_QG&-18V0'B2
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M Y.?=&;<9(L6I-6IM)*KJ1M0S=^&Y$8;PM3C'*=IFC T%])1U32,"ANEI\"
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M@WN?DJKXY OZWV>??3P6=1^&#)NPS<\?D2\*._[CN^[CARNO/O_TUZ[+.Q-
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MV!$D%_"OKF^O@G9]67[#HN#'&KU^8; ?9?CI[A ,?)>'L6_:TU2^]Z%$G%(
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MT[3QD^L"W9G9;EJ%;MF6"R-G\]/D3](VOZ+=(1]?WC/869YV6+)ZG^M2Z E
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M/"8!;E+!>L7$]40&VC9=50MZB8F'?#LPT;QF/TBOA#QY4LV#7" M^2#;R,+
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M>.84*3CB#H5RXXL@X_!90APM FE'"#[PJ[.URM'<-2SA6>JTVC75F_#MI>G
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MA@N\IU.#N=P6%CF9/)+%4IH2-C/?BBB[7D7>A >F;!P0K;^+CS$U?B=.J\T
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MK690&!W?V=_H"=VJC)7XT^2CS*#+SMZB+ZN5XA73U?>D6WJJ'2XMW=Z$O7*
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M4]Y47F=##Q6EE+ML@,L&^,5L &JEKKNQ'@Q-.'2R%4P.PBPX:D*TW2_.C"]
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MNS+"U;$DUN;SKV<Y[UW9-7X>G7@O8DR 3)@* 5:3]'J^X09$I<$\"NA]M J
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MFP,E\\(/0GLJJ\PEDY>F KTE ;1P J[?B'T81=IWZZ&EE_KLDT__F"BP"O;
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M'9:.-,N":PQ^J^I(QT7>Y1BN7QWJ-1O(L:7QBK9[ U:0" "!%"/45];!10V
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M+(LAW\Z73]Z]5+*IRYLF''  (DO51)K+W&"3 ^1<%24JAPN[QW;VA1@43G-
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M*ZN*H#GLW0KETT21 > Q^N-UW>9@SK34'S;[V#.4108/L;QMYW9&5TDAG@O
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MJ-.YW/#YT^JC3S^.@WDA@SOV$6@"4Z&@5.M(F52;W>Z+U4>??9QT#]9*)II
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MT\$X=F@J]YR@*A_EEOG9-U W:F[HLW B&M[ =@@-PKGMDBRYM$TT@G[@5OK
M_>9]"CFTXA$\)9&7#BY,%MCXH4+P1MR&%4G14YC7TUR7Z%;;^.!:9PZ$Y2P&
M:%3.;P0_R_^_-0)68UW24W#N(P9#W>[+0WFL#^TF/A6=JR/ OC1YC9#7%.>4
M!8O)*T[ZKH;3WH:S6F;,]4?6Y9%EE[?*NL 2Y;;#XLY)^(BOO?SOR@3H_<,
MG5[FC'OV(12D]+/2^SP2'W_/$\Y-6%S)6,9ZO\GJ3Z0,_)89;K5?/\-TR"9F
M5JM%*U3>]R,U?8@1(*EUP2K^,0:7S;TH_5^Z$M&,TM_AOY).E4AO*L9RB]46
MG!&$OQ#^8]!LGEICV"(EN'W(+A#T$PO;J7"JM*)CR)QKX9% 7CBDZKC,I:<T
ME/J4C.LOFP;=+.8+*RD6-]Y+Q>6( XYK$_X'06J(QS]PF_*S@A$&ZHJ474*O
MX[(LYFM8TP_,Z5S!&7E'@TEJX?DKC(L- U$IA4_4Y(J78]ML6#[1L>"UUWN1
M43;"+XC)*4]\I )E_D;6![>S.SO)Y%;Q1$>_E)Z0=%%Z';X*CCJ\.K+]A- /
MCEM]HR?&BXOR9$-!+PPB0'&9Q=E;Q\.-A<L>U<P,I+9W%4\ 38*+Q(J$HX6/
MPHBNGC#[.I$0;[\1]>'LMQ_*880]30B$,Y*G%H2WR#1/<4J<4M>!O&,LUM $
M8G@&LO"Y6HZE_,MB)!IT)GGHZM7NU%,V3N;-:^#>0X:'.C<I*R,3(1\G9XD5
M.=)&((;@^@!]AC;2F'85UK[92#E#4ORC;4$WE#\#^Z6PUYY_,>A^MOHN^M2R
MZTK1GO!SD],IWV0'7G=MN=DG])/;KAR9E[&\IJ>,\=(]CHK/1)820O(B:^%!
M\?&T3)Z7KR37P1BEIC=.4H8MO(<I0'J"/-3U.&0[XJ%K]_Q BDG<#BP2?Z=D
M%H[[4P?R?<7RON608M"?'M%%7=K?3[+][?1NG__7:SV.54.-4OQHR[3CFQMB
M9 ]V#3(N"BTIO4'$QVQ'-H+9$]2C'J"#TI+T-/Z/V7*$ (A](8<+A[&IE%=V
M$_SY>N#8CT(]_A/SF93]CO]Z]::F% /"4M148=HV$C<IY =8Q(TV5>%5VIE"
MBHE?69 I/-"& DS\I%#T',>0,X$JE5%<N+KWO.'7"Z$BXR,O?(7;6@F?5<;[
M9!1KUR):K70VNNSIV0 ^&R5#_ ;T[AT[2OY#?1F@N#B&]_UPSBEL0VBM(S^%
M_ EQ5#Q=UV'[[%?!33 Z-T;>='1YB QMJS^_>&YT)>BKKD+L<JA5AXVO%2^A
MX_AQD^*LIR%&$Q6/#DA4J]GE=""=QWVY1ZB2UH51H\L[QI"OT.$F\-'(YC6$
M,;\]A1H4QXQ[:=8<RC<\JYVM#F+9V[;>4'U(R/.Y4+FN\+HN,T+*0K7LL(JG
MY>>[[/W+WG_/#_>?7[]ZGFW1?O51_?'</MU;B1M2"6]-YW75KW=A#["TJ4;]
M)W_475<A8ZR-0*58)1LYC21H7]7;$[:U[!X)( SZ/!Y]HW"+Z>^X,QM/8C[9
MILAFF\8K ;-X"<DIR7!Z] ;TIM/W(#_'BH(6![!S_*@.2^<K($X;0T%^\&:G
MV22Q4,K-D! VTJ)U/[?>5R6]?TCKZ3.Y=)9YX2/1>M^WZSK.?4IQS![%GKEN
M;MO]K7KKD5U62EP1?3$QCX'H85N[<I-G"/#NG[1@.&577@^*N<"#4TPTOHA?
M]&8L.SLX0BI\6ZY/9-?KD(^+&#T*SH+F>==G^Z4YTPOD[_,_7B!_OSS(W^60
M?W*'?)3LX9JHKSW-%IRX@L:QM#M_LH)>89FK7G:HK][4ZS>TQP1>%-,)R0\B
MD,,XF+F'G^C:3FIZ<HUX7KG'FA[%X=4.UV,G,$Y"/R68O6D9UA]<.'H&*L#V
M8*O\I1T<EPWZY#9H5IH3!G-K+*Q><33:KUZ/5-5NP,DOQ.:ZI8P\-*5:#5'2
MIAMO@%JX907PZQK3M&O!S:#0M <B8)^,V.HN@KUQ'4M+5(75IZR"]F)7[S==
MU1C?TW]R"/9UHT3:KZ3>!2PC-!\(\O;-ZX1CRA&='^W]C_K^L86@C'=X0U:@
M];_B!$) C$,H;* @[9H2(4H 3AU&NG^EQ' #L6G!T;1$Y!4<69$%W$PQ3$T&
MIF+S&E A'JIZ[G3'1U*>\;ISJHIL4^$K$#CXXFLNON9G#P82;M,,169*.8)%
M6K\I="]+)TV(YN>HY;G.#NV'I1TO^[Q8W=3;H2_.[W?4Z&,C(=W_\]U&EVG/
MX@51UP!Q!KG/OHA4Z%2[J-=2B,##A/@!5.1)_JN$W ]9OYH@DR+9;5CRE&(6
M AJ6M0^44G<;/"8#PM%I9&49@FG#\2@F_+H:[@C&ECU">CSP"0#?HW!Z'UD)
MZ??%+5W<TN,U(>[U0JD)QW#"*FWEGF!E VM&V.85KS7Q2TKP:B*V1%0Y"E=N
M5UUS':U-9#J8YE5]AJ8,VJB@%N@0MAX D1'-!RU/R4QPF53^9MH:O$S&7S;?
M8SS<N4B K=X791E=I7798-338NL9+9*8:/-=[4)"8-NT ]"LN S7#/@'9^ZB
M#V1%C"G^B^F-64Y YS/YJBG&E<9):"\2QH&)=!$[T+$;\;6K.\-]\_X6RL0C
MD>T>!RXW2$MEV(V] XXST-HFQI@1^-<YR?\5982T(+%?X<L]"YC-#"259&,R
M&B<5*Z-"XY3,>C')1*]WX842Y8,06U&K4/W)Z+'IYS;4)QHBK-X27B)Z:%(]
MJ(@2_"IR0%<H+$7@]_PR3 =P&"OXL.69E/3PNUP^2^1DPO5ZE:)B+7#Z3:'Y
MUH%!99;F"65</Z'!E4E!A71VY;$.:[6CEU$<H]+ 5\UMW>D\Y#;)PKN*=K;W
M$()1WU,]L?74][3C0DI?B<)R G)^'K:UZ-$IGH"'=U>W=;LW8NOX+@4&+00Y
MG$UG;$D.2B\3?N50"'B9>7\9^Q@>>.P2/X$92AL@D=P(9L-PYZ;DSWS.=@SR
MG2MFR,?:A10I=RMN<:788),C/(7@9^U771LNR3\9'I62"UK:_M2CH)K!ITV%
M/<7'XM_8>6:9#(*G66W6>Y1KRL0J='@%TB@CD36']<>2-+C'H>UL$G@B> X,
MRLOG/$B%*['PFQYS#EBL_N"DD/C>\X"^ YZYD<6DBI.-?+N=D^],[7[;EQ(1
M,A,>X[ZZ<.0U&Y<W@E])4?$R]%TIS_RA)?IY >C'[Q+6988P,JF/^^A6?(Z,
M(T]]ENJE1KT$;S1>_$%&Y@#LK@"4C6L ^ XOD*OQG\$2FXK%/7XOF__V>HC.
MQ4G*_($/CLS-QK'U9M,C6VI_"DZ*!'J\6TSX=;"B";P_L9-9R+:U=<;>!MFR
M:1+G*($L*5*T2;D)_U]C:!7<_PH/*U:;\D $#@6AOQ%+'D($V+<"YA+^:7Z/
MB.*&C.9RBE6<QU^:.B39<O":>\T:47T955JZS1<:[B<NIJ],S=ENG!/P>#?1
M*@POX.;%6IKFL/U'^L3N<](&K*<,*6XG\8GG1U&]CJ)\AT(@/_3MTZ_1AXO*
MSHKGM*W\_<O]@>\Q'<[Z2B*&Y4&8R8F!.1QQXZ(BVL\.0.?<>NL=R7$Q80G]
M/K9IB%*.2*FR&6<WS2FAS-.=<,K&V8H'? "(JLA'H)]F<>Y4S+LX_WGJ08ZZ
MI@J_LZ=-J)_J!F7:$>P<# 2G7_<?BUA57(\J;4*UVPK0)C2;CF&_<2U\9FK(
MBMLVM:1M//K^8T,<!RMQ_M3^"RZC8M5'M2:O9C1C56:%]#LJSIIX;EU>:/N-
M7 >[)L@\OTDM"D*I]L9T01!?,+<3J']<S&33J-'1D%@!:*MEHGMH+T,QE\K7
M/]EY=YP6IO7%!DJ?NZ*_0#ZSI;)-^"!2 8OJ.B:]TDN.(8+E7FR ]'<.%V[U
MBU$_DE&37PU?C,<E.00=B)AET(,EV.]11[G1S"62B3M0=(7CM-(RIP]<6<J>
M&:8D0[ ?OYCUQ:S?M]!+JC>-*<,8X8#@IR2F]"&5CNL8]12!AVG*XTI 0FQQ
M,>6+*3]&V'$;L@8GI.G#_-I <Y@:":&%5$9,?]2UD7]I]GJ9;/C=)Y?)ALMD
MP\6/_BQ^=#[MBF7<MA=&6X2[^@/,(.#BX1WA&-VUDCH$J$^%E1?5D7I]2?$N
MAO^XAL_F>@N,RVW5U*A2H)E;"B>0*]U+=R<S^H5R11^['B'ANPU1M5X:3-JZ
MT; )-LK0V\_<X+(3+COA$79",/&JN:$^%UD_K#%8L=8^*$7$C%D"^O;$3R#M
M)W),.D30:10"&0"J&XP7,\G,#$DNU^$OEGZQ]/<^N7%*V<6$LD\8X#Q,96AO
M*AAPM%#I$.$W+[#BB\'^C :;^-W,<A6,P?&WBK$HBU8DE?C^JV]>*ZC@UPFC
MS<E<[VE^JV*[[X G;>_8([8NF(L4N^HFO$##ER'>6&@'$WJP%U84)F/L$[2G
MCBR!ZY^:W(I]N:O[F1OVU#WV,K#2JE#Z&!-N6;I^(7PG\O8F<ZQ=[TG_F0-=
M1?*ES>[8Q[<>MX-C:).;!0567U:,"(U '1EK7\8/UEO'ODOH@7AG@^<2.\Y^
MKU>QY]C*.)UPE3-$3L +^'O1]5B\.PN8&FU^TI$'OM4QZ$SDTYX(AD?PH;("
M+0C1 9W \LX2JMHNLAW4K_IP^3WLLFR8,7=/!E+X+[9,@&XR4@E7.ME>U3U;
M/5GHSH\58FO&K84D56R=2>MG35:7G/%WC2_M -LM(DTOOGV-)6VJ,5RADCU%
M6;)C$2],"XCIQU_^]4M&J@3?TQ&8"A#S29_4H1S5(S%:V[PDAUL/V>]@DRKI
M;!,U#II4H$W'\&[2O=&_T-X5.)NO::0S'(;AC38J > 8W 4RG(S9P(<1;&<5
M7!6M!MQ$/W:WU0D.BL4Y(N:($84.GBQ;1+4%"BP!WL10I.NV(][.9ZL_CQTY
M^ *%@'X(SR#88)D'H"VGKT93\VN%5W2^UF 0U.7O&:((@,@9\>^1W +5.N/]
M[E2A+0*)N$6.=C;F#!/6^>IMV <-GI<I\!,Y$V$E[\-W(7XK_.#U2<'GJ<H1
MCCOZH4&&!]3]Q ?MS?\H#^O\0]&EPEE#!KNG!;BMJSMQ*&IG(&<IMU6:&$.]
M*=A\M@T*_P',^H02E@ZU3C5)/5T"6=]I=4-;@$A;:15:]]L*?ZTZ:J90(RO\
M3;BWX=MX3\&VG[\,^?55^(<=$52</O!C9HZ2W4(;6BH>?A 0$1T)9YV/B1G-
MF+,"]0CH?F 99CIL@DM2T9$'N:AGJZ_B((Q@(&<WEMGG<G##<;S^@BDBVC L
M!?5'S.*%\S+-$L3)6OS!L^W#O>Z96<QGCG/ TD750#<\D<5SV!LER_R9@H?(
M!<L\J#OQV9DS5-&?XJ<'&/*Q6;KI)NQ\VJ?8;QIZV)JF B";&D7?G7B"7-K8
M6!-#:E4^35DU5AO;ENM\T$U (3IDQ=[UNJ:YT%T#E\/N;8&S(4I^3B59D#YP
MU#8C04'"6.9]]T]8?HQBJ'L75%@E@#$+^V]7W^Q$04PQ.]D\H8<=8[X'\X5V
M$_Y*B"X>*'$"VT#\V5=3NT@"*MT8:4P%C;-BQ5."=*&;CND&%DV'J"Z#%1*$
M>_%GPLHM\H5(JOZWUX[8))G$"]:Y+C?5 4%"\$O#&..W=+I+I4KQ:9B/A4]U
M)C$P!2E_&0U*V^XF/,]_2P1BVNFI"T(P %U=FV"3W&C3XD+.)9N0FW138XP9
M\MHW4W%=WH3!\89#('@Y7Y"_S;0KMJV_G$L?O,9<%"#6SH ?'G)"%+R+<7IZ
M _O '>;,'GZA(C%>KS6*J$5\?C1.)T7GCE"8/!D%9W:29OUG>T<]1*+XN:V:
M- A:.BH1FEL$(P%DW ?+N4'!E/\8-X5NC3V\6=!TUV[K[L"[0U/[Q*7]Q[EM
MBD&.L>M')D:&-<*B[!4CP%;>K(^/BVD\2615JW@;DPUGPBS *N&D9"]]K(NE
M^'0GR@H?2 ?BNCY:N($1VO@.<)$Q]*&UEN^2U LYW)J]B\0F9UQ#E&\Q)Y%,
M]//0RN*6=9T\=@A<;.,D)2QF[F6<"*V?I/6R1E6VZZ%"%%*G8*E8'SN_BQ5F
M?GBX&W^6]9,F/$TB!FMC^35MP5<L-8$5V88TK>-.NO7."W:1U=OPL]DV(I6*
M$%+4*+NZ"#\>:XD_(A'9*,&K"R#R-3(+K;+G\Y$]4]3-I1GTGCA\]R=SZ70+
MN7IRE4S1T.E^17%DOI-M16'7TFYNQ>KPB01H*WJ#U\054.72BM-XG0*2F0"C
M*8<QCHV_0\0R(0%<CD7DS*8VQK:N]IM>J0,XG\G0S,)2F 8O\<WW)R\E.5I>
M-Q-=8F LV8(/%E7^?^R]:7,;U[4N_/G>7X'*/8-4U60T>$I\[JFB*2E18EMZ
M)3FN\^FM!K!!=@1T(]T-TLBOOWL]:]AK=S<H.K%DB4'5.;%( CWL8>TU/.MY
ME/I"5?I<.^L'/.:.^-$O'A[QHQ\??O0]QJL@]$@2JV,%Q.:7:G4MI-FRT]R?
M%F7CNXN*"=OJ@XP0293 *)*=/VX0=06N%P/.,S2;2BRME(K*8W$Z>UJ75A61
M_(QG> @752?I,'H])1*1JK((@N_E;.]8OH'3K ?UVQC)-O0%;I?#5RU*+N8H
M1Q8%/#+^'9U!SZ08EYX"7-="PG(+@/\-J;_!$]UPP(@+QP>2N3J 09E<3?X-
MJT=*$>M.IRW:D.HK5A262JYRH"1%7ZH;NV#"UJ7D+IQG%4<Z.BU:(U#/0,H-
M7O!26'?>&>>S=\H3+>O.">).']X4+/@\OW]V+KX!]4E%_0$5=2)2XWTK#D6<
M@"4W3T&+S6N4$)V4TM1P4C1>,2[J=4861Y^-NUW=73]@RFGC:D:\-0P6X%A<
M/ 6)U%B#F! W3ENLX.B8R\YH17OV0-%H"E9Q4-?TL*F%AG;\H##$T00RB4/U
M-JRKRX;,N#JBK=K?>/O)UW,$*RUA)YAG@Q_*F\4Q8T<I>1.#-.H<TT<AV^E=
MRV[=7--?DHM9+LLMDX,DMS:DB7.\3A*IE\MFFPZMZ]%G=(99N,_N#)R&W#-1
M5/GN/.4T,7("< TS.=3(K'N\"Q8MVUZUVX[>0!$=%'I$-Y]NFX,[[IR]>ZYK
M@ L460=%.H86>\[RN/,I/Y8R0KUINI=WD>MHTG'@4&3,SQ/T%Q0X=YTD'E9@
M >MZ5U+,(OZ2J/>6N7*N T/:(^8.EH7<>KIROL.';$JED<@"Q$BZ82N4U+J8
M&,!5XXJ^P]'," H/C),;ICPSBR-+:S]YL.?>(".[RQV@S 9B321OTU(^!XWB
MZ>RL$]K$I)UK*VF8'J!7+\?S7 BGF_)WY6.G"EUM5@$%QD9\*'A9IAC-I>6]
MJ^[9<@$0:E?;/.Z1,O#F&RW#RMEXJZG-S&Q<$^$:/H82QLF68RHZC"TR7H;?
M'8/U"IN%_$8.D@+RE71E.0_5O5ORDX#@B:$7/IEWYVR<\^FHE(WL(\ SG.W?
M#QRZS"<:4#F:;^=]I33!2,/P<35TA*+S?Z,BN7\&]A390&YC9)P=Z\M SZ1.
M%\3<G&)=,9"L*]R#F+@?4_AUV4LD%\ZWQGD7[1E<DY(H!P$7^0ZEH4</'CXH
M]/W/F_JB14K4/*\P.TO*GSF<D;T(_M!UF>G@59WDA;D^/V]$F\^SMKI"57Y8
MY'EFKFYW^HC3^;P]MKCRJM$^4DB >#IPIMCM-)\=+T;_F#S1'*V<]_?)MX<U
M=(5G]^(RHYNX35EV($BY4'D4HQM$*-=<CJF$\2XTE\[)4[ZV7SI5)GJ,-6BI
MR'>G!P=ABHY<6OYWSG!$Y^AL=T'$J(\>/'K$<_W\U5E<K-U,-F%T3HF5]EI6
M^+1L]F%!'B.:)V$>SEM?E$R5B_1!/!PO&NQ18UBUQ79O'J>VKH7/,C[A%_=%
M3E$I[G%$,9^Q7B=DY?22>IV^-K5/9;C/%7YF+RDW](U;W/J[)S!61,K(19,*
MM?3$Z J&T'[+)?:5+,)[JZJ-(TJ$OOS8C^]_+:?F=ETNA I6KF^.PD6Y-39^
MD\MF0D-$%OHWENWB/X\&Z//[7 :@.63D'=_L-9V+T#"6,L"30,Z'EAA%OHB>
M\8^[.(7Q\Z(NEDEW;#+"3 #9.PG3VV9W<3F[V$67B)'F'0J;G5IQ#>T*JW$*
M$':V#V7;926^(O'O GMP6%@D>81QJ[\-E\T:M)+WPNG%:3+9EZ6>=>?L]H7[
M; SD= C+3(YA1X.F-,@DV12?89>T.GGDF1*Z2:@!18IY/ 4M$T8KN"V#T(Y"
MOHX/'![,]";V)0R2CKVG<L;L*CQG&MI$S[?0VC8]*:FIWCV_YXR3#"YI4]AQ
M0(>+3K/6Q$E(.WH;<<+]H9'Q#(><L-C[(D*9,UR.]'65&:.R72ZA,U#;$_"O
MX/ER[Q;+J<72*)(P1S%J*U*3JG?BLW& [(!_X]1M2Y6452D?/8 9(!N]1FR2
M:$.2L_-ZMZ541MPVNVBK+L,:D4,=PYA=MQ8":[=S?(\+- +2Y'1"_NT#,AGF
M: F_^<YOY4F)GIEY'X/1AY0;/*VJ9@3$AO 4Y,W&8 #V*84-<1=P^_=V2U9'
MO&'ZK=#IKQC0S6-)1=?R NX>.<2B8T#>&K\3^P450O22[>ZS-^?TVTVU/*$#
ME3/FZS)N0,)>=-<A;-E89V3].&+9NBC!M+Q\'!IS0PH076\QN_J<-R1C51J)
M?DV=OA>"&QVD1U&:C^-(=W+?9B^-VIT6Y4:YJJ.#/V]W=(K067PS5V6>"2/3
MB&F&\%5<K)#-I*H9VTD^E5$("4'IV+40[G2B9Z1]T#5M][5G,$0ZL>.@Q00S
M"$-BR[_+E;<X%M8UF65]5/6:3VQD/BA2COLNKK+_JOY['J\<O=!EH *!JG#R
M4\/?16CK\"67H9;G1'^"GJM3#L@37D/YT?PM ;YX'55=MZ-RD49/<;IW4'Z8
M_2EZ73HM$D]+8U.-"IFBDS#+\5FSD:'<2%BO3CC$6/(XQS?<Q<$'<)&?]>FK
MYZ_YV.%K1X>]N1Y_F$8LK@DMOM -!S>+9HY01S,&#B_V@[-?G.TU]=NMXE$!
M_R"M4]EZ#"Z)<QT?^.63LV],0R(X<OO,>?GAY;>PGNR(=M%52*@,4>>F%935
M'S A@@K3!X!B&FW!H<L03=!Z';U;=172<U"4W6LG&KNB>)P8NC) [(@X^*"(
M@T='Q,&_!.)@PF.TCJTAG[E+?L^@\K(?E")CG <"&#F9J9X@24M%W;FP,YU(
M69J;'4#Q(S.?1YO.DN=I@"JX@2T0 W]PZ;2)YTGG^GHO22[YJG[JZ2X>'2&:
M[!]J&%OK2F2C)!J+@\>$^)2K)PP\,$WJPXX+-%/O6QCL81SF'P1=4$!/X1P<
M8A(*X.)&10G?E8+>T+*S[1/1=E80XU!,GBQ:<4,CY!XWR]DMLJ\2JSGEEMT[
M)&4'<6HT'&#W>] AIXESL UUEFP\F>1JF6B*:61-I.2VP6@'1R7G>GT)VV</
M%[J.6,XDS^<NFG;;2%\'U9/BAKN*_N[RI)8<AK#!B"<5W4'2O%D$':_[T$F)
MCA'[=BDD<>M$M)@=B!!P_+@T0Z?H<\IL:#(W;D,J*+E:=EP.R4<:39W/-7GM
M0DD.T42RWX.83E\@[0FLPLDECR+QX'ZKO&T1"8 T12I+RM:#Q:5H#6[H;EK\
MU;5&C=34ATZBB%T<XH[9W_>&%\I">>M]HFU')5U1L]F[OC&J01$$&_4C7K!T
M%J55?Z"OS=8?F3S?)<RCM(=C3^C4@7WCX1IIHC#2 $VCR7WG\,>:(S5H19_K
M1<DX3DUC\,[F-O(!WM40.B8:!0;<P66KVM9/C:3WF61Y=>PQ2[ZEHX)W.R@6
MQIW5[+:<8/%:UP>125#58NO$8SY >NBPW[T<S&UQ'\4' 'X, !]6Q?4GN1Y3
M.#'UVF,U)2FG*GJ;X>#51=,VD#J4B#':.FQ!SB'56GQ<-M?U=2EU>*1?&E.5
M7-R0S^1[<B^JUDK-*['3[!55L<Q)&%39:<3,9%J-Q(VVH17R%TP]2?[B5D3&
M=;48Q<@$CE;'&4IDGJ1(R'9=,DV38D"::. N>T"7(&%']YL'G,Q# R &HB A
MN1& 99;IPAR&-[KF?8;ER' /50B]*!$J%U8-E;7S"P")?@&0T#O@C--C58P'
MZYTL.WS>2YFU3^HQ4T>,.$VNO9D!-T->D+MG%*?:%[1Q9 @:EB+XWB&&AR#8
M3@^](3JH\)(%R' "]'<9E^.&D#Y8DW2^7>-0].JTM(;WC-%(0@?.L+*?O1'P
MLL)'&*1!#B_7\7=M7. ,2MZ00:AX>^S:6M-$";9Y.S#.E,TS1MOHY>W= M+B
M!X^47]B3V%!^E]2.90WZO_H"_/@7N2,2&JWLA(C_>=23"M.4XE4\- \S3V9V
M.5-LFF?M!"P(9^N)0\\!ULU0;G<6Y/TCM1^S0J55 04A1W"&55NJH%^P@NQH
M[@@Z/&"O*^NT-SV(RRD'"JXF:W0KG1(KTN! (=89C@_S&7Y:A+"\(69>0N&S
M:^#%(17G\/[<2G\KF-^@EX"6$Z$@6#C6D:CZ <@:,5G7EH$DJ3FWJ4_0'L=^
M7<:RBH#U;7BG\#$ !RTP,IQ,T9K!KVZDWA-L#0Z4 Z%E2L+1;W_;J98S8NN\
M@U+,QKOMSFHWH>4X.)4N*Q;$,YUG+)#H]7(3:OP>84&O:"T!Y(_,0L(;Q4M/
M$>IQNRX5&9$.$[I!]0)0\)7J(W\RK^/&M= U=4V5[8S7".%_#?<AWI5<^NVE
MM)_']Z9OA>7D!?M0QI/Z+!%@HXNRR?JBC/A-I>KR)0KY&=K"NC0+P6H*8Y]C
MU/&2=^# P6VDDHK8O8'WD!EW.^P-VQ,=ZDY50O!TN+U>)RD3Z]Z_>WOEYG/7
MEM-P(Q0WG\#%SSF"F?PY,8O\8X?O#;W="*)%<9+*8E,:BS\F7+$T.1/N&OK+
M%D9S!B@_^%)&GCLBUNN3U0["U;G1$"9+UT_T8[QXL^N978$ILK&)M 6$$ A-
M*SH+:27OO26?NH>S2"G!/.YVS@XTI\Y._$;HU7?D#C8$G_CZ5V?S/([.;A-:
M)8H,JFZO\7P,?]7CG^ZZ]Z1(^F%;(N)MX!2P3&XB<L'.@0JST%MN=YSEN+M^
MXRNAD('E2$PGQ:AKE):R=P )$$V*T9.RJ39+?)QSXDB8O'\&K>^H_8S,S00Y
MH<\-.^(QG[E(C1H3Q:/H@  LNC,<-#VVX\IQ+[18E]4FOM'+ W^1/'S<V7-
M)'O;PCL@B0:E(\[ 5W$3]YDL[I1Z=C',(YJ5;]J4:Z-2 ]01<SKB.)<,1%)
M_^)&MCPG:N\9*JSR]V/(^\ZL&#(>L0FY+\UV#":S2),E/+,"V&*()'8K$^O@
MRT('XTVW\>]P(G]T8PTA+8=*LR*M-':ZF2.'NH#[H&9HS6&E(E!#]%G6$LW4
MMG?.3$3O\1* W^LP/&=O,_&ILZ@[,._J880@I+G2M0T7^*<M[_+*)>)19.2U
M27< ;C@ZJ0LR WI55XB<J/Y/>"0CD?&259Z1Y-*7T4[<GWK*Z*[WB2S'KR2-
M1Z^DUI3ZRMRI1$&M%WUD"^56X)14'AP3UY;' ;C?ZXR4(TXQ,S[I]H=,6MY-
MS$[A9347<LI;D#9,]!0>-))'_I9/&$WU^(BF^I= 4ZE3?C;)Y7I+WRJ%ZA-8
MJ2VE_-*7,CBRJYBQ+ZJ$L Z4,/RZA\VS/,RR+:\)^Z 0 OYTUB4_N";U_B!B
M&#.=NH:UR>>T8AZHVB!9!M"(,=+AE(PV>].-?"\X/]+ 61D/+U59&!1QYS/8
M(E@@)&ZEX*FTBSC:AAS58EA;&9EN.K!8>?Z0"3<7[?4N=T*I-@X8DU9+&#!J
MQLLLA#05!,_XYC8:J/*"PZ@LA6R'VA5#'RAU@(]U\470:(U/]%7'UXDKM;$N
M%8*EM,NWTD6@B?M, >30WD*2NKYH;MA8TL+P<T?<() "(AP!_\DCH<Z;?'M&
MDV]^GU+G-V.V^7O-*K["C#*;<;\09/_1@Z]?HN;XF7P&OWSX]7UA@LSN N;_
M."[L=S:S35,S^_4E,QXR8""0AR4<$&Y$E2L$PS'Y[NC2@1]+CE+%?3&[^FU-
MB;1\<Y>I5J)K*5L+<&)RZY $"..:I6$E]%RAUP$44V]!MH;: QP./JY0=K*X
M&S]#266-FDO&0?(J7J;'L_U!\2$ZZ05[XV/\Z-R>)"""O.HV_KA@;_0/W[TD
MUSL-'Y-9Z5(9"B8E09MB8JO9*X'JRDT/[>JL.IZ"Y#S;?_[="^HBSJTX.^?#
M1W?HMH(Q<-,X4.TBQ$LNH&"3'38#Y.#=BP9_E.*9<!S[@]%9 N!%6Z:Y3!9.
MFMS5R+V3;/^6?@9B#;XF ZPVN]HX4.39NJV!&8>@5:Y)^2YBU]6Y#A=2],OL
MJ%O)*+B@G"@8YJXW-0)N?;4N)043R9M*2Y+#HNN10L9Y-TZ^:[:8AS#D^2ZG
MW;-" )=X8+"!LN$$',1@1Q:SZ9&0BIS&J4U-/13PP@ &L3!D?AT R*>]TS13
M(3?U@P,@E\:=OP2QF'6B1';@_/06C+JCZ#<>B\G^R(!J=[(8]<DAY9?3]G":
MP_J"#^;<,F5][:EQ+%M73%Q ;RNYS=Z3RTI=BSU"G:X,XS,/^X;3E_%;4^];
M3/NH@9;3(F2H;[;H75APS8?@E$;)P&WKJ]4)ZU'8M)S._E(UBN=MU/\Z/^/>
M.:E1RMBFB9S8/;[5<M#J2,<X.J2NLEN-*=A<QG/5ECOAY9G3R!):,\OF\#<6
M4BQP!.KXZ.GL#.L#_;_#4J<K51YH(QAP^P;KO*:CY"!UD^A7C-CTD!Q:HIF!
MN)3KL->R+I60:"W3*U&RBQLC)\%^OJ,X63DT>LK2SCX^8)-.[H/].W.3>)TJ
MBYU XCUMFL<E>G.?[_T#3F;!>3K+]QQJWA@= IV=J34ESB?<,6,$F"2#'!/;
M.6B]9"WS*M(0J#BB,7X7EYJ8; ^+&;I*DV.6ZPV4AI,?9,+&RAP?*[SMO6AO
M1,-MQ^6')%*<IE4]A#+^UV(;].I?D]M'L[<P/?# 1%#L9VRK3WLU(XWV"K"F
M5ZDGG>CV7L?3FLW8IY_1T63A"^@Z-8NWTOH@V^T*A_\ZJ.R&_%J+1^LJKNLE
M%XVP\/N6*1K$EEO!,#I@<3?@!@F"*!\2MHW5Z)-<0VZ'FK!W-Y?VYK:#DON5
M/LQ?K0DMJG75[]S%! YF:Q?@3^I /8&JQZ!(74P($ B-5[4*K-](UTQ@'EB8
MRXK28X)O [.=KJ#3V6N""(F[RHUT7LL&0K6W6A5$_R%O&;1K,J/NZ7[_ 5?&
M42+\SDF$XP37+J650 W@-VBXX"1;)E(?7/?@IN-AFE3:+S=,(<2PL<O)BXC4
M2XXF'8W8KZPJ?ES]_YJK_W"_<H[[\ZVW3.L?/7-&*;$ @;]:)L_9'9?Z<:F_
MYX=SBO0W)[-A[YW-YH*46&94I(K93=JTB)PD7/(X)88,'U?Z<:5_H)4^WYO"
MMZ07(!EL"F\N-[J._G?=#=.2TKL%+K_R@N@#*:=Q7,''%?Q!5["X)+Q&FU;H
M9+B.@B7+JYNY++CL(MCB/LY\H. 1!1629B2T^\7E<1$?%_%[?SB7/P:52=-F
M.6X':B"O>-(7.:[2XRI]SP_'O>=C@'MJ7N3SWS7:Y!THC)UP%U@V,U*DZSW^
MG9.2Q^5\7,[O>SD+>F\:&"C<T\>%>%R([_OA*D)H*")4*L/<N"3MT0EA9.1\
MJIK]L2W/8S_-%Y\=^VD^OGZ:H]F\<V9SE:2*-R'T3$\)0H $H>+: BIR2I[X
MUR 02T' **.+8B-W\QAK?6QF];A\[]SRQ6(C,2-#A.$WT^)O=/*GU9F+Y!3)
M@TW\"8[U5E#._?ZXJ(^+^KVG".KHA"P4T9BK4T)JNJL$"L\ULXMJ807DRVH;
M?__7)OK#,T)N\N(F3[C<5KWT@50]7SO+]W[$#O%QD=^Y14[\;+O>\R$[%Z/+
MNBV8?HZ5^[B:D*'_RYXA]4G?B=@3^B0JG0/6)=\V7:QP71,*KS2<7G5,J!WW
MQ0=(J*G\++#V9-:9-GPU>QOVB0GQN!2/2_$]/UPFBBT"7][R3IO01K#NK$/J
MK/)QQ1Y7[/M. J\R#'Z;0K^R+M?[+CH6P@B-&+!#!S2X_KA:O 63:CDGILN=
M-1"A*1C$ D960!W\,784S4RB!QPTOXY(FK GCEO@N 4^' K"-7Q<E>M=:C16
MF1/K+SFNR^.Z?,\/QZ3@RH; K("+M@F+IFXVU2+UZ1X7XW$QOG?/EOFM)_K?
MLHR8\V,'@D?'-7I<HQ^@M*$=OU?->K>9;-@\+L3C0OP "]$(C:G65J.E618C
M*?#V):N!=Y<B]DI@Q-:S(J_:0!P(M)X#5DB9E#JU:N?3#61TXQ7-1B^K-BRL
M-M=07U XEBF.B_^#X1NY9@SV?E>9H*7)#FTGJC=K8E=**;(AR]I 19"Y&@<L
MU"S:2^V:<NGC,C\N\P^;-4BZ:-'^,@G9C'471*&QVW=]V'1?TPH^KL[CZGR_
M#T?$T<WRI&].^%\9$8L*4B>\FA"!G7YD"_,#J5)D-'\_@_/FLKJXC"Z:4LHX
M@O%$"!.7 &O R>7&7ESG]):%AP8JA4E5'>Q:X+/ADQ0J;JLX .(],C]<>CSO
M8(IY$@)D/I/CXS5E+_3'_$3T*G3,WL99):MV&8@ ;Q^_V6V(>K#>;>8D4;'B
M#TD& .^AY5D>VP./K"Q"VX;B-^;K0>=.5:L3O!2Q>N)K9$YCH>^INMFZ7$!H
MQPB@BHS^"92(-G+\Q'_;$66R,@_)8\4W\L_/C$]51Y4ZXMMN:E7TBQ,<6)(D
MI'7"HG1R*>)D8XTT]L29-]'F5/A/XZ>)P)$W*;-GQN7-#*-\W22:Q]?% BOP
MZ_!322K:A2GK;N.-JFW5,Y^T3#TSAG.$P0(G;K;<E(#AI5DO57-<=L&UR)BQ
M1@KIB/1$#QMWWA)DFDSWS6QD<35 8H?H1ZGXTV:\B/- $)-9.>^:=JZ#A;22
MWL.)>)B>.%R[2U8PBN,1%T'-_.H'V;UN6&(L#Z=<.4W+S%4=T]"!=*^TJ]_
M&39;-L04W_3^4A7_QBY7J"9=O,>RHOB+]OQJ*E%&I%D$9V<*5YT/5FCIXUOR
M \DZ:_&7]1W4*CPSUD4."7AWE5T?-\Z:6JCC* JQ%[.[*X7VTM<PT2(@A+8>
MX:0:-L)03[2>S7K=7(M:INX_L>:.1&[J.$CW@X@5N,DS>?<YVX:>]EOO*TCN
MB:I56@K&]MHIW2LK/\AMTU.=.KX_?[&;%.R(191#)Z]EEXZK944^F0B#DK>:
M^*1[A%JF(R :=Y_XVE.6094?$T5'1XY*7A(UBD)J]1(2;(QOCF:ME),GK0$?
MO^;<@M>0[>V[3/0\,R7W/"MO4'%)_=[]@A8&/&9N4@VKT)*U==R%_@/+,.^S
M!Q/E*Q!FX@S(E^E0,:LM2?G)T9\J!E8'09?Q)I0\1/3 8B!Y 2_]&/*:4U9&
MN@OQ*L=!A(P<?1=.2N>$%)M,EBH>!QO1B95']E.0NST9G: ?%1A=M&D@:,.%
M1<+.?1\#D3;0LEHS";9D+8R5)#/=;A,%HK3N;N5!GLZ>[5IR#DB*4WP5>E%P
M6O-KBG-.69.X$CHEZ 8Y85,KO:ERE6-JE7Q\N) !U #CJ["MM$3V3*#H>#3'
M,0)U%E"BA_O\DX_JT9UWE_M2]6+7U5OR^ [N#UK"@TK73+01P=V=3T7!V\4@
M-(,^(6S7@<1XKD5^B"[X1Y\ZCH=EG3T$;5,LI^"7A<B+Q!O,3:1C-:.%TN]M
MEY&6.=D4+S\NCVEI.#JMF?H$1.&V4@1@SZS$0BI!8'MV;[]IRG8INIRT^,F!
M+9EOFWS@&ZT1<Q2;NJ-M'W(392[F<3.P\&[H>LN*^[T[B$ZD+XLE:0!=<M8$
MH[FCJZF8-0F=E"+?6_L>@R+:1E(1+%CRA,VEV\/^L' 7X:?3W@12A8F+6=15
MCLIT'[23]O-C)^W'UTG[@4*0>N\<C-;T@#DF*Y1-Q#70Y4$"6P,R.RS\RH8$
MGDD<Y)0:H*_4\0PX(;M5) R%NA40!1\&ZSX#P 'R[2B*<P0R'0NU=&R8[$GX
MB<Z8SK@'7U/XT<W.9C^J XLW61[Z_J,'CSZ;O6RK*W*87ZY+;L7"N<3R/M2A
M%8U[!]&6?;.3A$2]E^2&C//0H>.#Q!EB%2M#-H/?>!LD9A8'MZ,SK(104[S"
M11LHIT!_JUVZ)GUI6U9(9=%#307[ U^M5$=/G7"Y(,^*</[G_3-\C,4QB]^B
MCIRA3YT)3Z?#3DYB#\^MY9RS>G'RE.](2/;B6EKR)A.O<6XEZ0I9J!KGY5+)
MMLG5DCHW>U9: E>! >Z[%F7:81(&&C>:V8.?[ZKKBZ:EU"127\+0PG)-Y=Z%
M## +%:GOQ,=;19>('0_U0KQ*!!.,[[IL#8'7$ZF\C\:Q'IV/!XY3O<M,;C-A
MV[4X!%.;F?N_[F)DM=J3_<6 ?0?G^.'#@NS*%X6$7Q E0NYG:HYGS362;OP+
M3A^3!A+_5+!'_9-*-3]^=/K@WS4!.I'CGHS9AH4"RE^Z%60IJ_+B@F#MS/RW
M3[;5IV12"AEI8'F,A7#2I^6F<1\'<(/PTQA=O86'.5\'HW5QNP#"'.*<4AJ]
M65/\H.I\:H%8B<X]+'%KKM?"OAQ-.(-105'+YGERH_BP%1[_8+B2M\WZ**!I
MYKU9JA8+A@)"0C(C\27H(Q0 ,#WSQ">O)=M<AY7(3LMC^IO+Y3@4R5] #8N,
MGYQ%9I?PV$.-$E]M.%PW6G(LQDWR31($<^Z$F(@IZ\%KJ6*9;E+FNBLV_QF'
MS08Q3<68Z9R+MZ I@?K1FM!?W$E]OCHP,+*HX6P6:@ 7,"/JE$I"BS_A#5(\
M0W=U/PWQU50\5P]5&&M%;I7FCY*Z(;9AR2UN0SF\^#-9F76Y[4)QRTW#9D=S
M;#JUG_*4ZKI_;MD6EQ"Z==,5)EC_OJM7Y573B@#IC0U:F9J2^+L;T;,>[B;0
M>N2(VN%$W-$]]N9VZD$6C]AYOE3.E"S)I_, \WYPTN&?RHSJC%E#OO7&L1BC
MI,BX7/STIBLN+ALJM=)R8FH \ XU*6.?O@=18E?]'Q0SS(F>//^&82C#HN Y
M/?>E:)(7;;CP<F DTG-(C'A1T:%/[YHKF;+07;U/7H(Z4SH"%K+3)^!;T'!J
M]Z'(]2S%PE6V87P%?LHH9;L A;R:6QQCC'C3IKZN+PC+X#::*C"+D^(W,I?<
M0>* K<R70YGZ5K=;!*XVI3G=F=:%5*34NO#JC*^WZX36IR4GE^O\TRO?AH!4
M)X.N#AK(75O?>$8W[="H9*?VIVQ)G&DGO4K.>O@\?!?]RF[%%N+[LEN6?YN=
M2SI U+%2'6UM9WR<A+)=>ME0^6Z[6P<QZA.30\B#0%<92E02V]/@)+C585Q,
MIS8F,O1*")6*?V(1;C"F=_<T>3&1R$CU&IXAQ=U,KHIHCYQ( F.>>'44JM;H
MM<5!3&>NV90R9&L:@IE6&1!7%S]O.<B,RLQ7?R\-+Z!/D()"5M.D[.J)/H%_
MK,%),97_T07-QZ ,%J1?9T-F/D2(V5M#29EQ.O$R%U8<_MNNZ2T0UO'"2_"H
MI!9,K2$7'EQV>/N)[I:J4HLC38-P$O]Q(C4E=WW<E./WMJFCMSW?K==$QSJ;
MHUX6'>H21CNP6=[5,APN3<B1,5>B7U;UV]GKRQ"2&NB+-^>S;_2JJ,)AV/$M
MD2ZM>GL%I"1PSN0@)JDD8__[37\(X$0PN@8)9O8ZA<-[L6!$&:\QFP?(-HWM
M&HYE@BU(LA6U6>00*"6<SN-ZVO;<QJ&#-DX./^//R"DZSS*R=M:JO:O#=?2Z
MPK(J<XN;! 5O5!+4-UAQROF.G(8O$U#!AE,M0MQ.+6V!9;/8I4U**)AV]B2:
MB&NR;?$_,HZ;\FT8%5R38SH/DO@!K%G0#'F2;K"6-8MKN:>^#YMM(CT>KN/H
M*U%Y@SVR37/%[HT8\T'7U290Z08Q=<)6W=U3;F*:"8&SXA0$4EDZ[Y@V0A['
M$5F2=V*T8_P+A9OU."+F>\A3"!HW+@3:B<54WE"SFVYYI#*2I JYA*5)Q9T$
M9:/4)"5(JR5 V>*09UE6#\J)5^0E.%HP&RKY\NVOJRZ)QE/M*FRJW09&R.,^
M-57JP#TB*TYFCNM+R8P(I$ORB? #*#A2&K@1+!%HXH,I;I'5G>^UQJ7YY'?C
MF3(H13PUS-PQS*/JT--%0ZIG;KG=$N6BW2+M%78J=+_,^E!N--_N1H7F:-7N
M1 /-KX(8#_YSN]C=?$Y2UF]1.>VGCL%#%W:O8Z-P.CN;]K2R%SNJQ1X[?_Z9
M]DO"-',*A%4E_AX-:,(0Y*W!/1PGMHOBHLZ126@$^^B7[\?65'E$*GWQQ1&I
M]/$AE8Y&]<X9U>1VQ:O5H4T>7UZ8+&MU)Y*-Y73]QVI$CXOUSBU62Q%1F09
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M_T%DN5Y5W=MN]LKZ:&9DA;[Q H8OC&OMT[>Z>BR=/4?6BWN(, )H](D1Z#J
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M1JO18@V "Z\AD-\R:>NLRD5(OD%\"<4%7;)@!)7@4"E#4AM+95UQ<&9&B%?
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M:A+*H!!*J>T9EHP=/VF"4@:+/P7#1=0 T:QDI2[ZNASP28@C9334X[2[C!_
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M0-;*X,"=-":??3X[/WUV^NIT]K(DV.9G7Q2SSQ]@?#[_XG3V?4-+=E_<=E7
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M9&BBY@1/"W>1M [1 FP2<2H+;%&;2XS[ MDB/MA.Z;3KE&?4)5H ;DBYENP
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MB[#TAJ$2LWD7 (.IX*?X*'%8DU0JD$+FLTZ(O0''%"[0Q9$DXOC<:N#2L@_
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M;A *:T?GH5=G=ZT/!KR)1SPU)%\$'8$>8\Y-.+PP18%OM=Y1(Y=0L+"R^(R
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M#5^!&A!4#Y.JVQ*14U,#O1W(X]&P$<^-NIFM64N('"-P*?0HB2,"+[3;2BD
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M[/=-W-=?%9+N2IU>YRAL:.+-'.!'<("_!0\&P(5 5\&[53M-*?1F#2DWGXL
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M("Z^4=+Y$(C8#G%.4K@'#-UPGN4OKEYC&D"*(=_0MF9-0\IE=]% C\W"E$]
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MWS6S6:^9M4X32,4F=#P+Y!*^S;?1,H:?O+7?&6][[X!A096-+7]&!R,!O?W
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MQFOW"0>TNP S8!UFR&(:7M@C:8^Q0PM 8&6EYP75_YJ>==9]\>-Q61<:;QB
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MR01T,35!,F%[ GO H5=L)PK94#LI)3'#&GGX=L\Y*: ';Y&0LN:8[,\JO_^
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M])@M)S&,"C?):\L>@DFB*;24%#H81)/(L2AIN; D2OA-!9Y?^L9#<Y+F)$T
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MTHI%*Y8"L<<\Q;*.G#&M$%ZJ$ H4)2M#GIEN#G HD(:Z.8 FJVW!-M>JNTB
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MA!H(%LUXS;L"!R")Z?K3AS]GJ*=2^3GOV,4GQ-'TT=%IYET?[V[BE^5MEC)
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MU-/5:(TBK&XV*Q6S4ME=MI*^_2\WMZP#7'!+W%+MFHW&/G)+@4R!@_>6U7R
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MO(:-O,CV\/M@6CG-1(FM E7$^P5PL^3_.S%.-%3W8]O!?4[_'0&II__FAL'
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M#T"L0_RM-G&9Y\#YA6P<A/AT'-H.'B@?N<9_@F>-'[I1E#!P#\<AL_%7\7,
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M&551!MZPG0/:VBZX9[^S$)[2OH_)4,"7_N*"O(U8MA= I8?X\I]]K9<\PC?
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M/Q,/+:HY-IZDF[^G%/-W9$#;BX?<E@1Z4*+9&R)PC!S$08ZQNC-'L"EZXY3
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M,"O)55;)13%OZQ!N]Y?O1]A0K_MXQ)0Z8#UE;0%S&Y+%.:>_H4 WD%7$_DJ
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M8HSQ#'/GNEC2I*QWJGT&>G0<TLF<#YF #Y,V"-(:\>6K>$4PF$V<J#([699
M,GQ!L/:W4'VZUHSLM<W2_$KYG?M,\[U^GWF,!/)<&E]>+1M@3%NZ81@%2GD3
MU-TC^OO>CP/\//5Q;##$HZ0_G"):QALRPT9*PG(.40M_][7>.'0]S6PH3I]V
M'I!:&J,20]8M5)[@Q,1#55^3B]_^;4I)?Q\CR> 9"1K5M7$21@E"M,")/@_=
M_E!*&VYR_1VVGQR0PEF0Z0C1QM%8:D/\,P'Q(ZVE;1D!Y,1)2V!;AD!K54-
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MS"UW;5IK2)%-$VEN<YHJ_5@ 5HAFP[U8T,F=))/L]T J*U:,ZZVVJ;<:L\F
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MC"3OE.Z/X]_(Q#6IS7!(P%=DWT>P!J_L8W5J<2'*%<RJ1>]Y:5E17#DI:5L
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M2TL1!HXBJ>B5R$*)HAUXG>6$?/YCV" 3X!GF#J>C@? SS!5])K?#C3&4"M<
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M"]NISO[L=2[ 6SLC_<%U^_>OUQ=GG1Y<,AC Y9+'LO"8ML1C+Z:3W::/-'N
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M%\N0H5%\A.;S \YN1UQ]Q&@D<1H4,@H]A^^$Y7_KCGGB>O..R9Q'PO;5+D^
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MX1OMT;(O\$$,X3B8V)__#U!+ P04    "  PB&U<D?0&,W50   5T0$ #0
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M$#=E593?!U%3%T_QG4O]HD54SM(<+EZ^#^A%M7I?[T19.H,ORW0VU^_^H,'
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M]+@GSQU-?#I-L]37G(.%BD N ;M")1P$SAM55D4>TM\%\,M2OF'-)0%1%]?
M 8L2F*/YA/Z6LLA@S_'[*B W&GR[6!2Y_I%DF[Y OLO([P:4TH @G:9E5<O;
M=H,C>$KER+S$D$2HE1=YB)[)*,WCK,$S'[(<36M\44F*$XIKG"K\6K4?P*/0
MCT&^+[\/3L.8#=4<Y $].%@6%8B9B@;8OTPARJ1E<07/A,7F;_&*.(*9DFSB
M[T1Z 15%,[:IX*)ED:5Q"B0VNIHKVI=Z7A;-;!X45SFLV3Q=XDV718WB2OW9
MI/4UR:]2535,>2*[%/$[:6NO0#".=X,?BY+>'ET6:1+EL<(')44SJ4-6<1:L
MBHI$U:K)3_#Z93 J9#!1[OY*%AY\96BN=?=*S>5VCM1?<+B'E18ZL0/#H&-\
M0(RN[RB;?\Q!?E%$9>(<8KZ 3S*N,?V."_Z2Z*DHJYNL_B=FFN2/S:*J^N'>
MFY]>_%>_\.7;=] ]*:LGWY#OCKY"C[7WK!\OSLW#^M03YP6M>^?3G;*XZGZ)
M:D+PYJ?7O[ZRCML)JA3[ VY;XZ1=,8S5SM:V9_/>\WUQZ?K_?/ML;M20-T<_
MG>R\  /EOW:.?KPX.0<IG5U%U]5348'P#.3*6X"GH)[R2AZ 9@.<(,-(P+_M
MT?_@OBA^-RM1J=WQ?^HL^L\O^Q>='<L?N.079\>_I/F[ED][8!T^3 O9Y*PZ
M4_D,O&]K.<9AK^!?(?^/4<YT97^_-V&4CDETQ35)(#"*2'834:.$ 882!<M,
M1?C7K$FSFJ1=#N0CX1>@1 7BH20YC +I,LKP42Q5R;A=+D&HD?).EE5075>U
M6HQ9?(/@0G<&RLK1T1C>-E59D=-;1B_&] "PBQ<*AGE99)<XJ$51PE/JIERF
M=9,HU E@&BC 4Y+,.-9I&35)&, WI8+S7,&0(E8K4,K]ZU^9$;FP,-,:#+HH
MS4$QL<H1/1:>J_)9-,/7@HZ"OY*UB(^",43HAT$13&I3FO_1P*OPH5=%DR4P
MMP@>!#._1K-2O<>)LF^'+PU&H'*H&JB%E0@KKD/]MD6$.P&ODG5B9P7,J='S
MP<^3IDIS4$OP(9']Q#H1J->B-KARO>#-@6]QXXP KW#:E^, ^ 0\(%<S($I%
MR@),*LVR:9/AHJ*SHXEKUMO _%8E14%%J^BGM00^JDI[MIQQ^ ,0RO%=(*'[
M?F#/305+ E]-HS1KV"\31V4)CVMJ>GP67>&EN*=E$QNW#+WYY(SW*X(;R9M0
MU9Y7ICMT"B>3S@CZ'ZFGL$RP2I=ID1D_!,YFFL*RI!$,!&8+H[FRKKSU"X\D
M?PD4-RE)'Y-'GH-F5Z;L\#L6=T8PBD171J46#LS5&.\VQ**?4'9'R(K<LBPN
MT\HX4%I+C8?^JDQK6!;62&G4<9'0[NJ]WY"@:*Q )XK<^G PBP6LYX+V#/\=
MFSMI9)$),6@OO^^-TPZ>=:_=A7MBM81MG<,SR/2 TTHV"?#7NB$%FG@E7)'&
M<]*=X<$I<+<(>(L*@:+RO*A7G&+X&,.52=@:(]L+\PC^A"GD0 BC@[TQ:!/7
MVE]$SB8T!50&-Y0T?KWB\,X4SA$/Q\Z3)VBX#RV?*A=ICFIW/]DZ+D<XGGJV
M0.:P'31I.C=X?HA/]R\/6@YZR+2,!WL[,!.^#PY^6@S,'U9G!I]R.!3PW>C!
MV#(F6HDEW%JV9XWVZ7*I(C@*=![IV-=S/-8Q:"Z5RN Q"F;#<X8SGHDB/!7[
MIE@NB[)N<F++12#,'Q:.\S1PZ4H00R4Y_+IK=IFJ*V 53'8P#36#O>:54Y?H
MC 4:JU7I[0V=ID2QD"U F4U1.,B,O(WS=VVS'?/]TPM8^JH!6=#Q4]/)PH4?
M9+UX=E".(,^;P#DQ7V(< ]_9?E@<HZTKM"HC, _M<&[YQ3ICB6F X(V)FFBE
M2+3F*MN8>S1 [1FJ!;2FF&3#JT>\BW=I#N1" KJ"U4F 8%\7-1)-54?BUD5*
M 9*9%:33T*OP$,QX>,1%.UYWS;?9GB[!KN^N*RPFZ&P\&%HQ9_]0P#"C(PXD
M)/0>A$UE#T@-S$7B05'@36WJ/JO%"QS2P-W+Y1"3%46K3G\)A\+52?03^*B8
MUPOA)E]:A.$C'&GW;V"!@Z:PPOX^GJ?*"?0$9T"T<<>!\J4M[2<W8!ZL,F!:
MILL\RF?$,8_9#=<U8]!@(<X<Q\VB$=5FE$X#T(Q*.FY&=491IO<&Q'"&0FC_
M8 SF0PZ"A247*-K:T6;]=ZXO;Z)R4+- I<M$19_"H8_!  \Y&>&:KH9#U$19
MB'93RA;2C-UF(FPI(L5^28[[LOMO_W"4C$>'I 'MW\>_87A"/G!-4S*'!D6&
M%^:(M:[])X?W0V(9"[2_$KKGP=[N_C]("439* ^!@TX&"7\"(6I8HG@0*_L6
MGVSMNL T%ZJ<8>P:5Q34P40L#]#!E3%;@)7!_DR9_N6]KM<PDJ>(4+#/P1>)
M-*_J(GXW+S+0_]OC"=+%0B4H$K)KT1R$/P\]%K5[]R8)_37DZ>R_Q3IG79>N
M0P/BA64->1'] ;*^OM8C'5Q2H0JR.:JFO 2"K%8.!*B23-I(EGA*8KW T4]P
M!VLF1_J27Q%5E:H[:T;!3?CZ+=R6PCJ4*;I*M P%L8/+Y+P:C8D(S"&R1,CX
M39K2$=UP8.@5SF%R#QD=K(K5%7LJ*MC@(D1Q2):J CZBSP&M@58AC>:IK*1B
M^89OSX%Q)>+GQ >B+,WD&'FRC;P31HRBI&Q?U]9C/*J[PF.U1+G(R<(1;BMO
M01UD8 G4/3N?& =L3<8&:"QH>F+F!VJ ,-Q I704KI#4[>5]BX)?[!_LN%PJ
MZ,YYQ31Q"DYB2E68"<$BPPQ(%Z)%9<N&C "[^"OF22O\U&@-83 ' _<2.0/1
M-JM9VE:(XC^;M)*,"-8XT)IRWQ1T&+[1XI=-"::V/D.N7O8]^XG(8''>8*,B
M[@$LW4_P:HKM3C(0$NJ]*N.T(K<4KI[P6/I,.3S=IYEX#]NPOO:JG57.H&YC
M3"*$6%=42GA5'2PSX+GHEC,)126(Y7% RG]1,G&3RR#5&G#;X/0T<I>%6 H
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M2AAGM6CL**#BE (@5#^=**H []=_"'_(N&(9?B*J:QT^P4 ^12#>H>+(K2N
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MV:.(MF1K<A*EVXG'P4M8;1+VP.V!S8[#951'@VR!^"Q.=_55<AK,<F!*G B
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MI\1^7,Z%4YW.E="LLHJ5RT.B)K2B-CW<^X@2:>R'MDX-SHE)F"(C6(<ZGN_
M*XGSF/:?,HV$/$8355\I-6#KZSPW5_/EJ>I96C]*Q^WS*?QX6[_<W^V7&ZUQ
MS(T_K6?N"[&4#K>6TJU82H]OT5)ZO+64O@Q+Z889%C=,/FX93+JO4X^EQ%8/
M7'=#@VGB6$K\J#MI*J&23HQ2ZCW@]X/[75]AST)HU'FYZ^$>:\(F7;'GEENQ
ML8*[8EZ]_U+-J^O/UKQRL):T;LT&"[QK?_<!0\OP*QB>;UVC=!X/06V!OEY*
M5;KD)COKIL^<UM0)S#1'7$ZMW6KMGR;2.5EC8R4(K%?OV"3<X9&E"R2FG^%=
MP*GS1:MTT@V"M#?^T^5$.6T!/(/.V_3"Q<%R[2H7R(I6' ?O6E&ERAA9,&IE
M-7L<9:RA@Z@6ZI)L5A^&Z]&>VTB[G^BYLWN7JAX[1$4D (OFI8(0X_B0+!!-
M?2VJF_;:$L9(D)ND=KR/B-PJ-0YQ<FWPU$#IVM%2SDUE<F[X'6-=8@B&-K=V
M,67D7^XNL]?1^"(X+D=T?U7P+"MW6NSQH-\+R[-,:%@S9,]43"LOJ5\'TI&R
MW"P(2D(?I;MJET$U75\+[L '^0#&:P''N_5&D7<*>I, 7HQ-QW#/&VM$H%$8
MA#2JON=4IJPE,<O1\TP?6H^6PJP\>L9:8?S"^;D5X^\D<0GMF.LMP)AGP@X/
MMV77"G>5<@DXP<8JGBB"P.F  [9J)D'JD<)()5/I=/P5J*H?IJ8R"773:S\F
MQ6B] AMNDO]LX3DU;7>0X+JE-7Y9S>H$:G.\Z3IJ4-"7Y8$>(&1Z7O+%7YLD
M115C&V5)!;>>35-UD$6WJ2E_86I*WSGN)81M@DC^Q126_?TNHP?#+B-L-L,J
MX;E%S+)E-V^<J J=MLH)MIG-W: 0$!_ FL?(V=\^23!NY>+U"^,1);2[BL>@
MV*84=/-Q(!5=_SX6"!N99A3,N/K<:,[P)8B?U, _2;="9%C81Z8A\X+XB8.=
M%SO<L+!-2(YU#W16H$V9BWX7!S(JJ\L[T<=27192"\UZ6(7'$1D&G7]*/!/V
MHJU']!RD[Q'<XZ& >ZS(!%VOXT[=_%DYR\3W#?K%30A$5XIN0!\Q!</$+4#K
MO2A*Q7> '85Q,&)S9%H;1.HKK3WKU>7'Z&"176)6LST5R:U7=]4?L:.F7/2C
M@&./0P>$3:LRW?1<> ,%8AU%U$-%\YUB*W51!Y< S1L5)5:NXO[-5<9X**SI
M#YJ.(@I;PW#8JJ65CQ^J1\C:.K3K92/5OM,J41F)'>NNVL:O;A:_>G*+\:LG
MV_C55QF_^N3(7YM KH.F\IMKA:Z!!]11+P+SU"P6M9L$[:YVML4*G+U>%?0(
M,V5 PMP/5^$D26-I7SKVCKM7CKAZ,!:1+A;H?].AAR;'%F;44 ][Y@SWL":&
M[71!)J3V">P#]_P>ZE&PO^]7 ))?@*07,&-[/ZO_MI&> %[) KL3;_<3,\J!
MGXD"2L &*L!0TT)0ZJ*V>L4&L"#?DQ#\H#=:3Z?>U[]!!'V6Q]>/2&_2WG+E
MT3U"U1J=)DUL>_EAA*ZJI'$+-4M.E!BYIFA4 S45W(L^Z&E$'VKOI'H?LW=L
MJI.5@EDAP'&74=:0 NF]I^WJ0JCNR;6#?<D<QDXM-J<;#XCI(.ZHOP^,!PO.
MVZ-VB>C@,ED@F(L6[_)'2$,+3*Y5/^>A,F&SLN2LC$H0<-3C. 4)*EC2:"N5
M$H7&E2)^H U!'09M ?]TV2GY'C6H=(<U\1Q*U/LJ[&N%+@[;HGV#ATO"X9)S
MU61?P=P#$8#,TVUJ.=#^<?"I;21F5N?1[".F2!1'&]RA.:]=8E=*6#^<T%#O
M/NT&/S+4\;*H+"9![Z4AEWE2#RXRD."Y3N$QCQ_I*!1"ZO[*32T=6J,U<%"*
M].IXCV$6'&55P2_7$P+:20@WOR@KG8^N/_K+SV>,.[ .=.8D9F"D2EHZX0$?
M'K<24Z52@H1UUT'J@=]LIF>]+O*=8]W]= "2?C V?V+BCB9A5QI(;5)_VHZB
M,D^E-*7^6*T7*Y\ZQN:*QJI /E?(O;7)^VN>8@C@;<W'W?38Y436*X2!I[:Y
M\'E)X0)N#RLA%0U:;H'VR3-\E0,)S].EOIG'Q \0#2C6R4.L(%HN6G+XY)JY
M3J(N02-<D@&0996C7I$B"V*2@45-,UBW<ZWMJ-MWI3P:'415D27.HSG#!O%6
MO7;(-^N[C*FT5,?=\=P^D/W 3A8Z!M6*K, *TD.H*?,2K"QNQ(NQ#O3] 2M
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M!UU0 <!;*@"H'&#9A\.,=8+E&%@3+!H&J_:D8\"?POIMUV*M,A$  K(0K^8
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M6"-!1EY;]"H#T&G#? Y@TT$+U+NUX"T.UQ^:H<0*7CZ;WFU19/TUZ/=#HG
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ML1H;&/2+BR*C;'4QV-Y(2S98[A?$7GUU@P##I;86!1$U:M#^)->-.] MQ@_
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M9X,OJY6[J6=$NVX7*FDI2H>*5HV[R:F9(">>.5>1ZI[6#65[!:Y-@'GUC.4
M!@3Y'^EK*E)QK 2WH_)"1;F (7EJ)ARC;A-KZZ99L3(FZ%GQ298!.C,(]3BZ
M/_E+H*]#OT+Z3F>Z\W[BP(/6E .9Z_:,^6?L_LHS=D25Y\(H>WT]IO8,ZR+>
M4V57HA?<H1G!:HXPC=#L"SPY2!KI]L*X,W N,)6Z:FV>J:82J(=J7I3U#NXY
MQ01+C+C:\HSA88BP6$3OTT6ST+Q#QQHE#QQS\^%1?);%SV5-97Z-/6@X&AZM
M/>?MPW&!UEA38GZ[Z9%BQ.$NCFSG &2B6R&]X2VC@S&!2<C0]0 TA@2)-+=)
M.IT2D61RQ'@M V\Q]>DJFTSYA0\;C&L?QW5_S++7>D$62M7=]PZ^5F:D83I<
MHK&2W3Z=BB/T;\1,6R3E<A*/IE KT-OL.APWG>D3W@%0>^M=>.B?N^$0F;DJ
M,.V0]?*$M@9"E%*]A2B<V&?30\]<+>EH1YY[9<OJ/%;W8"6K:X/TPU;@L3'5
MF-P%MKSN XM(IW[(QD@VJ=%"'!%!6[N)G/7;V:XLTI%N-(,M9RI,_C X$#;8
M(W3O>9;<0] S4RY5\;IBV*<;85%XA]::2ZB-LRS@(C36BT6 :&<>)NL32U")
M'ZCJ<7KI<Z*G4G!Z5I.O0 )R><'(:1\VN=:-F>'61$7U?(S5!>Q[;$,&O]0C
M/'9'Z*@=+V32GA/6-  1P><4:7-G#TL75?H^&#T4#%]MX%C]</6T&(4FCLM&
MZ<(';C+:]U#37(A;8+G!/<1URIH%G&]@9$:/Y0$F#$S+Z^\]F#T&>.]H?TS6
MDV\=:0RU&Q2>[09'U(1C4F$9-@QBX_6W5*M]',[\^E+Y]#2K>*X2E(!.W FM
M7U?26AV^V^?#L!"!=FEQDA;?H/)*9YF<A4 $/>,P[I)&E.>(&%I)$=KJ14UT
M_G\NN$)R8!.PIZ^'TAOI?)4(O[J<]ZZBI1%#P"G6QXT.]VC_JQX O9YV2WCD
M@A%.E\2>="^BL^D:[5(R3&;:1*F<]9QH4IGHHQQ>#='$9WQCBOF+"67K>K^9
MZ_WA;;K>'VY=[UO7^P=HEP\_3+L<$@VY:$EN;D\^6+4JD/947)YSBR<&%>V%
M@G%K_6T/<H>A52TM<1 GS:HS+5O,M5B*TM0RUCU!<(U:5Q7Z+O>&K\Z(N6E"
MS^,-$WI.WF/0.GB#4.1S]$N\\?TV7A[(P>.]GVS:3P]QVD94@VD.6JW2*K&F
M'6WAK,6FMY%M1O/0>'_<D<0"4Y)//P9.I;$*1:\G1!^VF]QG&=A01F\WN>J^
M#=$.5&@UUC%!\#!B+Q-6>"-*Q9\I1I?FGGIM/X^[O&Z ([0)#,;,+W0:G>0L
M= L_YX*:X<3%"))1LMZZU>R@H(#9)^!+,I_( 7$"+4KV*M*L(PEF&N.(]LS!
MV$P==\>#O?L8I7-C-K:014>%O*O]",^X'Y#?&U]IL\S\#M*L['D>-T-RFMAE
M'=?, _>%G6;>X*16=8".P38-@_;F&)65^G=0PPZ!KS()CL)Z,SCZ6-#@NG5(
MO12XVA2;Z;KF^JJQ=/P]' &)*2\X>L_)**T@R),G3]S9@AVE7?6VJT.:#[W1
M>%5U =,T+7$V#&$B,T0D+*,$)YP0JA_TE&T-BJ5@0+#G-]SR=O*HTQ*V<J6,
MN'9]1T#[O.%V45G[992!_0M'PICXAI%@]SKZU;8IGL-!PYG(7;*/-.'QID.]
MP0C[1Z.!-+PIC,-@DU$2W=/6TH\<.TT4FW]F3*L=FSC2G?TP^.]_CQ;+IT?!
MP7V8.U4V22M)>T )VP/W<]*VF_2H1L**35?S#JU8!EB(O=?[\YC-_SC*8I,7
MU_;)3Y3?J"@*V.253LJF_3F*WJ4B^:M=112LPSX8%1WE#CZ_L_RT*91159C.
MC' CG\P)(AFU[N4#IW=!QDX&Z^3:>8"9 R< D@*62C>2=ONH5D'5G=>1GFRH
M([TE/R6KQG[6,P=&*!1PD\Q.S&#7P1]J&Y+BO11)L(\A?(1I: ">V<7("I#
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M6L^PY\#D7-'MKIIR^$@#<IP21-OKD[=O@]\U1!KJ&</X@N15H5+2I$<W<#T
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M 8<;6@?Q;U^#K_N$_Q4N1T?:2G)_7[KW@P>W6 1!M0J;%D&TTN"_N'J"ON*
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MQB#-V\<[*E*B0%"P7T@TU>&.3U0[+YG_F/&1KG4[^AGXU0H!6,#,D/CWBS'
M\_BFY>-DT +#;[V!A<]8"=@763S (6'E1&6*&Q@T)LP/["W+7=Z$$E&ZJFWU
MEK[_C%+&C_?^<E2K4(;"T'&^2ENRSY'L^.8???>!@%Z<&]#/E9Y#?QI78&]W
M]T^VH^>IJ=1/:?41:/L/DO#P1<JOXJ]AQTK6*J(B2A)</"M,TC%8H%D*RD<M
M#"R5MQG(3(@'3>^GV<]MW0P919%&>,N>MGK 0^^MOOW^_LZ!G1PS0V\%NOS:
ML6J)=V65WIOZ'O0$DO<#VO9LO+%Y U.25KTE$BK61!IDVP>6#*F$OH*5[F[
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MTOJ*L!MXF\^-NB+LS.)Z*-9K7$-3GX/X"-/RNG?S&0HD^0Q/S$- D(AYFUP
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MP*(>2>.H E(B=N-0G30GF46BTB+D+NQYFIB'KIB3&+V4(!S88E0H?;>3-.G
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M(;=6"T@.(8NQ:PE@0C%E,,EPH80'X#Y@KN.W%-!!PO)<@<5?91E@ H6("HK
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M@;-VZW4;V\D5F&:O$U-%P(^(S*CJ&@L5FJ=&V2M(3+M&F,B8*#.@BOJ*)<(
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M7IY94CR<,A-:%+"\OOVV.$1##7-;^\X?HAB:VQN>D<TU]&]02P,$%     @
M,(AM7&(R )J_*0  /"T   H   !L;V=O;&<N:G!GM7H+-%3M_^^N2"B32KI@
M>D.24"Z)9+\E2<I4*LEEWE(AR2O)N,VN)*68(B:*>;M(I4RY))E,<IETF]QO
M989QR7V/RQAF[SWG\3O____\USIGG?,_9ZVSS=YKEOT\SWZ^M\_W\V'+F^5"
M:.'NG4X[H5FS9D%_@1](W@;90[-GS9KY_-LQ1W'.S#%706&.HM)<):69<YZR
MJO*\>2KSE)14%JBHJ,X'AY*R&FG!?+69[S.+S$R?F04^\^<IS9O_?WW(/T#J
M\R!DUKTYLU9#L]5GS5&?):^ R! T2W'6OP[HWXY9L^<H*,X%6U)1!0,*%X+M
MSYDS&VQ644$!W(T&]R$%=<5%?VS<-G?Q_F-*JX.7F%VZ_6">[O;791H':E ]
M\^/G+BNK+-5<MGR%_AJ#M8;K+"PW66VVMK'?X;#3<9?3;M>#APZ['7$_ZG/B
MY"E?/__3(>=#+X31PB-BKL1>C;MV/3XI^4Y**O-N6OK#1X^SGF0_??8\+[^@
M\$W1V^)W'\LK*JMXGZH_U];5-S0V-;>T=G2*NKI[>G_W]8M'Q\8G))/2J>D9
MNV9!<V;]^_&_M$L=V#4;Q$!!:<:N6;/#9@:H*RC^L7'NHFW[E8X%+UYM=FG>
MDNVW'[PN4]8U/X!J'#]7H[)4SZ)#7SQCVK\L^Z\9=OG_R;+_,.Q_V-4*S9\S
M"P1OCCH$0SCV,'XM]##98NF<]Y"QAN:]7IRG83PK<G#)?@?H_]NI<\?UU.;K
MI7?FU+G&2K^)[Y4+9D?-B>ZD+#ZM[M]ZEJ7C[41J'[BR+9.*X; Q][1 NIZ<
M2)CT:U[044WM+2LE5RTZ4F5IQ)H4$.YRJ,TNNI^!:7R1L+C2-IG#+ZE+J[]2
M'$?3H*760@XQ[_&G_ TZB-Q2"FR*Y[-_F-&UKVS@'LE%UM%N=-)-<GUP%I.?
MM! )GYZ40PI?&_10[XNE*QI,AMFA"W;_LG0R,1FVK38Y2YHN)Y#>C.@HCJGE
M5 TJJLIW]'\8T.K9[H%GMDM^#0R3+B/+7Y2:^!G:[ET2]OJF5YOOW1/L#V_#
MKK]_LZZ4I"E^EC]-B@W>ETIU(87\\'L8+ZOKGQV_]I__VFG^OW/H3C_H7T&,
M-_]3<<G^?YWS?5(T%H@K<^10";[.9]+!\4+) ][3YXD]AT*?U& 36%A)YIB(
MF>#[3@XQKMMN>^ID0"A4>WH_>M'F=S@S=%#2N%\.T9V,2N3098ZG%_T;\B8N
M87REA[L/R_TMT5J4N4L.A77_I(]-(I*ZKW*(&RH^G-]I])+N^/9=NO-U/=MJ
M@PB<M2 AVW4!Y1:A6XE&(T,J[.58;S\%6R0353'$<JB"BN:L;GHQQ-D6L(1I
M0VVMN,U#R%A!(CSM3R9NL$LMR"U;JMKGU2?OJPV-7K,E)_B*RFB('+HU,%6&
MLN-#J8K2ASSW&M/<\[]\G-\F]GP?5;8M#CS!((XZ4G^X8>ICA J5-#2"'ANT
M;'KS1GJC0R_1^'@+?,%4!/>/^%"F_>60L=*N+E$M=VEGD-JKC544BRP)_[?W
M[*]_$Q^7J;"T2 \*6/$ZJ]&/@>*PN+.K>1C7_TJ[QV*B=[H"R^&@1?$%<FC9
M[QJ!?]A^[Z-.M;L&]@<3#H[S#4D_O5)Z.M )PQ&[D(F[D;$/'#0^1H5(Q1VF
M+;R.W*Q.@98T9B_*B[.@86TW!F2L=:NLY5"I@%'LG52?7_20NY*P1<KJW72,
MQ$*T:%",(F[B[P_T,KW>2W*T>=-N>,BKF$GNY.BN 06DS L6/K8Y[^A6C-]]
MF+Q'#KE+@H7O7:_)(53W:^[OOXQ"K>V*]N"O2,Z) :/V$E K,4\P@Y>T[[ *
M%H8N9:/LP_&4_)^G#_<95Z:\8(V+SXKQAP(YM-JM/^B2;>0CS!F]RF)+D8-Y
MC>?W'B 5M'JW>*K>B+S+=W12FEL<T-&_7_KM65,LY6([;\FLRJAN.:1(P?,M
MJ<U*$E.Q5:7VXAUUA;C]MLSO>J]*,W=UWAO2W.C!*.9C!>RO7!4Y5 8RIX#*
ML%@V84R2'-\;M =DHUO8L;DY(8&F>$%B>]&#RVQOUE:S=<?]RT;);P^.!E.O
M]Q)JUO@S$M9Z<H10G6 1CNQ'L) )HVZF":PBI2%KT\L8@IJ-=+3'Z<0%/Y5#
MI]]G/M"<WG'.@V$T*9Y"1IL:X].B:?89\9DFB^%=BH;+V3?ED#"?BQX(1 CE
M6-E66D#54:6KY]E+O />3?OE>0C:MW+V[PP<UA^S<T&Z4Z)T'R%EU8("_K7Q
MR,BA+9(CS -UPSYCQL,O!R?25K]C$!&.!BV_'S#=GE%:_S2X=L7@$_V7ZQVP
M<5]"[8:T$FWOL>8@,C,O?QM?K(#)K[>HA='5K:5]H-!"D;(S] 7 +0Z^1.6/
M(+:ME8AV7+:C5*OQ@F.( 1Y93>2*B);:'&;3Y5Z?[.M7^'G^PIY2)3"S 2G;
M1^@B91O.PPH#Q#)4)U9$FD_+[!2Y<#*G1R/#UYN(=$[L9YB"S?4@@N?3/ E5
M*GM,U'$AVY7B.=M#F;O%J<RY.>01\^[PZV.\B03"?MB(Y /[#BW/+O#$XA[O
MWZ7F8+SMGRN=:=2U2)DG(GP("KC, CYY2LRQ\7KROM/8^6",4ZW%O1LL0U.]
M*$Z:',H-YOV!&8$(7/8CZKS-\-?P"9(JYBSF73W/5SZM8[I(X-[WQI5SR=BJ
MLYW2'G:+9-ZG%TK_2.>W+I<Y\#]%+XB_==_M!KV96N1;3FZV[V!C^N1%F'/@
M0_=J68DS=8+9>I\U]KU=@)^(ZZ,R[0Q!;M\MW4#4$.9O:^30*4'+Y#[Q_'TB
M33?4\W23+GFLMIT_^3?=++TV4RV+<O$[+?YO.,!0N8Q=,<"5&F5C2P(ZO K2
MN?'(J;O#YZ_%I1E@!U8D'I=#'R*O&[4AQX.DUKR.()Y@<5D'-?ZH_N1'T\6[
MP5.LK,+(_C487S(,A^ES\4(&>;RV('-V9*P-"N]?\E=Z^/*>9T<%]D_;'&W5
MDLK6!27N0"92.ECH 58K=S\>!Q_G:V$':@LBHR-DY>IM7[03ZDL/AH07;? 0
MP9+:XC\HF?2OI:$*D1.6%]EE.X&%'/H:\M2C]KG ^965T0 -%4X#!P_U@Q7Y
MC @Y=)%S2(BK?HR(O<K <YY8QG8QR0&CW>H_#4:V6O&FFQZXKJO8SBIX6F#=
M)_)SH7\C/[E3RRW)^FW4(9 :&V :\0.$<A#:5L:<-H@;'UDLO5&U(JNRX+#F
M)"-HR05TAVWUN?MRZ$723Z1M=^>#W:'K(C=K'UH7:3Z\S]]LCIOP!E+6#B_V
M(/PF+W'1X&#J(RKJP)4:7N4"6-@NU>_D:P00*VJC-H;\$R"'6C:697MOK3C'
MD]"ZQNR0Z3ZO(S>+U+=K3:A_<U[I\GAJ5?1CM]6W$Q7I?P);'1&AB*5-5"!O
M@A)*-?O@!1S#E\TTETB:L/1]@T&B!\NLM5VD%0P0/: B#M,6B2V0;SJH%:%F
MLJ[OY.9WMWIW459N7YP/1Y9]V\15^-<(*WC4D0.*+>9&/!Z$7X4#M.TE>?@5
MSA_B@ .U0Q89SA7O=J3?2=U4._5ZAT_XW%ERZ WRTI=JPK:77KTCOM.+ZLA*
M6A/:&Z1K$.$(^?I%.50]\\0%)H9PIRGI.FO<D4,"J]]C$59>JOI5%\R)'__0
MI6C]/7JA] 8J(-3$P>%+Z!NDZVI:N8*W-5'VI;N(UY2S2L0.=@V_>0NA\AH-
M(U2T'U/DT#RE:R>I"YMY/=ZTR$.,P7>%!32 ]-W)LD]RJ._Q2=[[<\?-!AU(
MG7\VIJ[1V&3WS\-XH[N_5=8^O*BR]I_[^Y1ZLS'-$$*Y.D3F%;4X3UQT93"!
MS\!4DIRT7_A,IG^[5)TDP(MUP8ID[EVX.XNNE)QV <;RV /?XJLU=1-3IN:
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MJ@6UP,E?H7=[\9WP)*?U+$Z2B(APHG)>F*W5R)J/Z,,GA!H;L EK?B5;ZBY
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M+6K#>WS,IHO. 3&/U"G-P _V6;!_&H##RM\Z@C(BF\K\B:: B\72WR;\[UO
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MSCK$8?XT!QR<GQ(2'"KMK;]SE_5?"%[86UL,VS=*%%X.;!LHM"4=R49=KF_
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M8R:,;Y  @YI:<:.8_[#RSO+M L?.:VV.),E!K0;>>R _@[@I0ZUG@94Q!D@
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M+<2@5&U$3M6XCL17YP225\/O3A#C!+U4#4%<1&):471:/GW-"#*R_,A=OZN
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M2M'B%#><12%#S"%7_M\Y7 )R^'>2T$7E)>8W1\6"!+Y1\]W:B4S:H2'O[5E
MB'5/-]^6\ETFG-%/NO^E]99)PF!ME7W6W5R.23UC2GZ='P8#K6N[(B3\SQII
M!E9XJ/U%O37U$8W'%R=62Y=$"V&A3<0'>P,O%SL]7Z-7M[9XP#M9(?R"-1:R
M&KKR3AM.+?8Y+$-/M\8??7SC-CXG()?.\*8*0EL@@<_&;031&>5H2ZEU49%T
ME( =P)<N5QOB9M8Y!M;9O%1@3UNL7]&CWC 6SW@)9@^\62\@X7.VSM0Z8=<+
M^0YBA^PA>D4&CE#;YYG3NA503Y'F3#HIKE."8 66B-FR)J(G]#4.3MXMWR;G
MSFLCN5:XG!?I:[Z!Q#.Z4Y\-S$[,I'KQ+7,4/KQ]]YY*+#.K6BH7Y?WN B<3
M1CP5O;+^X7?/"&8F1'RF&!MI)(SPYB1Z(8TY=67+#.E9SL;QI[DEQ$OI[+LD
MY0W9]47'#@&KU<WSHHUP5C,D "_E>4CK^Z!#'4\M0T$NOC(V*T$02/NJZO\D
MHLKXI<PCH3?HD@1^UY# RNM^@0X\)NXN<96']8NIIG;@FG-IMSXVAB:#?>OS
MFIGV@7[/KL]X155S# 39UV*7AUBJ*3[226NC<,H%0]T[>_7^.'9-(I%TA5^/
MO5*#B9-,"XPM2VN"R<'P>CAC=/^ZA )(V\(@EQCR[G&5Q>A2>V]CD>+T72/5
M(0XJ)@W,HME].:9<%X4OPGGX0T3AETRNHWG*Z?)L1%(WS44C<TZ_GQ8>'N<C
M] ;@I;"6@8N.-=J) PD,CNO1R3607=K]ZS(";6:?^\H^GZ];]KVX-6(AS/7P
M./8\"$^*T<J57+"VWE^[H2N%6MFI-CH&O)#M9&!<KSO(S72S S^EZ OQ#BSM
MC4^1!-R]1+.+5S3#OBY\L(9N@R&EO[O>2"&D)J:[O$)B%136;/DX,'C,T$=V
M=EC<91+A:N;<?G](,+Q_-*O#$1^\M4:YE"$9N'">H+EWJ=9[N>CG(T2\WWE[
M3@_& 4,"0:U=)<-E7G$#6-FW>\L3PU4BWN(%'NC$4BOL"%T[T#S(,GU=4E0^
M:<_%-#8,E_<=0F>?5@J=H7^$,R=?E;%_[9;/A_I/3-]X(C*00/>"M9\YZM(^
MNVC.+S!LN8Q& E;;!L]AAVEV&1;P?=Z4# 8H$G@!LVTFOE7MSA]<)PS"=3K%
M'[:4SWGX\(:#F6WL5NC=;<-7F$?C'V"/>K30FOO>(E1.Y)! .1'F4FRG9!!L
M<*; ^/K>W(OV;9C#W#Q/B,%:9*TV^-VZ[1*7!5=7R',[X5NC])X/M:)A]P)>
MK\324I19))9A2&(^6X;MJYH&3;^3\65KYBB>X-H3UJ^&>R*!-_4IBRO:8@-6
M&#S!!K5M%-T?!^KT.-4SJN5?T2I*>^[:?%1=?N.T\H"T@6V-?[L0\F-J/3C,
M \,-O.9Z^*2]LY,EQ$JH@USR!;U5D_PN506<9Y<@VG?9N\5\E[Y6U*(^9<<@
MZ^U*>8=H!'7+B[4^#9VH;3NQF_;Z%%%+UU24<H@;#PS[:?6Y7GWFF[%ANC&V
MO!3'Q3CZ>-J0<<YU.P]:0.5)V[>>UN73=MI6<[FT*W:1?#PZ[>58F]P?>'QG
M9'&.E\9?;_FMX*< =1+>6^IPLJ5K9)41;P'?8LKE.[SXBC$,+<S)JQ?  3Y6
M+U=\6^)%^Z?1T?4U[<<2K0;]LY@2BZ*IL/?L[:=NL.GOZ?B>W#6$)_5%!O'.
M"D(:M<.S%?+)56()%*4%SZRI\-1T.=#XU:2,]HH,6F@R*V8W%N9"EMXX\LDS
M@W'=!K+%?16V;'4/*DN3,GY8(0$DH'6"0 (7NP]0&7ULFK'H[FD4$G!D7P==
MWI1L*(R@FA9P.B%'U%WTWV]2@8^^OR\QYV'YW31F]^:^D:%[E3#OIF,5(ZEX
M4(C6F-:-AS3L"O;G/;<_--]GXF;O,; C-K?G=A2)(D$"_'BQ::;0K$'&[%OH
M^9.,)S<YZM/W1=-DG(O@8-X%NGGN$D<5#"<VLXA&,LX/XF]8;\2]3$Z(JF%M
MBG]=XO565VU,5DT-W47OEK&2GJ0MA,2CFWM_,.I U;QB5Q&&Z-7/)$("7RK2
MRD^4^A/7(<O- [3PY8S3R&IEC*646%S#<G>+[EI$F#/'L?Y8>/ARCT)$K862
MH8(-43.<$<=M3XS!>/F#ZY0QP8V3^OT'],HRD5_ONL+$M*/+A?NM-[Q]Y3_N
M&W,8UGO D0!LM_LB?QJ1OVR'D<RGH$)U\%1A_DD+)/AN^O0!6_93M>)N@Q#5
MA%YESA4-2M8"528'-2W;M]N*W6%/^C'#TZ3I7M"H):Z%#^\"J;2SQ)KOEB6K
M:FAFFQ!I7X\[UIUHZJEN?77DP.&>.26[[NKLP!M[5.&0FL\':CN+_(:U%%N=
M,\2,IIS\VJR63LA-H2R)B^G&:&>+7&B8PV1=2L1KX8%\ZF[:B<%=<,/<EKF[
M2-,:;Q/! L%A*EL+5'KJK?,LW<AX+<+2XL!,3:W&LAD61[LA6DB1EFD_5BNT
MJ/;)=[*:;C_&& DX!%CJ^YX/S#=4Y6$X7(Q>BI[<0[PZSIZ2=#[7IC5X"PIR
M65'T"T(\AN/4(9C*G+V=6^*JN!X'?Y2-S<TZY;D9^91&;T(UUX&?6DW(#T.^
MOVM^\YRYKEB$3')'C2;M32;8=0M@R^]IO%B]B'*F(]S1CJZ;#*\_6;4M=89Z
MAO;TG;(QK>QT>.](WC?;H'DR05Y=,U8]]>*1RKT'&H8? J1DB]680N$=_?9E
M7ZXCS!>>OQ"K4B]QM!0B2&&$8M>)4,[XE1=&E5;1F_38BUXK$:\HP#W"@6X6
MUKCZP?G\/+(-N,]D+Q7R]4H_A.YY9'1>H!8H:W[!,0HGOY( 5*=!!0^_)8D$
MLD<;DB1:)3*?W\2BGTI#/1YD(5NYJ'2C9O!TJKF!@EC]0O12_HM/"1]:1[,E
MUY2GB(2$LT($QK?77*%68<F2/&X0[[=R)ASR6EG-$(@J$=J>2!J4U"LU)VR
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M#Q3";SF#,._:-8T8/I1U>*[)OJ@U]M[GXQS/88)T72FPL4NZ]\BSPJD,C8M
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MBY1R*K'LUI?BVXR@Z>$88CZWKM^T3]ZRK,?5FU'%CI3Z8OEC""<"]VABD2-
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MY0<-4'IG.R]/B[4K&V3CDX5_1KZPVS/8LRR^;^QW>1(=X1<SCJP]C_.(YV$
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M%0]>U+S!VZ$ E^Q6EB=#MHI,#,+=C!KT0!1*ZNZ&3#)*2=2*9E /.]_O^LD
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MK2QC^5QK[6LV(H] _!3)KTO-X@4]L?'%))34-G6];_L#QOW"3W#G^@.^N=8
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MOP1KX1EE<1@9+Z#O!N\V!==(DZO6+ 528K>JZ@_U [M%_.8?8.+^"I2V<E"
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M6C]=9).109Z4J_<$!"8X)((;3^H?C\-%J3;#AZ]0N^0VMA&=$>\6O]I-(C:
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MV:494-K@\J]/+33)W;@O9+F6D)P7*:4A"X[92M* %%/10(\JZ)?6%"8J[G.
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M>? T3TJ6Y"4RAU[=)?:.]#0!KT_FUU \/.JB>X7 Y5M^)5%>#6I1&TJ+A(
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MZFGK37=UC,X4:#>XCR4/R%")P7]9NE,M*6N0X!0C8*TZ:JG)5<M.%8Z$K6N
M*JUDF30F;A"B1YZY-MF>[(1&Z^^E3=3MKY>&LUY"7:[&5IM"CEH('5 3.;!&
MS!4"Z3J0(C+2W&?>7N=:7N^7Q\=57EVB5N#U5_X-GM.U"J<W*NS%QR2'%8<3
M"DK^FGR9;9"7T T^0J\-99:A,3B%?V'W3D(9<H83.S4VC'K1<J+7L3"840@A
M*%@J22/'KI^KOCU:>J.0NCC@+7=2B?BV'2')%JMLBWH979T*@/W #;O<V[=@
MIKBC'[]IV253;\;0?3T4V?XXO'[==+7>7$31!4DVA7Z R'#N(4/.@T1Y7CS5
M UR2E5D&C?%8;3D=G$H8^B0;J$!,1&U[VU,K_02!\#J3QEA[GC)4#NBF(HQY
ME=%\9#<K \/D;2IJQ!29DMY0JYM/0_&FMQXL,]C<.JP#D,F13^PW"-=;\FSS
M'OHUS(OU,-Y+9VNI54  CQ(T3HR[QE1F)YL-O%D2ZRJ6X\H/G<PX"!2M3HRV
MPX(5=B)1)CP8ZT-.(?#J)*S*2M 55/3PKY:-1Q$C* DN! *V6VKC%7(<5-+;
M"QT:7U6!\3IYA<2G969&BD,#,(6-QRQ*63(>!2AY*:I.X=*G1:&X(T#L\493
MJMA5S>RL-L.N"-&:1N<9 ^9RGF->VY'2@ )RA2CK.R[5,SQN5PA28\9Y,6+!
M)0AA8JXL ^>I4LKBW'P4>%A;,7^"P%F3<FHR$$-K #8CK-%FG]T^6AHB=(<%
M3W76YZ+\C8NS%GW.XQ $+>0EJY-*54K(\2*Z>KU'-3_U;4\JBQY3*$- (6$[
M"IOQH-$V,("K#7;)G'S6 JC6]GV'8Y?=_E=!-!^---M <<(K$7/6DAE1?>GL
MS0B0I.U,4I) KT\]*2,,&5+A@<X[0KJ\).2G>/[898 =#CR?E%!0+UH?!#^
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M.1"&FF4@J 4#[CB3U 'QU8V8QT59M727$;4^1F[@XM<6V AN"0)#,@%-#7J
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M%%5(CA6T+KY[=3*+PXY0OGXP'@-\D<Y$&/-PJ^WB/[;T=EY$N-<&U[GEJ W
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MIU*T2L\&$,!U"C5^=A%ZY26Y[R6(S*F&'FT[OZA\AJG\NQN<#HK5QL$CAG*
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M0@ %;LR6ZW;$(FM>Q+E*&UQ*20D'UU(C:P-/FB Z+\-JB@(??G>Z+:@..#J
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M\L)>NLAY45!2R BODJHT.I3?Q<9T77+\?F#)5L./KG*NL9G]S80\\VX IDD
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M(C9CH:$1("41A5LC_G#3+CX*6R-PZE:<./!DQ);+C#:Q,W.,%FJ/F/KJ,R
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MK4?<:;0:[4>I.K+7Y!I&,*LLH8!"MOQ:S MV$V]5LNQO6QG>^)8!7[E:5_\
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M?.,("IV>XO&8CNQFD5=E%*1[JRD?JU;^+JU;?*ELK]H\E3;\4T#'"+U%6?\
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M\Z**W2S/7V&(=#;&83Z;A'4*DNBM2*C4=[O7U4N(^@)\5+<,5^08]7(M&O;
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MEJ42;A'?6?E=IU(KY:,5:P&I35^23H$2+>[!O)?AMA "FPRIQ!%0H^?31(0
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M;X]_?;2Y%4Y]+](FJR1T Z5U;JE0X52Y"(@$E2VV6]^7*AO7B1[4(.*<CI=
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M%257052/;ZG:#XZYCL%AZ91#C))''5-UCN\Q]./&7'4FTVYYZ:$1FJ-NG90
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M\$8C;YJ9W9M^UVV'%QQAR_DNI=EK=="0TE0ZD@^/PU;:4D3HCEVJJ5ITAL@
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MJCR52QV3^$]$[0M D$K/&8R"Q9@)2'Q(9A2*J#-?;*E^)"?+QU CF,<H*/\
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M H7&VP"#\3KYQ9QK-HU7T%6Y G4J$WAJS7E\R&=LB8Q(3"DGPJD_$:[FJ@M
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M""D*1_*#KV>L99&N">L3-E>U^?PI_P"TWAG&<WRC*G<DO);M;,E4AEMT[@'
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MO!5=9XVP"UXM_F.+:6[%^UQW%OVN,L(:2XCPVI3T\=4I]X^R6'1_FM+J<>7
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MK?<4J6VVY% ]MPG^^!J#8(QA6T.E 'J4@84R;![4Z<8<QXK,=]LCVW'&Q0I
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MT>BK;7)BR5B/'5X[2LC6$WENO%MW'50*UP[T1=FT2 VRMY4I](IN2HJZC\-
M*;W9PK#;K,8PX/@I[&@OS1;7FK@I$9E0^H6A7R@#QKHM&PM=DJIX6AE=SM8;
M6S4,N)W/1G7QT?\ ;'B#Z5U OR-(PB]&CO/5!''X<24^].^F:,B[DJ4ZI ^=
M0)!%3Y#5:EC8[.YN5<./WL"$MCFRUW;+<;LC#3;UAF)FMHC*HVO<JM%T.J_9
MC#?PZ(E-*Z7 SC"D,R=?(-V?1.:COW!U/O\ N#JU\X^5'7T\M0S9RW!*L#*,
M+X2]WX@F_+8MWN]EM<FZ7-U/MI]A^.R0I(WKH*T\ -*:P'MVYP$QVYRE>(G=
ME0+)L=GX[;[@X\\EM3T5M=F3'(*EA9VK2 /AH)](8S@(MR')M>#M 18L#2DX
MK'MJ8BV4+C-M//.&B-I3N-3XU.B\$3]JHEA@?(F;'DV:JFUJ<=5;R93[02%[
MD(/E\-3(V[>J<;&2,)MSRV)RZS/)AN-H@26UKEM/-HZM*Z$)2?$Z"]P67D>D
M:85F[5+ZTN]AURJ7X!V_8?P_G=ZO^!V=NQ#+&B[>([: EA:U=2H>0)/CJD1N
MG>-I&BUV_P!Q.M,Q(T%'J1?Q&L9CIN+^T!3+RI"J)8IZ4\O37 <83JJ+)4R[
M30(9O91:<:G6V]QXAN%UGM_0K;37<Z@G]0W>6A[+S8RYV,DJV0PN,.T^"G3&
M0_6)L617>5&E-V9[<J.DU2A"S0"A\Q74JO.9/%5N]"?)&W]^<:F+2N$GZ>0E
M-Q8=A&HI2H_3YZNO'O QE4^Y"X(H3+E&4S >C1/JG)K32W77R '5)\ H?#5O
MAL M56FB>7IRL\MC&[M,CN!5R_S.WOD1FQN0E:A0]?(#4F7<Z/3HIS,QZ! V
M^8JBUWV_?M4C]Q?? 5%B2% AH+-3T5Y:J=ND9-"CU.W@>M51[O.&;1S+Q!EO
M'-MN$JS9/?+:J&(,1SVVW9*%5!]0GKY:8HRLJ/#G] 59>W[<<6DGX3U^2 ?9
MOVO\B< 8'B6"\E9JYE(LX=*(GO+<9:C/=?:)4:DTZ4U[S'M77>Y&  G>2M4'
M2;8E8W(9F4<'2K0G&,*F95@.92PVN1;-RE6E:E]20?!!KX::;/+&T -0:XR(
M,ZJV=NO4D6&7-E-*<^I:3*B-NFJU+'0_AH[6G>]NNBK'T;6DY\5AM<87^:\8
ML-3%VM26D^\X\17WNIZ:+4F[GX*:NP1^TC-(!QB,J4IY5PN+,=2X4=1)"5!/
M@*>.C\[<-5=HAC7]5MX];G;I:(=XF%H2Y;B5?2.'I1?4@Z4/J"5VR!KE/]PQ
MF1=[S;Y#[:(]H@MJC+HHT65?\FG_ &"A?^YN\D^)PR%&9:CO1F@PR0\U<'@5
M+13J *]->M@.5W'R))U"F-JL0>:*C($9C>%I=:1M)(\/AUT;:QPCPHLA;[@/
MS5Y>%6BSQ_;$%?N4<?HKX>X=;5VQ'MJ-6*=QO#K;L(%=WQ2JQ8JV\R%Q527U
M/J<_2*-^9U2_S3'\%BL7Y?/VR2%4$LN-VBYW5^<JW^Q(6CV4*:4?IU)'G3UU
MD-8Y 6CSVVM'1$JTQ+,4KMTUM3S*?Z3*%DE"3\-6BFQCG!#W7WL9HFB^<9VF
M#&5=[#":CW>6?;?FI_6X@>"5:@7J#2_.40H\[-C!UR$.;TW)=QEB)<IH3,9<
M47([?RAE231*NOATT-Y!IR#YHQ0&A6HXTS*M-LC2+JJ>N)1U4J-\JZ*Z=#\-
M")X9'-T.BDF(F0$*-W"Q6M^%=X45T"\[5/#W"-[QVDIW'QU7YZ<KO$(WQ<@B
ML@>:^:/E[(;[G7>38\?Q&[O8ID/%#W[[=U/.*%MG)2[1U*TFB:TUY)1@JP$.
M&YY6GV>+]YX?,=!T711W)<CR7-(;DN2)5CO4=7MI@.I4Q[P1LW)4GIK!.<A>
M^9P<, +2^+@KMJM+ N8G>KP#D&<Y9B6*8C)>C6E,I-[R]U"R ZB,KW36GC4#
M5I_+NVZ$.\0=/O0SO?BI;;HW,TQ]RM)V:]Q&"Y8UD''MN;5#DX$^W9G%)!]I
MY'Z!0#Q-1UTQW-VU%"XS.'J0.IR(9(YNW0!6E[DKG:)6.X_9S->DNW>2AB';
M&OG;]YL@]4I\!JO7.1D,(TRI/'V(I)-IR,KW<[/<K?8[9'E.L1!<D1&OI"0%
MJVD"B>M1H3[TKAG"M-RI#!'Z3DHSQGE6R7=[6PI*VE1F:,(Z4.T5H?74FM.Y
MI]2JC&.>\J.(Q]BZ"; >9#BWTT:$HBJ3XC:==R0M<<H^R<M;@!3#"8-F7#E6
M2\W-J$Y!:<_HONI3N6!1*34^NBU2%KFX*"SROW]%S [RN*^?>3\7Q;#>*KI%
M@OV^\MW=]J*NBRPT]4J*_ BGEK1.VY:5=Q+QNR%7.XJ\L\0#7;<%7+PCASDY
M&-6.'E&6KOTFU0$2)#"&P%+6E("D5'D-5&]6ALVY W0(Q#$Z"M&7.R5.KO$G
MSL,QRWJ;$9QN6MJ)'C&BZCS-/35;$'LQN8#H24><UKB'#R7/'F/M-N/-F<8C
M?<G9A7!K'[@5/29;57@AI>X#T(_'5D[)[B/&P/B!P3XKBSQ\-\;)/!6AY\[6
M./<UQOCF1;D-VF9851XK<:$U[:@INAZ;?(TT&=RDTLI>YR.TI6UX?:'13NWI
ML.+XH['<6Z+=9TKCRU,.$!*DMTJH*T(FK?42C(]*@7)F-C):=4$^2N..$N0^
M-<6S#,'$W96&J.3V6ZE\(:@R67:I^:OEZ:NO$\O-4@]A@RTJKV>W:UR43O&'
M-U3;@^/9!>.4+)R[!S^",:RVTG')4HO-M?3*3U0>I%2KUT6G,GM[=F"FKOT@
M)?D:KH%BCMTEV)BUS+F\Y^UH+4%V&3\[B5;@X'$]**T0XB_*T#(Z+/\ F[#'
ML+6M"LQ8,OR+)HME:N<9-IN-M3].][AWE6T;4'U-1UU:V<P^33&BSVK0+9"5
MDEV2ZV^:Y,D7A"V'U?UZ*V+*2KP%?(:YL6' C5%[51Q 4\6K]YCQ(\:W_NB(
M*/Z,MQP'::>/KJRQ3>XW(.B$20EKL83W'E,MB,T_(;=N,8!$=E]Q)J?/8"?+
M1.$' \5"L$9PMN=,DEEMU]9=42EMYIBH437I7X:D33/+<8496)[9F5_[U8[Q
MD)JJ(\51V:43\OG\=6/\N)'.Y$M/@%3N^/\ 2#YKI7_+KZ#W+'_%?__7^]+-
M''6L1RAUEOWGF[=.<:9\-ZA$<(3_ !.H/*.(JR$>#3^I$.):'6X@>A<W]:Y2
MVB:W<6(,]+:(\]\*:DMR*_(L*H1UU\NQ/?\ B'BOI"V<CY:*9M3(3"%VYT,P
M M24QG&E?.XL^)J-$([3WZ%5F9\A=^$X";)L.DQU\._6LNH^G?9D)H$H(ZFI
MU#=5;@CS5AAM2-?N'55FS2)(LPOULQ:>EJYSB)=NA1VE**RGKM4H]$I.JU:E
M^F_#J%?>WFPO!WZDIHNEJY$RG$\<8N=W.""*=TV-:R'#(IXC>KP"M56]S9\&
MZHA!'&V?TKBA]POMG7S?>\69?GR\5L-L<<=7<&7%NR'G&A4J01^FM-><+W(^
MB\R.(.?#"WWM#:X^H9P$Y]B& 6' \'GV_!KQ(N*U2U_5O2G_ 'EE]KY#[G4T
M_CK.N^.=LW)A.6!HZ=/!1[]2!\S@#A'SES N.>9K);\$S-AV]VNR3Q>LM5$2
MI"&R%50D%/QU%XV_)59OBT)ZH38XSVNFJ*ER<XQQG$(MDL5N:G8O8D,H>C//
MAM26D) "B3UHFF@]N)TT3WC64G/P^Y-PWI(F%H;H5P9[O<DYHM?/]WRG@[)7
M9>'72SNSVF[8Z9$5L1D47NVU (IK=_RWI\5=K!MH8E:NK?&R/K-\\KH[]J[,
M<_Y3X(-\N=X0+PBX/,7B5,0FJZ&A2GH.OIJL?F-QC*MD"$Y855[]5S&X?U75
MF_6NVB\6J'*3(>7*CH8>,I1.Q1\54/EJJ5W9:G*SCLQX+T_8Q"B_1EU%QC.(
M*H]#M"$!5*FE 3I\C3"D"4 C*'N4X[<(,^(]95"6N0G=NF*V)VTZA(&A\\0:
M-%9()6&+*E5Q3;Y.(2)MQEMVA<5A<793:%KV^1\]#)7;M"O.-G:)3A5KP_D"
MPXW OU]GR O'K/&???FMBBD%D$JJ3Y=-1?I#(0#XZ*==:\.+QU37$SG%^5,
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M1JA/RWF=]Q#&,AR7';(U?+I;GF8D2TOT2MYM1 +J:=:)'77O',]F0$]5(@X
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MI%4G\=5CO[C8+E@R1'7R"L?;]E\58QRMQ\5<CE''HV5NQ9-KG&+-0Q]/&O\
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MI8JZ61\H! \37PT1KVRUNJKL];><JJ?<=Q*QW4XI9Y67XJT+;A%VAW[%([Q
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M?;_S+G'>9>\TRG)1<,>P[9,QNW./J7#2H'^=FNVM/4:UF*U'%Q>W W'Q "1
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M\_B;*>;.WS).#<,?>9NV<+9BW2^V8'VX<=#@6:N(\]5[MW-6Y]4.H.5?G2-
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MK!VN.?-?0L7&[V _!;BKG"G%3;+XFI?;28TN,L.-J3Y?I)\M!+$YW GHE5<
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MXQ]QJ0\M*42:BH%3YC4ZJ=0F;%+#-_BI=8KU:9WU\A%Y9^G<2ZB\I?4$MIW
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M#J/EWNP$SA,B0YD6=<,AG(Q<%Z>S WVZ?R/LI2CXN]RV80C/\6K/Q=JGI]:
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M0JG0GI!)73-$^>LF<RN!<OOI-J!A0Y^YG4MG2ZS$*+!8U)4ZM%S\M//Q)M@
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M)?[L(-.EL'<YGZFX)*YCF&\_:*=FX98<X\'NL_:=LW_&F-=_B[/?&?N#KWZ
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M(,I "W)(HX+XU@IKE!=Z+)/ #;99PO 'O+][7';TN,H>A1E43_##H1B7*Z:
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MX[(KTDCP. %QKTY@ BWZ(#.";<V!5<7H;BFH@"4"JP@<GU47N@('$[NGM;W
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M+-^W#]5:?N/8#*WD*FWX+',&.'H:JOBB]:' \OXY$4 P$('$N *;@%HHB4P
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M;]K^@D3?!<K'M[ ,!%^[D2_[&U:MX"$H&]>KP/OCVI<P(ZVP"LK->PY0QB%
M!$8EB "7#Z&CE C$-:O\@F:9"(S%$4Y"E466VS8#Y-G95L9A>]2]Z!?[6W25
M'-L36PF$YF8HBZM%X"G 276,H4LI5FHFOO!^H?\!'5K*ELK$BMC&YP2/+/1*
M%>C[&'+YK;YQ IC6YU-%7>OJ96K9=^^$<XM%B:1A_> B3U@13?K98!5K%M@F
MO@(Q- GE,G883;&D %3L%5?7*]>F0G,TLLJR&'I=+?UXHTS?&3)>UQB2[,1?
MA8N(;F\60M4/%8'IL2/86E"TA]/"9+7B+FV@=RA,(/;DXO<O[/DN@.NT95!
M>0S'Q>"0Z1/[[U,0 0P;&+;A'BDKP? 'L9S&B+4E>R+@>00OZ$0X5.% >!8-
MXACV7_95P9]\ A5 (A @IQ:!]T<T+Q[H+#;]&VI0_Y(:A53D_ILD4,^"<+'A
M1MXY(L"4K%@=\XQE<W3;Y/)!AFM+AEG'C) [4D6([='X,940=]&,FZY:.L7%
M'TO\CHXURGX:I5<IN"?MM9%53^")]@!GAB'B2E-\ZCU,:?I:\!US(FVK&^<G
M-%%%44AKPH,SY<7HF?X! IX/=VT*"K8*/2-;8_"J(O@8#>0;9MD@ZWFZ"F(E
M?U9(]+SK][=Z\!2(R8?_R]@]@__GU$ &^3LYUCMQ<(('5.N21&]3\F@V5:^.
M0WCM''8QD(BB6?&[1N"(#U0]#$+9A*@15-]:C!!(&_;?SB8"!TVA?.A"(QI/
M"47OP*0?^#KV[VW![L^V,/+?LX5_;9G_%>&@_Z6F_DNB,?Q9-$7_1C2AF"Y'
MT$HCULV)\-JIP9<!7PC:=O^ _;KKC:HG%2VO9552362>+^1S7YB)+ Y3G?OF
M!:?^]K,B>DU%J4)=@T)NO,W>44>_:_9-O?%-4247'_S/[0KQA^@F?V#ZN-S_
ML6J\GJ8#/\7M@67WA;W(0O^9(TO3;UJIQN6L8G*,">11NOP7ZAXXA8H-YV3Z
MU]Y 2EFKB4IVX-5>6D9.OA[!BV'[/D8=YUR/*HBL,OI"<56DGH1AE_L%Y99:
M_1!<%*7_!B^)(>GLD4=<?V[?P%94Y-AT 5E9G7?(];@.YV-N!F54SZKU;9O1
MB6,W>E,?EO)-N^DP=;&>5S?>A6^*O-LL-AWO7%Q]W%9#Y:*1^N#I>>[@T/.H
M8+0EF@*O^Q$7F3CB>K:^MI(*QYU!!&S:/+EL;5R<!)@5;N8]S6R^2U+/P(?B
M1-L?>1;Q"87$*V$5)Z+]%41QV1.?9%C2L92?8IQK<FU9%$[E^S7:I=&VV4AD
M/HX^=N^3Z]>9I]U+;RF_,5WG<M#^QL5U3M[&FK1F'=YO.Z#GK1=D?T"=3J^^
M]O LE8546VWWAYB<3CT"7]_7%0.JJQ8&U!%>V4.#L"-94EI+1Q^&'*DQ]$NR
MH;E2&#$;;?BD1==K26UY(HA1S>P9^@45&]!#G[HKZVJDZUW=*%GJ-6CM>2*^
M1J_(\6KFZ2B[S<IPRI-GVMB"COM8;5U[LZS=W8US&TOUD>/*:$V?-65NES2Y
M\M!ZJKQS??96C)(E[=>6("KR2#6RU0OR:8<G"2?WTI'^E<=PBK6L,N2^;V*6
M8YW3Y"N3LCSBCO8#/OV*TN'#SDVQK=$LW<-<+R;M9X:%W^\JE5]_-<QUBF)U
M\JC%EY:#&\Q3,?Z+4XDFUC*<T799"X:WYV0L>H*+SD[WJ/'E%?-;!EV4I(\7
M"U2XHVL63.IEU_DPZRP=Q]6\SB7=J)X.)B\>2Z%+ K[::I,82KX8"L0_O&Q<
M,B<G:B44/*W^\>:D;]D+AD9GP*[]Y@@FL ]L-1K!T_[R4M]A6='_I[WO#&MR
M6_8/TJ0(Z*9(#9LF4D20)BV $D00!*17I1L!D19J!*0W@2TH7;I :*&#"1V5
MWB6 ]")%"#5 2&[8YYQ]SB[__[WGW@_WR_VP\CSO/._,K/*\,_-;:];D>,/O
M_"+E^<4\$H2:#:SMFATQ9G&%[4A8X87BL7<W4:OP;3R%)@'0^9 LM9YH1W[#
M=Y8UD*0Q!7'[U.37.9I57-Z4,B^ Q[:K$^AJ8LCQ4Q4Q!JE#85G%"  F+7 ?
M4RS1'F6DX X^GM^^_/5NW^]>N6?_G[ZBS"YI:)<5#G_FH@==:KSQKB5Q1=WR
M[=)/(:8>?RJAU;D.VC7>%SLEF86MG9IN"4>/PI8JUZP.29$$P-!A#=J@Q_$D
ML'0E'S-Z0$2(3QAUU52&B3^ \_8\BQ.TE(A-P7_LQH?5S$S08 ;P&F*1L(TI
M L#>]$?QKVB0YC<T./W_1X.,L$]-103 5U<B!!Z>+$&4W9I7QT6?9)V%'8#.
M1)*;Y!IPSU;;81>XHG?/I:W] Y92+UFU1 <L0F*?[G?S5^RB+U)HW"BFL*HE
M825-3^<2'[ P?Y4I;P'JFI"3VHF3UU\N_2DFN.P+';"62I8RAH/.O5N ]ZNI
MTK?QQIK3?>(*K]QM\%B1.Q',:>SA::Z.P@_[F8ST!GLX+FDE--QK9>7J0MT.
MY/27V E_"7O6)];.=@&KW;]X'Z/8N87,1HHE0UIMG\VP:+*Y5[J*6]2E\)T-
M!Y3L!R*O#"+YH*"%PBV3^>^ER&M0F+ZTDE#C*65XM2OUQ1KP&]%KL3$3:9&.
M%Q!) A0+C+[6I#_0_QB?X+^3.D^F9]'*U/%082AO=[4G]BV%OV?+NIO>1#CV
M:'XVX@ 4)5K\U?$P-2)S52MUPJ3I,NCPF?2/%:BR@PE#I?Q8#J6;<YGT2J6S
M B_&3[.N;M*GV'*FO="L>5BGN&VHOTW0U)A)6_QVNDXDW4\]UDU--,L6GU$)
M^P;J3!WZ*9?O)S+*F]F05I\ [UC2S$&1?-_\#2-K#,;@ST2G'W@R'B5\3#?<
M#:B.\/IPMI0KG26Q)*@J(2>CO\/>ZCL1;#T!E^*4_7XH,2U2N^!=E^AC)]_;
M;QL*7N(K:+^VK73X8U1VJLAR-?OI[S,+[/[PK*+R(/%1I(;W(P S?]Q-2GWM
M\@SD#1P_YB@:YU.\GKPRO U.;169B_HV)](V<P,N %5H4/_%TNJ&/\(_[YGA
MG+NNQD?CM,I]U0I/VCP&L KG=T@RUBSOJ2EE>Q^I]MA<\)1N3?6]_+ I=E[>
M'$R7<I<7KJ%?MM-3BI=ZCV@HOO&-5E,,C[=M;=WMN:74J6?\(8:^F?XHUI?<
M)[RKQ,D^@#.!]1>^N0J."UK&K#CZ)<B7/CN]JT*)>>@WU;6G;\>=]5WDTUUQ
M(E:788.FBWAL]*];Q\QB$:@U43<"P%^-&$ 8LGQU('[K]O$5 P2 0E^@P4'S
MP/'JT2?,\8:W_?:_Q0LTZR4^P?Q#,NN\7(AHI1/#<D9>!MJ.0)UOE#_!1N.#
M)X!''58XM<<!8;#C%<=3(FC;ZQWZN\;;_R.%<JO=<HO0*>U&N?25><G3MV\.
MNU\7W-, NG,^\MHR@^U4G@M0@<2?+HCA>>J/]Z>2%B R# TJ3K*B<21BS!0P
MTF/#K+]);]Q80#!1&Z;CN7;Q3ARC#F:I!>4PT#+XW^O<BP#76WB?LUTYG_^%
MB7R"7>U"CW^8.[,<W]!-A?A8_SR4+)[PVO<5Y2Y\'!N](-J-%Q@YP"\11;AE
MBB)2033K<9\,F"]H<H4DF&X_?LX1PDHI-29B:'< 5?*93;6P0P-WM*']=77)
MY43P(TWT,__:"^#O9[<"V0["[4G^VC5(RH9/UM[ =L+0@%F3#.R_RN9X\LT!
MMW>ZQ''0A/#^PV2=IR.P=%CM,Q.=(I+G_*2 9I.(OP=NJ?]]$N$KL $04N7_
M%/Z_%%:APOP?E*C;>>D_0L;WCMY8>LS9SBTRTF 3]%)"0\%W'(7C-^T^(S\
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M<O,<;)68$,$6,I?HR./Q4JKKNWZ3WR"1^0UOL X9O:]B;,@ROVX9-&-AJPO
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M,MMGJT..9CN4!GDKD4LCZX(.CZX=YK?+&+XW!;@@E+66ND7/&B=>V^ZYN4
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M*UH(#EQO"LSFZ]F1#4#?.G20RW%4/P1PI.")>ER3%T7#P2-5DY9BT.CK/F3
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M@T^ZDWGVQBLQQV</MBF-?,3,:7+;[7!PMZV*>W4(]X>D0#$P7D4LX,:%B\Y
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M@LA*.S(%Y,(O")<0&93*SXV3X^6+)AT5^V[Z5.VPM:9F.IG1O5GR%V%AM7\
M7 !':>EOBR)6+D7;2;4@:;#[X+#J-Y/&;1K1- K2$G;ZC2$@B(YX["5N1%&
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MZI4#E=*L"!6_#20T-J"7YC/\DTU=?;729)XG\HP6&7B?Y:>+"14E48PZJ$A
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M^>IFU34\"S)<Q.PU]*3*[FM2 /(Q/H;:/SJF-TAY[X50/=/H*F2.#^%%A6G
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M^V_7<9:S),?^5<\<)-LGF>;LP*VA-W/DK>%Q8(<.> R=)QJ%9'-L,E=Y'Z*
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M8_;O<3+\Y_/SSXE/9$W6;F[X0?/U,N&Y\*3WS_YEG9[[!+0'>=(88@3!4NC
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MY =H)!^\>@>Q!+]R\A"GAT,W'"0>67X7&=NU2U%&I/'9X/L]#=>(FDN-=FF
MB_L6X1R_E1W%F*1VIJ/AA[Z?,:#%E5LR?*Y![U\8[5=R+5(5://69.[58GC^
MIR84.P_:=@?'HJ3.'?%P'"T :6+*[JBT&!>T[H3 B/'5!)TA:XV I-[!*1&$
MV0"([$=/'I(>^9@;S1Z^<8J+=8,X<@)1" W>-^[RXU,+85GTJBEF2W!DG%0(
M )<S +"%KW!I- Z<27AR6*D$#;JA,Y_W]EL51$8'Y* HV?1_H S;EI\)SSP+
MFL: #PQ]NCXXL25J7O4N8V?5DAU9L*M%U3&)N?N1 (! "LW1MS2AKBZI$6!
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M-0"G ZVP&$,VK+<CR>]!U@SA#/"'<6+5_.]CZO\53:DXPP8'7QX,2__8%Q%
M@&"4LV5"\1W[;SM%>8+2'=6@!RA^;79K!2MDW^::VVX_>>7D'!=$5;@&PC.P
MX;]>Q%6'I[,0&,\*0$U:B300@1<*("-Z&1=N&[MWK9&/68M4?CZ)X'\;8IFT
M03:ZS.ANNSC#&1+A1K7,_\8BN;I7$FPR+9D9(O5-';4890Y0JOMF.M%6,\^T
M?#7*^,V=K>=#&_OF&O6BY\8JC8ACA1XM^5)D9!]W\2"=-=E0: $S?>EWF^)
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MS&1:972=IYQ(3,?LW#X)EGC*2P2_E#@B=<2;[WBC9U"G)ZBA,HBB9E8 A-M
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MWB)A7H/Q_TT 4$L! A0#%     @ ,(AM7-\?T'>4$0  .M$  !$
M     ( !     &-R=F\M,C R-3$R,S$N>'-D4$L! A0#%     @ ,(AM7,(.
M71X&"P  A9D  !4              ( !PQ$  &-R=F\M,C R-3$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( #"(;5Q#0=][8$,  (AT!0 5              "
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M! !E>%\Y,S(Q.#@N:'1M4$L! A0#%     @ ,(AM7"5AR^8')0  F]H   T
M             ( !W;4$ &5X7SDS,C$X.2YH=&U02P$"% ,4    "  PB&U<
MT%Q4V7,(  !=*P  #0              @ $/VP0 97A?.3,R,3DP+FAT;5!+
M 0(4 Q0    ( #"(;5Q_)42&< @  )<J   -              "  :WC! !E
M>%\Y,S(Q.3$N:'1M4$L! A0#%     @ ,(AM7'W)^)(O!0  JAL   T
M         ( !2.P$ &5X7SDS,C$Y,BYH=&U02P$"% ,4    "  PB&U<78)[
M82(%  #N&@  #0              @ &B\00 97A?.3,R,3DS+FAT;5!+ 0(4
M Q0    ( #"(;5P%J*2F<P,  (T*   -              "  >_V! !E>%\Y
M,S(T,C0N:'1M4$L! A0#%     @ ,(AM7&(R )J_*0  /"T   H
M     ( !C?H$ &QO9V]L9RYJ<&=02P$"% ,4    "  PB&U<G/77;G0U @"K
M7 ( "               @ %T) 4 ;6EC92YJ<&=02P$"% ,4    "  PB&U<
M?_0,Q']<  "F=@  $               @ $.6@< <#)B97AT96YT:6]N+FIP
M9U!+ 0(4 Q0    ( #"(;5R\-L9<Y <! (93 0 ,              "  ;NV
D!P!P:7!E;&EN92YJ<&=02P4&     !$ $0 0!   R;X(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>crvo20251231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crvo="http://www.diffusionpharma.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crvo-20251231.xsd" xlink:type="simple"/>
    <context id="d_2025-01-01_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherResearchAndDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:StockBasedCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:PersonnelCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherClinicalAndNonclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:OtherClinicalAndNonclinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:RecoveryAfterStrokeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:RecoveryAfterStrokeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:FrontotemporalDisordersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:FrontotemporalDisordersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:DementiaWithLewyBodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">crvo:DementiaWithLewyBodiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crvo:StockOptionVestingTermsAsImprobableToProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2025EquityPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2025EquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:InducementOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-01-01_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crvo:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:May2025AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-05-12_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:May2025AtthemarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-11</startDate>
            <endDate>2024-12-11</endDate>
        </period>
    </context>
    <context id="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-26</startDate>
            <endDate>2024-02-26</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:SeriesACommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalEIPCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalDiffusionCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:HistoricalDiffusionCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="i_2024-04-01_ClassOfWarrantOrRightAxis-PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvo:SeriesAWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-03-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-08-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="i_2023-01-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:NationalInstituteOfAgingGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-08-01</startDate>
            <endDate>2014-08-31</endDate>
        </period>
    </context>
    <context id="i_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvo:VertexOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-08-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:OpenMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crvo:OpenMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="i_2026-03-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2026-03-12</instant>
        </period>
    </context>
    <context id="i_2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-11909">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2025-01-01_2025-12-31" id="ixv-11910">2025</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="d_2025-01-01_2025-12-31" id="ixv-11911">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag contextRef="d_2025-01-01_2025-12-31" id="ixv-11912">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d_2025-01-01_2025-12-31" id="ixv-11913">0001053691</dei:EntityCentralIndexKey>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-12-31" id="c948">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="d_2025-01-01_2025-12-31" id="c947">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c946">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c945">false</ecd:Rule10b51ArrAdoptedFlag>
    <us-gaap:NumberOfReportableSegments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c867"
      unitRef="Pure">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c782"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c781"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="-3"
      id="c683"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember"
      id="c640">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember"
      id="c637">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember"
      id="c634">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember"
      decimals="INF"
      id="c633"
      unitRef="Pure">5</crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-12-31_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember"
      decimals="-3"
      id="c631"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      id="c630">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember"
      id="c628">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember"
      id="c627">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember"
      id="c620">2027-04-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember"
      id="c617">2028-04-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember"
      id="c614">2026-02-28</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <crvo:PaymentsForLicenseAgreement
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="-3"
      id="c489"
      unitRef="USD">0</crvo:PaymentsForLicenseAgreement>
    <crvo:PaymentsForLicenseAgreement
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="-3"
      id="c488"
      unitRef="USD">0</crvo:PaymentsForLicenseAgreement>
    <us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration contextRef="i_2025-12-31" id="c301">http://fasb.org/us-gaap/2025#GrantsReceivableCurrent</us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="d_2024-01-01_2024-12-31" id="c300">http://fasb.org/us-gaap/2025#Revenues</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="d_2025-01-01_2025-12-31" id="c299">http://fasb.org/us-gaap/2025#Revenues</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c298"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DeferredOfferingCosts
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c297"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c295"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c294"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <crvo:ImpairmentOfMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c293"
      unitRef="USD">0</crvo:ImpairmentOfMarketableSecurities>
    <crvo:ImpairmentOfMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c292"
      unitRef="USD">0</crvo:ImpairmentOfMarketableSecurities>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="d_2025-01-01_2025-12-31" id="c50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="d_2025-01-01_2025-12-31" id="c49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="d_2025-01-01_2025-12-31" id="c42">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="d_2025-01-01_2025-12-31" id="c41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="d_2025-01-01_2025-12-31" id="c40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="d_2025-01-01_2025-12-31" id="c38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <dei:DocumentType contextRef="d_2025-01-01_2025-12-31" id="c3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2025-01-01_2025-12-31" id="c4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2025-01-01_2025-12-31" id="c5">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2025-01-01_2025-12-31" id="c6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2025-01-01_2025-12-31" id="c7">001-37942</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="d_2025-01-01_2025-12-31" id="c8">CervoMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2025-01-01_2025-12-31" id="c9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2025-01-01_2025-12-31" id="c10">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2025-01-01_2025-12-31" id="c11">20 Park Plaza, Suite 424</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2025-01-01_2025-12-31" id="c12">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2025-01-01_2025-12-31" id="c13">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2025-01-01_2025-12-31" id="c14">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2025-01-01_2025-12-31" id="c15">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2025-01-01_2025-12-31" id="c16">744-4400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2025-01-01_2025-12-31" id="c17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2025-01-01_2025-12-31" id="c18">CRVO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2025-01-01_2025-12-31" id="c19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2025-01-01_2025-12-31" id="c20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2025-01-01_2025-12-31" id="c21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2025-01-01_2025-12-31" id="c22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2025-01-01_2025-12-31" id="c23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2025-01-01_2025-12-31" id="c24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2025-01-01_2025-12-31" id="c25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2025-01-01_2025-12-31" id="c26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2025-01-01_2025-12-31" id="c27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="d_2025-01-01_2025-12-31" id="c28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="d_2025-01-01_2025-12-31" id="c29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i_2025-06-30"
      decimals="-5"
      id="c30"
      unitRef="USD">39900000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i_2026-03-12"
      decimals="INF"
      id="c31"
      unitRef="Share">9258719</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c35">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cybersecurity Risk Management Program Overview&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;span style="-sec-ix-hidden:c38"&gt;We recognize the critical role that properly managing cybersecurity risk plays in maintaining the trust and confidence of our stockholders, the patients in our clinical trials, our employees, our business partners and our other stakeholders. Accordingly, our cybersecurity program is designed to identify, assess, manage and mitigate material risks from cybersecurity threats through a variety of measures, including risk assessments, implementation of security measures, and ongoing monitoring of systems and networks. In collaboration with our third-party IT service providers, a cross-functional team comprised of representatives from our administrative, finance and legal functions actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We also engage external experts, including IT experts, other consultants, and auditors to evaluate our cybersecurity measures and risk management processes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;We also identify our cybersecurity threat risks by comparing our processes to industry standards and best practices as well as by engaging experts to manage our information systems. To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, the activities we undertake include the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws, including industry-specific laws such as HIPAA, as applicable;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;through our policies, practices and contracts (as applicable), employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;employ technical safeguards that are designed to protect our information systems from cybersecurity threats, which are evaluated and improved through vulnerability assessments and other evaluations on a routine basis;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;leverage threat intelligence available to us and our third-party IT service provider to help us identify, protect, detect, respond and recover if there is an actual or potential cybersecurity incident; and&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 18pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 18pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&#x25cf;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;carry information security risk insurance that provides protection against the potential losses arising from a cybersecurity incident.&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Board Oversight of Cybersecurity Risk Management and Governance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



&lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Management's Role in Cybersecurity Risk Management and Governance&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;span style="-sec-ix-hidden:c49"&gt;We depend on and engage various other third parties, including suppliers, vendors, and service providers, to support key elements of our business including our IT infrastructure. We have implemented various control processes designed to address cybersecurity threat risks associated with our use of such third-party service providers. We perform diligence on third parties that have access to our systems, data or facilities that house such systems or data, and continually monitor cybersecurity threat risks identified through such diligence. Our management is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents, including through the receipt of notifications from service providers and reliance on communications with risk management, legal, IT, and/or compliance personnel. In addition, cybersecurity risks and posture are, as appropriate and applicable, a factor considered in the selection process prior to our engagement of third-party service providers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;span style="-sec-ix-hidden:c50"&gt;In response to an identified cybersecurity incident, a group comprised of appropriate management personnel, our third-party IT service providers and, depending on the scope and severity of the incident, additional third-party subject matters experts, will be assembled to develop and implement a response strategy to contain, control, and remediate the cybersecurity incident, including securing our affected systems and/or information, mitigating harmful effects of the incident, preventing further compromises, and communicating information to affected parties, regulatory agencies and law enforcement, as necessary. This group will also report any such cybersecurity incident to the Audit Committee of the Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Assessment of Cybersecurity Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The potential impact of risks from cybersecurity threats are assessed on an ongoing basis by both management and the Board, including how such risks could materially affect our business strategy, operational results, and financial condition, and from time-to-time we engage third-parties to provide independent risk assessments.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;As of the date of this Annual Report, we have not experienced a cybersecurity incident that results in a material effect on our business strategy, results of operations or financial condition, but we cannot provide assurance that we will not be materially affected in the future by such an incident or risks related thereto.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the heading &lt;i&gt;Item 1A. Risk Factors &lt;/i&gt;&#x2013;&lt;i&gt; General Risks Related to Our Business and Operations&lt;/i&gt;, which disclosures are incorporated by reference herein.&lt;/p&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="d_2025-01-01_2025-12-31" id="c39">We recognize the critical role that properly managing cybersecurity risk plays in maintaining the trust and confidence of our stockholders, the patients in our clinical trials, our employees, our business partners and our other stakeholders. Accordingly, our cybersecurity program is designed to identify, assess, manage and mitigate material risks from cybersecurity threats through a variety of measures, including risk assessments, implementation of security measures, and ongoing monitoring of systems and networks. In collaboration with our third-party IT service providers, a cross-functional team comprised of representatives from our administrative, finance and legal functions actively monitor the current threat landscape in an effort to identify material risks arising from new and evolving cybersecurity threats. We also engage external experts, including IT experts, other consultants, and auditors to evaluate our cybersecurity measures and risk management processes.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c43">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="d_2025-01-01_2025-12-31" id="c44">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c45">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c46">Our Board is responsible for general oversight of our risk environment and associated management policies and practices and has delegated to our Audit Committee the responsibility for oversight of certain major risk categories and exposures, including with respect to cybersecurity and management processes to monitor and control them. The Audit Committee meets regularly throughout the year and, on no less than a quarterly basis, receives and reviews a report from management, including our Chief Financial Officer and General Counsel, regarding our IT, cybersecurity, data security, and physical security risk, including any suspected material or immaterial cybersecurity incidents during the preceding quarter, if any, and discusses such matters with appropriate management and other personnel. In addition, on a semi-annual basis, the Audit Committee receives a report from our primary third-party IT and cybersecurity provider regarding our IT environment, overall cybersecurity risk management program and strategy and education regarding emerging trends and threats.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="d_2025-01-01_2025-12-31" id="c47">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="d_2025-01-01_2025-12-31" id="c48">Our executive management team is responsible for assessing and managing material risks from cybersecurity threats and possess relevant experience and expertise in various disciplines that are key to effectively managing such risks. The experience and expertise of our executive management team is also supplemented by our external IT service providers that collectively have extensive, broad experience and expertise in these areas. Our executive management team reports information about such risks to the Audit Committee of the Board on at least a quarterly basis.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="d_2025-01-01_2025-12-31" id="c51">As of the date of this Annual Report, we have not experienced a cybersecurity incident that results in a material effect on our business strategy, results of operations or financial condition, but we cannot provide assurance that we will not be materially affected in the future by such an incident or risks related thereto.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <dei:AuditorFirmId contextRef="d_2025-01-01_2025-12-31" id="c55">49</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2025-01-01_2025-12-31" id="c56">RSM US LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2025-01-01_2025-12-31" id="c57">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2025-12-31"
      decimals="0"
      id="c63"
      unitRef="USD">8235469</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2024-12-31"
      decimals="0"
      id="c64"
      unitRef="USD">8999496</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c65"
      unitRef="USD">12628970</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c66"
      unitRef="USD">29922523</us-gaap:MarketableSecuritiesCurrent>
    <crvo:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2025-12-31"
      decimals="0"
      id="c67"
      unitRef="USD">1267005</crvo:PrepaidExpensesDepositsAndOtherAssets>
    <crvo:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2024-12-31"
      decimals="0"
      id="c68"
      unitRef="USD">1905360</crvo:PrepaidExpensesDepositsAndOtherAssets>
    <us-gaap:DeferredOfferingCosts
      contextRef="i_2025-12-31"
      decimals="0"
      id="c69"
      unitRef="USD">320581</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c70"
      unitRef="USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c71"
      unitRef="USD">426993</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c72"
      unitRef="USD">2254231</us-gaap:GrantsReceivableCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c73"
      unitRef="USD">22879018</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c74"
      unitRef="USD">43081610</us-gaap:AssetsCurrent>
    <us-gaap:Assets
      contextRef="i_2025-12-31"
      decimals="0"
      id="c75"
      unitRef="USD">22879018</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2024-12-31"
      decimals="0"
      id="c76"
      unitRef="USD">43081610</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c78"
      unitRef="USD">1454118</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c79"
      unitRef="USD">1511440</us-gaap:AccountsPayableCurrent>
    <crvo:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i_2025-12-31"
      decimals="0"
      id="c80"
      unitRef="USD">3201999</crvo:AccruedExpensesAndOtherCurrentLiabilities>
    <crvo:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i_2024-12-31"
      decimals="0"
      id="c81"
      unitRef="USD">2367842</crvo:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c82"
      unitRef="USD">4656117</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c83"
      unitRef="USD">3879282</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="i_2025-12-31"
      decimals="0"
      id="c84"
      unitRef="USD">4656117</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2024-12-31"
      decimals="0"
      id="c85"
      unitRef="USD">3879282</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c87"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c88"
      unitRef="USDPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c89"
      unitRef="Share">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="INF"
      id="c90"
      unitRef="Share">30000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c91"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c92"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c93"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c94"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i_2025-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c95"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2024-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember"
      decimals="-3"
      id="c96"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c97"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c98"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c99"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c100"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c101"
      unitRef="Share">9252719</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c102"
      unitRef="Share">9252719</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c103"
      unitRef="Share">8702719</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c104"
      unitRef="Share">8702719</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i_2025-12-31"
      decimals="0"
      id="c105"
      unitRef="USD">9252</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2024-12-31"
      decimals="0"
      id="c106"
      unitRef="USD">8702</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2025-12-31"
      decimals="0"
      id="c107"
      unitRef="USD">115905684</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2024-12-31"
      decimals="0"
      id="c108"
      unitRef="USD">109868913</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2025-12-31"
      decimals="0"
      id="c109"
      unitRef="USD">5816</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2024-12-31"
      decimals="0"
      id="c110"
      unitRef="USD">56197</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="0"
      id="c111"
      unitRef="USD">-97697851</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2024-12-31"
      decimals="0"
      id="c112"
      unitRef="USD">-70731484</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="0"
      id="c113"
      unitRef="USD">18222901</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="0"
      id="c114"
      unitRef="USD">39202328</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2025-12-31"
      decimals="0"
      id="c115"
      unitRef="USD">22879018</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2024-12-31"
      decimals="0"
      id="c116"
      unitRef="USD">43081610</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c120"
      unitRef="USD">4006510</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c121"
      unitRef="USD">9737974</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c123"
      unitRef="USD">21817072</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c124"
      unitRef="USD">18798343</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c125"
      unitRef="USD">10484315</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c126"
      unitRef="USD">9166762</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c127"
      unitRef="USD">32301387</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c128"
      unitRef="USD">27965105</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c129"
      unitRef="USD">-28294877</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c130"
      unitRef="USD">-18227131</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c132"
      unitRef="USD">-8327</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c133"
      unitRef="USD">-991</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c134"
      unitRef="USD">1336837</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c135"
      unitRef="USD">1937427</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c136"
      unitRef="USD">1328510</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c137"
      unitRef="USD">1936436</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c138"
      unitRef="USD">-26966367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c139"
      unitRef="USD">-16290695</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c141"
      unitRef="USDPerShare">-2.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c142"
      unitRef="USDPerShare">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c143"
      unitRef="Share">9041760</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c144"
      unitRef="Share">8073155</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c146"
      unitRef="USD">-50381</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c147"
      unitRef="USD">56197</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c148"
      unitRef="USD">-27016748</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c149"
      unitRef="USD">-16234498</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c153"
      unitRef="Share">5674520</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c154"
      unitRef="USD">5674</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c155"
      unitRef="USD">61811889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c156"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c157"
      unitRef="USD">-54440789</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2023-12-31"
      decimals="0"
      id="c158"
      unitRef="USD">7376774</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c159"
      unitRef="Share">2083262</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c160"
      unitRef="USD">2083</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c161"
      unitRef="USD">46396523</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c162"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c163"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c164"
      unitRef="USD">46398606</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c166"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c168"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c169"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c170"
      unitRef="USD">255724</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c171"
      unitRef="Share">944937</crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <crvo:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c172"
      unitRef="USD">945</crvo:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <crvo:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c173"
      unitRef="USD">-945</crvo:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <crvo:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c174"
      unitRef="USD">0</crvo:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <crvo:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c175"
      unitRef="USD">0</crvo:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <crvo:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c176"
      unitRef="USD">0</crvo:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c178"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c179"
      unitRef="USD">1405722</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c180"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c181"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c182"
      unitRef="USD">1405722</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c184"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c185"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c186"
      unitRef="USD">56197</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c187"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c188"
      unitRef="USD">56197</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c190"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c191"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c192"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c193"
      unitRef="USD">-16290695</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c194"
      unitRef="USD">-16290695</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c195"
      unitRef="Share">8702719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c196"
      unitRef="USD">8702</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c197"
      unitRef="USD">109868913</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c198"
      unitRef="USD">56197</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c199"
      unitRef="USD">-70731484</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2024-12-31"
      decimals="0"
      id="c200"
      unitRef="USD">39202328</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c201"
      unitRef="Share">550000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c202"
      unitRef="USD">550</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c203"
      unitRef="USD">4588137</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c204"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c205"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c206"
      unitRef="USD">4588687</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c207"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c208"
      unitRef="USD">1448634</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c209"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c210"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c211"
      unitRef="USD">1448634</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c212"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c213"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c214"
      unitRef="USD">-50381</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c215"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c216"
      unitRef="USD">-50381</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c217"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c218"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c219"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c220"
      unitRef="USD">-26966367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c221"
      unitRef="USD">-26966367</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c222"
      unitRef="Share">9252719</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="0"
      id="c223"
      unitRef="USD">9252</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="0"
      id="c224"
      unitRef="USD">115905684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="c225"
      unitRef="USD">5816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="0"
      id="c226"
      unitRef="USD">-97697851</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2025-12-31"
      decimals="0"
      id="c227"
      unitRef="USD">18222901</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c232"
      unitRef="USD">-26966367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c233"
      unitRef="USD">-16290695</us-gaap:NetIncomeLoss>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c235"
      unitRef="USD">854077</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c236"
      unitRef="USD">1205197</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c237"
      unitRef="USD">1448634</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c238"
      unitRef="USD">1405722</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c240"
      unitRef="USD">-638355</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c241"
      unitRef="USD">641089</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c242"
      unitRef="USD">310581</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInDeferredCharges
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c243"
      unitRef="USD">-0</us-gaap:IncreaseDecreaseInDeferredCharges>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c244"
      unitRef="USD">-67322</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c245"
      unitRef="USD">848969</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c246"
      unitRef="USD">834157</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c247"
      unitRef="USD">690290</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c248"
      unitRef="USD">-1827238</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c249"
      unitRef="USD">1338827</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c250"
      unitRef="USD">-23449963</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c251"
      unitRef="USD">-16530827</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c253"
      unitRef="USD">25402751</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c254"
      unitRef="USD">48101129</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c255"
      unitRef="USD">43500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c256"
      unitRef="USD">19440000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c257"
      unitRef="USD">18097249</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c258"
      unitRef="USD">-28661129</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <crvo:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c260"
      unitRef="USD">0</crvo:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <crvo:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c261"
      unitRef="USD">46398606</crvo:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember"
      decimals="0"
      id="c262"
      unitRef="USD">4588687</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2024-01-01_2024-12-31_SubsidiarySaleOfStockAxis-OpenMarketSalesAgreementMember"
      decimals="-3"
      id="c263"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c264"
      unitRef="USD">4588687</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c265"
      unitRef="USD">46398606</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c266"
      unitRef="USD">-764027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c267"
      unitRef="USD">1206650</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="0"
      id="c268"
      unitRef="USD">8999496</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2023-12-31"
      decimals="0"
      id="c269"
      unitRef="USD">7792846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2025-12-31"
      decimals="0"
      id="c270"
      unitRef="USD">8235469</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2024-12-31"
      decimals="0"
      id="c271"
      unitRef="USD">8999496</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <crvo:OptionsGranted
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c273"
      unitRef="USD">0</crvo:OptionsGranted>
    <crvo:OptionsGranted
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c274"
      unitRef="USD">255724</crvo:OptionsGranted>
    <crvo:CashlessExerciseOfWarrants
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c275"
      unitRef="USD">0</crvo:CashlessExerciseOfWarrants>
    <crvo:CashlessExerciseOfWarrants
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c276"
      unitRef="USD">945</crvo:CashlessExerciseOfWarrants>
    <crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c277"
      unitRef="USD">10000</crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c278"
      unitRef="USD">0</crvo:DebtOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:NatureOfOperations contextRef="d_2025-01-01_2025-12-31" id="c279">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note 1. The Company and Description of Business&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company is a corporation organized under the laws of the state of Delaware and headquartered in Boston, Massachusetts. The Company is a clinical-stage biotechnology company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral, small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. The Company recently completed its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB funded primarily by a $21.3 million grant from the NIA.&lt;/p&gt;
</us-gaap:NatureOfOperations>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c282"
      unitRef="USD">21300000</us-gaap:GovernmentAssistanceAmountCumulative>
    <crvo:LiquidityDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c283">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note 2. Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Liquidity and Capital Resources&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has $20.9 million of cash, cash equivalents, and marketable securities as of December&#160;31, 2025, has generated negative cash flows from operations and had an accumulated deficit of $97.7 million as of December&#160;31, 2025. The Company expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s future viability is dependent on its ability to raise additional capital to finance its operations and pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. These conditions cause substantial doubt regarding the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company will continue to require additional financing to advance its current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. The Company intends to continue to seek funds through equity offerings, debt financings or other capital sources, including grants, potential collaborations, licenses and other similar arrangements. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. If the Company does raise additional capital through public or private equity offerings, the ownership interest of its existing stockholders will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect the Company's stockholders&#x2019; rights. If the Company raises additional capital through a debt financing, it may be subject to covenants limiting or restricting the Company's ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on the Company's financial condition and on its ability to pursue its business plans and strategies. If the Company is unable to raise sufficient capital when needed, it may need to delay, reduce or terminate planned activities to reduce costs, including development or commercialization activities for neflamapimod. The Company might also be required to seek funds through arrangements with third parties that require it to relinquish certain of its rights to neflamapimod or otherwise agree to terms unfavorable to the Company.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Accordingly, substantial doubt about the Company&#x2019;s ability to continue as a going concern is not alleviated. Based on its current operating plan, the Company does not believe its existing cash, cash equivalents and marketable securities on hand of $20.9 million as of December&#160;31, 2025 will enable the Company to fund its operating expenses and capital expenditure requirements for at least twelve months from the issuance of these consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of the uncertainty described in this Note 2.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company is subject to certain additional risks and uncertainties as well, and any one or more of these factors could materially affect the Company&#x2019;s financial condition, future operations and liquidity needs. Many of these risks and uncertainties are outside of the Company&#x2019;s control, including internal and external factors that may affect the success or failure of the Company&#x2019;s research and development efforts, the length of time and cost of developing and commercializing the Company&#x2019;s current or future product candidates, whether and when any such product candidates become approved drugs, and how significant a drug&#x2019;s market share will be, if approved, among others.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</crvo:LiquidityDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c286"
      unitRef="USD">20900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c287"
      unitRef="USD">-97700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c288"
      unitRef="USD">20900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2025-01-01_2025-12-31" id="c289">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note 3. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The consolidated financial statements have been prepared in conformity with US GAAP as defined by the FASB.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in US government securities, commercial paper, and corporate debt securities.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the years ended December&#160;31, 2025 and 2024.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper, US government debt securities, and corporate debt securities with original maturities of greater than 90 days from date of purchase. These securities are carried at fair value, with unrealized gains and losses reported on the consolidated statements of operations and comprehensive loss and accumulated other comprehensive income within stockholders&#x2019; equity until realized. Purchase discounts are accreted using the effective interest method over the term of the related security and such accretion is included in interest income on the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company evaluates its investments in marketable securities for impairment at each reporting period when the fair value is below amortized cost. If the Company intends to sell the security, or it is more likely than not the Company will be required to sell the security before recovery of amortized cost, the entire impairment is included in earnings. The Company did &lt;span style="-sec-ix-hidden:c292"&gt;&lt;span style="-sec-ix-hidden:c293"&gt;not&lt;/span&gt;&lt;/span&gt; record any impairment on marketable securities during years ended December&#160;31, 2025 and 2024. There was &lt;span style="-sec-ix-hidden:c294"&gt;&lt;span style="-sec-ix-hidden:c295"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses as of December&#160;31, 2025 or December 31, 2024.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Equity Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company capitalizes costs directly associated with equity financings as deferred offering costs on its consolidated balance sheet. These costs remain capitalized until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. With respect to financings conducted on an ongoing basis, such as at-the-market offerings, costs are recognized ratably as funds are received in proportion to the aggregate offering amount. If a financing is abandoned, any remaining deferred offering costs are expensed.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2025, there were $0.3 million of deferred offering costs related to the Sales Agreement. There were &lt;span style="-sec-ix-hidden:c297"&gt;no&lt;/span&gt; deferred offering costs as of December 31, 2024, as the Sales Agreement was entered into in May 2025.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 1&lt;/i&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement&#160; &#160; date;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 2&lt;/i&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 3&lt;/i&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for leases in accordance with ASC Topic 842, Leases, which requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and expense recognition in the statement of operations and comprehensive loss as well as the reduction of the ROU asset. The standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the standard.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU assets, lease liabilities, current and lease liabilities, non-current. Fixed rent payments are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A substantial portion of the Company's ongoing research and development activities are conducted by third-party service providers. The Company records an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. The Company monitors subject enrollment levels and related activity to the extent reasonably possible and makes judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of nonclinical studies and clinical trial expenses.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Patent Costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;






&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The fair value of stock options is determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. The Company uses the &#x201c;simplified method&#x201d; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the Company stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical data and the plain-vanilla nature of the Company&#x2019;s stock-based awards.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&#x2014;The Company has limited information on the volatility of its common stock as the shares were not actively traded on any public markets until recently. The expected volatility is derived from the historical stock volatility of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#x2019;s business over a period equivalent to the expected term of the stock-based awards.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the expected term.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Dividend Rate&lt;/i&gt;&#x2014;The expected dividend is &lt;span style="-sec-ix-hidden:c298"&gt;zero&lt;/span&gt; as the Company has not paid, nor does it anticipate paying, any dividends on its stock options in the foreseeable future.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognizes funding received from the NIA Grant as &lt;span style="-sec-ix-hidden:c299"&gt;&lt;span style="-sec-ix-hidden:c300"&gt;grant revenue&lt;/span&gt;&lt;/span&gt;, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#x2019;s consolidated balance sheets as accounts receivable. Amounts received in advance of services rendered are recorded as &lt;span style="-sec-ix-hidden:c301"&gt;deferred grant revenue&lt;/span&gt; on the Company's consolidated balance sheets. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/p&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statements of operations and comprehensive loss for the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognizes interest and penalties, if any, related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related liability lines in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;






&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that, when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,598,337&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,609,289&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;992,701&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;636,802&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,591,038&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,246,091&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): &#x201c;Improvements to Income Tax Disclosures&#x201d; ("ASU 2023-09"). ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements as well. The guidance in ASU 2023-09 is effective for annual reporting periods in fiscal years beginning after December 15, 2024 and was adopted prospectively by the Company during the year ended December 31, 2025. The adoption of ASU 2023-09 impacted the Company&#x2019;s income tax disclosures only and did not have an impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses" ("ASU 2024-03"). ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the statement of operations and comprehensive loss, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1230626933632093">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The consolidated financial statements have been prepared in conformity with US GAAP as defined by the FASB.&lt;/p&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c672057077238655">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2025-01-01_2025-12-31" id="c195056151544557">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, grant revenue, expenses, and related disclosures. On an ongoing basis, the Company&#x2019;s management evaluates its estimates, including estimates related to money market accounts, clinical trial accruals, stock-based compensation expense, grant revenue, and expenses during the reporting period. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ significantly from those estimates or assumptions.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2025-01-01_2025-12-31" id="c186189958115787">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. Management also believes that the Company is not exposed to significant credit risk as it relates to marketable securities because the Company invests in US government securities, commercial paper, and corporate debt securities.&lt;/p&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1501932333504427">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company considers all highly-liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the years ended December&#160;31, 2025 and 2024.&lt;/p&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="d_2025-01-01_2025-12-31" id="c198602627716646">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Marketable Securities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper, US government debt securities, and corporate debt securities with original maturities of greater than 90 days from date of purchase. These securities are carried at fair value, with unrealized gains and losses reported on the consolidated statements of operations and comprehensive loss and accumulated other comprehensive income within stockholders&#x2019; equity until realized. Purchase discounts are accreted using the effective interest method over the term of the related security and such accretion is included in interest income on the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company evaluates its investments in marketable securities for impairment at each reporting period when the fair value is below amortized cost. If the Company intends to sell the security, or it is more likely than not the Company will be required to sell the security before recovery of amortized cost, the entire impairment is included in earnings. The Company did &lt;span style="-sec-ix-hidden:c292"&gt;&lt;span style="-sec-ix-hidden:c293"&gt;not&lt;/span&gt;&lt;/span&gt; record any impairment on marketable securities during years ended December&#160;31, 2025 and 2024. There was &lt;span style="-sec-ix-hidden:c294"&gt;&lt;span style="-sec-ix-hidden:c295"&gt;no&lt;/span&gt;&lt;/span&gt; allowance for credit losses as of December&#160;31, 2025 or December 31, 2024.&lt;/p&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1248359349055138">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Equity Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company capitalizes costs directly associated with equity financings as deferred offering costs on its consolidated balance sheet. These costs remain capitalized until such financings are consummated, at which time such costs are recorded against the gross proceeds from the applicable financing. With respect to financings conducted on an ongoing basis, such as at-the-market offerings, costs are recognized ratably as funds are received in proportion to the aggregate offering amount. If a financing is abandoned, any remaining deferred offering costs are expensed.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2025, there were $0.3 million of deferred offering costs related to the Sales Agreement. There were &lt;span style="-sec-ix-hidden:c297"&gt;no&lt;/span&gt; deferred offering costs as of December 31, 2024, as the Sales Agreement was entered into in May 2025.&lt;/p&gt;
</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="i_2025-12-31"
      decimals="-5"
      id="c296"
      unitRef="USD">300000</us-gaap:DeferredOfferingCosts>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2025-01-01_2025-12-31" id="c1407950745977928">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 1&lt;/i&gt; &#x2013; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement&#160; &#160; date;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 2&lt;/i&gt; &#x2013; Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 36pt;"&gt;&lt;i&gt;Level 3&lt;/i&gt; &#x2013; Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/p&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1360073335887342">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for leases in accordance with ASC Topic 842, Leases, which requires a lessee to recognize an ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and expense recognition in the statement of operations and comprehensive loss as well as the reduction of the ROU asset. The standard provides a number of optional practical expedients in transition. The Company has elected to apply (i) the practical expedient, which allows us to not separate lease and non-lease components, for new leases and (ii) the short-term lease exemption for all leases with an original term of less than 12 months, for purposes of applying the recognition and measurements requirements in the standard.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the consolidated balance sheet as ROU assets, lease liabilities, current and lease liabilities, non-current. Fixed rent payments are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2025-01-01_2025-12-31" id="c1328155059331015">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs include salaries and benefits, consultants&#x2019; fees, process development costs and stock-based compensation, as well as fees paid to third parties that conduct certain research and development activities on the Company&#x2019;s behalf.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A substantial portion of the Company's ongoing research and development activities are conducted by third-party service providers. The Company records an estimate of expense for nonclinical studies and clinical trials in the period the expense is incurred. Estimates are based on the services performed pursuant to contracts with research institutions, CROs in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with nonclinical development activities, and CMOs in connection with the production of materials for clinical trials. Further, the Company records expenses related to clinical trials based on the level of subject enrollment and activity according to the related agreement. The Company monitors subject enrollment levels and related activity to the extent reasonably possible and makes judgments and estimates in determining the expense balance in each reporting period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates. To date, the Company has not experienced significant changes in its estimates of nonclinical studies and clinical trial expenses.&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c939816001636911">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Patent Costs &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2025-01-01_2025-12-31" id="c228747670814631">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Stock-based compensation for employee and non-employee awards is measured on the grant date based on the fair value of the award and recognized on a straight-line basis over the requisite service period. The fair value of stock options to purchase common stock are measured using the Black-Scholes option pricing model. The Company accounts for forfeitures as they occur.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The fair value of stock options is determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires judgment and estimation by management.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Term&lt;/i&gt;&#x2014;The expected term represents the period that stock-based awards are expected to be outstanding. The Company uses the &#x201c;simplified method&#x201d; to estimate the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the Company stock options, taking into consideration multiple vesting tranches. The Company utilizes this method due to lack of historical data and the plain-vanilla nature of the Company&#x2019;s stock-based awards.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&#x2014;The Company has limited information on the volatility of its common stock as the shares were not actively traded on any public markets until recently. The expected volatility is derived from the historical stock volatility of comparable peer public companies within its industry. These companies are considered to be comparable to the Company&#x2019;s business over a period equivalent to the expected term of the stock-based awards.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Risk-Free Interest Rate&lt;/i&gt;&#x2014;The risk-free interest rate is based on the US Treasury yield curve in effect at the date of grant for zero-coupon US Treasury notes with maturities approximately equal to the expected term.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Expected Dividend Rate&lt;/i&gt;&#x2014;The expected dividend is &lt;span style="-sec-ix-hidden:c298"&gt;zero&lt;/span&gt; as the Company has not paid, nor does it anticipate paying, any dividends on its stock options in the foreseeable future.&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1454054950249432">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Grant Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company generates revenue from government contracts that reimburse the Company for certain allowable costs for funded projects.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognizes funding received from the NIA Grant as &lt;span style="-sec-ix-hidden:c299"&gt;&lt;span style="-sec-ix-hidden:c300"&gt;grant revenue&lt;/span&gt;&lt;/span&gt;, rather than as a reduction of research and development expenses, because the Company is the principal in conducting the research and development activities and these contracts are central to its ongoing operations. Revenue is recognized as the qualifying expenses related to the contracts are incurred. Revenue recognized upon incurring qualifying expenses in advance of receipt of funding is recorded in the Company&#x2019;s consolidated balance sheets as accounts receivable. Amounts received in advance of services rendered are recorded as &lt;span style="-sec-ix-hidden:c301"&gt;deferred grant revenue&lt;/span&gt; on the Company's consolidated balance sheets. The related costs incurred by the Company are included in research and development expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/p&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c361740509823571">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax basis of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the statements of operations and comprehensive loss for the period that includes the enactment date.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#x2019;s historical operating performance and the recorded cumulative net losses in prior fiscal periods, the net deferred tax assets have been fully offset by a valuation allowance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company records uncertain tax positions using a two-step process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position. Second, for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recognizes interest and penalties, if any, related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying consolidated statements of operations and comprehensive loss. Accrued interest and penalties are included on the related liability lines in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c971734295572104">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities such as common stock warrants and stock options which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that, when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,598,337&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,609,289&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;992,701&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;636,802&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,591,038&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,246,091&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2025-01-01_2025-12-31" id="c324">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,598,337&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,609,289&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock options&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;992,701&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;636,802&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,591,038&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,246,091&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c327"
      unitRef="Share">2598337</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c328"
      unitRef="Share">2609289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember"
      decimals="INF"
      id="c329"
      unitRef="Share">992701</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertiblePreferredStockMember"
      decimals="INF"
      id="c330"
      unitRef="Share">636802</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c331"
      unitRef="Share">3591038</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="INF"
      id="c332"
      unitRef="Share">3246091</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2025-01-01_2025-12-31" id="c1170336935306844">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): &#x201c;Improvements to Income Tax Disclosures&#x201d; ("ASU 2023-09"). ASU 2023-09 is intended to improve income tax disclosure requirements by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) the disaggregation of income taxes paid by jurisdiction. The guidance makes several other changes to the income tax disclosure requirements as well. The guidance in ASU 2023-09 is effective for annual reporting periods in fiscal years beginning after December 15, 2024 and was adopted prospectively by the Company during the year ended December 31, 2025. The adoption of ASU 2023-09 impacted the Company&#x2019;s income tax disclosures only and did not have an impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In November 2024, the FASB issued ASU No. 2024-03, "Disaggregation of Income Statement Expenses" ("ASU 2024-03"). ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the statement of operations and comprehensive loss, as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2025-01-01_2025-12-31" id="c333">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 4. Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s financial instruments consist primarily of cash, cash equivalents, marketable securities, and accounts payable. The Company&#x2019;s cash, cash equivalents, and accounts payable approximate fair value due to their relatively short maturities.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table presents the Company&#x2019;s assets that are measured at fair value on a recurring basis:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash equivalents:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market accounts&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,300,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;999,330&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,139,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,238,538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,552&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td class="q2qselectedlineitem" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,300,291&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,628,300&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash equivalents (money market accounts)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,559,336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,032,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,951,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,938,520&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,559,336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,922,523&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The fair values of the Company&#x2019;s Level 2 marketable securities are estimated primarily based on benchmark yields, reported trades, market-based quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications, which represent a market approach. In general, a market approach is utilized if there is readily available and relevant market activity for an individual security. This valuation technique may change from period to period, based on the relevance and availability of market data.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following is a summary of the Company's marketable securities which provides a reconciliation of amortized cost basis to fair value including cumulative unrealized gains and losses as of December&#160;31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,134,856&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,024&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,139,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,237,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,238,538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,504&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;48&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,552&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,623,154&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,816&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,628,970&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,019,334&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,393&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,032,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,920,620&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,440&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,951,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,926,372&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,938,520&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,866,326&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;58,981&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,922,523&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;There were no transfers among Level 1, Level 2 or Level 3 categories in the years ended December&#160;31, 2025 and 2024.&lt;/p&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="DA23F0E7-2DC8-4577-86A4-2D574B981D73">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash equivalents:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Money market accounts&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,300,291&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;999,330&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,139,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,238,538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,552&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="q2qselectedlineitem" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td class="q2qselectedlineitem" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,300,291&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;13,628,300&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td class="q2qselectedlineitem" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Cash equivalents (money market accounts)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,559,336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Marketable securities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,032,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,951,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,938,520&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;7,559,336&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,922,523&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c404"
      unitRef="USD">6300291</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c405"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c406"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c407"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c408"
      unitRef="USD">999330</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2025-12-31_CashAndCashEquivalentsAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c409"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c410"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c411"
      unitRef="USD">11139880</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c412"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c413"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c414"
      unitRef="USD">1238538</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c415"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c416"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="0"
      id="c417"
      unitRef="USD">250552</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c418"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c419"
      unitRef="USD">6300291</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c420"
      unitRef="USD">13628300</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2025-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c421"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c425"
      unitRef="USD">7559336</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c426"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2024-12-31_CashAndCashEquivalentsAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c427"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c428"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c429"
      unitRef="USD">18032943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c430"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c431"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c432"
      unitRef="USD">7951060</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c433"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c434"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="0"
      id="c435"
      unitRef="USD">3938520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember_FinancialInstrumentAxis-USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="c436"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c437"
      unitRef="USD">7559336</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="0"
      id="c438"
      unitRef="USD">29922523</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2024-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="c439"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="c5F8349FF-4697-4E6E-901C-B39E13217903">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,134,856&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,024&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,139,880&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,237,794&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,238,538&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,504&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;48&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250,552&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,623,154&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,816&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;12,628,970&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Fair Value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Commercial paper&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,019,334&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;16,393&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(2,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,032,943&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US treasury bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,920,620&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;30,440&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,951,060&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US government agency bonds&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,926,372&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,148&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,938,520&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,866,326&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;58,981&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(2,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;29,922,523&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c443"
      unitRef="USD">11134856</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c444"
      unitRef="USD">5024</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="-3"
      id="c445"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c446"
      unitRef="USD">11139880</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c447"
      unitRef="USD">1237794</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c448"
      unitRef="USD">744</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="-3"
      id="c449"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c450"
      unitRef="USD">1238538</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c451"
      unitRef="USD">250504</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c452"
      unitRef="USD">48</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c453"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c454"
      unitRef="USD">250552</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2025-12-31"
      decimals="0"
      id="c455"
      unitRef="USD">12623154</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2025-12-31"
      decimals="0"
      id="c456"
      unitRef="USD">5816</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c457"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2025-12-31"
      decimals="0"
      id="c458"
      unitRef="USD">12628970</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c462"
      unitRef="USD">18019334</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c463"
      unitRef="USD">16393</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c464"
      unitRef="USD">2784</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"
      decimals="0"
      id="c465"
      unitRef="USD">18032943</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c466"
      unitRef="USD">7920620</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c467"
      unitRef="USD">30440</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="-3"
      id="c468"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasuryBondSecuritiesMember"
      decimals="0"
      id="c469"
      unitRef="USD">7951060</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c470"
      unitRef="USD">3926372</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c471"
      unitRef="USD">12148</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="-3"
      id="c472"
      unitRef="USD">-0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31_FinancialInstrumentAxis-USTreasurySecuritiesMember"
      decimals="0"
      id="c473"
      unitRef="USD">3938520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2024-12-31"
      decimals="0"
      id="c474"
      unitRef="USD">29866326</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2024-12-31"
      decimals="0"
      id="c475"
      unitRef="USD">58981</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2024-12-31"
      decimals="0"
      id="c476"
      unitRef="USD">2784</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2024-12-31"
      decimals="0"
      id="c477"
      unitRef="USD">29922523</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c478">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note 5. Significant Agreements and Contracts&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Vertex Option and License Agreement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In August 2012, the Company entered the Vertex Agreement to acquire an exclusive license to develop and commercialize a drug candidate, &#x201c;VX-745,&#x201d; from Vertex. In August 2014, the Company exercised its option to acquire the license and paid an option fee of $100,000, which was expensed as incurred as a component of research and development expense.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Vertex Agreement granted the Company the exclusive worldwide use of VX-745 in the field of diagnosis, treatment and prevention of AD and related CNS disorders in humans.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As part of the Vertex Agreement, the Company is obligated to make certain payments totaling up to approximately $117.0 million upon achievement of certain regulatory and sales milestones, and royalties on net sales of products on indications covered by the Vertex Agreement. The first expected milestone events concern filing of an NDA with the FDA for marketing approval of neflamapimod in the US, or a similar filing for a non-US major market, as specified in the Vertex Agreement, and such royalties will be on a sliding scale of percentages of net sales in the low- to mid-teens, depending on the amount of net sales in the applicable years. The Company is also obligated to make a milestone payment to Vertex upon net sales reaching a certain specified amount in any 12-month period. The Vertex Agreement states that royalties will be reduced by 50% during any portion of the royalty term when there is no valid claim of an issued patent within specified patent rights covering the licensed product. The Company also has the right to deduct, on a country by country basis, from royalties otherwise payable to Vertex under the terms of the Vertex Agreement, 50% of all royalties, upfront fees, milestones and other payments paid by the Company or any of the Company&#x2019;s affiliates or sublicensees to third parties under licenses that are necessary for the development, manufacture, sale or use of a licensed product, provided that in no event will the royalty payable to Vertex be reduced to less than 50% of the rates specified in the Vertex Agreement, subject to certain adjustments specified therein. The Company has made a total of $100,000 in payments to Vertex related to the Vertex Agreement. &lt;span style="-sec-ix-hidden:c488"&gt;&lt;span style="-sec-ix-hidden:c489"&gt;No&lt;/span&gt;&lt;/span&gt; payments were made during the years ended December&#160;31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;National Institute of Aging Grant&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In January 2023, the Company was awarded a $21.0 million grant from the NIA to support its RewinD-LB Trial, a Phase 2b study of neflamapimod in patients with DLB and, in August 2024, the Company was awarded an additional $0.3 million under the grant. The grant monies were expected to be received over a period of three years including $6.7 million in 2023, $8.4 million in 2024 and $6.2 million in 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The total revenue recognized from the NIA Grant was $4.0 million and $9.7 million for the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, aggregate total cash funding of $20.5 million has been received from the NIA Grant, resulting in approximately $0.6 million in funding remaining. The Company has recorded $0.4 million as a receivable in the consolidated balance sheet at December&#160;31, 2025, for allowable expenses incurred prior to December&#160;31, 2025, which is expected to be received subsequent to December&#160;31, 2025. As of December 31, 2024, $2.3 million was recorded as a receivable in the consolidated balance sheet, for allowable expenses incurred during the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In March 2025, the Company received access to 90% of the year 3 funding and, in June 2025, the Company received access to an additional 8% of the year 3 funding provided for in the NIA Grant, due to then-current NIA policy as a result of the US government currently being funded on the basis of a continuing resolution. Accordingly, as of December 31, 2025, we determined that the receipt of the remaining 2% of funding is not probable and we would not account for the remaining 2% of funding unless and until received. In January 2026, we were informed that we will not receive the final 2% of year 3 grant funding that remained unavailable as of December 31, 2025, or approximately $0.1&#160;million, as a result of agency-wide reductions in NIA funding.&lt;/p&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="0"
      id="c481"
      unitRef="USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ContractualObligation
      contextRef="i_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="-6"
      id="c482"
      unitRef="USD">117000000</us-gaap:ContractualObligation>
    <crvo:AgreementMilestonePeriodForNetSales
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      id="c483">P12M</crvo:AgreementMilestonePeriodForNetSales>
    <crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="1"
      id="c484"
      unitRef="Pure">0.50</crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments>
    <crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="1"
      id="c485"
      unitRef="Pure">0.50</crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments>
    <crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="1"
      id="c486"
      unitRef="Pure">0.50</crvo:AgreementMaximumDeductionPercentageOfFeesAndPayments>
    <crvo:PaymentsForLicenseAgreement
      contextRef="d_2014-08-01_2014-08-31_TypeOfArrangementAxis-VertexOptionAndLicenseAgreementMember"
      decimals="0"
      id="c487"
      unitRef="USD">100000</crvo:PaymentsForLicenseAgreement>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="i_2023-01-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-6"
      id="c492"
      unitRef="USD">21000000</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmountCumulative
      contextRef="i_2024-08-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c493"
      unitRef="USD">300000</us-gaap:GovernmentAssistanceAmountCumulative>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2023-01-01_2023-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c494"
      unitRef="USD">6700000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c495"
      unitRef="USD">8400000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c496"
      unitRef="USD">6200000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:Revenues
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-6"
      id="c497"
      unitRef="USD">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-01-01_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c498"
      unitRef="USD">9700000</us-gaap:Revenues>
    <crvo:ProceedsFromGrants
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c499"
      unitRef="USD">20500000</crvo:ProceedsFromGrants>
    <crvo:GrantFundingRemaining
      contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c500"
      unitRef="USD">600000</crvo:GrantFundingRemaining>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c501"
      unitRef="USD">400000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2024-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c502"
      unitRef="USD">2300000</us-gaap:DeferredRevenueCurrent>
    <crvo:GrantAmountReceivedPercentage
      contextRef="d_2025-01-01_2025-03-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="1"
      id="c503"
      unitRef="Pure">0.90</crvo:GrantAmountReceivedPercentage>
    <crvo:GrantAmountReceivedPercentage
      contextRef="d_2025-01-01_2025-06-30_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="2"
      id="c504"
      unitRef="Pure">0.08</crvo:GrantAmountReceivedPercentage>
    <crvo:GrantAmountRemainingPercentage
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="2"
      id="c505"
      unitRef="Pure">0.02</crvo:GrantAmountRemainingPercentage>
    <crvo:GrantAmountRemainingPercentage
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="2"
      id="c506"
      unitRef="Pure">0.02</crvo:GrantAmountRemainingPercentage>
    <crvo:GrantAmountCanceledPercentage
      contextRef="d_2025-01-01_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="2"
      id="c507"
      unitRef="Pure">0.02</crvo:GrantAmountCanceledPercentage>
    <crvo:GrantFundingCanceled
      contextRef="i_2025-12-31_TypeOfArrangementAxis-NationalInstituteOfAgingGrantMember"
      decimals="-5"
      id="c508"
      unitRef="USD">100000</crvo:GrantFundingCanceled>
    <crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c509">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 6. Prepaid Expenses&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Prepaid expenses consisted of the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;677,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,149,343&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Insurance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;405,795&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;443,141&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119,803&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;95,218&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dues and memberships&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19,975&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;205,881&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,267,005&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,905,360&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</crvo:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c524">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;677,604&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,149,343&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Insurance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;405,795&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;443,141&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional services&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;119,803&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;95,218&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dues and memberships&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43,828&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,777&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19,975&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;205,881&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,267,005&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,905,360&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <crvo:PrepaidClinicalExpenses
      contextRef="i_2025-12-31"
      decimals="0"
      id="c527"
      unitRef="USD">677604</crvo:PrepaidClinicalExpenses>
    <crvo:PrepaidClinicalExpenses
      contextRef="i_2024-12-31"
      decimals="0"
      id="c528"
      unitRef="USD">1149343</crvo:PrepaidClinicalExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="i_2025-12-31"
      decimals="0"
      id="c529"
      unitRef="USD">405795</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i_2024-12-31"
      decimals="0"
      id="c530"
      unitRef="USD">443141</us-gaap:PrepaidInsurance>
    <crvo:PrepaidProfessionalServices
      contextRef="i_2025-12-31"
      decimals="0"
      id="c531"
      unitRef="USD">119803</crvo:PrepaidProfessionalServices>
    <crvo:PrepaidProfessionalServices
      contextRef="i_2024-12-31"
      decimals="0"
      id="c532"
      unitRef="USD">95218</crvo:PrepaidProfessionalServices>
    <crvo:PrepaidDuesAndMembershipsCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c533"
      unitRef="USD">43828</crvo:PrepaidDuesAndMembershipsCurrent>
    <crvo:PrepaidDuesAndMembershipsCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c534"
      unitRef="USD">11777</crvo:PrepaidDuesAndMembershipsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c535"
      unitRef="USD">19975</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c536"
      unitRef="USD">205881</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c537"
      unitRef="USD">1267005</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c538"
      unitRef="USD">1905360</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c539">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 7. Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee compensation costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,061,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;803,193&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical development costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,484,318&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,158,783&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;532,076&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;249,527&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State franchise and excise tax&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,456&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,456&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;83,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,883&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,201,999&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,367,842&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;
</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c554">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Employee compensation costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,061,766&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;803,193&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Clinical development costs&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,484,318&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,158,783&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;532,076&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;249,527&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State franchise and excise tax&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,456&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;40,456&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;83,383&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,883&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,201,999&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,367,842&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c557"
      unitRef="USD">1061766</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c558"
      unitRef="USD">803193</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <crvo:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c559"
      unitRef="USD">1484318</crvo:AccruedClinicalStudiesExpensesCurrent>
    <crvo:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c560"
      unitRef="USD">1158783</crvo:AccruedClinicalStudiesExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c561"
      unitRef="USD">532076</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c562"
      unitRef="USD">249527</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c563"
      unitRef="USD">40456</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c564"
      unitRef="USD">40456</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c565"
      unitRef="USD">83383</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c566"
      unitRef="USD">115883</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2025-12-31"
      decimals="0"
      id="c567"
      unitRef="USD">3201999</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2024-12-31"
      decimals="0"
      id="c568"
      unitRef="USD">2367842</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c569">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 8. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has a short-term lease for office space in Boston, Massachusetts. Lease expense was approximately $57,112 and $34,692 for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Research and Development Arrangements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In the course of normal business operations, the Company enters into agreements with universities and CROs to assist in the performance of research and development activities and with CDMOs to assist with CMC-related activities. Expenditures to CROs and other CDMOs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of cash.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Defined Contribution Retirement Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company has established its 401(k) Plan, which covers all employees who qualify under the terms of the plan. Eligible employees may elect to contribute to the 401(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#x2019;s compensation. There were total contributions under the 401(k) Plan of $0.4 million and $0.2 million for the years ended December&#160;31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#x2019;s legal predecessor, under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On December 30, 2014, the Company filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a related hearing on April 14, 2015, the court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. On November 19, 2018 at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds not to dismiss the case and an arbitration hearing was scheduled, originally for November 2020 but later postponed due to the COVID-19 pandemic and related restrictions on gatherings in the State of California. In addition, following the November 2018 hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On October 22, 2021, following a determination by the bankruptcy trustee not to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on February 23, 2022 at which an initial trial date of May 24, 2023 was set, and the parties have agreed to stipulate to mediation in advance of the trial. On October 20, 2022, the parties filed a joint stipulation to continue the trial and certain deadlines related to the mediation in order to allow plaintiff&#x2019;s counsel to continue to seek treatment for an ongoing medical issue. On November 1, 2022, based on the parties' joint stipulation, the court entered an order continuing the trial date to October 25, 2023, on October 6, 2023, the court entered an order further continuing the trial date to April 24, 2024, and on March 3, 2024, based on an additional joint stipulation of the parties, the court entered an order continuing the trial date to October 23, 2024. On September 4, 2024, due to certain delays in discovery as a result of, among other things, plaintiff's counsel's health complications, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto. On October 9, 2024, based on the parties' joint stipulation, the court entered an order continuing the trial date to April 30, 2025. On January 6, 2025, the Company filed a Motion for Summary Adjudication against plaintiff&#x2019;s claims for promissory fraud, negligent misrepresentation, and common counts. On February 21, 2025, the parties filed a joint stipulation to continue the trial and certain deadlines related thereto and, on March 12, 2025, the court entered an order continuing the trial date to November 26, 2025. On October 22, 2025, pursuant to an additional joint stipulation to continue the trial and certain deadlines related thereto filed by the parties, the court entered an order continuing the trial date to May 13, 2026.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company is defending itself vigorously against the claims alleged in this matter. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material adverse effect on the Company&#x2019;s financial position, results of operations and cash flows.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;




</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c572"
      unitRef="USD">57112</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c573"
      unitRef="USD">34692</us-gaap:OperatingLeaseExpense>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="d_2025-01-01_2025-12-31"
      decimals="1"
      id="c574"
      unitRef="Pure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c575"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c576"
      unitRef="USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-5"
      id="c577"
      unitRef="USD">200000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c578">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;Note 9. Stockholders' Equity and Common Stock Warrants&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;April 2024 Private Placement&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On April 1, 2024, pursuant to and in accordance with the terms of a securities purchase agreement with certain purchasers named therein, the Company completed the 2024 Private Placement of an aggregate of 2,083,262 shares of common stock, 2,532,285 Series A Warrants and 449,023 Pre-Funded Warrants. The aggregate upfront gross proceeds from the 2024 Private Placement were approximately $50.0 million, before deducting approximately $3.6 million of offering fees and expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Pre-Funded Warrants and Series A Warrants were classified as a component of stockholders&#x2019; equity within additional paid-in capital. The Pre-Funded Warrants and Series A Warrants are equity classified because they (i) are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, (ii) are immediately exercisable, (iii) do not embody an obligation for the Company to repurchase its shares, (iv) permit the holders to receive a fixed number of shares of common stock upon exercise, (v) are indexed to the Company&#x2019;s common stock and (vi) meet the equity classification criteria.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2025, the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of exercise price per share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration date&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Historical Diffusion common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,434&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;96.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c614"&gt;February 2026&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Historical EIP common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43,618&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19.81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c617"&gt;April 2028&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,532,285&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c620"&gt;April 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,598,337&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 15%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On February 11, 2026, the remaining historical Diffusion common stock warrants expired unexercised.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;February 2024 Pre-Funded Warrant Exercise&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On February 26, 2024, following the effectiveness of an amendment eliminating certain beneficial ownership limitations set forth therein, 499,995 previously outstanding pre-funded warrants to purchase common stock issued in connection with the closing of the Merger were exercised in full by the holder thereof pursuant to the cashless exercise provision of the pre-funded warrants. Upon exercise, 36 shares were withheld in lieu of a cash payment of the exercise price and the holder was issued 495,959 shares of common stock.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;December 2024 Pre-Funded Warrant Exercise&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On December 11, 2024, 449,023 Pre-Funded Warrants to purchase common stock issued in connection with the closing of the 2024 Private Placement were exercised in full by the holder thereof pursuant to the cashless exercise provision of the Pre-Funded Warrants. Upon exercise, 45 shares were withheld in lieu of a cash payment of the exercise price and the holder was issued 448,978 shares of common stock.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;May 2025 At-The-Market Offering&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On May 12, 2025, the Company entered into the Sales Agreement with Leerink Partners LLC, as sales agent, pursuant to which the Company may offer and sell shares of common stock from time-to-time with an aggregate offering price of up to $50.0 million under an &#x201c;at-the-market" offering program. During the year ended December&#160;31, 2025, the Company sold 550,000 shares of common stock to an institutional investor in a block sale for proceeds of $4.7 million, net of $0.1 million of issuance costs.&lt;/p&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c581"
      unitRef="Share">2083262</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-04-01_ClassOfWarrantOrRightAxis-SeriesAWarrantMember"
      decimals="INF"
      id="c582"
      unitRef="Share">2532285</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2024-04-01_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c583"
      unitRef="Share">449023</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-7"
      id="c584"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2024-04-01_2024-04-01_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c585"
      unitRef="USD">3600000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c609">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 7%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Range of exercise price per share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration date&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Historical Diffusion common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;22,434&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;96.12&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c614"&gt;February 2026&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Historical EIP common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;43,618&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19.81&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c617"&gt;April 2028&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Series A common stock warrants&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,532,285&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;$&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;39.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 15%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;span style="-sec-ix-hidden:c620"&gt;April 2027&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 51%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,598,337&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right; width: 7%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 15%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember"
      decimals="INF"
      id="c612"
      unitRef="Share">22434</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalDiffusionCommonStockWarrantsMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c613"
      unitRef="USDPerShare">96.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember"
      decimals="INF"
      id="c615"
      unitRef="Share">43618</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-HistoricalEIPCommonStockWarrantsMember"
      decimals="INF"
      id="c616"
      unitRef="USDPerShare">19.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember"
      decimals="INF"
      id="c618"
      unitRef="Share">2532285</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2025-12-31_ClassOfWarrantOrRightAxis-SeriesACommonStockWarrantsMember"
      decimals="INF"
      id="c619"
      unitRef="USDPerShare">39.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c621"
      unitRef="Share">2598337</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crvo:ClassOfWarrantOrRightExercised
      contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c596"
      unitRef="Share">499995</crvo:ClassOfWarrantOrRightExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c597"
      unitRef="Share">36</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2024-02-26_2024-02-26_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c598"
      unitRef="Share">495959</crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <crvo:ClassOfWarrantOrRightExercised
      contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c599"
      unitRef="Share">449023</crvo:ClassOfWarrantOrRightExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c600"
      unitRef="Share">45</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="d_2024-12-11_2024-12-11_ClassOfWarrantOrRightAxis-PrefundedWarrantMember"
      decimals="INF"
      id="c601"
      unitRef="Share">448978</crvo:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <crvo:ShareSalesAgreementMaximumAmount
      contextRef="i_2025-05-12_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"
      decimals="-7"
      id="c602"
      unitRef="USD">50000000</crvo:ShareSalesAgreementMaximumAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"
      decimals="INF"
      id="c604"
      unitRef="Share">550000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"
      decimals="-5"
      id="c606"
      unitRef="USD">4700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="d_2025-01-01_2025-12-31_SubsidiarySaleOfStockAxis-May2025AtthemarketOfferingMember"
      decimals="-5"
      id="c608"
      unitRef="USD">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c622">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 10. Stock-Based Compensation Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;2015 Equity Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company&#x2019;s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company&#x2019;s Board. On January 1, 2025, the number of shares available for future issuance under the 2015 Equity Plan increased by 348,109. As of December&#160;31, 2025, the term of the 2015 Equity Plan had expired and no additional shares will be issued thereunder.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;2018 Employee, Director and Consultant Equity Incentive Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On March 28, 2018, EIP adopted the 2018 Plan, which was assumed by the Company pursuant to and in accordance with the terms of the Merger Agreement. Under the 2018 Plan, the Company may issue incentive stock options, non-qualified stock options, stock grants, and other stock-based awards to employees, directors, and consultants, as specified in the 2018 Plan and subject to applicable SEC and Nasdaq rules and regulations. The Board has the authority to determine to whom options or stock will be granted, the number of shares, the term, and the exercise price. Options granted under the 2018 Plan have a term of up to &lt;span style="-sec-ix-hidden:c627"&gt;ten&lt;/span&gt; years and generally vest over a &lt;span style="-sec-ix-hidden:c628"&gt;four-year&lt;/span&gt; period with 25% of the options vesting after &lt;span style="-sec-ix-hidden:c630"&gt;one-year&lt;/span&gt; of service and the remainder vesting monthly thereafter. As of December&#160;31, 2025, there were &lt;span style="-sec-ix-hidden:c631"&gt;no&lt;/span&gt; shares available for issuance.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Inducement Grants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the year ended December 31, 2024, the Company granted stock options to purchase an aggregate of 71,712 shares of common stock as material inducements to the employment of &lt;span style="-sec-ix-hidden:c633"&gt;five&lt;/span&gt; new employees, in each case, in accordance with Nasdaq Listing Rule 5635(c)(4). Each such inducement option has a term of &lt;span style="-sec-ix-hidden:c634"&gt;ten&lt;/span&gt; years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In June 2025, the Company granted a stock option to purchase an aggregate of 54,000 shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of &lt;span style="-sec-ix-hidden:c637"&gt;ten&lt;/span&gt; years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In October 2025, the Company granted a stock option to purchase an aggregate of 75,000 shares of common stock as material inducements to the employment of a new employee in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement option has a term of &lt;span style="-sec-ix-hidden:c640"&gt;ten&lt;/span&gt; years and vests over a 36-month period commencing on the last day of the month in which the grant date occurred (subject to the employee's continued employment with the Company).&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;2025 Equity Plan&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On April 14, 2025, the Board approved the 2025 Equity Plan, and the 2025 Equity Plan was subsequently approved by the Company's stockholders at its 2025 Annual Meeting of Stockholders on June 23, 2025. As of December&#160;31, 2025, there were 735,200 shares available for future issuance under the 2025 Equity Plan.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;482,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;965,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,186,900&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,448,634&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,405,722&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The following table summarizes the activity related to all stock option grants for the year ended December&#160;31, 2025:&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;contractual term (in years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;636,802&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;466,600&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.61&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(68,367&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;45.84&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(42,334&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8.22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;992,701&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;561,358&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Black-Scholes option pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="8" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;5.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;5.25&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.35&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3.89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.46&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;71.55&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;76.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;76.06&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;At December&#160;31, 2025, there was $1.9 million of unrecognized compensation expense that will be recognized over a weighted-average period of 2.0 years.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;During the year ended December 31, 2024, the Company granted 39,721 options in lieu of 2023 executive bonus compensation. &lt;span style="-sec-ix-hidden:c683"&gt;No&lt;/span&gt; similar event occurred during the year ended December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Effective May 31, 2024, the Company separated from its former Chief Financial Officer. Based on the terms of his separation agreement, unvested shares under previously granted option awards continued to vest on the schedule provided for in the applicable option award agreement through September 30, 2025. The Company accounted for the change in vesting terms as an improbable-to-probable modification of his stock options and recognized $0.3 million of expense in relation to this modification during the year ended December 31, 2024. In addition, the exercise period for any shares under previously granted option awards vested as of May 31, 2024 was extended to September 30, 2025. The Company accounted for the change in exercise terms as a probable-to-probable modification of his stock options and recognized $12,000 of expense in relation to this modification during the year ended December 31, 2024. As of October 1, 2025, all such option awards expired unexercised.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On April 14, 2025, the Board approved a separation agreement with the Company&#x2019;s former Chief Operating Officer, pursuant to which the executive's employment with the Company concluded effective July 1, 2025. Based on the terms of his separation agreement, unvested shares under previously granted option awards will continue to vest on the schedule provided for in the applicable option award agreement through September 30, 2026. The Company accounted for the change in vesting terms of his unvested stock options as an improbable-to-probable modification of his stock options and recognized $0.2 million of expense in relation to this modification during the year ended December&#160;31, 2025. In addition, the exercise period for any shares under previously granted option awards vested as of April 14, 2025 was extended to September 30, 2026. The Company accounted for the change in exercise terms as probable-to-probable modification of his stock options and recognized $0.1 million of expense in relation to this modification during the year ended December&#160;31, 2025.&lt;/p&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <crvo:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis
      contextRef="d_2025-01-01_2025-12-31_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="2"
      id="c625"
      unitRef="Pure">0.04</crvo:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
    <crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease
      contextRef="i_2025-01-01_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="INF"
      id="c626"
      unitRef="Share">348109</crvo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-The2018EmployeeDirectorAndConsultantEquityIncentivePlanMember_VestingAxis-ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="c629"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember"
      decimals="INF"
      id="c632"
      unitRef="Share">71712</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2024-01-01_2024-12-31_PlanNameAxis-InducementOptionsMember"
      id="c635">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember"
      decimals="INF"
      id="c636"
      unitRef="Share">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-06-01_2025-06-30_PlanNameAxis-InducementOptionsMember"
      id="c638">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember"
      decimals="INF"
      id="c639"
      unitRef="Share">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2025-10-01_2025-10-31_PlanNameAxis-InducementOptionsMember"
      id="c641">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2025-12-31_PlanNameAxis-The2025EquityPlanMember"
      decimals="INF"
      id="c642"
      unitRef="Share">735200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c691">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;482,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;965,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,186,900&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,448,634&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,405,722&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="c694"
      unitRef="USD">482669</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="c695"
      unitRef="USD">218822</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c696"
      unitRef="USD">965965</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="c697"
      unitRef="USD">1186900</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c698"
      unitRef="USD">1448634</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31"
      decimals="0"
      id="c699"
      unitRef="USD">1405722</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c700">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;per share&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;contractual term (in years)&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Aggregate intrinsic value&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 52%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Balance at January 1, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;636,802&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;19.38&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.6&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Granted&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;466,600&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.61&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expired&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(68,367&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;45.84&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Forfeited&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(42,334&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8.22&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Outstanding at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;992,701&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;8.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Exercisable at December 31, 2025&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;561,358&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;15.92&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c703"
      unitRef="Share">636802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2024-12-31"
      decimals="INF"
      id="c704"
      unitRef="USDPerShare">19.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2024-01-01_2024-12-31" id="c705">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c706"
      unitRef="Share">466600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c707"
      unitRef="USDPerShare">4.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c708"
      unitRef="Share">68367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c709"
      unitRef="USDPerShare">45.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c710"
      unitRef="Share">42334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2025-01-01_2025-12-31"
      decimals="INF"
      id="c711"
      unitRef="USDPerShare">8.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c712"
      unitRef="Share">992701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c713"
      unitRef="USDPerShare">11.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2025-01-01_2025-12-31" id="c714">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c715"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c716"
      unitRef="Share">561358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2025-12-31"
      decimals="INF"
      id="c717"
      unitRef="USDPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2025-01-01_2025-12-31" id="c718">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c719"
      unitRef="USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c720">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="8" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 24%; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected term (in years)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;5.24&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;5.25&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5.76&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Risk-free interest rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.35&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;3.89&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.46&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Expected volatility&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;71.55&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;76.68&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;76.06&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;-&lt;/td&gt;
			&lt;td style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;80.03&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Dividend yield&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c723">P5Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c724">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c725">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c726">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c727"
      unitRef="Pure">0.0368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c728"
      unitRef="Pure">0.0435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c729"
      unitRef="Pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c730"
      unitRef="Pure">0.0446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c731"
      unitRef="Pure">0.7155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c732"
      unitRef="Pure">0.7668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="4"
      id="c733"
      unitRef="Pure">0.7606</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c734"
      unitRef="Pure">0.8003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c735"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c736"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c680"
      unitRef="USD">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c681">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2024-01-01_2024-12-31_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c682"
      unitRef="Share">39721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="d_2024-01-01_2024-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="-5"
      id="c685"
      unitRef="USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefFinancialOfficerMember"
      decimals="0"
      id="c687"
      unitRef="USD">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember"
      decimals="-5"
      id="c688"
      unitRef="USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="d_2025-01-01_2025-12-31_AwardTypeAxis-StockOptionVestingTermsAsImprobableToProbableMember_TitleOfIndividualAxis-ChiefOperatingOfficerMember"
      decimals="-5"
      id="c690"
      unitRef="USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c737">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 11. Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosures required for income taxes in the Company&#x2019;s annual consolidated financial statements. The guidance is effective for annual periods beginning after December 15, 2024. The Company adopted ASU 2023-09 prospectively, and the adoption impacted the Company&#x2019;s income tax disclosures only and did not have an impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of December&#160;31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b style="font-size: 10pt; text-align: center;"&gt;2024&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;%&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;%&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Rate reconciliation:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(5,671,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(3,421,046&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(710,002&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(1,121,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(526,015&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,188,171&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4,443,812&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(27.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;176,562&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;605,298&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;36,689&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total provision&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Significant components of the Company's deferred tax assets for federal income taxes as of December&#160;31, 2025 and 2024 consisted of the following:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,388,936&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,417,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,367,496&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,228,255&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized research expenditures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,289,629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,392,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;977,321&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;698,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Charitable contributions&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,130&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,321&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Intangibles&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;182,441&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;193,106&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,207,953&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,931,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(27,687,487&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(18,557,844&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaids&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred tax assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company does &lt;span style="-sec-ix-hidden:c781"&gt;&lt;span style="-sec-ix-hidden:c782"&gt;not&lt;/span&gt;&lt;/span&gt; have unrecognized tax benefits as of December&#160;31, 2025 or 2024. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&#160;31, 2025, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance increased by $9.1 million during the year ended December&#160;31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2025, the Company had NOL carryforwards of approximately $16.6 million and $4.8 million for federal and state tax purposes, respectively. Federal NOL carryforwards will not expire and state NOL carryforwards will begin to expire in 2038, if not utilized. The TCJA enacted on December 22, 2017 limits a taxpayer&#x2019;s ability to utilize NOL deduction in a year to 80% taxable income for federal NOLs arising in tax years beginning after 2017, however, federal NOLs post 2017 have no expiration.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2025, the Company also had federal and state research credit carryforwards of $2.3 million and $0.1 million, respectively. The federal and state research credits will begin to expire in 2038 and 2034, respectively. Generally, utilization of the NOL carryforwards and credits may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Code, which provides for limitations on NOL carryforwards and certain built-in losses following ownership changes, and Section 383 of the Code, which provides for special limitations on certain excess credits, as well as similar state provisions. Accordingly, the Company&#x2019;s ability to utilize NOL carryforwards may be limited as the result of such an &#x201c;ownership change.&#x201d; A formal Section 382 study was performed through December 31, 2023 which concluded&#160;there have been no historical section 382 ownership changes, thus the NOL carryforwards were not subject to an annual limitation through December 31, 2023. The Company has not conducted a study since December 31, 2023 to assess whether a change of control has occurred. If the Company has experienced a change of control, as defined by Section 382, subsequent to the last study, utilization of the net operating loss carryforwards or research and development tax credit carryforwards could be subject to an annual limitation under Section 382. With respect to Diffusion, the Company deems the historical Diffusion tax attributes (NOLs/Credits) are unusable due to the IRC Section 382 limitation. ASC 740-10-25 states that a &#x201c;write off might be appropriate if there is only a remote likelihood that the entity will utilize the carryforward (i.e. NOL), it is acceptable for the entity to write off the deferred tax assets against the valuation allowance, thereby eliminating the need to disclose the gross amounts.&#x201d; As such, the Company has written off these attributes.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company files federal and state income tax returns in jurisdictions with varying statutes of limitations. Due to its NOL carryforwards, the Company&#x2019;s income tax returns generally remain subject to examination by federal and state tax authorities. The Company is currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company uses the &#x201c;more likely than not&#x201d; criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and believes that its income tax filing positions and deductions will be sustained upon examination. Accordingly, no reserves for uncertain income tax positions or related accruals for interest and penalties have been recorded as of December&#160;31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;





&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements as of December&#160;31, 2025:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Rate reconciliation:&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US Federal statutory tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,671,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State and local income tax, net of federal (national) income tax effect (a)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,121,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Changes in valuation allowances&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,188,171&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;605,298&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total provision&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;(a) State taxes in Illinois and Massachusetts&#160;made up the majority of the tax effect in this category&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;During the year ended December 31, 2025, the Company did not pay any federal income taxes. Additionally, the amount paid in state income taxes, net of refunds received, was immaterial for the year ended December 31, 2025.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;On July 4, 2025, the US government enacted the OBBBA, which includes, among other provisions, changes to the US corporate income tax system including the allowance of immediate expensing of qualifying research and development expenses and permanent extensions of certain provisions within the Tax Cuts and Jobs Act. The Company has analyzed the impacts of the OBBBA and reflected them in the current period, resulting in a decrease to the deferred tax asset and valuation allowance of approximately $18.0 million gross ($5.1M tax effected) due to immediate expensing of domestic research and development expenditures.&lt;/p&gt;

&lt;p style="margin: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/p&gt;




</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="d_2025-01-01_2025-12-31"
      id="c7593A477-E1C1-401C-A587-1E6BE6E78E83">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b style="font-size: 10pt; text-align: center;"&gt;2024&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;%&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;%&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 48%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Rate reconciliation:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(5,671,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(3,421,046&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(710,002&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.4&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(1,121,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;(526,015&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Change in valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;6,188,171&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;4,443,812&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(27.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Share-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;176,562&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1.1&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Other&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;605,298&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;36,689&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(0.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total provision&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Percentage&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Rate reconciliation:&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;US Federal statutory tax rate&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(5,671,648&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;State and local income tax, net of federal (national) income tax effect (a)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Tax credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(1,121,821&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4.2&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Changes in valuation allowances&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,188,171&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;(22.9&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Nontaxable or nondeductible items&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;605,298&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2.3&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total provision&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.0&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c805"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2024-01-01_2024-12-31"
      decimals="2"
      id="c806"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c807"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c808"
      unitRef="Pure">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c809"
      unitRef="Pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c810"
      unitRef="Pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c811"
      unitRef="Pure">-0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c812"
      unitRef="Pure">-0.273</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c813"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c814"
      unitRef="Pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c815"
      unitRef="Pure">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="d_2024-01-01_2024-12-31"
      decimals="3"
      id="c816"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c817"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2024-01-01_2024-12-31"
      decimals="-3"
      id="c818"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2025-01-01_2025-12-31" id="c819">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax assets:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net operating loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,388,936&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,417,666&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development credits&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,367,496&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,228,255&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Capitalized research expenditures&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,289,629&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;6,392,545&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;977,321&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;698,886&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Charitable contributions&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,130&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,321&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Intangibles&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;182,441&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;193,106&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;28,207,953&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,931,779&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Less valuation allowance&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(27,687,487&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(18,557,844&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total deferred tax assets&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Prepaids&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(520,466&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(373,935&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Deferred tax assets, net&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2025-12-31"
      decimals="0"
      id="c823"
      unitRef="USD">21388936</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2024-12-31"
      decimals="0"
      id="c824"
      unitRef="USD">10417666</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2025-12-31"
      decimals="0"
      id="c825"
      unitRef="USD">2367496</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2024-12-31"
      decimals="0"
      id="c826"
      unitRef="USD">1228255</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <crvo:DeferredTaxAssetsCapitalizedResearchExpenditures
      contextRef="i_2025-12-31"
      decimals="0"
      id="c827"
      unitRef="USD">3289629</crvo:DeferredTaxAssetsCapitalizedResearchExpenditures>
    <crvo:DeferredTaxAssetsCapitalizedResearchExpenditures
      contextRef="i_2024-12-31"
      decimals="0"
      id="c828"
      unitRef="USD">6392545</crvo:DeferredTaxAssetsCapitalizedResearchExpenditures>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2025-12-31"
      decimals="0"
      id="c829"
      unitRef="USD">977321</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2024-12-31"
      decimals="0"
      id="c830"
      unitRef="USD">698886</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="i_2025-12-31"
      decimals="0"
      id="c831"
      unitRef="USD">2130</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards
      contextRef="i_2024-12-31"
      decimals="0"
      id="c832"
      unitRef="USD">1321</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i_2025-12-31"
      decimals="0"
      id="c833"
      unitRef="USD">182441</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i_2024-12-31"
      decimals="0"
      id="c834"
      unitRef="USD">193106</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2025-12-31"
      decimals="0"
      id="c835"
      unitRef="USD">28207953</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2024-12-31"
      decimals="0"
      id="c836"
      unitRef="USD">18931779</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2025-12-31"
      decimals="0"
      id="c837"
      unitRef="USD">27687487</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2024-12-31"
      decimals="0"
      id="c838"
      unitRef="USD">18557844</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2025-12-31"
      decimals="0"
      id="c839"
      unitRef="USD">520466</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2024-12-31"
      decimals="0"
      id="c840"
      unitRef="USD">373935</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i_2025-12-31"
      decimals="0"
      id="c842"
      unitRef="USD">520466</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i_2024-12-31"
      decimals="0"
      id="c843"
      unitRef="USD">373935</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2025-12-31"
      decimals="0"
      id="c844"
      unitRef="USD">520466</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2024-12-31"
      decimals="0"
      id="c845"
      unitRef="USD">373935</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2025-12-31"
      decimals="-3"
      id="c846"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2024-12-31"
      decimals="-3"
      id="c847"
      unitRef="USD">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-5"
      id="c783"
      unitRef="USD">9100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c784"
      unitRef="USD">16600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c785"
      unitRef="USD">4800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c786"
      unitRef="USD">2300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2025-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c787"
      unitRef="USD">100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c852"
      unitRef="USD">5671648</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2025-01-01_2025-12-31"
      decimals="2"
      id="c853"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c854"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c855"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c856"
      unitRef="USD">1121821</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c857"
      unitRef="Pure">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c858"
      unitRef="USD">6188171</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c859"
      unitRef="Pure">-0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="0"
      id="c860"
      unitRef="USD">605298</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="d_2025-01-01_2025-12-31"
      decimals="3"
      id="c861"
      unitRef="Pure">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c862"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2025-01-01_2025-12-31"
      decimals="-3"
      id="c863"
      unitRef="Pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="d_2025-01-01_2025-12-31" id="c864">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 12. Segments&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM, or decision-making group, in deciding how to allocate resources in assessing performance. CervoMed Inc. has one reportable segment which consists of the development of clinical and nonclinical product candidates for treatments for age-related neurologic disorders and other medical indications. The Company&#x2019;s CODM is the Chief Executive Officer.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The accounting policies of the Company&#x2019;s &lt;span style="-sec-ix-hidden:c867"&gt;single&lt;/span&gt; segment are the same as those described in the summary of significant accounting policies. To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. The CODM assesses the financial performance for the Company's segment based on net loss. The CODM also uses internal budget versus forecasted expense and cash forecast models in making certain decisions. Such models are reviewed to assess the entity-wide/single-segment operating results and performance, including how long cash-on-hand is expected to be sufficient. The measure of segment assets is reported on the consolidated balance sheet as total assets. The segment measure of loss is reported on the consolidated statement of operations and comprehensive loss as net loss.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the year ended December&#160;31, 2025 and 2024:&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Grant revenue&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,006,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,737,974&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Dementia with Lewy bodies&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,052,512&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,102,842&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Frontotemporal disorders (incl. nfvPPA)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,217,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Recovery after stroke&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,427,966&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;391,659&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other clinical* and nonclinical&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,504,863&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,499,202&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel costs, excluding stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,745,558&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,187,221&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;482,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other research and development expenses, including CMC**&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,385,720&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,361,744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total research and development expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,817,072&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,798,343&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative expenses:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel costs, excluding stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,988,705&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,995,114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;965,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,186,900&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,752,710&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,684,386&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Insurance, taxes and similar fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,166,374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;985,481&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other general and administrative expenses, including IT, facilities, supplies and similar costs***&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;610,561&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;314,879&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total general and administrative expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,484,315&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,166,760&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,328,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,936,436&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(26,966,367&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(16,290,693&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;


&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;* - Includes early-stage clinical studies that are not indication-specific and related costs.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;** - Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;*** - Includes, among other things, costs related to IT systems, rent and other facilities, office supplies, and similar costs.&lt;/p&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="d_2025-01-01_2025-12-31" id="c902">
&lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="border-collapse: collapse; width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/p&gt;

			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr class="finHeading" style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2025&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Grant revenue&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,006,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,737,974&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development expenses:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Dementia with Lewy bodies&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;7,052,512&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;12,102,842&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Frontotemporal disorders (incl. nfvPPA)&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,217,784&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;36,853&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Recovery after stroke&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,427,966&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;391,659&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other clinical* and nonclinical&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,504,863&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,499,202&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel costs, excluding stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;5,745,558&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,187,221&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;482,669&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;218,822&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other research and development expenses, including CMC**&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,385,720&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,361,744&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total research and development expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;21,817,072&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;18,798,343&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;General and administrative expenses:&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Personnel costs, excluding stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;4,988,705&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3,995,114&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Stock-based compensation&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;965,965&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,186,900&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Professional fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,752,710&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;2,684,386&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Insurance, taxes and similar fees&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;1,166,374&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;985,481&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other general and administrative expenses, including IT, facilities, supplies and similar costs***&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;610,561&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;314,879&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Total general and administrative expenses&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;10,484,315&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;9,166,760&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"&gt;Other income&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,328,510&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,936,436&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;
			&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Net loss&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(26,966,367&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(16,290,693&lt;/td&gt;
			&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c905"
      unitRef="USD">4006510</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c906"
      unitRef="USD">9737974</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember"
      decimals="0"
      id="c907"
      unitRef="USD">7052512</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-DementiaWithLewyBodiesMember"
      decimals="0"
      id="c908"
      unitRef="USD">12102842</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember"
      decimals="0"
      id="c909"
      unitRef="USD">1217784</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-FrontotemporalDisordersMember"
      decimals="0"
      id="c910"
      unitRef="USD">36853</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember"
      decimals="0"
      id="c911"
      unitRef="USD">1427966</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-RecoveryAfterStrokeMember"
      decimals="0"
      id="c912"
      unitRef="USD">391659</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember"
      decimals="0"
      id="c913"
      unitRef="USD">2504863</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherClinicalAndNonclinicalMember"
      decimals="0"
      id="c914"
      unitRef="USD">2499202</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember"
      decimals="0"
      id="c915"
      unitRef="USD">5745558</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-PersonnelCostsMember"
      decimals="0"
      id="c916"
      unitRef="USD">2187221</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember"
      decimals="0"
      id="c917"
      unitRef="USD">482669</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-StockBasedCompensationMember"
      decimals="0"
      id="c918"
      unitRef="USD">218822</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember"
      decimals="0"
      id="c919"
      unitRef="USD">3385720</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember_NatureOfExpenseAxis-OtherResearchAndDevelopmentCostsMember"
      decimals="0"
      id="c920"
      unitRef="USD">1361744</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c921"
      unitRef="USD">21817072</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c922"
      unitRef="USD">18798343</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c923"
      unitRef="USD">4988705</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c924"
      unitRef="USD">3995114</us-gaap:LaborAndRelatedExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c925"
      unitRef="USD">965965</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c926"
      unitRef="USD">1186900</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ProfessionalFees
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c927"
      unitRef="USD">2752710</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c928"
      unitRef="USD">2684386</us-gaap:ProfessionalFees>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c929"
      unitRef="USD">1166374</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:TaxesExcludingIncomeAndExciseTaxes
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c930"
      unitRef="USD">985481</us-gaap:TaxesExcludingIncomeAndExciseTaxes>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c931"
      unitRef="USD">610561</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c932"
      unitRef="USD">314879</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c933"
      unitRef="USD">10484315</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c934"
      unitRef="USD">9166760</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c935"
      unitRef="USD">1328510</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c936"
      unitRef="USD">1936436</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2025-01-01_2025-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c937"
      unitRef="USD">-26966367</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2024-01-01_2024-12-31_ConsolidationItemsAxis-OperatingSegmentsMember"
      decimals="0"
      id="c938"
      unitRef="USD">-16290693</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2025-01-01_2025-12-31" id="c939">
&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;Note 13. Subsequent Events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The company evaluated subsequent events from December&#160;31, 2025 to the date the financial statements were issued, noting no events requiring disclosure.&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="d_2025-01-01_2025-12-31" id="c942">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 54pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;ITEM 9B.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;OTHER INFORMATION&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;i&gt;Adoption, Termination or Modification of Trading Arrangements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;During the year ended&#160;December&#160;31, 2025, &lt;span style="-sec-ix-hidden:c945"&gt;&lt;span style="-sec-ix-hidden:c946"&gt;&lt;span style="-sec-ix-hidden:c947"&gt;&lt;span style="-sec-ix-hidden:c948"&gt;none&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act),&#160;adopted,&#160;terminated&#160;or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).&lt;/p&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="d_2025-01-01_2025-12-31" id="c952">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <ecd:AwardTmgHowMnpiCnsdrdTextBlock contextRef="d_2025-01-01_2025-12-31" id="c953">
&lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;

		&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 54pt;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;ITEM 11.&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="width: auto;"&gt;
			&lt;p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;EXECUTIVE COMPENSATION&lt;/b&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/tbody&gt;&lt;/table&gt;

&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;The additional information required by Item 11 of Form 10-K is incorporated herein by reference from our Proxy Statement, to be filed with the SEC within 120 days after December&#160;31, 2025, the end of the fiscal year to which this Annual Report relates, including the information set forth under the captions, &#x201c;&lt;i&gt;Executive Compensation&lt;/i&gt;,&#x201d; &#x201c;&lt;i&gt;Director Compensation&lt;/i&gt;,&#x201d; &#x201c;&lt;i&gt;Compensation Committee Report&lt;/i&gt;,&#x201d; and &#x201c;&lt;i&gt;Corporate Governance &lt;/i&gt;&#x2013;&lt;i&gt; Compensation Committee Interlocks and Insider Participation&lt;/i&gt;.&#x201d;&lt;/p&gt;
</ecd:AwardTmgHowMnpiCnsdrdTextBlock>
    <ecd:AwardTmgMnpiCnsdrdFlag contextRef="d_2025-01-01_2025-12-31" id="c956">false</ecd:AwardTmgMnpiCnsdrdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc xlink:href="#c913" xlink:label="c913" xlink:type="locator"/>
        <link:loc xlink:href="#c914" xlink:label="c914" xlink:type="locator"/>
        <link:footnote id="f6ff8e636-6d49-477d-83f3-18bd69e4239d" xlink:label="f6ff8e636-6d49-477d-83f3-18bd69e4239d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Includes early-stage clinical studies that are not indication-specific and related costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c913"
          xlink:to="f6ff8e636-6d49-477d-83f3-18bd69e4239d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c914"
          xlink:to="f6ff8e636-6d49-477d-83f3-18bd69e4239d"
          xlink:type="arc"/>
        <link:loc xlink:href="#c919" xlink:label="c919" xlink:type="locator"/>
        <link:loc xlink:href="#c920" xlink:label="c920" xlink:type="locator"/>
        <link:footnote id="f2b6adf8e-c033-448f-a62e-7f630299d7ff" xlink:label="f2b6adf8e-c033-448f-a62e-7f630299d7ff" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Includes, among other things, CMC-related costs, shipping, packaging and storage costs, certain consulting costs, and other miscellaneous research development expenses.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c919"
          xlink:to="f2b6adf8e-c033-448f-a62e-7f630299d7ff"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c920"
          xlink:to="f2b6adf8e-c033-448f-a62e-7f630299d7ff"
          xlink:type="arc"/>
        <link:loc xlink:href="#c855" xlink:label="c855" xlink:type="locator"/>
        <link:loc xlink:href="#c854" xlink:label="c854" xlink:type="locator"/>
        <link:footnote id="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a" xlink:label="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">State taxes in Illinois and Massachusetts&#160;made up the majority of the tax effect in this category</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c855"
          xlink:to="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c854"
          xlink:to="f4022d1c8-917d-4079-aa94-f6b2d3a4f05a"
          xlink:type="arc"/>
        <link:loc xlink:href="#c931" xlink:label="c931" xlink:type="locator"/>
        <link:loc xlink:href="#c932" xlink:label="c932" xlink:type="locator"/>
        <link:footnote id="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f" xlink:label="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Includes, among other things, costs related to IT systems, rent and other facilities, office supplies, and similar costs.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c931"
          xlink:to="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c932"
          xlink:to="f0db6e9fa-c04d-4eef-9a1c-502cfaa71b6f"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
